DSSTox_RID	DSSTox_CID	DSSTox_Generic_SID	DSSTox_FileID	STRUCTURE_Formula	STRUCTURE_MolecularWeight	STRUCTURE_ChemicalType	STRUCTURE_TestedForm_DefinedOrganic	STRUCTURE_Shown	TestSubstance_ChemicalName	TestSubstance_CASRN	TestSubstance_Description	ChemicalNote	STRUCTURE_ChemicalName_IUPAC	STRUCTURE_SMILES	STRUCTURE_Parent_SMILES	STRUCTURE_InChI	STRUCTURE_InChIKey	StudyType	Endpoint	Species	ChemicalReplicateCount	ChemClass_MRDD_grouping	TherapeuticCategory	Dose_MRDD_mg	Dose_MRDD_mmol	LOGINV_MRDD_mmol	ActivityScore_FDAMDD	ActivityCategory_MRDD_mmol	ActivityCategory_MCASE_mg	Note_FDAMDD			
22540	2540	22540	1_FDAMDD_v3b	C21H18ClNO6	415.82372	defined organic	parent	tested chemical	Acemetacin	53164-05-9	single chemical compound	blank	[({1-[(4-chlorophenyl)carbonyl]-2-methyl-5-(methyloxy)-1H-indol-3-yl}acetyl)oxy]acetic acid	C1=C(OC)C=C3C(=C1)N(C(=O)C2=CC=C(Cl)C=C2)C(C)=C3CC(=O)OCC(O)=O	C1=C(OC)C=C3C(=C1)N(C(=O)C2=CC=C(Cl)C=C2)C(C)=C3CC(=O)OCC(O)=O	"InChI=1/C21H18ClNO6/c1-12-16(10-20(26)29-11-19(24)25)17-9-15(28-2)7-8-18(17)23(12)21(27)13-3-5-14(22)6-4-13/h3-9H,10-11H2,1-2H3,(H,24,25)/f/h24H"	FSQKKOOTNAMONP-LQFNOIFHCH	Clinical Reports 	Maximum Recommended Daily Dose	human	1	blank	anti inflammatory	3	0.007214596	2.141788005	35	Moderate	Moderate	form of drug administered not known			
22541	2541	22541	2_FDAMDD_v3b	C19H15NO6	353.3255	defined organic	parent	tested chemical	Acenocoumarol	152-72-7	single chemical compound		4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one	C1=CC=C3C(=C1)OC(=O)C(C(CC(C)=O)C2=CC=C(N(=O)=O)C=C2)=C3O	C1=CC=C3C(=C1)OC(=O)C(C(CC(C)=O)C2=CC=C(N(=O)=O)C=C2)=C3O	"InChI=1/C19H15NO6/c1-11(21)10-15(12-6-8-13(9-7-12)20(24)25)17-18(22)14-4-2-3-5-16(14)26-19(17)23/h2-9,15,22H,10H2,1H3"	VABCILAOYCMVPS-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticoagulant	0.2	0.00056605	3.247144987	48	High-Moderate	High	form of drug administered not known			
22542	6	20006	3_FDAMDD_v3b	C8H9NO2	151.1626	defined organic	parent	tested chemical	Acetaminophen	103-90-2	single chemical compound		N-(4-hydroxyphenyl)acetamide	C1(=CC=C(C=C1)O)NC(C)=O	C1(=CC=C(C=C1)O)NC(C)=O	"InChI=1/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)/f/h9H"	RZVAJINKPMORJF-BGGKNDAXCW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; antipyretic	50	0.330769648	0.480474349	17	Low	Low	form of drug administered not known			
22543	2543	22543	4_FDAMDD_v3b	C8H9NO	135.1632	defined organic	parent	tested chemical	Acetanilide	103-84-4	single chemical compound		N-phenylacetamide	C1=CC=CC=C1NC(C)=O	C1=CC=CC=C1NC(C)=O	"InChI=1/C8H9NO/c1-7(10)9-8-5-3-2-4-6-8/h2-6H,1H3,(H,9,10)/f/h9H"	FZERHIULMFGESH-BGGKNDAXCW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipyretic; analgesic	5	0.036992317	1.431888461	27	Low-Moderate	Low	form of drug administered not known			
22544	2544	22544	5_FDAMDD_v3b	C4H6N4O3S2	222.24544	defined organic	parent	tested chemical	Acetazolamide	59-66-5	single chemical compound		"N-[5-(aminosulfonyl)-1,3,4-thiadiazol-2-yl]acetamide"	N1N=C(S(N)(=O)=O)SC=1NC(C)=O	N1N=C(S(N)(=O)=O)SC=1NC(C)=O	"InChI=1/C4H6N4O3S2/c1-2(9)6-3-7-8-4(12-3)13(5,10)11/h1H3,(H2,5,10,11)(H,6,7,9)/f/h6H,5H2"	BZKPWHYZMXOIDC-WQDBGGICCO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		carbonic anhydrase inhibitor; diuretic	16.7	0.075142149	1.124116388	24	Low	Low	form of drug administered not known; Na salt [1424-27-7]			
22545	7	20007	6_FDAMDD_v3b	C15H20N2O4S	324.3953	defined organic	parent	tested chemical	Acetohexamide	968-81-0	single chemical compound		4-acetyl-N-[(cyclohexylamino)carbonyl]benzenesulfonamide	O=S(=O)(C1=CC=C(C=C1)C(=O)C)NC(=O)NC2CCCCC2	O=S(=O)(C1=CC=C(C=C1)C(=O)C)NC(=O)NC2CCCCC2	"InChI=1/C15H20N2O4S/c1-11(18)12-7-9-14(10-8-12)22(20,21)17-15(19)16-13-5-3-2-4-6-13/h7-10,13H,2-6H2,1H3,(H2,16,17,19)/f/h16-17H"	VGZSUPCWNCWDAN-XQMQJMAZCC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	25	0.077066468	1.113134545	24	Low	Low	form of drug administered not known			
22546	2546	22546	7_FDAMDD_v3b	C2H5NO2	75.0666	defined organic	parent	tested chemical	Acetohydroxamic acid	546-88-3	single chemical compound		N-hydroxyacetamide	CC(=O)NO	CC(=O)NO	"InChI=1/C2H5NO2/c1-2(4)3-5/h5H,1H3,(H,3,4)/f/h3H"	RRUDCFGSUDOHDG-TULZNQERCP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiurolithic; antibacterial adjunct	16.7	0.222469114	0.652730275	18	Low	Low	form of drug administered not known			
22547	2547	22547	8_FDAMDD_v3b	C23H29N3O2S	411.56026	defined organic	parent	tested chemical	Acetophenazine	2751-68-0	single chemical compound		1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)ethanone	C1=CC=C3C(=C1)N(CCCN2CCN(CCO)CC2)C4=C(S3)C=CC(C(C)=O)=C4	C1=CC=C3C(=C1)N(CCCN2CCN(CCO)CC2)C4=C(S3)C=CC(C(C)=O)=C4	"InChI=1/C23H29N3O2S/c1-18(28)19-7-8-23-21(17-19)26(20-5-2-3-6-22(20)29-23)10-4-9-24-11-13-25(14-12-24)15-16-27/h2-3,5-8,17,27H,4,9-16H2,1H3"	WNTYBHLDCKXEOT-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	10	0.024297778	1.614433433	29	Low-Moderate	Low	form of drug administered not known			
22548	2548	22548	9_FDAMDD_v3b	C14H14N3NaO5S2	391.39783	defined organic	salt Na	tested chemical	Acetosulfone	128-12-1	single chemical compound		sodium acetyl({5-amino-2-[(4-aminophenyl)sulfonyl]phenyl}sulfonyl)azanide	[Na+].O=S(=O)([N-]C(C)=O)c1cc(N)ccc1S(=O)(=O)c2ccc(N)cc2	O=S(=O)(NC(C)=O)c1cc(N)ccc1S(=O)(=O)c2ccc(N)cc2	"InChI=1/C14H15N3O5S2.Na/c1-9(18)17-24(21,22)14-8-11(16)4-7-13(14)23(19,20)12-5-2-10(15)3-6-12;/h2-8H,15-16H2,1H3,(H,17,18);/q;+1/p-1/fC14H14N3O5S2.Na/q-1;m"	PVGBHEUCHKGFQP-AJGVBKPGCQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.170414844	0.76849258	20	Low	Low	form of drug administered not known			
22549	2549	22549	10_FDAMDD_v3b	C9H6I3NO3	556.86225	defined organic	parent	tested chemical	Acetrizoic acid	85-36-9	single chemical compound		"3-(acetylamino)-2,4,6-triiodobenzoic acid"	C1(I)=CC(I)=C(NC(C)=O)C(I)=C1C(O)=O	C1(I)=CC(I)=C(NC(C)=O)C(I)=C1C(O)=O	"InChI=1/C9H6I3NO3/c1-3(14)13-8-5(11)2-4(10)6(7(8)12)9(15)16/h2H,1H3,(H,13,14)(H,15,16)/f/h13,15H"	GNOGSFBXBWBTIG-YENFCIRVCA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	100	0.179577624	0.745747778	19	Low	Low	form of drug administered not known			
22550	21	20021	11_FDAMDD_v3b	C5H9NO3S	163.1949	defined organic	parent	tested chemical	Acetylcysteine	616-91-1	single chemical compound	stereochem	N-acetyl-L-cysteine	CC(=O)N[C@@H](CS)C(=O)O	CC(=O)N[C@@H](CS)C(=O)O	"InChI=1/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1/f/h6,8H"	PWKSKIMOESPYIA-JVBVHTJODB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		mucolytic; corneal vulnerary	10	0.061276425	1.212706583	25	Low-Moderate	Low	form of drug administered not known			
22551	2551	22551	12_FDAMDD_v3b	C43H66O14	806.97574	defined organic	parent	tested chemical	Acetyldigitoxin	1111-39-3	single chemical compound	stereochem; tautomers	"(3beta,5beta)-3-{[3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide"	CC(=O)O[C@H]1C[C@@H](O[C@H](C)[C@H]1O)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@@H]8[C@@H](C)O[C@@H](O[C@@H]5C[C@H]6CC[C@H]4[C@@]7(O)CC[C@H](C=3COC(=O)C=3)[C@@]7(C)CC[C@@H]4[C@@]6(C)CC5)C[C@@H]8O	CC(=O)O[C@H]1C[C@@H](O[C@H](C)[C@H]1O)O[C@H]2[C@@H](O)C[C@@H](O[C@@H]2C)O[C@@H]8[C@@H](C)O[C@@H](O[C@@H]5C[C@H]6CC[C@H]4[C@@]7(O)CC[C@H](C=3COC(=O)C=3)[C@@]7(C)CC[C@@H]4[C@@]6(C)CC5)C[C@@H]8O	"InChI=1/C43H66O14/c1-21-38(48)33(54-24(4)44)19-37(51-21)57-40-23(3)53-36(18-32(40)46)56-39-22(2)52-35(17-31(39)45)55-27-9-12-41(5)26(16-27)7-8-30-29(41)10-13-42(6)28(11-14-43(30,42)49)25-15-34(47)50-20-25/h15,21-23,26-33,35-40,45-46,48-49H,7-14,16-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29+,30-,31+,32+,33+,35+,36+,37+,38-,39-,40-,41+,42-,43+/m1/s1"	HPMZBILYSWLILX-UMDUKNJSBP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cardiotonic	0.00333	4.12652E-06	5.384416245	71	High	High	form of drug administered not known			
22552	2552	22552	13_FDAMDD_v3b	C19H22N2OS	326.45578	defined organic	parent	tested chemical	Acetylpromazine	61-00-7	single chemical compound		1-{10-[3-(dimethylamino)propyl]-10H-phenothiazin-2-yl}ethanone	C1=CC=C2C(=C1)N(CCCN(C)C)C3=C(S2)C=CC(C(C)=O)=C3	C1=CC=C2C(=C1)N(CCCN(C)C)C3=C(S2)C=CC(C(C)=O)=C3	"InChI=1/C19H22N2OS/c1-14(22)15-9-10-19-17(13-15)21(12-6-11-20(2)3)16-7-4-5-8-18(16)23-19/h4-5,7-10,13H,6,11-12H2,1-3H3"	NOSIYYJFMPDDSA-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		tranquilizer	0.15	0.00045948	3.337733103	49	High-Moderate	High	form of drug administered not known			
22553	2553	22553	14_FDAMDD_v3b	C21H26O3	326.42934	defined organic	parent	tested chemical	Acitretin	55079-83-9	single chemical compound	stereochem	"(2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoic acid"	C1(C)=C(OC)C=C(C)C(C=CC(C)=CC=CC(C)=CC(O)=O)=C1C	C1(C)=C(OC)C=C(C)C(C=CC(C)=CC=CC(C)=CC(O)=O)=C1C	"InChI=1/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+/f/h22H"	IHUNBGSDBOWDMA-CDPNKHFKDR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsoriatic	1.25	0.003829313	2.416879174	38	Moderate	High	form of drug administered not known			
22554	2554	22554	15_FDAMDD_v3b	C42H53NO15	811.86792	defined organic	parent	tested chemical	Aclacinomycin A	57576-44-0	single chemical compound	stereochem	"methyl (1R,2R,4S)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-4-{[2,3,6-trideoxy-4-O-{2,6-dideoxy-4-O-[(2R,6S)-6-methyl-5-oxotetrahydro-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl}-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate"	COC(=O)[C@@H]4c3cc2C(=O)c1cccc(O)c1C(=O)c2c(O)c3[C@H](C[C@]4(O)CC)O[C@@H]7O[C@@H](C)[C@@H](O[C@H]6C[C@H](O)[C@H](O[C@H]5CCC(=O)[C@H](C)O5)[C@H](C)O6)[C@H](C7)N(C)C	COC(=O)[C@@H]4c3cc2C(=O)c1cccc(O)c1C(=O)c2c(O)c3[C@H](C[C@]4(O)CC)O[C@@H]7O[C@@H](C)[C@@H](O[C@H]6C[C@H](O)[C@H](O[C@H]5CCC(=O)[C@H](C)O5)[C@H](C)O6)[C@H](C7)N(C)C	"InChI=1/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1"	USZYSDMBJDPRIF-SVEJIMAYBG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	2.7	0.003325664	2.478121617	39	Moderate	Moderate	form of drug administered not known			
22555	2555	22555	16_FDAMDD_v3b	C22H24N2O2	348.43816	defined organic	parent	tested chemical	Acrivastine	87848-99-5	single chemical compound	stereochem	(2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid	C(=CCN1CCCC1)(C2=CC=C(C)C=C2)C3=CC=CC(C=CC(O)=O)=N3	C(=CCN1CCCC1)(C2=CC=C(C)C=C2)C3=CC=CC(C=CC(O)=O)=N3	"InChI=1/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+/f/h25H"	PWACSDKDOHSSQD-NTOVBENVDD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	0.533	0.001529683	2.815398503	43	Moderate	High	form of drug administered not known			
22556	2556	22556	17_FDAMDD_v3b	C8H11N5O3	225.20464	defined organic	parent	tested chemical	Acyclovir	59277-89-3	single chemical compound		"2-amino-9-{[(2-hydroxyethyl)oxy]methyl}-1,9-dihydro-6H-purin-6-one"	N1C(N)=NC2=C(C1=O)N=CN2COCCO	N1C(N)=NC2=C(C1=O)N=CN2COCCO	"InChI=1/C8H11N5O3/c9-8-11-6-5(7(15)12-8)10-3-13(6)4-16-2-1-14/h3,14H,1-2,4H2,(H3,9,11,12,15)/f/h12H,9H2"	MKUXAQIIEYXACX-TVNKGWMHCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiviral	13.3	0.059057398	1.228725693	25	Low-Moderate	Low	form of drug administered not known			
22557	2557	22557	18_FDAMDD_v3b	C5H5N5	135.1267	defined organic	parent	tested chemical	Adenine	73-24-5	single chemical compound		9H-purin-6-amine	NC1=NC=NC2=C1N=CN2	NC1=NC=NC2=C1N=CN2	"InChI=1/C5H5N5/c6-4-3-5(9-1-7-3)10-2-8-4/h1-2H,(H3,6,7,8,9,10)/f/h9H,6H2"	GFFGJBXGBJISGV-KYDDBTJZCX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		research	15	0.111006929	0.954649912	22	Low	Low	form of drug administered not known			
22558	2558	22558	19_FDAMDD_v3b	C10H13N5O4	267.24132	defined organic	parent	tested chemical	Adenosine	58-61-7	single chemical compound	stereochem	adenosine	NC1=NC=NC2=C1N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O	NC1=NC=NC2=C1N=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O	"InChI=1/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1/f/h11H2"	OIRDTQYFTABQOQ-ONGDMJDYDQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiarrhythmic	2	0.007483873	2.125873613	35	Moderate	High	form of drug administered not known			
22559	2559	22559	20_FDAMDD_v3b	C10H16N5O13P3	507.181023	defined organic	parent	tested chemical	Adenosine triphosphate	56-65-5	single chemical compound	stereochem	adenosine 5'-(tetrahydrogen triphosphate)	OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]3O[C@@H](n2cnc1c(N)ncnc12)[C@H](O)[C@@H]3O	OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]3O[C@@H](n2cnc1c(N)ncnc12)[C@H](O)[C@@H]3O	"InChI=1/C10H16N5O13P3/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(26-10)1-25-30(21,22)28-31(23,24)27-29(18,19)20/h2-4,6-7,10,16-17H,1H2,(H,21,22)(H,23,24)(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1/f/h18-19,21,23H,11H2"	ZKHQWZAMYRWXGA-FJYXAIENDD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		coenzyme	0.2	0.000394337	3.404133	49	High-Moderate	High	form of drug administered not known			
22560	2560	22560	21_FDAMDD_v3b	C10H14N5O7P	347.221221	defined organic	parent	tested chemical	Adenosine-5-phosphate	61-19-8	single chemical compound	stereochem	5'-adenylic acid	OP(O)(=O)OC[C@H]3O[C@@H](n2cnc1c(N)ncnc12)[C@@H](O)[C@@H]3O	OP(O)(=O)OC[C@H]3O[C@@H](n2cnc1c(N)ncnc12)[C@@H](O)[C@@H]3O	"InChI=1/C10H14N5O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1/f/h18-19H,11H2"	UDMBCSSLTHHNCD-WLZLVAIBDR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiarrhythmic	0.333	0.000959043	3.018162026	45	High-Moderate	High	form of drug administered not known			
22561	2561	22561	22_FDAMDD_v3b	C20H25NO2	311.418	defined organic	parent	tested chemical	Adiphenine	64-95-9	single chemical compound		2-(diethylamino)ethyl diphenylacetate	C2=CC=CC(C(C(=O)OCCN(CC)CC)C1=CC=CC=C1)=C2	C2=CC=CC(C(C(=O)OCCN(CC)CC)C1=CC=CC=C1)=C2	"InChI=1/C20H25NO2/c1-3-21(4-2)15-16-23-20(22)19(17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,19H,3-4,15-16H2,1-2H3"	JGOAIQNSOGZNBX-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	7.5	0.024083386	1.618282448	29	Low-Moderate	Low	form of drug administered not known			
22562	2562	22562	23_FDAMDD_v3b	C16H14FN3O	283.3003	defined organic	parent	tested chemical	Afloqualone	56287-74-2	single chemical compound		6-amino-2-(fluoromethyl)-3-(2-methylphenyl)quinazolin-4(3H)-one	C1(N)=CC=C3C(=C1)C(=O)N(C2=CC=CC=C2C)C(CF)=N3	C1(N)=CC=C3C(=C1)C(=O)N(C2=CC=CC=C2C)C(CF)=N3	"InChI=1/C16H14FN3O/c1-10-4-2-3-5-14(10)20-15(9-17)19-13-7-6-11(18)8-12(13)16(20)21/h2-8H,9,18H2,1H3"	VDOSWXIDETXFET-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	1	0.003529823	2.452247034	39	Moderate	High	form of drug administered not known			
22563	2563	22563	24_FDAMDD_v3b	C12H15N3O2S	265.3314	defined organic	parent	tested chemical	Albendazole	54965-21-8	single chemical compound		methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate	COC(=O)NC=1Nc2ccc(cc2N=1)SCCC	COC(=O)NC=1Nc2ccc(cc2N=1)SCCC	"InChI=1/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)/f/h13,15H"	HXHWSAZORRCQMX-YENFCIRVCU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anthelmintic	13.3	0.050125993	1.299937008	26	Low-Moderate	Low	form of drug administered not known			
22564	1255	21255	25_FDAMDD_v3b	C13H21NO3	239.3138	defined organic	parent	tested chemical	Albuterol	18559-94-9	single chemical compound	"racemic mixture of (1R,S); structure shown without stereochem"	"4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol"	OC(C1=CC=C(C(=C1)CO)O)CNC(C)(C)C	OC(C1=CC=C(C(=C1)CO)O)CNC(C)(C)C	"InChI=1/C13H21NO3/c1-13(2,3)14-7-12(17)9-4-5-11(16)10(6-9)8-15/h4-6,12,14-17H,7-8H2,1-3H3"	NDAUXUAQIAJITI-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator; tocolytic	0.533	0.002227201	2.652240534	41	Moderate	High	form of drug administered not known			
22565	2565	22565	26_FDAMDD_v3b	C10H16N2OS	212.3118	defined organic	parent	tested chemical	Albutoin	830-89-7	single chemical compound		5-(2-methylpropyl)-3-prop-2-en-1-yl-2-thioxoimidazolidin-4-one	C=CCN1C(=O)C(CC(C)C)NC1=S	C=CCN1C(=O)C(CC(C)C)NC1=S	"InChI=1/C10H16N2OS/c1-4-5-12-9(13)8(6-7(2)3)11-10(12)14/h4,7-8H,1,5-6H2,2-3H3,(H,11,14)/f/h11H"	RATGSRSDPNECNO-WXRBYKJCCI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	40	0.188402152	0.724914141	19	Low	Low	form of drug administered not known			
22566	38	20038	27_FDAMDD_v3b	C11H11ClO3	226.6562	defined organic	parent	tested chemical	Alclofenac	22131-79-9	single chemical compound		[3-chloro-4-(prop-2-en-1-yloxy)phenyl]acetic acid	C1(OCC=C)=CC=C(CC(=O)O)C=C1Cl	C1(OCC=C)=CC=C(CC(=O)O)C=C1Cl	"InChI=1/C11H11ClO3/c1-2-5-15-10-4-3-8(6-9(10)12)7-11(13)14/h2-4,6H,1,5,7H2,(H,13,14)/f/h13H"	ARHWPKZXBHOEEE-NDKGDYFDCL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; antipyretic; anti inflammatory	1.67	0.007367987	2.132651132	35	Moderate	High	form of drug administered not known			
22567	2419	22419	28_FDAMDD_v3b	C21H28O5	360.444	defined organic	parent	tested chemical	Aldosterone	52-39-1	single chemical compound	stereochem; tautomers	"(11beta)-11,21-dihydroxy-3,20-dioxopregn-4-en-18-al"	[C@]12([C@]([C@@]3(CCC4[C@@]([C@@]([C@H](C1)O)3[H])(CCC(=O)C=4)C)[H])(CC[C@H]2C(=O)CO)[H])C=O	[C@]12([C@]([C@@]3(CCC4[C@@]([C@@]([C@H](C1)O)3[H])(CCC(=O)C=4)C)[H])(CC[C@H]2C(=O)CO)[H])C=O	"InChI=1/C21H28O5/c1-20-7-6-13(24)8-12(20)2-3-14-15-4-5-16(18(26)10-22)21(15,11-23)9-17(25)19(14)20/h8,11,14-17,19,22,25H,2-7,9-10H2,1H3/t14-,15-,16+,17-,19+,20-,21+/m0/s1"	PQSUYGKTWSAVDQ-ZVIOFETBBV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		mineralcorticoid	0.00833	2.31104E-05	4.636192799	63	High	High	form of drug administered not known			
22568	2568	22568	29_FDAMDD_v3b	C4H13NO7P2	249.096042	defined organic	parent	tested chemical	Alendronic Acid	66376-36-1	single chemical compound		"(4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid)"	OC(P(O)(O)=O)(CCCN)P(O)(O)=O	OC(P(O)(O)=O)(CCCN)P(O)(O)=O	"InChI=1/C4H13NO7P2/c5-3-1-2-4(6,13(7,8)9)14(10,11)12/h6H,1-3,5H2,(H2,7,8,9)(H2,10,11,12)/f/h7-8,10-11H"	OGSPWJRAVKPPFI-WMXLOSIUCK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiosteoporotic	0.667	0.002677682	2.572240993	40	Moderate	High	form of drug administered not known			
22569	2569	22569	30_FDAMDD_v3b	C27H44O2	400.63706	defined organic	parent	tested chemical	Alfacalcidol	41294-56-8	single chemical compound	stereochem	"(1S,3R,5E,7Z)-9,10-secocholesta-5,7,10-triene-1,3-diol"	O[C@@H]3C\C(=C\C=C2/CCC[C@@]1(C)[C@H]2CC[C@@H]1[C@H](C)CCCC(C)C)C(=C)[C@@H](O)C3	O[C@@H]3C\C(=C\C=C2/CCC[C@@]1(C)[C@H]2CC[C@@H]1[C@H](C)CCCC(C)C)C(=C)[C@@H](O)C3	"InChI=1/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11-,22-12+/t19-,23-,24-,25+,26+,27-/m1/s1"	OFHCOWSQAMBJIW-GITLSTMWBJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vitamin D source	0.003	7.48807E-06	5.125629865	69	High	High	form of drug administered not known			
22570	2570	22570	31_FDAMDD_v3b	C21H32N6O3	416.51718	defined organic	parent	tested chemical	Alfentanil	71195-58-9	single chemical compound		"N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl]-4-[(methyloxy)methyl]piperidin-4-yl}-N-phenylpropanamide"	N3=NN(CC)C(=O)N3CCN2CCC(COC)(N(C1=CC=CC=C1)C(=O)CC)CC2	N3=NN(CC)C(=O)N3CCN2CCC(COC)(N(C1=CC=CC=C1)C(=O)CC)CC2	"InChI=1/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3"	IDBPHNDTYPBSNI-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	0.245	0.000588211	3.230466835	47	High-Moderate	High	form of drug administered not known			
22571	2571	22571	32_FDAMDD_v3b	C12H13Cl2N3	270.15772	defined organic	parent	tested chemical	Alinidine	33178-86-8	single chemical compound		"N-(2,6-dichlorophenyl)-N-prop-2-en-1-yl-4,5-dihydro-1H-imidazol-2-amine"	C2=CC=C(Cl)C(N(CC=C)C1=NCCN1)=C2Cl	C2=CC=C(Cl)C(N(CC=C)C1=NCCN1)=C2Cl	"InChI=1/C12H13Cl2N3/c1-2-8-17(12-15-6-7-16-12)11-9(13)4-3-5-10(11)14/h2-5H,1,6-8H2,(H,15,16)/f/h15H"	OXTYVEUAQHPPMV-YAQRNVERCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiarrhythmic	1.33	0.00492305	2.307765741	37	Moderate	High	form of drug administered not known			
22572	2572	22572	33_FDAMDD_v3b	C10H12N2O3	208.21388	defined organic	parent	tested chemical	Allobarbital	52-43-7	single chemical compound		"5,5-diprop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione"	O=C1NC(=O)NC(=O)C1(CC=C)CC=C	O=C1NC(=O)NC(=O)C1(CC=C)CC=C	"InChI=1/C10H12N2O3/c1-3-5-10(6-4-2)7(13)11-9(15)12-8(10)14/h3-4H,1-2,5-6H2,(H2,11,12,13,14,15)/f/h11-12H"	FDQGNLOWMMVRQL-WYCIUFAECF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	3.33	0.01599317	1.796065444	31	Moderate	Moderate	form of drug administered not known			
22573	2573	22573	34_FDAMDD_v3b	C5H4N4O	136.1115	defined organic	parent	tested chemical	Allopurinol	315-30-0	single chemical compound	tautomers	"1H-pyrazolo[3,4-d]pyrimidin-4-ol"	N1C=NC2=C(C=1O)C=NN2	N1C=NC2=C(C=1O)C=NN2	"InChI=1/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)/f/h9-10H"	OFCNXPDARWKPPY-XMBMESGPCU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiurolithic	13.3	0.097714007	1.010043179	22	Low	Low	form of drug administered not known			
22574	2574	22574	35_FDAMDD_v3b	C21H32O	300.47818	defined organic	parent	tested chemical	Allylestrenol	432-60-0 	single chemical compound	stereochem	(17beta)-17-prop-2-en-1-ylestr-4-en-17-ol	C=CC[C@]2(O)CC[C@H]3[C@@H]4CC\C1=C\CCC[C@@H]1[C@H]4CC[C@]23C	C=CC[C@]2(O)CC[C@H]3[C@@H]4CC\C1=C\CCC[C@@H]1[C@H]4CC[C@]23C	"InChI=1/C21H32O/c1-3-12-21(22)14-11-19-18-9-8-15-6-4-5-7-16(15)17(18)10-13-20(19,21)2/h3,6,16-19,22H,1,4-5,7-14H2,2H3/t16-,17+,18+,19-,20-,21-/m0/s1"	ATXHVCQZZJYMCF-XUDSTZEEBM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		progestogen	0.25	0.000832007	3.079872931	46	High-Moderate	High	form of drug administered not known			
22575	2575	22575	36_FDAMDD_v3b	C16H23NO2	261.3593	defined organic	parent	tested chemical	Alphaprodine	77-20-3	single chemical compound	stereochem	"(3S,4R)-1,3-dimethyl-4-phenylpiperidin-4-yl propanoate"	O=C(CC)O[C@@]1([C@@]2=CC=CC=C2)[C@@H](C)CN(C)CC1	O=C(CC)O[C@@]1([C@@]2=CC=CC=C2)[C@@H](C)CN(C)CC1	"InChI=1/C16H23NO2/c1-4-15(18)19-16(14-8-6-5-7-9-14)10-11-17(3)12-13(16)2/h5-9,13H,4,10-12H2,1-3H3/t13-,16+/m0/s1"	UVAZQQHAVMNMHE-XJKSGUPXBM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	0.5	0.001913075	2.718267954	42	Moderate	High	form of drug administered not known; structure modified v3b			
22576	2576	22576	37_FDAMDD_v3b	C21H32O3	332.47698	defined organic	parent	tested chemical	Alphaxalone	23930-19-0	single chemical compound	stereochem	"(3alpha,5alpha)-3-hydroxypregnane-11,20-dione"	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@H](O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C	"InChI=1/C21H32O3/c1-12(22)16-6-7-17-15-5-4-13-10-14(23)8-9-20(13,2)19(15)18(24)11-21(16,17)3/h13-17,19,23H,4-11H2,1-3H3/t13-,14+,15-,16+,17-,19+,20-,21+/m0/s1"	DUHUCHOQIDJXAT-OLVMNOGEBO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anesthetic	0.675	0.002030216	2.692457808	41	Moderate	High	form of drug administered not known			
22577	2577	22577	38_FDAMDD_v3b	C17H13ClN4	308.76492	defined organic	parent	tested chemical	Alprazolam	28981-97-7	single chemical compound		"8-chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine"	C1=C(Cl)C=C3C(=C1)N4C(CN=C3C2=CC=CC=C2)=NN=C4C	C1=C(Cl)C=C3C(=C1)N4C(CN=C3C2=CC=CC=C2)=NN=C4C	"InChI=1/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3"	VREFGVBLTWBCJP-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	0.167	0.000540865	3.266911481	48	High-Moderate	High	form of drug administered not known			
22578	2578	22578	39_FDAMDD_v3b	C20H34O5	354.48096	defined organic	parent	tested chemical	Alprostadil	745-65-3	single chemical compound	stereochem	"(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid"	O[C@@H]1CC(=O)[C@H](CCCCCCC(O)=O)[C@H]1/C=C/[C@@H](O)CCCCC	O[C@@H]1CC(=O)[C@H](CCCCCCC(O)=O)[C@H]1/C=C/[C@@H](O)CCCCC	"InChI=1/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1/f/h24H"	GMVPRGQOIOIIMI-IJVTXSQGDV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vasodilator	0.0001	2.82103E-07	6.549592913	84	High	High	form of drug administered not known			
22579	2579	22579	40_FDAMDD_v3b	C9H18N6	210.2794	defined organic	parent	tested chemical	Altretamine	645-05-6	single chemical compound		"N,N,N',N',N'',N''-hexamethyl-1,3,5-triazine-2,4,6-triamine"	N1=C(N(C)C)N=C(N(C)C)N=C1N(C)C	N1=C(N(C)C)N=C(N(C)C)N=C1N(C)C	InChI=1/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3	UUVWYPNAQBNQJQ-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	5.41	0.025727675	1.589599464	29	Low-Moderate	Low	form of drug administered not known			
22580	2117	22117	41_FDAMDD_v3b	C10H17N	151.251	defined organic	parent	tested chemical	Amantadine	768-94-5	single chemical compound		adamantan-1-amine	NC13CC(CC(C3)C2)CC2C1	NC13CC(CC(C3)C2)CC2C1	"InChI=1/C10H17N/c11-10-4-7-1-8(5-10)3-9(2-7)6-10/h7-9H,1-6,11H2"	DKNWSYNQZKUICI-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiviral; antiparkinsonian	6.67	0.044098882	1.355572421	26	Low-Moderate	Low	form of drug administered not known			
22581	2581	22581	42_FDAMDD_v3b	C8H11N7S	237.28484	defined organic	parent	tested chemical	Ambazone	539-21-9	single chemical compound	stereochem	"(2E)-2-{(4E)-4-[(aminocarbonothioyl)hydrazono]cyclohexa-2,5-dien-1-ylidene}hydrazinecarboximidamide"	C1C(=NNC(N)=N)C=CC(=NNC(N)=S)C=1	C1C(=NNC(N)=N)C=CC(=NNC(N)=S)C=1	"InChI=1/C8H11N7S/c9-7(10)14-12-5-1-3-6(4-2-5)13-15-8(11)16/h1-4H,(H4,9,10,14)(H3,11,15,16)/b12-5-,13-6+/f/h9,14-15H,10-11H2/b9-7?,12-5-,13-6+"	MLMFUKWWZIZRHX-KOKNFSNADS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	0.167	0.000703795	3.152553521	46	High-Moderate	High	form of drug administered not known			
22582	2582	22582	43_FDAMDD_v3b	C28H42Cl4N4O2	608.47068	defined organic	salt 2Cl	tested chemical	Ambenonium chloride	115-79-7	single chemical compound	ammonium	"2,2'-[(1,2-dioxoethane-1,2-diyl)diimino]bis{N-[(2-chlorophenyl)methyl]-N,N-diethylethanaminium} dichloride"	[Cl-].[Cl-].Clc2ccccc2C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](Cc1ccccc1Cl)(CC)CC	Clc2ccccc2C[N+](CC)(CC)CCNC(=O)C(=O)NCC[N+](Cc1ccccc1Cl)(CC)CC	"InChI=1/C28H40Cl2N4O2.2ClH/c1-5-33(6-2,21-23-13-9-11-15-25(23)29)19-17-31-27(35)28(36)32-18-20-34(7-3,8-4)22-24-14-10-12-16-26(24)30;;/h9-16H,5-8,17-22H2,1-4H3;2*1H/fC28H42Cl2N4O2.2Cl/h31-32H;2*1h/q+2;2*-1"	DXUUXWKFVDVHIK-ZVSBXUMXCY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cholinesterase inhibitor	1.67	0.002744586	2.561523185	40	Moderate	High	form of drug administered not known			
22583	2583	22583	44_FDAMDD_v3b	C13H18Br2N2O	378.10282	defined organic	parent	tested chemical	Ambroxol	18683-91-5	single chemical compound	stereochem	"trans-4-{[(2-amino-3,5-dibromophenyl)methyl]amino}cyclohexanol"	O[C@@H]2CC[C@@H](NCc1cc(Br)cc(Br)c1N)CC2	O[C@@H]2CC[C@@H](NCc1cc(Br)cc(Br)c1N)CC2	"InChI=1/C13H18Br2N2O/c14-9-5-8(13(16)12(15)6-9)7-17-10-1-3-11(18)4-2-10/h5-6,10-11,17-18H,1-4,7,16H2/t10-,11-"	JBDGDEWWOUBZPM-XYPYZODXBS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		expectorant	2	0.005289566	2.276579921	37	Moderate	High	form of drug administered not known			
22584	2584	22584	45_FDAMDD_v3b	C15H23N3O3S	325.42642	defined organic	parent	tested chemical	Amdinocillin	32887-01-7	single chemical compound	stereochem	"(2S,5R,6R)-6-{[(1E)-azepan-1-ylmethylidene]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	O=C(O)[C@@H]2N3C(=O)[C@@H](/N=C/N1CCCCCC1)[C@H]3SC2(C)C	O=C(O)[C@@H]2N3C(=O)[C@@H](/N=C/N1CCCCCC1)[C@H]3SC2(C)C	"InChI=1/C15H23N3O3S/c1-15(2)11(14(20)21)18-12(19)10(13(18)22-15)16-9-17-7-5-3-4-6-8-17/h9-11,13H,3-8H2,1-2H3,(H,20,21)/b16-9+/t10-,11+,13-/m1/s1/f/h20H"	BWWVAEOLVKTZFQ-QZPBSIJIDZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	15	0.046093369	1.33636155	26	Low-Moderate	Low	form of drug administered not known			
22585	2585	22585	46_FDAMDD_v3b	C5H15N2O3PS	214.222961	defined organic	parent	tested chemical	Amifostine	20537-88-6	single chemical compound	stereochem	S-{2-[(3-aminopropyl)amino]ethyl} dihydrogen thiophosphate	P(O)(=O)(O)SCCNCCCN	P(O)(=O)(O)SCCNCCCN	"InChI=1/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10)/f/h8-9H"	JKOQGQFVAUAYPM-DEPUQRHOCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		mucolytic	24.6	0.114833629	0.939930911	22	Low	Low	form of drug administered not known			
22586	2586	22586	47_FDAMDD_v3b	C22H43N5O13	585.60252	defined organic	parent	tested chemical	Amikacin	37517-28-5	single chemical compound	stereochem	"(2S)-4-amino-N-{(1R,2S,3S,4R,5S)-5-amino-2-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-4-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-3-hydroxycyclohexyl}-2-hydroxybutanamide"	NCC[C@H](O)C(=O)N[C@@H]3C[C@H](N)[C@@H](O[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H]3O[C@H]2O[C@H](CO)[C@@H](O)[C@H](N)[C@H]2O	NCC[C@H](O)C(=O)N[C@@H]3C[C@H](N)[C@@H](O[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O)[C@H](O)[C@H]3O[C@H]2O[C@H](CO)[C@@H](O)[C@H](N)[C@H]2O	"InChI=1/C22H43N5O13/c23-2-1-8(29)20(36)27-7-3-6(25)18(39-22-16(34)15(33)13(31)9(4-24)37-22)17(35)19(7)40-21-14(32)11(26)12(30)10(5-28)38-21/h6-19,21-22,28-35H,1-5,23-26H2,(H,27,36)/t6-,7+,8-,9+,10+,11-,12+,13+,14+,15-,16+,17-,18+,19-,21+,22+/m0/s1/f/h27H"	LKCWBDHBTVXHDL-VLZSSAFWDT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	15	0.025614644	1.591511678	29	Low-Moderate	Low	form of drug administered not known			
22587	70	20070	48_FDAMDD_v3b	C6H13NO2	131.1742	defined organic	parent	tested chemical	Aminocaproic acid	60-32-2	single chemical compound		6-aminohexanoic acid	OC(=O)CCCCCN	OC(=O)CCCCCN	"InChI=1/C6H13NO2/c7-5-3-1-2-4-6(8)9/h1-5,7H2,(H,8,9)/f/h8H"	SLXKOJJOQWFEFD-FZOZFQFYCD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		hemostatic	200	1.524690069	-0.183181571	9	Low	Low	form of drug administered not known			
22588	2588	22588	49_FDAMDD_v3b	C19H20N8O5	440.4127	defined organic	parent	tested chemical	"Aminofolic acid, 4-"	54-62-6	single chemical compound		"N-[(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}phenyl)carbonyl]glutamic acid"	C3=C(C(=O)NC(CCC(O)=O)C(O)=O)C=CC(NCC1=NC2C(N=C1)=NC(N)=NC=2N)=C3	C3=C(C(=O)NC(CCC(O)=O)C(O)=O)C=CC(NCC1=NC2C(N=C1)=NC(N)=NC=2N)=C3	"InChI=1/C19H20N8O5/c20-15-14-16(27-19(21)26-15)23-8-11(24-14)7-22-10-3-1-9(2-4-10)17(30)25-12(18(31)32)5-6-13(28)29/h1-4,8,12,22H,5-7H2,(H,25,30)(H,28,29)(H,31,32)(H4,20,21,23,26,27)/f/h25,28,31H,20-21H2"	TVZGACDUOSZQKY-PXIYXWEJCU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		rodenticide	0.00833	1.89141E-05	4.723214833	64	High	High	form of drug administered not known			
22589	2589	22589	50_FDAMDD_v3b	C13H16N2O2	232.27834	defined organic	parent	tested chemical	Aminoglutethimide	125-84-8	single chemical compound		"3-(4-aminophenyl)-3-ethylpiperidine-2,6-dione"	N2C(=O)CCC(C1=CC=C(N)C=C1)(CC)C2=O	N2C(=O)CCC(C1=CC=C(N)C=C1)(CC)C2=O	"InChI=1/C13H16N2O2/c1-2-13(8-7-11(16)15-12(13)17)9-3-5-10(14)6-4-9/h3-6H,2,7-8,14H2,1H3,(H,15,16,17)/f/h15H"	ROBVIMPUHSLWNV-YAQRNVERCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	16.7	0.071896501	1.143292242	24	Low	Low	form of drug administered not known			
22590	2590	22590	51_FDAMDD_v3b	C9H10N2O3	194.1873	defined organic	parent	tested chemical	Aminohippuric acid	61-78-9	single chemical compound		N-[(4-aminophenyl)carbonyl]glycine	C1=C(N)C=CC(C(=O)NCC(O)=O)=C1	C1=C(N)C=CC(C(=O)NCC(O)=O)=C1	"InChI=1/C9H10N2O3/c10-7-3-1-6(2-4-7)9(14)11-5-8(12)13/h1-4H,5,10H2,(H,11,14)(H,12,13)/f/h11-12H"	HSMNQINEKMPTIC-WYCIUFAECJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory; antifungal	10	0.051496674	1.288220823	26	Low-Moderate	Low	form of drug administered not known			
22591	2591	22591	52_FDAMDD_v3b	C7H7NO3	153.13538	defined organic	parent	tested chemical	Aminosalicylic acid	65-49-6	single chemical compound		4-amino-2-hydroxybenzoic acid	C1=C(N)C=C(O)C(C(O)=O)=C1	C1=C(N)C=C(O)C(C(O)=O)=C1	"InChI=1/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)/f/h10H"	WUBBRNOQWQTFEX-KZFATGLACO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	200	1.306033916	-0.115954455	10	Low	Low	form of drug administered not known			
22592	2592	22592	53_FDAMDD_v3b	C25H29I2NO3	645.3116	defined organic	parent	tested chemical	Amiodarone	1951-25-3	single chemical compound		"(2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone"	C1=CC=C3C(=C1)OC(CCCC)=C3C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2	C1=CC=C3C(=C1)OC(CCCC)=C3C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2	"InChI=1/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3"	IYIKLHRQXLHMJQ-UHFFFAOYAO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiarrhythmic; antianginal	26.7	0.04137536	1.383258211	27	Low-Moderate	Low	form of drug administered not known			
22593	2593	22593	54_FDAMDD_v3b	C10H12N4OS	236.29348	defined organic	parent	tested chemical	Amithiozone	104-06-3	single chemical compound	stereochem	N-(4-{(E)-[(aminocarbonothioyl)hydrazono]methyl}phenyl)acetamide	C1=C(NC(C)=O)C=CC(C=NNC(N)=S)=C1	C1=C(NC(C)=O)C=CC(C=NNC(N)=S)=C1	"InChI=1/C10H12N4OS/c1-7(15)13-9-4-2-8(3-5-9)6-12-14-10(11)16/h2-6H,1H3,(H,13,15)(H3,11,14,16)/b12-6+/f/h13-14H,11H2"	SRVJKTDHMYAMHA-QPXNDVMFDX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	2.5	0.010580063	1.97551173	33	Moderate	High-Moderate	form of drug administered not known			
22594	2594	22594	55_FDAMDD_v3b	C20H23N	277.40332	defined organic	parent	tested chemical	Amitriptyline	50-48-6	single chemical compound		"3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine"	C1=CC=C2C(=C1)CCC3=C(C2=CCCN(C)C)C=CC=C3	C1=CC=C2C(=C1)CCC3=C(C2=CCCN(C)C)C=CC=C3	"InChI=1/C20H23N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-12H,7,13-15H2,1-2H3"	KRMDCWKBEZIMAB-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	5	0.018024298	1.74414165	31	Moderate	Low	form of drug administered not known			
22595	2595	22595	56_FDAMDD_v3b	C16H14N2O4	298.29336	defined organic	parent	tested chemical	Amlenanox	68302-57-8	single chemical compound		"2-amino-7-(1-methylethyl)-5-oxo-5H-chromeno[2,3-b]pyridine-3-carboxylic acid"	C1=C(C(C)C)C=C2C(=C1)OC3=C(C2=O)C=C(C(=O)O)C(N)=N3	C1=C(C(C)C)C=C2C(=C1)OC3=C(C2=O)C=C(C(=O)O)C(N)=N3	"InChI=1/C16H14N2O4/c1-7(2)8-3-4-12-9(5-8)13(19)10-6-11(16(20)21)14(17)18-15(10)22-12/h3-7H,1-2H3,(H2,17,18)(H,20,21)/f/h20H,17H2"	SGRYPYWGNKJSDL-XFDRBGHPCI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiallergic; antiasthmatic	2.5	0.008381011	2.076703577	34	Moderate	High-Moderate	form of drug administered not known			
22596	2596	22596	57_FDAMDD_v3b	C20H25ClN2O5	408.8759	defined organic	parent	tested chemical	Amlodipine	88150-42-9	single chemical compound		"3-ethyl 5-methyl 2-{[(2-aminoethyl)oxy]methyl}-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate"	C2=C(Cl)C(C1C(C(=O)OC)=C(C)NC(COCCN)=C1C(=O)OCC)=CC=C2	C2=C(Cl)C(C1C(C(=O)OC)=C(C)NC(COCCN)=C1C(=O)OCC)=CC=C2	"InChI=1/C20H25ClN2O5/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21/h5-8,17,23H,4,9-11,22H2,1-3H3"	HTIQEAQVCYTUBX-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antianginal; antihypertensive	0.167	0.000408437	3.388875042	49	High-Moderate	High	form of drug administered not known			
22597	2597	22597	58_FDAMDD_v3b	C20H22ClN3O	355.86118	defined organic	parent	tested chemical	Amodiaquine	86-42-0	single chemical compound		4-[(7-chloroquinolin-4-yl)amino]-2-[(diethylamino)methyl]phenol	C1(Cl)=CC=C3C(=C1)N=CC=C3NC2=CC(CN(CC)CC)=C(O)C=C2	C1(Cl)=CC=C3C(=C1)N=CC=C3NC2=CC(CN(CC)CC)=C(O)C=C2	"InChI=1/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)/f/h23H"	OVCDSSHSILBFBN-MPIMZMORCM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimalarial	3.33	0.009357582	2.028836381	34	Moderate	Moderate	form of drug administered not known			
22598	2598	22598	59_FDAMDD_v3b	C17H16ClN3O	313.78144	defined organic	parent	tested chemical	Amoxapine	14028-44-5	single chemical compound		"2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine"	C1=C(Cl)C=C3C(=C1)OC4=C(N=C3N2CCNCC2)C=CC=C4	C1=C(Cl)C=C3C(=C1)OC4=C(N=C3N2CCNCC2)C=CC=C4	"InChI=1/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2"	QWGDMFLQWFTERH-UHFFFAOYAA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	10	0.031869316	1.496627252	28	Low-Moderate	Low	form of drug administered not known			
22599	2599	22599	60_FDAMDD_v3b	C16H25N3O8S	419.45	defined organic	complex 3H2O	tested chemical	Amoxicillin	61336-70-7	single chemical compound	"stereochem, parent [26787-78-0]"	"(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate"	[H][C@@]12[C@]([H])(NC([C@H](N)C3=CC=C(O)C=C3)=O)C(N1[C@@H]([C@@](O)=O)C(C)(C)S2)=O.O.O.O	[H][C@@]12[C@]([H])(NC([C@H](N)C3=CC=C(O)C=C3)=O)C(N1[C@@H]([C@@](O)=O)C(C)(C)S2)=O	"InChI=1/C16H19N3O5S.3H2O/c1-16(2)11(15(23)24)19-13(22)10(14(19)25-16)18-12(21)9(17)7-3-5-8(20)6-4-7;;;/h3-6,9-11,14,20H,17H2,1-2H3,(H,18,21)(H,23,24);3*1H2/t9-,10-,11+,14-;;;/m1.../s1/f/h18,23H;;;"	MQXQVCLAUDMCEF-TZNLBGPWDT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	25	0.05960186	1.22474019	25	Low-Moderate	Low	form of drug administered not known; structure modified v3b			
22600	2600	22600	61_FDAMDD_v3b	C9H13N	135.20622	defined organic	parent	tested chemical	Amphetamine	300-62-9	single chemical compound		1-phenylpropan-2-amine	C1=CC=CC(CC(N)C)=C1	C1=CC=CC(CC(N)C)=C1	"InChI=1/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3"	KWTSXDURSIMDCE-UHFFFAOYAO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		CNS stimulant; anorexic	1	0.007396109	2.130996671	35	Moderate	High	form of drug administered not known			
22601	2601	22601	62_FDAMDD_v3b	C47H73NO17	924.079	defined organic	parent	tested chemical	Amphotericin B	1397-89-3	single chemical compound	stereochem	"(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36R,37S)-33-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid"	O[C@H]3[C@@H](N)[C@H](O)[C@@H](C)O[C@H]3O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(O)=O)[C@H](C1)O2	O[C@H]3[C@@H](N)[C@H](O)[C@@H](C)O[C@H]3O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(O)=O)[C@H](C1)O2	"InChI=1/C47H73NO17/c1-27-17-15-13-11-9-7-5-6-8-10-12-14-16-18-34(64-46-44(58)41(48)43(57)30(4)63-46)24-38-40(45(59)60)37(54)26-47(61,65-38)25-33(51)22-36(53)35(52)20-19-31(49)21-32(50)23-39(55)62-29(3)28(2)42(27)56/h5-18,27-38,40-44,46,49-54,56-58,61H,19-26,48H2,1-4H3,(H,59,60)/b6-5+,9-7+,10-8+,13-11+,14-12+,17-15+,18-16+/t27-,28-,29-,30+,31+,32+,33-,34-,35+,36+,37-,38-,40+,41-,42+,43+,44-,46-,47+/m0/s1/f/h59H"	APKFDSVGJQXUKY-YQFBPWLTDP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antifungal	1.5	0.001623238	2.789617842	42	Moderate	High	form of drug administered not known			
22602	2602	22602	63_FDAMDD_v3b	C16H19N3O4S	349.40476	defined organic	parent	tested chemical	Ampicillin	69-53-4	single chemical compound	stereochem	"(2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	O=C(O)[C@@H]2N3C(=O)[C@@H](NC(=O)[C@H](N)c1ccccc1)[C@H]3SC2(C)C	O=C(O)[C@@H]2N3C(=O)[C@@H](NC(=O)[C@H](N)c1ccccc1)[C@H]3SC2(C)C	"InChI=1/C16H19N3O4S/c1-16(2)11(15(22)23)19-13(21)10(14(19)24-16)18-12(20)9(17)8-6-4-3-5-7-8/h3-7,9-11,14H,17H2,1-2H3,(H,18,20)(H,22,23)/t9-,10-,11+,14-/m1/s1/f/h18,22H"	AVKUERGKIZMTKX-KXDAXDHGDU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	58.3	0.166855197	0.777660262	20	Low	Low	form of drug administered not known			
22603	2603	22603	64_FDAMDD_v3b	C10H9N3O	187.19796	defined organic	parent	tested chemical	Amrinone	60719-84-8	single chemical compound		"5-amino-3,4'-bipyridin-6(1H)-one"	C2(N)C(=O)NC=C(C1=CC=NC=C1)C=2	C2(N)C(=O)NC=C(C1=CC=NC=C1)C=2	"InChI=1/C10H9N3O/c11-9-5-8(6-13-10(9)14)7-1-3-12-4-2-7/h1-6H,11H2,(H,13,14)/f/h13H"	RNLQIBCLLYYYFJ-NDKGDYFDCE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cardiotonic	0.75	0.004006454	2.397239848	38	Moderate	High	form of drug administered not known			
22604	2604	22604	65_FDAMDD_v3b	C21H19N3O3S	393.4589	defined organic	parent	tested chemical	"AMSA, M-"	51264-14-3	single chemical compound		N-[4-(acridin-9-ylamino)-3-(methyloxy)phenyl]methanesulfonamide	C4=C(OC)C(NC1C3C(N=C2C=1C=CC=C2)=CC=CC=3)=CC=C4NS(=O)(=O)C	C4=C(OC)C(NC1C3C(N=C2C=1C=CC=C2)=CC=CC=3)=CC=C4NS(=O)(=O)C	"InChI=1/C21H19N3O3S/c1-27-20-13-14(24-28(2,25)26)11-12-19(20)23-21-15-7-3-5-9-17(15)22-18-10-6-4-8-16(18)21/h3-13,24H,1-2H3,(H,22,23)/f/h23H"	XCPGHVQEEXUHNC-MPIMZMORCD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	3.24	0.008234659	2.084354363	34	Moderate	Moderate	form of drug administered not known			
22605	2605	25455	66_FDAMDD_v3b	C5H11NO2	117.1463	defined organic	parent	tested chemical	Amyl nitrite I	110-46-3	single chemical compound		3-methylbutyl nitrite	CC(C)CCON=O	CC(C)CCON=O	"InChI=1/C5H11NO2/c1-5(2)3-4-8-6-7/h5H,3-4H2,1-2H3"	OWFXIOWLTKNBAP-UHFFFAOYAO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	5	0.042681672	1.369758572	26	Low-Moderate	Low	form of drug administered not known			
22606	2606	22606	67_FDAMDD_v3b	C5H11NO2	117.14634	defined organic	parent	representative isomer in mixture	Amyl nitrite II	8017-89-8	mixture or formulation	mixture of isomers; 2-methylbutyl nitrite shown	2-methylbutyl nitrite	CCC(C)CON=O	CCC(C)CON=O	"InChI=1/C5H11NO2/c1-3-5(2)4-8-6-7/h5H,3-4H2,1-2H3"	SPPJRKXICASMOA-UHFFFAOYAK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	5	0.042681658	1.36975872	26	Low-Moderate	Low	form of drug administered not known			
22607	2607	22607	68_FDAMDD_v3b	C17H19N5	293.36626	defined organic	parent	tested chemical	Anastrozole	120511-73-1	single chemical compound		"2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)benzene-1,3-diyl]bis(2-methylpropanenitrile)"	C2=C(C(C)(C)C#N)C=C(C(C)(C)C#N)C=C2CN1N=CN=C1	C2=C(C(C)(C)C#N)C=C(C(C)(C)C#N)C=C2CN1N=CN=C1	"InChI=1/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3"	YBBLVLTVTVSKRW-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		androgen	0.0167	5.69254E-05	4.244693693	59	High	High	form of drug administered not known			
22608	357	20357	69_FDAMDD_v3b	C9H11N3O4	225.2013	defined organic	parent	tested chemical	Ancitabine	31698-14-3	single chemical compound	stereochem	"(2R,3R,3aS,9aR)-2-(hydroxymethyl)-6-imino-2,3,3a,9a-tetrahydro-6H-furo[2',3':4,5][1,3]oxazolo[3,2-a]pyrimidin-3-ol"	N=C\2/N=C3/O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N3/C=C/2	N=C\2/N=C3/O[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N3/C=C/2	"InChI=1/C9H11N3O4/c10-5-1-2-12-8-7(16-9(12)11-5)6(14)4(3-13)15-8/h1-2,4,6-8,10,13-14H,3H2/t4-,6-,7+,8-/m1/s1"	BBDAGFIXKZCXAH-CCXZUQQUBM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	20	0.088809434	1.051540898	23	Low	Low	form of drug administered not known			
22609	2609	22609	70_FDAMDD_v3b	C19H30O2	290.4403	defined organic	parent	tested chemical	Androstenediol	521-17-5	single chemical compound	stereochem	"(3beta,17beta)-androst-5-ene-3,17-diol"	O[C@@H]3C\C4=C\C[C@@H]1[C@H](CC[C@]2(C)[C@@H](O)CC[C@@H]12)[C@@]4(C)CC3	O[C@@H]3C\C4=C\C[C@@H]1[C@H](CC[C@]2(C)[C@@H](O)CC[C@@H]12)[C@@]4(C)CC3	"InChI=1/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-17,20-21H,4-11H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1"	QADHLRWLCPCEKT-LOVVWNRFBV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anabolic	2.5	0.008607621	2.065116868	34	Moderate	High-Moderate	form of drug administered not known			
22610	2610	22610	71_FDAMDD_v3b	C22H28N2O2	352.46992	defined organic	parent	tested chemical	Anileridine	144-14-9	single chemical compound		ethyl 1-[2-(4-aminophenyl)ethyl]-4-phenylpiperidine-4-carboxylate	C3=CC=C(C2(C(=O)OCC)CCN(CCC1=CC=C(N)C=C1)CC2)C=C3	C3=CC=C(C2(C(=O)OCC)CCN(CCC1=CC=C(N)C=C1)CC2)C=C3	"InChI=1/C22H28N2O2/c1-2-26-21(25)22(19-6-4-3-5-7-19)13-16-24(17-14-22)15-12-18-8-10-20(23)11-9-18/h3-11H,2,12-17,23H2,1H3"	LKYQLAWMNBFNJT-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	3.33	0.009447615	2.024677826	34	Moderate	Moderate	form of drug administered not known			
22611	2611	22611	72_FDAMDD_v3b	C16H12O3	252.26468	defined organic	parent	tested chemical	Anisindione	117-37-3	single chemical compound		"2-[4-(methyloxy)phenyl]-1H-indene-1,3(2H)-dione"	C1=CC=C3C(=C1)C(=O)C(C2=CC=C(OC)C=C2)C3=O	C1=CC=C3C(=C1)C(=O)C(C2=CC=C(OC)C=C2)C3=O	"InChI=1/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3"	XRCFXMGQEVUZFC-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticoagulant	5	0.019820452	1.702886444	30	Moderate	Low	form of drug administered not known			
22612	2612	22612	73_FDAMDD_v3b	C17H32BrNO2	362.34548	defined organic	salt Br	tested chemical	Anisotropine methylbromide	80-50-2	single chemical compound	ammonium; stereochem	"(3-endo)-8,8-dimethyl-3-[(2-propylpentanoyl)oxy]-8-azoniabicyclo[3.2.1]octane bromide"	O=C(C(CCC)CCC)O[C@@H]1C[C@@H](CC2)[N@+](C)(C)[C@H]2C1.[Br-]	O=C(C(CCC)CCC)O[C@@H]1C[C@@H](CC2)[N@+](C)(C)[C@H]2C1	"InChI=1/C17H32NO2.BrH/c1-5-7-13(8-6-2)17(19)20-16-11-14-9-10-15(12-16)18(14,3)4;/h13-16H,5-12H2,1-4H3;1H/q+1;/p-1/t14-,15-;/m1./s1/fC17H32NO2.Br/h;1h/qm;-1"	QSFKGMJOKUZAJM-PONBPAILDH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	2.5	0.006899493	2.16118284	35	Moderate	High-Moderate	form of drug administered not known			
22613	2613	22613	74_FDAMDD_v3b	C17H19N3	265.35286	defined organic	parent	tested chemical	Antazoline	91-75-8	single chemical compound		"N-(4,5-dihydro-1H-imidazol-2-ylmethyl)-N-(phenylmethyl)aniline"	C3=CC=CC(CN(CC1NCCN=1)C2=CC=CC=C2)=C3	C3=CC=CC(CN(CC1NCCN=1)C2=CC=CC=C2)=C3	"InChI=1/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19)/f/h18H"	REYFJDPCWQRWAA-GPQMBLKYCE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	5	0.018842834	1.724853769	30	Moderate	Low	form of drug administered not known			
22614	2614	22614	75_FDAMDD_v3b	C17H17NO2	267.32238	defined organic	parent	tested chemical	Apomorphine	58-00-4	single chemical compound	stereochem	"(6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol"	OC1=C(O)C=CC2=C1C4=C3[C@@](N(C)CCC3=CC=C4)([H])C2	OC1=C(O)C=CC2=C1C4=C3[C@@](N(C)CCC3=CC=C4)([H])C2	"InChI=1/C17H17NO2/c1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12/h2-6,13,19-20H,7-9H2,1H3/t13-/m1/s1"	VMWNQDUVQKEIOC-CYBMUJFWBH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		emetic	1.67	0.006247139	2.204318848	36	Moderate	High	form of drug administered not known; structure modified v3b			
22615	2615	22615	76_FDAMDD_v3b	C22H30N2	322.487	defined organic	parent	tested chemical	Aprindine	37640-71-4	single chemical compound		"N-(2,3-dihydro-1H-inden-2-yl)-N',N'-diethyl-N-phenylpropane-1,3-diamine"	C1=CC=C3C(=C1)CC(N(CCCN(CC)CC)C2=CC=CC=C2)C3	C1=CC=C3C(=C1)CC(N(CCCN(CC)CC)C2=CC=CC=C2)C3	"InChI=1/C22H30N2/c1-3-23(4-2)15-10-16-24(21-13-6-5-7-14-21)22-17-19-11-8-9-12-20(19)18-22/h5-9,11-14,22H,3-4,10,15-18H2,1-2H3"	NZLBHDRPUJLHCE-UHFFFAOYAO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiarrhythmic	5	0.015504501	1.809542208	31	Moderate	Low	form of drug administered not known			
22616	2616	22616	77_FDAMDD_v3b	C10H14N2O3	210.22976	defined organic	parent	tested chemical	Aprobarbital	77-02-1	single chemical compound		"5-(1-methylethyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione"	N1C(=O)NC(=O)C(CC=C)(C(C)C)C1=O	N1C(=O)NC(=O)C(CC=C)(C(C)C)C1=O	"InChI=1/C10H14N2O3/c1-4-5-10(6(2)3)7(13)11-9(15)12-8(10)14/h4,6H,1,5H2,2-3H3,(H2,11,12,13,14,15)/f/h11-12H"	UORJNBVJVRLXMQ-WYCIUFAECI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	2.67	0.01270039	1.896182933	32	Moderate	High-Moderate	form of drug administered not known			
22617	2617	22617	78_FDAMDD_v3b	C8H13NO2	155.19432	defined organic	parent	tested chemical	Arecoline	63-75-2	single chemical compound		"methyl 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxylate"	C1CC=C(C(=O)OC)CN1C	C1CC=C(C(=O)OC)CN1C	"InChI=1/C8H13NO2/c1-9-5-3-4-7(6-9)8(10)11-2/h4H,3,5-6H2,1-2H3"	HJJPJSXJAXAIPN-UHFFFAOYAX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anthelmintic	0.0333	0.00021457	3.668431589	52	High	High	form of drug administered not known			
22618	2618	22618	79_FDAMDD_v3b	C6H14N4O2	174.20096	defined organic	parent	tested chemical	Arginine	7200-25-1	single chemical compound		arginine	NC(=N)NCCCC(N)C(O)=O	NC(=N)NCCCC(N)C(O)=O	"InChI=1/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/f/h8,10-11H,9H2"	ODKSFYDXXFIFQN-MYOKTFMPCK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		ammonia detoxicant; diagnostic aid	500	2.870248247	-0.45791946	6	Low	Low	form of drug administered not known			
22619	2619	22619	80_FDAMDD_v3b	C15H21N3O2S3	371.54114	defined organic	parent	tested chemical	Arotinolol	68377-92-4	single chemical compound		"5-[2-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}thio)-1,3-thiazol-4-yl]thiophene-2-carboxamide"	C2C=C(C1=CSC(SCC(O)CNC(C)(C)C)=N1)SC=2C(=O)N	C2C=C(C1=CSC(SCC(O)CNC(C)(C)C)=N1)SC=2C(=O)N	"InChI=1/C15H21N3O2S3/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20)/f/h16H2"	BHIAIPWSVYSKJS-ZHLVXTBQCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal; antiarrhythmic	0.333	0.000896267	3.047562676	45	High-Moderate	High	form of drug administered not known			
22620	106	20106	81_FDAMDD_v3b	C6H8O6	176.1241	defined organic	parent	tested chemical	Ascorbic acid	50-81-7	single chemical compound	stereochem; tautomers	L-ascorbic acid	OC=1[C@H](OC(=O)C=1O)[C@@H](O)CO	OC=1[C@H](OC(=O)C=1O)[C@@H](O)CO	"InChI=1/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1"	CIWBSHSKHKDKBQ-JLAZNSOCBT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vitamin C deficiency	100	0.567781468	0.245818787	14	Low	Low	form of drug administered not known			
22621	2621	22621	82_FDAMDD_v3b	C4H7NO4	133.1027	defined organic	parent	tested chemical	"Aspartic acid, L-"	56-84-8	single chemical compound	stereochem	L-aspartic acid	OC(C[C@@H](C(O)=O)N)=O	OC(C[C@@H](C(O)=O)N)=O	"InChI=1/C4H7NO4/c5-2(4(8)9)1-3(6)7/h2H,1,5H2,(H,6,7)(H,8,9)/t2-/m0/s1/f/h6,8H"	CKLJMWTZIZZHCS-WHFJSZMODF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		roborant	100	0.75129956	0.124186865	13	Low	Low	form of drug administered not known; structure modified v3b			
22622	108	20108	83_FDAMDD_v3b	C9H8O4	180.1574	defined organic	parent	tested chemical	Aspirin	50-78-2	single chemical compound		2-(acetyloxy)benzoic acid	OC(=O)C1=C(C=CC=C1)OC(=O)C	OC(=O)C1=C(C=CC=C1)OC(=O)C	"InChI=1/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)/f/h11H"	BSYNRYMUTXBXSQ-WXRBYKJCCW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; antipyretic; anti inflammatory	66.7	0.370231808	0.431526272	16	Low	Low	form of drug administered not known			
22623	110	20110	84_FDAMDD_v3b	C28H31FN4O	458.5703	defined organic	parent	tested chemical	Astemizole	68844-77-9	single chemical compound		1-[(4-fluorophenyl)methyl]-N-(1-{2-[4-(methyloxy)phenyl]ethyl}piperidin-4-yl)-1H-benzimidazol-2-amine	C1=CC=C5C(=C1)N(CC2=CC=C(F)C=C2)C(NC4CCN(CCC3=CC=C(OC)C=C3)CC4)=N5	C1=CC=C5C(=C1)N(CC2=CC=C(F)C=C2)C(NC4CCN(CCC3=CC=C(OC)C=C3)CC4)=N5	"InChI=1/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31)/f/h30H"	GXDALQBWZGODGZ-SREBMQDQCD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiallergic; antiarrhythmic	0.167	0.000364175	3.438689452	50	High	High	form of drug administered not known			
22624	2624	22624	85_FDAMDD_v3b	C17H35N5O6	405.4897	defined organic	parent	tested chemical	Astromicin A	55779-06-1	single chemical compound	stereochem	"(1R,2S,3S,4R,5S,6R)-2-amino-5-[glycyl(methyl)amino]-3,6-dihydroxy-4-(methyloxy)cyclohexyl 2,6-diamino-2,3,4,6,7-pentadeoxy-beta-L-lyxo-heptopyranoside"	N[C@@H]2CC[C@H](O[C@@H]2O[C@@H]1[C@@H](N)[C@H](O)[C@H](OC)[C@@H](N(C)C(=O)CN)[C@H]1O)[C@@H](N)C	N[C@@H]2CC[C@H](O[C@@H]2O[C@@H]1[C@@H](N)[C@H](O)[C@H](OC)[C@@H](N(C)C(=O)CN)[C@H]1O)[C@@H](N)C	"InChI=1/C17H35N5O6/c1-7(19)9-5-4-8(20)17(27-9)28-15-11(21)13(24)16(26-3)12(14(15)25)22(2)10(23)6-18/h7-9,11-17,24-25H,4-6,18-21H2,1-3H3/t7-,8+,9-,11-,12-,13-,14+,15+,16+,17+/m0/s1"	BIDUPMYXGFNAEJ-APGVDKLIBJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Astromicin	antibacterial	6.67	0.016449246	1.783853993	31	Moderate	Low	form of drug administered not known			
22625	2625	22625	86_FDAMDD_v3b	C15H32N4O5	348.43838	defined organic	parent	tested chemical	Astromicin B	54783-95-8	single chemical compound	stereochem	"(1R,2S,3S,4R,5S,6R)-2-amino-3,6-dihydroxy-5-(methylamino)-4-(methyloxy)cyclohexyl 2,6-diamino-2,3,4,6,7-pentadeoxy-beta-L-lyxo-heptopyranoside"	N[C@@H]2CC[C@H](O[C@@H]2O[C@@H]1[C@@H](N)[C@H](O)[C@H](OC)[C@@H](NC)[C@H]1O)[C@@H](N)C	N[C@@H]2CC[C@H](O[C@@H]2O[C@@H]1[C@@H](N)[C@H](O)[C@H](OC)[C@@H](NC)[C@H]1O)[C@@H](N)C	"InChI=1/C15H32N4O5/c1-6(16)8-5-4-7(17)15(23-8)24-13-9(18)11(20)14(22-3)10(19-2)12(13)21/h6-15,19-21H,4-5,16-18H2,1-3H3/t6-,7+,8-,9-,10-,11-,12+,13+,14+,15+/m0/s1"	WFMQYKIRAVMXSU-LCVFDZPEBS	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Astromicin	antibacterial	6.67	0.019142553	1.718000152	30	Moderate	Low	form of drug administered not known			
22626	2626	22626	87_FDAMDD_v3b	C15H17NS2	275.43218	defined organic	parent	tested chemical	Asverin	5169-78-8	single chemical compound		3-(di-2-thienylmethylidene)-1-methylpiperidine	C3C=CSC=3C(=C1CN(C)CCC1)C2SC=CC=2	C3C=CSC=3C(=C1CN(C)CCC1)C2SC=CC=2	"InChI=1/C15H17NS2/c1-16-8-2-5-12(11-16)15(13-6-3-9-17-13)14-7-4-10-18-14/h3-4,6-7,9-10H,2,5,8,11H2,1H3"	JWIXXNLOKOAAQT-UHFFFAOYAP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antitussive	5	0.018153289	1.741044675	31	Moderate	Low	form of drug administered not known			
22627	2627	22627	88_FDAMDD_v3b	C23H30ClN3O	399.9568	defined organic	parent	tested chemical	Atabrine	83-89-6	single chemical compound		"N~4~-[6-chloro-2-(methyloxy)acridin-9-yl]-N~1~,N~1~-diethylpentane-1,4-diamine"	C1=C(Cl)C=C2C(=C1)C(NC(C)CCCN(CC)CC)=C3C(=N2)C=CC(OC)=C3	C1=C(Cl)C=C2C(=C1)C(NC(C)CCCN(CC)CC)=C3C(=N2)C=CC(OC)=C3	"InChI=1/C23H30ClN3O/c1-5-27(6-2)13-7-8-16(3)25-23-19-11-9-17(24)14-22(19)26-21-12-10-18(28-4)15-20(21)23/h9-12,14-16H,5-8,13H2,1-4H3,(H,25,26)/f/h25H"	GPKJTRJOBQGKQK-LNNLXFCOCD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antithelmintic; antimalarial	5	0.01250135	1.903043081	32	Moderate	Low	form of drug administered not known			
22628	2628	22628	89_FDAMDD_v3b	C14H22N2O3	266.33608	defined organic	parent	tested chemical	Atenolol	29122-68-7	single chemical compound		2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide	C1=C(CC(N)=O)C=CC(OCC(O)CNC(C)C)=C1	C1=C(CC(N)=O)C=CC(OCC(O)CNC(C)C)=C1	"InChI=1/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)/f/h15H2"	METKIMKYRPQLGS-YHSKDTNECH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal; antiarrhythmic	3.33	0.012503	1.90298577	32	Moderate	Moderate	form of drug administered not known			
22629	2629	22629	90_FDAMDD_v3b	C22H19ClO3	366.83746	defined organic	parent	tested chemical	Atovaquone	95233-18-4	single chemical compound	stereochem	"2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione"	OC=2C(=O)c1ccccc1C(=O)C=2[C@@H]3CC[C@H](CC3)c4ccc(Cl)cc4	OC=2C(=O)c1ccccc1C(=O)C=2[C@@H]3CC[C@H](CC3)c4ccc(Cl)cc4	"InChI=1/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,26H,5-8H2/t13-,15-"	KUCQYCKVKVOKAY-CTYIDZIIBB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiprotozoal; antimalarial; antifungal	37.5	0.102225111	0.99044241	22	Low	Low	form of drug administered not known			
22630	2630	22630	91_FDAMDD_v3b	C65H82N2O18S2	1243.47918	defined organic	complex 2 benzenesulfonate [2(C6H5O3S)]	tested chemical	Atracurium Besylate	64228-81-5	single chemical compound	ammonium; parent [64228-79-1]	"2,2'-{pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-{[3,4-bis(methyloxy)phenyl]methyl}-2-methyl-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinolinium] bisbenzenesulfonate"	[O-]S(=O)(=O)c1ccccc1.[O-]S(=O)(=O)c1ccccc1.COc1ccc(cc1OC)CC5c6cc(OC)c(OC)cc6CC[N+]5(C)CCC(=O)OCCCCCOC(=O)CC[N+]3(C)CCc4cc(OC)c(OC)cc4C3Cc2ccc(OC)c(OC)c2	COc1ccc(cc1OC)CC5c6cc(OC)c(OC)cc6CC[N+]5(C)CCC(=O)OCCCCCOC(=O)CC[N+]3(C)CCc4cc(OC)c(OC)cc4C3Cc2ccc(OC)c(OC)c2	"InChI=1/C53H72N2O12.2C6H6O3S/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6;2*7-10(8,9)6-4-2-1-3-5-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3;2*1-5H,(H,7,8,9)/q+2;;/p-2/fC53H72N2O12.2C6H5O3S/qm;2*-1"	XXZSQOVSEBAPGS-MHQNKWFZCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	0.5	0.000402098	3.395668514	49	High-Moderate	High	form of drug administered not known			
22631	113	20113	92_FDAMDD_v3b	C17H23NO3	289.3736	defined organic	parent	tested chemical	Atropine	51-55-8	single chemical compound	stereochem	(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate	O=C(O[C@@H]2C[C@@H](CC3)N(C)[C@H]3C2)C(CO)C1=CC=CC=C1	O=C(O[C@@H]2C[C@@H](CC3)N(C)[C@H]3C2)C(CO)C1=CC=CC=C1	"InChI=1/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14-,16?/m1/s1"	RKUNBYITZUJHSG-UIDSBSESBB	Clinical Reports 	Maximum Recommended Daily Dose	human	1	Atropine	anticholinergic; mydriatic; antispasmodic	0.00133	4.59613E-06	5.337607266	71	High	High	form of drug administered not known			
22632	2632	22632	93_FDAMDD_v3b	C17H23NO4	305.36882	defined organic	parent	tested chemical	Atropine N-oxide	4438-22-6	single chemical compound	stereochem; ammonium	(3-endo)-8-methyl-8-oxido-8-azabicyclo[3.2.1]oct-3-yl 3-hydroxy-2-phenylpropanoate	O=C(O[C@@H]2C[C@@H](CC3)[N@+]([O-])(C)[C@H]3C2)C(CO)C1=CC=CC=C1	O=C(O[C@@H]2C[C@@H](CC3)[N@+]([O-])(C)[C@H]3C2)C(CO)C1=CC=CC=C1	"InChI=1/C17H23NO4/c1-18(21)13-7-8-14(18)10-15(9-13)22-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14-,15-,16?,18?/m1/s1"	HGWPFSBHDACWNL-WLJMEOEHBL	Clinical Reports 	Maximum Recommended Daily Dose	human	1	Atropine	anticholinergic	0.05	0.000163736	3.785854687	54	High	High	form of drug administered not known			
22633	116	20116	94_FDAMDD_v3b	C8H12N4O5	244.2047	defined organic	parent	tested chemical	"Azacytidine, 5-"	320-67-2	single chemical compound	stereochem	"4-amino-1-beta-D-ribofuranosyl-1,3,5-triazin-2(1H)-one"	N/C1=N/C(=O)N(/C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	N/C1=N/C(=O)N(/C=N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O	"InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1/f/h9H2"	NMUSYJAQQFHJEW-QUSQBIOGDY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	20.3	0.083126983	1.08025798	23	Low	Low	form of drug administered not known			
22634	2634	22634	95_FDAMDD_v3b	C16H24N4O4	336.3817	defined organic	complex 2H2O	tested chemical	Azapropazone dihydrate	22304-30-9	single chemical compound	parent [13539-59-8]	"5-(dimethylamino)-9-methyl-2-propyl-1H-pyrazolo[1,2-a][1,2,4]benzotriazine-1,3(2H)-dione dihydrate"	C1(C)=CC=C2C(=C1)N3N(C(N(C)C)=N2)C(=O)C(CCC)C3=O.O.O	C1(C)=CC=C2C(=C1)N3N(C(N(C)C)=N2)C(=O)C(CCC)C3=O	"InChI=1/C16H20N4O2.2H2O/c1-5-6-11-14(21)19-13-9-10(2)7-8-12(13)17-16(18(3)4)20(19)15(11)22;;/h7-9,11H,5-6H2,1-4H3;2*1H2"	LLMGYOJUHDRDFJ-UHFFFAOYAK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; anti inflammatory	30	0.0891844	1.049711106	23	Low	Low	form of drug administered not known			
22635	2635	22635	96_FDAMDD_v3b	C14H17N3O9	371.29948	defined organic	parent	tested chemical	"Azaribine,6-"	2169-64-4	single chemical compound	stereochem	"2-(2,3,5-tri-O-acetyl-beta-D-ribofuranosyl)-1,2,4-triazine-3,5(2H,4H)-dione"	CC(=O)OC[C@H]2O[C@@H](N1\N=C/C(=O)NC1=O)[C@H](OC(C)=O)[C@@H]2OC(C)=O	CC(=O)OC[C@H]2O[C@@H](N1\N=C/C(=O)NC1=O)[C@H](OC(C)=O)[C@@H]2OC(C)=O	"InChI=1/C14H17N3O9/c1-6(18)23-5-9-11(24-7(2)19)12(25-8(3)20)13(26-9)17-14(22)16-10(21)4-15-17/h4,9,11-13H,5H2,1-3H3,(H,16,21,22)/t9-,11-,12-,13-/m1/s1/f/h16H"	QQOBRRFOVWGIMD-NPQZJABCDV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic; antipsoriatic	170	0.457851436	0.33927542	15	Low	Low	form of drug administered not known			
22636	2636	22636	97_FDAMDD_v3b	C20H22N2	290.40208	defined organic	parent	tested chemical	Azatadine	3964-81-6	single chemical compound		"11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine"	C1=CC=C3C(=C1)C(=C2CCN(C)CC2)C4=C(CC3)C=CC=N4	C1=CC=C3C(=C1)C(=C2CCN(C)CC2)C4=C(CC3)C=CC=N4	"InChI=1/C20H22N2/c1-22-13-10-16(11-14-22)19-18-7-3-2-5-15(18)8-9-17-6-4-12-21-20(17)19/h2-7,12H,8-11,13-14H2,1H3"	SEBMTIQKRHYNIT-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	0.0333	0.000114669	3.940555489	55	High	High	form of drug administered not known			
22637	119	20119	98_FDAMDD_v3b	C9H7N7O2S	277.2626	defined organic	parent	tested chemical	Azathioprine	446-86-6	single chemical compound	tautomers	6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-7H-purine	[O-][N+](C(N=C3)=C(SC1=NC=NC2=C1NC=N2)N3C)=O	[O-][N+](C(N=C3)=C(SC1=NC=NC2=C1NC=N2)N3C)=O	"InChI=1/C9H7N7O2S/c1-15-4-14-7(16(17)18)9(15)19-8-5-6(11-2-10-5)12-3-13-8/h2-4H,1H3,(H,10,11,12,13)/f/h10H"	LMEKQMALGUDUQG-KZFATGLACK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		immunosuppressant; antirheumatic	5	0.018033446	1.743921287	31	Moderate	Low	form of drug administered not known			
22638	2638	22638	99_FDAMDD_v3b	C22H24ClN3O	381.89846	defined organic	parent	tested chemical	Azelastine	58581-89-8	single chemical compound		4-[(4-chlorophenyl)methyl]-2-(1-methylazepan-4-yl)phthalazin-1(2H)-one	C1=CC=C4C(=C1)C(=O)N(C2CCCN(C)CC2)N=C4CC3=CC=C(Cl)C=C3	C1=CC=C4C(=C1)C(=O)N(C2CCCN(C)CC2)N=C4CC3=CC=C(Cl)C=C3	"InChI=1/C22H24ClN3O/c1-25-13-4-5-18(12-14-25)26-22(27)20-7-3-2-6-19(20)21(24-26)15-16-8-10-17(23)11-9-16/h2-3,6-11,18H,4-5,12-15H2,1H3"	MBUVEWMHONZEQD-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiallergic; antiasthmatic; antihistaminic	0.133	0.00034826	3.458096266	50	High	High	form of drug administered not known			
22639	2639	22639	100_FDAMDD_v3b	C20H23N5O6S	461.49152	defined organic	parent	tested chemical	Azlocillin	37091-66-0	single chemical compound	stereochem	"(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(2S)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)[C@@H](NC(=O)N1CCNC1=O)c2ccccc2)[C@H]4SC3(C)C	O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)[C@@H](NC(=O)N1CCNC1=O)c2ccccc2)[C@H]4SC3(C)C	"InChI=1/C20H23N5O6S/c1-20(2)13(17(28)29)25-15(27)12(16(25)32-20)22-14(26)11(10-6-4-3-5-7-10)23-19(31)24-9-8-21-18(24)30/h3-7,11-13,16H,8-9H2,1-2H3,(H,21,30)(H,22,26)(H,23,31)(H,28,29)/t11-,12+,13-,16+/m0/s1/f/h21-23,28H"	JTWOMNBEOCYFNV-HDVCKUAJDT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	100	0.216688705	0.664163725	19	Low	Low	form of drug administered not known			
22640	2640	22640	101_FDAMDD_v3b	C13H17N5O8S2	435.43278	defined organic	parent	tested chemical	Aztreonam	78110-38-0	single chemical compound	stereochem	"2-({[(1Z)-1-(2-amino-1,3-thiazol-4-yl)-2-{[(2S,3S)-2-methyl-4-oxo-1-sulfoazetidin-3-yl]amino}-2-oxoethylidene]amino}oxy)-2-methylpropanoic acid"	Nc1nc(cs1)\C(=N\OC(C)(C)C(O)=O)C(=O)N[C@@H]2C(=O)N([C@H]2C)S(O)(=O)=O	Nc1nc(cs1)\C(=N\OC(C)(C)C(O)=O)C(=O)N[C@@H]2C(=O)N([C@H]2C)S(O)(=O)=O	"InChI=1/C13H17N5O8S2/c1-5-7(10(20)18(5)28(23,24)25)16-9(19)8(6-4-27-12(14)15-6)17-26-13(2,3)11(21)22/h4-5,7H,1-3H3,(H2,14,15)(H,16,19)(H,21,22)(H,23,24,25)/b17-8-/t5-,7-/m0/s1/f/h16,21,23H,14H2"	WZPBZJONDBGPKJ-PSZCVDLGDL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	133	0.305443242	0.515069479	17	Low	Low	form of drug administered not known			
22641	2641	22641	102_FDAMDD_v3b	C10H12ClNO2	213.66078	defined organic	parent	tested chemical	Baclofen	1134-47-0	single chemical compound		4-amino-3-(4-chlorophenyl)butanoic acid	C(=O)(O)CC(C1=CC=C(Cl)C=C1)CN	C(=O)(O)CC(C1=CC=C(Cl)C=C1)CN	"InChI=1/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)/f/h13H"	KPYSYYIEGFHWSV-NDKGDYFDCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	1.33	0.00622482	2.205873169	36	Moderate	High	form of drug administered not known			
22642	2642	22642	103_FDAMDD_v3b	C20H27N5O3	385.46008	defined organic	parent	tested chemical	Bamifylline	2016-63-9	single chemical compound		"7-{2-[ethyl(2-hydroxyethyl)amino]ethyl}-1,3-dimethyl-8-(phenylmethyl)-3,7-dihydro-1H-purine-2,6-dione"	N1(C)C(=O)N(C)C2=C(C1=O)N(CCN(CCO)CC)C(CC3=CC=CC=C3)=N2	N1(C)C(=O)N(C)C2=C(C1=O)N(CCN(CCO)CC)C(CC3=CC=CC=C3)=N2	"InChI=1/C20H27N5O3/c1-4-24(12-13-26)10-11-25-16(14-15-8-6-5-7-9-15)21-18-17(25)19(27)23(3)20(28)22(18)2/h5-9,26H,4,10-14H2,1-3H3"	VVUYEFBRTFASAH-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator	30	0.077829071	1.108858152	24	Low	Low	form of drug administered not known			
22643	2643	22643	104_FDAMDD_v3b	C8H12N2O3	184.19248	defined organic	parent	tested chemical	Barbital	57-44-3	single chemical compound		"5,5-diethylpyrimidine-2,4,6(1H,3H,5H)-trione"	C1(=O)C(CC)(CC)C(=O)NC(=O)N1	C1(=O)C(CC)(CC)C(=O)NC(=O)N1	"InChI=1/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13)/f/h9-10H"	FTOAOBMCPZCFFF-XMBMESGPCA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	10	0.054291033	1.265271895	25	Low-Moderate	Low	form of drug administered not known			
22644	2644	22644	105_FDAMDD_v3b	C20H25NO3	327.4174	defined organic	parent	tested chemical	Benactyzine	302-40-9	single chemical compound		2-(diethylamino)ethyl hydroxy(diphenyl)acetate	OC(C(=O)OCCN(CC)CC)(C1=CC=CC=C1)C2=CC=CC=C2	OC(C(=O)OCCN(CC)CC)(C1=CC=CC=C1)C2=CC=CC=C2	"InChI=1/C20H25NO3/c1-3-21(4-2)15-16-24-19(22)20(23,17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,23H,3-4,15-16H2,1-2H3"	IVQOFBKHQCTVQV-UHFFFAOYAA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant; anticholinergic	0.15	0.000458131	3.339010496	49	High-Moderate	High	form of drug administered not known			
22645	2645	22645	106_FDAMDD_v3b	C24H28N2O5	424.48952	defined organic	parent	tested chemical	Benazepril	86541-75-5	single chemical compound	stereochem	"[(3S)-3-({(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}amino)-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl]acetic acid"	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]3CCc2ccccc2N(CC(O)=O)C3=O	CCOC(=O)[C@H](CCc1ccccc1)N[C@H]3CCc2ccccc2N(CC(O)=O)C3=O	"InChI=1/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1/f/h27H"	XPCFTKFZXHTYIP-CSVALHDMDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; ACE inhibitor	1.33	0.003133175	2.504015332	39	Moderate	High	form of drug administered not known			
22646	2646	22646	107_FDAMDD_v3b	C19H31NO	289.45554	defined organic	parent	tested chemical	Bencyclane	2179-37-5	single chemical compound		"N,N-dimethyl-3-{[1-(phenylmethyl)cycloheptyl]oxy}propan-1-amine"	C2CCCCCC2(CC1=CC=CC=C1)OCCCN(C)C	C2CCCCCC2(CC1=CC=CC=C1)OCCCN(C)C	"InChI=1/C19H31NO/c1-20(2)15-10-16-21-19(13-8-3-4-9-14-19)17-18-11-6-5-7-12-18/h5-7,11-12H,3-4,8-10,13-17H2,1-2H3"	FYJJXENSONZJRG-UHFFFAOYAM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vasodilator	10	0.03454762	1.461581866	28	Low-Moderate	Low	form of drug administered not known			
22647	2647	22647	108_FDAMDD_v3b	C15H14F3N3O4S2	421.4145696	defined organic	parent	tested chemical	Bendroflumethiazide	73-48-3	single chemical compound		"3-(phenylmethyl)-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide"	C1(S(N)(=O)=O)=C(C(F)(F)F)C=C3C(=C1)S(=O)(=O)NC(CC2=CC=CC=C2)N3	C1(S(N)(=O)=O)=C(C(F)(F)F)C=C3C(=C1)S(=O)(=O)NC(CC2=CC=CC=C2)N3	"InChI=1/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)/f/h19H2"	HDWIHXWEUNVBIY-SDRQFZCRCV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic; antihypertensive	0.333	0.000790196	3.102265313	46	High-Moderate	High	form of drug administered not known			
22648	2648	22648	109_FDAMDD_v3b	C28H31N3O6	505.56224	defined organic	parent	tested chemical	Benidipene	105979-17-7	single chemical compound	stereochem; ammonium	"methyl (3R)-1-(phenylmethyl)piperidin-3-yl (4R)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate"	[O-][N+](=O)c1cccc(c1)[C@@H]/2C(\C(=O)OC)=C(\C)NC(\C)=C\2C(=O)O[C@@H]4CCCN(Cc3ccccc3)C4	[O-][N+](=O)c1cccc(c1)[C@@H]/2C(\C(=O)OC)=C(\C)NC(\C)=C\2C(=O)O[C@@H]4CCCN(Cc3ccccc3)C4	"InChI=1/C28H31N3O6/c1-18-24(27(32)36-3)26(21-11-7-12-22(15-21)31(34)35)25(19(2)29-18)28(33)37-23-13-8-14-30(17-23)16-20-9-5-4-6-10-20/h4-7,9-12,15,23,26,29H,8,13-14,16-17H2,1-3H3/t23-,26-/m1/s1"	QZVNQOLPLYWLHQ-ZEQKJWHPBC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; Ca channel blocker	0.133	0.000263073	3.579922988	51	High	High	form of drug administered not known			
22649	2649	22649	110_FDAMDD_v3b	C17H15NO5	313.3047	defined organic	parent	tested chemical	Benorylate	5003-48-5	single chemical compound		4-(acetylamino)phenyl 2-(acetyloxy)benzoate	C2(OC(C)=O)=CC=CC=C2C(=O)OC1=CC=C(NC(C)=O)C=C1	C2(OC(C)=O)=CC=CC=C2C(=O)OC1=CC=C(NC(C)=O)C=C1	"InChI=1/C17H15NO5/c1-11(19)18-13-7-9-14(10-8-13)23-17(21)15-5-3-4-6-16(15)22-12(2)20/h3-10H,1-2H3,(H,18,19)/f/h18H"	FEJKLNWAOXSSNR-GPQMBLKYCD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; antipyretic; anti inflammatory	133	0.424506878	0.372115269	15	Low	Low	form of drug administered not known			
22650	2650	22650	111_FDAMDD_v3b	C16H12ClNO3	301.72438	defined organic	parent	tested chemical	Benoxaprofen	51234-28-7	single chemical compound	retired CASRN [67434-14-4]	"2-[2-(4-chlorophenyl)-1,3-benzoxazol-5-yl]propanoic acid"	C1=C(C(C)C(O)=O)C=C3C(=C1)OC(C2=CC=C(Cl)C=C2)=N3	C1=C(C(C)C(O)=O)C=C3C(=C1)OC(C2=CC=C(Cl)C=C2)=N3	"InChI=1/C16H12ClNO3/c1-9(16(19)20)11-4-7-14-13(8-11)18-15(21-14)10-2-5-12(17)6-3-10/h2-9H,1H3,(H,19,20)/f/h19H"	MITFXPHMIHQXPI-LILDFLRNCM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; anti inflammatory	10	0.033142831	1.479610404	28	Low-Moderate	Low	form of drug administered not known			
22651	2651	22651	112_FDAMDD_v3b	C10H15N3O5	257.2432	defined organic	parent	tested chemical	Benserazide	322-35-0	single chemical compound		"2-amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanohydrazide"	C1(O)=C(O)C=CC(CNNC(=O)C(N)CO)=C1O	C1(O)=C(O)C=CC(CNNC(=O)C(N)CO)=C1O	"InChI=1/C10H15N3O5/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16/h1-2,6,12,14-17H,3-4,11H2,(H,13,18)/f/h13H"	BNQDCRGUHNALGH-NDKGDYFDCE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiparkinsonian	3.33	0.012944949	1.88789967	32	Moderate	Moderate	form of drug administered not known			
22652	2652	22652	113_FDAMDD_v3b	C17H12Br2O3	424.08338	defined organic	parent	tested chemical	Benzbromarone	3562-84-3	single chemical compound		"(3,5-dibromo-4-hydroxyphenyl)(2-ethyl-1-benzofuran-3-yl)methanone"	C1=CC=C3C(=C1)OC(CC)=C3C(=O)C2=CC(Br)=C(O)C(Br)=C2	C1=CC=C3C(=C1)OC(CC)=C3C(=O)C2=CC(Br)=C(O)C(Br)=C2	"InChI=1/C17H12Br2O3/c1-2-13-15(10-5-3-4-6-14(10)22-13)16(20)9-7-11(18)17(21)12(19)8-9/h3-8,21H,2H2,1H3"	WHQCHUCQKNIQEC-UHFFFAOYAA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		uricosuric	5	0.011790134	1.928481248	33	Moderate	Low	form of drug administered not known			
22653	1804	21804	114_FDAMDD_v3b	C9H11NO2	165.1914	defined organic	parent	tested chemical	Benzocaine	94-09-7	single chemical compound		ethyl 4-aminobenzoate	C1=CC(N)=CC=C1C(=O)OCC	C1=CC(N)=CC=C1C(=O)OCC	"InChI=1/C9H11NO2/c1-2-12-9(11)7-3-5-8(10)6-4-7/h3-6H,2,10H2,1H3"	BLFLLBZGZJTVJG-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		topical anesthetic	1.2	0.007264301	2.138806188	35	Moderate	High	form of drug administered not known			
22654	2654	22654	115_FDAMDD_v3b	C18H19N	249.35016	defined organic	parent	tested chemical	Benzoctamine	17243-39-9	single chemical compound		"1-(9,10-ethanoanthracen-9(10H)-yl)-N-methylmethanamine"	C1=CC=C2C(=C1)C3(CNC)C4=C(C2CC3)C=CC=C4	C1=CC=C2C(=C1)C3(CNC)C4=C(C2CC3)C=CC=C4	"InChI=1/C18H19N/c1-19-12-18-11-10-13(14-6-2-4-8-16(14)18)15-7-3-5-9-17(15)18/h2-9,13,19H,10-12H2,1H3"	GNRXCIONJWKSEA-UHFFFAOYAC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic; skeletal muscle relaxant	1	0.004010425	2.396809651	38	Moderate	High	form of drug administered not known			
22655	2655	22655	116_FDAMDD_v3b	C30H53NO11	603.74192	defined organic	parent	tested chemical	Benzonatate	104-31-4	single chemical compound		"3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl 4-(butylamino)benzoate"	C1(NCCCC)=CC=C(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C=C1	C1(NCCCC)=CC=C(C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC)C=C1	"InChI=1/C30H53NO11/c1-3-4-9-31-29-7-5-28(6-8-29)30(32)42-27-26-41-25-24-40-23-22-39-21-20-38-19-18-37-17-16-36-15-14-35-13-12-34-11-10-33-2/h5-8,31H,3-4,9-27H2,1-2H3"	MAFMQEKGGFWBAB-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antitussive	10	0.016563369	1.780851332	31	Moderate	Low	form of drug administered not known			
22656	2656	22656	117_FDAMDD_v3b	C17H21N	239.35534	defined organic	parent	tested chemical	Benzphetamine	156-08-1	single chemical compound	stereochem	(2S)-N-benzyl-N-methyl-1-phenylpropan-2-amine	C[C@H](N(C)CC2=CC=CC=C2)CC1=CC=CC=C1	C[C@H](N(C)CC2=CC=CC=C2)CC1=CC=CC=C1	"InChI=1/C17H21N/c1-15(13-16-9-5-3-6-10-16)18(2)14-17-11-7-4-8-12-17/h3-12,15H,13-14H2,1-2H3/t15-/m0/s1"	YXKTVDFXDRQTKV-HNNXBMFYBE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anorexic	2.5	0.010444722	1.981103112	33	Moderate	High-Moderate	form of drug administered not known; structure modified v3b			
22657	2657	22657	118_FDAMDD_v3b	C22H32N2O5	404.49988	defined organic	parent	tested chemical	Benzquinamide	63-12-7	single chemical compound		"3-[(diethylamino)carbonyl]-9,10-bis(methyloxy)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl acetate"	C1(OC)=C(OC)C=C2C(=C1)C3N(CC2)CC(C(=O)N(CC)CC)C(OC(C)=O)C3	C1(OC)=C(OC)C=C2C(=C1)C3N(CC2)CC(C(=O)N(CC)CC)C(OC(C)=O)C3	"InChI=1/C22H32N2O5/c1-6-23(7-2)22(26)17-13-24-9-8-15-10-20(27-4)21(28-5)11-16(15)18(24)12-19(17)29-14(3)25/h10-11,17-19H,6-9,12-13H2,1-5H3"	JSZILQVIPPROJI-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic; antiemeic	0.417	0.001030903	2.986782342	45	High-Moderate	High	form of drug administered not known			
22658	2658	22658	119_FDAMDD_v3b	C15H14ClN3O4S3	431.93736	defined organic	parent	tested chemical	Benzthiazide	91-33-8	single chemical compound		"6-chloro-3-{[(phenylmethyl)thio]methyl}-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide"	C1(S(N)(=O)=O)=C(Cl)C=C3C(=C1)S(=O)(=O)NC(CSCC2=CC=CC=C2)=N3	C1(S(N)(=O)=O)=C(Cl)C=C3C(=C1)S(=O)(=O)NC(CSCC2=CC=CC=C2)=N3	"InChI=1/C15H14ClN3O4S3/c16-11-6-12-14(7-13(11)25(17,20)21)26(22,23)19-15(18-12)9-24-8-10-4-2-1-3-5-10/h1-7H,8-9H2,(H,18,19)(H2,17,20,21)/f/h19H,17H2"	NDTSRXAMMQDVSW-HWHDIUAICZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic; antihypertensive	3.33	0.007709451	2.112976536	35	Moderate	Moderate	form of drug administered not known			
22659	2659	22659	120_FDAMDD_v3b	C21H25NO	307.4293	defined organic	parent	tested chemical	Benztropine	86-13-5	single chemical compound	stereochem	(3-endo)-3-[(diphenylmethyl)oxy]-8-methyl-8-azabicyclo[3.2.1]octane	CN1[C@H]2C[C@@H](OC(C4=CC=CC=C4)C3=CC=CC=C3)C[C@H]1CC2	CN1[C@H]2C[C@@H](OC(C4=CC=CC=C4)C3=CC=CC=C3)C[C@H]1CC2	"InChI=1/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19-/m1/s1"	GIJXKZJWITVLHI-RTBURBONBA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	0.1	0.000325278	3.487745256	50	High	High	form of drug administered not known			
22660	152	20152	121_FDAMDD_v3b	C7H8O	108.1378	defined organic	parent	tested chemical	Benzyl alcohol	100-51-6	single chemical compound		phenylmethanol	OCC1=CC=CC=C1	OCC1=CC=CC=C1	"InChI=1/C7H8O/c8-6-7-4-2-1-3-5-7/h1-5,8H,6H2"	WVDDGKGOMKODPV-UHFFFAOYAH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	5	0.046237301	1.335007526	26	Low-Moderate	Low	form of drug administered not known			
22661	2661	22661	122_FDAMDD_v3b	C17H22NO	256.36268	defined organic	parent	tested chemical	Bephenium	7181-73-9	single chemical compound	ammonium	"N,N-dimethyl-N-(phenylmethyl)-2-(phenyloxy)ethanaminium"	C[N+](C)(Cc1ccccc1)CCOc2ccccc2	C[N+](C)(Cc1ccccc1)CCOc2ccccc2	"InChI=1/C17H22NO/c1-18(2,15-16-9-5-3-6-10-16)13-14-19-17-11-7-4-8-12-17/h3-12H,13-15H2,1-2H3/q+1"	AVWWVJUMXRXPNF-UHFFFAOYAA	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Bephenium	anthelmintic	41.7	0.162660181	0.788718748	20	Low	Low	form of drug administered not known			
22662	2662	22662	123_FDAMDD_v3b	C28H29NO4	443.53416	defined organic	complex hydroxynaphthoate (C11H7O3)	tested chemical	Bephenium hydroxynaphthoate	3818-50-6	single chemical compound	ammonium; parent [7181-73-9]	"N,N-dimethyl-N-(phenylmethyl)-2-(phenyloxy)ethanaminium 3-hydroxynaphthalene-2-carboxylate"	C[N+](C)(Cc1ccccc1)CCOc2ccccc2.[O-]C(=O)c1cc2ccccc2cc1O	C[N+](C)(Cc1ccccc1)CCOc2ccccc2	"InChI=1/C17H22NO.C11H8O3/c1-18(2,15-16-9-5-3-6-10-16)13-14-19-17-11-7-4-8-12-17;12-10-6-8-4-2-1-3-7(8)5-9(10)11(13)14/h3-12H,13-15H2,1-2H3;1-6,12H,(H,13,14)/q+1;/p-1/fC17H22NO.C11H7O3/qm;-1"	PMPQCPQAHTXCDK-LZCVAEDVCX	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Bephenium	anthelmintic	41.7	0.094017561	1.026791019	23	Low	Low	form of drug administered not known			
22663	2663	22663	124_FDAMDD_v3b	C24H34N2O	366.53956	defined organic	parent	tested chemical	Bepridil	64706-54-3	single chemical compound		N-{3-[(2-methylpropyl)oxy]-2-pyrrolidin-1-ylpropyl}-N-(phenylmethyl)aniline	N(CC(N1CCCC1)COCC(C)C)(CC2=CC=CC=C2)C3C=CC=CC=3	N(CC(N1CCCC1)COCC(C)C)(CC2=CC=CC=C2)C3C=CC=CC=3	"InChI=1/C24H34N2O/c1-21(2)19-27-20-24(25-15-9-10-16-25)18-26(23-13-7-4-8-14-23)17-22-11-5-3-6-12-22/h3-8,11-14,21,24H,9-10,15-20H2,1-2H3"	UIEATEWHFDRYRU-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antianginal	6.67	0.018197217	1.73999502	31	Moderate	Low	form of drug administered not known			
22664	253	20253	125_FDAMDD_v3b	C40H56	536.8726	defined organic	parent	tested chemical	beta-Carotene	7235-40-7	single chemical compound	C.I. 75130; stereochem	"beta,beta-carotene"	CC2(C)CCCC(\C)=C2\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(/C)CCCC1(C)C	CC2(C)CCCC(\C)=C2\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(/C)CCCC1(C)C	"InChI=1/C40H56/c1-31(19-13-21-33(3)25-27-37-35(5)23-15-29-39(37,7)8)17-11-12-18-32(2)20-14-22-34(4)26-28-38-36(6)24-16-30-40(38,9)10/h11-14,17-22,25-28H,15-16,23-24,29-30H2,1-10H3/b12-11+,19-13+,20-14+,27-25+,28-26+,31-17+,32-18+,33-21+,34-22+"	OENHQHLEOONYIE-JLTXGRSLBT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vitamin A precursor; UV screen	0.05	9.3132E-05	4.030901235	56	High	High	form of drug administered not known			
22665	2665	22665	126_FDAMDD_v3b	C8H12N2	136.19428	defined organic	parent	tested chemical	Betahistine	5638-76-6	single chemical compound		N-methyl-2-pyridin-2-ylethanamine	C1=CC=CC(CCNC)=N1	C1=CC=CC(CCNC)=N1	"InChI=1/C8H12N2/c1-9-7-5-8-4-2-3-6-10-8/h2-4,6,9H,5,7H2,1H3"	UUQMNUMQCIQDMZ-UHFFFAOYAQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vasodilator	0.8	0.005873962	2.231068881	36	Moderate	High	form of drug administered not known			
22666	2666	22666	127_FDAMDD_v3b	C5H11NO2	117.14634	defined organic	parent	tested chemical	Betaine	107-43-7	single chemical compound	ammonium; zwitterion; alternate CASRN [590-30-7]	(trimethylammonio)acetate	[O-]C(=O)C[N+](C)(C)C	[O-]C(=O)C[N+](C)(C)C	"InChI=1/C5H11NO2/c1-6(2,3)4-5(7)8/h4H2,1-3H3"	KWIUHFFTVRNATP-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		hepatoprotectant	8.33	0.071107642	1.148083723	24	Low	Low	form of drug administered not known			
22667	2667	22667	128_FDAMDD_v3b	C22H29FO5	392.4610632	defined organic	parent	tested chemical	Betamethasone	378-44-9	single chemical compound	stereochem; tautomers	"(11beta,16beta)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione"	F[C@]1([C@](C)2C=C3)[C@@H](O)C[C@@]([C@]([C@@](CO)=O)(O)[C@@H]4C)(C)[C@](C4)([H])[C@@]([H])1CCC2=CC3=O	F[C@]1([C@](C)2C=C3)[C@@H](O)C[C@@]([C@]([C@@](CO)=O)(O)[C@@H]4C)(C)[C@](C4)([H])[C@@]([H])1CCC2=CC3=O	"InChI=1/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1"	UREBDLICKHMUKA-CXSFZGCWBM	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 7	Betamethasone	glucocorticoid	0.15	0.000382204	3.417705317	49	High-Moderate	High	form of drug administered not known; structure modified v3b			
22668	2668	22668	129_FDAMDD_v3b	C24H31FO6	434.4977432	defined organic	parent	tested chemical	Betamethasone acetate	987-24-6	single chemical compound	stereochem; tautomers	"(11beta,16beta)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl acetate"	F[C@]1([C@](C)2C=C3)[C@@H](O)C[C@@]([C@]([C@@](CO)=O)(O)[C@@H]4C)(C)[C@](C4)([H])[C@@]([H])1CCC2=CC3=O	F[C@]1([C@](C)2C=C3)[C@@H](O)C[C@@]([C@]([C@@](CO)=O)(O)[C@@H]4C)(C)[C@](C4)([H])[C@@]([H])1CCC2=CC3=O	"InChI=1/C24H31FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h7-8,10,13,17-19,28,30H,5-6,9,11-12H2,1-4H3/t13-,17+,18+,19+,21+,22+,23+,24+/m1/s1"	AKUJBENLRBOFTD-RPRRAYFGBQ	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 7	Betamethasone	glucocorticoid	0.15	0.000345226	3.461896266	50	High	High	form of drug administered not known; structure modified v3b			
22669	2669	22669	130_FDAMDD_v3b	C28H37FO7	504.5875832	defined organic	parent	tested chemical	Betamethasone acibutate	5534-05-4	single chemical compound	stereochem; tautomers	"(11beta,16beta)-21-(acetyloxy)-9-fluoro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-methylpropanoate"	CC(C)C(=O)O[C@]4(C(=O)COC(C)=O)[C@@H](C)C[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)/C=C\C(=O)/C=C3/CC[C@@H]12	CC(C)C(=O)O[C@]4(C(=O)COC(C)=O)[C@@H](C)C[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)/C=C\C(=O)/C=C3/CC[C@@H]12	"InChI=1/C28H37FO7/c1-15(2)24(34)36-28(23(33)14-35-17(4)30)16(3)11-21-20-8-7-18-12-19(31)9-10-25(18,5)27(20,29)22(32)13-26(21,28)6/h9-10,12,15-16,20-22,32H,7-8,11,13-14H2,1-6H3/t16-,20-,21-,22-,25-,26-,27-,28-/m0/s1"	KGNVBESWWSSQAN-QEVRMTOFBC	Clinical Reports 	Maximum Recommended Daily Dose	human	3 of 7	Betamethasone	glucocorticoid	0.15	0.000297272	3.5268453	51	High	High	form of drug administered not known			
22670	2670	22670	131_FDAMDD_v3b	C29H33FO6	496.5671232	defined organic	parent	tested chemical	Betamethasone benzoate	22298-29-9	single chemical compound	stereochem; tautomers	"(11beta,16beta)-9-fluoro-11,21-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl benzoate"	F[C@]1([C@](C)2C=C3)[C@@H](O)C[C@@]([C@]([C@](CO)=O)(OC(C5=CC=CC=C5)=O)[C@H]4C)(C)[C@](C4)([H])[C@@]([H])1CCC2=CC3=O	F[C@]1([C@](C)2C=C3)[C@@H](O)C[C@@]([C@]([C@](CO)=O)(OC(C5=CC=CC=C5)=O)[C@H]4C)(C)[C@](C4)([H])[C@@]([H])1CCC2=CC3=O	"InChI=1/C29H33FO6/c1-17-13-22-21-10-9-19-14-20(32)11-12-26(19,2)28(21,30)23(33)15-27(22,3)29(17,24(34)16-31)36-25(35)18-7-5-4-6-8-18/h4-8,11-12,14,17,21-23,31,33H,9-10,13,15-16H2,1-3H3/t17-,21-,22-,23-,26-,27-,28-,29-/m0/s1"	SOQJPQZCPBDOMF-YCUXZELOBA	Clinical Reports 	Maximum Recommended Daily Dose	human	4 of 7	Betamethasone	glucocorticoid	0.15	0.000302074	3.519886703	51	High	High	form of drug administered not known; structure modified v3b			
22671	2671	22671	132_FDAMDD_v3b	C29H39FO7	518.6141632	defined organic	parent	tested chemical	Betamethasone butyrate propionate	5534-02-1	single chemical compound	stereochem; tautomers	"(11beta,16beta)-9-fluoro-11-hydroxy-16-methyl-3,20-dioxo-21-(propanoyloxy)pregna-1,4-dien-17-yl butanoate"	CCC(=O)OCC(=O)[C@@]4(OC(=O)CCC)[C@@H](C)C[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)/C=C\C(=O)/C=C3/CC[C@@H]12	CCC(=O)OCC(=O)[C@@]4(OC(=O)CCC)[C@@H](C)C[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)/C=C\C(=O)/C=C3/CC[C@@H]12	"InChI=1/C29H39FO7/c1-6-8-25(35)37-29(23(33)16-36-24(34)7-2)17(3)13-21-20-10-9-18-14-19(31)11-12-26(18,4)28(20,30)22(32)15-27(21,29)5/h11-12,14,17,20-22,32H,6-10,13,15-16H2,1-5H3/t17-,20-,21-,22-,26-,27-,28-,29-/m0/s1"	VXOWJCTXWVWLLC-REGDIAEZBP	Clinical Reports 	Maximum Recommended Daily Dose	human	5 of 7	Betamethasone	glucocorticoid	0.15	0.000289232	3.538753114	51	High	High	form of drug administered not known			
22672	2672	22672	133_FDAMDD_v3b	C28H37FO7	504.5875832	defined organic	parent	tested chemical	Betamethasone dipropionate	5593-20-4	single chemical compound	stereochem; tautomers	"(11beta,16beta)-9-fluoro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate"	F[C@]1([C@](C)2C=C3)[C@@H](O)C[C@@]([C@]([C@@](COC(CC)=O)=O)(OC(CC)=O)[C@H]4C)(C)[C@](C4)([H])[C@@]([H])1CCC2=CC3=O	F[C@]1([C@](C)2C=C3)[C@@H](O)C[C@@]([C@]([C@@](COC(CC)=O)=O)(OC(CC)=O)[C@H]4C)(C)[C@](C4)([H])[C@@]([H])1CCC2=CC3=O	"InChI=1/C28H37FO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19-,20-,21-,25-,26-,27-,28-/m0/s1"	CIWBQSYVNNPZIQ-XYWKZLDCBG	Clinical Reports 	Maximum Recommended Daily Dose	human	6 of 7	Betamethasone	glucocorticoid	0.15	0.000297272	3.5268453	51	High	High	form of drug administered not known; structure modified v3b			
22673	2673	22673	134_FDAMDD_v3b	C27H37FO6	476.5774832	defined organic	parent	tested chemical	Betamethasone valerate	2152-44-5	single chemical compound	stereochem; tautomers	"(11beta,16beta)-9-fluoro-11,21-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl pentanoate"	F[C@]1([C@](C)2C=C3)[C@@H](O)C[C@@]([C@]([C@@](CO)=O)(OC(CCCC)=O)[C@H]4C)(C)[C@](C4)([H])[C@@]([H])1CCC2=CC3=O	F[C@]1([C@](C)2C=C3)[C@@H](O)C[C@@]([C@]([C@@](CO)=O)(OC(CCCC)=O)[C@H]4C)(C)[C@](C4)([H])[C@@]([H])1CCC2=CC3=O	"InChI=1/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19-,20-,21-,24-,25-,26-,27-/m0/s1"	SNHRLVCMMWUAJD-SUYDQAKGBY	Clinical Reports 	Maximum Recommended Daily Dose	human	7 of 7	Betamethasone	glucocorticoid	0.15	0.000314744	3.50204226	50	High	High	form of drug administered not known; structure modified v3b			
22674	2674	22674	135_FDAMDD_v3b	C18H29NO3	307.42776	defined organic	parent	tested chemical	Betaxolol	63659-18-7	single chemical compound		1-[(4-{2-[(cyclopropylmethyl)oxy]ethyl}phenyl)oxy]-3-[(1-methylethyl)amino]propan-2-ol	C2CC2COCCC1=CC=C(OCC(O)CNC(C)C)C=C1	C2CC2COCCC1=CC=C(OCC(O)CNC(C)C)C=C1	"InChI=1/C18H29NO3/c1-14(2)19-11-17(20)13-22-18-7-5-15(6-8-18)9-10-21-12-16-3-4-16/h5-8,14,16-17,19-20H,3-4,9-13H2,1-2H3"	NWIUTZDMDHAVTP-UHFFFAOYAU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antiglaucomic	0.667	0.002169615	2.663617247	41	Moderate	High	form of drug administered not known			
22675	2675	22675	136_FDAMDD_v3b	C5H9N3	111.14506	defined organic	parent	tested chemical	Betazole	105-20-4	single chemical compound		2-(1H-pyrazol-3-yl)ethanamine	C1(CCN)C=CNN=1	C1(CCN)C=CNN=1	"InChI=1/C5H9N3/c6-3-1-5-2-4-7-8-5/h2,4H,1,3,6H2,(H,7,8)/f/h7H"	JXDFEQONERDKSS-QDQILVOLCQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	0.5	0.004498625	2.34692016	37	Moderate	High	form of drug administered not known			
22676	2676	22676	137_FDAMDD_v3b	C7H17ClN2O2	196.67508	defined organic	salt Cl	tested chemical	Bethanechol	590-63-6	single chemical compound	ammonium; parent [674-38-4]	"2-[(aminocarbonyl)oxy]-N,N,N-trimethylpropan-1-aminium chloride"	NC(=O)OC(C)C[N+](C)(C)C.[Cl-]	NC(=O)OC(C)C[N+](C)(C)C	"InChI=1/C7H16N2O2.ClH/c1-6(11-7(8)10)5-9(2,3)4;/h6H,5H2,1-4H3,(H-,8,10);1H/fC7H17N2O2.Cl/h8H2;1h/q+1;-1"	XXRMYXBSBOVVBH-JKIPEYGXCW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cholinergic	3.33	0.016931479	1.771305102	31	Moderate	Moderate	form of drug administered not known			
22677	2677	22677	138_FDAMDD_v3b	C10H15N3	177.2462	defined organic	parent	tested chemical	Bethanidine	55-73-2	single chemical compound	tautomers	"1,2-dimethyl-3-(phenylmethyl)guanidine"	C1=CC=CC(CNC(NC)=NC)=C1	C1=CC=CC(CNC(NC)=NC)=C1	"InChI=1/C10H15N3/c1-11-10(12-2)13-8-9-6-4-3-5-7-9/h3-7H,8H2,1-2H3,(H2,11,12,13)/f/h11,13H/b12-10+"	NIVZHWNOUVJHKV-YPHFWIDBDY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	3.33	0.018787427	1.7261327	30	Moderate	Moderate	form of drug administered not known			
22678	2678	22678	139_FDAMDD_v3b	C18H14F4N2O4S	430.3733728	defined organic	parent	tested chemical	Bicalutamide	90357-06-5	single chemical compound	stereochem	(2R)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide	O=S(=O)(C[C@](C)(O)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F)c2ccc(F)cc2	O=S(=O)(C[C@](C)(O)C(=O)Nc1ccc(C#N)c(c1)C(F)(F)F)c2ccc(F)cc2	"InChI=1/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)/t17-/m0/s1/f/h24H"	LKJPYSCBVHEWIU-ARSKLOKFDL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiandrogen; antineoplastic	0.833	0.001935529	2.713200392	42	Moderate	High	form of drug administered not known			
22679	2679	22679	140_FDAMDD_v3b	C10H16N2O3S	244.31064	defined organic	parent	tested chemical	Biotin	58-85-5	single chemical compound	stereochem	"5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoic acid"	O=C1N[C@@H]2[C@H](CCCCC(O)=O)SC[C@@H]2N1	O=C1N[C@@H]2[C@H](CCCCC(O)=O)SC[C@@H]2N1	"InChI=1/C10H16N2O3S/c13-8(14)4-2-1-3-7-9-6(5-16-7)11-10(15)12-9/h6-7,9H,1-5H2,(H,13,14)(H2,11,12,15)/t6-,7-,9-/m0/s1/f/h11-13H"	YBJHBAHKTGYVGT-JRUXAZBRDC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	0.00333	1.36302E-05	4.865498148	66	High	High	form of drug administered not known			
22680	2680	22680	141_FDAMDD_v3b	C21H29NO	311.46106	defined organic	parent	tested chemical	Biperiden	514-65-8	single chemical compound		1-bicyclo[2.2.1]hept-2-en-1-yl-1-phenyl-3-piperidin-1-ylpropan-1-ol	C4=CC(C(O)(CCN1CCCCC1)C23CCC(C=C2)C3)=CC=C4	C4=CC(C(O)(CCN1CCCCC1)C23CCC(C=C2)C3)=CC=C4	"InChI=1/C21H29NO/c23-21(19-7-3-1-4-8-19,13-16-22-14-5-2-6-15-22)20-11-9-18(17-20)10-12-20/h1,3-4,7-9,11,18,23H,2,5-6,10,12-17H2"	DDKIYQCGJUBFIE-UHFFFAOYAM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic; antiparkinsonian	0.2	0.000642135	3.192373762	47	High-Moderate	High	form of drug administered not known			
22681	2681	22681	142_FDAMDD_v3b	C22H19NO4	361.3906	defined organic	parent	tested chemical	Bisacodyl	603-50-9	single chemical compound		"(pyridin-2-ylmethylene)di-4,1-phenylene diacetate"	C3=CC(C(C1=CC=C(OC(C)=O)C=C1)C2=CC=C(OC(C)=O)C=C2)=NC=C3	C3=CC(C(C1=CC=C(OC(C)=O)C=C1)C2=CC=C(OC(C)=O)C=C2)=NC=C3	"InChI=1/C22H19NO4/c1-15(24)26-19-10-6-17(7-11-19)22(21-5-3-4-14-23-21)18-8-12-20(13-9-18)27-16(2)25/h3-14,22H,1-2H3"	KHOITXIGCFIULA-UHFFFAOYAS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cathartic	0.25	0.000691772	3.160036843	47	High-Moderate	High	form of drug administered not known			
22682	2682	22682	143_FDAMDD_v3b	C18H31NO4	325.44304	defined organic	parent	tested chemical	Bisoprolol	66722-44-9	single chemical compound		1-[(1-methylethyl)amino]-3-({4-[({2-[(1-methylethyl)oxy]ethyl}oxy)methyl]phenyl}oxy)propan-2-ol	C1=CC(COCCOC(C)C)=CC=C1OCC(O)CNC(C)C	C1=CC(COCCOC(C)C)=CC=C1OCC(O)CNC(C)C	"InChI=1/C18H31NO4/c1-14(2)19-11-17(20)13-23-18-7-5-16(6-8-18)12-21-9-10-22-15(3)4/h5-8,14-15,17,19-20H,9-13H2,1-4H3"	VHYCDWMUTMEGQY-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.333	0.001023221	2.990030755	45	High-Moderate	High	form of drug administered not known			
22683	2683	22683	144_FDAMDD_v3b	C28H31NO5	461.54944	defined organic	parent	tested chemical	Bitolterol	30392-40-6	single chemical compound		"4-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,2-diyl bis(4-methylbenzoate)"	C(=O)(OC2=C(OC(=O)C1=CC=C(C)C=C1)C=CC(C(O)CNC(C)(C)C)=C2)C3C=CC(C)=CC=3	C(=O)(OC2=C(OC(=O)C1=CC=C(C)C=C1)C=CC(C(O)CNC(C)(C)C)=C2)C3C=CC(C)=CC=3	"InChI=1/C28H31NO5/c1-18-6-10-20(11-7-18)26(31)33-24-15-14-22(23(30)17-29-28(3,4)5)16-25(24)34-27(32)21-12-8-19(2)9-13-21/h6-16,23,29-30H,17H2,1-5H3"	FZGVEKPRDOIXJY-UHFFFAOYAR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator	0.037	8.01648E-05	4.096016504	57	High	High	form of drug administered not known			
22684	2684	22684	145_FDAMDD_v3b	C23H28N2O3	380.48002	defined organic	parent	tested chemical	Bopindolol	62658-63-3	single chemical compound		"2-[(1,1-dimethylethyl)amino]-1-{[(2-methyl-1H-indol-4-yl)oxy]methyl}ethyl benzoate"	C2=CC(OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1)=C3C(=C2)NC(C)=C3	C2=CC(OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1)=C3C(=C2)NC(C)=C3	"InChI=1/C23H28N2O3/c1-16-13-19-20(25-16)11-8-12-21(19)27-15-18(14-24-23(2,3)4)28-22(26)17-9-6-5-7-10-17/h5-13,18,24-25H,14-15H2,1-4H3"	UUOJIACWOAYWEZ-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.0167	4.38919E-05	4.357615385	60	High	High	form of drug administered not known			
22685	2685	22685	146_FDAMDD_v3b	C18H24BrNO3S	414.35706	defined organic	complex tosylate (C7H7O3S)	tested chemical	Bretylium tosylate	61-75-6	single chemical compound	ammonium; parent [59-41-6]	"N-[(2-bromophenyl)methyl]-N,N-dimethylethanaminium 4-methylbenzenesulfonate"	Brc1ccccc1C[N+](C)(C)CC.[O-]S(=O)(=O)c1ccc(C)cc1	Brc1ccccc1C[N+](C)(C)CC	"InChI=1/C11H17BrN.C7H8O3S/c1-4-13(2,3)9-10-7-5-6-8-11(10)12;1-6-2-4-7(5-3-6)11(8,9)10/h5-8H,4,9H2,1-3H3;2-5H,1H3,(H,8,9,10)/q+1;/p-1/fC11H17BrN.C7H7O3S/qm;-1"	KVWNWTZZBKCOPM-RZSCDUAOCL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiadrenergic; cardiac depressant	5	0.012066887	1.918404739	33	Moderate	Low	form of drug administered not known			
22686	2686	22686	147_FDAMDD_v3b	C14H20Br2N2	376.13	defined organic	parent	tested chemical	Bromhexine	3572-43-8	single chemical compound		"2,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}aniline"	C2(Br)=CC(Br)=C(N)C(CN(C)C1CCCCC1)=C2	C2(Br)=CC(Br)=C(N)C(CN(C)C1CCCCC1)=C2	"InChI=1/C14H20Br2N2/c1-18(12-5-3-2-4-6-12)9-10-7-11(15)8-13(16)14(10)17/h7-8,12H,2-6,9,17H2,1H3"	OJGDCBLYJGHCIH-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		expectorant; mucolytic	0.8	0.002126924	2.672247987	41	Moderate	High	form of drug administered not known			
22687	2687	22687	148_FDAMDD_v3b	C32H40BrN5O5	654.5945	defined organic	parent	tested chemical	Bromocriptine	25614-03-3	single chemical compound	stereochem	"(5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman"	BrC=7Nc1cccc\6c1C=7C[C@@H]2C/6=C/[C@H](CN2C)C(=O)N[C@@]3(O[C@]5(O)N(C3=O)[C@@H](CC(C)C)C(=O)N4CCC[C@H]45)C(C)C	BrC=7Nc1cccc\6c1C=7C[C@@H]2C/6=C/[C@H](CN2C)C(=O)N[C@@]3(O[C@]5(O)N(C3=O)[C@@H](CC(C)C)C(=O)N4CCC[C@H]45)C(C)C	"InChI=1/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1/f/h35H"	OZVBMTJYIDMWIL-SRXMRUCYDK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		enzyme inhibitor; antiparkinsonian	1.67	0.002551198	2.593255881	40	Moderate	High	form of drug administered not known			
22688	2688	22688	149_FDAMDD_v3b	C17H20BrNO	334.2508	defined organic	parent	tested chemical	Bromodiphenhydramine	118-23-0	single chemical compound		"2-{[(4-bromophenyl)(phenyl)methyl]oxy}-N,N-dimethylethanamine"	C2=CC(C(OCCN(C)C)C1=CC=C(Br)C=C1)=CC=C2	C2=CC(C(OCCN(C)C)C1=CC=C(Br)C=C1)=CC=C2	"InChI=1/C17H20BrNO/c1-19(2)12-13-20-17(14-6-4-3-5-7-14)15-8-10-16(18)11-9-15/h3-11,17H,12-13H2,1-2H3"	NUNIWXHYABYXKF-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	2.5	0.007479414	2.126132447	35	Moderate	High-Moderate	form of drug administered not known			
22689	1374	21374	150_FDAMDD_v3b	CHBr3	252.7306	defined organic	parent	tested chemical	Bromoform	75-25-2	single chemical compound		bromoform	BrC(Br)Br	BrC(Br)Br	InChI=1/CHBr3/c2-1(3)4/h1H	DIKBFYAXUHHXCS-UHFFFAOYAM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic; antitussive	25	0.098919561	1.00471782	22	Low	Low	form of drug administered not known			
22690	2690	22690	151_FDAMDD_v3b	C21H23BrFNO2	420.3152232	defined organic	parent	tested chemical	Bromperidol	10457-90-6	single chemical compound		4-[4-(4-bromophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one	C3=C(Br)C=CC(C2(O)CCN(CCCC(=O)C1=CC=C(F)C=C1)CC2)=C3	C3=C(Br)C=CC(C2(O)CCN(CCCC(=O)C1=CC=C(F)C=C1)CC2)=C3	"InChI=1/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2"	RKLNONIVDFXQRX-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	0.833	0.001981846	2.702930118	41	Moderate	High	form of drug administered not known			
22691	2691	22691	152_FDAMDD_v3b	C16H19BrN2	319.23946	defined organic	parent	tested chemical	Brompheniramine	86-22-6	single chemical compound		"3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine"	C2=CC(C(C1=CC=C(Br)C=C1)CCN(C)C)=NC=C2	C2=CC(C(C1=CC=C(Br)C=C1)CCN(C)C)=NC=C2	"InChI=1/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3"	ZDIGNSYAACHWNL-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	0.4	0.001252978	2.902056576	44	Moderate	High	form of drug administered not known			
22692	2692	22692	153_FDAMDD_v3b	C15H10BrClN4S	393.6887	defined organic	parent	tested chemical	Brotizolam	57801-81-7	single chemical compound		"2-bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine"	C1=C(Br)SC3=C1C(C2=CC=CC=C2Cl)=NCC4N3C(C)=NN=4	C1=C(Br)SC3=C1C(C2=CC=CC=C2Cl)=NCC4N3C(C)=NN=4	"InChI=1/C15H10BrClN4S/c1-8-19-20-13-7-18-14(9-4-2-3-5-11(9)17)10-6-12(16)22-15(10)21(8)13/h2-6H,7H2,1H3"	UMSGKTJDUHERQW-UHFFFAOYAU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	0.00417	1.05921E-05	4.975016894	67	High	High	form of drug administered not known			
22693	324	20324	154_FDAMDD_v3b	C27H18N4Na2O9S2	652.56014	defined organic	salt 2Na	tested chemical	Brown HT	4553-89-3	single chemical compound		"disodium 4,4'-{[2,4-dihydroxy-5-(hydroxymethyl)benzene-1,3-diyl]di(E)diazene-2,1-diyl}dinaphthalene-1-sulfonate"	OCC1=C(C(=C(C(=C1)/N=N/C2=C3C=CC=CC3=C(C=C2)S(=O)(=O)[O-])O)/N=N/C4=C5C=CC=CC5=C(C=C4)S(=O)(=O)[O-])O.[Na+].[Na+]	OCC1=C(C(=C(C(=C1)/N=N/C2=C3C=CC=CC3=C(C=C2)S(=O)(=O)O)O)/N=N/C4=C5C=CC=CC5=C(C=C4)S(=O)(=O)O)O	"InChI=1/C27H20N4O9S2.2Na/c32-14-15-13-22(30-28-20-9-11-23(41(35,36)37)18-7-3-1-5-16(18)20)27(34)25(26(15)33)31-29-21-10-12-24(42(38,39)40)19-8-4-2-6-17(19)21;;/h1-13,32-34H,14H2,(H,35,36,37)(H,38,39,40);;/q;2*+1/p-2/b30-28+,31-29+;;/fC27H18N4O9S2.2Na/q-2;2m"	BIRIBMFCDVVRKL-FOZOEQIPDY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		food additive	1.5	0.002298639	2.638529283	41	Moderate	High	form of drug administered not known			
22694	2694	22694	155_FDAMDD_v3b	C28H33ClN2	433.02802	defined organic	parent	tested chemical	Buclizine	82-95-1	single chemical compound		"1-[(4-chlorophenyl)(phenyl)methyl]-4-{[4-(1,1-dimethylethyl)phenyl]methyl}piperazine"	C4=C(Cl)C=CC(C(C1=CC=CC=C1)N3CCN(CC2=CC=C(C(C)(C)C)C=C2)CC3)=C4	C4=C(Cl)C=CC(C(C1=CC=CC=C1)N3CCN(CC2=CC=C(C(C)(C)C)C=C2)CC3)=C4	"InChI=1/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3"	MOYGZHXDRJNJEP-UHFFFAOYAM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiemetic	2.5	0.005773298	2.238575991	36	Moderate	High-Moderate	form of drug administered not known			
22695	2695	22695	156_FDAMDD_v3b	C16H19ClO3	294.77326	defined organic	parent	tested chemical	Bucloxic acid	32808-51-8	single chemical compound		4-(3-chloro-4-cyclohexylphenyl)-4-oxobutanoic acid	C2CCCC(C1=C(Cl)C=C(C(=O)CCC(O)=O)C=C1)C2	C2CCCC(C1=C(Cl)C=C(C(=O)CCC(O)=O)C=C1)C2	"InChI=1/C16H19ClO3/c17-14-10-12(15(18)8-9-16(19)20)6-7-13(14)11-4-2-1-3-5-11/h6-7,10-11H,1-5,8-9H2,(H,19,20)/f/h19H"	IJTPQQVCKPZIMV-LILDFLRNCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	20	0.067848759	1.168458089	24	Low	Low	form of drug administered not known			
22696	202	20202	157_FDAMDD_v3b	C25H34O6	430.54	defined organic	parent	tested chemical	Budesonide	51333-22-3	single chemical compound	stereochem; tautomers	"(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one"	O=[C@](CO)[C@]([C@H]2C1)(O[C@@](CCC)([H])O2)[C@](C[C@@H]3O)(C)[C@@]1([C@@]([C@@]([C@](C)4C=C5)3[H])(CCC4=CC5=O)[H])[H]	O=[C@](CO)[C@]([C@H]2C1)(O[C@@](CCC)([H])O2)[C@](C[C@@H]3O)(C)[C@@]1([C@@]([C@@]([C@](C)4C=C5)3[H])(CCC4=CC5=O)[H])[H]	"InChI=1/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21+,22+,23-,24-,25+/m0/s1"	VOVIALXJUBGFJZ-VXKMTNQYBX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	0.00433	1.00571E-05	4.99752561	67	High	High	form of drug administered not known; structure modified v3b			
22697	2697	22697	158_FDAMDD_v3b	C17H25NO4	307.3847	defined organic	parent	tested chemical	Buflomedil	55837-25-7	single chemical compound		"4-pyrrolidin-1-yl-1-[2,4,6-tris(methyloxy)phenyl]butan-1-one"	C2(OC)=CC(OC)=CC(OC)=C2C(=O)CCCN1CCCC1	C2(OC)=CC(OC)=CC(OC)=C2C(=O)CCCN1CCCC1	"InChI=1/C17H25NO4/c1-20-13-11-15(21-2)17(16(12-13)22-3)14(19)7-6-10-18-8-4-5-9-18/h11-12H,4-10H2,1-3H3"	OWYLAEYXIQKAOL-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		peripheral vasodilator	10	0.032532524	1.487682247	28	Low-Moderate	Low	form of drug administered not known			
22698	2698	22698	159_FDAMDD_v3b	C19H22N2O3	326.38958	defined organic	parent	tested chemical	Bumadizone	3583-64-0	single chemical compound		"2-[(1,2-diphenylhydrazino)carbonyl]hexanoic acid"	C2=CC(N(C(=O)C(CCCC)C(=O)O)NC1=CC=CC=C1)=CC=C2	C2=CC(N(C(=O)C(CCCC)C(=O)O)NC1=CC=CC=C1)=CC=C2	"InChI=1/C19H22N2O3/c1-2-3-14-17(19(23)24)18(22)21(16-12-8-5-9-13-16)20-15-10-6-4-7-11-15/h4-13,17,20H,2-3,14H2,1H3,(H,23,24)/f/h23H"	FLWFHHFTIRLFPV-MPIMZMORCO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; antipyretic; anti inflammatory	11	0.033702056	1.4723436	28	Low-Moderate	Low	form of drug administered not known			
22699	2699	22699	160_FDAMDD_v3b	C17H20N2O5S	364.4161	defined organic	parent	tested chemical	Bumetanide	28395-03-1	single chemical compound		3-(aminosulfonyl)-5-(butylamino)-4-(phenyloxy)benzoic acid	S(=O)(=O)(N)C2=C(OC1=CC=CC=C1)C(NCCCC)=CC(C(=O)O)=C2	S(=O)(=O)(N)C2=C(OC1=CC=CC=C1)C(NCCCC)=CC(C(=O)O)=C2	"InChI=1/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)/f/h20H,18H2"	MAEIEVLCKWDQJH-VFSNKAIFCQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic	0.167	0.000458267	3.338881085	49	High-Moderate	High	form of drug administered not known			
22700	2700	22700	161_FDAMDD_v3b	C19H27N5O3	373.44938	defined organic	parent	tested chemical	Bunazosin	80755-51-7	single chemical compound		"2-(4-butanoyl-1,4-diazepan-1-yl)-6,7-bis(methyloxy)quinazolin-4-amine"	C1(OC)=C(OC)C=C3C(=C1)N=C(N2CCCN(C(=O)CCC)CC2)N=C3N	C1(OC)=C(OC)C=C3C(=C1)N=C(N2CCCN(C(=O)CCC)CC2)N=C3N	"InChI=1/C19H27N5O3/c1-4-6-17(25)23-7-5-8-24(10-9-23)19-21-14-12-16(27-3)15(26-2)11-13(14)18(20)22-19/h11-12H,4-10H2,1-3H3,(H2,20,21,22)/f/h20H2"	RHLJLALHBZGAFM-HPHMPNDVCA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.05	0.000133887	3.873261738	55	High	High	form of drug administered not known			
22701	2701	22701	162_FDAMDD_v3b	C14H20N2O2	248.3208	defined organic	parent	tested chemical	Bunitrolol	34915-68-9	single chemical compound		"2-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)benzonitrile"	C1=CC=CC(OCC(O)CNC(C)(C)C)=C1C#N	C1=CC=CC(OCC(O)CNC(C)(C)C)=C1C#N	"InChI=1/C14H20N2O2/c1-14(2,3)16-9-12(17)10-18-13-7-5-4-6-11(13)8-15/h4-7,12,16-17H,9-10H2,1-3H3"	VCVQSRCYSKKPBA-UHFFFAOYAU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal; antiarrhythmic	0.667	0.002686042	2.570887265	40	Moderate	High	form of drug administered not known			
22702	2702	22702	163_FDAMDD_v3b	C17H25NO3	291.3853	defined organic	parent	tested chemical	Bunolol	27591-01-1	single chemical compound		"(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate"	O=C2C1=C(CCC2)C(OCC(O)CNC(C)(C)C)=CC=C1	O=C2C1=C(CCC2)C(OCC(O)CNC(C)(C)C)=CC=C1	"InChI=1/C17H25NO3/c1-17(2,3)18-10-12(19)11-21-16-9-5-6-13-14(16)7-4-8-15(13)20/h5-6,9,12,18-19H,4,7-8,10-11H2,1-3H3"	IXHBTMCLRNMKHZ-UHFFFAOYAM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiglaucoma	0.25	0.000857971	3.06652763	45	High-Moderate	High	form of drug administered not known; structure modified v3b			
22703	2703	22703	164_FDAMDD_v3b	C18H28N2O	288.4277	defined organic	parent	tested chemical	Bupivacaine	38396-39-3	single chemical compound	retired CASRN [2180-92-9]	"1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide"	C2CN(CCCC)C(C(=O)NC1=C(C)C=CC=C1C)CC2	C2CN(CCCC)C(C(=O)NC1=C(C)C=CC=C1C)CC2	"InChI=1/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/f/h19H"	LEBVLXFERQHONN-LILDFLRNCK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		local anesthetic	3.75	0.013001525	1.886005699	32	Moderate	Moderate	form of drug administered not known			
22704	2704	22704	165_FDAMDD_v3b	C14H22ClNO2	271.78298	defined organic	parent	tested chemical	Bupranolol	14556-46-8	single chemical compound		"1-[(2-chloro-5-methylphenyl)oxy]-3-[(1,1-dimethylethyl)amino]propan-2-ol"	C1(C)=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1	C1(C)=CC=C(Cl)C(OCC(O)CNC(C)(C)C)=C1	"InChI=1/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3"	HQIRNZOQPUAHHV-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal; antiarrhythmic; antiglaucomic	6.67	0.02454164	1.610096422	29	Low-Moderate	Low	form of drug administered not known			
22705	2705	22705	166_FDAMDD_v3b	C29H41NO4	467.64014	defined organic	parent	tested chemical	Buprenorphine	52485-79-7	single chemical compound	stereochem	"(5alpha,6beta,14beta,18R)-17-(cyclopropylmethyl)-18-[(1S)-1-hydroxy-1,2,2-trimethylpropyl]-6-(methyloxy)-18,19-dihydro-4,5-epoxy-6,14-ethenomorphinan-3-ol"	CC(C)(C)[C@@](C)(O)[C@H]7C[C@]53CC[C@]7(OC)[C@@H]1Oc6c2c(C[C@H]5N(CC[C@@]123)CC4CC4)ccc6O	CC(C)(C)[C@@](C)(O)[C@H]7C[C@]53CC[C@]7(OC)[C@@H]1Oc6c2c(C[C@H]5N(CC[C@@]123)CC4CC4)ccc6O	"InChI=1/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1"	RMRJXGBAOAMLHD-IHFGGWKQBA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	0.533	0.001139765	2.943184573	44	Moderate	High	form of drug administered not known; activity value changed in v3a; ActivityCategory_MRDD_mmol changed from High to Moderate in v3a			
22706	2706	22706	167_FDAMDD_v3b	C13H18ClNO	239.74112	defined organic	parent	tested chemical	Bupropion	34911-55-2	single chemical compound		"1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one"	C1=CC(Cl)=CC(C(=O)C(C)NC(C)(C)C)=C1	C1=CC(Cl)=CC(C(=O)C(C)NC(C)(C)C)=C1	"InChI=1/C13H18ClNO/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10/h5-9,15H,1-4H3"	SNPPWIUOZRMYNY-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	7.5	0.031283745	1.504681267	28	Low-Moderate	Low	form of drug administered not known			
22707	2707	22707	168_FDAMDD_v3b	C21H31N5O2	385.50314	defined organic	parent	tested chemical	Buspirone	36505-84-7	single chemical compound		"8-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-8-azaspiro[4.5]decane-7,9-dione"	C3C4(CC(=O)N(CCCCN2CCN(C1=NC=CC=N1)CC2)C3=O)CCCC4	C3C4(CC(=O)N(CCCCN2CCN(C1=NC=CC=N1)CC2)C3=O)CCCC4	"InChI=1/C21H31N5O2/c27-18-16-21(6-1-2-7-21)17-19(28)26(18)11-4-3-10-24-12-14-25(15-13-24)20-22-8-5-9-23-20/h5,8-9H,1-4,6-7,10-17H2"	QWCRAEMEVRGPNT-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	1	0.002594013	2.58602792	40	Moderate	High	form of drug administered not known			
22708	910	20910	169_FDAMDD_v3b	C6H14O6S2	246.3018	defined organic	parent	tested chemical	Busulfan	55-98-1	single chemical compound		"butane-1,4-diyl dimethanesulfonate"	O(S(=O)(=O)C)CCCCOS(=O)(C)=O	O(S(=O)(=O)C)CCCCOS(=O)(C)=O	"InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3"	COVZYZSDYWQREU-UHFFFAOYAO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.133	0.000539988	3.267615945	48	High-Moderate	High	form of drug administered not known			
22709	2709	22709	170_FDAMDD_v3b	C10H16N2O3	212.24564	defined organic	parent	tested chemical	Butabarbital	125-40-6	single chemical compound		"5-ethyl-5-(1-methylpropyl)pyrimidine-2,4,6(1H,3H,5H)-trione"	C1(=O)C(C(C)CC)(CC)C(=O)NC(=O)N1	C1(=O)C(C(C)CC)(CC)C(=O)NC(=O)N1	"InChI=1/C10H16N2O3/c1-4-6(3)10(5-2)7(13)11-9(15)12-8(10)14/h6H,4-5H2,1-3H3,(H2,11,12,13,14,15)/f/h11-12H"	ZRIHAIZYIMGOAB-WYCIUFAECJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	2	0.009423044	2.025808782	34	Moderate	High	form of drug administered not known			
22710	2710	22710	171_FDAMDD_v3b	C18H28N4O	316.44112	defined organic	parent	tested chemical	Butalamine	22131-35-7	single chemical compound		"N,N-dibutyl-N'-(3-phenyl-1,2,4-oxadiazol-5-yl)ethane-1,2-diamine"	C2(C1=CC=CC=C1)N=C(NCCN(CCCC)CCCC)ON=2	C2(C1=CC=CC=C1)N=C(NCCN(CCCC)CCCC)ON=2	"InChI=1/C18H28N4O/c1-3-5-13-22(14-6-4-2)15-12-19-18-20-17(21-23-18)16-10-8-7-9-11-16/h7-11H,3-6,12-15H2,1-2H3,(H,19,20,21)/f/h19H"	VYWQZAARVNRSTR-LILDFLRNCK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		peripheral vasodilator	4	0.012640582	1.898232922	32	Moderate	Moderate	form of drug administered not known			
22711	2711	22711	172_FDAMDD_v3b	C11H16N2O3	224.25634	defined organic	parent	tested chemical	Butalbital	77-26-9	single chemical compound		"5-(2-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione"	C1(=O)C(CC=C)(CC(C)C)C(=O)NC(=O)N1	C1(=O)C(CC=C)(CC(C)C)C(=O)NC(=O)N1	"InChI=1/C11H16N2O3/c1-4-5-11(6-7(2)3)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)/f/h12-13H"	UZVHFVZFNXBMQJ-BAINRFMOCY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	5	0.022295914	1.651774726	30	Moderate	Low	form of drug administered not known			
22712	2712	22712	173_FDAMDD_v3b	C24H31N3OS	409.58744	defined organic	parent	tested chemical	Butaperazine	653-03-2	single chemical compound		1-{10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazin-2-yl}butan-1-one	C1=CC=C3C(=C1)N(CCCN2CCN(C)CC2)C4=C(S3)C=CC(C(=O)CCC)=C4	C1=CC=C3C(=C1)N(CCCN2CCN(C)CC2)C4=C(S3)C=CC(C(=O)CCC)=C4	"InChI=1/C24H31N3OS/c1-3-7-22(28)19-10-11-24-21(18-19)27(20-8-4-5-9-23(20)29-24)13-6-12-26-16-14-25(2)15-17-26/h4-5,8-11,18H,3,6-7,12-17H2,1-2H3"	DVLBYTMYSMAKHP-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	1.67	0.004077273	2.389630159	38	Moderate	High	form of drug administered not known			
22713	2713	22713	174_FDAMDD_v3b	C11H16ClN3O4S2	353.84544	defined organic	parent	tested chemical	Buthiazide	2043-38-1	single chemical compound		"6-chloro-3-(2-methylpropyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide"	C1(S(N)(=O)=O)=C(Cl)C=C2C(=C1)S(=O)(=O)NC(CC(C)C)N2	C1(S(N)(=O)=O)=C(Cl)C=C2C(=C1)S(=O)(=O)NC(CC(C)C)N2	"InChI=1/C11H16ClN3O4S2/c1-6(2)3-11-14-8-4-7(12)9(20(13,16)17)5-10(8)21(18,19)15-11/h4-6,11,14-15H,3H2,1-2H3,(H2,13,16,17)/f/h13H2"	HGBFRHCDYZJRAO-DLGLGFIGCC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic; antihypertensive	0.25	0.000706523	3.150873595	46	High-Moderate	High	form of drug administered not known			
22714	2714	22714	175_FDAMDD_v3b	C21H29NO2	327.46046	defined organic	parent	tested chemical	Butorphanol	42408-82-2	single chemical compound	stereochem	"17-(cyclobutylmethyl)morphinan-3,14-diol"	Oc3ccc4C[C@H]1N(CC[C@@]2(CCCC[C@@]12O)c4c3)CC5CCC5	Oc3ccc4C[C@H]1N(CC[C@@]2(CCCC[C@@]12O)c4c3)CC5CCC5	"InChI=1/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1"	IFKLAQQSCNILHL-QHAWAJNXBI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	0.267	0.000815366	3.088647606	46	High-Moderate	High	form of drug administered not known			
22715	2715	22715	176_FDAMDD_v3b	C21H27N	293.44578	defined organic	parent	tested chemical	Butriptyline	35941-65-2	single chemical compound		"3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl)-N,N,2-trimethylpropan-1-amine"	C1(CC(C)CN(C)C)C3=C(CCC2=C1C=CC=C2)C=CC=C3	C1(CC(C)CN(C)C)C3=C(CCC2=C1C=CC=C2)C=CC=C3	"InChI=1/C21H27N/c1-16(15-22(2)3)14-21-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)21/h4-11,16,21H,12-15H2,1-3H3"	ALELTFCQZDXAMQ-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	2.5	0.008519461	2.06958786	34	Moderate	High-Moderate	form of drug administered not known			
22716	2716	22716	177_FDAMDD_v3b	C29H40BrNO4	546.5352	defined organic	salt Br	tested chemical	Butropium bromide	29025-14-7	single chemical compound	ammonium; stereochem	8-{[4-(butyloxy)phenyl]methyl}-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-azoniabicyclo[3.2.1]octane bromide	O=C(O[C@@H]2C[C@@H](CC3)[N@@+](CCC4=CC=C(OCCCC)C=C4)(C)[C@H]3C2)[C@H](CO)C1=CC=CC=C1.[Br-]	O=C(O[C@@H]2C[C@@H](CC3)[N@@+](CCC4=CC=C(OCCCC)C=C4)(C)[C@H]3C2)[C@H](CO)C1=CC=CC=C1	"InChI=1/C29H40NO4.BrH/c1-3-4-18-33-26-14-10-22(11-15-26)16-17-30(2)24-12-13-25(30)20-27(19-24)34-29(32)28(21-31)23-8-6-5-7-9-23;/h5-11,14-15,24-25,27-28,31H,3-4,12-13,16-21H2,1-2H3;1H/q+1;/p-1/t24-,25-,27-,28-,30?;/m1./s1/fC29H40NO4.Br/h;1h/qm;-1"	SHLLSHCMBCKQTR-AMTFLJRMDM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antispasmotic; anticholinergic	0.5	0.000914854	3.038648134	45	High-Moderate	High	form of drug administered not known			
22717	220	20220	178_FDAMDD_v3b	C10H14O2	166.217	defined organic	parent	tested chemical	"Butylhydroquinone, t-"	1948-33-0	single chemical compound		"2-(1,1-dimethylethyl)benzene-1,4-diol"	CC(C)(C)c1cc(O)ccc1O	CC(C)(C)c1cc(O)ccc1O	"InChI=1/C10H14O2/c1-10(2,3)8-6-7(11)4-5-9(8)12/h4-6,11-12H,1-3H3"	BGNXCDMCOKJUMV-UHFFFAOYAP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antioxidant	0.2	0.001203246	2.919645444	44	Moderate	High	form of drug administered not known			
22718	2718	22718	179_FDAMDD_v3b	C21H30BrNO4	440.3712	defined organic	salt Br	tested chemical	Butylscopolammonium bromide	149-64-4	single chemical compound	stereochem; ammonium	"(1R,2R,4S,5S,7S)-9-butyl-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0~2,4~]nonane bromide"	OC[C@H](c1ccccc1)C(=O)O[C@@H]2C[C@@H]3[C@H]4O[C@H]4[C@H](C2)[N+]3(C)CCCC.[Br-]	OC[C@H](c1ccccc1)C(=O)O[C@@H]2C[C@@H]3[C@H]4O[C@H]4[C@H](C2)[N+]3(C)CCCC	"InChI=1/C21H30NO4.BrH/c1-3-4-10-22(2)17-11-15(12-18(22)20-19(17)26-20)25-21(24)16(13-23)14-8-6-5-7-9-14;/h5-9,15-20,23H,3-4,10-13H2,1-2H3;1H/q+1;/p-1/t15-,16-,17-,18+,19-,20+,22?;/m1./s1/fC21H30NO4.Br/h;1h/qm;-1"	HOZOZZFCZRXYEK-SWSUGWEUDU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antispasmotic	1.33	0.003020179	2.519967268	39	Moderate	High	form of drug administered not known			
22719	2719	22719	180_FDAMDD_v3b	C26H37N5O2	451.60428	defined organic	parent	tested chemical	Cabergoline	81409-90-7	single chemical compound	stereochem	(8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@@H]2c3cccc4N\C=C(\C[C@H]2N(C1)CC=C)c34	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@@H]2c3cccc4N\C=C(\C[C@H]2N(C1)CC=C)c34	"InChI=1/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1/f/h27H"	KORNTPPJEAJQIU-VXXMIMLHDS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidyskinetic; prolactin inhibitor; antiparkinsonian; dopamine receptor antagonist	0.02	4.42866E-05	4.353728054	60	High	High	form of drug administered not known			
22720	232	20232	181_FDAMDD_v3b	C8H10N4O2	194.1906	defined organic	parent	tested chemical	Caffeine	58-08-2	single chemical compound		"1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione"	O=C1C2=C(N=CN2C)N(C(=O)N1C)C	O=C1C2=C(N=CN2C)N(C(=O)N1C)C	"InChI=1/C8H10N4O2/c1-10-4-9-6-5(10)7(13)12(3)8(14)11(6)2/h4H,1-3H3"	RYYVLZVUVIJVGH-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		CNS stimulant	10	0.051495798	1.288228204	26	Low-Moderate	Low	form of drug administered not known			
22721	2721	22721	182_FDAMDD_v3b	C27H44O2	400.63706	defined organic	parent	tested chemical	Calcifediol	19356-17-3	single chemical compound	stereochem	"(3S,5Z,7E)-9,10-secocholesta-5,7,10-triene-3,25-diol"	O[C@@H]1C/C(C(=C)CC1)=C/C=C3\CCC[C@@]2(C)[C@H]3CC[C@@H]2[C@H](C)CCCC(C)(C)O	O[C@@H]1C/C(C(=C)CC1)=C/C=C3\CCC[C@@]2(C)[C@H]3CC[C@@H]2[C@H](C)CCCC(C)(C)O	"InChI=1/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1"	JWUBBDSIWDLEOM-DTOXIADCBI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		calcium regulator	0.00333	8.31176E-06	5.080306887	68	High	High	form of drug administered not known			
22722	2722	22722	183_FDAMDD_v3b	C27H44O3	416.63646	defined organic	parent	tested chemical	Calcitriol	32222-06-3	single chemical compound	stereochem	"(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol"	O[C@@H]3C\C(=C\C=C2/CCC[C@@]1(C)[C@H]2CC[C@@H]1[C@H](C)CCCC(C)(C)O)C(=C)[C@@H](O)C3	O[C@@H]3C\C(=C\C=C2/CCC[C@@]1(C)[C@H]2CC[C@@H]1[C@H](C)CCCC(C)(C)O)C(=C)[C@@H](O)C3	"InChI=1/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1"	GMRQFYUYWCNGIN-NKMMMXOEBI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		calcium regulator	0.00005	1.20009E-07	6.920787268	89	High	High	form of drug administered not known			
22723	2723	22723	184_FDAMDD_v3b	C21H32O2	316.47758	defined organic	parent	tested chemical	Calusterone	17021-26-0	single chemical compound	stereochem	"(7beta,8xi,17beta)-17-hydroxy-7,17-dimethylandrost-4-en-3-one"	C[C@]43CCC(=O)\C=C4\C[C@H](C)[C@@H]1[C@@H]3CC[C@]2(C)[C@@](C)(O)CC[C@@H]12	C[C@]43CCC(=O)\C=C4\C[C@H](C)[C@@H]1[C@@H]3CC[C@]2(C)[C@@](C)(O)CC[C@@H]12	"InChI=1/C21H32O2/c1-13-11-14-12-15(22)5-8-19(14,2)16-6-9-20(3)17(18(13)16)7-10-21(20,4)23/h12-13,16-18,23H,5-11H2,1-4H3/t13-,16-,17-,18+,19-,20-,21-/m0/s1"	IVFYLRMMHVYGJH-PVPPCFLZBH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	5	0.015798907	1.801372945	31	Moderate	Low	form of drug administered not known			
22724	2724	22724	185_FDAMDD_v3b	C20H21NO4	339.38504	defined organic	parent	tested chemical	Canadine	522-97-4	single chemical compound		"9,10-bis(methyloxy)-5,8,13,13a-tetrahydro-6H-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline"	C1=C(OC)C(OC)=C2C(=C1)CC3N(C2)CCC4=C3C=C5C(=C4)OCO5	C1=C(OC)C(OC)=C2C(=C1)CC3N(C2)CCC4=C3C=C5C(=C4)OCO5	"InChI=1/C20H21NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,8-9,16H,5-7,10-11H2,1-2H3"	VZTUIEROBZXUFA-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		Ca channel blocker	33.3	0.098118644	1.008248461	22	Low	Low	form of drug administered not known			
22725	2725	22725	186_FDAMDD_v3b	C24H20N6O3	440.454	defined organic	parent	tested chemical	Candesartan	139481-59-7	single chemical compound		2-(ethyloxy)-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylic acid	OC(=O)c4cccc5nc(OCC)n(Cc1ccc(cc1)c2ccccc2C\3=N\N=N/N/3)c45	OC(=O)c4cccc5nc(OCC)n(Cc1ccc(cc1)c2ccccc2C\3=N\N=N/N/3)c45	"InChI=1/C24H20N6O3/c1-2-33-24-25-20-9-5-8-19(23(31)32)21(20)30(24)14-15-10-12-16(13-11-15)17-6-3-4-7-18(17)22-26-28-29-27-22/h3-13H,2,14H2,1H3,(H,31,32)(H,26,27,28,29)/f/h26,31H"	HTQMVQVXFRQIKW-NEQLIHFBCV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.267	0.000606193	3.217389297	47	High-Moderate	High	form of drug administered not known			
22726	2726	22726	187_FDAMDD_v3b	C22H30O4	358.4712	defined organic	parent	tested chemical	Canrenoate	4138-96-9	single chemical compound	stereochem	"3-[(8R,9S,10R,13S,14S,17R)-17-hydroxy-10,13-dimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]propanoic acid"	OC(=O)CC[C@]2(O)CC[C@H]3[C@@H]4\C=C/C1=C/C(=O)CC[C@]1(C)[C@H]4CC[C@]23C	OC(=O)CC[C@]2(O)CC[C@H]3[C@@H]4\C=C/C1=C/C(=O)CC[C@]1(C)[C@H]4CC[C@]23C	"InChI=1/C22H30O4/c1-20-9-5-15(23)13-14(20)3-4-16-17(20)6-10-21(2)18(16)7-11-22(21,26)12-8-19(24)25/h3-4,13,16-18,26H,5-12H2,1-2H3,(H,24,25)/t16-,17+,18+,20+,21+,22-/m1/s1/f/h24H"	PBKZPPIHUVSDNM-LMSWTUBMDW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic	13.3	0.037102004	1.430602629	27	Low-Moderate	Low	form of drug administered not known			
22727	2727	22727	188_FDAMDD_v3b	C40H52O2	564.8397	defined organic	parent	tested chemical	Canthaxanthin	514-78-3	single chemical compound	stereochem	"beta,beta-carotene-4,4'-dione"	O=C1C(C)=C(C(C)(C)CC1)/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C(C(C)(C)CC2)=C(C)C2=O	O=C1C(C)=C(C(C)(C)CC1)/C=C/C(C)=C/C=C/C(C)=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C(C(C)(C)CC2)=C(C)C2=O	"InChI=1/C40H52O2/c1-29(17-13-19-31(3)21-23-35-33(5)37(41)25-27-39(35,7)8)15-11-12-16-30(2)18-14-20-32(4)22-24-36-34(6)38(42)26-28-40(36,9)10/h11-24H,25-28H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,29-15+,30-16+,31-19+,32-20+"	FDSDTBUPSURDBL-DKLMTRRABT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antioxidant	25	0.044260345	1.353985205	26	Low-Moderate	Low	form of drug administered not known; structure modified v3b			
22728	2728	22728	189_FDAMDD_v3b	C9H18N2O2	186.25142	defined organic	parent	tested chemical	Capuride	5579-13-5	single chemical compound		N-(aminocarbonyl)-2-ethyl-3-methylpentanamide	CCC(C)C(C(=O)NC(N)=O)CC	CCC(C)C(C(=O)NC(N)=O)CC	"InChI=1/C9H18N2O2/c1-4-6(3)7(5-2)8(12)11-9(10)13/h6-7H,4-5H2,1-3H3,(H3,10,11,12,13)/f/h11H,10H2"	HLSLSXBFTXUKCY-XGEAKUCACK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		hypnotic	6.67	0.035811808	1.445973759	27	Low-Moderate	Low	form of drug administered not known			
22729	2729	22729	190_FDAMDD_v3b	C18H27NO2	289.41248	defined organic	parent	tested chemical	Caramiphen	77-22-5	single chemical compound		2-(diethylamino)ethyl 1-phenylcyclopentanecarboxylate	C2=CC=CC=C2C1(C(=O)OCCN(CC)CC)CCCC1	C2=CC=CC=C2C1(C(=O)OCCN(CC)CC)CCCC1	"InChI=1/C18H27NO2/c1-3-19(4-2)14-15-21-17(20)18(12-8-9-13-18)16-10-6-5-7-11-16/h5-7,10-11H,3-4,8-9,12-15H2,1-2H3"	OFAIGZWCDGNZGT-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antitussive	5	0.01727638	1.76254725	31	Moderate	Low	form of drug administered not known			
22730	2730	22730	191_FDAMDD_v3b	C6H15ClN2O2	182.6485	defined organic	salt Cl	tested chemical	Carbachol	51-83-2	single chemical compound	ammonium	"2-[(aminocarbonyl)oxy]-N,N,N-trimethylethanaminium chloride"	NC(=O)OCC[N+](C)(C)C.[Cl-]	NC(=O)OCC[N+](C)(C)C	"InChI=1/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H/fC6H15N2O2.Cl/h7H2;1h/q+1;-1"	AIXAANGOTKPUOY-MLFJRGSCCV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cholinergic; miotic	0.0667	0.000365182	3.437490276	50	High	High	form of drug administered not known			
22731	2731	22731	192_FDAMDD_v3b	C15H12N2O	236.2686	defined organic	parent	tested chemical	Carbamazepine	298-46-4	single chemical compound		"5H-dibenzo[b,f]azepine-5-carboxamide"	C1=CC=C2C(=C1)N(C(N)=O)C3=C(C=C2)C=CC=C3	C1=CC=C2C(=C1)N(C(N)=O)C3=C(C=C2)C=CC=C3	"InChI=1/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)/f/h16H2"	FFGPTBGBLSHEPO-ZHLVXTBQCX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; anticonvulsant	26.7	0.113006976	0.946894747	22	Low	Low	form of drug administered not known			
22732	2732	22732	193_FDAMDD_v3b	C10H11N4NaO5S	322.27291	defined organic	salt Na	tested chemical	Carbazochrome	51460-26-5	single chemical compound	stereochem	"sodium (5E)-5-[(aminocarbonyl)hydrazono]-1-methyl-6-oxo-2,3,5,6-tetrahydro-1H-indole-2-sulfonate"	[Na+].NC(=O)N\N=C1/C=C\2/CC(N(C)C/2=C\C1=O)S([O-])(=O)=O	NC(=O)N\N=C1/C=C\2/CC(N(C)C/2=C\C1=O)S(O)(=O)=O	"InChI=1/C10H12N4O5S.Na/c1-14-7-4-8(15)6(12-13-10(11)16)2-5(7)3-9(14)20(17,18)19;/h2,4,9H,3H2,1H3,(H3,11,13,16)(H,17,18,19);/q;+1/p-1/b12-6+;/fC10H11N4O5S.Na/h13H,11H2;/q-1;m"	HLFCZZKCHVSOAP-YEONXLIODJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		hemostatic	3	0.00930888	2.031102546	34	Moderate	Moderate	form of drug administered not known			
22733	2733	22733	194_FDAMDD_v3b	C34H50O7	570.7566	defined organic	parent	tested chemical	Carbenoxolone	5697-56-3	single chemical compound	stereochem	(3beta)-3-[(3-carboxypropanoyl)oxy]-11-oxoolean-12-en-30-oic acid	OC(=O)CCC(=O)O[C@H]3CC[C@]2(C)[C@H]4C(=O)/C=C1/[C@@H]5C[C@](C)(CC[C@]5(C)CC[C@@]1(C)[C@]4(C)CC[C@H]2C3(C)C)C(O)=O	OC(=O)CCC(=O)O[C@H]3CC[C@]2(C)[C@H]4C(=O)/C=C1/[C@@H]5C[C@](C)(CC[C@]5(C)CC[C@@]1(C)[C@]4(C)CC[C@H]2C3(C)C)C(O)=O	"InChI=1/C34H50O7/c1-29(2)23-10-13-34(7)27(32(23,5)12-11-24(29)41-26(38)9-8-25(36)37)22(35)18-20-21-19-31(4,28(39)40)15-14-30(21,3)16-17-33(20,34)6/h18,21,23-24,27H,8-17,19H2,1-7H3,(H,36,37)(H,39,40)/t21-,23-,24-,27+,30+,31-,32-,33+,34+/m0/s1/f/h36,39H"	OBZHEBDUNPOCJG-JNOLXMIIDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiulcerative	5	0.008760302	2.057480938	34	Moderate	Low	form of drug administered not known			
22734	2734	22734	195_FDAMDD_v3b	C20H31NO3	333.46504	defined organic	parent	tested chemical	Carbetapentane	77-23-6	single chemical compound		2-{[2-(diethylamino)ethyl]oxy}ethyl 1-phenylcyclopentanecarboxylate	C2=CC=CC=C2C1(C(=O)OCCOCCN(CC)CC)CCCC1	C2=CC=CC=C2C1(C(=O)OCCOCCN(CC)CC)CCCC1	"InChI=1/C20H31NO3/c1-3-21(4-2)14-15-23-16-17-24-19(22)20(12-8-9-13-20)18-10-6-5-7-11-18/h5-7,10-11H,3-4,8-9,12-17H2,1-2H3"	CFJMRBQWBDQYMK-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antitussive	2	0.00599763	2.222020314	36	Moderate	High	form of drug administered not known			
22735	2735	22735	196_FDAMDD_v3b	C10H14N2O4	226.2292	defined organic	parent	tested chemical	Carbidopa	28860-95-9	single chemical compound	stereochem	"(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid"	Oc1ccc(C[C@](C)(NN)C(O)=O)cc1O	Oc1ccc(C[C@](C)(NN)C(O)=O)cc1O	"InChI=1/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1/f/h15H"	TZFNLOMSOLWIDK-GEPYNMGZDS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiparkinsonian	0.833	0.003682106	2.433903658	38	Moderate	High	form of drug administered not known; H20 [38821-49-7]			
22736	2736	22736	197_FDAMDD_v3b	C7H10N2O2S	186.2315	defined organic	parent	tested chemical	Carbimazole	22232-54-8	single chemical compound		"ethyl 3-methyl-2-thioxo-2,3-dihydro-1H-imidazole-1-carboxylate"	C1(=S)N(C)C=CN1C(=O)OCC	C1(=S)N(C)C=CN1C(=O)OCC	"InChI=1/C7H10N2O2S/c1-3-11-7(10)9-5-4-8(2)6(9)12/h4-5H,3H2,1-2H3"	CFOYWRHIYXMDOT-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		thyroid inhibitor	1	0.005369661	2.270053141	37	Moderate	High	form of drug administered not known			
22737	2737	22737	198_FDAMDD_v3b	C16H19ClN2O	290.78786	defined organic	parent	tested chemical	Carbinoxamine	486-16-8	single chemical compound		"2-{[(4-chlorophenyl)(pyridin-2-yl)methyl]oxy}-N,N-dimethylethanamine"	C2=CC=C(C(OCCN(C)C)C1=CC=C(Cl)C=C1)N=C2	C2=CC=C(C(OCCN(C)C)C1=CC=C(Cl)C=C1)N=C2	"InChI=1/C16H19ClN2O/c1-19(2)11-12-20-16(15-5-3-4-10-18-15)13-6-8-14(17)9-7-13/h3-10,16H,11-12H2,1-2H3"	OJFSXZCBGQGRNV-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	0.4	0.001375573	2.86151628	43	Moderate	High	form of drug administered not known			
22738	2738	22738	199_FDAMDD_v3b	C5H9NO4S	179.19426	defined organic	parent	tested chemical	Carbocysteine	2387-59-9	single chemical compound	"mixture of D,L [638-23-3] isomers, structure shown without stereochem"	S-(carboxymethyl)cysteine	OC(=O)CSCC(N)C(O)=O	OC(=O)CSCC(N)C(O)=O	"InChI=1/C5H9NO4S/c6-3(5(9)10)1-11-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/f/h7,9H"	GBFLZEXEOZUWRN-AUDIXQRPCH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		mucolytic; expectorant	37.5	0.209270096	0.679292826	19	Low	Low	form of drug administered not known			
22739	2739	22739	200_FDAMDD_v3b	C21H36O5	368.50754	defined organic	parent	tested chemical	Carboprost	35700-23-3	single chemical compound	stereochem	"(5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oic acid"	O=C(O)CCC/C=C\C[C@@H]1[C@H]([C@H](O)C[C@@H]1O)/C=C/[C@@](CCCCC)(C)O	O=C(O)CCC/C=C\C[C@@H]1[C@H]([C@H](O)C[C@@H]1O)/C=C/[C@@](CCCCC)(C)O	"InChI=1/C21H36O5/c1-3-4-9-13-21(2,26)14-12-17-16(18(22)15-19(17)23)10-7-5-6-8-11-20(24)25/h5,7,12,14,16-19,22-23,26H,3-4,6,8-11,13,15H2,1-2H3,(H,24,25)/b7-5-,14-12+/t16-,17-,18+,19-,21+/m1/s1/f/h24H"	DLJKPYFALUEJCK-PXVZNKHODF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		oxytocic	0.2	0.00054273	3.265416383	48	High-Moderate	High	form of drug administered not known			
22740	252	20252	201_FDAMDD_v3b	C7H13BrN2O2	237.0943	defined organic	parent	tested chemical	Carbromal	77-65-6	single chemical compound		N-(aminocarbonyl)-2-bromo-2-ethylbutanamide	BrC(C(=O)NC(=O)N)(CC)CC	BrC(C(=O)NC(=O)N)(CC)CC	"InChI=1/C7H13BrN2O2/c1-3-7(8,4-2)5(11)10-6(9)12/h3-4H2,1-2H3,(H3,9,10,11,12)/f/h10H,9H2"	OPNPQXLQERQBBV-ACESRIFFCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	16.7	0.070436109	1.152204642	24	Low	Low	form of drug administered not known			
22741	2741	22741	202_FDAMDD_v3b	C11H17N3O3S	271.33598	defined organic	parent	tested chemical	Carbutamide	339-43-5	single chemical compound		4-amino-N-[(butylamino)carbonyl]benzenesulfonamide	C1=C(N)C=CC(S(=O)(=O)NC(=O)NCCCC)=C1	C1=C(N)C=CC(S(=O)(=O)NC(=O)NCCCC)=C1	"InChI=1/C11H17N3O3S/c1-2-3-8-13-11(15)14-18(16,17)10-6-4-9(12)5-7-10/h4-7H,2-3,8,12H2,1H3,(H2,13,14,15)/f/h13-14H"	VDTNNGKXZGSZIP-KGCNKATMCQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	16.7	0.061547311	1.210790915	25	Low-Moderate	Low	form of drug administered not known			
22742	2742	22742	203_FDAMDD_v3b	C26H27NO10	513.49328	defined organic	parent	tested chemical	Carminomycin	50935-04-1	single chemical compound	stereochem	"(1S,3S)-3-acetyl-3,5,10,12-tetrahydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside"	CC(=O)[C@@]4(O)C[C@H](O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1)c5c(O)c3C(=O)c2c(O)cccc2C(=O)c3c(O)c5C4	CC(=O)[C@@]4(O)C[C@H](O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1)c5c(O)c3C(=O)c2c(O)cccc2C(=O)c3c(O)c5C4	"InChI=1/C26H27NO10/c1-9-21(30)13(27)6-16(36-9)37-15-8-26(35,10(2)28)7-12-18(15)25(34)20-19(23(12)32)22(31)11-4-3-5-14(29)17(11)24(20)33/h3-5,9,13,15-16,21,29-30,32,34-35H,6-8,27H2,1-2H3/t9-,13-,15-,16-,21+,26-/m0/s1"	XREUEWVEMYWFFA-CSKJXFQVBD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.676	0.001316473	2.880588068	43	Moderate	High	form of drug administered not known			
22743	2743	22743	204_FDAMDD_v3b	C5H9Cl2N3O2	214.0499	defined organic	parent	tested chemical	Carmustine	154-93-8	single chemical compound		"1,3-bis(2-chloroethyl)-1-nitrosourea"	N(C(=O)NCCCl)(N=O)CCCl	N(C(=O)NCCCl)(N=O)CCCl	"InChI=1/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)/f/h8H"	DLGOEMSEDOSKAD-FZOZFQFYCY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.0833	0.000389162	3.409870028	49	High-Moderate	High	form of drug administered not known			
22744	2744	22744	205_FDAMDD_v3b	C7H15NO3	161.1989	defined organic	parent	tested chemical	Carnitine	461-06-3	single chemical compound	ammonium	3-hydroxy-4-(trimethylammonio)butanoate	C[N+](C)(C)CC(O)CC([O-])=O	C[N+](C)(C)CC(O)CC([O-])=O	"InChI=1/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3"	PHIQHXFUZVPYII-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihyperlipoproteinemic	16.7	0.103598722	0.984645603	22	Low	Low	form of drug administered not known			
22745	2745	22745	206_FDAMDD_v3b	C24H31N3O2S	425.58684	defined organic	parent	tested chemical	Carphenazine	2622-30-2	single chemical compound		1-(10-{3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl}-10H-phenothiazin-2-yl)propan-1-one	C1=CC=C3C(=C1)N(CCCN2CCN(CCO)CC2)C4=C(S3)C=CC(C(=O)CC)=C4	C1=CC=C3C(=C1)N(CCCN2CCN(CCO)CC2)C4=C(S3)C=CC(C(=O)CC)=C4	"InChI=1/C24H31N3O2S/c1-2-22(29)19-8-9-24-21(18-19)27(20-6-3-4-7-23(20)30-24)11-5-10-25-12-14-26(15-13-25)16-17-28/h3-4,6-9,18,28H,2,5,10-17H2,1H3"	XZSMZRXAEFNJCU-UHFFFAOYAR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	6.67	0.015672477	1.804862356	31	Moderate	Low	form of drug administered not known			
22746	2746	22746	207_FDAMDD_v3b	C16H24N2O3	292.37336	defined organic	parent	tested chemical	Carteolol	51781-06-7	single chemical compound		"5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-3,4-dihydroquinolin-2(1H)-one"	C1=CC(OCC(O)CNC(C)(C)C)=C2C(=C1)NC(=O)CC2	C1=CC(OCC(O)CNC(C)(C)C)=C2C(=C1)NC(=O)CC2	"InChI=1/C16H24N2O3/c1-16(2,3)17-9-11(19)10-21-14-6-4-5-13-12(14)7-8-15(20)18-13/h4-6,11,17,19H,7-10H2,1-3H3,(H,18,20)/f/h18H"	LWAFSWPYPHEXKX-GPQMBLKYCB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal; antiarrhythmic; antiglaucomic	0.167	0.000571187	3.243221328	47	High-Moderate	High	form of drug administered not known			
22747	2747	22747	208_FDAMDD_v3b	C24H26N2O4	406.47424	defined organic	parent	tested chemical	Carvedilol	72956-09-3	single chemical compound		1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol	C1C=CC2=C(C=1)C4=C(N2)C=CC=C4OCC(O)CNCCOC3=C(OC)C=CC=C3	C1C=CC2=C(C=1)C4=C(N2)C=CC=C4OCC(O)CNCCOC3=C(OC)C=CC=C3	"InChI=1/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3"	OGHNVEJMJSYVRP-UHFFFAOYAP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal	0.417	0.001025895	2.988896973	45	High-Moderate	High	form of drug administered not known			
22748	2748	22748	209_FDAMDD_v3b	C15H14ClN3O4S	367.80736	defined organic	parent	tested chemical	Cefaclor	53994-73-3	single chemical compound	stereochem	"(6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(/Cl)CS[C@@H]1[C@@H]3NC(=O)[C@H](N)c2ccccc2)C(O)=O	O=C3N1/C(=C(/Cl)CS[C@@H]1[C@@H]3NC(=O)[C@H](N)c2ccccc2)C(O)=O	"InChI=1/C15H14ClN3O4S/c16-8-6-24-14-10(13(21)19(14)11(8)15(22)23)18-12(20)9(17)7-4-2-1-3-5-7/h1-5,9-10,14H,6,17H2,(H,18,20)(H,22,23)/t9-,10-,14-/m1/s1/f/h18,22H"	QYIYFLOTGYLRGG-UZCNBTKTDQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	25	0.067970364	1.167680407	24	Low	Low	form of drug administered not known			
22749	2749	22749	210_FDAMDD_v3b	C16H17N3O5S	363.38828	defined organic	parent	tested chemical	Cefadroxil	50370-12-2	single chemical compound	stereochem	"(6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(/C)CS[C@@H]1[C@@H]3NC(=O)[C@H](N)c2ccc(O)cc2)C(O)=O	O=C3N1/C(=C(/C)CS[C@@H]1[C@@H]3NC(=O)[C@H](N)c2ccc(O)cc2)C(O)=O	"InChI=1/C16H17N3O5S/c1-7-6-25-15-11(14(22)19(15)12(7)16(23)24)18-13(21)10(17)8-2-4-9(20)5-3-8/h2-5,10-11,15,20H,6,17H2,1H3,(H,18,21)(H,23,24)/t10-,11-,15-/m1/s1/f/h18,23H"	BOEGTKLJZSQCCD-GTUSEHSGDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	16.7	0.045956353	1.337654445	26	Low-Moderate	Low	form of drug administered not known			
22750	2750	22750	211_FDAMDD_v3b	C18H18N6O5S2	462.50272	defined organic	parent	tested chemical	Cefamandole	34444-01-4	single chemical compound	stereochem	"(6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)[C@H](O)c2ccccc2)CSc4nnnn4C)C(O)=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)[C@H](O)c2ccccc2)CSc4nnnn4C)C(O)=O	"InChI=1/C18H18N6O5S2/c1-23-18(20-21-22-23)31-8-10-7-30-16-11(15(27)24(16)12(10)17(28)29)19-14(26)13(25)9-5-3-2-4-6-9/h2-6,11,13,16,25H,7-8H2,1H3,(H,19,26)(H,28,29)/t11-,13-,16-/m1/s1/f/h19,28H"	OLVCFLKTBJRLHI-YKYLJYCNDB	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Cefamandole	antibacterial	100	0.216214945	0.665114291	19	Low	Low	form of drug administered not known			
22751	2751	22751	212_FDAMDD_v3b	C19H17N6NaO6S2	512.4946	defined organic	salt Na	tested chemical	Cefamandole nafate	42540-40-9	single chemical compound	stereochem	"sodium (6R,7R)-7-{[(2R)-2-(formyloxy)-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate"	[Na+].O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)[C@H](OC=O)c2ccccc2)CSc4nnnn4C)C([O-])=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)[C@H](OC=O)c2ccccc2)CSc4nnnn4C)C(O)=O	"InChI=1/C19H18N6O6S2.Na/c1-24-19(21-22-23-24)33-8-11-7-32-17-12(16(28)25(17)13(11)18(29)30)20-15(27)14(31-9-26)10-5-3-2-4-6-10;/h2-6,9,12,14,17H,7-8H2,1H3,(H,20,27)(H,29,30);/q;+1/p-1/t12-,14-,17-;/m1./s1/fC19H17N6O6S2.Na/h20H;/q-1;m"	ICZOIXFFVKYXOM-AIQAISKFDB	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Cefamandole	antibacterial	100	0.195124007	0.709689294	19	Low	Low	form of drug administered not known			
22752	2752	22752	213_FDAMDD_v3b	C18H18N6O5S2	462.50272	defined organic	parent	tested chemical	Cefatrizine	51627-14-6	single chemical compound	stereochem; tautomers	"(6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-8-oxo-3-[(1H-1,2,3-triazol-4-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	[H][C@]1(NC([C@H](N)C4=CC=C(O)C=C4)=O)[C@]2([H])N(C(C(O)=O)=C(CSC3=CNN=N3)CS2)C1=O	[H][C@]1(NC([C@H](N)C4=CC=C(O)C=C4)=O)[C@]2([H])N(C(C(O)=O)=C(CSC3=CNN=N3)CS2)C1=O	"InChI=1/C18H18N6O5S2/c19-12(8-1-3-10(25)4-2-8)15(26)21-13-16(27)24-14(18(28)29)9(7-31-17(13)24)6-30-11-5-20-23-22-11/h1-5,12-13,17,25H,6-7,19H2,(H,21,26)(H,28,29)(H,20,22,23)/t12-,13-,17-/m1/s1/f/h20-21,28H"	UOCJDOLVGGIYIQ-UHHNFKOVDF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	16.7	0.036107896	1.44239782	27	Low-Moderate	Low	form of drug administered not known			
22753	2753	22753	214_FDAMDD_v3b	C14H14N8O4S3	454.50716	defined organic	parent	tested chemical	Cefazolin	25953-19-9	single chemical compound	stereochem	"(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)Cn2cnnn2)CSc4nnc(C)s4)C(O)=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)Cn2cnnn2)CSc4nnc(C)s4)C(O)=O	"InChI=1/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1/f/h16,25H"	MLYYVTUWGNIJIB-JIWNMBEODB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.146752364	0.833414895	20	Low	Low	form of drug administered not known			
22754	2754	22754	215_FDAMDD_v3b	C16H15N5O7S2	453.4496	defined organic	parent	tested chemical	Cefixime	79350-37-1	single chemical compound	stereochem	"(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(carboxymethyl)oxy]imino}acetyl]amino}-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OCC(O)=O)\c2csc(N)n2)C=C)C(O)=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OCC(O)=O)\c2csc(N)n2)C=C)C(O)=O	"InChI=1/C16H15N5O7S2/c1-2-6-4-29-14-10(13(25)21(14)11(6)15(26)27)19-12(24)9(20-28-3-8(22)23)7-5-30-16(17)18-7/h2,5,10,14H,1,3-4H2,(H2,17,18)(H,19,24)(H,22,23)(H,26,27)/b20-9-/t10-,14-/m1/s1/f/h19,22,26H,17H2"	OKBVVJOGVLARMR-YZSCBPTQDK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	13.3	0.029330713	1.532677382	28	Low-Moderate	Low	form of drug administered not known			
22755	2755	22755	216_FDAMDD_v3b	C16H17N9O5S3	511.55848	defined organic	parent	tested chemical	Cefmenoxime	65085-01-0	single chemical compound	stereochem	"(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)/c2csc(N)n2)CSc4nnnn4C)C(O)=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)/c2csc(N)n2)CSc4nnnn4C)C(O)=O	"InChI=1/C16H17N9O5S3/c1-24-16(20-22-23-24)33-4-6-3-31-13-9(12(27)25(13)10(6)14(28)29)19-11(26)8(21-30-2)7-5-32-15(17)18-7/h5,9,13H,3-4H2,1-2H3,(H2,17,18)(H,19,26)(H,28,29)/b21-8-/t9-,13-/m1/s1/f/h19,28H,17H2"	HJJDBAOLQAWBMH-LBKJQUFLDN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.130385875	0.884769454	21	Low	Low	form of drug administered not known			
22756	2756	22756	217_FDAMDD_v3b	C15H17N7O5S3	471.53438	defined organic	parent	tested chemical	Cefmetazole	56796-20-4	single chemical compound	stereochem	"(6R,7S)-7-({[(cyanomethyl)thio]acetyl}amino)-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C2N1/C(=C(\CS[C@@H]1[C@]2(OC)NC(=O)CSCC#N)CSc3nnnn3C)C(O)=O	O=C2N1/C(=C(\CS[C@@H]1[C@]2(OC)NC(=O)CSCC#N)CSc3nnnn3C)C(O)=O	"InChI=1/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/t13-,15+/m1/s1/f/h17,24H"	SNBUBQHDYVFSQF-AMZBGSNHDE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	100	0.212073614	0.673513363	19	Low	Low	form of drug administered not known			
22757	2757	22757	218_FDAMDD_v3b	C20H20N6O7S4	584.6688	defined organic	parent	tested chemical	Cefodizime	69739-16-8	single chemical compound	stereochem	"(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-({[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]thio}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)/c2csc(N)n2)CSc4nc(C)c(CC(O)=O)s4)C(O)=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)/c2csc(N)n2)CSc4nc(C)c(CC(O)=O)s4)C(O)=O	"InChI=1/C20H20N6O7S4/c1-7-10(3-11(27)28)37-20(22-7)36-5-8-4-34-17-13(16(30)26(17)14(8)18(31)32)24-15(29)12(25-33-2)9-6-35-19(21)23-9/h6,13,17H,3-5H2,1-2H3,(H2,21,23)(H,24,29)(H,27,28)(H,31,32)/b25-12-/t13-,17-/m1/s1/f/h24,27,31H,21H2"	XDZKBRJLTGRPSS-LGPDDRENDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	33.3	0.056955322	1.244465685	25	Low-Moderate	Low	form of drug administered not known			
22758	2758	22758	219_FDAMDD_v3b	C18H18N6O8S3	542.56592	defined organic	parent	tested chemical	Cefonicid	61270-58-4	single chemical compound	stereochem	"(6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-8-oxo-3-({[1-(sulfomethyl)-1H-tetrazol-5-yl]thio}methyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)[C@H](O)c2ccccc2)CSc4nnnn4CS(O)(=O)=O)C(O)=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)[C@H](O)c2ccccc2)CSc4nnnn4CS(O)(=O)=O)C(O)=O	"InChI=1/C18H18N6O8S3/c25-13(9-4-2-1-3-5-9)14(26)19-11-15(27)24-12(17(28)29)10(6-33-16(11)24)7-34-18-20-21-22-23(18)8-35(30,31)32/h1-5,11,13,16,25H,6-8H2,(H,19,26)(H,28,29)(H,30,31,32)/t11-,13-,16-/m1/s1/f/h19,28,30H"	DYAIAHUQIPBDIP-VFAPHZIUDB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	16.7	0.03077967	1.51173604	28	Low-Moderate	Low	form of drug administered not known			
22759	2759	22759	220_FDAMDD_v3b	C25H27N9O8S2	645.66738	defined organic	parent	tested chemical	Cefoperazone	62893-19-0	single chemical compound	stereochem	"(6R,7R)-7-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-(4-hydroxyphenyl)acetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C4N1/C(=C(\CS[C@@H]1[C@@H]4NC(=O)[C@H](NC(=O)N2CCN(CC)C(=O)C2=O)c3ccc(O)cc3)CSc5nnnn5C)C(O)=O	O=C4N1/C(=C(\CS[C@@H]1[C@@H]4NC(=O)[C@H](NC(=O)N2CCN(CC)C(=O)C2=O)c3ccc(O)cc3)CSc5nnnn5C)C(O)=O	"InChI=1/C25H27N9O8S2/c1-3-32-8-9-33(21(39)20(32)38)24(42)27-15(12-4-6-14(35)7-5-12)18(36)26-16-19(37)34-17(23(40)41)13(10-43-22(16)34)11-44-25-28-29-30-31(25)2/h4-7,15-16,22,35H,3,8-11H2,1-2H3,(H,26,36)(H,27,42)(H,40,41)/t15-,16-,22-/m1/s1/f/h26-27,40H"	GCFBRXLSHGKWDP-YZNZJDDKDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	200	0.309757015	0.50897885	17	Low	Low	form of drug administered not known			
22760	2760	22760	221_FDAMDD_v3b	C20H21N7O6S2	519.55404	defined organic	parent	tested chemical	Ceforanide	60925-61-3	single chemical compound	stereochem	"(6R,7R)-7-({[2-(aminomethyl)phenyl]acetyl}amino)-3-({[1-(carboxymethyl)-1H-tetrazol-5-yl]thio}methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)Cc2ccccc2CN)CSc4nnnn4CC(O)=O)C(O)=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)Cc2ccccc2CN)CSc4nnnn4CC(O)=O)C(O)=O	"InChI=1/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1/f/h22,29,32H"	SLAYUXIURFNXPG-FTHPKKNZDD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	33.3	0.064093429	1.193186493	25	Low	Low	form of drug administered not known			
22761	2761	22761	222_FDAMDD_v3b	C16H17N5O7S2	455.46548	defined organic	parent	tested chemical	Cefotaxime	63527-52-6	single chemical compound	stereochem; tautomers	"(6R,7R)-3-[(acetyloxy)methyl]-7-({(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)\c2csc(N)n2)COC(C)=O)C(O)=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)\c2csc(N)n2)COC(C)=O)C(O)=O	"InChI=1/C16H17N5O7S2/c1-6(22)28-3-7-4-29-14-10(13(24)21(14)11(7)15(25)26)19-12(23)9(20-27-2)8-5-30-16(17)18-8/h5,10,14H,3-4H2,1-2H3,(H2,17,18)(H,19,23)(H,25,26)/b20-9+/t10-,14-/m1/s1/f/h19,25H,17H2"	GPRBEKHLDVQUJE-VEWNRTKBDL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	200	0.439111214	0.357425471	15	Low	Low	form of drug administered not known			
22762	2762	22762	223_FDAMDD_v3b	C17H17N7O8S4	575.61898	defined organic	parent	tested chemical	Cefotetan	69712-56-7	single chemical compound	stereochem	"(6R,7S)-7-({[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino)-7-methoxy-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C1[C@](NC(C3S\C(S3)=C(C(O)=O)/C(N)=O)=O)(OC)[C@]2([H])N1C(C(O)=O)=C(CSC4=NN=NN4C)CS2	O=C1[C@](NC(C3S\C(S3)=C(C(O)=O)/C(N)=O)=O)(OC)[C@]2([H])N1C(C(O)=O)=C(CSC4=NN=NN4C)CS2	"InChI=1/C17H17N7O8S4/c1-23-16(20-21-22-23)34-4-5-3-33-15-17(32-2,14(31)24(15)7(5)11(29)30)19-9(26)13-35-12(36-13)6(8(18)25)10(27)28/h13,15H,3-4H2,1-2H3,(H2,18,25)(H,19,26)(H,27,28)(H,29,30)/b12-6-/t13?,15-,17+/m1/s1/f/h19,27,29H,18H2"	SRZNHPXWXCNNDU-QLVVOTHLDC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.115875262	0.936009272	22	Low	Low	form of drug administered not known; structure modified v3b			
22763	2763	22763	224_FDAMDD_v3b	C18H23N9O4S3	525.62812	defined organic	parent	tested chemical	Cefotiam	61622-34-2	single chemical compound	stereochem	"(6R,7R)-7-{[(2-amino-1,3-thiazol-4-yl)acetyl]amino}-3-[({1-[2-(dimethylamino)ethyl]-1H-tetrazol-5-yl}thio)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)Cc2csc(N)n2)CSc4nnnn4CCN(C)C)C(O)=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)Cc2csc(N)n2)CSc4nnnn4CCN(C)C)C(O)=O	"InChI=1/C18H23N9O4S3/c1-25(2)3-4-26-18(22-23-24-26)34-7-9-6-32-15-12(14(29)27(15)13(9)16(30)31)21-11(28)5-10-8-33-17(19)20-10/h8,12,15H,3-7H2,1-2H3,(H2,19,20)(H,21,28)(H,30,31)/t12-,15-/m1/s1/f/h21,30H,19H2"	QYQDKDWGWDOFFU-WDAPPIQIDK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	100	0.190248573	0.720678591	19	Low	Low	form of drug administered not known			
22764	2764	22764	225_FDAMDD_v3b	C16H17N3O7S2	427.45208	defined organic	parent	tested chemical	Cefoxitin	35607-66-0	single chemical compound	stereochem	"(6R,7S)-3-{[(aminocarbonyl)oxy]methyl}-7-(methyloxy)-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C1[C@](NC(CC3=CC=CS3)=O)(OC)[C@]2([H])N1C(C(O)=O)=C(COC(N)=O)CS2	O=C1[C@](NC(CC3=CC=CS3)=O)(OC)[C@]2([H])N1C(C(O)=O)=C(COC(N)=O)CS2	"InChI=1/C16H17N3O7S2/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22)/t14-,16+/m1/s1/f/h18,21H,17H2"	WZOZEZRFJCJXNZ-BPLXXLJGDR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	200	0.467888705	0.329857439	15	Low	Low	form of drug administered not known			
22765	2765	22765	226_FDAMDD_v3b	C15H17N5O6S2	427.45538	defined organic	parent	tested chemical	Cefpodoxime	80210-62-4	single chemical compound	stereochem; tautomers	"(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)/c2csc(N)n2)COC)C(O)=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)/c2csc(N)n2)COC)C(O)=O	"InChI=1/C15H17N5O6S2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13H,3-4H2,1-2H3,(H2,16,17)(H,18,21)(H,23,24)/b19-8-/t9-,13-/m1/s1/f/h18,23H,16H2"	WYUSVOMTXWRGEK-IXFSIYRGDJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Cefpodoxime	antibacterial	10	0.023394255	1.630890788	29	Low-Moderate	Low	form of drug administered not known			
22766	2766	22766	227_FDAMDD_v3b	C21H27N5O9S2	557.59718	defined organic	parent	tested chemical	Cefpodoxime proxetil	87239-81-4	single chemical compound	stereochem; tautomers	"1-({[(1-methylethyl)oxy]carbonyl}oxy)ethyl (6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-[(methyloxy)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)\c2csc(N)n2)COC)C(=O)OC(C)OC(=O)OC(C)C	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)\c2csc(N)n2)COC)C(=O)OC(C)OC(=O)OC(C)C	"InChI=1/C21H27N5O9S2/c1-9(2)33-21(30)35-10(3)34-19(29)15-11(6-31-4)7-36-18-14(17(28)26(15)18)24-16(27)13(25-32-5)12-8-37-20(22)23-12/h8-10,14,18H,6-7H2,1-5H3,(H2,22,23)(H,24,27)/b25-13-/t10?,14-,18-/m1/s1/f/h24H,22H2"	LTINZAODLRIQIX-DWNPDFQGDP	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Cefpodoxime	antibacterial	10	0.017934094	1.746320569	31	Moderate	Low	form of drug administered not known			
22767	2767	22767	228_FDAMDD_v3b	C18H19N3O5S	389.42556	defined organic	parent	representative isomer in mixture	Cefprozil	92665-29-7	mixture or formulation	"mixture of Z,E isomers; structure shown Z; stereochem"	"(6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-8-oxo-3-[(1Z)-prop-1-en-1-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	N/31[C@@H]([C@@H](C1=O)NC([C@H](N)c2ccc(cc2)O)=O)SCC(=C\3C(=O)O)\C=C/C	N/31[C@@H]([C@@H](C1=O)NC([C@H](N)c2ccc(cc2)O)=O)SCC(=C\3C(=O)O)\C=C/C	"InChI=1/C18H19N3O5S/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26)/b3-2-/t12-,13-,17-/m1/s1/f/h20,25H"	WDLWHQDACQUCJR-NEIIIGCYDT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	16.7	0.042883677	1.367707982	26	Low-Moderate	Low	form of drug administered not known			
22768	2768	22768	229_FDAMDD_v3b	C16H19N3O5S	365.40416	defined organic	parent	tested chemical	Cefroxadine	51762-05-1	single chemical compound	stereochem	"(6R,7R)-7-{[(2R)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetyl]amino}-3-methoxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C1N(C(C(O)=O)=C(OC)CS2)[C@@]2([H])[C@@]([H])1NC([C@H](N)C3=CCC=CC3)=O	O=C1N(C(C(O)=O)=C(OC)CS2)[C@@]2([H])[C@@]([H])1NC([C@H](N)C3=CCC=CC3)=O	"InChI=1/C16H19N3O5S/c1-24-9-7-25-15-11(14(21)19(15)12(9)16(22)23)18-13(20)10(17)8-5-3-2-4-6-8/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1/f/h18,22H"	RDMOROXKXONCAL-KPHHXKKPDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	33.3	0.091131967	1.040329254	23	Low	Low	form of drug administered not known; structure modified v3b			
22769	2769	22769	230_FDAMDD_v3b	C22H20N4O8S2	532.5462	defined organic	parent	tested chemical	Cefsulodin	62587-73-9	single chemical compound	stereochem; ammonium; zwitterion	"(6R,7R)-3-{[4-(aminocarbonyl)pyridinium-1-yl]methyl}-8-oxo-7-{[phenyl(sulfo)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(c2ccccc2)S(O)(=O)=O)C[n+]4ccc(cc4)C(N)=O)C([O-])=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(c2ccccc2)S(O)(=O)=O)C[n+]4ccc(cc4)C(N)=O)C([O-])=O	"InChI=1/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17?,21-/m1/s1/f/h24,32H,23H2"	SYLKGLMBLAAGSC-KJUZAPTDDL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	100	0.187777136	0.72635729	19	Low	Low	form of drug administered not known			
22770	2770	22770	231_FDAMDD_v3b	C22H22N6O7S2	546.57608	defined organic	parent	tested chemical	Ceftazidime	72558-82-8	single chemical compound	stereochem; ammonium; zwitterion	"(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetyl}amino)-8-oxo-3-(pyridinium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate"	O=C1[C@@H](NC(/C(C4=CSC(N)=N4)=N/OC(C)(C)C(O)=O)=O)[C@]2([H])N1C(C([O-])=O)=C(C[N+]3=CC=CC=C3)CS2	O=C1[C@@H](NC(/C(C4=CSC(N)=N4)=N/OC(C)(C)C(O)=O)=O)[C@]2([H])N1C(C([O-])=O)=C(C[N+]3=CC=CC=C3)CS2	"InChI=1/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18-/m1/s1/f/h25,33H,23H2"	ORFOPKXBNMVMKC-OFCFLKAKDM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	133	0.243333005	0.613798981	18	Low	Low	form of drug administered not known; pentahydrate [78439-06-2]			
22771	2771	22771	232_FDAMDD_v3b	C13H12N8O4S3	440.48058	defined organic	parent	tested chemical	Ceftezole	26973-24-0	single chemical compound	stereochem	"(6R,7R)-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-3-[(1,3,4-thiadiazol-2-ylthio)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)Cn2cnnn2)CSc4nncs4)C(O)=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)Cn2cnnn2)CSc4nncs4)C(O)=O	"InChI=1/C13H12N8O4S3/c22-7(1-20-4-14-18-19-20)16-8-10(23)21-9(12(24)25)6(2-26-11(8)21)3-27-13-17-15-5-28-13/h4-5,8,11H,1-3H2,(H,16,22)(H,24,25)/t8-,11-/m1/s1/f/h16,24H"	DZMVCVMFETWNIU-AEYBGAGNDX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.151425518	0.819800932	20	Low	Low	form of drug administered not known			
22772	2772	22772	233_FDAMDD_v3b	C13H13N5O5S2	383.40282	defined organic	parent	tested chemical	Ceftizoxime	68401-81-0	single chemical compound	stereochem	"(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)/c2csc(N)n2)C(O)=O	O=C3N1/C(=C\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)/c2csc(N)n2)C(O)=O	"InChI=1/C13H13N5O5S2/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22)/b17-7-/t8-,11-/m1/s1/f/h16,21H,14H2"	NNULBSISHYWZJU-BHJHJVPYDK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	100	0.260822286	0.583655303	18	Low	Low	form of drug administered not known			
22773	2773	22773	234_FDAMDD_v3b	C18H18N8O7S3	554.57992	defined organic	parent	tested chemical	Ceftriaxone	73384-59-5	single chemical compound	stereochem; tautomers	"(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	N1\2C(=O)[C@H]([C@H]1SC/C(=C/2C(=O)O)CS/C3=N/C(C(=N/N3C)\O)=O)NC(C(\c4nc(N)sc4)=N/OC)=O	N1\2C(=O)[C@H]([C@H]1SC/C(=C/2C(=O)O)CS/C3=N/C(C(=N/N3C)\O)=O)NC(C(\c4nc(N)sc4)=N/OC)=O	"InChI=1/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1/f/h21,29,31H,19H2"	VAAUVRVFOQPIGI-GFNSOUMQDY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.120271214	0.919838307	21	Low	Low	form of drug administered not known			
22774	2774	22774	235_FDAMDD_v3b	C16H16N4O8S	424.3852	defined organic	parent	tested chemical	Cefuroxime	55268-75-2	single chemical compound	stereochem	"(6R,7R)-3-{[(aminocarbonyl)oxy]methyl}-7-({(2E)-2-furan-2-yl-2-[(methyloxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)\c2ccco2)COC(N)=O)C(O)=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)\c2ccco2)COC(N)=O)C(O)=O	"InChI=1/C16H16N4O8S/c1-26-19-9(8-3-2-4-27-8)12(21)18-10-13(22)20-11(15(23)24)7(5-28-16(17)25)6-29-14(10)20/h2-4,10,14H,5-6H2,1H3,(H2,17,25)(H,18,21)(H,23,24)/b19-9+/t10-,14-/m1/s1/f/h18,23H,17H2"	JFPVXVDWJQMJEE-LPXIZCLTDP	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 3	Cefuroxime	antibacterial	16.7	0.039351042	1.405043759	27	Low-Moderate	Low	form of drug administered not known			
22775	2775	22775	236_FDAMDD_v3b	C20H22N4O10S	510.47448	defined organic	parent	tested chemical	Cefuroxime axetil	64544-07-6	single chemical compound	stereochem	"1-(acetyloxy)ethyl (6R,7R)-3-{[(aminocarbonyl)oxy]methyl}-7-({(2E)-2-furan-2-yl-2-[(methyloxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)\c2ccco2)COC(N)=O)C(=O)OC(C)OC(C)=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)\c2ccco2)COC(N)=O)C(=O)OC(C)OC(C)=O	"InChI=1/C20H22N4O10S/c1-9(25)33-10(2)34-19(28)15-11(7-32-20(21)29)8-35-18-14(17(27)24(15)18)22-16(26)13(23-30-3)12-5-4-6-31-12/h4-6,10,14,18H,7-8H2,1-3H3,(H2,21,29)(H,22,26)/b23-13+/t10?,14-,18-/m1/s1/f/h22H,21H2"	KEJCWVGMRLCZQQ-RSALOGKHDK	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 3	Cefuroxime	antibacterial	16.7	0.032714662	1.485257564	28	Low-Moderate	Low	form of drug administered not known			
22776	2776	22776	237_FDAMDD_v3b	C23H28N4O11S	568.55362	defined organic	parent	tested chemical	Cefuroxime pivoxetil	100680-33-9	single chemical compound	stereochem	"1-{[2-methyl-2-(methyloxy)propanoyl]oxy}ethyl (6R,7R)-3-{[(aminocarbonyl)oxy]methyl}-7-({(2E)-2-furan-2-yl-2-[(methyloxy)imino]acetyl}amino)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)\c2ccco2)COC(N)=O)C(=O)OC(C)OC(=O)C(C)(C)OC	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)C(=N\OC)\c2ccco2)COC(N)=O)C(=O)OC(C)OC(=O)C(C)(C)OC	"InChI=1/C23H28N4O11S/c1-11(38-21(31)23(2,3)33-4)37-20(30)16-12(9-36-22(24)32)10-39-19-15(18(29)27(16)19)25-17(28)14(26-34-5)13-7-6-8-35-13/h6-8,11,15,19H,9-10H2,1-5H3,(H2,24,32)(H,25,28)/b26-14+/t11?,15-,19-/m1/s1/f/h25H,24H2"	MGYPWVCKENORQX-NVOPFNSQDK	Clinical Reports 	Maximum Recommended Daily Dose	human	3 of 3	Cefuroxime	antibacterial	16.7	0.029372779	1.532054958	28	Low-Moderate	Low	form of drug administered not known			
22777	2777	22777	238_FDAMDD_v3b	C17H14F3N3O2S	381.3722	defined organic	parent	tested chemical	Celecoxib	169590-42-5	single chemical compound		4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide	C3(S(N)(=O)=O)=CC=C(N2N=C(C(F)(F)F)C=C2C1=CC=C(C)C=C1)C=C3	C3(S(N)(=O)=O)=CC=C(N2N=C(C(F)(F)F)C=C2C1=CC=C(C)C=C1)C=C3	"InChI=1/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)/f/h21H2"	RZEKVGVHFLEQIL-QVUQFMIFCW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory; antiarthritic	6.67	0.017489476	1.757223198	31	Moderate	Low	form of drug administered not known			
22778	259	20259	239_FDAMDD_v3b	C20H33N3O4	379.4984	defined organic	parent	tested chemical	Celiprolol	56980-93-9	single chemical compound		"3-[3-acetyl-4-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)phenyl]-1,1-diethylurea"	C1(=C(C=CC(=C1)NC(N(CC)CC)=O)OCC(CNC(C)(C)C)O)C(C)=O	C1(=C(C=CC(=C1)NC(N(CC)CC)=O)OCC(CNC(C)(C)C)O)C(C)=O	"InChI=1/C20H33N3O4/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26)/f/h22H"	JOATXPAWOHTVSZ-QWOVJGMICP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal	6.67	0.017575832	1.755084115	31	Moderate	Low	form of drug administered not known			
22779	2779	22779	240_FDAMDD_v3b	C13H13N3O6S	339.32382	defined organic	parent	tested chemical	Cephacetrile	10206-21-0	single chemical compound	stereochem	"(6R,7R)-3-[(acetyloxy)methyl]-7-[(cyanoacetyl)amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)CC#N)COC(C)=O)C(O)=O	O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)CC#N)COC(C)=O)C(O)=O	"InChI=1/C13H13N3O6S/c1-6(17)22-4-7-5-23-12-9(15-8(18)2-3-14)11(19)16(12)10(7)13(20)21/h9,12H,2,4-5H2,1H3,(H,15,18)(H,20,21)/t9-,12-/m1/s1/f/h15,20H"	RRYMAQUWDLIUPV-GFFDLXNODK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	100	0.294703743	0.530614348	17	Low	Low	form of drug administered not known			
22780	2780	22780	241_FDAMDD_v3b	C16H17N3O4S	347.38888	defined organic	parent	tested chemical	Cephalexin	15686-71-2	single chemical compound	stereochem	"(6R,7R)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(/C)CS[C@@H]1[C@@H]3NC(=O)[C@H](N)c2ccccc2)C(O)=O	O=C3N1/C(=C(/C)CS[C@@H]1[C@@H]3NC(=O)[C@H](N)c2ccccc2)C(O)=O	"InChI=1/C16H17N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-6,10-11,15H,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1/f/h18,22H"	ZAIPMKNFIOOWCQ-KPHHXKKPDB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.192003843	0.716690079	19	Low	Low	form of drug administered not known			
22781	2781	22781	242_FDAMDD_v3b	C18H19N3O6S	405.42496	defined organic	parent	tested chemical	Cephaloglycin	3577-01-3	single chemical compound	stereochem	"(6R,7R)-3-[(acetyloxy)methyl]-7-{[(2R)-2-amino-2-phenylacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C1N(C(C(O)=O)=C(COC(C)=O)CS2)[C@@]2([H])[C@@]([H])1NC([C@H](N)C3=CC=CC=C3)=O	O=C1N(C(C(O)=O)=C(COC(C)=O)CS2)[C@@]2([H])[C@@]([H])1NC([C@H](N)C3=CC=CC=C3)=O	"InChI=1/C18H19N3O6S/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10/h2-6,12-13,17H,7-8,19H2,1H3,(H,20,23)(H,25,26)/t12-,13-,17-/m1/s1/f/h20,25H"	FUBBGQLTSCSAON-UTNIVKLSDO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	33.3	0.082136038	1.085466249	23	Low	Low	form of drug administered not known			
22782	2782	22782	243_FDAMDD_v3b	C19H17N3O4S2	415.48598	defined organic	parent	tested chemical	Cephaloridine	50-59-9	single chemical compound	stereochem; ammonium; zwitterion	"(6R,7R)-8-oxo-3-(pyridinium-1-ylmethyl)-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)Cc2cccs2)C[n+]4ccccc4)C([O-])=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)Cc2cccs2)C[n+]4ccccc4)C([O-])=O	"InChI=1/C19H17N3O4S2/c23-14(9-13-5-4-8-27-13)20-15-17(24)22-16(19(25)26)12(11-28-18(15)22)10-21-6-2-1-3-7-21/h1-8,15,18H,9-11H2,(H-,20,23,25,26)/t15-,18-/m1/s1/f/h20H"	CZTQZXZIADLWOZ-ZUKAWQGZDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.160534899	0.79443054	20	Low	Low	form of drug administered not known			
22783	2783	22783	244_FDAMDD_v3b	C16H16N2O6S2	396.43804	defined organic	parent	tested chemical	Cephalothin	153-61-7	single chemical compound	stereochem	"(6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-[(2-thienylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C1N(C(C(O)=O)=C(COC(C)=O)CS2)[C@@]2([H])[C@@]([H])1NC(CC3=CC=CS3)=O	O=C1N(C(C(O)=O)=C(COC(C)=O)CS2)[C@@]2([H])[C@@]([H])1NC(CC3=CC=CS3)=O	"InChI=1/C16H16N2O6S2/c1-8(19)24-6-9-7-26-15-12(14(21)18(15)13(9)16(22)23)17-11(20)5-10-3-2-4-25-10/h2-4,12,15H,5-7H2,1H3,(H,17,20)(H,22,23)/t12-,15-/m1/s1/f/h17,22H"	XIURVHNZVLADCM-OQJUERBUDY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	100	0.252246227	0.59817532	18	Low	Low	form of drug administered not known			
22784	2784	22784	245_FDAMDD_v3b	C17H17N3O6S2	423.46338	defined organic	parent	tested chemical	Cephapirin	21593-23-7	single chemical compound	stereochem	"(6R,7R)-3-[(acetyloxy)methyl]-8-oxo-7-{[(pyridin-4-ylthio)acetyl]amino}-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)CSc2ccncc2)COC(C)=O)C(O)=O	O=C3N1/C(=C(\CS[C@@H]1[C@@H]3NC(=O)CSc2ccncc2)COC(C)=O)C(O)=O	"InChI=1/C17H17N3O6S2/c1-9(21)26-6-10-7-28-16-13(15(23)20(16)14(10)17(24)25)19-12(22)8-27-11-2-4-18-5-3-11/h2-5,13,16H,6-8H2,1H3,(H,19,22)(H,24,25)/t13-,16-/m1/s1/f/h19,24H"	UQLLWWBDSUHNEB-ULQZQHJVDW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	100	0.236147929	0.62681586	18	Low	Low	form of drug administered not known			
22785	2785	22785	246_FDAMDD_v3b	C16H19N3O4S	349.40476	defined organic	parent	tested chemical	Cephradine	38821-53-3	single chemical compound	stereochem	"(6R,7R)-7-{[(2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C1N(C(C(O)=O)=C(C)CS2)[C@@]2([H])[C@@]([H])1NC([C@H](N)C3=CCC=CC3)=O	O=C1N(C(C(O)=O)=C(C)CS2)[C@@]2([H])[C@@]([H])1NC([C@H](N)C3=CCC=CC3)=O	"InChI=1/C16H19N3O4S/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23)/t10-,11-,15-/m1/s1/f/h18,22H"	RDLPVSKMFDYCOR-KPHHXKKPDD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.190896083	0.719202983	19	Low	Low	form of drug administered not known			
22786	2786	22786	247_FDAMDD_v3b	C26H34FNO5	459.5502632	defined organic	parent	tested chemical	Cerivastatin	145599-86-6	single chemical compound	stereochem	"(3R,5S,6E)-7-{4-(4-fluorophenyl)-2,6-bis(1-methylethyl)-5-[(methyloxy)methyl]pyridin-3-yl}-3,5-dihydroxyhept-6-enoic acid"	CC(C)c1nc(c(/C=C/[C@@H](O)C[C@@H](O)CC(O)=O)c(c1COC)c2ccc(F)cc2)C(C)C	CC(C)c1nc(c(/C=C/[C@@H](O)C[C@@H](O)CC(O)=O)c(c1COC)c2ccc(F)cc2)C(C)C	"InChI=1/C26H34FNO5/c1-15(2)25-21(11-10-19(29)12-20(30)13-23(31)32)24(17-6-8-18(27)9-7-17)22(14-33-5)26(28-25)16(3)4/h6-11,15-16,19-20,29-30H,12-14H2,1-5H3,(H,31,32)/b11-10+/t19-,20-/m1/s1/f/h31H"	SEERZIQQUAZTOL-CMHQMAEVDV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihyperlipoproteinemic	0.005	1.08802E-05	4.963363015	67	High	High	form of drug administered not known			
22787	2787	22787	248_FDAMDD_v3b	C21H25ClN2O3	388.8878	defined organic	parent	tested chemical	Cetirizine	83881-51-0	single chemical compound		[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]acetic acid	C(C1=CC=C(Cl)C=C1)(C2=CC=CC=C2)N3CCN(CCOCC(O)=O)CC3	C(C1=CC=C(Cl)C=C1)(C2=CC=CC=C2)N3CCN(CCOCC(O)=O)CC3	"InChI=1/C21H25ClN2O3/c22-19-8-6-18(7-9-19)21(17-4-2-1-3-5-17)24-12-10-23(11-13-24)14-15-27-16-20(25)26/h1-9,21H,10-16H2,(H,25,26)/f/h25H"	ZKLPARSLTMPFCP-LNNLXFCOCW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	16.8	0.043200121	1.364515037	26	Low-Moderate	Low	form of drug administered not known			
22788	2788	22788	249_FDAMDD_v3b	C20H38Cl2N2O3S2	489.5633	defined organic	complex bis 2HCl H2O	tested chemical	Cevimeline	153504-70-2	single chemical compound	stereochem; parent [107233-08-9]	"(2R,2'R)-2'-methylspiro[4-azabicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane] dihydrochloride hydrate"	C[C@@H]3O[C@]1(CS3)C2CCN(CC2)C1.C[C@@H]6O[C@]4(CS6)C5CCN(CC5)C4.O.Cl.Cl	C[C@@H]3O[C@]2(CN1CCC2CC1)CS3	"InChI=1/2C10H17NOS.2ClH.H2O/c2*1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11;;;/h2*8-9H,2-7H2,1H3;2*1H;1H2/t2*8-,10-;;;/m11.../s1"	ZSTLCHCDLIUXJE-GMLJRNIPBF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		selective agonist (tear and salivary production)	3	0.00612791	2.212687599	36	Moderate	Moderate	form of drug administered not known; structure modified v3b			
22789	2789	22789	250_FDAMDD_v3b	C17H20ClNO	289.7998	defined organic	parent	tested chemical	Chlophedianol	791-35-5	single chemical compound		1-(2-chlorophenyl)-3-(dimethylamino)-1-phenylpropan-1-ol	C2=CC=C(C(O)(CCN(C)C)C1=CC=CC=C1Cl)C=C2	C2=CC=C(C(O)(CCN(C)C)C1=CC=CC=C1Cl)C=C2	"InChI=1/C17H20ClNO/c1-19(2)13-12-17(20,14-8-4-3-5-9-14)15-10-6-7-11-16(15)18/h3-11,20H,12-13H2,1-2H3"	WRCHFMBCVFFYEQ-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antitussive	1.67	0.005762599	2.23938161	36	Moderate	High	form of drug administered not known			
22790	88	20088	251_FDAMDD_v3b	C8H11Cl3O6	309.52834	defined organic	parent	tested chemical	Chloralose-alpha	15879-93-3	single chemical compound	stereochem	"1,2-O-[(1R)-2,2,2-trichloroethylidene]-alpha-D-glucofuranose"	O[C@H]1[C@@H]([C@H](O)CO)O[C@H]2[C@@H]1O[C@@H]([C@@](Cl)(Cl)Cl)O2	O[C@H]1[C@@H]([C@H](O)CO)O[C@H]2[C@@H]1O[C@@H]([C@@](Cl)(Cl)Cl)O2	"InChI=1/C8H11Cl3O6/c9-8(10,11)7-16-5-3(14)4(2(13)1-12)15-6(5)17-7/h2-7,12-14H,1H2/t2-,3+,4-,5-,6-,7-/m1/s1"	OJYGBLRPYBAHRT-IPQSZEQABF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	8.33	0.026911914	1.570055417	29	Low-Moderate	Low	form of drug administered not known; structure modified v3b			
22791	263	20263	252_FDAMDD_v3b	C14H19Cl2NO2	304.2122	defined organic	parent	tested chemical	Chlorambucil	305-03-3	single chemical compound		4-{4-[bis(2-chloroethyl)amino]phenyl}butanoic acid	ClCCN(C1=CC=C(C=C1)CCCC(=O)O)CCCl	ClCCN(C1=CC=C(C=C1)CCCC(=O)O)CCCl	"InChI=1/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)/f/h18H"	JCKYGMPEJWAADB-GPQMBLKYCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.2	0.000657436	3.182146631	47	High-Moderate	High	form of drug administered not known			
22792	265	20265	253_FDAMDD_v3b	C11H12Cl2N2O5	323.1294	defined organic	parent	tested chemical	Chloramphenicol	56-75-7	single chemical compound	stereochem	"2,2-dichloro-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]acetamide"	O=C(C(Cl)Cl)N[C@H](CO)[C@@H](C1=CC=C([N+]([O-])=O)C=C1)O	O=C(C(Cl)Cl)N[C@H](CO)[C@@H](C1=CC=C([N+]([O-])=O)C=C1)O	"InChI=1/C11H12Cl2N2O5/c12-10(13)11(18)14-8(5-16)9(17)6-1-3-7(4-2-6)15(19)20/h1-4,8-10,16-17H,5H2,(H,14,18)/t8-,9-/m1/s1/f/h14H"	WIIZWVCIJKGZOK-TUYINDPHDP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial; antirickettsial	100	0.309473542	0.509376474	17	Low	Low	form of drug administered not known			
22793	2793	22793	254_FDAMDD_v3b	C16H14ClN3O	299.75486	defined organic	parent	tested chemical	Chlordiazepoxide	58-25-3	single chemical compound		"7-chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide"	C1=C(Cl)C=C3C(=C1)N=C(NC)CN(=O)=C3C2=CC=CC=C2	C1=C(Cl)C=C3C(=C1)N=C(NC)CN(=O)=C3C2=CC=CC=C2	"InChI=1/C16H14ClN3O/c1-18-15-10-20(21)16(11-5-3-2-4-6-11)13-9-12(17)7-8-14(13)19-15/h2-9H,10H2,1H3,(H,18,19)/f/h18H"	ANTSCNMPPGJYLG-GPQMBLKYCL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	1.67	0.005571219	2.254049762	36	Moderate	High	form of drug administered not known			
22794	2794	22794	255_FDAMDD_v3b	C11H16ClN5	253.73124	defined organic	parent	tested chemical	Chlorguanide	500-92-5	single chemical compound		N-(4-chlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide	C1=C(Cl)C=CC(NC(=N)NC(=N)NC(C)C)=C1	C1=C(Cl)C=CC(NC(=N)NC(=N)NC(C)C)=C1	"InChI=1/C11H16ClN5/c1-7(2)15-10(13)17-11(14)16-9-5-3-8(12)4-6-9/h3-7H,1-2H3,(H5,13,14,15,16,17)/f/h13-17H"	SSOLNOMRVKKSON-FLTHVXQUCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimalarial	3.33	0.013124123	1.881929708	32	Moderate	Moderate	form of drug administered not known			
22795	2795	22795	256_FDAMDD_v3b	C8H15Cl3O3	265.5619	defined organic	parent	tested chemical	Chlorhexadol	3563-58-4	single chemical compound		"2-methyl-4-[(2,2,2-trichloro-1-hydroxyethyl)oxy]pentan-2-ol"	C(O)(C(Cl)(Cl)Cl)OC(C)CC(C)(O)C	C(O)(C(Cl)(Cl)Cl)OC(C)CC(C)(O)C	"InChI=1/C8H15Cl3O3/c1-5(4-7(2,3)13)14-6(12)8(9,10)11/h5-6,12-13H,4H2,1-3H3"	QVFWZNCVPCJQOP-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		hypnotic	26.7	0.100541531	0.997654506	22	Low	Low	form of drug administered not known			
22796	2796	22796	257_FDAMDD_v3b	C21H27ClO3	362.89028	defined organic	parent	tested chemical	Chlormadinone	1961-77-9	single chemical compound	stereochem	"6-chloro-17-hydroxypregna-4,6-diene-3,20-dione"	CC(=O)[C@@]2(O)CC[C@H]3[C@@H]4/C=C(/Cl)\C1=C\C(=O)CC[C@]1(C)[C@H]4CC[C@]23C	CC(=O)[C@@]2(O)CC[C@H]3[C@@H]4/C=C(/Cl)\C1=C\C(=O)CC[C@]1(C)[C@H]4CC[C@]23C	"InChI=1/C21H27ClO3/c1-12(23)21(25)9-6-16-14-11-18(22)17-10-13(24)4-7-19(17,2)15(14)5-8-20(16,21)3/h10-11,14-16,25H,4-9H2,1-3H3/t14-,15+,16+,19-,20+,21+/m1/s1"	VUHJZBBCZGVNDZ-TTYLFXKOBS	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Chlormadinone	progestogen; antineoplastic	0.0333	9.17633E-05	4.037331102	56	High	High	form of drug administered not known			
22797	274	20274	258_FDAMDD_v3b	C23H29ClO4	404.92696	defined organic	parent	tested chemical	Chlormadinone acetate	302-22-7	single chemical compound	stereochem	"6-chloro-3,20-dioxopregna-4,6-dien-17-yl acetate"	CC(=O)[C@]2(CC[C@H]3[C@@H]4/C=C(/Cl)\C1=C\C(=O)CC[C@]1(C)[C@H]4CC[C@]23C)OC(C)=O	CC(=O)[C@]2(CC[C@H]3[C@@H]4/C=C(/Cl)\C1=C\C(=O)CC[C@]1(C)[C@H]4CC[C@]23C)OC(C)=O	"InChI=1/C23H29ClO4/c1-13(25)23(28-14(2)26)10-7-18-16-12-20(24)19-11-15(27)5-8-21(19,3)17(16)6-9-22(18,23)4/h11-12,16-18H,5-10H2,1-4H3/t16-,17+,18+,21-,22+,23+/m1/s1"	QMBJSIBWORFWQT-DFXBJWIEBX	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Chlormadinone	progestogen; antineoplastic	0.0333	8.22371E-05	4.08493246	57	High	High	form of drug administered not known			
22798	2798	22798	259_FDAMDD_v3b	C11H12ClNO3S	273.73588	defined organic	parent	tested chemical	Chlormezanone	80-77-3	single chemical compound		"2-(4-chlorophenyl)-3-methyl-1,3-thiazinan-4-one 1,1-dioxide"	C2CC(=O)N(C)C(C1=CC=C(Cl)C=C1)S2(=O)=O	C2CC(=O)N(C)C(C1=CC=C(Cl)C=C1)S2(=O)=O	"InChI=1/C11H12ClNO3S/c1-13-10(14)6-7-17(15,16)11(13)8-2-4-9(12)5-3-8/h2-5,11H,6-7H2,1H3"	WEQAYVWKMWHEJO-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic; skeletal muscle relaxant	6.67	0.024366554	1.613205892	29	Low-Moderate	Low	form of drug administered not known			
22799	2799	22799	260_FDAMDD_v3b	C13H19ClN2O2	270.75516	defined organic	parent	tested chemical	Chloroprocaine	133-16-4	single chemical compound		2-(diethylamino)ethyl 4-amino-2-chlorobenzoate	C1=C(N)C=C(Cl)C(C(=O)OCCN(CC)CC)=C1	C1=C(N)C=C(Cl)C(C(=O)OCCN(CC)CC)=C1	"InChI=1/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3"	VDANGULDQQJODZ-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		local anesthetic	8.33	0.030765803	1.511931741	28	Low-Moderate	Low	form of drug administered not known			
22800	2800	22800	261_FDAMDD_v3b	C7H6ClN3O4S2	295.7232	defined organic	parent	tested chemical	Chlorothiazide	58-94-6	single chemical compound		"6-chloro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide"	NS(=O)(=O)c2cc1c(/N=C\NS1(=O)=O)cc2Cl	NS(=O)(=O)c2cc1c(/N=C\NS1(=O)=O)cc2Cl	"InChI=1/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)/f/h11H,9H2"	JBMKAUGHUNFTOL-NTGMBSGFCK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic	33.3	0.112605301	0.948441164	22	Low	Low	form of drug administered not known			
22801	2801	22801	262_FDAMDD_v3b	C9H5Cl2NO	214.0481	defined organic	parent	tested chemical	Chloroxine	773-76-2	single chemical compound		"5,7-dichloroquinolin-8-ol"	C1(Cl)=CC(Cl)=C2C(=C1O)N=CC=C2	C1(Cl)=CC(Cl)=C2C(=C1O)N=CC=C2	"InChI=1/C9H5Cl2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H"	WDFKMLRRRCGAKS-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiseborrhetic	66.7	0.311612203	0.506385543	17	Low	Low	form of drug administered not known			
22802	320	20320	263_FDAMDD_v3b	C9H16ClN3O7	313.69224	defined organic	parent	tested chemical	Chlorozotocin	54749-90-5	single chemical compound	stereochem	2-({[(2-chloroethyl)(nitroso)amino]carbonyl}amino)-2-deoxy-alpha-D-glucopyranose	O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(=O)N(CCCl)N=O	O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(=O)N(CCCl)N=O	"InChI=1/C9H16ClN3O7/c10-1-2-13(12-19)9(18)11-5-7(16)6(15)4(3-14)20-8(5)17/h4-8,14-17H,1-3H2,(H,11,18)/t4-,5-,6-,7-,8+/m1/s1/f/h11H"	MYBLAOJMRYYKMS-WOOJMJPXDS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	4.05	0.012910743	1.889048752	32	Moderate	Moderate	form of drug administered not known			
22803	2803	22803	264_FDAMDD_v3b	C10H12ClNO4	245.65958	defined organic	parent	tested chemical	Chlorphenesin carbamate	886-74-8	single chemical compound		3-[(4-chlorophenyl)oxy]-2-hydroxypropyl carbamate	C1=C(Cl)C=CC(OCC(O)COC(N)=O)=C1	C1=C(Cl)C=CC(OCC(O)COC(N)=O)=C1	"InChI=1/C10H12ClNO4/c11-7-1-3-9(4-2-7)15-5-8(13)6-16-10(12)14/h1-4,8,13H,5-6H2,(H2,12,14)/f/h12H2"	SKPLBLUECSEIFO-GAJRPKRDCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		topical antifungal	40	0.162826949	0.788273714	20	Low	Low	form of drug administered not known			
22804	2804	22804	265_FDAMDD_v3b	C16H19ClN2	274.78846	defined organic	parent	tested chemical	Chlorpheniramine	132-22-9	single chemical compound		"3-(4-chlorophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine"	C2=CC(C(CCN(C)C)C1=CC=C(Cl)C=C1)=NC=C2	C2=CC(C(CCN(C)C)C1=CC=C(Cl)C=C1)=NC=C2	"InChI=1/C16H19ClN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3"	SOYKEARSMXGVTM-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	0.133	0.000484009	3.315146849	48	High-Moderate	High	form of drug administered not known			
22805	2805	22805	266_FDAMDD_v3b	C18H22ClNO	303.82638	defined organic	parent	tested chemical	Chlorphenoxamide	77-38-3	single chemical compound		"2-{[1-(4-chlorophenyl)-1-phenylethyl]oxy}-N,N-dimethylethanamine"	C2(Cl)=CC=C(C(C)(OCCN(C)C)C1=CC=CC=C1)C=C2	C2(Cl)=CC=C(C(C)(OCCN(C)C)C1=CC=CC=C1)C=C2	"InChI=1/C18H22ClNO/c1-18(21-14-13-20(2)3,15-7-5-4-6-8-15)16-9-11-17(19)12-10-16/h4-12H,13-14H2,1-3H3"	KKHPNPMTPORSQE-UHFFFAOYAK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiamebic	37.5	0.123425754	0.908594211	21	Low	Low	form of drug administered not known			
22806	2806	22806	267_FDAMDD_v3b	C10H14ClN	183.67786	defined organic	parent	tested chemical	Chlorphentermine	461-78-9	single chemical compound		1-(4-chlorophenyl)-2-methylpropan-2-amine	C1=C(Cl)C=CC(CC(C)(C)N)=C1	C1=C(Cl)C=CC(CC(C)(C)N)=C1	"InChI=1/C10H14ClN/c1-10(2,12)7-8-3-5-9(11)6-4-8/h3-6H,7,12H2,1-2H3"	ZCKAMNXUHHNZLN-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anorexic	1.08	0.005879859	2.230633055	36	Moderate	High	form of drug administered not known			
22807	2807	22807	268_FDAMDD_v3b	C11H15Cl2N5	288.1763	defined organic	parent	tested chemical	Chlorproguanil	537-21-3	single chemical compound		"N-(3,4-dichlorophenyl)-N'-(1-methylethyl)imidodicarbonimidic diamide"	C1(Cl)=C(Cl)C=CC(NC(=N)NC(=N)NC(C)C)=C1	C1(Cl)=C(Cl)C=CC(NC(=N)NC(=N)NC(C)C)=C1	"InChI=1/C11H15Cl2N5/c1-6(2)16-10(14)18-11(15)17-7-3-4-8(12)9(13)5-7/h3-6H,1-2H3,(H5,14,15,16,17,18)/f/h14-18H"	ISZNZKHCRKXXAU-HNCZQRRQCH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimalarial	0.333	0.001155543	2.937214027	44	Moderate	High	form of drug administered not known			
22808	2808	22808	269_FDAMDD_v3b	C17H19ClN2S	318.86416	defined organic	parent	tested chemical	Chlorpromazine	50-53-3	single chemical compound		"3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine"	C1=CC2=C(C=C1)N(CCCN(C)C)C3=C(S2)C=CC(Cl)=C3	C1=CC2=C(C=C1)N(CCCN(C)C)C3=C(S2)C=CC(Cl)=C3	"InChI=1/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3"	ZPEIMTDSQAKGNT-UHFFFAOYAX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiemetic; antipsychotic	16.7	0.052373399	1.280889237	25	Low-Moderate	Low	form of drug administered not known			
22809	322	20322	270_FDAMDD_v3b	C10H13ClN2O3S	276.7398	defined organic	parent	tested chemical	Chlorpropamide	94-20-2	single chemical compound		4-chloro-N-[(propylamino)carbonyl]benzenesulfonamide	O=S(=O)(C1=CC=C(C=C1)Cl)NC(=O)NCCC	O=S(=O)(C1=CC=C(C=C1)Cl)NC(=O)NCCC	"InChI=1/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14)/f/h12-13H"	RKWGIWYCVPQPMF-BAINRFMOCW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	12.5	0.045168783	1.34516161	26	Low-Moderate	Low	form of drug administered not known			
22810	2810	22810	271_FDAMDD_v3b	C18H18ClNS	315.86022	defined organic	parent	tested chemical	Chlorprothixene	113-59-7	single chemical compound	stereochem; tautomers	"(3E)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine"	C1=CC=C2C(=C1)C(=CCCN(C)C)C3=C(S2)C=CC(Cl)=C3	C1=CC=C2C(=C1)C(=CCCN(C)C)C3=C(S2)C=CC(Cl)=C3	"InChI=1/C18H18ClNS/c1-20(2)11-5-7-14-15-6-3-4-8-17(15)21-18-10-9-13(19)12-16(14)18/h3-4,6-10,12H,5,11H2,1-2H3/b14-7+"	WSPOMRSOLSGNFJ-VGOFMYFVBI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	3.33	0.010542638	1.9770507	33	Moderate	Moderate	form of drug administered not known			
22811	2811	22811	272_FDAMDD_v3b	C22H23ClN2O8	478.8796	defined organic	parent	tested chemical	Chlortetracycline	57-62-5	single chemical compound	stereochem	"(4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide"	CN(C)[C@@H]2C(\O)=C(\C(N)=O)C(=O)[C@@]3(O)C(/O)=C4/C(=O)c1c(O)ccc(Cl)c1[C@@](C)(O)[C@H]4C[C@@H]23	CN(C)[C@@H]2C(\O)=C(\C(N)=O)C(=O)[C@@]3(O)C(/O)=C4/C(=O)c1c(O)ccc(Cl)c1[C@@](C)(O)[C@H]4C[C@@H]23	"InChI=1/C22H23ClN2O8/c1-21(32)7-6-8-15(25(2)3)17(28)13(20(24)31)19(30)22(8,33)18(29)11(7)16(27)12-10(26)5-4-9(23)14(12)21/h4-5,7-8,15,26,28-29,32-33H,6H2,1-3H3,(H2,24,31)/t7-,8-,15-,21-,22-/m0/s1/f/h24H2"	CYDMQBQPVICBEU-LRSTVQQODJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial; antiamebic	33.3	0.069537312	1.157782103	24	Low	Low	form of drug administered not known			
22812	2812	22812	273_FDAMDD_v3b	C14H11ClN2O4S	338.76614	defined organic	parent	tested chemical	Chlorthalidone	77-36-1	single chemical compound		"2-chloro-5-(1-hydroxy-3-oxo-2,3-dihydro-1H-isoindol-1-yl)benzenesulfonamide"	C1=CC=C3C(=C1)C(O)(C2=CC(S(N)(=O)=O)=C(Cl)C=C2)NC3=O	C1=CC=C3C(=C1)C(O)(C2=CC(S(N)(=O)=O)=C(Cl)C=C2)NC3=O	"InChI=1/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)/f/h17H,16H2"	JIVPVXMEBJLZRO-QDYITYEQCH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic; antihypertensive	0.833	0.002458923	2.609254994	40	Moderate	High	form of drug administered not known			
22813	2813	22813	274_FDAMDD_v3b	C7H4ClNO2	169.56516	defined organic	parent	tested chemical	Chlorzoxazone	95-25-0	single chemical compound	tautomers	"5-chloro-1,3-benzoxazol-2(3H)-one"	C1=C(Cl)C=C2C(=C1)OC(=O)N2	C1=C(Cl)C=C2C(=C1)OC(=O)N2	"InChI=1/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10)/f/h9H"	TZFWDZFKRBELIQ-BGGKNDAXCM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	33.3	0.196384682	0.706892391	19	Low	Low	form of drug administered not known			
22814	2814	22814	275_FDAMDD_v3b	C20H2Cl4I4Na2O5	1017.6363	defined organic	salt 2Na	tested chemical	CI Acid red 94	632-69-9	single chemical compound		"disodium 2,3,4,5-tetrachloro-6-(2,4,5,7-tetraiodo-6-oxido-3-oxo-3H-xanthen-9-yl)benzoate"	[Na+].[Na+].[O-]C(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C=2c3cc(I)c([O-])c(I)c3OC=1C=2\C=C(\I)C(=O)C=1I	OC(=O)c4c(Cl)c(Cl)c(Cl)c(Cl)c4C=2c3cc(I)c(O)c(I)c3OC=1C=2\C=C(\I)C(=O)C=1I	"InChI=1/C20H4Cl4I4O5.2Na/c21-10-8(9(20(31)32)11(22)13(24)12(10)23)7-3-1-5(25)16(29)14(27)18(3)33-19-4(7)2-6(26)17(30)15(19)28;;/h1-2,29H,(H,31,32);;/q;2*+1/p-2/fC20H2Cl4I4O5.2Na/h29h;;/q-2;2m"	UWBXIFCTIZXXLS-FQQRRAIECI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	2	0.001965339	2.706562595	41	Moderate	High	form of drug administered not known			
22815	2815	22815	276_FDAMDD_v3b	C34H24N6Na4O14S4	960.8052	defined organic	salt 4Na	tested chemical	CI Direct Blue 53	314-13-6	single chemical compound	C.I. 23860	"tetrasodium 6,6'-[(3,3'-dimethylbiphenyl-4,4'-diyl)di(E)diazene-2,1-diyl]bis(4-amino-5-hydroxynaphthalene-1,3-disulfonate)"	[O-]S(=O)(C1=CC(S([O-])(=O)=O)=C(C2=C1C=CC(/N=N/C3=CC=C(C6=CC=C(C(C)=C6)/N=N/C5=CC=C(C4=C5O)C(S([O-])(=O)=O)=CC(S([O-])(=O)=O)=C4N)C=C3C)=C2O)N)=O.[Na+].[Na+].[Na+].[Na+]	OS(=O)(=O)c6cc(c(N)c5c6ccc(/N=N/c1ccc(cc1C)c4ccc(/N=N/c3ccc2c(cc(c(N)c2c3O)S(O)(=O)=O)S(O)(=O)=O)c(C)c4)c5O)S(O)(=O)=O	"InChI=1/C34H28N6O14S4.4Na/c1-15-11-17(3-7-21(15)37-39-23-9-5-19-25(55(43,44)45)13-27(57(49,50)51)31(35)29(19)33(23)41)18-4-8-22(16(2)12-18)38-40-24-10-6-20-26(56(46,47)48)14-28(58(52,53)54)32(36)30(20)34(24)42;;;;/h3-14,41-42H,35-36H2,1-2H3,(H,43,44,45)(H,46,47,48)(H,49,50,51)(H,52,53,54);;;;/q;4*+1/p-4/b39-37+,40-38+;;;;/fC34H24N6O14S4.4Na/q-4;4m"	ATNOAWAQFYGAOY-ZMCKBSJRDR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	0.333	0.000346584	3.460191111	50	High	High	form of drug administered not known			
22816	2816	22816	277_FDAMDD_v3b	C32H22N6Na2O6S2	696.66322	defined organic	salt 2Na	tested chemical	CI Direct Red 28	573-58-0	single chemical compound	C.I. 22120	"disodium 3,3'-[biphenyl-4,4'-diyldi(E)diazene-2,1-diyl]bis(4-aminonaphthalene-1-sulfonate)"	[Na+].[Na+].[O-]S(=O)(=O)c5cc(/N=N/c1ccc(cc1)c2ccc(cc2)/N=N/c4cc(c3ccccc3c4N)S([O-])(=O)=O)c(N)c6ccccc56	OS(=O)(=O)c5cc(/N=N/c1ccc(cc1)c2ccc(cc2)/N=N/c4cc(c3ccccc3c4N)S(O)(=O)=O)c(N)c6ccccc56	"InChI=1/C32H24N6O6S2.2Na/c33-31-25-7-3-1-5-23(25)29(45(39,40)41)17-27(31)37-35-21-13-9-19(10-14-21)20-11-15-22(16-12-20)36-38-28-18-30(46(42,43)44)24-6-2-4-8-26(24)32(28)34;;/h1-18H,33-34H2,(H,39,40,41)(H,42,43,44);;/q;2*+1/p-2/b37-35+,38-36+;;/fC32H22N6O6S2.2Na/q-2;2m"	IQFVPQOLBLOTPF-BFXBVCAWDS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	3.75	0.005382802	2.268991615	37	Moderate	Moderate	form of drug administered not known			
22817	2817	22817	278_FDAMDD_v3b	C22H20O13	492.3864	defined organic	parent	tested chemical	CI Natural Red 4	1260-17-9	single chemical compound	stereochem	"(1R)-1,5-anhydro-1-(7-carboxy-1,3,4,6-tetrahydroxy-8-methyl-9,10-dioxo-9,10-dihydroanthracen-2-yl)-D-glucitol"	O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]1CO)c4c(O)c3C(=O)c2c(C)c(C(O)=O)c(O)cc2C(=O)c3c(O)c4O	O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@@H]1CO)c4c(O)c3C(=O)c2c(C)c(C(O)=O)c(O)cc2C(=O)c3c(O)c4O	"InChI=1/C22H20O13/c1-4-8-5(2-6(24)9(4)22(33)34)13(25)10-11(15(8)27)16(28)12(18(30)17(10)29)21-20(32)19(31)14(26)7(3-23)35-21/h2,7,14,19-21,23-24,26,28-32H,3H2,1H3,(H,33,34)/t7-,14-,19+,20-,21-/m1/s1/f/h33H"	DGQLVPJVXFOQEV-MFOAEAKKDY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	8.33	0.016917608	1.771661048	31	Moderate	Low	form of drug administered not known			
22818	2322	22322	279_FDAMDD_v3b	C15H14O6	290.272	defined organic	parent	tested chemical	Cianidanol	154-23-4	single chemical compound	stereochem	"(2R,3S)-2-(3,4-dihydroxyphenyl)-3,4-dihydro-2H-chromene-3,5,7-triol"	O[C@H]1CC3=C(C=C(O)C=C3O)O[C@@H]1[C@@]2=CC(O)=C(O)C=C2	O[C@H]1CC3=C(C=C(O)C=C3O)O[C@@H]1[C@@]2=CC(O)=C(O)C=C2	"InChI=1/C15H14O6/c16-8-4-11(18)9-6-13(20)15(21-14(9)5-8)7-1-2-10(17)12(19)3-7/h1-5,13,15-20H,6H2/t13-,15+/m0/s1"	PFTAWBLQPZVEMU-DZGCQCFKBX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		hepatoprotectant; antidiarrheal	33.3	0.114719987	0.940360912	22	Low	Low	form of drug administered not known; (-) isomer [490-46-0]			
22819	2819	22819	280_FDAMDD_v3b	C18H18N2	262.34892	defined organic	parent	tested chemical	Cifenline	53267-01-9	single chemical compound		"2-(2,2-diphenylcyclopropyl)-4,5-dihydro-1H-imidazole"	C4=CC=C(C3(C1=CC=CC=C1)C(C2=NCCN2)C3)C=C4	C4=CC=C(C3(C1=CC=CC=C1)C(C2=NCCN2)C3)C=C4	"InChI=1/C18H18N2/c1-3-7-14(8-4-1)18(15-9-5-2-6-10-15)13-16(18)17-19-11-12-20-17/h1-10,16H,11-13H2,(H,19,20)/f/h19H"	IPOBOOXFSRWSHL-LILDFLRNCD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiarrhythmic	6.5	0.024776165	1.605965924	29	Low-Moderate	Low	form of drug administered not known			
22820	329	20329	281_FDAMDD_v3b	C10H16N6S	252.3392	defined organic	parent	tested chemical	Cimetidine	51481-61-9	single chemical compound	tautomers	2-cyano-1-methyl-3-(2-{[(5-methyl-1H-imidazol-4-yl)methyl]thio}ethyl)guanidine	C1(CSCCNC(NC)=NC#N)=C(C)NC=N1	C1(CSCCNC(NC)=NC#N)=C(C)NC=N1	"InChI=1/C10H16N6S/c1-8-9(16-7-15-8)5-17-4-3-13-10(12-2)14-6-11/h7H,3-5H2,1-2H3,(H,15,16)(H2,12,13,14)/f/h12-13,15H/b14-10+"	AQIXAKUUQRKLND-CMEUZDGQDL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiulcerative	40	0.15851679	0.799924731	20	Low	Low	form of drug administered not known			
22821	2821	22821	282_FDAMDD_v3b	C26H28N2	368.51392	defined organic	parent	tested chemical	Cinnarizine	298-57-7	single chemical compound	stereochem	1-(diphenylmethyl)-4-[(2E)-3-phenylprop-2-en-1-yl]piperazine	C4=CC=CC(C(C1=CC=CC=C1)N3CCN(CC=CC2=CC=CC=C2)CC3)=C4	C4=CC=CC(C(C1=CC=CC=C1)N3CCN(CC=CC2=CC=CC=C2)CC3)=C4	"InChI=1/C26H28N2/c1-4-11-23(12-5-1)13-10-18-27-19-21-28(22-20-27)26(24-14-6-2-7-15-24)25-16-8-3-9-17-25/h1-17,26H,18-22H2/b13-10+"	DERZBLKQOCDDDZ-JLHYYAGUBG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic; peripheral vasodilator	3.75	0.010176006	1.99242263	33	Moderate	Moderate	form of drug administered not known			
22822	2822	22822	283_FDAMDD_v3b	C12H10N2O5	262.2182	defined organic	parent	tested chemical	Cinoxacin	28657-80-9	single chemical compound		"1-ethyl-4-oxo-1,4-dihydro[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid"	C1C3=C(C=C2C=1C(=O)C(C(=O)O)=NN2CC)OCO3	C1C3=C(C=C2C=1C(=O)C(C(=O)O)=NN2CC)OCO3	"InChI=1/C12H10N2O5/c1-2-14-7-4-9-8(18-5-19-9)3-6(7)11(15)10(13-14)12(16)17/h3-4H,2,5H2,1H3,(H,16,17)/f/h16H"	VDUWPHTZYNWKRN-WYUMXYHSCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	16.7	0.063687418	1.195946361	25	Low-Moderate	Low	form of drug administered not known			
22823	331	20331	284_FDAMDD_v3b	C13H14Cl2O3	289.1545	defined organic	parent	tested chemical	Ciprofibrate	52214-84-3	single chemical compound		"2-{[4-(2,2-dichlorocyclopropyl)phenyl]oxy}-2-methylpropanoic acid"	ClC1(C(C2=CC=C(C=C2)OC(C(=O)O)(C)C)C1)Cl	ClC1(C(C2=CC=C(C=C2)OC(C(=O)O)(C)C)C1)Cl	"InChI=1/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17)/f/h16H"	KPSRODZRAIWAKH-WYUMXYHSCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihyperlipoproteinemic	1.67	0.005775459	2.238413484	36	Moderate	High	form of drug administered not known			
22824	2824	22824	285_FDAMDD_v3b	C17H18FN3O3	331.3415232	defined organic	parent	tested chemical	Ciprofloxacin	85721-33-1	single chemical compound		"1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylic acid"	C2(N1CCNCC1)=C(F)C=C4C(=C2)N(C3CC3)C=C(C(=O)O)C4=O	C2(N1CCNCC1)=C(F)C=C4C(=C2)N(C3CC3)C=C(C(=O)O)C4=O	"InChI=1/C17H18FN3O3/c18-13-7-11-14(8-15(13)20-5-3-19-4-6-20)21(10-1-2-10)9-12(16(11)22)17(23)24/h7-10,19H,1-6H2,(H,23,24)/f/h23H"	MYSWGUAQZAJSOK-MPIMZMORCO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	13.3	0.040139853	1.396424223	27	Low-Moderate	Low	form of drug administered not known			
22825	2825	22825	286_FDAMDD_v3b	C23H29ClFN3O4	465.9454632	defined organic	parent	tested chemical	Cisapride	81098-60-4	single chemical compound		4-amino-5-chloro-N-[1-{3-[(4-fluorophenyl)oxy]propyl}-3-(methyloxy)piperidin-4-yl]-2-(methyloxy)benzamide	C3=CC(F)=CC=C3OCCCN2CCC(NC(=O)C1=CC(Cl)=C(N)C=C1OC)C(OC)C2	C3=CC(F)=CC=C3OCCCN2CCC(NC(=O)C1=CC(Cl)=C(N)C=C1OC)C(OC)C2	"InChI=1/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/f/h27H"	DCSUBABJRXZOMT-LELJVTLKCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		peristaltic stimulant	1.33	0.002854411	2.544483447	40	Moderate	High	form of drug administered not known			
22826	2826	22826	287_FDAMDD_v3b	C20H21FN2O	324.3919432	defined organic	parent	tested chemical	Citalopram	59729-33-8	single chemical compound		"1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile"	CN(C)CCCC1(C3=CC=C(F)C=C3)OCC2=CC(C#N)=CC=C21	CN(C)CCCC1(C3=CC=C(F)C=C3)OCC2=CC(C#N)=CC=C21	"InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3"	WSEQXVZVJXJVFP-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	1	0.003082691	2.511070059	39	Moderate	High	form of drug administered not known			
22827	332	20332	288_FDAMDD_v3b	C6H8O7	192.1235	defined organic	parent	tested chemical	Citric acid	77-92-9	single chemical compound		"2-hydroxypropane-1,2,3-tricarboxylic acid"	OC(CC(=O)O)(CC(=O)O)C(=O)O	OC(CC(=O)O)(CC(=O)O)C(=O)O	"InChI=1/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/f/h7,9,11H"	KRKNYBCHXYNGOX-CUNNJMNPCP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bactericide	100	0.520498533	0.28358049	14	Low	Low	form of drug administered not known			
22828	2828	22828	289_FDAMDD_v3b	C10H12ClN5O3	285.687	defined organic	parent	tested chemical	Cladribine	4291-63-8	single chemical compound	stereochem	2-chloro-2'-deoxyadenosine	Nc3nc(Cl)nc2c3ncn2[C@H]1C[C@H](O)[C@@H](CO)O1	Nc3nc(Cl)nc2c3ncn2[C@H]1C[C@H](O)[C@@H](CO)O1	"InChI=1/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1/f/h12H2"	PTOAARAWEBMLNO-WQWZRESVDN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.09	0.00031503	3.501647969	50	High	High	form of drug administered not known; ActivityCategory_MRDD_mmol changed from Moderate to High in v3a			
22829	2829	22829	290_FDAMDD_v3b	C38H69NO13	747.9534	defined organic	parent	tested chemical	Clarithromycin	81103-11-9	single chemical compound	stereochem	"6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-12,13-dihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-7-methoxy-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione"	CN(C)[C@H]3C[C@@H](C)O[C@@H](O[C@@H]2C(C)[C@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)OC)[C@@H]3O	CN(C)[C@H]3C[C@@H](C)O[C@@H](O[C@@H]2C(C)[C@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)OC)[C@@H]3O	"InChI=1/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22?,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1"	AGOYDEPGAOXOCK-LERDGGEFBP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	8.33	0.011137057	1.953229539	33	Moderate	Low	form of drug administered not known			
22830	2830	22830	291_FDAMDD_v3b	C8H9NO5	199.16076	defined organic	parent	tested chemical	Clavulanic acid	58001-44-8	single chemical compound	stereochem	"(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	O=C(C2)N([C@]([H])1[C@@](O)=O)[C@]2([H])O\C1=C/CO	O=C(C2)N([C@]([H])1[C@@](O)=O)[C@]2([H])O\C1=C/CO	"InChI=1/C8H9NO5/c10-2-1-4-7(8(12)13)9-5(11)3-6(9)14-4/h1,6-7,10H,2-3H2,(H,12,13)/b4-1-/t6-,7-/m1/s1/f/h12H"	HZZVJAQRINQKSD-UFPVBIFCDT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	6.25	0.031381684	1.503323758	28	Low-Moderate	Low	form of drug administered not known; structure modified v3b			
22831	2831	22831	292_FDAMDD_v3b	C20H24ClN3O2	373.87646	defined organic	parent	tested chemical	Clebopride	55905-53-8	single chemical compound		4-amino-5-chloro-2-(methyloxy)-N-[1-(phenylmethyl)piperidin-4-yl]benzamide	C3=C(Cl)C(N)=CC(OC)=C3C(=O)NC2CCN(CC1=CC=CC=C1)CC2	C3=C(Cl)C(N)=CC(OC)=C3C(=O)NC2CCN(CC1=CC=CC=C1)CC2	"InChI=1/C20H24ClN3O2/c1-26-19-12-18(22)17(21)11-16(19)20(25)23-15-7-9-24(10-8-15)13-14-5-3-2-4-6-14/h2-6,11-12,15H,7-10,13,22H2,1H3,(H,23,25)/f/h23H"	BVPWJMCABCPUQY-MPIMZMORCO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiemetic; antispasmodic	0.025	6.6867E-05	4.174788113	58	High	High	form of drug administered not known			
22832	2832	22832	293_FDAMDD_v3b	C21H26ClNO	343.89024	defined organic	parent	tested chemical	Clemastine	15686-51-8	single chemical compound	stereochem	(2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine	ClC2=CC=[C@@](C=C2)[C@@](OCC[C@@H]3N(C)CCC3)(C)C1=CC=CC=C1	ClC2=CC=[C@@](C=C2)[C@@](OCC[C@@H]3N(C)CCC3)(C)C1=CC=CC=C1	"InChI=1/C21H26ClNO/c1-21(17-7-4-3-5-8-17,18-10-12-19(22)13-11-18)24-16-14-20-9-6-15-23(20)2/h3-5,7-8,10-13,20H,6,9,14-16H2,1-2H3/t20-,21-/m1/s1"	YNNUSGIPVFPVBX-NHCUHLMSBN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	0.134	0.000389659	3.409315052	49	High-Moderate	High	form of drug administered not known; structure modified v3b			
22833	2833	22833	294_FDAMDD_v3b	C12H18Cl2N2O	277.19012	defined organic	parent	tested chemical	Clenbuterol	37148-27-9	single chemical compound		"1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino]ethanol"	C1(Cl)=C(N)C(Cl)=CC(C(O)CNC(C)(C)C)=C1	C1(Cl)=C(N)C(Cl)=CC(C(O)CNC(C)(C)C)=C1	"InChI=1/C12H18Cl2N2O/c1-12(2,3)16-6-10(17)7-4-8(13)11(15)9(14)5-7/h4-5,10,16-17H,6,15H2,1-3H3"	STJMRWALKKWQGH-UHFFFAOYAC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiasthmatic	0.001	3.60763E-06	5.442777746	72	High	High	form of drug administered not known			
22834	2834	22834	295_FDAMDD_v3b	C16H19ClO2	278.77386	defined organic	parent	tested chemical	Clidanac	34148-01-1	single chemical compound		"6-chloro-5-cyclohexyl-2,3-dihydro-1H-indene-1-carboxylic acid"	C1=C(C2CCCCC2)C(Cl)=CC3=C1CCC3C(=O)O	C1=C(C2CCCCC2)C(Cl)=CC3=C1CCC3C(=O)O	"InChI=1/C16H19ClO2/c17-15-9-13-11(6-7-12(13)16(18)19)8-14(15)10-4-2-1-3-5-10/h8-10,12H,1-7H2,(H,18,19)/f/h18H"	OIRAEJWYWSAQNG-GPQMBLKYCB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory; antipyretic	0.75	0.002690353	2.570190785	40	Moderate	High	form of drug administered not known			
22835	2835	22835	296_FDAMDD_v3b	C22H26BrNO3	432.35074	defined organic	salt Br	tested chemical	Clidinium bromide	3485-62-9	single chemical compound	ammonium	3-{[hydroxy(diphenyl)acetyl]oxy}-1-methyl-1-azoniabicyclo[2.2.2]octane bromide	C4=CC=C(C(O)(C(=O)OC1C[N+]2(C)CCC1CC2)C3=CC=CC=C3)C=C4.[Br-]	C4=CC=C(C(O)(C(=O)OC1C[N+]2(C)CCC1CC2)C3=CC=CC=C3)C=C4	"InChI=1/C22H26NO3.BrH/c1-23-14-12-17(13-15-23)20(16-23)26-21(24)22(25,18-8-4-2-5-9-18)19-10-6-3-7-11-19;/h2-11,17,20,25H,12-16H2,1H3;1H/q+1;/p-1/fC22H26NO3.Br/h;1h/qm;-1"	GKEGFOKQMZHVOW-NMECZXBLCK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	0.333	0.000770208	3.113391973	46	High-Moderate	High	form of drug administered not known			
22836	2836	22836	297_FDAMDD_v3b	C18H33ClN2O5S	424.98302	defined organic	parent	tested chemical	Clindamycin	18323-44-9	single chemical compound	stereochem	"methyl 7-chloro-6,7,8-trideoxy-6-{[(4R)-1-methyl-4-propyl-L-prolyl]amino}-1-thio-L-threo-alpha-D-galacto-octopyranoside"	O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]1SC)[C@H](NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](C)Cl	O[C@@H]1[C@@H](O)[C@@H](O)[C@H](O[C@@H]1SC)[C@H](NC(=O)[C@@H]2C[C@@H](CCC)CN2C)[C@H](C)Cl	"InChI=1/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9-,10+,11-,12+,13-,14+,15+,16+,18+/m0/s1/f/h20H"	KDLRVYVGXIQJDK-DFSFUPPTDI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	30	0.070591056	1.151250324	24	Low-Moderate	Low	form of drug administered not known			
22837	2837	22837	298_FDAMDD_v3b	C9H5ClINO	305.4996	defined organic	parent	tested chemical	Clioquinol	130-26-7	single chemical compound		5-chloro-7-iodoquinolin-8-ol	C1(I)=CC(Cl)=C2C(=C1O)N=CC=C2	C1(I)=CC(Cl)=C2C(=C1O)N=CC=C2	"InChI=1/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H"	QCDFBFJGMNKBDO-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		topical anti infective; antiamebic 	25	0.081833168	1.087070637	23	Low	Low	form of drug administered not known			
22838	2838	22838	299_FDAMDD_v3b	C14H22ClNO	255.78358	defined organic	parent	tested chemical	Clobutinol	14860-49-2	single chemical compound		"1-(4-chlorophenyl)-4-(dimethylamino)-2,3-dimethylbutan-2-ol"	C1=C(Cl)C=CC(CC(C)(O)C(C)CN(C)C)=C1	C1=C(Cl)C=CC(CC(C)(O)C(C)CN(C)C)=C1	"InChI=1/C14H22ClNO/c1-11(10-16(3)4)14(2,17)9-12-5-7-13(15)8-6-12/h5-8,11,17H,9-10H2,1-4H3"	KVHHQGIIZCJATJ-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antitussive	4	0.01563822	1.80581267	31	Moderate	Moderate	form of drug administered not known			
22839	2839	22839	300_FDAMDD_v3b	C27H22Cl2N4	473.39638	defined organic	parent	tested chemical	Clofazimine	2030-63-9	single chemical compound	stereochem	"(3Z)-N,5-bis(4-chlorophenyl)-3-[(1-methylethyl)imino]-3,5-dihydrophenazin-2-amine"	C1=CC=C3C(=C1)N(C2=CC=C(Cl)C=C2)C5C(=N3)C=C(NC4=CC=C(Cl)C=C4)C(=NC(C)C)C=5	C1=CC=C3C(=C1)N(C2=CC=C(Cl)C=C2)C5C(=N3)C=C(NC4=CC=C(Cl)C=C4)C(=NC(C)C)C=5	"InChI=1/C27H22Cl2N4/c1-17(2)30-24-16-27-25(15-23(24)31-20-11-7-18(28)8-12-20)32-22-5-3-4-6-26(22)33(27)21-13-9-19(29)10-14-21/h3-17,31H,1-2H3/b30-24-"	WDQPAMHFFCXSNU-KRUMMXJUBA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	3.33	0.007034274	2.152780699	35	Moderate	Moderate	form of drug administered not known			
22840	336	20336	301_FDAMDD_v3b	C12H15ClO3	242.6987	defined organic	parent	tested chemical	Clofibrate	637-07-0	single chemical compound		ethyl 2-[(4-chlorophenyl)oxy]-2-methylpropanoate	CC(OC1=CC=C(C=C1)Cl)(C(=O)OCC)C	CC(OC1=CC=C(C=C1)Cl)(C(=O)OCC)C	"InChI=1/C12H15ClO3/c1-4-15-11(14)12(2,3)16-10-7-5-9(13)6-8-10/h5-8H,4H2,1-3H3"	KNHUKKLJHYUCFP-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihyperlipoproteinemic	33.3	0.137207163	0.862623217	21	Low	Low	form of drug administered not known			
22841	2841	22841	302_FDAMDD_v3b	C16H22ClNO4	327.80318	defined organic	parent	tested chemical	Clofibride	26717-47-5	single chemical compound		4-(dimethylamino)-4-oxobutyl 2-[(4-chlorophenyl)oxy]-2-methylpropanoate	C1=C(Cl)C=CC(OC(C)(C)C(=O)OCCCC(=O)N(C)C)=C1	C1=C(Cl)C=CC(OC(C)(C)C(=O)OCCCC(=O)N(C)C)=C1	"InChI=1/C16H22ClNO4/c1-16(2,22-13-9-7-12(17)8-10-13)15(20)21-11-5-6-14(19)18(3)4/h7-10H,5-6,11H2,1-4H3"	CXQGFLBVUNUQIA-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihyperlipoproteinemic	45	0.137277497	0.862400649	21	Low	Low	form of drug administered not known			
22842	2842	22842	303_FDAMDD_v3b	C6H8ClNS	161.65242	defined organic	parent	tested chemical	Clomethiazole	533-45-9	single chemical compound		"5-(2-chloroethyl)-4-methyl-1,3-thiazole"	S1C=NC(C)=C1CCCl	S1C=NC(C)=C1CCCl	"InChI=1/C6H8ClNS/c1-5-6(2-3-7)9-4-8-5/h4H,2-3H2,1H3"	PCLITLDOTJTVDJ-UHFFFAOYAC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic; anticonvulsant	6.4	0.039591118	1.402402237	27	Low-Moderate	Low	form of drug administered not known			
22843	2843	22843	304_FDAMDD_v3b	C26H28ClNO	405.9596	defined organic	parent	representative isomer in mixture	Clomiphene	911-45-5	mixture or formulation	"mixture of Z,E isomers; structure shown Z; stereochem"	"2-({4-[(Z)-2-chloro-1,2-diphenylethenyl]phenyl}oxy)-N,N-diethylethanamine"	C3=CC=CC(C(Cl)=C(C1=CC=CC=C1)C2=CC=C(OCCN(CC)CC)C=C2)=C3	C3=CC=CC(C(Cl)=C(C1=CC=CC=C1)C2=CC=C(OCCN(CC)CC)C=C2)=C3	"InChI=1/C26H28ClNO/c1-3-28(4-2)19-20-29-24-17-15-22(16-18-24)25(21-11-7-5-8-12-21)26(27)23-13-9-6-10-14-23/h5-18H,3-4,19-20H2,1-2H3/b26-25-"	GKIRPKYJQBWNGO-QPLCGJKRBN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		gonad stimulating	1.67	0.00411371	2.385766345	38	Moderate	High	form of drug administered not known			
22844	2844	22844	305_FDAMDD_v3b	C19H23ClN2	314.85232	defined organic	parent	tested chemical	Clomipramine	303-49-1	single chemical compound		"3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine"	N2(CCCN(C)C)C1=CC(Cl)=CC=C1CCC3=C2C=CC=C3	N2(CCCN(C)C)C1=CC(Cl)=CC=C1CCC3=C2C=CC=C3	"InChI=1/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3"	GDLIGKIOYRNHDA-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	4.17	0.013244305	1.877970843	32	Moderate	Moderate	form of drug administered not known			
22845	2845	22845	306_FDAMDD_v3b	C15H10ClN3O3	315.7112	defined organic	parent	tested chemical	Clonazepam	1622-61-3	single chemical compound		"5-(2-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one"	N2=C(C1=CC=CC=C1Cl)C3=C(NC(=O)C2)C=CC(N(=O)=O)=C3	N2=C(C1=CC=CC=C1Cl)C3=C(NC(=O)C2)C=CC(N(=O)=O)=C3	"InChI=1/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)/f/h18H"	DGBIGWXXNGSACT-GPQMBLKYCY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	0.133	0.000421271	3.375438348	49	High-Moderate	High	form of drug administered not known			
22846	2846	22846	307_FDAMDD_v3b	C9H9Cl2N3	230.09386	defined organic	parent	tested chemical	Clonidine	4205-90-7	single chemical compound		"2,6-dichloro-N-imidazolidin-2-ylideneaniline"	C2=CC=C(Cl)C(N=C1NCCN1)=C2Cl	C2=CC=C(Cl)C(N=C1NCCN1)=C2Cl	"InChI=1/C9H9Cl2N3/c10-6-2-1-3-7(11)8(6)14-9-12-4-5-13-9/h1-3H,4-5H2,(H2,12,13,14)/f/h12-13H"	GJSURZIOUXUGAL-BAINRFMOCE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.04	0.000173842	3.759845038	53	High	High	form of drug administered not known			
22847	2847	22847	308_FDAMDD_v3b	C14H20ClN3O3S	345.8449	defined organic	parent	tested chemical	Clopamide	636-54-4	single chemical compound		"3-(aminosulfonyl)-4-chloro-N-(2,6-dimethylpiperidin-1-yl)benzamide"	C2=C(Cl)C(S(=O)(=O)N)=CC(C(=O)NN1C(C)CCCC1C)=C2	C2=C(Cl)C(S(=O)(=O)N)=CC(C(=O)NN1C(C)CCCC1C)=C2	"InChI=1/C14H20ClN3O3S/c1-9-4-3-5-10(2)18(9)17-14(19)11-6-7-12(15)13(8-11)22(16,20)21/h6-10H,3-5H2,1-2H3,(H,17,19)(H2,16,20,21)/f/h17H,16H2"	LBXHRAWDUMTPSE-QDYITYEQCL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; diuretic	1	0.00289147	2.538881376	40	Moderate	High	form of drug administered not known			
22848	2848	22848	309_FDAMDD_v3b	C16H16ClNO2S	321.82174	defined organic	parent	tested chemical	Clopidogrel	113665-84-2	single chemical compound	stereochem	"methyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate"	Clc1ccccc1[C@H](N2Cc3ccsc3CC2)C(=O)OC	Clc1ccccc1[C@H](N2Cc3ccsc3CC2)C(=O)OC	"InChI=1/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1"	GKTWGGQPFAXNFI-HNNXBMFYBE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antithrombotic	1.25	0.003884138	2.410705366	38	Moderate	High	form of drug administered not known			
22849	2849	22849	310_FDAMDD_v3b	C21H25ClO5	392.8732	defined organic	parent	tested chemical	Cloprednol	5251-34-3	single chemical compound	stereochem; tautomers	"(11beta)-6-chloro-11,17,21-trihydroxypregna-1,4,6-triene-3,20-dione"	OCC(=O)[C@@]2(O)CC[C@H]3[C@@H]4/C=C(/Cl)\C1=C\C(=O)\C=C/[C@]1(C)[C@H]4[C@@H](O)C[C@]23C	OCC(=O)[C@@]2(O)CC[C@H]3[C@@H]4/C=C(/Cl)\C1=C\C(=O)\C=C/[C@]1(C)[C@H]4[C@@H](O)C[C@]23C	"InChI=1/C21H25ClO5/c1-19-5-3-11(24)7-14(19)15(22)8-12-13-4-6-21(27,17(26)10-23)20(13,2)9-16(25)18(12)19/h3,5,7-8,12-13,16,18,23,25,27H,4,6,9-10H2,1-2H3/t12-,13-,16-,18+,19-,20-,21-/m0/s1"	YTJIBEDMAQUYSZ-FDNPDPBUBI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		glucocorticoid	0.208	0.000529433	3.276189069	48	High-Moderate	High	form of drug administered not known			
22850	2850	22850	311_FDAMDD_v3b	C10H14ClN	183.67786	defined organic	parent	tested chemical	Clortermine	10389-73-8	single chemical compound		1-(2-chlorophenyl)-2-methylpropan-2-amine	C1=CC=C(Cl)C(CC(C)(C)N)=C1	C1=CC=C(Cl)C(CC(C)(C)N)=C1	"InChI=1/C10H14ClN/c1-10(2,12)7-8-5-3-4-6-9(8)11/h3-6H,7,12H2,1-2H3"	HXCXASJHZQXCKK-UHFFFAOYAM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anorexic	0.833	0.004535114	2.343411809	37	Moderate	High	form of drug administered not known			
22851	2851	22851	312_FDAMDD_v3b	C18H18ClN3S	343.87362	defined organic	parent	tested chemical	Clothiapine	2058-52-8	single chemical compound		"2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine"	S2C4=C(N=C(N1CCN(C)CC1)C3=C2C=CC(Cl)=C3)C=CC=C4	S2C4=C(N=C(N1CCN(C)CC1)C3=C2C=CC(Cl)=C3)C=CC=C4	"InChI=1/C18H18ClN3S/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3"	KAAZGXDPUNNEFN-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	0.25	0.000727011	3.138458852	46	High-Moderate	High	form of drug administered not known			
22852	2852	22852	313_FDAMDD_v3b	C16H15ClN2OS	318.8211	defined organic	parent	tested chemical	Clotiazepam	33671-46-4	single chemical compound		"5-(2-chlorophenyl)-7-ethyl-1-methyl-1,3-dihydro-2H-thieno[2,3-e][1,4]diazepin-2-one"	N2=C(C1=CC=CC=C1Cl)C3=C(N(C)C(=O)C2)SC(CC)=C3	N2=C(C1=CC=CC=C1Cl)C3=C(N(C)C(=O)C2)SC(CC)=C3	"InChI=1/C16H15ClN2OS/c1-3-10-8-12-15(11-6-4-5-7-13(11)17)18-9-14(20)19(2)16(12)21-10/h4-8H,3,9H2,1-2H3"	CHBRHODLKOZEPZ-UHFFFAOYAO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	1	0.003136555	2.503547056	39	Moderate	High	form of drug administered not known			
22853	2853	22853	314_FDAMDD_v3b	C19H18ClN3O5S	435.88132	defined organic	parent	tested chemical	Cloxacillin	61-72-3	single chemical compound	stereochem	"(2S,5R,6R)-6-({[3-(2-chlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	O=C(O)[C@H]3N4C(=O)[C@H](NC(=O)c2c(C)onc2c1ccccc1Cl)[C@@H]4SC3(C)C	O=C(O)[C@H]3N4C(=O)[C@H](NC(=O)c2c(C)onc2c1ccccc1Cl)[C@@H]4SC3(C)C	"InChI=1/C19H18ClN3O5S/c1-8-11(12(22-28-8)9-6-4-5-7-10(9)20)15(24)21-13-16(25)23-14(18(26)27)19(2,3)29-17(13)23/h4-7,13-14,17H,1-3H3,(H,21,24)(H,26,27)/t13-,14+,17-/m1/s1/f/h21,26H"	LQOLIRLGBULYKD-ZEOGXVOZDL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	33.3	0.076396942	1.116924024	24	Low	Low	form of drug administered not known			
22854	2854	22854	315_FDAMDD_v3b	C17H14Cl2N2O2	349.21126	defined organic	parent	tested chemical	Cloxazolam	24166-13-0	single chemical compound		"10-chloro-11b-(2-chlorophenyl)-7,11b-dihydro-1H-[1,3]oxazolo[3,4-d][1,4]benzodiazepin-6(5H)-one"	C1=C(Cl)C=C2C(=C1)NC(=O)CN3COCC23C4=C(Cl)C=CC=C4	C1=C(Cl)C=C2C(=C1)NC(=O)CN3COCC23C4=C(Cl)C=CC=C4	"InChI=1/C17H14Cl2N2O2/c18-11-5-6-15-13(7-11)17(12-3-1-2-4-14(12)19)9-23-10-21(17)8-16(22)20-15/h1-7H,8-10H2,(H,20,22)/f/h20H"	KBQMTDVLODBZBT-UYBDAZJACX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	0.2	0.000572719	3.242058243	47	High-Moderate	High	form of drug administered not known			
22855	2855	22855	316_FDAMDD_v3b	C18H19ClN4	326.82326	defined organic	parent	tested chemical	Clozapine	5786-21-0	single chemical compound		"8-chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine"	C1(Cl)=CC=C3C(=C1)N=C(N2CCN(C)CC2)C4=C(N3)C=CC=C4	C1(Cl)=CC=C3C(=C1)N=C(N2CCN(C)CC2)C4=C(N3)C=CC=C4	"InChI=1/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3"	QZUDBNBUXVUHMW-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	15	0.045896366	1.338221699	26	Low-Moderate	Low	form of drug administered not known			
22856	341	20341	317_FDAMDD_v3b	C18H21NO3	299.3642	defined organic	parent	tested chemical	Codeine	76-57-3	single chemical compound	stereochem	"(5alpha,6alpha)-17-methyl-3-(methyloxy)-7,8-didehydro-4,5-epoxymorphinan-6-ol"	O[C@@H]1C2[C@@]34C5=C(C=CC(=C5O2)OC)CC(C3C=C1)N(C)CC4	O[C@@H]1C2[C@@]34C5=C(C=CC(=C5O2)OC)CC(C3C=C1)N(C)CC4	"InChI=1/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3-6,11-13,17,20H,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1"	OROGSEYTTFOCAN-DNJOTXNNBG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic; antitussive	6	0.020042477	1.698048613	30	Moderate	Low	form of drug administered not known			
22857	2857	22857	318_FDAMDD_v3b	C21H28O5	360.44402	defined organic	parent	tested chemical	Cortisone	53-06-5	single chemical compound	stereochem; tautomers 	"17,21-dihydroxypregn-4-ene-3,11,20-trione"	OCC(=O)[C@@]3(O)CC[C@H]2[C@@H]4CC\C1=C\C(=O)CC[C@]1(C)[C@H]4C(=O)C[C@@]23C	OCC(=O)[C@@]3(O)CC[C@H]2[C@@H]4CC\C1=C\C(=O)CC[C@]1(C)[C@H]4C(=O)C[C@@]23C	"InChI=1/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1"	MFYSYFVPBJMHGN-ZPOLXVRWBW	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Cortisone	glucocorticoid	5	0.01387178	1.85786782	32	Moderate	Low	form of drug administered not known			
22858	2858	22858	319_FDAMDD_v3b	C23H30O6	402.4807	defined organic	parent	tested chemical	Cortisone acetate	50-04-4	single chemical compound	stereochem; tautomers 	"17-hydroxy-3,11,20-trioxopregn-4-en-21-yl acetate"	CC(=O)OCC(=O)[C@@]3(O)CC[C@H]2[C@@H]4CC\C1=C\C(=O)CC[C@]1(C)[C@H]4C(=O)C[C@@]23C	CC(=O)OCC(=O)[C@@]3(O)CC[C@H]2[C@@H]4CC\C1=C\C(=O)CC[C@]1(C)[C@H]4C(=O)C[C@@]23C	"InChI=1/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h10,16-17,20,28H,4-9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1"	ITRJWOMZKQRYTA-RFZYENFJBQ	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Cortisone	glucocorticoid	5	0.012422956	1.905775055	32	Moderate	Low	form of drug administered not known			
22859	348	20348	320_FDAMDD_v3b	C9H6O2	146.1427	defined organic	parent	tested chemical	Coumarin	91-64-5	single chemical compound		2H-chromen-2-one	O=C1OC2=C(C=CC=C2)C=C1	O=C1OC2=C(C=CC=C2)C=C1	InChI=1/C9H6O2/c10-9-6-5-7-3-1-2-4-8(7)11-9/h1-6H	ZYGHJZDHTFUPRJ-UHFFFAOYAC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		pharmaceutic aid	1.67	0.011427187	1.942060656	33	Moderate	High	form of drug administered not known			
22860	2860	22860	321_FDAMDD_v3b	C23H16O11	468.36654	defined organic	parent	tested chemical	Cromolyn	16110-51-3	single chemical compound		"5,5'-[(2-hydroxypropane-1,3-diyl)bis(oxy)]bis(4-oxo-4H-chromene-2-carboxylic acid)"	C1(=O)C4=C(OC(C(=O)O)=C1)C=CC=C4OCC(O)COC3C2C(=O)C=C(C(=O)O)OC=2C=CC=3	C1(=O)C4=C(OC(C(=O)O)=C1)C=CC=C4OCC(O)COC3C2C(=O)C=C(C(=O)O)OC=2C=CC=3	"InChI=1/C23H16O11/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30)/f/h27,29H"	IMZMKUWMOSJXDT-CATZCVBWCO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		prophylactic antiasthmatic; antiallergic	13.3	0.028396563	1.546734221	28	Low-Moderate	Low	form of drug administered not known			
22861	2861	22861	322_FDAMDD_v3b	C15H23N3O4S	341.42582	defined organic	parent	tested chemical	Cyclacillin	3485-14-1	single chemical compound	stereochem	"(2S,5R,6R)-6-{[(1-aminocyclohexyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	O=C(O)[C@@H]2N3C(=O)[C@@H](NC(=O)C1(N)CCCCC1)[C@H]3SC2(C)C	O=C(O)[C@@H]2N3C(=O)[C@@H](NC(=O)C1(N)CCCCC1)[C@H]3SC2(C)C	"InChI=1/C15H23N3O4S/c1-14(2)9(12(20)21)18-10(19)8(11(18)23-14)17-13(22)15(16)6-4-3-5-7-15/h8-9,11H,3-7,16H2,1-2H3,(H,17,22)(H,20,21)/t8-,9+,11-/m1/s1/f/h17,20H"	HGBLNBBNRORJKI-LNONHFHSDY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	33.3	0.097532167	1.010852128	22	Low	Low	form of drug administered not known			
22862	2862	22862	323_FDAMDD_v3b	C17H24O3	276.37066	defined organic	parent	tested chemical	Cyclandelate	456-59-7	single chemical compound		"3,3,5-trimethylcyclohexyl hydroxy(phenyl)acetate"	C2C(C)(C)CC(OC(=O)C(O)C1=CC=CC=C1)CC2C	C2C(C)(C)CC(OC(=O)C(O)C1=CC=CC=C1)CC2C	"InChI=1/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3"	WZHCOOQXZCIUNC-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vasodilator	26.7	0.096609387	1.014980674	23	Low	Low	form of drug administered not known			
22863	2863	22863	324_FDAMDD_v3b	C18H25NO	271.3972	defined organic	parent	tested chemical	Cyclazocine	3572-80-3	single chemical compound		"3-(cyclopropylmethyl)-6,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol"	Oc1ccc2c(c1)C3(C)CCN(CC2C3C)CC4CC4	Oc1ccc2c(c1)C3(C)CCN(CC2C3C)CC4CC4	"InChI=1/C18H25NO/c1-12-17-9-14-5-6-15(20)10-16(14)18(12,2)7-8-19(17)11-13-3-4-13/h5-6,10,12-13,17,20H,3-4,7-9,11H2,1-2H3"	YQYVFVRQLZMJKJ-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic antagonist	0.0667	0.000245765	3.609479529	52	High	High	form of drug administered not known			
22864	2864	22864	325_FDAMDD_v3b	C18H22N2	266.38068	defined organic	parent	tested chemical	Cyclizine	82-92-8	single chemical compound		1-(diphenylmethyl)-4-methylpiperazine	C3N(C(C1=CC=CC=C1)C2=CC=CC=C2)CCN(C)C3	C3N(C(C1=CC=CC=C1)C2=CC=CC=C2)CCN(C)C3	"InChI=1/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3"	UVKZSORBKUEBAZ-UHFFFAOYAX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiemetic	3.33	0.012500907	1.90305849	32	Moderate	Moderate	form of drug administered not known			
22865	2865	22865	326_FDAMDD_v3b	C12H16N2O3	236.26704	defined organic	parent	tested chemical	Cyclobarbital	52-31-3	single chemical compound		"5-cyclohex-1-en-1-yl-5-ethylpyrimidine-2,4,6(1H,3H,5H)-trione"	C2(=O)NC(=O)C(C1=CCCCC1)(CC)C(=O)N2	C2(=O)NC(=O)C(C1=CCCCC1)(CC)C(=O)N2	"InChI=1/C12H16N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h6H,2-5,7H2,1H3,(H2,13,14,15,16,17)/f/h13-14H"	WTYGAUXICFETTC-KGCNKATMCW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	6.67	0.028230768	1.549277306	28	Low-Moderate	Low	form of drug administered not known			
22866	2866	22866	327_FDAMDD_v3b	C23H24O4	364.43426	defined organic	parent	tested chemical	Cyclofenil	2624-43-3	single chemical compound		"(cyclohexylidenemethanediyl)dibenzene-4,1-diyl diacetate"	C3=C(OC(=O)C)C=CC(C(=C1CCCCC1)C2=CC=C(OC(C)=O)C=C2)=C3	C3=C(OC(=O)C)C=CC(C(=C1CCCCC1)C2=CC=C(OC(C)=O)C=C2)=C3	"InChI=1/C23H24O4/c1-16(24)26-21-12-8-19(9-13-21)23(18-6-4-3-5-7-18)20-10-14-22(15-11-20)27-17(2)25/h8-15H,3-7H2,1-2H3"	GVOUFPWUYJWQSK-UHFFFAOYAR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		gonad stimulating	6.67	0.018302341	1.737493364	31	Moderate	Low	form of drug administered not known			
22867	2867	22867	328_FDAMDD_v3b	C11H14ClN5	251.71536	defined organic	parent	tested chemical	Cycloguanil	516-21-2	single chemical compound		"1-(4-chlorophenyl)-6,6-dimethyl-1,6-dihydro-1,3,5-triazine-2,4-diamine"	C2=CC(N1C(N)=NC(N)=NC1(C)C)=CC=C2Cl	C2=CC(N1C(N)=NC(N)=NC1(C)C)=CC=C2Cl	"InChI=1/C11H14ClN5/c1-11(2)16-9(13)15-10(14)17(11)8-5-3-7(12)4-6-8/h3-6H,1-2H3,(H4,13,14,15,16)/f/h13-14H2"	QMNFFXRFOJIOKZ-AONCVQJMCY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimalarial	0.333	0.001322923	2.878465484	43	Moderate	High	form of drug administered not known			
22868	2868	22868	329_FDAMDD_v3b	C13H18ClN3O4S2	379.88272	defined organic	parent	tested chemical	Cyclopenthiazide	742-20-1	single chemical compound		"6-chloro-3-(cyclopentylmethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide"	C1(S(N)(=O)=O)=C(Cl)C=C3C(=C1)S(=O)(=O)NC(CC2CCCC2)N3	C1(S(N)(=O)=O)=C(Cl)C=C3C(=C1)S(=O)(=O)NC(CC2CCCC2)N3	"InChI=1/C13H18ClN3O4S2/c14-9-6-10-12(7-11(9)22(15,18)19)23(20,21)17-13(16-10)5-8-3-1-2-4-8/h6-8,13,16-17H,1-5H2,(H2,15,18,19)/f/h15H2"	BKYKPTRYDKTTJY-YHSKDTNECV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.025	6.58098E-05	4.18170953	58	High	High	form of drug administered not known			
22869	364	20364	330_FDAMDD_v3b	C7H15Cl2N2O2P	261.086	defined organic	parent	tested chemical	Cyclophosphamide	50-18-0	single chemical compound		"N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide"	ClCCN(CCCl)[P]1(=O)NCCCO1	ClCCN(CCCl)[P]1(=O)NCCCO1	"InChI=1/C7H15Cl2N2O2P/c8-2-5-11(6-3-9)14(12)10-4-1-7-13-14/h1-7H2,(H,10,12)/f/h10H"	CMSMOCZEIVJLDB-KZFATGLACB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	5	0.019150778	1.71781358	30	Moderate	Low	form of drug administered not known			
22870	2870	22870	331_FDAMDD_v3b	C3H6N2O2	102.09194	defined organic	parent	tested chemical	Cycloserine	68-41-7	single chemical compound	stereochem	(4R)-4-aminoisoxazolidin-3-one	O=C1[C@H](N)CON1	O=C1[C@H](N)CON1	"InChI=1/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6)/t2-/m1/s1/f/h5H"	DYDCUQKUCUHJBH-FIXCMCSDDT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	16.7	0.163578045	0.786274985	20	Low	Low	form of drug administered not known; structure modified v3b			
22871	2871	22871	332_FDAMDD_v3b	C14H16ClN3O4S2	389.87754	defined organic	parent	tested chemical	Cyclothiazide	2259-96-3	single chemical compound		"3-bicyclo[2.2.1]hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide"	C1(S(N)(=O)=O)=C(Cl)C=C4C(=C1)S(=O)(=O)NC(C2C3C=CC(C2)C3)N4	C1(S(N)(=O)=O)=C(Cl)C=C4C(=C1)S(=O)(=O)NC(C2C3C=CC(C2)C3)N4	"InChI=1/C14H16ClN3O4S2/c15-10-5-11-13(6-12(10)23(16,19)20)24(21,22)18-14(17-11)9-4-7-1-2-8(9)3-7/h1-2,5-9,14,17-18H,3-4H2,(H2,16,19,20)/f/h16H2"	BOCUKUHCLICSIY-ZHLVXTBQCJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic; antihypertensive	0.1	0.000256491	3.590928217	51	High	High	form of drug administered not known			
22872	2872	22872	333_FDAMDD_v3b	C21H21N	287.39814	defined organic	parent	tested chemical	Cyproheptadine	129-03-3	single chemical compound		"4-(5H-dibenzo[a,d][7]annulen-5-ylidene)-1-methylpiperidine"	C2=CC4=C(C(=C1CCN(C)CC1)C3=C2C=CC=C3)C=CC=C4	C2=CC4=C(C(=C1CCN(C)CC1)C3=C2C=CC=C3)C=CC=C4	"InChI=1/C21H21N/c1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21/h2-11H,12-15H2,1H3"	JJCFRYNCJDLXIK-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic; antipruritic	0.5	0.001739747	2.759513949	42	Moderate	High	form of drug administered not known			
22873	2873	22873	334_FDAMDD_v3b	C22H27ClO3	374.90098	defined organic	parent	tested chemical	Cyproterone	2098-66-0	single chemical compound	stereochem	"(1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-acetyl-5-chloro-1-hydroxy-8b,10a-dimethyl-2,3,3a,3b,7a,8,8a,8b,8c,9,10,10a-dodecahydrocyclopenta[a]cyclopropa[g]phenanthren-7(1H)-one"	CC(=O)[C@@]3(O)CC[C@H]4[C@@H]5/C=C(/Cl)\C2=C\C(=O)[C@@H]1C[C@@H]1[C@]2(C)[C@H]5CC[C@]34C	CC(=O)[C@@]3(O)CC[C@H]4[C@@H]5/C=C(/Cl)\C2=C\C(=O)[C@@H]1C[C@@H]1[C@]2(C)[C@H]5CC[C@]34C	"InChI=1/C22H27ClO3/c1-11(24)22(26)7-5-14-12-9-18(23)17-10-19(25)13-8-16(13)21(17,3)15(12)4-6-20(14,22)2/h9-10,12-16,26H,4-8H2,1-3H3/t12-,13+,14-,15-,16-,20-,21-,22-/m0/s1"	DUSHUSLJJMDGTE-ZJPMUUANBL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiandrogen	5	0.013336855	1.874946571	32	Moderate	Low	form of drug administered not known			
22874	366	20366	335_FDAMDD_v3b	C24H29ClO4	416.9377	defined organic	parent	tested chemical	Cyproterone acetate	427-51-0	single chemical compound	stereochem	"(1R,3aS,3bR,7aR,8aS,8bS,8cS,10aS)-1-acetyl-5-chloro-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,7,7a,8,8a,8b,8c,9,10,10a-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-1-yl acetate"	O=C1[C@H]3[C@H](C3)[C@@]([C@]4([H])[C@@]([C@@]5([H])[C@]([C@@](CC5)(OC(C)=O)[C@@](C)=O)(C)CC4)([H])C=C2Cl)(C)C2=C1	O=C1[C@H]3[C@H](C3)[C@@]([C@]4([H])[C@@]([C@@]5([H])[C@]([C@@](CC5)(OC(C)=O)[C@@](C)=O)(C)CC4)([H])C=C2Cl)(C)C2=C1	"InChI=1/C24H29ClO4/c1-12(26)24(29-13(2)27)8-6-16-14-10-20(25)19-11-21(28)15-9-18(15)23(19,4)17(14)5-7-22(16,24)3/h10-11,14-18H,5-9H2,1-4H3/t14-,15+,16-,17-,18-,22-,23-,24-/m0/s1"	UWFYSQMTEOIJJG-FDTZYFLXBD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiandrogen	5	0.011992199	1.921101162	33	Moderate	Low	form of drug administered not known; structure modified v3b			
22875	2875	22875	336_FDAMDD_v3b	C2H7NS	77.14868	defined organic	parent	tested chemical	Cysteamine	60-23-1	single chemical compound		2-aminoethanethiol	SCCN	SCCN	"InChI=1/C2H7NS/c3-1-2-4/h4H,1-3H2"	UFULAYFCSOUIOV-UHFFFAOYAX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidote to acetaminophen	33.3	0.431634086	0.364884266	15	Low	Low	form of drug administered not known			
22876	2876	22876	337_FDAMDD_v3b	C3H7NO2S	121.15818	defined organic	parent	tested chemical	Cysteine	52-90-4	single chemical compound	stereochem	L-cysteine	OC(=O)[C@@H](N)CS	OC(=O)[C@@H](N)CS	"InChI=1/C3H7NO2S/c4-2(1-7)3(5)6/h2,7H,1,4H2,(H,5,6)/t2-/m0/s1/f/h5H"	XUJNEKJLAYXESH-SNQCPAJUDK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	100	0.825367301	0.083352741	12	Low	Low	form of drug administered not known			
22877	2877	22877	338_FDAMDD_v3b	C9H13N3O5	243.2166	defined organic	parent	tested chemical	Cytarabine	147-94-4	single chemical compound	stereochem	4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one	O=C1N([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)C=CC(N)=N1	O=C1N([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)C=CC(N)=N1	"InChI=1/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1/f/h10H2"	UHDGCWIWMRVCDJ-JEMZYTBMDI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic; antiviral	2.7	0.011101216	1.954629449	33	Moderate	Moderate	form of drug administered not known			
22878	369	20369	339_FDAMDD_v3b	C6H10N6O	182.1832	defined organic	parent	tested chemical	Dacarbazine	4342-03-4	single chemical compound	tautomers	"4-[(1E)-3,3-dimethyltriaz-1-en-1-yl]-1H-imidazole-5-carboxamide"	O=C(N)C1=C(N=CN1)/N=N/N(C)C	O=C(N)C1=C(N=CN1)/N=N/N(C)C	"InChI=1/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+/f/h8H,7H2"	FDKXTQMXEQVLRF-WXKHNMGTDH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	4.5	0.024700411	1.607295812	29	Low-Moderate	Moderate	form of drug administered not known			
22879	31	20031	340_FDAMDD_v3b	C62H86N12O16	1255.417	defined organic	parent	tested chemical	Dactinomycin	50-76-0	single chemical compound	stereochem	"2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxohexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide"	C12C(OC3=C(N=1)C(=CC=C3C)C(N[C@@H]4C(N[C@@H](C(N5[C@@H](CCC5)C(N(CC(N([C@H](C(O[C@H]4C)=O)C(C)C)C)=O)C)=O)=O)C(C)C)=O)=O)=C(C(C(=C2C(N[C@@H]6C(N[C@@H](C(N7[C@@H](CCC7)C(N(CC(N([C@H](C(O[C@H]6C)=O)C(C)C)C)=O)C)=O)=O)C(C)C)=O)=O)N)=O)C	C12C(OC3=C(N=1)C(=CC=C3C)C(N[C@@H]4C(N[C@@H](C(N5[C@@H](CCC5)C(N(CC(N([C@H](C(O[C@H]4C)=O)C(C)C)C)=O)C)=O)=O)C(C)C)=O)=O)=C(C(C(=C2C(N[C@@H]6C(N[C@@H](C(N7[C@@H](CCC7)C(N(CC(N([C@H](C(O[C@H]6C)=O)C(C)C)C)=O)C)=O)=O)C(C)C)=O)=O)N)=O)C	"InChI=1/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1/f/h65-68H"	RJURFGZVJUQBHK-HQANWYOLDQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.015	1.19482E-05	4.922696746	66	High	High	form of drug administered not known			
22880	2880	22880	341_FDAMDD_v3b	C22H27NO2	337.45528	defined organic	parent	tested chemical	Danazol	17230-88-5	single chemical compound	stereochem	"(1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol"	O[C@@]3(C#C)CC[C@H]2[C@@H]4CC/C1=C/c5oncc5C[C@]1(C)[C@H]4CC[C@@]23C	O[C@@]3(C#C)CC[C@H]2[C@@H]4CC/C1=C/c5oncc5C[C@]1(C)[C@H]4CC[C@@]23C	"InChI=1/C22H27NO2/c1-4-22(24)10-8-18-16-6-5-15-11-19-14(13-23-25-19)12-20(15,2)17(16)7-9-21(18,22)3/h1,11,13,16-18,24H,5-10,12H2,2-3H3/t16-,17+,18+,20+,21+,22+/m1/s1"	POZRVZJJTULAOH-LHZXLZLDBO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antigonadotropin	13.3	0.03941263	1.404364587	27	Low-Moderate	Low	form of drug administered not known			
22881	2881	22881	342_FDAMDD_v3b	C14H10N4O5	314.253	defined organic	parent	representative isomer in mixture	Dantrolene	7261-97-4	mixture or formulation	"mixture of Z,E isomers; structure shown E; stereochem"	"1-({(1E)-[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)imidazolidine-2,4-dione"	C3(N(=O)=O)=CC=C(C2OC(C=NN1C(=O)NC(=O)C1)=CC=2)C=C3	C3(N(=O)=O)=CC=C(C2OC(C=NN1C(=O)NC(=O)C1)=CC=2)C=C3	"InChI=1/C14H10N4O5/c19-13-8-17(14(20)16-13)15-7-11-5-6-12(23-11)9-1-3-10(4-2-9)18(21)22/h1-7H,8H2,(H,16,19,20)/b15-7+/f/h16H"	OZOMQRBLCMDCEG-MAHVCGICDT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	6.67	0.021224937	1.673153598	30	Moderate	Low	form of drug administered not known			
22882	371	20371	343_FDAMDD_v3b	C12H12N2O2S	248.3009	defined organic	parent	tested chemical	Dapsone	80-08-0	single chemical compound		"4,4'-sulfonyldianiline"	O=S(=O)(C1=CC=C(C=C1)N)C2=CC=C(C=C2)N	O=S(=O)(C1=CC=C(C=C1)N)C2=CC=C(C=C2)N	"InChI=1/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2"	MQJKPEGWNLWLTK-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial; dermatitis herpetiformis suppressant	5	0.020136858	1.696008289	30	Moderate	Low	form of drug administered not known			
22883	2883	22883	344_FDAMDD_v3b	C27H29NO10	527.5199	defined organic	parent	tested chemical	Daunorubicin	20830-81-3	single chemical compound	stereochem	"(1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside"	CC(=O)[C@@]4(O)C[C@H](O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1)c5c(O)c3C(=O)c2c(OC)cccc2C(=O)c3c(O)c5C4	CC(=O)[C@@]4(O)C[C@H](O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1)c5c(O)c3C(=O)c2c(OC)cccc2C(=O)c3c(O)c5C4	"InChI=1/C27H29NO10/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3/t10-,14-,16-,17-,22+,27-/m0/s1"	STQGQHZAVUOBTE-VGBVRHCVBQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	1.08	0.002047316	2.688815092	41	Moderate	High	form of drug administered not known			
22884	505	20505	345_FDAMDD_v3b	C4H11NO	89.1362	defined organic	parent	tested chemical	Deanol	108-01-0	single chemical compound		2-(dimethylamino)ethanol	CN(CCO)C	CN(CCO)C	"InChI=1/C4H11NO/c1-5(2)3-4-6/h6H,3-4H2,1-2H3"	UEEJHVSXFDXPFK-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	15	0.168281798	0.773962857	20	Low	Low	form of drug administered not known			
22885	2885	22885	346_FDAMDD_v3b	C10H13N3	175.23032	defined organic	parent	tested chemical	Debrisoquin	1131-64-2	single chemical compound		"3,4-dihydroisoquinoline-2(1H)-carboximidamide"	C1=CC=C2C(=C1)CN(C(N)=N)CC2	C1=CC=C2C(=C1)CN(C(N)=N)CC2	"InChI=1/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)/f/h11H,12H2"	JWPGJSVJDAJRLW-HPXYYLAHCB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	5	0.028533875	1.54463925	28	Low-Moderate	Low	form of drug administered not known			
22886	2886	22886	347_FDAMDD_v3b	C16H38Br2N2	418.2943	defined organic	salt 2Br	tested chemical	Decamethonium bromide	541-22-0	single chemical compound	ammonium	"N,N,N,N',N',N'-hexamethyldecane-1,10-diaminium dibromide"	[Br-].[Br-].C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	C[N+](C)(C)CCCCCCCCCC[N+](C)(C)C	"InChI=1/C16H38N2.2BrH/c1-17(2,3)15-13-11-9-7-8-10-12-14-16-18(4,5)6;;/h7-16H2,1-6H3;2*1H/q+2;;/p-2/fC16H38N2.2Br/h;2*1h/qm;2*-1"	HLXQFVXURMXRPU-BELDXPJJCM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	0.0417	9.96906E-05	4.001345892	56	High	High	form of drug administered not known			
22887	2887	22887	348_FDAMDD_v3b	C25H48N6O8	560.68402	defined organic	parent	tested chemical	Deferoxamine	70-51-9	single chemical compound		N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide	NCCCCCN(O)C(=O)CCC(=O)NCCCCCN(O)C(=O)CCC(=O)NCCCCCN(O)C(C)=O	NCCCCCN(O)C(=O)CCC(=O)NCCCCCN(O)C(=O)CCC(=O)NCCCCCN(O)C(C)=O	"InChI=1/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)/f/h27-28H"	UBQYURCVBFRUQT-VEORKLDJCD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		parenteral chelating agent	100	0.178353576	0.748718178	20	Low	Low	form of drug administered not known			
22888	2888	22888	349_FDAMDD_v3b	C24H34O5	402.52376	defined organic	parent	tested chemical	Dehydrocholic acid	81-23-2	single chemical compound	stereochem	"(5beta)-3,7,12-trioxocholan-24-oic acid"	OC(=O)CC[C@@H](C)[C@H]4CC[C@@H]3[C@]4(C)C(=O)C[C@H]1[C@H]3C(=O)C[C@@H]2CC(=O)CC[C@]12C	OC(=O)CC[C@@H](C)[C@H]4CC[C@@H]3[C@]4(C)C(=O)C[C@H]1[C@H]3C(=O)C[C@@H]2CC(=O)CC[C@]12C	"InChI=1/C24H34O5/c1-13(4-7-21(28)29)16-5-6-17-22-18(12-20(27)24(16,17)3)23(2)9-8-15(25)10-14(23)11-19(22)26/h13-14,16-18,22H,4-12H2,1-3H3,(H,28,29)/t13-,14+,16-,17+,18+,22+,23+,24-/m1/s1/f/h28H"	OHXPGWPVLFPUSM-MIVYEIAUDZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		choleretic	37.5	0.093162202	1.030760253	23	Low	Low	form of drug administered not known			
22889	379	20379	350_FDAMDD_v3b	C19H28O2	288.4244	defined organic	parent	tested chemical	Dehydroepiandrosterone	53-43-0	single chemical compound	stereochem	(3beta)-3-hydroxyandrost-5-en-17-one	O[C@@H]3C\C4=C\C[C@@H]2[C@H](CC[C@]1(C)C(=O)CC[C@H]12)[C@@]4(C)CC3	O[C@@H]3C\C4=C\C[C@@H]2[C@H](CC[C@]1(C)C(=O)CC[C@H]12)[C@@]4(C)CC3	"InChI=1/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-16,20H,4-11H2,1-2H3/t13-,14-,15-,16-,18-,19-/m0/s1"	FMGSKLZLMKYGDP-USOAJAOKBL	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Dehydroepiandrosterone	androgen	3.33	0.011545486	1.937587764	33	Moderate	Moderate	form of drug administered not known			
22890	380	20380	351_FDAMDD_v3b	C21H30O3	330.4611	defined organic	parent	tested chemical	Dehydroepiandrosterone acetate	853-23-6	single chemical compound	stereochem	(3beta)-17-oxoandrost-5-en-3-yl acetate	CC(=O)O[C@@H]3C\C4=C\C[C@@H]2[C@H](CC[C@]1(C)C(=O)CC[C@H]12)[C@@]4(C)CC3	CC(=O)O[C@@H]3C\C4=C\C[C@@H]2[C@H](CC[C@]1(C)C(=O)CC[C@H]12)[C@@]4(C)CC3	"InChI=1/C21H30O3/c1-13(22)24-15-8-10-20(2)14(12-15)4-5-16-17-6-7-19(23)21(17,3)11-9-18(16)20/h4,15-18H,5-12H2,1-3H3/t15-,16-,17-,18-,20-,21-/m0/s1"	NCMZQTLCXHGLOK-ZKHIMWLXBR	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Dehydroepiandrosterone	androgen	3.33	0.010076829	1.996676111	34	Moderate	Moderate	form of drug administered not known			
22891	2891	22891	352_FDAMDD_v3b	C29H36O4	448.59374	defined organic	parent	tested chemical	Deladroxone	24356-94-3	single chemical compound	stereochem	"(4aR,4bS,6aS,6bS,8R,9aR,10aS,10bR)-6b-acetyl-4a,6a,8-trimethyl-8-phenyl-3,4,4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-tetradecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one"	CC(=O)[C@@]53O[C@@](C)(O[C@@H]5C[C@H]2[C@@H]4CC\C1=C\C(=O)CC[C@]1(C)[C@H]4CC[C@@]23C)c6ccccc6	CC(=O)[C@@]53O[C@@](C)(O[C@@H]5C[C@H]2[C@@H]4CC\C1=C\C(=O)CC[C@]1(C)[C@H]4CC[C@@]23C)c6ccccc6	"InChI=1/C29H36O4/c1-18(30)29-25(32-28(4,33-29)19-8-6-5-7-9-19)17-24-22-11-10-20-16-21(31)12-14-26(20,2)23(22)13-15-27(24,29)3/h5-9,16,22-25H,10-15,17H2,1-4H3/t22-,23+,24+,25-,26+,27+,28-,29-/m1/s1"	AHBKIEXBQNRDNL-FVCOMRFXBW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		acne treatment	2.5	0.005572971	2.2539132	36	Moderate	High-Moderate	form of drug administered not known			
22892	2892	22892	353_FDAMDD_v3b	C22H28N6O3S	456.56112	defined organic	parent	tested chemical	Delavirdine	136817-59-9	single chemical compound		N-{2-[(4-{3-[(1-methylethyl)amino]pyridin-2-yl}piperazin-1-yl)carbonyl]-1H-indol-5-yl}methanesulfonamide	CS(=O)(=O)Nc1cc2\C=C(/Nc2cc1)C(=O)N3CCN(CC3)c4ncccc4NC(C)C	CS(=O)(=O)Nc1cc2\C=C(/Nc2cc1)C(=O)N3CCN(CC3)c4ncccc4NC(C)C	"InChI=1/C22H28N6O3S/c1-15(2)24-19-5-4-8-23-21(19)27-9-11-28(12-10-27)22(29)20-14-16-13-17(26-32(3,30)31)6-7-18(16)25-20/h4-8,13-15,24-26H,9-12H2,1-3H3"	WHBIGIKBNXZKFE-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiviral	6.67	0.014609216	1.835373091	32	Moderate	Low	form of drug administered not known			
22893	2893	22893	354_FDAMDD_v3b	C21H21ClN2O8	464.85304	defined organic	parent	tested chemical	Demeclocycline	127-33-3	single chemical compound	stereochem; tautomers	"(4S,4aS,5aS,6S,12aS)-7-chloro-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide"	CN(C)[C@@H]1C(\O)=C(\C(N)=O)C(=O)[C@@]2(O)C(/O)=C3/C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12	CN(C)[C@@H]1C(\O)=C(\C(N)=O)C(=O)[C@@]2(O)C(/O)=C3/C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12	"InChI=1/C21H21ClN2O8/c1-24(2)14-7-5-6-10(16(27)12-9(25)4-3-8(22)11(12)15(6)26)18(29)21(7,32)19(30)13(17(14)28)20(23)31/h3-4,6-7,14-15,25-26,28-29,32H,5H2,1-2H3,(H2,23,31)/t6-,7-,14-,15-,21-/m0/s1/f/h23H2"	FMTDIUIBLCQGJB-JAPDVFOJDV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	15	0.032268263	1.491224416	28	Low-Moderate	Low	form of drug administered not known			
22894	2894	22894	355_FDAMDD_v3b	C23H32O4	372.49778	defined organic	parent	tested chemical	Deoxycorticosterone acetate	56-47-3	single chemical compound	stereochem	"3,20-dioxopregn-4-en-21-yl acetate"	CC(=O)OCC(=O)[C@H]2CC[C@H]3[C@@H]4CC\C1=C\C(=O)CC[C@]1(C)[C@H]4CC[C@]23C	CC(=O)OCC(=O)[C@H]2CC[C@H]3[C@@H]4CC\C1=C\C(=O)CC[C@]1(C)[C@H]4CC[C@]23C	"InChI=1/C23H32O4/c1-14(24)27-13-21(26)20-7-6-18-17-5-4-15-12-16(25)8-10-22(15,2)19(17)9-11-23(18,20)3/h12,17-20H,4-11,13H2,1-3H3/t17-,18-,19-,20+,22-,23-/m0/s1"	VPGRYOFKCNULNK-ACXQXYJUBE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		mineralcorticoid	1.67	0.004483248	2.348407218	37	Moderate	High	form of drug administered not known			
22895	383	20383	356_FDAMDD_v3b	C32H38N2O8	578.65272	defined organic	parent	tested chemical	Deserpidine	131-01-1	single chemical compound	stereochem	"methyl (3beta,16beta,17alpha,18beta,20alpha)-17-(methyloxy)-18-({[3,4,5-tris(methyloxy)phenyl]carbonyl}oxy)yohimban-16-carboxylate"	O=C(C4=CC(OC)=C(C(OC)=C4)OC)O[C@@H]1C[C@@]3([H])[C@@](C[C@](N5C3)([H])C2=C(CC5)C(C=CC=C6)=C6N2)([H])[C@H]([C@](OC)=O)[C@H]1OC	O=C(C4=CC(OC)=C(C(OC)=C4)OC)O[C@@H]1C[C@@]3([H])[C@@](C[C@](N5C3)([H])C2=C(CC5)C(C=CC=C6)=C6N2)([H])[C@H]([C@](OC)=O)[C@H]1OC	"InChI=1/C32H38N2O8/c1-37-24-12-17(13-25(38-2)29(24)39-3)31(35)42-26-14-18-16-34-11-10-20-19-8-6-7-9-22(19)33-28(20)23(34)15-21(18)27(30(26)40-4)32(36)41-5/h6-9,12-13,18,21,23,26-27,30,33H,10-11,14-16H2,1-5H3/t18-,21+,23-,26-,27+,30+/m1/s1"	CVBMAZKKCSYWQR-WCGOZPBSBL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.0167	2.88601E-05	4.539701528	62	High	High	form of drug administered not known			
22896	2896	22896	357_FDAMDD_v3b	C18H22N2	266.38068	defined organic	parent	tested chemical	Desipramine	50-47-5	single chemical compound		"3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine"	N1(CCCNC)C3=C(CCC2=C1C=CC=C2)C=CC=C3	N1(CCCNC)C3=C(CCC2=C1C=CC=C2)C=CC=C3	"InChI=1/C18H22N2/c1-19-13-6-14-20-17-9-4-2-7-15(17)11-12-16-8-3-5-10-18(16)20/h2-5,7-10,19H,6,11-14H2,1H3"	HCYAFALTSJYZDH-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	5	0.01877013	1.726532719	30	Moderate	Low	form of drug administered not known			
22897	2897	22897	358_FDAMDD_v3b	C47H74O19	943.07906	defined organic	parent	tested chemical	Deslanoside	17598-65-1	single chemical compound	stereochem; tautomers	"(3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide"	O=C\1OC/C(=C/1)[C@H]2CC[C@@]9(O)[C@]2(C)[C@H](O)C[C@H]3[C@H]9CC[C@@H]4C[C@H](CC[C@]34C)O[C@@H]8O[C@H](C)[C@@H](O[C@@H]7O[C@H](C)[C@@H](O[C@@H]6O[C@H](C)[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)C6)[C@@H](O)C7)[C@@H](O)C8	O=C\1OC/C(=C/1)[C@H]2CC[C@@]9(O)[C@]2(C)[C@H](O)C[C@H]3[C@H]9CC[C@@H]4C[C@H](CC[C@]34C)O[C@@H]8O[C@H](C)[C@@H](O[C@@H]7O[C@H](C)[C@@H](O[C@@H]6O[C@H](C)[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)C6)[C@@H](O)C7)[C@@H](O)C8	"InChI=1/C47H74O19/c1-20-41(64-36-16-30(50)42(21(2)60-36)65-37-17-31(51)43(22(3)61-37)66-44-40(56)39(55)38(54)32(18-48)63-44)29(49)15-35(59-20)62-25-8-10-45(4)24(13-25)6-7-27-28(45)14-33(52)46(5)26(9-11-47(27,46)57)23-12-34(53)58-19-23/h12,20-22,24-33,35-44,48-52,54-57H,6-11,13-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,33-,35+,36+,37+,38-,39+,40-,41-,42-,43-,44+,45+,46+,47+/m1/s1"	OBATZBGFDSVCJD-LALPQLPRBH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cardiotonic	0.00008	8.48285E-08	7.071458115	90	High	High	form of drug administered not known			
22898	2898	22898	359_FDAMDD_v3b	C22H30O	310.473	defined organic	parent	tested chemical	Desogestrel	54024-22-5	single chemical compound	stereochem	"(17alpha)-13-Ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol"	C#C[C@]3(O)CC[C@H]2[C@@H]4CC\C1=C\CCC[C@@H]1[C@H]4C(=C)C[C@@]23CC	C#C[C@]3(O)CC[C@H]2[C@@H]4CC\C1=C\CCC[C@@H]1[C@H]4C(=C)C[C@@]23CC	"InChI=1/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1"	RPLCPCMSCLEKRS-BPIQYHPVBN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		progestogen	0.0025	8.05223E-06	5.094083829	68	High	High	form of drug administered not known			
22899	384	20384	360_FDAMDD_v3b	C22H29FO5	392.4611	defined organic	parent	tested chemical	Dexamethasone	50-02-2	single chemical compound	stereochem; tautomers	"(11beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione"	OCC(=O)[C@@]4(O)[C@H](C)C[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)/C=C\C(=O)/C=C3/CC[C@@H]12	OCC(=O)[C@@]4(O)[C@H](C)C[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)/C=C\C(=O)/C=C3/CC[C@@H]12	"InChI=1/C22H29FO5/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,23)17(26)10-20(16,3)22(12,28)18(27)11-24/h6-7,9,12,15-17,24,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1"	UREBDLICKHMUKA-CXSFZGCWBM	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 6	Dexamethasone	glucocorticoid; anti inflammatory	0.15	0.000382203	3.417705358	49	High-Moderate	High	form of drug administered not known			
22900	2900	22900	361_FDAMDD_v3b	C29H33FO8	528.5659232	defined organic	parent	tested chemical	Dexamethasone acefurate	83880-70-0	single chemical compound	stereochem; tautomers	"(11beta,16alpha)-21-(acetyloxy)-9-fluoro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate"	O=C(O[C@]2(C(=O)COC(C)=O)[C@H](C)C[C@H]3[C@@H]4CC\C1=C\C(=O)/C=C\[C@]1(C)[C@@]4(F)[C@@H](O)C[C@]23C)c5ccco5	O=C(O[C@]2(C(=O)COC(C)=O)[C@H](C)C[C@H]3[C@@H]4CC\C1=C\C(=O)/C=C\[C@]1(C)[C@@]4(F)[C@@H](O)C[C@]23C)c5ccco5	"InChI=1/C29H33FO8/c1-16-12-21-20-8-7-18-13-19(32)9-10-26(18,3)28(20,30)23(33)14-27(21,4)29(16,24(34)15-37-17(2)31)38-25(35)22-6-5-11-36-22/h5-6,9-11,13,16,20-21,23,33H,7-8,12,14-15H2,1-4H3/t16-,20+,21+,23+,26+,27+,28+,29+/m1/s1"	DDIWRLSEGOVQQD-BJRLRHTOBF	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 6	Dexamethasone	glucocorticoid; anti inflammatory	0.15	0.000283787	3.547007902	51	High	High	form of drug administered not known			
22901	2901	22901	362_FDAMDD_v3b	C24H31FO6	434.4977432	defined organic	parent	tested chemical	Dexamethasone acetate	1177-87-3	single chemical compound	stereochem; tautomers	"(16alpha)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl acetate"	CC(=O)OCC(=O)[C@@]4(O)[C@H](C)C[C@@H]1[C@]4(C)CC(O)[C@]2(F)[C@@]3(C)/C=C\C(=O)/C=C3/CC[C@@H]12	CC(=O)OCC(=O)[C@@]4(O)[C@H](C)C[C@@H]1[C@]4(C)CC(O)[C@]2(F)[C@@]3(C)/C=C\C(=O)/C=C3/CC[C@@H]12	"InChI=1/C24H31FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h7-8,10,13,17-19,28,30H,5-6,9,11-12H2,1-4H3/t13-,17+,18+,19?,21+,22+,23+,24+/m1/s1"	AKUJBENLRBOFTD-XRYACJLUBP	Clinical Reports 	Maximum Recommended Daily Dose	human	3 of 6	Dexamethasone	glucocorticoid; anti inflammatory	0.15	0.000345226	3.461896266	50	High	High	form of drug administered not known			
22902	2902	22902	363_FDAMDD_v3b	C28H37FO7	504.5875832	defined organic	parent	tested chemical	Dexamethasone dipropionate	55541-30-5	single chemical compound	stereochem; tautomers	"(11beta,16alpha)-9-fluoro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropanoate"	CCC(=O)OCC(=O)[C@@]4(OC(=O)CC)[C@H](C)C[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)/C=C\C(=O)/C=C3/CC[C@@H]12	CCC(=O)OCC(=O)[C@@]4(OC(=O)CC)[C@H](C)C[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)/C=C\C(=O)/C=C3/CC[C@@H]12	"InChI=1/C28H37FO7/c1-6-23(33)35-15-22(32)28(36-24(34)7-2)16(3)12-20-19-9-8-17-13-18(30)10-11-25(17,4)27(19,29)21(31)14-26(20,28)5/h10-11,13,16,19-21,31H,6-9,12,14-15H2,1-5H3/t16-,19+,20+,21+,25+,26+,27+,28+/m1/s1"	CIWBQSYVNNPZIQ-PKWREOPIBJ	Clinical Reports 	Maximum Recommended Daily Dose	human	4 of 6	Dexamethasone	glucocorticoid; anti inflammatory	0.15	0.000297272	3.5268453	51	High	High	form of drug administered not known			
22903	2903	22903	364_FDAMDD_v3b	C38H59FO6	630.8698632	defined organic	parent	tested chemical	Dexamethasone palmitate	33755-46-3	single chemical compound	stereochem; tautomers	"(11beta,16alpha)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl hexadecanoate"	CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]4(O)[C@H](C)C[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)/C=C\C(=O)/C=C3/CC[C@@H]12	CCCCCCCCCCCCCCCC(=O)OCC(=O)[C@@]4(O)[C@H](C)C[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)/C=C\C(=O)/C=C3/CC[C@@H]12	"InChI=1/C38H59FO6/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-34(43)45-26-33(42)38(44)27(2)23-31-30-20-19-28-24-29(40)21-22-35(28,3)37(30,39)32(41)25-36(31,38)4/h21-22,24,27,30-32,41,44H,5-20,23,25-26H2,1-4H3/t27-,30+,31+,32+,35+,36+,37+,38+/m1/s1"	WDPYZTKOEFDTCU-WDJQFAPHBG	Clinical Reports 	Maximum Recommended Daily Dose	human	5 of 6	Dexamethasone	glucocorticoid; anti inflammatory	0.15	0.000237767	3.623848522	52	High	High	form of drug administered not known			
22904	2904	22904	365_FDAMDD_v3b	C27H37FO6	476.5774832	defined organic	parent	tested chemical	Dexamethasone valerate	14899-36-6	single chemical compound	stereochem; tautomers	"(11beta,16alpha)-9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl pentanoate"	CCCCC(=O)OCC(=O)[C@@]4(O)[C@H](C)C[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)/C=C\C(=O)/C=C3/CC[C@@H]12	CCCCC(=O)OCC(=O)[C@@]4(O)[C@H](C)C[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)/C=C\C(=O)/C=C3/CC[C@@H]12	"InChI=1/C27H37FO6/c1-5-6-7-23(32)34-15-22(31)27(33)16(2)12-20-19-9-8-17-13-18(29)10-11-24(17,3)26(19,28)21(30)14-25(20,27)4/h10-11,13,16,19-21,30,33H,5-9,12,14-15H2,1-4H3/t16-,19+,20+,21+,24+,25+,26+,27+/m1/s1"	FEROCCAEIIKMJT-OMPPIWKSBU	Clinical Reports 	Maximum Recommended Daily Dose	human	6 of 6	Dexamethasone	glucocorticoid; anti inflammatory	0.15	0.000314744	3.50204226	50	High	High	form of drug administered not known			
22905	2905	22905	366_FDAMDD_v3b	C16H19BrN2	319.23946	defined organic	parent	tested chemical	Dexbrompheniramine	132-21-8	single chemical compound	stereochem	"(3S)-3-(4-bromophenyl)-N,N-dimethyl-3-pyridin-2-ylpropan-1-amine"	Brc1ccc(cc1)[C@H](CCN(C)C)c2ccccn2	Brc1ccc(cc1)[C@H](CCN(C)C)c2ccccn2	"InChI=1/C16H19BrN2/c1-19(2)12-10-15(16-5-3-4-11-18-16)13-6-8-14(17)9-7-13/h3-9,11,15H,10,12H2,1-2H3/t15-/m0/s1"	ZDIGNSYAACHWNL-HNNXBMFYBC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	0.8	0.002505956	2.601026581	40	Moderate	High	form of drug administered not known			
22906	2906	22906	367_FDAMDD_v3b	C9H19NO4	205.25146	defined organic	parent	tested chemical	Dexpanthenol	81-13-0	single chemical compound		"2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutanamide"	C(C)(C)(C(O)C(=O)NCCCO)CO	C(C)(C)(C(O)C(=O)NCCCO)CO	"InChI=1/C9H19NO4/c1-9(2,6-12)7(13)8(14)10-4-3-5-11/h7,11-13H,3-6H2,1-2H3,(H,10,14)/f/h10H"	SNPLKNRPJHDVJA-KZFATGLACQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cholinergic	8.33	0.040584364	1.391641254	27	Low-Moderate	Low	form of drug administered not known			
22907	2907	22907	368_FDAMDD_v3b	C9H13N	135.20622	defined organic	parent	tested chemical	Dextroamphetamine	51-64-9	single chemical compound	stereochem	(2S)-1-phenylpropan-2-amine	N[C@@H](C)Cc1ccccc1	N[C@@H](C)Cc1ccccc1	"InChI=1/C9H13N/c1-8(10)7-9-5-3-2-4-6-9/h2-6,8H,7,10H2,1H3/t8-/m0/s1"	KWTSXDURSIMDCE-QMMMGPOBBF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		CNS stimulant; anorexic	1	0.007396109	2.130996671	35	Moderate	High	form of drug administered not known			
22908	2908	22908	369_FDAMDD_v3b	C18H25NO	271.3972	defined organic	parent	tested chemical	Dextromethorphan	125-71-3	single chemical compound	stereochem	"(9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan"	COc3ccc4C[C@H]1N(C)CC[C@@]2(CCCC[C@@H]12)c4c3	COc3ccc4C[C@H]1N(C)CC[C@@]2(CCCC[C@@H]12)c4c3	"InChI=1/C18H25NO/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18/h6-7,12,15,17H,3-5,8-11H2,1-2H3/t15-,17+,18+/m1/s1"	MKXZASYAUGDDCJ-NJAFHUGGBD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antitussive	2	0.007369273	2.132575367	35	Moderate	High	form of drug administered not known			
22909	2909	22909	370_FDAMDD_v3b	C25H32N2O2	392.53378	defined organic	parent	tested chemical	Dextromoramide	357-56-2	single chemical compound	stereochem	"(3S)-3-methyl-4-(morpholin-4-yl)-2,2-diphenyl-1-(pyrrolidin-1-yl)butan-1-one"	O=C(N2CCCC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)[C@H](C)CN1CCOCC1	O=C(N2CCCC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)[C@H](C)CN1CCOCC1	"InChI=1/C25H32N2O2/c1-21(20-26-16-18-29-19-17-26)25(22-10-4-2-5-11-22,23-12-6-3-7-13-23)24(28)27-14-8-9-15-27/h2-7,10-13,21H,8-9,14-20H2,1H3/t21-/m1/s1"	INUNXTSAACVKJS-OAQYLSRUBG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	0.333	0.000848335	3.071432803	46	High-Moderate	High	form of drug administered not known; structure modified v3b			
22910	2910	22910	371_FDAMDD_v3b	C6H12O6	180.1559	defined organic	parent	tested chemical	Dextrose	50-99-7	single chemical compound	stereochem	D-glucopyranose	O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O	O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O	"InChI=1/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6?/m1/s1"	WQZGKKKJIJFFOK-GASJEMHNBW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		fluid and nutrient replenisher	100	0.555074799	0.25564849	14	Low	Low	form of drug administered not known; monohydrate [5996-10-1]			
22911	2911	22911	372_FDAMDD_v3b	C16H23NO	245.35992	defined organic	parent	tested chemical	Dezocine	53648-55-8	single chemical compound	stereochem	"(5R,11S,13S)-13-amino-5-methyl-5,6,7,8,9,10,11,12-octahydro-5,11-methanobenzo[10]annulen-3-ol"	OC3=CC1=C(C=C3)C[C@]2([H])CCCCC[C@](C)1[C@H]2N	OC3=CC1=C(C=C3)C[C@]2([H])CCCCC[C@](C)1[C@H]2N	"InChI=1/C16H23NO/c1-16-8-4-2-3-5-12(15(16)17)9-11-6-7-13(18)10-14(11)16/h6-7,10,12,15,18H,2-5,8-9,17H2,1H3/t12-,15-,16+/m0/s1"	VTMVHDZWSFQSQP-VBNZEHGJBU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	0.167	0.000680633	3.16708715	47	High-Moderate	High	form of drug administered not known			
22912	2912	22912	373_FDAMDD_v3b	C11H8I3N2NaO4	635.8954	defined organic	salt Na	tested chemical	Diatrizoate	737-31-5	single chemical compound		"sodium 3,5-bis(acetylamino)-2,4,6-triiodobenzoate"	[O-]C(C1=C(I)C(NC(C)=O)=C(I)C(NC(C)=O)=C1I)=O.[Na+]	OC(C1=C(I)C(NC(C)=O)=C(I)C(NC(C)=O)=C1I)=O	"InChI=1/C11H9I3N2O4.Na/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18;/h1-2H3,(H,15,17)(H,16,18)(H,19,20);/q;+1/p-1/fC11H8I3N2O4.Na/h15-16H;/q-1;m"	ZEYOIOAKZLALAP-AKOBBZHVCT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	484	0.761131469	0.118540322	12	Low	Low	form of drug administered not known; structure modified v3b			
22913	406	20406	374_FDAMDD_v3b	C16H13ClN2O	284.7402	defined organic	parent	tested chemical	Diazepam	439-14-5	single chemical compound		"7-chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one"	CN1C2=C(C=C(C=C2)Cl)C(=NCC1=O)C3=CC=CC=C3	CN1C2=C(C=C(C=C2)Cl)C(=NCC1=O)C3=CC=CC=C3	"InChI=1/C16H13ClN2O/c1-19-14-8-7-12(17)9-13(14)16(18-10-15(19)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3"	AAOVKJBEBIDNHE-UHFFFAOYAM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic; skeletal muscle relaxant	0.667	0.002342486	2.630322952	41	Moderate	High	form of drug administered not known			
22914	2914	22914	375_FDAMDD_v3b	C8H7ClN2O2S	230.67138	defined organic	parent	tested chemical	Diazoxide	364-98-7	single chemical compound		"7-chloro-3-methyl-2H-1,2,4-benzothiadiazine 1,1-dioxide"	C1(Cl)=CC=C2C(=C1)S(=O)(=O)NC(C)=N2	C1(Cl)=CC=C2C(=C1)S(=O)(=O)NC(C)=N2	"InChI=1/C8H7ClN2O2S/c1-5-10-7-3-2-6(9)4-8(7)14(12,13)11-5/h2-4H,1H3,(H,10,11)/f/h11H"	GDLBFKVLRPITMI-WXRBYKJCCC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	8	0.034681372	1.459903727	27	Low-Moderate	Low	form of drug administered not known			
22915	2915	22915	376_FDAMDD_v3b	C18H37N5O8	451.51508	defined organic	parent	tested chemical	Dibekacin	34493-98-6	single chemical compound	stereochem	"(1R,2S,3S,4R,6S)-4,6-diamino-3-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranoside"	N[C@@H]3CC[C@@H](CN)O[C@@H]3O[C@H]2[C@H](O)[C@@H](O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O)[C@H](N)C[C@@H]2N	N[C@@H]3CC[C@@H](CN)O[C@@H]3O[C@H]2[C@H](O)[C@@H](O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O)[C@H](N)C[C@@H]2N	"InChI=1/C18H37N5O8/c19-4-6-1-2-7(20)17(28-6)30-15-8(21)3-9(22)16(14(15)27)31-18-13(26)11(23)12(25)10(5-24)29-18/h6-18,24-27H,1-5,19-23H2/t6-,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1"	JJCQSGDBDPYCEO-XVZSLQNABN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	3	0.006644296	2.177551005	36	Moderate	Moderate	form of drug administered not known			
22916	2916	22916	377_FDAMDD_v3b	C18H21N3O	295.37884	defined organic	parent	tested chemical	Dibenzepin	4498-32-2	single chemical compound		"10-[2-(dimethylamino)ethyl]-5-methyl-5,10-dihydro-11H-dibenzo[b,e][1,4]diazepin-11-one"	C1=CC=C2C(=C1)N(CCN(C)C)C(=O)C3=C(N2C)C=CC=C3	C1=CC=C2C(=C1)N(CCN(C)C)C(=O)C3=C(N2C)C=CC=C3	"InChI=1/C18H21N3O/c1-19(2)12-13-21-17-11-7-6-10-16(17)20(3)15-9-5-4-8-14(15)18(21)22/h4-11H,12-13H2,1-3H3"	QPGGEKPRGVJKQB-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	12	0.040625794	1.391198135	27	Low-Moderate	Low	form of drug administered not known			
22917	414	20414	378_FDAMDD_v3b	C6H12Br2O4	307.9651	defined organic	parent	tested chemical	Dibromodulcitol	10318-26-0	single chemical compound	stereochem	"1,6-dibromo-1,6-dideoxy-D-galactitol"	O[C@@H]([C@@H](O)[C@H](O)CBr)[C@@H](O)CBr	O[C@@H]([C@@H](O)[C@H](O)CBr)[C@@H](O)CBr	"InChI=1/C6H12Br2O4/c7-1-3(9)5(11)6(12)4(10)2-8/h3-6,9-12H,1-2H2/t3-,4+,5+,6-"	VFKZTMPDYBFSTM-GUCUJZIJBG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	4.87	0.01581348	1.800972542	31	Moderate	Moderate	form of drug administered not known			
22918	2918	22918	379_FDAMDD_v3b	C6H12Br2O4	307.9651	defined organic	parent	tested chemical	Dibromomannitol	488-41-5	single chemical compound	stereochem	"1,6-dibromo-1,6-dideoxy-D-mannitol"	O[C@H]([C@H](O)CBr)[C@H](O)[C@H](O)CBr	O[C@H]([C@H](O)CBr)[C@H](O)[C@H](O)CBr	"InChI=1/C6H12Br2O4/c7-1-3(9)5(11)6(12)4(10)2-8/h3-6,9-12H,1-2H2/t3-,4-,5+,6+/m0/s1"	VFKZTMPDYBFSTM-UNTFVMJOBU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	4.17	0.013540495	1.868365448	32	Moderate	Moderate	form of drug administered not known			
22919	2919	22919	380_FDAMDD_v3b	C15H18Cl6N2O5	519.03182	defined organic	complex 2 chloral [2(C2H3Cl3O2)]	tested chemical	Dichloralphenazone	480-30-8	single chemical compound		"1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one - 2,2,2-trichloroethane-1,1-diol (1:2)"	C2=CC=CC(N1C(=O)C=C(C)N1C)=C2.C(Cl)(Cl)(Cl)C(O)O.C(Cl)(Cl)(Cl)C(O)O	C2=CC=CC(N1C(=O)C=C(C)N1C)=C2	"InChI=1/C11H12N2O.2C2H3Cl3O2/c1-9-8-11(14)13(12(9)2)10-6-4-3-5-7-10;2*3-2(4,5)1(6)7/h3-8H,1-2H3;2*1,6-7H"	ATKXDQOHNICLQW-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	32.5	0.062616585	1.203310623	25	Low-Moderate	Low	form of drug administered not known			
22920	428	20428	381_FDAMDD_v3b	C2H2Cl2O2	128.9421	defined organic	parent	tested chemical	Dichloroacetic acid	79-43-6	single chemical compound		dichloroacetic acid	OC(=O)C(Cl)Cl	OC(=O)C(Cl)Cl	"InChI=1/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)/f/h5H"	JXTHNDFMNIQAHM-JSWHHWTPCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		caustic; keratolytic; topical astringent	66.7	0.517286441	0.286268905	14	Low	Low	form of drug administered not known			
22921	1824	21824	382_FDAMDD_v3b	C13H10Cl2O2	269.1233	defined organic	parent	tested chemical	Dichlorophen	97-23-4	single chemical compound		"2,2'-methanediylbis(4-chlorophenol)"	OC1=CC=C(Cl)C=C1CC2=CC(Cl)=CC=C2O	OC1=CC=C(Cl)C=C1CC2=CC(Cl)=CC=C2O	"InChI=1/C13H10Cl2O2/c14-10-1-3-12(16)8(6-10)5-9-7-11(15)2-4-13(9)17/h1-4,6-7,16-17H,5H2"	MDNWOSOZYLHTCG-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anthelmintic	100	0.371576894	0.429951299	16	Low	Low	form of drug administered not known			
22922	2922	22922	383_FDAMDD_v3b	C6H6Cl2N2O4S2	305.15884	defined organic	parent	tested chemical	Dichlorphenamide	120-97-8	single chemical compound		"4,5-dichlorobenzene-1,3-disulfonamide"	C1(S(N)(=O)=O)=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1	C1(S(N)(=O)=O)=CC(Cl)=C(Cl)C(S(N)(=O)=O)=C1	"InChI=1/C6H6Cl2N2O4S2/c7-4-1-3(15(9,11)12)2-5(6(4)8)16(10,13)14/h1-2H,(H2,9,11,12)(H2,10,13,14)/f/h9-10H2"	GJQPMPFPNINLKP-IUIWLCSJCC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		carbonic anhydrase inhibitor	3.33	0.01091235	1.962081722	33	Moderate	Moderate	form of drug administered not known			
22923	2923	22923	384_FDAMDD_v3b	C14H11Cl2NO2	296.1486	defined organic	parent	tested chemical	Diclofenac	15307-86-5	single chemical compound		"{2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid"	C2(CC(O)=O)=CC=CC=C2NC1=C(Cl)C=CC=C1Cl	C2(CC(O)=O)=CC=CC=C2NC1=C(Cl)C=CC=C1Cl	"InChI=1/C14H11Cl2NO2/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19/h1-7,17H,8H2,(H,18,19)/f/h18H"	DCOPUUMXTXDBNB-GPQMBLKYCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	3.75	0.012662562	1.897478416	32	Moderate	Moderate	form of drug administered not known			
22924	2924	22924	385_FDAMDD_v3b	C19H17Cl2N3O5S	470.32638	defined organic	parent	tested chemical	Dicloxacillin	3116-76-5	single chemical compound	stereochem	"(2S,5R,6R)-6-({[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)c2c(C)onc2c1c(Cl)cccc1Cl)[C@H]4SC3(C)C	O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)c2c(C)onc2c1c(Cl)cccc1Cl)[C@H]4SC3(C)C	"InChI=1/C19H17Cl2N3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1/f/h22,27H"	YFAGHNZHGGCZAX-COJWRSDQDE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	16.7	0.035507258	1.449682867	27	Low-Moderate	Low	form of drug administered not known			
22925	1729	21729	386_FDAMDD_v3b	C19H12O6	336.295	defined organic	parent	tested chemical	Dicumarol	66-76-2	single chemical compound	tautomers	"3,3'-methanediylbis(4-hydroxy-2H-chromen-2-one)"	O=C1OC2=CC=CC=C2C(O)=C1CC3=C(O)C4=CC=CC=C4OC3=O	O=C1OC2=CC=CC=C2C(O)=C1CC3=C(O)C4=CC=CC=C4OC3=O	"InChI=1/C19H12O6/c20-16-10-5-1-3-7-14(10)24-18(22)12(16)9-13-17(21)11-6-2-4-8-15(11)25-19(13)23/h1-8,20-21H,9H2"	DOBMPNYZJYQDGZ-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticoagulant	5	0.014867899	1.827750406	32	Moderate	Low	form of drug administered not known			
22926	2926	22926	387_FDAMDD_v3b	C19H35NO2	309.4867	defined organic	parent	tested chemical	Dicyclomine	77-19-0	single chemical compound		"2-(diethylamino)ethyl 1,1'-bi(cyclohexyl)-1-carboxylate"	C2(C(=O)OCCN(CC)CC)(C1CCCCC1)CCCCC2	C2(C(=O)OCCN(CC)CC)(C1CCCCC1)CCCCC2	"InChI=1/C19H35NO2/c1-3-20(4-2)15-16-22-18(21)19(13-9-6-10-14-19)17-11-7-5-8-12-17/h17H,3-16H2,1-2H3"	CURUTKGFNZGFSE-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	1.33	0.004297438	2.366790349	38	Moderate	High	form of drug administered not known			
22927	2927	22927	388_FDAMDD_v3b	C10H12N4O3	236.2273	defined organic	parent	tested chemical	Didanosine	69655-05-6	single chemical compound	stereochem; tautomers	"9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one"	O=C2C1=C(N=CN2)N([C@@H]3O[C@H](CO)CC3)C=N1	O=C2C1=C(N=CN2)N([C@@H]3O[C@H](CO)CC3)C=N1	"InChI=1/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1/f/h12H"	BXZVVICBKDXVGW-SEQJWAOGDM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiviral	6.67	0.028235517	1.549204252	28	Low-Moderate	Low	form of drug administered not known			
22928	2928	22928	389_FDAMDD_v3b	C10H21N3O	199.29324	defined organic	parent	tested chemical	Diethylcarbamazine	90-89-1	single chemical compound		"N,N-diethyl-4-methylpiperazine-1-carboxamide"	C1CN(C)CCN1C(=O)N(CC)CC	C1CN(C)CCN1C(=O)N(CC)CC	"InChI=1/C10H21N3O/c1-4-12(5-2)10(14)13-8-6-11(3)7-9-13/h4-9H2,1-3H3"	RCKMWOKWVGPNJF-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anthelmintic	6	0.03010639	1.521341317	28	Low-Moderate	Low	form of drug administered not known			
22929	2929	22929	390_FDAMDD_v3b	C13H19NO	205.29606	defined organic	parent	tested chemical	Diethylpropion	90-84-6	single chemical compound		2-(diethylamino)-1-phenylpropan-1-one	C1=CC=CC(C(=O)C(C)N(CC)CC)=C1	C1=CC=CC(C(=O)C(C)N(CC)CC)=C1	"InChI=1/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3"	XXEPPPIWZFICOJ-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anorexic	1.25	0.006088768	2.215470602	36	Moderate	High	form of drug administered not known			
22930	465	20465	391_FDAMDD_v3b	C18H20O2	268.3502	defined organic	parent	tested chemical	Diethylstilbestrol	56-53-1	single chemical compound	stereochem	"4,4'-(3E)-hex-3-ene-3,4-diyldiphenol"	OC2=CC=C(C=C2)/C(CC)=C(CC)/C1=CC=C(O)C=C1	OC2=CC=C(C=C2)/C(CC)=C(CC)/C1=CC=C(O)C=C1	"InChI=1/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+"	RGLYKWWBQGJZGM-ISLYRVAYBW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		estrogen	10	0.037264738	1.428701923	27	Low-Moderate	Low	form of drug administered not known			
22931	2931	22931	392_FDAMDD_v3b	C28H28N2O2	424.53412	defined organic	parent	tested chemical	Difenoxin	28782-42-5	single chemical compound		"1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid"	C4(C(=O)O)(C1=CC=CC=C1)CCN(CCC(C#N)(C2C=CC=CC=2)C3C=CC=CC=3)CC4	C4(C(=O)O)(C1=CC=CC=C1)CCN(CCC(C#N)(C2C=CC=CC=2)C3C=CC=CC=3)CC4	"InChI=1/C28H28N2O2/c29-22-28(24-12-6-2-7-13-24,25-14-8-3-9-15-25)18-21-30-19-16-27(17-20-30,26(31)32)23-10-4-1-5-11-23/h1-15H,16-21H2,(H,31,32)/f/h31H"	UFIVBRCCIRTJTN-VJSLDGLSCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiperistaltic; antidiarrheal	0.133	0.000313285	3.504060959	50	High	High	form of drug administered not known			
22932	2932	22932	393_FDAMDD_v3b	C13H8F2O3	250.1976264	defined organic	parent	tested chemical	Diflunisal	22494-42-4	single chemical compound		"2',4'-difluoro-4-hydroxybiphenyl-3-carboxylic acid"	C2(C(=O)O)C=C(C1=C(F)C=C(F)C=C1)C=CC=2O	C2(C(=O)O)C=C(C1=C(F)C=C(F)C=C1)C=CC=2O	"InChI=1/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)/f/h17H"	HUPFGZXOMWLGNK-HCKMINDGCL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; anti inflammatory	25	0.099921012	1.000343177	22	Low	Low	form of drug administered not known			
22933	2933	22933	394_FDAMDD_v3b	C41H64O13	764.93906	defined organic	parent	tested chemical	Digitoxin	71-63-6	single chemical compound	stereochem; tautomers	"(3beta,5beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide"	O=C\1OC/C(=C/1)[C@H]8CC[C@@]7(O)[C@]8(C)CC[C@H]2[C@H]7CC[C@@H]3C[C@H](CC[C@]23C)O[C@@H]6O[C@H](C)[C@@H](O[C@H]5C[C@H](O)[C@H](O[C@H]4C[C@H](O)[C@H](O)[C@@H](C)O4)[C@@H](C)O5)[C@@H](O)C6	O=C\1OC/C(=C/1)[C@H]8CC[C@@]7(O)[C@]8(C)CC[C@H]2[C@H]7CC[C@@H]3C[C@H](CC[C@]23C)O[C@@H]6O[C@H](C)[C@@H](O[C@H]5C[C@H](O)[C@H](O[C@H]4C[C@H](O)[C@H](O)[C@@H](C)O4)[C@@H](C)O5)[C@@H](O)C6	"InChI=1/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1"	WDJUZGPOPHTGOT-XUDUSOBPBI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cardiotonic	0.00002	2.61459E-08	7.582596842	96	High	High	form of drug administered not known			
22934	2934	22934	395_FDAMDD_v3b	C41H64O14	780.9385	defined organic	parent	tested chemical	Digoxin	20830-75-5	single chemical compound	stereochem; tautomers	"(3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide"	O=C\1OC/C(=C/1)[C@H]2CC[C@@]8(O)[C@]2(C)[C@H](O)C[C@H]3[C@H]8CC[C@@H]4C[C@H](CC[C@]34C)O[C@@H]7O[C@H](C)[C@@H](O[C@H]6C[C@H](O)[C@H](O[C@H]5C[C@H](O)[C@H](O)[C@@H](C)O5)[C@@H](C)O6)[C@@H](O)C7	O=C\1OC/C(=C/1)[C@H]2CC[C@@]8(O)[C@]2(C)[C@H](O)C[C@H]3[C@H]8CC[C@@H]4C[C@H](CC[C@]34C)O[C@@H]7O[C@H](C)[C@@H](O[C@H]6C[C@H](O)[C@H](O[C@H]5C[C@H](O)[C@H](O)[C@@H](C)O5)[C@@H](C)O6)[C@@H](O)C7	"InChI=1/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1"	LTMHDMANZUZIPE-PUGKRICDBP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cardiotonic	0.00001	1.28051E-08	7.892616834	100	High	High	form of drug administered not known			
22935	2935	22935	396_FDAMDD_v3b	C8H10N6	190.2052	defined organic	parent	tested chemical	Dihydralazine	484-23-1	single chemical compound		"1,4-bis(hydrazino)phthalazine"	C1=CC=CC2=C(NN)N=NC(NN)=C12	C1=CC=CC2=C(NN)N=NC(NN)=C12	"InChI=1/C8H10N6/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7/h1-4H,9-10H2,(H,11,13)(H,12,14)/f/h11-12H"	VQKLRVZQQYVIJW-WYCIUFAECN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	3.33	0.017507408	1.756778152	31	Moderate	Moderate	form of drug administered not known			
22936	2936	22936	397_FDAMDD_v3b	C18H23NO3	301.38012	defined organic	parent	tested chemical	Dihydrocodeine	125-28-0	single chemical compound	stereochem	"(5alpha,6alpha)-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-ol"	O[C@H]1CC[C@H]5[C@H]2Cc4ccc(OC)c3O[C@@H]1[C@]5(CCN2C)c34	O[C@H]1CC[C@H]5[C@H]2Cc4ccc(OC)c3O[C@@H]1[C@]5(CCN2C)c34	"InChI=1/C18H23NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-13,17,20H,4-5,7-9H2,1-2H3/t11-,12+,13-,17-,18-/m0/s1"	RBOXVHNMENFORY-DNJOTXNNBM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic; antitussive	3.2	0.01061782	1.973964623	33	Moderate	Moderate	form of drug administered not known			
22937	2937	22937	398_FDAMDD_v3b	C21H41N7O12	583.58994	defined organic	parent	tested chemical	Dihydrostreptomycin	128-46-1	single chemical compound	stereochem; tautomers	"N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-(hydroxymethyl)-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine"	NC(=N)N[C@@H]3[C@@H](O[C@@H]2O[C@@H](C)[C@](O)(CO)[C@H]2O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1NC)[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@H]3O	NC(=N)N[C@@H]3[C@@H](O[C@@H]2O[C@@H](C)[C@](O)(CO)[C@H]2O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1NC)[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@H]3O	"InChI=1/C21H41N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h5-18,26,29-36H,3-4H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1/f/h22,24,27-28H,23,25H2"	ASXBYYWOLISCLQ-WYVOKUTCDC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	16.7	0.028615983	1.543391326	28	Low-Moderate	Low	form of drug administered not known			
22938	2938	22938	399_FDAMDD_v3b	C28H46O	398.66424	defined organic	parent	tested chemical	Dihydrotachysterol	67-96-9	single chemical compound	stereochem	"(3S,5E,7E,10S,22E)-9,10-secoergosta-5,7,22-trien-3-ol"	O[C@@H]2C\C([C@@H](C)CC2)=C/C=C3/[C@@]1([H])[C@@](CCC3)(C)[C@]([C@H](C)/C=C/[C@H](C)C(C)C)([H])CC1	O[C@@H]2C\C([C@@H](C)CC2)=C/C=C3/[C@@]1([H])[C@@](CCC3)(C)[C@]([C@H](C)/C=C/[C@H](C)C(C)C)([H])CC1	"InChI=1/C28H46O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-22,25-27,29H,7-8,11,14-18H2,1-6H3/b10-9+,23-12+,24-13+/t20-,21-,22+,25-,26+,27-,28+/m0/s1"	ILYCWAKSDCYMBB-OPCMSESCBH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		regulator	0.0417	0.000104599	3.980471226	56	High	High	form of drug administered not known; structure modified v3b			
22939	2939	22939	400_FDAMDD_v3b	C9H9Cl2NO2	234.0793	defined organic	parent	tested chemical	Diloxanide	579-38-4	single chemical compound		"2,2-dichloro-N-(4-hydroxyphenyl)-N-methylacetamide"	Oc1ccc(cc1)N(C)C(=O)C(Cl)Cl	Oc1ccc(cc1)N(C)C(=O)C(Cl)Cl	"InChI=1/C9H9Cl2NO2/c1-12(9(14)8(10)11)6-2-4-7(13)5-3-6/h2-5,8,13H,1H3"	GZZZSOOGQLOEOB-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiamebic	25	0.106801413	0.971423001	22	Low	Low	form of drug administered not known			
22940	2940	22940	401_FDAMDD_v3b	C22H26N2O4S	414.51784	defined organic	parent	tested chemical	Diltiazem	42399-41-7	single chemical compound	stereochem	"(2S,3S)-5-[2-(dimethylamino)ethyl]-2-[4-(methyloxy)phenyl]-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate"	CN(C)CCN1c3ccccc3S[C@H]([C@@H](OC(C)=O)C1=O)c2ccc(OC)cc2	CN(C)CCN1c3ccccc3S[C@H]([C@@H](OC(C)=O)C1=O)c2ccc(OC)cc2	"InChI=1/C22H26N2O4S/c1-15(25)28-20-21(16-9-11-17(27-4)12-10-16)29-19-8-6-5-7-18(19)24(22(20)26)14-13-23(2)3/h5-12,20-21H,13-14H2,1-4H3/t20-,21+/m1/s1"	HSUGRBWQSSZJOP-RTWAWAEBBV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antianginal	8	0.019299531	1.714453239	30	Moderate	Low	form of drug administered not known			
22941	2941	22941	402_FDAMDD_v3b	C20H26N2	294.43384	defined organic	parent	tested chemical	Dimetacrine	4757-55-5	single chemical compound		"3-(9,9-dimethylacridin-10(9H)-yl)-N,N-dimethylpropan-1-amine"	C1=CC=C2C(=C1)N(CCCN(C)C)C3=C(C2(C)C)C=CC=C3	C1=CC=C2C(=C1)N(CCCN(C)C)C3=C(C2(C)C)C=CC=C3	"InChI=1/C20H26N2/c1-20(2)16-10-5-7-12-18(16)22(15-9-14-21(3)4)19-13-8-6-11-17(19)20/h5-8,10-13H,9,14-15H2,1-4H3"	RYQOGSFEJBUZBX-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	10	0.033963487	1.468987723	28	Low-Moderate	Low	form of drug administered not known			
22942	2942	22942	403_FDAMDD_v3b	C20H24N2	292.41796	defined organic	parent	tested chemical	Dimethindene	5636-83-9	single chemical compound		"N,N-dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethanamine"	C1=CC=C3C(=C1)CC(CCN(C)C)=C3C(C)C2=NC=CC=C2	C1=CC=C3C(=C1)CC(CCN(C)C)=C3C(C)C2=NC=CC=C2	"InChI=1/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3"	MVMQESMQSYOVGV-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	0.1	0.000341976	3.466004043	50	High	High	form of drug administered not known			
22943	499	20499	404_FDAMDD_v3b	C4H9NO	87.1204	defined organic	parent	tested chemical	Dimethylacetamide	127-19-5	single chemical compound		"N,N-dimethylacetamide"	CN(C)C(C)=O	CN(C)C(C)=O	InChI=1/C4H9NO/c1-4(6)5(2)3/h1-3H3	FXHOOIRPVKKKFG-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	0.583	0.006691888	2.174451306	35	Moderate	High	form of drug administered not known			
22944	2944	22944	405_FDAMDD_v3b	C40H48I2N2O6	906.62786	defined organic	salt 2I	tested chemical	Dimethyltubocurarine iodide	7601-55-0	single chemical compound	ammonium; stereochem	"2,2,2',2'-tetramethyl-6,6',7',12'-tetrakis(methyloxy)tubocuraran-2,2'-diium diiodide"	[I-].[I-].COc7ccc1cc7Oc6cc5c(CC[N+](C)(C)[C@H]5Cc4ccc(Oc3c2c(CC[N+](C)(C)[C@@H]2C1)cc(OC)c3OC)cc4)cc6OC	COc7ccc1cc7Oc6cc5c(CC[N+](C)(C)[C@H]5Cc4ccc(Oc3c2c(CC[N+](C)(C)[C@@H]2C1)cc(OC)c3OC)cc4)cc6OC	"InChI=1/C40H48N2O6.2HI/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36;;/h9-14,21-24,31-32H,15-20H2,1-8H3;2*1H/q+2;;/p-2/t31-,32+;;/m0../s1/fC40H48N2O6.2I/h;2*1h/qm;2*-1"	DIGFQJFCDPKEPF-FYBGXPHPDA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	0.4	0.000441195	3.355369069	49	High-Moderate	High	form of drug administered not known			
22945	2945	22945	406_FDAMDD_v3b	C22H29N9O6	515.52236	defined organic	complex diaceturate [2(C4H7NO3)]	tested chemical	Diminazene diaceturate	908-54-3	single chemical compound	stereochem	N-acetylglycine - 4-[(1E)-3-{4-[amino(imino)methyl]phenyl}triaz-1-en-1-yl]benzenecarboximidamide (2:1)	CC(=O)NCC(O)=O.CC(=O)NCC(O)=O.NC(=N)c2ccc(/N=N/Nc1ccc(cc1)C(N)=N)cc2	NC(=N)c2ccc(/N=N/Nc1ccc(cc1)C(N)=N)cc2	"InChI=1/C14H15N7.2C4H7NO3/c15-13(16)9-1-5-11(6-2-9)19-21-20-12-7-3-10(4-8-12)14(17)18;2*1-3(6)5-2-4(7)8/h1-8H,(H3,15,16)(H3,17,18)(H,19,20);2*2H2,1H3,(H,5,6)(H,7,8)/f/h15,17,19H,16,18H2;2*5,7H/b15-13?,17-14?,21-20+;;"	OKQSSSVVBOUMNZ-AJHJOXMQDP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiprotozoal	5	0.0096989	2.013277503	34	Moderate	Low	form of drug administered not known			
22946	2946	22946	407_FDAMDD_v3b	C20H34O5	354.48096	defined organic	parent	tested chemical	Dinoprost	551-11-1	single chemical compound	stereochem	"(5Z,9alpha,11alpha,13E,15S)-9,11,15-trihydroxyprosta-5,13-dien-1-oic acid"	O[C@@H]1C[C@H](O)[C@H](C/C=C\CCCC(O)=O)[C@H]1/C=C/[C@@H](O)CCCCC	O[C@@H]1C[C@H](O)[C@H](C/C=C\CCCC(O)=O)[C@H]1/C=C/[C@@H](O)CCCCC	"InChI=1/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1/f/h24H"	PXGPLTODNUVGFL-VNPGCWOVDY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		oxytocic; abortifacient	0.0125	3.52628E-05	4.4526829	61	High	High	form of drug administered not known			
22947	2947	22947	408_FDAMDD_v3b	C20H32O5	352.4651	defined organic	parent	tested chemical	Dinoprostone	363-24-6	single chemical compound	stereochem	"(5Z,11alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid"	O[C@@H]1CC(=O)[C@H](C/C=C\CCCC(O)=O)[C@H]1/C=C/[C@@H](O)CCCCC	O[C@@H]1CC(=O)[C@H](C/C=C\CCCC(O)=O)[C@H]1/C=C/[C@@H](O)CCCCC	"InChI=1/C20H32O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-17,19,21,23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,19+/m0/s1/f/h24H"	XEYBRNLFEZDVAW-BYBMZJNJDB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		oxytocic; abortifacient	0.025	7.0929E-05	4.149176112	58	High	High	form of drug administered not known			
22948	2948	22948	409_FDAMDD_v3b	C21H27NO4S	389.5084	defined organic	complex methyl sulfate (CH3O4S)	tested chemical	Diphemanil	62-97-5	single chemical compound	ammonium	"4-(diphenylmethylidene)-1,1-dimethylpiperidinium methyl sulfate"	[O-]S(=O)(=O)OC.C[N+]1(C)CC\C(CC1)=C(\c2ccccc2)c3ccccc3	C3=CC=CC(C(C1=CC=CC=C1)=C2CC[N+](C)(C)CC2)=C3	"InChI=1/C20H24N.CH4O4S/c1-21(2)15-13-19(14-16-21)20(17-9-5-3-6-10-17)18-11-7-4-8-12-18;1-5-6(2,3)4/h3-12H,13-16H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1/fC20H24N.CH3O4S/qm;-1"	BREMLQBSKCSNNH-ICGDQCNFCJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	13.3	0.034145605	1.466665187	28	Low-Moderate	Low	form of drug administered not known			
22949	2949	22949	410_FDAMDD_v3b	C17H21NO	255.35474	defined organic	parent	tested chemical	Diphenhydramine	58-73-1	single chemical compound		"2-[(diphenylmethyl)oxy]-N,N-dimethylethanamine"	C2=CC(C(C1=CC=CC=C1)OCCN(C)C)=CC=C2	C2=CC(C(C1=CC=CC=C1)OCCN(C)C)=CC=C2	"InChI=1/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3"	ZZVUWRFHKOJYTH-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	0.833	0.003262129	2.486498922	39	Moderate	High	form of drug administered not known			
22950	2950	22950	411_FDAMDD_v3b	C21H27NO	309.44518	defined organic	parent	tested chemical	Diphenidol	972-02-1	single chemical compound		"1,1-diphenyl-4-piperidin-1-ylbutan-1-ol"	C3=CC=C(C(O)(CCCN1CCCCC1)C2=CC=CC=C2)C=C3	C3=CC=C(C(O)(CCCN1CCCCC1)C2=CC=CC=C2)C=C3	"InChI=1/C21H27NO/c23-21(19-11-4-1-5-12-19,20-13-6-2-7-14-20)15-10-18-22-16-8-3-9-17-22/h1-2,4-7,11-14,23H,3,8-10,15-18H2"	OGAKLTJNUQRZJU-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiemetic	5	0.016157951	1.791613718	31	Moderate	Low	form of drug administered not known			
22951	2951	22951	412_FDAMDD_v3b	C30H32N2O2	452.58728	defined organic	parent	tested chemical	Diphenoxylate	915-30-0	single chemical compound		"ethyl 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylate"	C4=CC=CC(C3(C(=O)OCC)CCN(CCC(C#N)(C1=CC=CC=C1)C2=CC=CC=C2)CC3)=C4	C4=CC=CC(C3(C(=O)OCC)CCN(CCC(C#N)(C1=CC=CC=C1)C2=CC=CC=C2)CC3)=C4	"InChI=1/C30H32N2O2/c1-2-34-28(33)29(25-12-6-3-7-13-25)18-21-32(22-19-29)23-20-30(24-31,26-14-8-4-9-15-26)27-16-10-5-11-17-27/h3-17H,2,18-23H2,1H3"	HYPPXZBJBPSRLK-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiperistaltic; antidiarrheal	0.333	0.00073577	3.13325811	46	High-Moderate	High	form of drug administered not known			
22952	2952	22952	413_FDAMDD_v3b	C19H23NO	281.39202	defined organic	parent	tested chemical	Diphenylpyraline	147-20-6	single chemical compound		4-[(diphenylmethyl)oxy]-1-methylpiperidine	C3N(C)CCC(OC(C1=CC=CC=C1)C2=CC=CC=C2)C3	C3N(C)CCC(OC(C1=CC=CC=C1)C2=CC=CC=C2)C3	"InChI=1/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3"	OWQUZNMMYNAXSL-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	0.333	0.001183402	2.926867544	44	Moderate	High	form of drug administered not known			
22953	1322	21322	414_FDAMDD_v3b	C10H20N2S4	296.5392	defined organic	parent	tested chemical	Disulfiram	97-77-8	single chemical compound		"1,1',1'',1'''-[dithiobis(carbonothioylnitrilo)]tetraethane"	S=C(N(CC)CC)SSC(=S)N(CC)CC	S=C(N(CC)CC)SSC(=S)N(CC)CC	"InChI=1/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3"	AUZONCFQVSMFAP-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		alcohol deterrent	8.33	0.028090721	1.55143711	29	Low-Moderate	Low	form of drug administered not known			
22954	2954	22954	415_FDAMDD_v3b	C19H20N2O3	324.3737	defined organic	parent	tested chemical	Ditazole	18471-20-0	single chemical compound		"2,2'-[(4,5-diphenyl-1,3-oxazol-2-yl)imino]diethanol"	N3C(C1=CC=CC=C1)=C(C2=CC=CC=C2)OC=3N(CCO)CCO	N3C(C1=CC=CC=C1)=C(C2=CC=CC=C2)OC=3N(CCO)CCO	"InChI=1/C19H20N2O3/c22-13-11-21(12-14-23)19-20-17(15-7-3-1-4-8-15)18(24-19)16-9-5-2-6-10-16/h1-10,22-23H,11-14H2"	UUCMDZWCRNZCOY-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	20	0.06165728	1.210015639	25	Low-Moderate	Low	form of drug administered not known			
22955	2955	22955	416_FDAMDD_v3b	C23H23IN2S2	518.47659	defined organic	salt I	representative isomer in mixture	Dithiazanine iodide	514-73-8	mixture or formulation	"ammonium; stereochem; mixture of 5Z,E isomers; structure shown 5Z; parent [7187-55-5]"	"3-ethyl-2-[(1E,3E,5Z)-5-(3-ethyl-1,3-benzothiazol-2(3H)-ylidene)penta-1,3-dien-1-yl]-1,3-benzothiazol-3-ium iodide"	C1=CC=C4C(=C1)SC(=CC=CC=CC2SC3=C([N+]=2CC)C=CC=C3)N4CC.[I-]	C1=CC=C4C(=C1)SC(=CC=CC=CC2SC3=C([N+]=2CC)C=CC=C3)N4CC	"InChI=1/C23H23N2S2.HI/c1-3-24-18-12-8-10-14-20(18)26-22(24)16-6-5-7-17-23-25(4-2)19-13-9-11-15-21(19)27-23;/h5-17H,3-4H2,1-2H3;1H/q+1;/p-1/fC23H23N2S2.I/h;1h/qm;-1"	MNQDKWZEUULFPX-RWTGLYIQCP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anthelmintic	3.33	0.006422662	2.192284919	36	Moderate	Moderate	form of drug administered not known			
22956	2956	22956	417_FDAMDD_v3b	C5H10NNaS2	171.2594	defined organic	salt Na	tested chemical	Ditiocarb	148-18-5	single chemical compound		sodium diethyldithiocarbamate	[Na+].CCN(CC)C([S-])=S	CCN(CC)C(S)=S	"InChI=1/C5H11NS2.Na/c1-3-6(4-2)5(7)8;/h3-4H2,1-2H3,(H,7,8);/q;+1/p-1/fC5H10NS2.Na/q-1;m"	IOEJYZSZYUROLN-NTJUIWPWCB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		immunomodulator; chelating agent	10	0.058390955	1.233654418	25	Low-Moderate	Low	form of drug administered not known			
22958	2958	22958	418_FDAMDD_v3b	C18H23NO3	301.38012	defined organic	parent	tested chemical	Dobutamine	34368-04-2	single chemical compound		"4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol"	C2(O)=C(O)C=CC(CCNC(C)CCC1=CC=C(O)C=C1)=C2	C2(O)=C(O)C=CC(CCNC(C)CCC1=CC=C(O)C=C1)=C2	"InChI=1/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3"	JRWZLRBJNMZMFE-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cardiotonic	0.04	0.000132723	3.87705461	55	High	High	form of drug administered not known			
22959	2959	22959	419_FDAMDD_v3b	C20H37NaO7S	444.5583	defined organic	salt Na	tested chemical	Docusate	577-11-7	single chemical compound	parent [10041-19-7]	"sodium 1,4-bis[(2-ethylhexyl)oxy]-1,4-dioxobutane-2-sulfonate"	O=S(C(C(OCC(CCCC)CC)=O)CC(OCC(CCCC)CC)=O)([O-])=O.[Na+]	O=S(C(C(OCC(CCCC)CC)=O)CC(OCC(CCCC)CC)=O)(O)=O	"InChI=1/C20H38O7S.Na/c1-5-9-11-16(7-3)14-26-19(21)13-18(28(23,24)25)20(22)27-15-17(8-4)12-10-6-2;/h16-18H,5-15H2,1-4H3,(H,23,24,25);/q;+1/p-1/fC20H37O7S.Na/q-1;m"	APSBXTVYXVQYAB-GBLVWZQUCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		stool softener	5	0.010903106	1.962449746	33	Moderate	Low	form of drug administered not known			
22960	2960	22960	420_FDAMDD_v3b	C10H16N2O4S3	324.44004	defined organic	parent	tested chemical	Dorzolamide	120279-96-1	single chemical compound	stereochem	"(4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide"	O=S1(C(SC(S(N)(=O)=O)=C2)=C2[C@@H](NCC)C[C@@H]1C)=O	O=S1(C(SC(S(N)(=O)=O)=C2)=C2[C@@H](NCC)C[C@@H]1C)=O	"InChI=1/C10H16N2O4S3/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16)/t6-,8-/m0/s1/f/h11H2"	IAVUPMFITXYVAF-TXDCOMSSDC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiglaucomal agent; carbonic anhydrase inhibitor	1	0.003082234	2.511134446	39	Moderate	High	form of drug administered not known			
22961	2961	22961	421_FDAMDD_v3b	C19H21NS	295.44174	defined organic	parent	representative isomer in mixture	Dothiepin	113-53-1	mixture or formulation	"mixture of Z,E isomers; structure shown E; stereochem"	"(3E)-3-dibenzo[b,e]thiepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine"	C1=CC=C2C(=C1)C(=CCCN(C)C)C3=C(SC2)C=CC=C3	C1=CC=C2C(=C1)C(=CCCN(C)C)C3=C(SC2)C=CC=C3	"InChI=1/C19H21NS/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11+"	PHTUQLWOUWZIMZ-GZTJUZNOBJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	2.5	0.008461905	2.072531844	34	Moderate	High-Moderate	form of drug administered not known; HCl [897-15-4]			
22962	2962	22962	422_FDAMDD_v3b	C56H78Cl2N2O16	1106.12832	defined organic	salt 2Cl	tested chemical	Doxacurium chloride	106819-53-8	single chemical compound	ammonium; stereochem	"(1R,2S,1'S,2'R)-2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxypropane-3,1-diyl)]bis[2-methyl-6,7,8-tris(methyloxy)-1-{[3,4,5-tris(methyloxy)phenyl]methyl}-1,2,3,4-tetrahydroisoquinolinium] dichloride"	[Cl-].[Cl-].COc1cc(cc(OC)c1OC)C[C@H]5c6c(OC)c(OC)c(OC)cc6CC[N@+]5(C)CCCOC(=O)CCC(=O)OCCC[N@+]3(C)CCc4cc(OC)c(OC)c(OC)c4[C@H]3Cc2cc(OC)c(OC)c(OC)c2	COc1cc(cc(OC)c1OC)C[C@H]5c6c(OC)c(OC)c(OC)cc6CC[N@+]5(C)CCCOC(=O)CCC(=O)OCCC[N@+]3(C)CCc4cc(OC)c(OC)c(OC)c4[C@H]3Cc2cc(OC)c(OC)c(OC)c2	"InChI=1/C56H78N2O16.2ClH/c1-57(23-19-37-33-45(65-7)53(69-11)55(71-13)49(37)39(57)27-35-29-41(61-3)51(67-9)42(30-35)62-4)21-15-25-73-47(59)17-18-48(60)74-26-16-22-58(2)24-20-38-34-46(66-8)54(70-12)56(72-14)50(38)40(58)28-36-31-43(63-5)52(68-10)44(32-36)64-6;;/h29-34,39-40H,15-28H2,1-14H3;2*1H/q+2;;/p-2/t39-,40+,57-,58+;;/fC56H78N2O16.2Cl/h;2*1h/qm;2*-1"	APADFLLAXHIMFU-UFIRGPDVDP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant; neuromuscular blocker	0.05	4.52027E-05	4.344835507	60	High	High	form of drug administered not known			
22963	2963	22963	423_FDAMDD_v3b	C24H30N2O2	378.5072	defined organic	parent	tested chemical	Doxapram	309-29-5	single chemical compound		"1-ethyl-4-(2-morpholin-4-ylethyl)-3,3-diphenylpyrrolidin-2-one"	C4(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N(CC)CC4CCN3CCOCC3	C4(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)N(CC)CC4CCN3CCOCC3	"InChI=1/C24H30N2O2/c1-2-26-19-22(13-14-25-15-17-28-18-16-25)24(23(26)27,20-9-5-3-6-10-20)21-11-7-4-8-12-21/h3-12,22H,2,13-19H2,1H3"	XFDJYSQDBULQSI-UHFFFAOYAU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		respiratory stimulant	4	0.010567831	1.976014154	33	Moderate	Moderate	form of drug administered not known			
22964	2964	22964	424_FDAMDD_v3b	C23H25N5O5	451.4751	defined organic	parent	tested chemical	Doxazosin	74191-85-8	single chemical compound		"2-[4-(2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl)piperazin-1-yl]-6,7-bis(methyloxy)quinazolin-4-amine"	C1(OC)=C(OC)C=C5C(=C1)N=C(N4CCN(C(=O)C2OC3=C(OC2)C=CC=C3)CC4)N=C5N	C1(OC)=C(OC)C=C5C(=C1)N=C(N4CCN(C(=O)C2OC3=C(OC2)C=CC=C3)CC4)N=C5N	"InChI=1/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)/f/h24H2"	RUZYUOTYCVRMRZ-PECIQRARCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.267	0.000591395	3.228122542	47	High-Moderate	High	form of drug administered not known			
22965	551	20551	425_FDAMDD_v3b	C17H14ClFN2O3	348.7560632	defined organic	parent	tested chemical	Doxefazepam	40762-15-0	single chemical compound	tautomers	"7-chloro-5-(2-fluorophenyl)-3-hydroxy-1-(2-hydroxyethyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one"	C1=C(Cl)C=C3C(=C1)N(CCO)C(=O)C(O)N=C3C2=CC=CC=C2F	C1=C(Cl)C=C3C(=C1)N(CCO)C(=O)C(O)N=C3C2=CC=CC=C2F	"InChI=1/C17H14ClFN2O3/c18-10-5-6-14-12(9-10)15(11-3-1-2-4-13(11)19)20-16(23)17(24)21(14)7-8-22/h1-6,9,16,22-23H,7-8H2"	VOJLELRQLPENHL-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	0.333	0.000954822	3.020077533	45	High-Moderate	High	form of drug administered not known			
22966	2966	22966	426_FDAMDD_v3b	C19H21NO	279.37614	defined organic	parent	tested chemical	Doxepin	1668-19-5	single chemical compound	stereochem	"(3Z)-3-dibenzo[b,e]oxepin-11(6H)-ylidene-N,N-dimethylpropan-1-amine"	C1=CC=C2C(=C1)C(=CCCN(C)C)C3=C(CO2)C=CC=C3	C1=CC=C2C(=C1)C(=CCCN(C)C)C3=C(CO2)C=CC=C3	"InChI=1/C19H21NO/c1-20(2)13-7-11-17-16-9-4-3-8-15(16)14-21-19-12-6-5-10-18(17)19/h3-6,8-12H,7,13-14H2,1-2H3/b17-11-"	ODQWQRRAPPTVAG-BOPFTXTBBO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	5	0.017897019	1.747219308	31	Moderate	Low	form of drug administered not known			
22967	2967	22967	427_FDAMDD_v3b	C9H11FN2O5	246.1924432	defined organic	parent	tested chemical	Doxifluridine	3094-09-5	single chemical compound	stereochem	5'-deoxy-5-fluorouridine	F\C1=C\N(C(=O)NC1=O)[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O	F\C1=C\N(C(=O)NC1=O)[C@@H]2O[C@H](C)[C@@H](O)[C@H]2O	"InChI=1/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1/f/h11H"	ZWAOHEXOSAUJHY-PSQNQMENDU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	20	0.081237262	1.090244723	23	Low	Low	form of drug administered not known			
22968	2968	22968	428_FDAMDD_v3b	C11H14N4O4	266.25326	defined organic	parent	tested chemical	Doxofylline	69975-86-6	single chemical compound		"7-(1,3-dioxolan-2-ylmethyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione"	N1(C)C(=O)N(C)C3=C(C1=O)N(CC2OCCO2)C=N3	N1(C)C(=O)N(C)C3=C(C1=O)N(CC2OCCO2)C=N3	"InChI=1/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3"	HWXIGFIVGWUZAO-UHFFFAOYAA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator	13.3	0.04995244	1.301443293	26	Low-Moderate	Low	form of drug administered not known			
22969	1480	21480	429_FDAMDD_v3b	C27H29NO11	543.5193	defined organic	parent	tested chemical	Doxorubicin	23214-92-8	single chemical compound	"adriamycin, stereochem"	"(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside"	OCC(=O)[C@@]4(O)C[C@H](O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1)c5c(O)c3C(=O)c2c(OC)cccc2C(=O)c3c(O)c5C4	OCC(=O)[C@@]4(O)C[C@H](O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1)c5c(O)c3C(=O)c2c(OC)cccc2C(=O)c3c(O)c5C4	"InChI=1/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1"	AOJJSUZBOXZQNB-TZSSRYMLBG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	2.43	0.004470862	2.349608697	37	Moderate	High	form of drug administered not known			
22970	2970	22970	430_FDAMDD_v3b	C17H22N2O	270.3694	defined organic	parent	tested chemical	Doxylamine	469-21-6	single chemical compound		"N,N-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine"	C2=CC=C(C(C)(C1=NC=CC=C1)OCCN(C)C)C=C2	C2=CC=C(C(C)(C1=NC=CC=C1)OCCN(C)C)C=C2	"InChI=1/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3"	HCFDWZZGGLSKEP-UHFFFAOYAC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic; hypnotic	0.417	0.001542334	2.811821482	43	Moderate	High	form of drug administered not known			
22971	2971	22971	431_FDAMDD_v3b	C20H32O2	304.46688	defined organic	parent	tested chemical	Dromostanolone	58-19-5	single chemical compound	stereochem	"(2alpha,5alpha,17beta)-17-hydroxy-2-methylandrostan-3-one"	O=C2C[C@@H]3CC[C@H]1[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]1[C@@]3(C)C[C@H]2C	O=C2C[C@@H]3CC[C@H]1[C@@H]4CC[C@H](O)[C@@]4(C)CC[C@@H]1[C@@]3(C)C[C@H]2C	"InChI=1/C20H32O2/c1-12-11-20(3)13(10-17(12)21)4-5-14-15-6-7-18(22)19(15,2)9-8-16(14)20/h12-16,18,22H,4-11H2,1-3H3/t12-,13+,14+,15+,16+,18+,19+,20+/m1/s1"	IKXILDNPCZPPRV-RFMGOVQKBD	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Dromostanolone	antineoplastic	1.67	0.005484997	2.260823586	36	Moderate	High	form of drug administered not known			
22972	2972	22972	432_FDAMDD_v3b	C23H36O3	360.53014	defined organic	parent	tested chemical	Dromostanolone proprionate	521-12-0	single chemical compound	stereochem	"(2alpha,5alpha,17beta)-2-methyl-3-oxoandrostan-17-yl propanoate"	CCC(=O)O[C@H]4CC[C@@H]3[C@]4(C)CC[C@H]2[C@H]3CC[C@H]1CC(=O)[C@H](C)C[C@@]12C	CCC(=O)O[C@H]4CC[C@@H]3[C@]4(C)CC[C@H]2[C@H]3CC[C@H]1CC(=O)[C@H](C)C[C@@]12C	"InChI=1/C23H36O3/c1-5-21(25)26-20-9-8-17-16-7-6-15-12-19(24)14(2)13-23(15,4)18(16)10-11-22(17,20)3/h14-18,20H,5-13H2,1-4H3/t14-,15+,16+,17+,18+,20+,22+,23+/m1/s1"	NOTIQUSPUUHHEH-UXOVVSIBBM	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Dromostanolone	antineoplastic	1.67	0.004632068	2.334225106	37	Moderate	High	form of drug administered not known			
22973	2973	22973	433_FDAMDD_v3b	C22H22FN3O2	379.4273832	defined organic	parent	tested chemical	Droperidol	548-73-2	single chemical compound		"1-{1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one"	C1=CC=C4C(=C1)N(C3CCN(CCCC(=O)C2=CC=C(F)C=C2)CC=3)C(=O)N4	C1=CC=C4C(=C1)N(C3CCN(CCCC(=O)C2=CC=C(F)C=C2)CC=3)C(=O)N4	"InChI=1/C22H22FN3O2/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28)/f/h24H"	RMEDXOLNCUSCGS-LQFNOIFHCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	0.275	0.000724776	3.139795977	46	High-Moderate	High	form of drug administered not known			
22974	2974	22974	434_FDAMDD_v3b	C21H28O2	312.44582	defined organic	parent	tested chemical	Dydrogesterone	152-62-5	single chemical compound	stereochem	"(9beta,10alpha)-pregna-4,6-diene-3,20-dione"	CC(=O)[C@H]2CC[C@H]3[C@@H]4\C=C/C1=C/C(=O)CC[C@@]1(C)[C@@H]4CC[C@]23C	CC(=O)[C@H]2CC[C@H]3[C@@H]4\C=C/C1=C/C(=O)CC[C@@]1(C)[C@@H]4CC[C@]23C	"InChI=1/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h4-5,12,16-19H,6-11H2,1-3H3/t16-,17+,18-,19+,20+,21+/m0/s1"	JGMOKGBVKVMRFX-HQZYFCCVBZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		progestogen	0.5	0.001600277	2.795804715	42	Moderate	High	form of drug administered not known			
22975	2975	22975	435_FDAMDD_v3b	C10H14N4O4	254.24256	defined organic	parent	tested chemical	Dyphylline	479-18-5	single chemical compound		"7-(2,3-dihydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione"	N1(C)C(=O)N(C)C2=C(C1=O)N(CC(O)CO)C=N2	N1(C)C(=O)N(C)C2=C(C1=O)N(CC(O)CO)C=N2	"InChI=1/C10H14N4O4/c1-12-8-7(9(17)13(2)10(12)18)14(5-11-8)3-6(16)4-15/h5-6,15-16H,3-4H2,1-2H3"	KSCFJBIXMNOVSH-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator	60	0.235995106	0.627097002	18	Low	Low	form of drug administered not known			
22976	2976	22976	436_FDAMDD_v3b	C9H23INO3PS	383.227051	defined organic	salt I	tested chemical	Echothiophate	513-10-0	single chemical compound	ammonium	"2-{[bis(ethyloxy)phosphoryl]thio}-N,N,N-trimethylethanaminium iodide"	[N+](C)(C)(C)CCSP(=O)(OCC)OCC.[I-]	[N+](C)(C)(C)CCSP(=O)(OCC)OCC	"InChI=1/C9H23NO3PS.HI/c1-6-12-14(11,13-7-2)15-9-8-10(3,4)5;/h6-9H2,1-5H3;1H/q+1;/p-1/fC9H23NO3PS.I/h;1h/qm;-1"	OVXQHPWHMXOFRD-LZLAGNAICQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cholinergic	0.167	0.000435773	3.360739686	49	High-Moderate	High	form of drug administered not known			
22977	2977	22977	437_FDAMDD_v3b	C10H16N2O8	292.2426	defined organic	parent	tested chemical	Edetic acid	60-00-4	single chemical compound		"2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid"	N(CCN(CC(O)=O)CC(O)=O)(CC(O)=O)CC(O)=O	N(CCN(CC(O)=O)CC(O)=O)(CC(O)=O)CC(O)=O	"InChI=1/C10H16N2O8/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20)/f/h13,15,17,19H"	KCXVZYZYPLLWCC-RCPNDDNVCP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		pharmaceutic aid	70	0.239527023	0.620645483	18	Low	Low	form of drug administered not known			
22978	2978	22978	438_FDAMDD_v3b	C10H16ClNO	201.69314	defined organic	salt Cl	tested chemical	Edrophonium chloride	116-38-1	single chemical compound	ammonium	"N-ethyl-3-hydroxy-N,N-dimethylanilinium chloride"	C1(O)=CC=CC([N+](C)(C)CC)=C1.[Cl-]	C1(O)=CC=CC([N+](C)(C)CC)=C1	"InChI=1/C10H15NO.ClH/c1-4-11(2,3)9-6-5-7-10(12)8-9;/h5-8H,4H2,1-3H3;1H/fC10H16NO.Cl/h12H;1h/q+1;-1"	BXKDSDJJOVIHMX-ZKWTXODQCC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cholinergic	0.7	0.003470619	2.459593087	39	Moderate	High	form of drug administered not known			
22979	467	20467	439_FDAMDD_v3b	C6H12F2N2O2	182.1698	defined organic	parent	tested chemical	Eflornithine	70052-12-9	single chemical compound	retired CASRN [67037-37-0]	2-(difluoromethyl)ornithine	NC(CCCN)(C(=O)O)C(F)F	NC(CCCN)(C(=O)O)C(F)F	"InChI=1/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12)/f/h11H"	VLCYCQAOQCDTCN-WXRBYKJCCY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic; antineumocystis; antiprotozoal	400	2.195753632	-0.34158361	7	Low	Low	form of drug administered not known			
22980	2980	22980	440_FDAMDD_v3b	C29H40N2O4	480.6389	defined organic	parent	tested chemical	Emetine	483-18-1	single chemical compound	stereochem	"6',7',10,11-tetrakis(methyloxy)emetan"	COc4cc5CCN[C@H](C[C@H]1C[C@H]2c3cc(OC)c(OC)cc3CCN2C[C@@H]1CC)c5cc4OC	COc4cc5CCN[C@H](C[C@H]1C[C@H]2c3cc(OC)c(OC)cc3CCN2C[C@@H]1CC)c5cc4OC	"InChI=1/C29H40N2O4/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24/h13-16,18,21,24-25,30H,6-12,17H2,1-5H3/t18-,21-,24+,25-/m0/s1"	AUVVAXYIELKVAI-CKBKHPSWBK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiamebic	1	0.002080564	2.681818917	41	Moderate	High	form of drug administered not known			
22981	2981	22981	441_FDAMDD_v3b	C11H17N3O3	239.27098	defined organic	parent	tested chemical	Emorfazone	38957-41-4	single chemical compound		4-(ethyloxy)-2-methyl-5-morpholin-4-ylpyridazin-3(2H)-one	N2N(C)C(=O)C(OCC)=C(N1CCOCC1)C=2	N2N(C)C(=O)C(OCC)=C(N1CCOCC1)C=2	"InChI=1/C11H17N3O3/c1-3-17-10-9(8-12-13(2)11(10)15)14-4-6-16-7-5-14/h8H,3-7H2,1-2H3"	URJQOOISAKEBKW-UHFFFAOYAA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; anti inflammatory	3.33	0.013917275	1.856445795	32	Moderate	Moderate	form of drug administered not known			
22982	2982	22982	442_FDAMDD_v3b	C20H28N2O5	376.44672	defined organic	parent	tested chemical	Enalapril	75847-73-3	single chemical compound	stereochem	N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl-L-proline	O=C(O)[C@@H]2CCCN2C(=O)[C@H](C)N[C@@H](CCc1ccccc1)C(=O)OCC	O=C(O)[C@@H]2CCCN2C(=O)[C@H](C)N[C@@H](CCc1ccccc1)C(=O)OCC	"InChI=1/C20H28N2O5/c1-3-27-20(26)16(12-11-15-8-5-4-6-9-15)21-14(2)18(23)22-13-7-10-17(22)19(24)25/h4-6,8-9,14,16-17,21H,3,7,10-13H2,1-2H3,(H,24,25)/t14-,16-,17-/m0/s1/f/h24H"	GBXSMTUPTTWBMN-ZLNSRLEUDX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.667	0.001771831	2.751577684	42	Moderate	High	form of drug administered not known			
22983	2983	22983	443_FDAMDD_v3b	C22H28N2O2	352.46992	defined organic	parent	tested chemical	Encainide	37612-13-8	single chemical compound		4-methoxy-N-{2-[2-(1-methylpiperidin-2-yl)ethyl]phenyl}benzamide	O=C(NC2=CC=CC=C2CCC3N(C)CCCC3)C1=CC=C(OC)C=C1	O=C(NC2=CC=CC=C2CCC3N(C)CCCC3)C1=CC=C(OC)C=C1	"InChI=1/C22H28N2O2/c1-24-16-6-5-8-19(24)13-10-17-7-3-4-9-21(17)23-22(25)18-11-14-20(26-2)15-12-18/h3-4,7,9,11-12,14-15,19H,5-6,8,10,13,16H2,1-2H3,(H,23,25)/f/h23H"	PJWPNDMDCLXCOM-MPIMZMORCU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiarrhythmic	3.33	0.009447615	2.024677826	34	Moderate	Moderate	form of drug administered not known; structure modified v3b			
22984	2984	22984	444_FDAMDD_v3b	C15H17FN4O3	320.3188832	defined organic	parent	tested chemical	Enoxacin	74011-58-8	single chemical compound		"1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid"	C2(F)=C(N1CCNCC1)N=C3C(=C2)C(=O)C(C(O)=O)=CN3CC	C2(F)=C(N1CCNCC1)N=C3C(=C2)C(=O)C(C(O)=O)=CN3CC	"InChI=1/C15H17FN4O3/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20/h7-8,17H,2-6H2,1H3,(H,22,23)/f/h22H"	IDYZIJYBMGIQMJ-QWOVJGMICA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	20	0.06243778	1.204552546	25	Low-Moderate	Low	form of drug administered not known			
22985	2985	22985	445_FDAMDD_v3b	C10H15NO	165.2322	defined organic	parent	tested chemical	Ephedrine	299-42-3	single chemical compound	stereochem	"(1R,2S)-2-(methylamino)-1-phenylpropan-1-ol"	O[C@@H]([C@H](C)NC)[C@]1=CC=CC=C1	O[C@@H]([C@H](C)NC)[C@]1=CC=CC=C1	"InChI=1/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1"	KWGRBVOPPLSCSI-WPRPVWTQBH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator	1.67	0.010106989	1.995378214	33	Moderate	High	form of drug administered not known			
22986	2986	22986	446_FDAMDD_v3b	C9H13NO3	183.2044	defined organic	parent	tested chemical	Epinephrine	51-43-4	single chemical compound	stereochem	"4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol"	OC1=CC([C@H](CNC)O)=CC=C1O	OC1=CC([C@H](CNC)O)=CC=C1O	"InChI=1/C9H13NO3/c1-10-5-9(13)6-2-3-7(11)8(12)4-6/h2-4,9-13H,5H2,1H3/t9-/m0/s1"	UCTWMZQNUQWSLP-VIFPVBQEBW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		adrenergic; bronchodilator; mydriatic; antiglaucoma	0.0167	9.1155E-05	4.040219429	56	High	High	form of drug administered not known			
22987	2987	22987	447_FDAMDD_v3b	C27H29NO11	543.51926	defined organic	parent	tested chemical	Epirubicin	56420-45-2	single chemical compound	stereochem; tautomers	"(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside"	OCC(=O)[C@@]4(O)C[C@H](O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1)c5c(O)c3C(=O)c2c(OC)cccc2C(=O)c3c(O)c5C4	OCC(=O)[C@@]4(O)C[C@H](O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1)c5c(O)c3C(=O)c2c(OC)cccc2C(=O)c3c(O)c5C4	"InChI=1/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22-,27-/m0/s1"	AOJJSUZBOXZQNB-VTZDEGQIBI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	2.43	0.004470863	2.349608665	37	Moderate	High	form of drug administered not known			
22988	2988	22988	448_FDAMDD_v3b	C20H32O5	352.46508	defined organic	parent	tested chemical	Epoprostenol	35121-78-9	single chemical compound	stereochem	"(5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid"	O=C(O)CCC/C=C2\O[C@](C[C@H]1O)([H])[C@@](C2)([H])[C@H]1/C=C/[C@H](CCCCC)O	O=C(O)CCC/C=C2\O[C@](C[C@H]1O)([H])[C@@](C2)([H])[C@H]1/C=C/[C@H](CCCCC)O	"InChI=1/C20H32O5/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24)/b11-10+,15-8-/t14-,16+,17+,18+,19-/m0/s1/f/h23H"	KAQKFAOMNZTLHT-MVMWDFMBDN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		platelet aggregation inhibitor	0.00001	2.83716E-08	7.547116096	96	High	High	form of drug administered not known			
22989	2989	22989	449_FDAMDD_v3b	C23H24N2O4S	424.51266	defined organic	parent	tested chemical	Eprosartan	133040-01-4	single chemical compound	stereochem	4-({2-butyl-5-[(1E)-2-carboxy-3-(2-thienyl)prop-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid	N3C=C(C=C(CC1=CC=CS1)C(=O)O)N(CC2=CC=C(C(O)=O)C=C2)C=3CCCC	N3C=C(C=C(CC1=CC=CS1)C(=O)O)N(CC2=CC=C(C(O)=O)C=C2)C=3CCCC	"InChI=1/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+/f/h26,28H"	OROAFUQRIXKEMV-GSKVCIOQDU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	13.3	0.031330043	1.504039006	28	Low-Moderate	Low	form of drug administered not known			
22990	2990	22990	450_FDAMDD_v3b	C4H6N4O12	302.11004	defined organic	parent	tested chemical	Erythrityl tetranitrate	7297-25-8	single chemical compound	stereochem	"(2R,3S)-3,4-bis(nitrooxy)butane-1,2-diyl dinitrate"	[O-][N+](OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O)=O	[O-][N+](OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O)=O	"InChI=1/C4H6N4O12/c9-5(10)17-1-3(19-7(13)14)4(20-8(15)16)2-18-6(11)12/h3-4H,1-2H2/t3-,4+"	SNFOERUNNSHUGP-ZXZARUISBH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		coronary vasodilator	1.67	0.005527787	2.257448687	36	Moderate	High	form of drug administered not known; structure modified v3b			
22991	2991	22991	451_FDAMDD_v3b	C37H67NO13	733.92678	defined organic	parent	tested chemical	Erythromycin	114-07-8	single chemical compound	stereochem	"(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione"	CN(C)[C@H]3C[C@@H](C)O[C@@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)[C@@H]3O	CN(C)[C@H]3C[C@@H](C)O[C@@H](O[C@@H]2[C@@H](C)[C@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)[C@@H]3O	"InChI=1/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1"	ULGZDMOVFRHVEP-RWJQBGPGBH	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 4	Erythromycin	antibacterial	66.7	0.090881	1.041526901	23	Low	Low	form of drug administered not known			
22992	2992	22992	452_FDAMDD_v3b	C57H105NO16	1060.4407	defined organic	complex stearic acid (C18H36O2)	tested chemical	Erythromycin acistrate	96128-89-1	single chemical compound	stereochem	"octadecanoic acid and (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((2-acetate-3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione"	CCCCCCCCCCCCCCCCCC(O)=O.CC(=O)O[C@@H]3[C@H](C[C@@H](C)O[C@H]3O[C@@H]2[C@@H](C)[C@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)N(C)C	CC(=O)O[C@@H]3[C@H](C[C@@H](C)O[C@H]3O[C@@H]2[C@@H](C)[C@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)N(C)C	"InChI=1/C39H69NO14.C18H36O2/c1-15-27-39(11,47)32(43)21(4)29(42)19(2)17-37(9,46)34(54-36-31(51-25(8)41)26(40(12)13)16-20(3)49-36)22(5)30(23(6)35(45)52-27)53-28-18-38(10,48-14)33(44)24(7)50-28;1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h19-24,26-28,30-34,36,43-44,46-47H,15-18H2,1-14H3;2-17H2,1H3,(H,19,20)/t19-,20-,21+,22+,23-,24+,26+,27-,28+,30+,31-,32-,33+,34-,36+,37-,38-,39-;/m1./s1/f/h;19H"	FPEVNWDVXZGKCD-CKZXNXCQDN	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 4	Erythromycin	antibacterial	66.7	0.062898378	1.201360554	25	Low-Moderate	Low	form of drug administered not known			
22993	2993	22993	453_FDAMDD_v3b	C43H75NO16	862.0527	defined organic	parent	tested chemical	Erythromycin ethylsuccinate	1264-62-6	single chemical compound	stereochem	"(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((2- ethyl butanedioate -3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione"	CCOC(=O)CCC(=O)O[C@@H]3[C@H](C[C@@H](C)O[C@H]3O[C@@H]2[C@@H](C)[C@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)N(C)C	CCOC(=O)CCC(=O)O[C@@H]3[C@H](C[C@@H](C)O[C@H]3O[C@@H]2[C@@H](C)[C@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)N(C)C	"InChI=1/C43H75NO16/c1-15-29-43(11,52)36(48)24(5)33(47)22(3)20-41(9,51)38(25(6)34(26(7)39(50)57-29)59-32-21-42(10,53-14)37(49)27(8)56-32)60-40-35(28(44(12)13)19-23(4)55-40)58-31(46)18-17-30(45)54-16-2/h22-29,32,34-38,40,48-49,51-52H,15-21H2,1-14H3/t22-,23-,24+,25+,26-,27+,28+,29-,32+,34+,35-,36-,37+,38-,40+,41-,42-,43-/m1/s1"	NSYZCCDSJNWWJL-YXOIYICCBW	Clinical Reports 	Maximum Recommended Daily Dose	human	3 of 4	Erythromycin	antibacterial	66.7	0.07737346	1.111407983	24	Low	Low	form of drug administered not known			
22994	2994	22994	454_FDAMDD_v3b	C40H71NO14	789.99004	defined organic	parent	tested chemical	Erythromycin propionate	134-36-1	single chemical compound	stereochem	"Erythromycin, 2'-(3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((2- propanoate-3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione"	CCC(=O)O[C@@H]3[C@H](C[C@@H](C)O[C@H]3O[C@@H]2[C@@H](C)[C@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)N(C)C	CCC(=O)O[C@@H]3[C@H](C[C@@H](C)O[C@H]3O[C@@H]2[C@@H](C)[C@H](O[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](CC)[C@@](C)(O)[C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@]2(C)O)N(C)C	"InChI=1/C40H71NO14/c1-15-27-40(11,48)33(44)22(5)30(43)20(3)18-38(9,47)35(55-37-32(53-28(42)16-2)26(41(12)13)17-21(4)50-37)23(6)31(24(7)36(46)52-27)54-29-19-39(10,49-14)34(45)25(8)51-29/h20-27,29,31-35,37,44-45,47-48H,15-19H2,1-14H3/t20-,21-,22+,23+,24-,25+,26+,27-,29+,31+,32-,33-,34+,35-,37+,38-,39-,40-/m1/s1"	TYQXKHPOXXXCTP-CSLYCKPJBQ	Clinical Reports 	Maximum Recommended Daily Dose	human	4 of 4	Erythromycin	antibacterial	66.7	0.084431444	1.073495782	23	Low	Low	form of drug administered not known			
22995	2995	22995	455_FDAMDD_v3b	C16H25NO4	295.374	defined organic	parent	tested chemical	Esmolol	81147-92-4	single chemical compound		methyl 3-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]propanoate	C1=C(CCC(=O)OC)C=CC(OCC(O)CNC(C)C)=C1	C1=C(CCC(=O)OC)C=CC(OCC(O)CNC(C)C)=C1	"InChI=1/C16H25NO4/c1-12(2)17-10-14(18)11-21-15-7-4-13(5-8-15)6-9-16(19)20-3/h4-5,7-8,12,14,17-18H,6,9-11H2,1-3H3"	AQNDDEOPVVGCPG-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiarrhythmic	0.2	0.000677108	3.169342269	47	High-Moderate	High	form of drug administered not known; CASRN changed v3b			
22996	572	20572	456_FDAMDD_v3b	C16H11ClN4	294.73834	defined organic	parent	tested chemical	Estazolam	29975-16-4	single chemical compound	tautomers	"8-chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine"	C1=C(Cl)C=C3C(=C1)N4C(CN=C3C2=CC=CC=C2)=NN=C4	C1=C(Cl)C=C3C(=C1)N4C(CN=C3C2=CC=CC=C2)=NN=C4	"InChI=1/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2"	CDCHDCWJMGXXRH-UHFFFAOYAH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	0.0333	0.000112982	3.9469924	55	High	High	form of drug administered not known			
22997	573	20573	457_FDAMDD_v3b	C18H24O2	272.382	defined organic	parent	tested chemical	Estradiol	50-28-2	single chemical compound	stereochem	"(17beta)-estra-1(10),2,4-triene-3,17-diol"	Oc3cc4CC[C@@H]1[C@H](CC[C@]2(C)[C@@H](O)CC[C@@H]12)c4cc3	Oc3cc4CC[C@@H]1[C@H](CC[C@]2(C)[C@@H](O)CC[C@@H]12)c4cc3	"InChI=1/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1"	VOXZDWNPVJITMN-ZBRFXRBCBJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 7	Estradiol	estrogen	0.5	0.001835657	2.7362084	42	Moderate	High	form of drug administered not known			
22998	2998	22998	458_FDAMDD_v3b	C25H28O3	376.48802	defined organic	parent	tested chemical	Estradiol benzoate	50-50-0	single chemical compound	stereochem	"(17beta)-17-hydroxyestra-1(10),2,4-trien-3-yl benzoate"	O=c(Oc3cc4CC[C@@H]1[C@H](CC[C@]2(C)[C@@H](O)CC[C@@H]12)c4cc3)c5ccccc5	O=c(Oc3cc4CC[C@@H]1[C@H](CC[C@]2(C)[C@@H](O)CC[C@@H]12)c4cc3)c5ccccc5	"InChI=1/C25H28O3/c1-25-14-13-20-19-10-8-18(28-24(27)16-5-3-2-4-6-16)15-17(19)7-9-21(20)22(25)11-12-23(25)26/h2-6,8,10,15,20-23,26H,7,9,11-14H2,1H3/t20-,21-,22+,23+,25+/m1/s1"	UYIFTLBWAOGQBI-BZDYCCQFBH	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 7	Estradiol	estrogen	0.5	0.001328064	2.876781157	43	Moderate	High	form of drug administered not known			
22999	2999	22999	459_FDAMDD_v3b	C26H36O3	396.56224	defined organic	parent	tested chemical	Estradiol cypionate	313-06-4	single chemical compound	stereochem	"(17beta)-3-hydroxyestra-1(10),2,4-trien-17-yl 3-cyclopentylpropanoate"	Oc4cc5CC[C@@H]1[C@H](CC[C@]2(C)[C@H](CC[C@@H]12)OC(=O)CCC3CCCC3)c5cc4	Oc4cc5CC[C@@H]1[C@H](CC[C@]2(C)[C@H](CC[C@@H]12)OC(=O)CCC3CCCC3)c5cc4	"InChI=1/C26H36O3/c1-26-15-14-21-20-10-8-19(27)16-18(20)7-9-22(21)23(26)11-12-24(26)29-25(28)13-6-17-4-2-3-5-17/h8,10,16-17,21-24,27H,2-7,9,11-15H2,1H3/t21-,22-,23+,24+,26+/m1/s1"	UOACKFBJUYNSLK-XRKIENNPBA	Clinical Reports 	Maximum Recommended Daily Dose	human	3 of 7	Estradiol	estrogen	0.5	0.001260836	2.899341355	44	Moderate	High	form of drug administered not known			
23000	3000	23000	460_FDAMDD_v3b	C24H32O4	384.50848	defined organic	parent	tested chemical	Estradiol dipropionate	113-38-2	single chemical compound	stereochem	"(17beta)-estra-1(10),2,4-triene-3,17-diyl dipropanoate"	CCC(=O)Oc3cc4CC[C@@H]1[C@H](CC[C@]2(C)[C@H](CC[C@@H]12)OC(=O)CC)c4cc3	CCC(=O)Oc3cc4CC[C@@H]1[C@H](CC[C@]2(C)[C@H](CC[C@@H]12)OC(=O)CC)c4cc3	"InChI=1/C24H32O4/c1-4-22(25)27-16-7-9-17-15(14-16)6-8-19-18(17)12-13-24(3)20(19)10-11-21(24)28-23(26)5-2/h7,9,14,18-21H,4-6,8,10-13H2,1-3H3/t18-,19-,20+,21+,24+/m1/s1"	JQIYNMYZKRGDFK-RUFWAXPRBJ	Clinical Reports 	Maximum Recommended Daily Dose	human	4 of 7	Estradiol	estrogen	0.5	0.001300361	2.885935918	43	Moderate	High	form of drug administered not known			
23001	3001	23001	461_FDAMDD_v3b	C25H36O3	384.55154	defined organic	parent	tested chemical	Estradiol enanthate	4956-37-0	single chemical compound	stereochem	"(17beta)-3-hydroxyestra-1(10),2,4-trien-17-yl heptanoate"	CCCCCCC(=O)O[C@H]2CC[C@H]3[C@@H]4CCc1cc(O)ccc1[C@H]4CC[C@]23C	CCCCCCC(=O)O[C@H]2CC[C@H]3[C@@H]4CCc1cc(O)ccc1[C@H]4CC[C@]23C	"InChI=1/C25H36O3/c1-3-4-5-6-7-24(27)28-23-13-12-22-21-10-8-17-16-18(26)9-11-19(17)20(21)14-15-25(22,23)2/h9,11,16,20-23,26H,3-8,10,12-15H2,1-2H3/t20-,21-,22+,23+,25+/m1/s1"	RFWTZQAOOLFXAY-BZDYCCQFBH	Clinical Reports 	Maximum Recommended Daily Dose	human	5 of 7	Estradiol	estrogen	0.5	0.001300216	2.885984551	43	Moderate	High	form of drug administered not known			
23002	574	20574	462_FDAMDD_v3b	C42H50Cl4N2O4	788.6694	defined organic	parent	tested chemical	Estradiol mustard	22966-79-6	single chemical compound	stereochem	"(17beta)-estra-1(10),2,4-triene-3,17-diyl bis({4-[bis(2-chloroethyl)amino]phenyl}acetate)"	ClCCN(CCCl)C1=CC=C(CC(OC3=CC=C(C4=C3)[C@]2([H])[C@](CC4)([H])[C@@](CC[C@@H]5OC(CC6=CC=C(N(CCCl)CCCl)C=C6)=O)([H])[C@]5(C)CC2)=O)C=C1	ClCCN(CCCl)C1=CC=C(CC(OC3=CC=C(C4=C3)[C@]2([H])[C@](CC4)([H])[C@@](CC[C@@H]5OC(CC6=CC=C(N(CCCl)CCCl)C=C6)=O)([H])[C@]5(C)CC2)=O)C=C1	"InChI=1/C42H50Cl4N2O4/c1-42-17-16-36-35-13-11-34(51-40(49)26-29-2-7-32(8-3-29)47(22-18-43)23-19-44)28-31(35)6-12-37(36)38(42)14-15-39(42)52-41(50)27-30-4-9-33(10-5-30)48(24-20-45)25-21-46/h2-5,7-11,13,28,36-39H,6,12,14-27H2,1H3/t36-,37-,38+,39+,42+/m1/s1"	LRSFXIJGHRPOQQ-VZRQQIPSBM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		estrogen	16.67	0.021136867	1.674959391	30	Moderate	Low	form of drug administered not known			
23003	3003	23003	463_FDAMDD_v3b	C29H44O3	440.65786	defined organic	parent	tested chemical	Estradiol undecylate	3571-53-7	single chemical compound	stereochem	"(17beta)-3-hydroxyestra-1(10),2,4-trien-17-yl undecanoate"	CCCCCCCCCCC(=O)O[C@H]2CC[C@H]3[C@@H]4CCc1cc(O)ccc1[C@H]4CC[C@]23C	CCCCCCCCCCC(=O)O[C@H]2CC[C@H]3[C@@H]4CCc1cc(O)ccc1[C@H]4CC[C@]23C	"InChI=1/C29H44O3/c1-3-4-5-6-7-8-9-10-11-28(31)32-27-17-16-26-25-14-12-21-20-22(30)13-15-23(21)24(25)18-19-29(26,27)2/h13,15,20,24-27,30H,3-12,14,16-19H2,1-2H3/t24-,25-,26+,27+,29+/m1/s1"	TXHUMRBWIWWBGW-GVGNIZHQBA	Clinical Reports 	Maximum Recommended Daily Dose	human	6 of 7	Estradiol	estrogen	0.5	0.001134667	2.945131517	44	Moderate	High	form of drug administered not known			
23004	3004	23004	464_FDAMDD_v3b	C23H32O3	356.49838	defined organic	parent	tested chemical	Estradiol valerate	979-32-8	single chemical compound	stereochem	"(17beta)-3-hydroxyestra-1(10),2,4-trien-17-yl pentanoate"	CCCCC(=O)O[C@H]2CC[C@H]3[C@@H]4CCc1cc(O)ccc1[C@H]4CC[C@]23C	CCCCC(=O)O[C@H]2CC[C@H]3[C@@H]4CCc1cc(O)ccc1[C@H]4CC[C@]23C	"InChI=1/C23H32O3/c1-3-4-5-22(25)26-21-11-10-20-19-8-6-15-14-16(24)7-9-17(15)18(19)12-13-23(20,21)2/h7,9,14,18-21,24H,3-6,8,10-13H2,1-2H3/t18-,19-,20+,21+,23+/m1/s1"	RSEPBGGWRJCQGY-RBRWEJTLBF	Clinical Reports 	Maximum Recommended Daily Dose	human	7 of 7	Estradiol	estrogen	0.5	0.001402531	2.853087556	43	Moderate	High	form of drug administered not known			
23005	3005	23005	465_FDAMDD_v3b	C22H32N2O5S	436.56488	defined organic	complex piperazine (C4H19N2)	tested chemical	Estropipate	7280-37-7	single chemical compound	stereochem; stereochem; parent [53-16-7]	"17-oxoestra-1,3,5(10)-trien-3-yl hydrogen sulfate - piperazine (1:1)"	OS(=O)(=O)Oc1cc2CC[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]3c2cc1.C1CNCCN1	OS(=O)(=O)Oc1cc2CC[C@H]3[C@@H]4CCC(=O)[C@@]4(C)CC[C@@H]3c2cc1	"InChI=1/C18H22O5S.C4H10N2/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19;1-2-6-4-3-5-1/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22);5-6H,1-4H2/t14-,15-,16+,18+;/m1./s1/f/h20H;"	HZEQBCVBILBTEP-YMCYZWHFDU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		estrogen	0.0467	0.000106971	3.970731915	56	High	High	form of drug administered not known			
23006	3006	23006	466_FDAMDD_v3b	C10H24N2O2	204.30976	defined organic	parent	tested chemical	Ethambutol	74-55-5	single chemical compound	stereochem	"(2S,2'S)-2,2'-(ethane-1,2-diyldiimino)dibutan-1-ol"	OC[C@H](CC)NCCN[C@H](CO)CC	OC[C@H](CC)NCCN[C@H](CO)CC	"InChI=1/C10H24N2O2/c1-3-9(7-13)11-5-6-12-10(4-2)8-14/h9-14H,3-8H2,1-2H3/t9-,10-/m0/s1"	AEUTYOVWOVBAKS-UWVGGRQHBP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	25	0.122363219	0.912349105	21	Low	Low	form of drug administered not known			
23007	3007	23007	467_FDAMDD_v3b	C12H17NO3	223.26828	defined organic	parent	tested chemical	Ethamivan	304-84-7	single chemical compound		"N,N-diethyl-4-hydroxy-3-(methyloxy)benzamide"	C1(OC)=C(O)C=CC(C(=O)N(CC)CC)=C1	C1(OC)=C(O)C=CC(C(=O)N(CC)CC)=C1	"InChI=1/C12H17NO3/c1-4-13(5-2)12(15)9-6-7-10(14)11(8-9)16-3/h6-8,14H,4-5H2,1-3H3"	BQJODPIMMWWMFC-UHFFFAOYAU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		central and respiratory stimulant	4.17	0.018677082	1.728690972	31	Moderate	Moderate	form of drug administered not known			
23008	3008	23008	468_FDAMDD_v3b	C20H41NO3	343.54444	defined organic	complex oleic acid (C18H34O2)	tested chemical	Ethanolamine oleate	2272-11-9	single chemical compound	stereochem	(9Z)-octadec-9-enoic acid - 2-aminoethanol (1:1)	OC(=O)CCCCCCC/C=C\CCCCCCCC.NCCO	NCCO	"InChI=1/C18H34O2.C2H7NO/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;3-1-2-4/h9-10H,2-8,11-17H2,1H3,(H,19,20);4H,1-3H2/b10-9-;/f/h19H;"	KGWDUNBJIMUFAP-XIJKVINHDJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sclerosing agent	83.3	0.242472269	0.615337923	18	Low	Low	form of drug administered not known			
23009	3009	23009	469_FDAMDD_v3b	C24H29NO4	395.49136	defined organic	parent	tested chemical	Ethaverine	486-47-5	single chemical compound		"1-{[3,4-bis(ethyloxy)phenyl]methyl}-6,7-bis(ethyloxy)isoquinoline"	C1(OCC)=C(OCC)C=C3C(=C1)C(CC2=CC(OCC)=C(OCC)C=C2)=NC=C3	C1(OCC)=C(OCC)C=C3C(=C1)C(CC2=CC(OCC)=C(OCC)C=C2)=NC=C3	"InChI=1/C24H29NO4/c1-5-26-21-10-9-17(14-22(21)27-6-2)13-20-19-16-24(29-8-4)23(28-7-3)15-18(19)11-12-25-20/h9-12,14-16H,5-8,13H2,1-4H3"	ZOWYFYXTIWQBEP-UHFFFAOYAB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antispasmodic	10	0.025285002	1.597137	29	Low-Moderate	Low	form of drug administered not known			
23010	3010	23010	470_FDAMDD_v3b	C7H9ClO	144.59876	defined organic	parent	representative isomer in mixture	Ethchlorvynol	113-18-8	mixture or formulation	"mixture of Z,E isomers; structure shown Z; stereochem "	(1Z)-1-chloro-3-ethylpent-1-en-4-yn-3-ol	C(O)(C=CCl)(C#C)CC	C(O)(C=CCl)(C#C)CC	"InChI=1/C7H9ClO/c1-3-7(9,4-2)5-6-8/h1,5-6,9H,4H2,2H3/b6-5-"	ZEHYJZXQEQOSON-WAYWQWQTBD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	16.7	0.115492	0.937448098	22	Low	Low	form of drug administered not known			
23011	3011	23011	471_FDAMDD_v3b	C11H15NO4S	257.3061	defined organic	parent	tested chemical	Ethebenecid	1213-06-5	single chemical compound		4-[(diethylamino)sulfonyl]benzoic acid	C1(S(=O)(=O)N(CC)CC)=CC=C(C(=O)O)C=C1	C1(S(=O)(=O)N(CC)CC)=CC=C(C(=O)O)C=C1	"InChI=1/C11H15NO4S/c1-3-12(4-2)17(15,16)10-7-5-9(6-8-10)11(13)14/h5-8H,3-4H2,1-2H3,(H,13,14)/f/h13H"	UACOQEQOBAQRDQ-NDKGDYFDCV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		uricosuric	50	0.194321083	0.711480078	19	Low	Low	form of drug administered not known			
23012	581	20581	472_FDAMDD_v3b	C9H11NO2	165.1891	defined organic	parent	tested chemical	Ethenzamide	938-73-8	single chemical compound		2-ethoxybenzamide	NC(=O)C1=C(C=CC=C1)OCC	NC(=O)C1=C(C=CC=C1)OCC	"InChI=1/C9H11NO2/c1-2-12-8-6-4-3-5-7(8)9(10)11/h3-6H,2H2,1H3,(H2,10,11)/f/h10H2"	SBNKFTQSBPKMBZ-GIMVELNWCI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic	66.7	0.403779668	0.393855553	16	Low	Low	form of drug administered not known			
23013	3013	23013	473_FDAMDD_v3b	C9H13NO2	167.20502	defined organic	parent	tested chemical	Ethinamate	126-52-3	single chemical compound		1-ethynylcyclohexyl carbamate	C1CCCC(OC(N)=O)(C#C)C1	C1CCCC(OC(N)=O)(C#C)C1	"InChI=1/C9H13NO2/c1-2-9(12-8(10)11)6-4-3-5-7-9/h1H,3-7H2,(H2,10,11)/f/h10H2"	GXRZIMHKGDIBEW-GIMVELNWCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	16.7	0.099877384	1.000532841	22	Low	Low	form of drug administered not known			
23014	576	20576	474_FDAMDD_v3b	C20H24O2	296.4034	defined organic	parent	tested chemical	Ethinyl estradiol	57-63-6	single chemical compound	stereochem	"(17beta)-17-ethynylestra-1(10),2,4-triene-3,17-diol"	[H][C@]14[C@@]([C@]3([H])CC[C@@](O)(C#C)[C@](C)3CC4)([H])CCC2=CC(O)=CC=C12	[H][C@]14[C@@]([C@]3([H])CC[C@@](O)(C#C)[C@](C)3CC4)([H])CCC2=CC(O)=CC=C12	"InChI=1/C20H24O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,5,7,12,16-18,21-22H,4,6,8-11H2,2H3/t16-,17-,18+,19+,20+/m1/s1"	BFPYWIDHMRZLRN-SLHNCBLABF	Clinical Reports 	Maximum Recommended Daily Dose	human	1	Estradiol	estrogen	0.0005	1.68689E-06	5.772913177	76	High	High	form of drug administered not known			
23015	577	20577	475_FDAMDD_v3b	C8H10N2S	166.2434	defined organic	parent	tested chemical	Ethionamide	536-33-4	single chemical compound		2-ethylpyridine-4-carbothioamide	NC(=S)C1=CC(=NC=C1)CC	NC(=S)C1=CC(=NC=C1)CC	"InChI=1/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11)/f/h9H2"	AEOCXXJPGCBFJA-JSGPKCTECX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	16.7	0.100455116	0.998027941	22	Low	Low	form of drug administered not known			
23016	3016	23016	476_FDAMDD_v3b	C21H28O2	312.44582	defined organic	parent	tested chemical	Ethisterone	434-03-7	single chemical compound	stereochem	(17alpha)-17-hydroxypregn-4-en-20-yn-3-one	C[C@]43CCC(=O)\C=C4\CC[C@@H]1[C@@H]3CC[C@]2(C)[C@@](O)(CC[C@@H]12)C#C	C[C@]43CCC(=O)\C=C4\CC[C@@H]1[C@@H]3CC[C@]2(C)[C@@](O)(CC[C@@H]12)C#C	"InChI=1/C21H28O2/c1-4-21(23)12-9-18-16-6-5-14-13-15(22)7-10-19(14,2)17(16)8-11-20(18,21)3/h1,13,16-18,23H,5-12H2,2-3H3/t16-,17+,18+,19+,20+,21+/m1/s1"	CHNXZKVNWQUJIB-CEGNMAFCBM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		progestogen	1.67	0.005344927	2.272058248	37	Moderate	High	form of drug administered not known			
23017	3017	23017	477_FDAMDD_v3b	C16H23NO2	261.35932	defined organic	parent	tested chemical	Ethoheptazine	77-15-6	single chemical compound		ethyl 1-methyl-4-phenylazepane-4-carboxylate	C2(C1=CC=CC=C1)(C(=O)OCC)CCCN(C)CC2	C2(C1=CC=CC=C1)(C(=O)OCC)CCCN(C)CC2	"InChI=1/C16H23NO2/c1-3-19-15(18)16(14-8-5-4-6-9-14)10-7-12-17(2)13-11-16/h4-6,8-9H,3,7,10-13H2,1-2H3"	WGJHHMKQBWSQIY-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic	10	0.038261501	1.417237992	27	Low-Moderate	Low	form of drug administered not known			
23018	3018	23018	478_FDAMDD_v3b	C19H24N2S	312.47226	defined organic	parent	tested chemical	Ethopropazine	522-00-9	single chemical compound		"N,N-diethyl-1-(10H-phenothiazin-10-yl)propan-2-amine"	C1=CC=C2C(=C1)N(CC(C)N(CC)CC)C3=C(S2)C=CC=C3	C1=CC=C2C(=C1)N(CC(C)N(CC)CC)C3=C(S2)C=CC=C3	"InChI=1/C19H24N2S/c1-4-20(5-2)15(3)14-21-16-10-6-8-12-18(16)22-19-13-9-7-11-17(19)21/h6-13,15H,4-5,14H2,1-3H3"	CDOZDBSBBXSXLB-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiparkinsonian; anticholinergic	10	0.032002841	1.494811469	28	Low-Moderate	Low	form of drug administered not known			
23019	3019	23019	479_FDAMDD_v3b	C7H11NO2	141.16774	defined organic	parent	tested chemical	Ethosuximide	77-67-8	single chemical compound		"3-ethyl-3-methylpyrrolidine-2,5-dione"	C1(C)(CC)CC(=O)NC1=O	C1(C)(CC)CC(=O)NC1=O	"InChI=1/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)/f/h8H"	HAPOVYFOVVWLRS-FZOZFQFYCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	16.7	0.118298982	0.927018991	22	Low	Low	form of drug administered not known			
23020	3020	23020	480_FDAMDD_v3b	C11H12N2O2	204.22518	defined organic	parent	tested chemical	Ethotoin	86-35-1	single chemical compound		"3-ethyl-5-phenylimidazolidine-2,4-dione"	C2(C1C(=O)N(CC)C(=O)N1)=CC=CC=C2	C2(C1C(=O)N(CC)C(=O)N1)=CC=CC=C2	"InChI=1/C11H12N2O2/c1-2-13-10(14)9(12-11(13)15)8-6-4-3-5-7-8/h3-7,9H,2H2,1H3,(H,12,15)/f/h12H"	SZQIFWWUIBRPBZ-XWKXFZRBCY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	50	0.244827793	0.611139283	18	Low	Low	form of drug administered not known			
23021	3021	23021	481_FDAMDD_v3b	C9H10N2O3S2	258.3173	defined organic	parent	tested chemical	Ethoxzolamide	452-35-7	single chemical compound		"6-(ethyloxy)-1,3-benzothiazole-2-sulfonamide"	C1(OCC)=CC=C2C(=C1)SC(S(N)(=O)=O)=N2	C1(OCC)=CC=C2C(=C1)SC(S(N)(=O)=O)=N2	"InChI=1/C9H10N2O3S2/c1-2-14-6-3-4-7-8(5-6)15-9(11-7)16(10,12)13/h3-5H,2H2,1H3,(H2,10,12,13)/f/h10H2"	OUZWUKMCLIBBOG-GIMVELNWCY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		carbonic anhydrase inhibitor; diuretic	8.33	0.032247163	1.491508491	28	Low-Moderate	Low	form of drug administered not known			
23022	584	20584	482_FDAMDD_v3b	C2H6O	46.0684	defined organic	parent	tested chemical	Ethyl alcohol	64-17-5	single chemical compound		ethanol	CCO	CCO	"InChI=1/C2H6O/c1-2-3/h3H,2H2,1H3"	LFQSCWFLJHTTHZ-UHFFFAOYAB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		topical antiseptic	100	2.170685329	-0.336596871	7	Low	Low	form of drug administered not known			
23023	2001	22001	483_FDAMDD_v3b	C4H8O2	88.1051	defined organic	parent	tested chemical	Ethylacetate	141-78-6	single chemical compound		ethyl acetate	CC(=O)OCC	CC(=O)OCC	"InChI=1/C4H8O2/c1-3-6-4(2)5/h3H2,1-2H3"	XEKOWRVHYACXOJ-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	25	0.283752019	0.54706104	17	Low	Low	form of drug administered not known			
23024	3024	23024	484_FDAMDD_v3b	C20H32O	288.46748	defined organic	parent	tested chemical	Ethylestrenol	965-90-2	single chemical compound	stereochem	(17beta)-17-ethylestr-4-en-17-ol	CC[C@]2(O)CC[C@H]3[C@@H]4CC\C1=C\CCC[C@@H]1[C@H]4CC[C@]23C	CC[C@]2(O)CC[C@H]3[C@@H]4CC\C1=C\CCC[C@@H]1[C@H]4CC[C@]23C	"InChI=1/C20H32O/c1-3-20(21)13-11-18-17-9-8-14-6-4-5-7-15(14)16(17)10-12-19(18,20)2/h6,15-18,21H,3-5,7-13H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1"	AOXRBFRFYPMWLR-XGXHKTLJBV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anabolic	0.0667	0.000231222	3.635971027	52	High	High	form of drug administered not known			
23025	3025	23025	485_FDAMDD_v3b	C20H28O2	300.43512	defined organic	parent	tested chemical	Ethynodiol	1231-93-2	single chemical compound	stereochem	"(3beta,17beta)-17-ethynylestr-4-ene-3,17-diol"	O[C@H]\1CC[C@H]4C(=C/1)/CC[C@@H]2[C@@H]4CC[C@]3(C)[C@@](O)(CC[C@@H]23)C#C	O[C@H]\1CC[C@H]4C(=C/1)/CC[C@@H]2[C@@H]4CC[C@]3(C)[C@@](O)(CC[C@@H]23)C#C	"InChI=1/C20H28O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,14-18,21-22H,4-11H2,2H3/t14-,15-,16+,17+,18-,19-,20-/m0/s1"	JYILPERKVHXLNF-QMNUTNMBBO	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Ethynodiol	progestogen	0.0167	5.5586E-05	4.255034228	59	High	High	form of drug administered not known			
23026	614	20614	486_FDAMDD_v3b	C24H32O4	384.50848	defined organic	parent	tested chemical	Ethynodiol diacetate	297-76-7	single chemical compound	stereochem	"(3beta,17beta)-17-ethynylestr-4-ene-3,17-diyl diacetate"	CC(=O)O[C@H]\1CC[C@H]4C(=C/1)/CC[C@@H]2[C@@H]4CC[C@]3(C)[C@@](CC[C@@H]23)(C#C)OC(C)=O	CC(=O)O[C@H]\1CC[C@H]4C(=C/1)/CC[C@@H]2[C@@H]4CC[C@]3(C)[C@@](CC[C@@H]23)(C#C)OC(C)=O	"InChI=1/C24H32O4/c1-5-24(28-16(3)26)13-11-22-21-8-6-17-14-18(27-15(2)25)7-9-19(17)20(21)10-12-23(22,24)4/h1,14,18-22H,6-13H2,2-4H3/t18-,19-,20+,21+,22-,23-,24-/m0/s1"	ONKUMRGIYFNPJW-KIEAKMPYBP	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Ethynodiol	progestogen	0.0167	4.34321E-05	4.362189451	60	High	High	form of drug administered not known			
23027	3027	23027	487_FDAMDD_v3b	C17H28N2O	276.41702	defined organic	parent	tested chemical	Etidocaine	36637-18-0	single chemical compound		"N-(2,6-dimethylphenyl)-2-[ethyl(propyl)amino]butanamide"	C1(C)=CC=CC(C)=C1NC(=O)C(N(CCC)CC)CC	C1(C)=CC=CC(C)=C1NC(=O)C(N(CCC)CC)CC	"InChI=1/C17H28N2O/c1-6-12-19(8-3)15(7-2)17(20)18-16-13(4)10-9-11-14(16)5/h9-11,15H,6-8,12H2,1-5H3,(H,18,20)/f/h18H"	VTUSIVBDOCDNHS-GPQMBLKYCU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		local anesthetic	6.67	0.024130207	1.617438947	29	Low-Moderate	Low	form of drug administered not known			
23028	3028	23028	488_FDAMDD_v3b	C2H8O7P2	206.0282	defined organic	parent	tested chemical	Etidronic acid	2809-21-4	single chemical compound		"(1-hydroxyethane-1,1-diyl)bis(phosphonic acid)"	C(O)(C)(P(O)(=O)O)P(O)(=O)O	C(O)(C)(P(O)(=O)O)P(O)(=O)O	"InChI=1/C2H8O7P2/c1-2(3,10(4,5)6)11(7,8)9/h3H,1H3,(H2,4,5,6)(H2,7,8,9)/f/h4-5,7-8H"	DBVJJBKOTRCVKF-QHPLZEHWCS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		calcium regulator	20	0.09707409	1.012896673	22	Low	Low	form of drug administered not known			
23029	3029	23029	489_FDAMDD_v3b	C10H15NO2	181.2316	defined organic	parent	tested chemical	Etilefrine	709-55-7	single chemical compound		3-[2-(ethylamino)-1-hydroxyethyl]phenol	C1=CC(O)=CC(C(O)CNCC)=C1	C1=CC(O)=CC(C(O)CNCC)=C1	"InChI=1/C10H15NO2/c1-2-11-7-10(13)8-4-3-5-9(12)6-8/h3-6,10-13H,2,7H2,1H3"	SQVIAVUSQAWMKL-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypotensive	0.833	0.004596329	2.337588923	37	Moderate	High	form of drug administered not known			
23030	3030	23030	490_FDAMDD_v3b	C17H15ClN4S	342.8458	defined organic	parent	tested chemical	Etizolam	40054-69-1	single chemical compound		"4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine"	C2(C1=CC=CC=C1Cl)=NCC4N(C3=C2C=C(CC)S3)C(C)=NN=4	C2(C1=CC=CC=C1Cl)=NCC4N(C3=C2C=C(CC)S3)C(C)=NN=4	"InChI=1/C17H15ClN4S/c1-3-11-8-13-16(12-6-4-5-7-14(12)18)19-9-15-21-20-10(2)22(15)17(13)23-11/h4-8H,3,9H2,1-2H3"	VMZUTJCNQWMAGF-UHFFFAOYAX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	0.0667	0.000194548	3.710973	53	High	High	form of drug administered not known			
23031	3031	23031	491_FDAMDD_v3b	C9H12N4O3	224.21658	defined organic	parent	tested chemical	Etofylline	519-37-9	single chemical compound		"7-(2-hydroxyethyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione"	N1(C)C(=O)N(C)C2=C(C1=O)N(CCO)C=N2	N1(C)C(=O)N(C)C2=C(C1=O)N(CCO)C=N2	"InChI=1/C9H12N4O3/c1-11-7-6(8(15)12(2)9(11)16)13(3-4-14)5-10-7/h5,14H,3-4H2,1-2H3"	NWPRCRWQMGIBOT-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator	8.33	0.037151579	1.430022723	27	Low-Moderate	Low	form of drug administered not known			
23032	3032	23032	492_FDAMDD_v3b	C19H21ClN4O5	420.84684	defined organic	parent	tested chemical	Etofylline clofibrate	54504-70-0	single chemical compound		"2-(1,3-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)ethyl 2-[(4-chlorophenyl)oxy]-2-methylpropanoate"	N1(C)C(=O)N(C)C3=C(C1=O)N(CCOC(=O)C(C)(C)OC2=CC=C(Cl)C=C2)C=N3	N1(C)C(=O)N(C)C3=C(C1=O)N(CCOC(=O)C(C)(C)OC2=CC=C(Cl)C=C2)C=N3	"InChI=1/C19H21ClN4O5/c1-19(2,29-13-7-5-12(20)6-8-13)17(26)28-10-9-24-11-21-15-14(24)16(25)23(4)18(27)22(15)3/h5-8,11H,9-10H2,1-4H3"	KYAKGJDISSNVPZ-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator	12.5	0.029702017	1.527214058	28	Low-Moderate	Low	form of drug administered not known			
23033	3033	23033	493_FDAMDD_v3b	C14H16N2O2	244.28904	defined organic	parent	tested chemical	Etomidate	33125-97-2	single chemical compound		ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate	N2C=C(C(=O)OCC)N(C(C)C1=CC=CC=C1)C=2	N2C=C(C(=O)OCC)N(C(C)C1=CC=CC=C1)C=2	"InChI=1/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3"	NPUKDXXFDDZOKR-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	0.6	0.002456107	2.609752732	40	Moderate	High	form of drug administered not known			
23034	3034	23034	494_FDAMDD_v3b	C19H28ClN5O	377.91152	defined organic	parent	tested chemical	Etoperidone	52942-31-1	single chemical compound		"2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-4,5-diethyl-2,4-dihydro-3H-1,2,4-triazol-3-one"	C3(=O)N(CC)C(CC)=NN3CCCN2CCN(C1=CC(Cl)=CC=C1)CC2	C3(=O)N(CC)C(CC)=NN3CCCN2CCN(C1=CC(Cl)=CC=C1)CC2	"InChI=1/C19H28ClN5O/c1-3-18-21-25(19(26)24(18)4-2)10-6-9-22-11-13-23(14-12-22)17-8-5-7-16(20)15-17/h5,7-8,15H,3-4,6,9-14H2,1-2H3"	IZBNNCFOBMGTQX-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	2.5	0.006615305	2.179450122	36	Moderate	High-Moderate	form of drug administered not known			
23035	3035	23035	495_FDAMDD_v3b	C29H32O13	588.5566	defined organic	parent	tested chemical	Etoposide	33419-42-0	single chemical compound	stereochem	"(8aR,9R)-9-[4-hydroxy-3,5-bis(methyloxy)phenyl]-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside"	COc1cc(cc(OC)c1O)[C@@H]5c2cc7OCOc7cc2C(O[C@@H]3O[C@@H]4CO[C@@H](C)O[C@H]4[C@H](O)[C@H]3O)C6COC(=O)[C@H]56	COc1cc(cc(OC)c1O)[C@@H]5c2cc7OCOc7cc2C(O[C@@H]3O[C@@H]4CO[C@@H](C)O[C@H]4[C@H](O)[C@H]3O)C6COC(=O)[C@H]56	"InChI=1/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15?,20-,21-,22+,24-,25-,26?,27-,29+/m1/s1"	VJJPUSNTGOMMGY-NBJJDLTABV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	2.7	0.004587494	2.33842447	37	Moderate	Moderate	form of drug administered not known			
23036	3036	23036	496_FDAMDD_v3b	C23H30O3	354.4825	defined organic	parent	tested chemical	Etretinate	54350-48-0	single chemical compound	stereochem	"ethyl (2E,4E,6E,8E)-3,7-dimethyl-9-[2,3,6-trimethyl-4-(methyloxy)phenyl]nona-2,4,6,8-tetraenoate"	C1(C)=C(OC)C=C(C)C(C=CC(C)=CC=CC(C)=CC(=O)OCC)=C1C	C1(C)=C(OC)C=C(C)C(C=CC(C)=CC=CC(C)=CC(=O)OCC)=C1C	"InChI=1/C23H30O3/c1-8-26-23(24)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(25-7)20(6)19(21)5/h9-15H,8H2,1-7H3/b11-9+,13-12+,16-10+,17-14+"	HQMNCQVAMBCHCO-DJRRULDNBE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsoriatic	1.5	0.004231521	2.373503541	38	Moderate	High	form of drug administered not known			
23037	3037	23037	497_FDAMDD_v3b	C20H24O2	296.40336	defined organic	parent	tested chemical	Exemestane	107868-30-4	single chemical compound	stereochem	"6-methylideneandrosta-1,4-diene-3,17-dione"	C[C@]41/C=C\C(=O)\C=C4\C(=C)C[C@H]2[C@@H]3CCC(=O)[C@@]3(C)CC[C@H]12	C[C@]41/C=C\C(=O)\C=C4\C(=C)C[C@H]2[C@@H]3CCC(=O)[C@@]3(C)CC[C@H]12	"InChI=1/C20H24O2/c1-12-10-14-15-4-5-18(22)20(15,3)9-7-16(14)19(2)8-6-13(21)11-17(12)19/h6,8,11,14-16H,1,4-5,7,9-10H2,2-3H3/t14-,15-,16-,19+,20-/m0/s1"	BFYIZQONLCFLEV-DAELLWKTBA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.4	0.001349512	2.869823131	43	Moderate	High	form of drug administered not known			
23038	3038	23038	498_FDAMDD_v3b	C14H19N5O4	321.33176	defined organic	parent	tested chemical	Famciclovir	104227-87-4	single chemical compound		"2-(acetoxymethyl)-4-(2-amino-4,5-dihydro-9H-purin-9-yl)butyl acetate"	C12N=C(N)N=CC=1N=CN2CCC(COC(=O)C)COC(=O)C	C12N=C(N)N=CC=1N=CN2CCC(COC(=O)C)COC(=O)C	"InChI=1/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18)/f/h15H2"	GGXKWVWZWMLJEH-YHSKDTNECV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiviral	25	0.077801211	1.109013644	24	Low	Low	form of drug administered not known			
23039	3039	23039	499_FDAMDD_v3b	C8H15N7O2S3	337.4454	defined organic	parent	tested chemical	Famotidine	76824-35-6	single chemical compound	stereochem; tautomers	"(1Z)-N'-(aminosulfonyl)-3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)thio]propanimidamide"	C1SC(N=C(N)N)=NC=1CSCCC(N)=NS(N)(=O)=O	C1SC(N=C(N)N)=NC=1CSCCC(N)=NS(N)(=O)=O	"InChI=1/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)/f/h9-12H2/b15-6-"	XUFQPHANEAPEMJ-ATRFEDIYDL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiulcerative	0.667	0.001976616	2.704077678	41	Moderate	High	form of drug administered not known			
23040	3040	23040	500_FDAMDD_v3b	C28H24Br2N6	604.33836	defined organic	salt 2Br	tested chemical	Fazadinium bromide	49564-56-9	single chemical compound	ammonium; stereochem	"1,1'-(E)-diazene-1,2-diylbis(3-methyl-2-phenyl-1H-imidazo[1,2-a]pyridin-4-ium) dibromide"	C6=CC(C4N(N=NN2C(C1=CC=CC=C1)=C(C)[N+]3=C2C=CC=C3)C5=[N+](C=4C)C=CC=C5)=CC=C6.[Br-].[Br-]	C6=CC(C4N(N=NN2C(C1=CC=CC=C1)=C(C)[N+]3=C2C=CC=C3)C5=[N+](C=4C)C=CC=C5)=CC=C6	"InChI=1/C28H24N6.2BrH/c1-21-27(23-13-5-3-6-14-23)33(25-17-9-11-19-31(21)25)29-30-34-26-18-10-12-20-32(26)22(2)28(34)24-15-7-4-8-16-24;;/h3-20H,1-2H3;2*1H/q+2;;/p-2/b30-29+;;/fC28H24N6.2Br/h;2*1h/qm;2*-1"	LBOZSXSPRGACHC-DTOQGQDKDM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	1	0.001654702	2.781280162	42	Moderate	High	form of drug administered not known			
23041	3041	23041	501_FDAMDD_v3b	C11H14N2O4	238.23986	defined organic	parent	tested chemical	Felbamate	25451-15-4	single chemical compound		"2-phenylpropane-1,3-diyl dicarbamate"	C1=CC=CC=C1C(COC(N)=O)COC(N)=O	C1=CC=CC=C1C(COC(N)=O)COC(N)=O	"InChI=1/C11H14N2O4/c12-10(14)16-6-9(7-17-11(13)15)8-4-2-1-3-5-8/h1-5,9H,6-7H2,(H2,12,14)(H2,13,15)/f/h12-13H2"	WKGXYQFOCVYPAC-KGJHZMDYCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	60	0.251847025	0.598863175	18	Low	Low	form of drug administered not known			
23042	3042	23042	502_FDAMDD_v3b	C18H19Cl2NO4	384.25376	defined organic	parent	tested chemical	Felodipine	72509-76-3	single chemical compound	retired CASRN [86189-69-7]; tautomers	"ethyl methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate"	C2(C)=C(C(=O)OCC)C(C1=CC=CC(Cl)=C1Cl)C(C(=O)OC)=C(C)N2	C2(C)=C(C(=O)OCC)C(C1=CC=CC(Cl)=C1Cl)C(C(=O)OC)=C(C)N2	"InChI=1/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3"	RZTAMFZIAATZDJ-UHFFFAOYAS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal	0.333	0.000866615	3.062173892	45	High-Moderate	High	form of drug administered not known			
23043	3043	23043	503_FDAMDD_v3b	C16H14O3	254.28056	defined organic	parent	tested chemical	Fenbufen	36330-85-5	single chemical compound		4-biphenyl-4-yl-4-oxobutanoic acid	C2=CC=CC(C1=CC=C(C(=O)CCC(O)=O)C=C1)=C2	C2=CC=CC(C1=CC=C(C(=O)CCC(O)=O)C=C1)=C2	"InChI=1/C16H14O3/c17-15(10-11-16(18)19)14-8-6-13(7-9-14)12-4-2-1-3-5-12/h1-9H,10-11H2,(H,18,19)/f/h18H"	ZPAKPRAICRBAOD-GPQMBLKYCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	15	0.05898996	1.2292219	25	Low-Moderate	Low	form of drug administered not known			
23044	3044	23044	504_FDAMDD_v3b	C12H16F3N	231.2573496	defined organic	parent	tested chemical	Fenfluramine	458-24-2	single chemical compound		N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine	C1=CC=C(C(F)(F)F)C=C1CC(C)NCC	C1=CC=C(C(F)(F)F)C=C1CC(C)NCC	"InChI=1/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3"	DBGIVFWFUFKIQN-UHFFFAOYAU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anorexic	2	0.008648374	2.063065548	34	Moderate	High	form of drug administered not known			
23045	3045	23045	505_FDAMDD_v3b	C15H14O3	242.26986	defined organic	parent	tested chemical	Fenoprofen	31879-05-7	single chemical compound		2-[3-(phenyloxy)phenyl]propanoic acid	C2(OC1=CC=CC=C1)=CC=CC(C(C)C(=O)O)=C2	C2(OC1=CC=CC=C1)=CC=CC(C(C)C(=O)O)=C2	"InChI=1/C15H14O3/c1-11(15(16)17)12-6-5-9-14(10-12)18-13-7-3-2-4-8-13/h2-11H,1H3,(H,16,17)/f/h16H"	RDJGLLICXDHJDY-WYUMXYHSCH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; anti inflammatory	50	0.206381429	0.685329384	19	Low	Low	form of drug administered not known			
23046	3046	23046	506_FDAMDD_v3b	C17H21NO4	303.35294	defined organic	parent	tested chemical	Fenoterol	13392-18-2	single chemical compound		"5-(1-hydroxy-2-{[2-(4-hydroxyphenyl)-1-methylethyl]amino}ethyl)benzene-1,3-diol"	C2(O)=CC(O)=CC(C(O)CNC(C)CC1=CC=C(O)C=C1)=C2	C2(O)=CC(O)=CC(C(O)CNC(C)CC1=CC=C(O)C=C1)=C2	"InChI=1/C17H21NO4/c1-11(6-12-2-4-14(19)5-3-12)18-10-17(22)13-7-15(20)9-16(21)8-13/h2-5,7-9,11,17-22H,6,10H2,1H3"	LSLYOANBFKQKPT-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator; tocolytic	0.0267	8.80163E-05	4.055436947	57	High	High	form of drug administered not known			
23047	3047	23047	507_FDAMDD_v3b	C12H17ClO2	228.71518	defined organic	parent	tested chemical	Fenpentadiol	15687-18-0	single chemical compound		"2-(4-chlorophenyl)-4-methylpentane-2,4-diol"	C1=C(Cl)C=CC(C(O)(C)CC(C)(O)C)=C1	C1=C(Cl)C=CC(C(O)(C)CC(C)(O)C)=C1	"InChI=1/C12H17ClO2/c1-11(2,14)8-12(3,15)9-4-6-10(13)7-5-9/h4-7,14-15H,8H2,1-3H3"	SNJDSTGQYRTZJT-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	10	0.043722502	1.35929499	26	Low-Moderate	Low	form of drug administered not known			
23048	3048	23048	508_FDAMDD_v3b	C15H20N2O2	260.3315	defined organic	parent	tested chemical	Fenspiride	5053-06-5	single chemical compound		"8-(2-phenylethyl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one"	C3=CC=CC(CCN1CCC2(CC1)OC(=O)NC2)=C3	C3=CC=CC(CCN1CCC2(CC1)OC(=O)NC2)=C3	"InChI=1/C15H20N2O2/c18-14-16-12-15(19-14)7-10-17(11-8-15)9-6-13-4-2-1-3-5-13/h1-5H,6-12H2,(H,16,18)/f/h16H"	FVNFBBAOMBJTST-WYUMXYHSCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator; alpha adrenergic blocker	8	0.03073005	1.512436734	28	Low-Moderate	Low	form of drug administered not known			
23049	3049	23049	509_FDAMDD_v3b	C22H28N2O	336.47052	defined organic	parent	tested chemical	Fentanyl	437-38-7	single chemical compound		N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide	C3=CC=CC=C3N(C(=O)CC)C2CCN(CCC1=CC=CC=C1)CC2	C3=CC=CC=C3N(C(=O)CC)C2CCN(CCC1=CC=CC=C1)CC2	"InChI=1/C22H28N2O/c1-2-22(25)24(20-11-7-4-8-12-20)21-14-17-23(18-15-21)16-13-19-9-5-3-6-10-19/h3-12,21H,2,13-18H2,1H3"	PJMPHNIQZUBGLI-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	0.107	0.000318007	3.497563242	50	High	High	form of drug administered not known; activity value changed in v3a; ActivityCategory_MRDD_mmol unchanged in v3a			
23050	3050	23050	510_FDAMDD_v3b	C17H12ClNO2S	329.8007	defined organic	parent	tested chemical	Fentiazac	18046-21-4	single chemical compound		"[4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetic acid"	O=C(O)CC1=C(C(C=C3)=CC=C3Cl)N=C(C2=CC=CC=C2)S1	O=C(O)CC1=C(C(C=C3)=CC=C3Cl)N=C(C2=CC=CC=C2)S1	"InChI=1/C17H12ClNO2S/c18-13-8-6-11(7-9-13)16-14(10-15(20)21)22-17(19-16)12-4-2-1-3-5-12/h1-9H,10H2,(H,20,21)/f/h20H"	JIEKMACRVQTPRC-UYBDAZJACR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	15	0.045482014	1.342160314	26	Low-Moderate	Low	form of drug administered not known; structure modified v3b			
23051	3051	23051	511_FDAMDD_v3b	C20H20N2O2	320.385	defined organic	parent	tested chemical	Feprazone	30748-29-9	single chemical compound		"4-(3-methylbut-2-en-1-yl)-1,2-diphenylpyrazolidine-3,5-dione"	C3(=O)C(CC=C(C)C)C(=O)N(C1=CC=CC=C1)N3C2=CC=CC=C2	C3(=O)C(CC=C(C)C)C(=O)N(C1=CC=CC=C1)N3C2=CC=CC=C2	"InChI=1/C20H20N2O2/c1-15(2)13-14-18-19(23)21(16-9-5-3-6-10-16)22(20(18)24)17-11-7-4-8-12-17/h3-13,18H,14H2,1-2H3"	RBBWCVQDXDFISW-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	12.5	0.039015559	1.408762162	27	Low-Moderate	Low	form of drug administered not known			
23052	625	20625	512_FDAMDD_v3b	C23H36N2O2	372.54414	defined organic	parent	tested chemical	Finasteride	98319-26-7	single chemical compound	stereochem	"(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(1,1-dimethylethyl)-4a,6a-dimethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide"	CC(C)(C)NC(=O)[C@H]4CC[C@@H]3[C@]4(C)CC[C@H]1[C@H]3CC[C@H]2NC(=O)\C=C/[C@]12C	CC(C)(C)NC(=O)[C@H]4CC[C@@H]3[C@]4(C)CC[C@H]1[C@H]3CC[C@H]2NC(=O)\C=C/[C@]12C	"InChI=1/C23H36N2O2/c1-21(2,3)25-20(27)17-8-7-15-14-6-9-18-23(5,13-11-19(26)24-18)16(14)10-12-22(15,17)4/h11,13-18H,6-10,12H2,1-5H3,(H,24,26)(H,25,27)/t14-,15-,16-,17+,18+,22-,23+/m0/s1/f/h24-25H"	DBEPLOCGEIEOCV-AUQDNANGDY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		prostatic hypertrophy treatment	0.0833	0.000223598	3.650532735	52	High	High	form of drug administered not known			
23053	3053	23053	513_FDAMDD_v3b	C24H25NO4	391.4596	defined organic	parent	tested chemical	Flavoxate	15301-69-6	single chemical compound		2-piperidin-1-ylethyl 3-methyl-4-oxo-2-phenyl-4H-chromene-8-carboxylate	C2=CC=C4C(=C2C(=O)OCCN1CCCCC1)OC(C3=CC=CC=C3)=C(C)C4=O	C2=CC=C4C(=C2C(=O)OCCN1CCCCC1)OC(C3=CC=CC=C3)=C(C)C4=O	"InChI=1/C24H25NO4/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25/h2,4-5,8-12H,3,6-7,13-16H2,1H3"	SPIUTQOUKAMGCX-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antispasmodic	13.3	0.033975409	1.468835307	28	Low-Moderate	Low	form of drug administered not known			
23054	3054	23054	514_FDAMDD_v3b	C17H20F6N2O3	414.3427192	defined organic	parent	tested chemical	Flecainide	54143-55-4	single chemical compound		"N-(piperidin-2-ylmethyl)-2,5-bis[(2,2,2-trifluoroethyl)oxy]benzamide"	C2=C(OCC(F)(F)F)C=CC(OCC(F)(F)F)=C2C(=O)NCC1CCCCN1	C2=C(OCC(F)(F)F)C=CC(OCC(F)(F)F)=C2C(=O)NCC1CCCCN1	"InChI=1/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)/f/h25H"	DJBNUMBKLMJRSA-LNNLXFCOCB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiarrhythmic	5	0.012067305	1.918389708	33	Moderate	Low	form of drug administered not known			
23055	3055	23055	515_FDAMDD_v3b	C20H14O3	302.32336	defined organic	parent	tested chemical	Florantyrone	519-95-9	single chemical compound		4-fluoranthen-8-yl-4-oxobutanoic acid	C1C=CC3=C2C=1C=CC=C2C4=C3C=CC(C(=O)CCC(O)=O)=C4	C1C=CC3=C2C=1C=CC=C2C4=C3C=CC(C(=O)CCC(O)=O)=C4	"InChI=1/C20H14O3/c21-18(9-10-19(22)23)13-7-8-14-15-5-1-3-12-4-2-6-16(20(12)15)17(14)11-13/h1-8,11H,9-10H2,(H,22,23)/f/h22H"	QOBAOSCOLAGPKI-QWOVJGMICQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		choleretic	16.7	0.055238867	1.257755235	25	Low-Moderate	Low	form of drug administered not known			
23056	3056	23056	516_FDAMDD_v3b	C19H17ClFN3O5S	453.8717832	defined organic	parent	tested chemical	Floxacillin	5250-39-5	single chemical compound	stereochem	"(2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methylisoxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	O=C2N1[C@]([C@@]([H])2NC(C3=C(C)ON=C3C(C(Cl)=CC=C4)=C4F)=O)([H])SC(C)(C)[C@@H]1[C@@](O)=O	O=C2N1[C@]([C@@]([H])2NC(C3=C(C)ON=C3C(C(Cl)=CC=C4)=C4F)=O)([H])SC(C)(C)[C@@H]1[C@@](O)=O	"InChI=1/C19H17ClFN3O5S/c1-7-10(12(23-29-7)11-8(20)5-4-6-9(11)21)15(25)22-13-16(26)24-14(18(27)28)19(2,3)30-17(13)24/h4-6,13-14,17H,1-3H3,(H,22,25)(H,27,28)/t13-,14+,17-/m1/s1/f/h22,27H"	UIOFUWFRIANQPC-COJWRSDQDY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.146957803	0.83280735	20	Low	Low	form of drug administered not known; structure modified v3b			
23057	3057	23057	517_FDAMDD_v3b	C9H11FN2O5	246.1924432	defined organic	parent	tested chemical	Floxuridine	50-91-9	single chemical compound	stereochem	2'-deoxy-5-fluorouridine	F\C1=C\N(C(=O)NC1=O)[C@H]2C[C@H](O)[C@@H](CO)O2	F\C1=C\N(C(=O)NC1=O)[C@H]2C[C@H](O)[C@@H](CO)O2	"InChI=1/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1/f/h11H"	ODKNJVUHOIMIIZ-HOWZBOOODJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiviral; antineoplastic	0.6	0.002437118	2.613123468	40	Moderate	High	form of drug administered not known			
23058	3058	23058	518_FDAMDD_v3b	C16H12FN3O3	313.2831832	defined organic	parent	tested chemical	Flubendazole	31430-15-6	single chemical compound		methyl {6-[(4-fluorophenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate	C3=C(F)C=CC(C(=O)C1=CC=C2C(=C1)NC(NC(=O)OC)=N2)=C3	C3=C(F)C=CC(C(=O)C1=CC=C2C(=C1)NC(NC(=O)OC)=N2)=C3	"InChI=1/C16H12FN3O3/c1-23-16(22)20-15-18-12-7-4-10(8-13(12)19-15)14(21)9-2-5-11(17)6-3-9/h2-8H,1H3,(H2,18,19,20,22)/f/h19-20H"	CPEUVMUXAHMANV-NPVYFSBICE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anthelmintic	1.67	0.00533064	2.273220612	37	Moderate	High	form of drug administered not known			
23059	3059	23059	519_FDAMDD_v3b	C4H4FN3O	129.0924632	defined organic	parent	tested chemical	Flucytosine	2022-85-7	single chemical compound		4-amino-5-fluoropyrimidin-2(1H)-one	C1=C(F)C(N)=NC(=O)N1	C1=C(F)C(N)=NC(=O)N1	"InChI=1/C4H4FN3O/c5-2-1-7-4(9)8-3(2)6/h1H,(H3,6,7,8,9)/f/h7H,6H2"	XRECTZIEBJDKEO-KOOMONESCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antifungal	150	1.161957842	-0.065190371	10	Low	Low	form of drug administered not known			
23060	3060	23060	520_FDAMDD_v3b	C10H13FN5O7P	365.2116842	defined organic	parent	tested chemical	Fludarabine phosphate	75607-67-9	single chemical compound	stereochem	2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)-9H-purin-6-amine	OP(O)(=O)OC[C@H]3O[C@@H](n2cnc1c(N)nc(F)nc12)[C@@H](O)[C@@H]3O	OP(O)(=O)OC[C@H]3O[C@@H](n2cnc1c(N)nc(F)nc12)[C@@H](O)[C@@H]3O	"InChI=1/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)/t3-,5-,6+,9-/m1/s1/f/h19-20H,12H2"	GIUYCYHIANZCFB-DOXDFKSTDC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.676	0.001850981	2.732597968	42	Moderate	High	form of drug administered not known			
23061	3061	23061	521_FDAMDD_v3b	C21H29FO5	380.4503632	defined organic	parent	tested chemical	Fludrocortisone	127-31-1	single chemical compound	stereochem; tautomers	"(11beta)-9-fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione"	OCC(=O)[C@@]4(O)CC[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)CCC(=O)/C=C3/CC[C@@H]12	OCC(=O)[C@@]4(O)CC[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)CCC(=O)/C=C3/CC[C@@H]12	"InChI=1/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1"	AAXVEMMRQDVLJB-BULBTXNYBK	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Fludrocortisone	mineralcorticoid	0.00167	4.38953E-06	5.357581532	71	High	High	form of drug administered not known			
23062	3062	23062	522_FDAMDD_v3b	C23H31FO6	422.4870432	defined organic	parent	tested chemical	Fludrocortisone acetate	514-36-3	single chemical compound	stereochem; tautomers	"(11beta)-9-fluoro-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl acetate"	CC(=O)OCC(=O)[C@@]4(O)CC[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)CCC(=O)/C=C3/CC[C@@H]12	CC(=O)OCC(=O)[C@@]4(O)CC[C@@H]1[C@]4(C)C[C@H](O)[C@]2(F)[C@@]3(C)CCC(=O)/C=C3/CC[C@@H]12	"InChI=1/C23H31FO6/c1-13(25)30-12-19(28)22(29)9-7-16-17-5-4-14-10-15(26)6-8-20(14,2)23(17,24)18(27)11-21(16,22)3/h10,16-18,27,29H,4-9,11-12H2,1-3H3/t16-,17-,18-,20-,21-,22-,23-/m0/s1"	SYWHXTATXSMDSB-GSLJADNHBU	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Fludrocortisone	mineralcorticoid	0.00167	3.95278E-06	5.403096923	72	High	High	form of drug administered not known			
23063	3063	23063	523_FDAMDD_v3b	C14H10F3NO2	281.2299096	defined organic	parent	tested chemical	Flufenamic acid	530-78-9	single chemical compound		2-{[3-(trifluoromethyl)phenyl]amino}benzoic acid	C2=CC=CC(NC1=CC(C(F)(F)F)=CC=C1)=C2C(O)=O	C2=CC=CC(NC1=CC(C(F)(F)F)=CC=C1)=C2C(O)=O	"InChI=1/C14H10F3NO2/c15-14(16,17)9-4-3-5-10(8-9)18-12-7-2-1-6-11(12)13(19)20/h1-8,18H,(H,19,20)/f/h19H"	LPEPZBJOKDYZAD-LILDFLRNCJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; anti inflammatory	10	0.035558096	1.449061507	27	Low-Moderate	Low	form of drug administered not known			
23064	3064	23064	524_FDAMDD_v3b	C15H14FN3O3	303.2883632	defined organic	parent	tested chemical	Flumazenil	78755-81-4	single chemical compound		"ethyl 8-fluoro-5-methyl-6-oxo-5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylate"	C1=C(F)C=C2C(=C1)N3C(CN(C)C2=O)=C(C(=O)OCC)N=C3	C1=C(F)C=C2C(=C1)N3C(CN(C)C2=O)=C(C(=O)OCC)N=C3	"InChI=1/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3"	OFBIFZUFASYYRE-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		benzodiazepine antagonist	0.05	0.00016486	3.782885743	54	High	High	form of drug administered not known			
23065	3065	23065	525_FDAMDD_v3b	C16H12FN3O3	313.2831832	defined organic	parent	tested chemical	Flunitrazepam	1622-62-4	single chemical compound		"5-(2-fluorophenyl)-1-methyl-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one"	N2=C(C1=CC=CC=C1F)C3=C(N(C)C(=O)C2)C=CC(N(=O)=O)=C3	N2=C(C1=CC=CC=C1F)C3=C(N(C)C(=O)C2)C=CC(N(=O)=O)=C3	"InChI=1/C16H12FN3O3/c1-19-14-7-6-10(20(22)23)8-12(14)16(18-9-15(19)21)11-4-2-3-5-13(11)17/h2-8H,9H2,1H3"	PPTYJKAXVCCBDU-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		hypnotic	0.0333	0.000106294	3.973492849	56	High	High	form of drug administered not known			
23066	634	20634	526_FDAMDD_v3b	C4H3FN2O2	130.0772	defined organic	parent	tested chemical	"Fluorouracil, 5-"	51-21-8	single chemical compound		"5-fluoropyrimidine-2,4(1H,3H)-dione"	O=C1C(=CNC(=O)N1)F	O=C1C(=CNC(=O)N1)F	"InChI=1/C4H3FN2O2/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)/f/h6-7H"	GHASVSINZRGABV-ZDKSUBDRCT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	12	0.092252908	1.035019934	23	Low	Low	form of drug administered not known			
23067	3067	23067	527_FDAMDD_v3b	C17H18F3NO	309.3261296	defined organic	parent	tested chemical	Fluoxetine	54910-89-3	single chemical compound		N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine	C2(C(F)(F)F)=CC=C(OC(CCNC)C1=CC=CC=C1)C=C2	C2(C(F)(F)F)=CC=C(OC(CCNC)C1=CC=CC=C1)C=C2	"InChI=1/C17H18F3NO/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20/h2-10,16,21H,11-12H2,1H3"	RTHCYVBBDHJXIQ-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	1.33	0.004299669	2.366564967	38	Moderate	High	form of drug administered not known			
23068	3068	23068	528_FDAMDD_v3b	C22H26F3N3OS	437.5215496	defined organic	parent	tested chemical	Fluphenazine	69-23-8	single chemical compound		2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethanol	C1=CC=C3C(=C1)N(CCCN2CCN(CCO)CC2)C4=C(S3)C=CC(C(F)(F)F)=C4	C1=CC=C3C(=C1)N(CCCN2CCN(CCO)CC2)C4=C(S3)C=CC(C(F)(F)F)=C4	"InChI=1/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2"	PLDUPXSUYLZYBN-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 3	Fluphenazine	antispsychotic	0.333	0.000761105	3.118555215	46	High-Moderate	High	form of drug administered not known			
23069	3069	23069	529_FDAMDD_v3b	C32H44F3N3O2S	591.7708696	defined organic	parent	tested chemical	Fluphenazine decanoate	5002-47-1	single chemical compound		2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl decanoate	O=C(CCCCCCCCC)OCCN(CC4)CCN4CCCN2C1=CC=CC=C1SC3=C2C=C(C(F)(F)F)C=C3	O=C(CCCCCCCCC)OCCN(CC4)CCN4CCCN2C1=CC=CC=C1SC3=C2C=C(C(F)(F)F)C=C3	"InChI=1/C32H44F3N3O2S/c1-2-3-4-5-6-7-8-14-31(39)40-24-23-37-21-19-36(20-22-37)17-11-18-38-27-12-9-10-13-29(27)41-30-16-15-26(25-28(30)38)32(33,34)35/h9-10,12-13,15-16,25H,2-8,11,14,17-24H2,1H3"	VIQCGTZFEYDQMR-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 3	Fluphenazine	antispsychotic	0.333	0.000562718	3.249709349	48	High-Moderate	High	form of drug administered not known			
23070	3070	23070	530_FDAMDD_v3b	C29H38F3N3O2S	549.6911	defined organic	parent	tested chemical	Fluphenazine enanthate	2746-81-8	single chemical compound		2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethyl heptanoate	O=C(CCCCCC)OCCN4CCN(CC4)CCCN1C(C=C3C(F)(F)F)=C(C=C3)SC2=C1C=CC=C2	O=C(CCCCCC)OCCN4CCN(CC4)CCCN1C(C=C3C(F)(F)F)=C(C=C3)SC2=C1C=CC=C2	"InChI=1/C29H38F3N3O2S/c1-2-3-4-5-11-28(36)37-21-20-34-18-16-33(17-19-34)14-8-15-35-24-9-6-7-10-26(24)38-27-13-12-23(22-25(27)35)29(30,31)32/h6-7,9-10,12-13,22H,2-5,8,11,14-21H2,1H3"	LRWSFOSWNAQHHW-UHFFFAOYAR	Clinical Reports 	Maximum Recommended Daily Dose	human	3 of 3	Fluphenazine	antispsychotic	0.333	0.000605795	3.217674472	47	High-Moderate	High	form of drug administered not known			
23071	3071	23071	531_FDAMDD_v3b	C21H23ClFN3O	387.8782232	defined organic	parent	tested chemical	Flurazepam	17617-23-1	single chemical compound		"7-chloro-1-[2-(diethylamino)ethyl]-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one"	C3=CC(F)=C(C1=NCC(=O)N(CCN(CC)CC)C2=C1C=C(Cl)C=C2)C=C3	C3=CC(F)=C(C1=NCC(=O)N(CCN(CC)CC)C2=C1C=C(Cl)C=C2)C=C3	"InChI=1/C21H23ClFN3O/c1-3-25(4-2)11-12-26-19-10-9-15(22)13-17(19)21(24-14-20(26)27)16-7-5-6-8-18(16)23/h5-10,13H,3-4,11-12,14H2,1-2H3"	SAADBVWGJQAEFS-UHFFFAOYAO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	0.5	0.001289064	2.889725393	44	Moderate	High	form of drug administered not known			
23072	3072	23072	532_FDAMDD_v3b	C19H18ClFN2O3	376.8092232	defined organic	parent	tested chemical	Flutazolam	27060-91-9	single chemical compound		"10-chloro-11b-(2-fluorophenyl)-7-(2-hydroxyethyl)-2,3,7,11b-tetrahydro[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one"	C1=C(Cl)C=C3C(=C1)N(CCO)C(=O)CN4C3(C2=CC=CC=C2F)OCC4	C1=C(Cl)C=C3C(=C1)N(CCO)C(=O)CN4C3(C2=CC=CC=C2F)OCC4	"InChI=1/C19H18ClFN2O3/c20-13-5-6-17-15(11-13)19(14-3-1-2-4-16(14)21)22(8-10-26-19)12-18(25)23(17)7-9-24/h1-6,11,24H,7-10,12H2"	WMFSSTNVXWNLKI-UHFFFAOYAC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	0.2	0.000530773	3.275091529	48	High-Moderate	High	form of drug administered not known			
23073	636	20636	533_FDAMDD_v3b	C24H26FNO4	411.4659	defined organic	parent	tested chemical	Fluvastatin	93957-54-1	single chemical compound	stereochem	"(3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid"	O=C(C[C@@H](C[C@@H](/C=C/C1=C(C2=C(N1C(C)C)C=CC=C2)C3=CC=C(C=C3)F)O)O)O	O=C(C[C@@H](C[C@@H](/C=C/C1=C(C2=C(N1C(C)C)C=CC=C2)C3=CC=C(C=C3)F)O)O)O	"InChI=1/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1/f/h29H"	FJLGEFLZQAZZCD-JJYPFDQXDN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihyperlipoproteinemic	0.667	0.001621033	2.790208015	42	Moderate	High	form of drug administered not known			
23074	2519	22519	534_FDAMDD_v3b	C19H19N7O6	441.3975	defined organic	parent	tested chemical	Folic acid	59-30-3	single chemical compound	stereochem; tautomers	"N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid"	O=C1N=C(N)NC(N=C2)=C1N=C2CNC3=CC=C(C=C3)C(N[C@@H](CCC(O)=O)C(O)=O)=O	O=C1N=C(N)NC(N=C2)=C1N=C2CNC3=CC=C(C=C3)C(N[C@@H](CCC(O)=O)C(O)=O)=O	"InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s1/f/h24-25,27,31H,20H2"	OVBPIULPVIDEAO-MIBLXQRJDO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		hematopoetic	0.0133	3.01316E-05	4.520978228	62	High	High	form of drug administered not known			
23075	3075	23075	535_FDAMDD_v3b	C21H24ClN3O3	401.88656	defined organic	parent	tested chemical	Fominoben	18053-31-1	single chemical compound		N-(3-chloro-2-{[methyl(2-morpholin-4-yl-2-oxoethyl)amino]methyl}phenyl)benzamide	C3OCCN(C(=O)CN(C)CC2=C(NC(=O)C1=CC=CC=C1)C=CC=C2Cl)C3	C3OCCN(C(=O)CN(C)CC2=C(NC(=O)C1=CC=CC=C1)C=CC=C2Cl)C3	"InChI=1/C21H24ClN3O3/c1-24(15-20(26)25-10-12-28-13-11-25)14-17-18(22)8-5-9-19(17)23-21(27)16-6-3-2-4-7-16/h2-9H,10-15H2,1H3,(H,23,27)/f/h23H"	KSNNEUZOAFRTDS-MPIMZMORCD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antitussive; respiratory stimulant	8	0.019906115	1.701013496	30	Moderate	Low	form of drug administered not known			
23076	3076	23076	536_FDAMDD_v3b	C19H25N3O2S2	391.5507	defined organic	parent	tested chemical	Fonazine	7456-24-8	single chemical compound		"10-[2-(dimethylamino)propyl]-N,N-dimethyl-10H-phenothiazine-2-sulfonamide"	C1=CC=C2C(=C1)N(CC(C)N(C)C)C3=C(S2)C=CC(S(=O)(=O)N(C)C)=C3	C1=CC=C2C(=C1)N(CC(C)N(C)C)C3=C(S2)C=CC(S(=O)(=O)N(C)C)=C3	"InChI=1/C19H25N3O2S2/c1-14(20(2)3)13-22-16-8-6-7-9-18(16)25-19-11-10-15(12-17(19)22)26(23,24)21(4)5/h6-12,14H,13H2,1-5H3"	VWNWVCJGUMZDIU-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimigraine	1.33	0.00339675	2.468936364	39	Moderate	High	form of drug administered not known			
23077	3077	23077	537_FDAMDD_v3b	C19H24N2O4	344.40486	defined organic	parent	tested chemical	Formoterol	73573-87-2	single chemical compound	stereochem	N-{2-hydroxy-5-[(1R)-1-hydroxy-2-({(1R)-1-methyl-2-[4-(methyloxy)phenyl]ethyl}amino)ethyl]phenyl}formamide	Oc1ccc(cc1NC=O)[C@@H](O)CN[C@H](C)Cc2ccc(OC)cc2	Oc1ccc(cc1NC=O)[C@@H](O)CN[C@H](C)Cc2ccc(OC)cc2	"InChI=1/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1/f/h21H"	BPZSYCZIITTYBL-FYAPXLMHDL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiasthmatic	2.67	0.007752504	2.11055801	35	Moderate	High-Moderate	form of drug administered not known			
23078	3078	23078	538_FDAMDD_v3b	CNa3O5P	191.950771	defined organic	salt 3Na	tested chemical	Foscarnet	63585-09-1	single chemical compound		trisodium dioxidophosphanecarboxylate oxide	[Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O	OC(=O)P(O)(O)=O	"InChI=1/CH3O5P.3Na/c2-1(3)7(4,5)6;;;/h(H,2,3)(H2,4,5,6);;;/q;3*+1/p-3/fCO5P.3Na/q-3;3m"	DFHAXXVZCFXGOQ-KBZFXTNNCD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiviral	120	0.625160292	0.204008615	13	Low	Low	form of drug administered not known			
23079	3079	23079	539_FDAMDD_v3b	C30H46NO7P	563.662501	defined organic	parent	tested chemical	Fosinopril	98048-97-6	single chemical compound	stereochem	(4S)-4-cyclohexyl-1-{[{[2-methyl-1-(propanoyloxy)propyl]oxy}(4-phenylbutyl)phosphoryl]acetyl}-L-proline	O=C(CP(=O)(CCCCc1ccccc1)OC(OC(=O)CC)C(C)C)N2C[C@@H](C[C@H]2C(O)=O)C3CCCCC3	O=C(CP(=O)(CCCCc1ccccc1)OC(OC(=O)CC)C(C)C)N2C[C@@H](C[C@H]2C(O)=O)C3CCCCC3	"InChI=1/C30H46NO7P/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35)/t25-,26+,30?,39?/m1/s1/f/h34H"	BIDNLKIUORFRQP-AIINYXMPDF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	1.33	0.002359568	2.627167502	41	Moderate	High	form of drug administered not known			
23080	3080	23080	540_FDAMDD_v3b	C14H17N3O	243.30428	defined organic	parent	tested chemical	Frovatriptan	158747-02-5	single chemical compound	stereochem	"(3R)-3-(methylamino)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide"	O=C(N)C(C=C3)=CC1=C3NC2=C1C[C@H](NC)CC2	O=C(N)C(C=C3)=CC1=C3NC2=C1C[C@H](NC)CC2	"InChI=1/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1/f/h15H2"	XPSQPHWEGNHMSK-KGBGUXBVDE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimigraine	0.125	0.00051376	3.289239736	48	High-Moderate	High	form of drug administered not known; structure modified v3b			
23081	3081	23081	541_FDAMDD_v3b	C6H12O6	180.1559	defined organic	parent	tested chemical	"Fructose, furanose form"	57-48-7	single chemical compound	stereochem	beta-D-fructofuranose	O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O)CO	O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(O)CO	"InChI=1/C6H12O6/c7-1-3-4(9)5(10)6(11,2-8)12-3/h3-5,7-11H,1-2H2/t3-,4-,5+,6-/m1/s1"	RFSUNEUAIZKAJO-ARQDHWQXBD	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Fructose	fluid and nutrient replenisher; ferric form as hematinic	417	2.314661912	-0.364487565	7	Low	Low	form of drug administered not known			
23082	3082	23082	542_FDAMDD_v3b	C6H12O6	180.15588	defined organic	parent	tested chemical	"Fructose, pyranose form"	7660-25-5	single chemical compound	stereochem	beta-D-fructopyranose	O[C@@H]1[C@@](O)(CO)OC[C@@H](O)[C@H]1O	O[C@@H]1[C@@](O)(CO)OC[C@@H](O)[C@H]1O	"InChI=1/C6H12O6/c7-2-6(11)5(10)4(9)3(8)1-12-6/h3-5,7-11H,1-2H2/t3-,4-,5+,6-/m1/s1"	LKDRXBCSQODPBY-ARQDHWQXBK	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Fructose	fluid and nutrient replenisher; ferric form as hematinic	417	2.314662169	-0.364487614	7	Low	Low	form of drug administered not known			
23083	648	20648	543_FDAMDD_v3b	C12H11ClN2O5S	330.7441	defined organic	parent	tested chemical	Furosemide	54-31-9	single chemical compound		5-(aminosulfonyl)-4-chloro-2-[(furan-2-ylmethyl)amino]benzoic acid	NS(C1=C(Cl)C=C(NCC2=CC=CO2)C(C(O)=O)=C1)(=O)=O	NS(C1=C(Cl)C=C(NCC2=CC=CO2)C(C(O)=O)=C1)(=O)=O	"InChI=1/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)/f/h16H,14H2"	ZZUFCTLCJUWOSV-CDZRGBSPCX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic; antihypertensive	10	0.030234855	1.519492106	28	Low-Moderate	Low	form of drug administered not known			
23084	3084	23084	544_FDAMDD_v3b	C17H26N4O3S2	398.5433	defined organic	parent	representative isomer in mixture	Fursultiamine	804-30-8	mixture or formulation	"mixture of Z,E isomers; structure shown E; stereochem"	N-[(4-amino-2-methylpyrimidin-5-yl)methyl]-N-{(1E)-4-hydroxy-1-methyl-2-[(tetrahydrofuran-2-ylmethyl)disulfanyl]but-1-en-1-yl}formamide	O=CN(/C(C)=C(CCO)/SSCC2OCCC2)CC1=C(N)N=C(C)N=C1	O=CN(/C(C)=C(CCO)/SSCC2OCCC2)CC1=C(N)N=C(C)N=C1	"InChI=1/C17H26N4O3S2/c1-12(16(5-6-22)26-25-10-15-4-3-7-24-15)21(11-23)9-14-8-19-13(2)20-17(14)18/h8,11,15,22H,3-7,9-10H2,1-2H3,(H2,18,19,20)/b16-12+/f/h18H2"	JTLXCMOFVBXEKD-XGUBBVCKDL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		enzyme cofactor	1.67	0.00419026	2.377759041	38	Moderate	High	form of drug administered not known; structure modified v3b			
23085	3085	23085	545_FDAMDD_v3b	C10H13NO2	179.21572	defined organic	parent	tested chemical	Fusaric acid	536-69-6	single chemical compound		5-butylpyridine-2-carboxylic acid	C1=C(CCCC)C=CC(C(O)=O)=N1	C1=C(CCCC)C=CC(C(O)=O)=N1	"InChI=1/C10H13NO2/c1-2-3-4-8-5-6-9(10(12)13)11-7-8/h5-7H,2-4H2,1H3,(H,12,13)/f/h12H"	DGMPVYSXXIOGJY-XWKXFZRBCV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	7.5	0.041849007	1.378314838	27	Low-Moderate	Low	form of drug administered not known			
23086	3086	23086	546_FDAMDD_v3b	C31H48O6	516.70922	defined organic	parent	tested chemical	Fusidic acid	6990-06-3	single chemical compound	stereochem	"(2Z)-2-[(3alpha,4alpha,5alpha,8alpha,9beta,11alpha,13alpha,14beta,16beta,17Z)-16-(acetyloxy)-3,11-dihydroxy-4,8,10,14-tetramethylgonan-17-ylidene]-6-methylhept-5-enoic acid"	C/C(C)=C\CC\C(=C4\[C@H](C[C@@]2(C)[C@H]4C[C@@H](O)[C@H]1[C@@]3(C)CC[C@@H](O)[C@@H](C)[C@@H]3CC[C@@]12C)OC(C)=O)C(O)=O	C/C(C)=C\CC\C(=C4\[C@H](C[C@@]2(C)[C@H]4C[C@@H](O)[C@H]1[C@@]3(C)CC[C@@H](O)[C@@H](C)[C@@H]3CC[C@@]12C)OC(C)=O)C(O)=O	"InChI=1/C31H48O6/c1-17(2)9-8-10-20(28(35)36)26-22-15-24(34)27-29(5)13-12-23(33)18(3)21(29)11-14-30(27,6)31(22,7)16-25(26)37-19(4)32/h9,18,21-25,27,33-34H,8,10-16H2,1-7H3,(H,35,36)/b26-20-/t18-,21-,22-,23+,24+,25-,27-,29-,30-,31-/m0/s1/f/h35H"	IECPWNUMDGFDKC-YLSUCPHCDU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	25	0.048383112	1.315306202	26	Low-Moderate	Low	form of drug administered not known			
23087	74	20074	547_FDAMDD_v3b	C9H17NO2	171.2388	defined organic	parent	tested chemical	Gabapentin	60142-96-3	single chemical compound		[1-(aminomethyl)cyclohexyl]acetic acid	NCC1(CC(=O)O)CCCCC1	NCC1(CC(=O)O)CCCCC1	"InChI=1/C9H17NO2/c10-7-9(6-8(11)12)4-2-1-3-5-9/h1-7,10H2,(H,11,12)/f/h11H"	UGJMXCAKCUNAIE-WXRBYKJCCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	20	0.11679596	0.93257218	22	Low	Low	form of drug administered not known			
23088	3088	23088	548_FDAMDD_v3b	C6H12O6	180.15588	defined organic	parent	tested chemical	Galactose	59-23-4	single chemical compound	stereochem	D-galactopyranose	O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O	O[C@H]1[C@@H](O)[C@@H](CO)OC(O)[C@@H]1O	"InChI=1/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4+,5-,6?/m1/s1"	WQZGKKKJIJFFOK-SVZMEOIVBA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid; hepatic function	100	0.555074861	0.255648441	14	Low	Low	form of drug administered not known			
23089	3089	23089	549_FDAMDD_v3b	C30H60I3N3O3	891.52911	defined organic	salt 3I	tested chemical	Gallamine triethiodide	65-29-2	single chemical compound	ammonium	"2,2',2''-[benzene-1,2,3-triyltris(oxy)]tris(N,N,N-triethylethanaminium) triiodide"	[I-].[I-].[I-].CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC	CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC	"InChI=1/C30H60N3O3.3HI/c1-10-31(11-2,12-3)22-25-34-28-20-19-21-29(35-26-23-32(13-4,14-5)15-6)30(28)36-27-24-33(16-7,17-8)18-9;;;/h19-21H,10-18,22-27H2,1-9H3;3*1H/q+3;;;/p-3/fC30H60N3O3.3I/h;3*1h/qm;3*-1"	REEUVFCVXKWOFE-FXOGYBOSCC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	2	0.002243337	2.649105533	41	Moderate	High	form of drug administered not known			
23090	652	20652	550_FDAMDD_v3b	C15H22O3	250.3334	defined organic	parent	tested chemical	Gemfibrozil	25812-30-0	single chemical compound		"5-[(2,5-dimethylphenyl)oxy]-2,2-dimethylpentanoic acid"	CC1=C(C=C(C=C1)C)OCCCC(C(=O)O)(C)C	CC1=C(C=C(C=C1)C)OCCCC(C(=O)O)(C)C	"InChI=1/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)/f/h16H"	HEMJJKBWTPKOJG-WYUMXYHSCS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihyperlipoproteinemic	20	0.079893454	1.097488802	23	Low	Low	form of drug administered not known			
23091	3091	23091	551_FDAMDD_v3b	C21H43N5O7	477.59542	defined organic	parent	tested chemical	Gentamicin C1	25876-10-2	single chemical compound	stereochem	"(1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl (6x)-2-amino-2,3,4,6,7-pentadeoxy-6-(methylamino)-alpha-D-erythro-heptopyranoside"	N[C@H]1[C@H](O[C@H]2OC[C@@](O)(C)[C@H](NC)[C@H]2O)[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)NC)CC[C@H]3N)[C@@H](N)C1	N[C@H]1[C@H](O[C@H]2OC[C@@](O)(C)[C@H](NC)[C@H]2O)[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)NC)CC[C@H]3N)[C@@H](N)C1	"InChI=1/C21H43N5O7/c1-9(25-3)13-6-5-10(22)19(31-13)32-16-11(23)7-12(24)17(14(16)27)33-20-15(28)18(26-4)21(2,29)8-30-20/h9-20,25-29H,5-8,22-24H2,1-4H3/t9?,10-,11+,12-,13+,14+,15-,16-,17+,18-,19-,20-,21+/m1/s1"	CEAZRRDELHUEMR-URQXQFDEBJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 3	Gentamicin	antibacterial	3	0.006281467	2.201938899	36	Moderate	Moderate	form of drug administered not known; CASRN corrected v3b; structure modified v3b			
23092	3092	23092	552_FDAMDD_v3b	C19H39N5O7	449.54226	defined organic	parent	tested chemical	Gentamicin C1a	26098-04-4	single chemical compound	stereochem	"(1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl 2,6-diamino-2,3,4,6-tetradeoxy-alpha-D-erythro-hexopyranoside"	N[C@H]1[C@H](O[C@H]2OC[C@@](O)(C)[C@H](NC)[C@H]2O)[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C1	N[C@H]1[C@H](O[C@H]2OC[C@@](O)(C)[C@H](NC)[C@H]2O)[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C1	"InChI=1/C19H39N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h8-18,24-27H,3-7,20-23H2,1-2H3/t8-,9+,10-,11+,12-,13+,14+,15-,16+,17+,18+,19-/m0/s1"	VEGXETMJINRLTH-BOZYPMBZBY	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 3	Gentamicin	antibacterial	3	0.006673455	2.17564927	36	Moderate	Moderate	form of drug administered not known; CASRN corrected v3b; structure modified v3b			
23093	3093	23093	553_FDAMDD_v3b	C20H41N5O7	463.56884	defined organic	parent	tested chemical	Gentamicin C2	25876-11-3	single chemical compound	stereochem	"(1R,2S,3S,4R,6S)-4,6-diamino-3-{[3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranosyl]oxy}-2-hydroxycyclohexyl (6x)-2,6-diamino-2,3,4,6,7-pentadeoxy-alpha-D-erythro-heptopyranoside"	N[C@H]1[C@H](O[C@H]2OC[C@@](O)(C)[C@H](NC)[C@H]2O)[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C1	N[C@H]1[C@H](O[C@H]2OC[C@@](O)(C)[C@H](NC)[C@H]2O)[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C1	"InChI=1/C20H41N5O7/c1-8(21)12-5-4-9(22)18(30-12)31-15-10(23)6-11(24)16(13(15)26)32-19-14(27)17(25-3)20(2,28)7-29-19/h8-19,25-28H,4-7,21-24H2,1-3H3/t8?,9-,10+,11-,12+,13+,14-,15-,16+,17-,18-,19-,20+/m1/s1"	XUFIWSHGXVLULG-IBLUXPFWBI	Clinical Reports 	Maximum Recommended Daily Dose	human	3 of 3	Gentamicin	antibacterial	3	0.006471531	2.188992981	36	Moderate	Moderate	form of drug administered not known; structure modified v3b			
23094	3094	23094	554_FDAMDD_v3b	C21H24O2	308.41406	defined organic	parent	tested chemical	Gestrinone	16320-04-0	single chemical compound	stereochem	"(17alpha)-13-Ethyl-17-hydroxy-18,19-dinorpregna-4,9,11-trien-20-yn-3-one"	O=C2C=C3C(CC2)=C1[C@](CC3)([H])[C@@](CC4)([H])[C@]([C@]4(O)C#C)(CC)C=C1	O=C2C=C3C(CC2)=C1[C@](CC3)([H])[C@@](CC4)([H])[C@]([C@]4(O)C#C)(CC)C=C1	"InChI=1/C21H24O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,9,11,13,18-19,23H,3,5-8,10,12H2,1H3/t18-,19+,20+,21+/m1/s1"	BJJXHLWLUDYTGC-ANULTFPQBO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antigonadotropin	0.0417	0.000135208	3.868998114	54	High	High	form of drug administered not known			
23095	3095	23095	555_FDAMDD_v3b	C15H21N3O3S	323.41054	defined organic	parent	tested chemical	Gliclazide	21187-98-4	single chemical compound		N-[(hexahydrocyclopenta[c]pyrrol-2(1H)-ylamino)carbonyl]-4-methylbenzenesulfonamide	C1CCC3C1CN(NC(=O)NS(=O)(=O)C2=CC=C(C)C=C2)C3	C1CCC3C1CN(NC(=O)NS(=O)(=O)C2=CC=C(C)C=C2)C3	"InChI=1/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)/f/h16-17H"	BOVGTQGAOIONJV-XQMQJMAZCQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	5.33	0.016480601	1.78302696	31	Moderate	Low	form of drug administered not known			
23096	3096	23096	556_FDAMDD_v3b	C27H33N3O6S	527.63242	defined organic	parent	tested chemical	Gliquidone	33342-05-1	single chemical compound		"N-[(cyclohexylamino)carbonyl]-4-{2-[4,4-dimethyl-7-(methyloxy)-1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl]ethyl}benzenesulfonamide"	C1(OC)=CC=C4C(=C1)C(=O)N(CCC3=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C3)C(=O)C4(C)C	C1(OC)=CC=C4C(=C1)C(=O)N(CCC3=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C3)C(=O)C4(C)C	"InChI=1/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)/f/h28-29H"	LLJFMFZYVVLQKT-LKHHGCNMCP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	1	0.001895259	2.722331473	42	Moderate	High	form of drug administered not known			
23097	3097	23097	557_FDAMDD_v3b	C20H27N5O5S	449.52388	defined organic	parent	tested chemical	Glisoxepide	25046-79-1	single chemical compound		N-{2-[4-({[(azepan-1-ylamino)carbonyl]amino}sulfonyl)phenyl]ethyl}-5-methylisoxazole-3-carboxamide	C3(C(=O)NCCC2=CC=C(S(=O)(=O)NC(=O)NN1CCCCCC1)C=C2)C=C(C)ON=3	C3(C(=O)NCCC2=CC=C(S(=O)(=O)NC(=O)NN1CCCCCC1)C=C2)C=C(C)ON=3	"InChI=1/C20H27N5O5S/c1-15-14-18(23-30-15)19(26)21-11-10-16-6-8-17(9-7-16)31(28,29)24-20(27)22-25-12-4-2-3-5-13-25/h6-9,14H,2-5,10-13H2,1H3,(H,21,26)(H2,22,24,27)/f/h21-22,24H"	ZKUDBRCEOBOWLF-HBAFCJMWCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	0.267	0.000593962	3.226241506	47	High-Moderate	High	form of drug administered not known			
23098	3098	23098	558_FDAMDD_v3b	C6H13NO5	179.1711	defined organic	parent	tested chemical	Glucosamine	3416-24-8	single chemical compound	stereochem	2-amino-2-deoxy-beta-D-glucopyranose	O[C@H]1[C@H](N)[C@@H](O)[C@H](O)[C@@H](CO)O1	O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1N	"InChI=1/C6H13NO5/c7-3-5(10)4(9)2(1-8)12-6(3)11/h2-6,8-11H,1,7H2/t2-,3-,4-,5-,6-/m1/s1"	MSWZFWKMSRAUBD-QZABAPFNBG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiarthritic	100	0.558125725	0.25326796	14	Low	Low	form of drug administered not known			
23099	659	20659	559_FDAMDD_v3b	C5H9NO4	147.1293	defined organic	parent	tested chemical	Glutamic acid	56-86-0	single chemical compound	stereochem	L-glutamic acid	O=C(O)CC[C@H](N)C(O)=O	O=C(O)CC[C@H](N)C(O)=O	"InChI=1/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1/f/h7,9H"	WHUUTDBJXJRKMK-IQTGVIGADK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		experimental antiepileptic	100	0.679674273	0.167699169	13	Low	Low	form of drug administered not known			
23100	3100	23100	560_FDAMDD_v3b	C5H10N2O3	146.1445	defined organic	parent	tested chemical	Glutamine	56-85-9	single chemical compound	stereochem	L-glutamine	NC(=O)CCC(N)C(O)=O	NC(=O)CCC(N)C(O)=O	"InChI=1/C5H10N2O3/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H2,7,8)(H,9,10)/t3-/m0/s1/f/h9H,7H2"	ZDXPYRJPNDTMRX-ISQTXBHGDW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	200	1.368508565	-0.13624752	10	Low	Low	form of drug administered not known			
23101	3101	23101	561_FDAMDD_v3b	C10H17N3O6S	307.32348	defined organic	parent	tested chemical	Glutathione	70-18-8	single chemical compound	stereochem	L-gamma-glutamyl-L-cysteinylglycine	O=C(NCC(O)=O)[C@@H](NC(=O)CC[C@H](N)C(O)=O)CS	O=C(NCC(O)=O)[C@@H](NC(=O)CC[C@H](N)C(O)=O)CS	"InChI=1/C10H17N3O6S/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)/t5-,6-/m0/s1/f/h12-13,15,18H"	RWSXRVCMGQZWBV-VSCBVDDUDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	5	0.016269502	1.788625738	31	Moderate	Low	form of drug administered not known			
23102	3102	23102	562_FDAMDD_v3b	C13H15NO2	217.2637	defined organic	parent	tested chemical	Glutethimide	77-21-4	single chemical compound		"3-ethyl-3-phenylpiperidine-2,6-dione"	C2(=O)CCC(C1=CC=CC=C1)(CC)C(=O)N2	C2(=O)CCC(C1=CC=CC=C1)(CC)C(=O)N2	"InChI=1/C13H15NO2/c1-2-13(10-6-4-3-5-7-10)9-8-11(15)14-12(13)16/h3-7H,2,8-9H2,1H3,(H,14,15,16)/f/h14H"	JMBQKKAJIKAWKF-YHMJCDSICI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	8.33	0.038340505	1.41634217	27	Low-Moderate	Low	form of drug administered not known			
23103	3103	23103	563_FDAMDD_v3b	C12H15N3O2S2	297.3964	defined organic	parent	tested chemical	Glybuzole	1492-02-0	single chemical compound		"N-[5-(1,1-dimethylethyl)-1,3,4-thiadiazol-2-yl]benzenesulfonamide"	N2N=C(C(C)(C)C)SC=2NS(=O)(=O)C1=CC=CC=C1	N2N=C(C(C)(C)C)SC=2NS(=O)(=O)C1=CC=CC=C1	"InChI=1/C12H15N3O2S2/c1-12(2,3)10-13-14-11(18-10)15-19(16,17)9-7-5-4-6-8-9/h4-8H,1-3H3,(H,14,15)/f/h15H"	NMWQEPCLNXHPDX-YAQRNVERCM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	12.5	0.042031444	1.376425694	27	Low-Moderate	Low	form of drug administered not known			
23104	662	20663	564_FDAMDD_v3b	C3H8O3	92.0938	defined organic	parent	tested chemical	Glycerol	56-81-5	single chemical compound		"propane-1,2,3-triol"	OCC(O)CO	OCC(O)CO	"InChI=1/C3H8O3/c4-1-3(6)2-5/h3-6H,1-2H2"	PEDCQBHIVMGVHV-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	999	10.84763578	-1.035335095	1	Low	Low	form of drug administered not known			
23105	3105	23105	565_FDAMDD_v3b	C3H9O6P	172.073721	defined organic	parent	tested chemical	Glycerophosphoric acid I	57-03-4	single chemical compound		"2,3-dihydroxypropyl dihydrogen phosphate"	C(OP(O)(=O)O)C(O)CO	C(OP(O)(=O)O)C(O)CO	"InChI=1/C3H9O6P/c4-1-3(5)2-9-10(6,7)8/h3-5H,1-2H2,(H2,6,7,8)/f/h6-7H"	AWUCVROLDVIAJX-ZDKSUBDRCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Glycerophosphoric acid	none	66.7	0.387624558	0.411588716	16	Low	Low	form of drug administered not known			
23106	3106	23106	566_FDAMDD_v3b	C3H9O6P	172.073721	defined organic	parent	tested chemical	Glycerophosphoric acid II	17181-54-3	single chemical compound		2-hydroxy-1-(hydroxymethyl)ethyl dihydrogen phosphate	C(OP(O)(=O)O)(CO)CO	C(OP(O)(=O)O)(CO)CO	"InChI=1/C3H9O6P/c4-1-3(2-5)9-10(6,7)8/h3-5H,1-2H2,(H2,6,7,8)/f/h6-7H"	DHCLVCXQIBBOPH-ZDKSUBDRCP	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Glycerophosphoric acid	none	66.7	0.387624558	0.411588716	16	Low	Low	form of drug administered not known			
23107	667	20667	567_FDAMDD_v3b	C2H5NO2	75.0666	defined organic	parent	tested chemical	Glycine	56-40-6	single chemical compound		glycine	NCC(O)=O	NCC(O)=O	"InChI=1/C2H5NO2/c3-1-2(4)5/h1,3H2,(H,4,5)/f/h4H"	DHMQDGOQFOQNFH-JLSKMEETCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	100	1.332150384	-0.124553254	10	Low	Low	form of drug administered not known			
23108	3108	23108	568_FDAMDD_v3b	C13H15N3O4S	309.3409	defined organic	parent	tested chemical	Glycodiazine	339-44-6	single chemical compound		N-(5-{[2-(methyloxy)ethyl]oxy}pyrimidin-2-yl)benzenesulfonamide	C2=CC=CC(S(=O)(=O)NC1=NC=C(OCCOC)C=N1)=C2	C2=CC=CC(S(=O)(=O)NC1=NC=C(OCCOC)C=N1)=C2	"InChI=1/C13H15N3O4S/c1-19-7-8-20-11-9-14-13(15-10-11)16-21(17,18)12-5-3-2-4-6-12/h2-6,9-10H,7-8H2,1H3,(H,14,15,16)/f/h16H"	QFWPJPIVLCBXFJ-WYUMXYHSCT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	33.3	0.107648229	0.967993111	22	Low	Low	form of drug administered not known			
23109	3109	23109	569_FDAMDD_v3b	C20H30BrNO3	412.3611	defined organic	salt Br	tested chemical	Glycopyrrolate	596-51-0	single chemical compound	ammonium	"3-[(3-cyclopentyl-3-hydroxy-3-phenylpropanoyl)oxy]-1,1-dimethylpyrrolidinium bromide"	C(O)(CC(=O)OC1C[N+](C)(C)CC1)(C2=CC=CC=C2)C3CCCC3.[Br-]	C(O)(CC(=O)OC1C[N+](C)(C)CC1)(C2=CC=CC=C2)C3CCCC3	"InChI=1/C20H30NO3.BrH/c1-21(2)13-12-18(15-21)24-19(22)14-20(23,17-10-6-7-11-17)16-8-4-3-5-9-16;/h3-5,8-9,17-18,23H,6-7,10-15H2,1-2H3;1H/q+1;/p-1/fC20H30NO3.Br/h;1h/qm;-1"	OTJVKCVDGMZYFJ-YJBVGUQECA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	0.0667	0.000161751	3.791151856	54	High	High	form of drug administered not known			
23110	3110	23110	570_FDAMDD_v3b	C30H30O8	518.5544	defined organic	parent	tested chemical	Gossypol	303-45-7	single chemical compound		"1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-bis(1-methylethyl)-2,2'-binaphthalene-8,8'-dicarbaldehyde"	C1(O)=C(O)C(C(C)C)=C4C(=C1C=O)C(O)=C(C2=C(C)C=C3C(=C2O)C(C=O)=C(O)C(O)=C3C(C)C)C(C)=C4	C1(O)=C(O)C(C(C)C)=C4C(=C1C=O)C(O)=C(C2=C(C)C=C3C(=C2O)C(C=O)=C(O)C(O)=C3C(C)C)C(C)=C4	"InChI=1/C30H30O8/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36/h7-12,33-38H,1-6H3"	QBKSWRVVCFFDOT-UHFFFAOYAH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	0.333	0.00064217	3.19235009	47	High-Moderate	High	form of drug administered not known			
23111	3111	23111	571_FDAMDD_v3b	C18H24N4O	312.40936	defined organic	parent	tested chemical	Granisetron	109889-09-0	single chemical compound	stereochem	1-methyl-N-[(3-endo)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide	CN4[C@@H]1CCC[C@H]4C[C@H](C1)NC(=O)c3nn(C)c2ccccc23	CN4[C@@H]1CCC[C@H]4C[C@H](C1)NC(=O)c3nn(C)c2ccccc23	"InChI=1/C18H24N4O/c1-21-13-6-5-7-14(21)11-12(10-13)19-18(23)17-15-8-3-4-9-16(15)22(2)20-17/h3-4,8-9,12-14H,5-7,10-11H2,1-2H3,(H,19,23)/t12-,13+,14-/f/h19H"	MFWNKCLOYSRHCJ-FDTRTOLWDE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiemetic	0.01	3.20093E-05	4.494724037	61	High	High	form of drug administered not known			
23112	674	20674	572_FDAMDD_v3b	C17H17ClO6	352.7663	defined organic	parent	tested chemical	Griseofulvin	126-07-8	single chemical compound	stereochem	"(2S,6'R)-7-chloro-2',4,6-trimethoxy-6'-methyl-3H,4'H-spiro[1-benzofuran-2,1'-cyclohex[2]ene]-3,4'-dione"	O=C2C1=C(OC)C=C(OC)C(Cl)=C1O[C@]32C(OC)=CC(C[C@@](C)3[H])=O	O=C2C1=C(OC)C=C(OC)C(Cl)=C1O[C@]32C(OC)=CC(C[C@@](C)3[H])=O	"InChI=1/C17H17ClO6/c1-8-5-9(19)6-12(23-4)17(8)16(20)13-10(21-2)7-11(22-3)14(18)15(13)24-17/h6-8H,5H2,1-4H3/t8-,17+/m1/s1"	DDUHZTYCFQRHIY-RBHXEPJQBE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antifungal	12.5	0.035434224	1.450577077	27	Low-Moderate	Low	form of drug administered not known			
23113	3113	23113	573_FDAMDD_v3b	C7H8O2	124.1372	defined organic	parent	tested chemical	Guaiacol	90-05-1	single chemical compound		2-methoxyphenol	C1=CC=CC(OC)=C1O	C1=CC=CC(OC)=C1O	"InChI=1/C7H8O2/c1-9-7-5-3-2-4-6(7)8/h2-5,8H,1H3"	LHGVFZTZFXWLCP-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		expectorant	11.2	0.090222754	1.044683923	23	Low	Low	form of drug administered not known			
23114	3114	23114	574_FDAMDD_v3b	C10H14O4	198.21576	defined organic	parent	tested chemical	Guaifenesin	93-14-1	single chemical compound		"3-{[2-(methyloxy)phenyl]oxy}propane-1,2-diol"	C1=CC=C(OC)C(OCC(O)CO)=C1	C1=CC=C(OC)C(OCC(O)CO)=C1	"InChI=1/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3"	HSRJKNPTNIJEKV-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		expectorant	20	0.10090015	0.996108186	22	Low	Low	form of drug administered not known			
23115	3115	23115	575_FDAMDD_v3b	C7H14N4	154.21286	defined organic	parent	tested chemical	Guancydine	1113-10-6	single chemical compound	tautomers	"2-cyano-1-(1,1-dimethylpropyl)guanidine"	CCC(C)(C)NC(N)=NC#N	CCC(C)(C)NC(N)=NC#N	"InChI=1/C7H14N4/c1-4-7(2,3)11-6(9)10-5-8/h4H2,1-3H3,(H3,9,10,11)/f/h11H,9H2/b10-6+"	VZVGEDRCVUKSEL-DELIZKJHDK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	10.4	0.067439252	1.171087252	24	Low	Low	form of drug administered not known			
23116	3116	23116	576_FDAMDD_v3b	C10H22N4	198.30848	defined organic	parent	tested chemical	Guanethidine	55-65-2	single chemical compound		1-(2-azocan-1-ylethyl)guanidine	C1CCCCCN(CCNC(N)=N)C1	C1CCCCCN(CCNC(N)=N)C1	"InChI=1/C10H22N4/c11-10(12)13-6-9-14-7-4-2-1-3-5-8-14/h1-9H2,(H4,11,12,13)/f/h11,13H,12H2"	ACGDKVXYNVEAGU-ZUIBBLPGCH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.833	0.004200526	2.376696284	38	Moderate	High	form of drug administered not known			
23117	3117	23117	577_FDAMDD_v3b	CH5N3	59.0705	defined organic	parent	tested chemical	Guanidine	113-00-8	single chemical compound		guanidine	C(=N)(N)N	C(=N)(N)N	"InChI=1/CH5N3/c2-1(3)4/h(H5,2,3,4)/f/h2H,3-4H2"	ZRALSGWEFCBTJO-HLDZQYPKCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	50	0.846446196	0.072400643	12	Low	Low	form of drug administered not known			
23118	3118	23118	578_FDAMDD_v3b	C17H12ClF3N2O	352.7381896	defined organic	parent	tested chemical	Halazepam	23092-17-3	single chemical compound		"7-chloro-5-phenyl-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one"	C1=C(Cl)C=C3C(=C1)N(CC(F)(F)F)C(=O)CN=C3C2=CC=CC=C2	C1=C(Cl)C=C3C(=C1)N(CC(F)(F)F)C(=O)CN=C3C2=CC=CC=C2	"InChI=1/C17H12ClF3N2O/c18-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)22-9-15(24)23(14)10-17(19,20)21/h1-8H,9-10H2"	WYCLKVQLVUQKNZ-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	2.67	0.007569353	2.12094122	35	Moderate	High-Moderate	form of drug administered not known			
23119	3119	23119	579_FDAMDD_v3b	C26H30Cl2F3NO	500.4237096	defined organic	parent	tested chemical	Halofantrine	69756-53-2	single chemical compound		"3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol"	C1=CC(C(F)(F)F)=CC2=C1C(C(O)CCN(CCCC)CCCC)=CC3=C2C=C(Cl)C=C3Cl	C1=CC(C(F)(F)F)=CC2=C1C(C(O)CCN(CCCC)CCCC)=CC3=C2C=C(Cl)C=C3Cl	"InChI=1/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3"	FOHHNHSLJDZUGQ-UHFFFAOYAC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimalarial	25	0.049957665	1.301397869	26	Low-Moderate	Low	form of drug administered not known			
23120	3120	23120	580_FDAMDD_v3b	C19H17ClF3NO4	415.7907896	defined organic	parent	tested chemical	Halofenate	26718-25-2	single chemical compound		2-(acetylamino)ethyl (4-chlorophenyl)[3-(trifluoromethyl)phenoxy]acetate	O=C(OCCNC(C)=O)C(OC2=CC=CC(C(F)(F)F)=C2)C1=CC=C(Cl)C=C1	O=C(OCCNC(C)=O)C(OC2=CC=CC(C(F)(F)F)=C2)C1=CC=C(Cl)C=C1	"InChI=1/C19H17ClF3NO4/c1-12(25)24-9-10-27-18(26)17(13-5-7-15(20)8-6-13)28-16-4-2-3-14(11-16)19(21,22)23/h2-8,11,17H,9-10H2,1H3,(H,24,25)/f/h24H"	BJBCSGQLZQGGIQ-LQFNOIFHCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihyperlipoproteinemic; uricosuric	16.7	0.04016443	1.396158394	27	Low-Moderate	Low	form of drug administered not known; structure modified v3b			
23121	3121	23121	581_FDAMDD_v3b	C19H23N3O4S	389.46862	defined organic	parent	tested chemical	Hetacillin	3511-16-8	single chemical compound	stereochem	"(2S,5R,6R)-6-(2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	[C@@H]1([C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)O)N3C(NC(C3=O)c4ccccc4)(C)C	[C@@H]1([C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)O)N3C(NC(C3=O)c4ccccc4)(C)C	"InChI=1/C19H23N3O4S/c1-18(2)13(17(25)26)21-15(24)12(16(21)27-18)22-14(23)11(20-19(22,3)4)10-8-6-5-7-9-10/h5-9,11-13,16,20H,1-4H3,(H,25,26)/t11?,12-,13+,16-/m1/s1/f/h25H"	DXVUYOAEDJXBPY-DYGQEUPBDJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	33.3	0.085501112	1.068028238	23	Low	Low	form of drug administered not known			
23122	3122	23122	582_FDAMDD_v3b	C12H16N2O3	236.26704	defined organic	parent	tested chemical	Hexobarbital	56-29-1	single chemical compound		"5-cyclohex-1-en-1-yl-2-hydroxy-1,5-dimethylpyrimidine-4,6(1H,5H)-dione"	C2(=O)C(C)(C1CCCCC=1)C(=O)N=C(O)N2C	C2(=O)C(C)(C1CCCCC=1)C(=O)N=C(O)N2C	"InChI=1/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)/f/h17H"	UYXAWHWODHRRMR-HCKMINDGCX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic; anesthetic	8.33	0.035256716	1.452758139	27	Low-Moderate	Low	form of drug administered not known			
23123	3123	23123	583_FDAMDD_v3b	C21H36N2O5S	428.58594	defined organic	complex methyl sulfate (CH3O4S)	tested chemical	Hexocyclium	115-63-9	single chemical compound	ammonium	"4-(2-cyclohexyl-2-hydroxy-2-phenylethyl)-1,1-dimethylpiperazin-1-ium methyl sulfate"	OC(CN1CC[N+](C)(C)CC1)(c2ccccc2)C3CCCCC3.[O-]S(=O)(=O)OC	OC(CN1CC[N+](C)(C)CC1)(c2ccccc2)C3CCCCC3	"InChI=1/C20H33N2O.CH4O4S/c1-22(2)15-13-21(14-16-22)17-20(23,18-9-5-3-6-10-18)19-11-7-4-8-12-19;1-5-6(2,3)4/h3,5-6,9-10,19,23H,4,7-8,11-17H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1/fC20H33N2O.CH3O4S/qm;-1"	NSILVESQCSUIAJ-WXOBMGSCCX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	1.67	0.003896535	2.409321449	38	Moderate	High	form of drug administered not known			
23124	699	20699	584_FDAMDD_v3b	C12H18O2	194.2701	defined organic	parent	tested chemical	Hexylresorcinol	136-77-6	single chemical compound		"4-hexylbenzene-1,3-diol"	OC1=C(C=CC(=C1)O)CCCCCC	OC1=C(C=CC(=C1)O)CCCCCC	"InChI=1/C12H18O2/c1-2-3-4-5-6-10-7-8-11(13)9-12(10)14/h7-9,13-14H,2-6H2,1H3"	WFJIVOKAWHGMBH-UHFFFAOYAH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihelmintic; antiseptic	16.67	0.085808367	1.066470364	23	Low	Low	form of drug administered not known			
23125	3125	23125	585_FDAMDD_v3b	C5H9N3	111.14506	defined organic	parent	tested chemical	Histamine	51-45-6	single chemical compound		2-(1H-imidazol-5-yl)ethanamine	C1N=CNC=1CCN	C1N=CNC=1CCN	"InChI=1/C5H9N3/c6-2-1-5-3-7-4-8-5/h3-4H,1-2,6H2,(H,7,8)/f/h8H"	NTYJJOPFIAHURM-FZOZFQFYCU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		gastrointestinal	0.0145	0.00013046	3.884522162	55	High	High	form of drug administered not known			
23126	3126	23126	586_FDAMDD_v3b	C6H9N3O2	155.15456	defined organic	parent	tested chemical	Histidine	71-00-1	single chemical compound	stereochem; tautomers	L-histidine	N[C@@H](C\C1=C\N=C/N1)C(O)=O	N[C@@H](C\C1=C\N=C/N1)C(O)=O	"InChI=1/C6H9N3O2/c7-5(6(10)11)1-4-2-8-3-9-4/h2-3,5H,1,7H2,(H,8,9)(H,10,11)/t5-/m0/s1/f/h9-10H"	HNDVDQJCIGZPNO-IFJFHIPQDC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	100	0.644518601	0.190764544	13	Low	Low	form of drug administered not known			
23127	3127	23127	587_FDAMDD_v3b	C17H24BrNO3	370.28136	defined organic	complex methyl bromide (CH3Br)	tested chemical	"Homatropine, dl methylbromide"	80-49-9	single chemical compound	stereochem; parent [87-00-3]	(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl hydroxy(phenyl)acetate - bromomethane (1:1)	CN3[C@@H]1CC[C@H]3CC(C1)OC(=O)C(O)c2ccccc2.BrC	CN3[C@@H]1CC[C@H]3CC(C1)OC(=O)C(O)c2ccccc2	"InChI=1/C16H21NO3.CH3Br/c1-17-12-7-8-13(17)10-14(9-12)20-16(19)15(18)11-5-3-2-4-6-11;1-2/h2-6,12-15,18H,7-10H2,1H3;1H3/t12-,13+,14+,15?;"	NAABJORKYJMVLT-RDYJJYPNBI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	0.667	0.001801333	2.744406016	42	Moderate	High	form of drug administered not known			
23128	3128	23128	588_FDAMDD_v3b	C20H24N2O2S	356.4818	defined organic	parent	tested chemical	Hycanthone	3105-97-3	single chemical compound		1-{[2-(diethylamino)ethyl]amino}-4-(hydroxymethyl)-9H-thioxanthen-9-one	C1=CC=C2C(=C1)C(=O)C3=C(S2)C(CO)=CC=C3NCCN(CC)CC	C1=CC=C2C(=C1)C(=O)C3=C(S2)C(CO)=CC=C3NCCN(CC)CC	"InChI=1/C20H24N2O2S/c1-3-22(4-2)12-11-21-16-10-9-14(13-23)20-18(16)19(24)15-7-5-6-8-17(15)25-20/h5-10,21,23H,3-4,11-13H2,1-2H3"	MFZWMTSUNYWVBU-UHFFFAOYAX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihelmintic	10	0.028051923	1.552037362	29	Low-Moderate	Low	form of drug administered not known			
23129	3129	23129	589_FDAMDD_v3b	C8H8N4	160.17592	defined organic	parent	tested chemical	Hydralazine	86-54-4	single chemical compound		1-hydrazinophthalazine	C1=CC=C2C(=C1)C(NN)=NN=C2	C1=CC=C2C(=C1)C(NN)=NN=C2	"InChI=1/C8H8N4/c9-11-8-7-4-2-1-3-6(7)5-10-12-8/h1-5H,9H2,(H,11,12)/f/h11H"	RPTUSVTUFVMDQK-WXRBYKJCCB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	3.33	0.020789642	1.682152994	30	Moderate	Moderate	form of drug administered not known			
23130	713	20713	590_FDAMDD_v3b	C7H8ClN3O4S2	297.7391	defined organic	parent	tested chemical	Hydrochlorothiazide	58-93-5	single chemical compound		"6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide"	O=S1(=O)C2=C(C=C(C(=C2)S(=O)(=O)N)Cl)NCN1	O=S1(=O)C2=C(C=C(C(=C2)S(=O)(=O)N)Cl)NCN1	"InChI=1/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)/f/h9H2"	JZUFKLXOESDKRF-JSGPKCTECK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic	3.33	0.011184289	1.951391638	33	Moderate	Moderate	form of drug administered not known			
23131	3131	23131	591_FDAMDD_v3b	C18H21NO3	299.36424	defined organic	parent	tested chemical	Hydrocodone	125-29-1	single chemical compound	stereochem; tautomers	"(5alpha)-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one"	[C@]325c1c4c(OC)ccc1C[C@H]([C@@H]2CCC([C@@H]3O4)=O)N(CC5)C	[C@]325c1c4c(OC)ccc1C[C@H]([C@@H]2CCC([C@@H]3O4)=O)N(CC5)C	"InChI=1/C18H21NO3/c1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19/h3,6,11-12,17H,4-5,7-9H2,1-2H3/t11-,12+,17-,18-/m0/s1"	LLPOLZWFYMWNKH-CMKMFDCUBC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic	0.75	0.002505309	2.601138658	40	Moderate	High	form of drug administered not known			
23132	3132	23132	592_FDAMDD_v3b	C8H8F3N3O4S2	331.2920296	defined organic	parent	tested chemical	Hydroflumethiazide	135-09-1	single chemical compound		"6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide"	C1(S(=O)(=O)N)=C(C(F)(F)F)C=C2C(=C1)S(=O)(=O)NCN2	C1(S(=O)(=O)N)=C(C(F)(F)F)C=C2C(=C1)S(=O)(=O)NCN2	"InChI=1/C8H8F3N3O4S2/c9-8(10,11)4-1-5-7(2-6(4)19(12,15)16)20(17,18)14-3-13-5/h1-2,13-14H,3H2,(H2,12,15,16)/f/h12H2"	DMDGGSIALPNSEE-GAJRPKRDCJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; diuretic	3.33	0.010051555	1.997766754	34	Moderate	Moderate	form of drug administered not known			
23133	3133	23133	593_FDAMDD_v3b	C17H19NO3	285.33766	defined organic	parent	tested chemical	Hydromorphone	466-99-9	single chemical compound	stereochem; tautomers	"(5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one"	[C@]325c1c4c(O)ccc1C[C@H]([C@@H]2CCC([C@@H]3O4)=O)N(CC5)C	[C@]325c1c4c(O)ccc1C[C@H]([C@@H]2CCC([C@@H]3O4)=O)N(CC5)C	"InChI=1/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1"	WVLOADHCBXTIJK-YNHQPCIGBL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic	0.4	0.001401848	2.853299104	43	Moderate	High	form of drug administered not known			
23134	3134	23134	594_FDAMDD_v3b	C9H13NO	151.20562	defined organic	parent	tested chemical	Hydroxyamphetamide	103-86-6	single chemical compound		4-(2-aminopropyl)phenol	C1=C(O)C=CC(CC(N)C)=C1	C1=C(O)C=CC(CC(N)C)=C1	"InChI=1/C9H13NO/c1-7(10)6-8-2-4-9(11)5-3-8/h2-5,7,11H,6,10H2,1H3"	GIKNHHRFLCDOEU-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		adrenergic; mydriatic	4	0.026454043	1.577507942	29	Low-Moderate	Moderate	form of drug administered not known			
23135	3135	23135	595_FDAMDD_v3b	C18H26ClN3O	335.87154	defined organic	parent	tested chemical	Hydroxychloroquine	118-42-3	single chemical compound	alternate CASRN [747-36-4]	2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol	C1=C(Cl)C=C2C(=C1)C(NC(C)CCCN(CC)CCO)=CC=N2	C1=C(Cl)C=C2C(=C1)C(NC(C)CCCN(CC)CCO)=CC=N2	"InChI=1/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)/f/h21H"	XXSMGPRMXLTPCZ-PKSOQXRJCE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimalarial; antirheumatic; lupus erythematosus suppressant	10	0.029773288	1.526173206	28	Low-Moderate	Low	form of drug administered not known			
23136	3136	23136	596_FDAMDD_v3b	C16H16N4O	280.32444	defined organic	parent	tested chemical	Hydroxystilbamidine	495-99-8	single chemical compound	stereochem	4-[(E)-2-{4-[amino(imino)methyl]phenyl}ethenyl]-3-hydroxybenzenecarboximidamide	C2=C(C(N)=N)C=C(O)C(C=CC1=CC=C(C(N)=N)C=C1)=C2	C2=C(C(N)=N)C=C(O)C(C=CC1=CC=C(C(N)=N)C=C1)=C2	"InChI=1/C16H16N4O/c17-15(18)12-5-2-10(3-6-12)1-4-11-7-8-13(16(19)20)9-14(11)21/h1-9,21H,(H3,17,18)(H3,19,20)/b4-1+/f/h17,19H,18,20H2/b4-1+,17-15?,19-16?"	TUESWZZJYCLFNL-WPYYECMSDL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiprotozoal	4.17	0.014875621	1.827524908	32	Moderate	Moderate	form of drug administered not known			
23137	3137	23137	597_FDAMDD_v3b	C21H27ClN2O2	374.90428	defined organic	parent	tested chemical	Hydroxyzine	68-88-2	single chemical compound		2-[(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethyl)oxy]ethanol	C3(Cl)=CC=C(C(C1=CC=CC=C1)N2CCN(CCOCCO)CC2)C=C3	C3(Cl)=CC=C(C(C1=CC=CC=C1)N2CCN(CCOCCO)CC2)C=C3	"InChI=1/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2"	ZQDWXGKKHFNSQK-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic; antihistaminic	6.67	0.017791208	1.749794565	31	Moderate	Low	form of drug administered not known			
23138	3138	23138	598_FDAMDD_v3b	C17H25NO4	307.3847	defined organic	parent	tested chemical	Ibopamine	66195-31-1	single chemical compound		"4-[2-(methylamino)ethyl]benzene-1,2-diyl bis(2-methylpropanoate)"	C1=C(CCNC)C=C(OC(=O)C(C)C)C(OC(=O)C(C)C)=C1	C1=C(CCNC)C=C(OC(=O)C(C)C)C(OC(=O)C(C)C)=C1	"InChI=1/C17H25NO4/c1-11(2)16(19)21-14-7-6-13(8-9-18-5)10-15(14)22-17(20)12(3)4/h6-7,10-12,18H,8-9H2,1-5H3"	WDKXLLJDNUBYCY-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cardiotonic	10	0.032532524	1.487682247	28	Low-Moderate	Low	form of drug administered not known			
23139	732	20732	599_FDAMDD_v3b	C13H18O2	206.284	defined organic	parent	tested chemical	Ibuprofen	15687-27-1	single chemical compound		2-[4-(2-methylpropyl)phenyl]propanoic acid	CC(C1=CC=C(C=C1)CC(C)C)C(=O)O	CC(C1=CC=C(C=C1)CC(C)C)C(=O)O	"InChI=1/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)/f/h14H"	HEFNNWSXXWATRW-YHMJCDSICY	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Ibuprofen	anti inflammatory	40	0.193907429	0.712405553	19	Low	Low	form of drug administered not known			
23140	3140	23140	600_FDAMDD_v3b	C19H23NO2	297.39142	defined organic	parent	tested chemical	Ibuprofen piconol	112017-99-9	single chemical compound		pyridin-2-ylmethyl 2-[4-(2-methylpropyl)phenyl]propanoate	C2(CC(C)C)=CC=C(C(C)C(=O)OCC1=NC=CC=C1)C=C2	C2(CC(C)C)=CC=C(C(C)C(=O)OCC1=NC=CC=C1)C=C2	"InChI=1/C19H23NO2/c1-14(2)12-16-7-9-17(10-8-16)15(3)19(21)22-13-18-6-4-5-11-20-18/h4-11,14-15H,12-13H2,1-3H3"	ACEWLPOYLGNNHV-UHFFFAOYAA	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Ibuprofen	anti inflammatory	40	0.134502872	0.871268443	21	Low	Low	form of drug administered not known			
23141	733	20733	601_FDAMDD_v3b	C11H16N4O4	268.2691	defined organic	parent	tested chemical	ICRF-159	21416-67-1	single chemical compound	retired CASRN [21416-87-5]	"4,4'-propane-1,2-diyldipiperazine-2,6-dione"	C2C(=O)NC(=O)CN2CC(C)N1CC(=O)NC(=O)C1	C2C(=O)NC(=O)CN2CC(C)N1CC(=O)NC(=O)C1	"InChI=1/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/f/h12-13H"	BMKDZUISNHGIBY-BAINRFMOCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	4.17	0.015544094	1.808434597	31	Moderate	Moderate	form of drug administered not known			
23142	3142	23142	602_FDAMDD_v3b	C26H27NO9	497.49388	defined organic	parent	tested chemical	Idarubicin	58957-92-9	single chemical compound	stereochem	"(1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside"	CC(=O)[C@@]4(O)C[C@H](O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1)c5c(O)c3C(=O)c2ccccc2C(=O)c3c(O)c5C4	CC(=O)[C@@]4(O)C[C@H](O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1)c5c(O)c3C(=O)c2ccccc2C(=O)c3c(O)c5C4	"InChI=1/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1"	XDXDZDZNSLXDNA-TZNDIEGXBV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial; antineoplastic	2.7	0.005427202	2.265423978	37	Moderate	Moderate	form of drug administered not known			
23143	3143	23143	603_FDAMDD_v3b	C12H17N3O4S	299.3461	defined organic	parent	tested chemical	Imipenem	64221-86-9	single chemical compound	stereochem; tautomers	"(5R,6S)-6-[(1R)-1-hydroxyethyl]-3-({2-[(iminomethyl)amino]ethyl}thio)-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid"	N21/C(=C(/SCCNC=N)C[C@@H]1[C@H](C2=O)[C@H](O)C)C(=O)O	N21/C(=C(/SCCNC=N)C[C@@H]1[C@H](C2=O)[C@H](O)C)C(=O)O	"InChI=1/C12H17N3O4S/c1-6(16)9-7-4-8(20-3-2-14-5-13)10(12(18)19)15(7)11(9)17/h5-7,9,16H,2-4H2,1H3,(H2,13,14)(H,18,19)/t6-,7-,9-/m1/s1/f/h13-14,18H"	ZSKVGTPCRGIANV-DAFYAXEJDV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.222819004	0.65204777	18	Low	Low	form of drug administered not known; H2O [74431-23-5]			
23144	3144	23144	604_FDAMDD_v3b	C36H49N5O5	631.8048	defined organic	complex H2O	tested chemical	Indinavir	180683-37-8	single chemical compound	stereochem	"(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide hydrate"	O.O[C@@H]5Cc1ccccc1[C@@H]5NC(=O)[C@H](Cc2ccccc2)C[C@H](O)CN4CCN(Cc3cnccc3)C[C@H]4C(=O)NC(C)(C)C	O[C@@H]5Cc1ccccc1[C@@H]5NC(=O)[C@H](Cc2ccccc2)C[C@H](O)CN4CCN(Cc3cnccc3)C[C@H]4C(=O)NC(C)(C)C	"InChI=1/C36H47N5O4.H2O/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43;/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45);1H2/t28-,29+,31+,32-,33+;/m1./s1/f/h38-39H;"	XTYSXGHMTNTKFH-XVGRLZDODL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiviral	16.7	0.026432215	1.57786645	29	Low-Moderate	Low	form of drug administered not known			
23145	3145	23145	605_FDAMDD_v3b	C43H47N2NaO6S2	774.96285	defined organic	salt Na	tested chemical	Indocyanine green	3599-32-4	single chemical compound	ammonium; stereochem	"sodium 4-[(2E)-2-{(2Z,4Z,6Z)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)-1H-benzo[e]indolium-2-yl]hepta-2,4,6-trien-1-ylidene}-1,1-dimethyl-1,2-dihydro-3H-benzo[e]indol-3-yl]butane-1-sulfonate"	[Na+].[O-]S(=O)(=O)CCCC[N+]=6c2ccc1ccccc1c2C(C)(C)C=6/C=C/C=C/C=C/C=C5\N(CCCCS([O-])(=O)=O)c4ccc3ccccc3c4C5(C)C	OS(=O)(=O)CCCC[N+]=6c2ccc1ccccc1c2C(C)(C)C=6/C=C/C=C/C=C/C=C5\N(CCCCS(O)(=O)=O)c4ccc3ccccc3c4C5(C)C	"InChI=1/C43H48N2O6S2.Na/c1-42(2)38(44(28-14-16-30-52(46,47)48)36-26-24-32-18-10-12-20-34(32)40(36)42)22-8-6-5-7-9-23-39-43(3,4)41-35-21-13-11-19-33(35)25-27-37(41)45(39)29-15-17-31-53(49,50)51;/h5-13,18-27H,14-17,28-31H2,1-4H3,(H-,46,47,48,49,50,51);/q;+1/p-1/fC43H47N2O6S2.Na/q-1;m"	MOFVSTNWEDAEEK-ZYXOCHKMCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	0.5	0.000645192	3.19031088	47	High-Moderate	High	form of drug administered not known			
23146	3146	23146	606_FDAMDD_v3b	C6H12O6	180.15588	defined organic	parent	tested chemical	Inositol	87-89-8	single chemical compound	stereochem	"(1r,2R,3S,4s,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol"	O[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O	O[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O	"InChI=1/C6H12O6/c7-1-2(8)4(10)6(12)5(11)3(1)9/h1-12H/t1-,2-,3-,4+,5-,6-"	CDAISMWEOUEBRE-GPIVLXJGBG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vitamin B complex; lipotropic	100	0.555074861	0.255648441	14	Low	Low	form of drug administered not known			
23147	3147	23147	607_FDAMDD_v3b	C42H30N6O12	810.7206	defined organic	parent	tested chemical	Inositol niacinate	6556-11-2	single chemical compound	stereochem	"cyclohexane-1,2,3,4,5,6-hexayl hexapyridine-3-carboxylate"	O=C(O[C@H]6[C@H](OC(=O)c1cccnc1)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c3cccnc3)[C@@H](OC(=O)c4cccnc4)[C@@H]6OC(=O)c5cccnc5)c7cccnc7	O=C(O[C@H]6[C@H](OC(=O)c1cccnc1)[C@H](OC(=O)c2cccnc2)[C@H](OC(=O)c3cccnc3)[C@@H](OC(=O)c4cccnc4)[C@@H]6OC(=O)c5cccnc5)c7cccnc7	"InChI=1/C42H30N6O12/c49-37(25-7-1-13-43-19-25)55-31-32(56-38(50)26-8-2-14-44-20-26)34(58-40(52)28-10-4-16-46-22-28)36(60-42(54)30-12-6-18-48-24-30)35(59-41(53)29-11-5-17-47-23-29)33(31)57-39(51)27-9-3-15-45-21-27/h1-24,31-36H/t31-,32-,33-,34+,35-,36-"	MFZCIDXOLLEMOO-GYSGTQPEBK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vasodilator	66.7	0.082272487	1.084745374	23	Low	Low	form of drug administered not known			
23148	3148	23148	608_FDAMDD_v3b	C24H20I6N4O8	1253.86442	defined organic	parent	tested chemical	Iocarmic acid	10397-75-8	single chemical compound		"3,3'-[(1,6-dioxohexane-1,6-diyl)diimino]bis{2,4,6-triiodo-5-[(methylamino)carbonyl]benzoic acid}"	C2(I)=C(C(=O)NC)C(I)=C(NC(=O)CCCCC(=O)NC1=C(I)C(C(=O)NC)=C(I)C(C(O)=O)=C1I)C(I)=C2C(O)=O	C2(I)=C(C(=O)NC)C(I)=C(NC(=O)CCCCC(=O)NC1=C(I)C(C(=O)NC)=C(I)C(C(O)=O)=C1I)C(I)=C2C(O)=O	"InChI=1/C24H20I6N4O8/c1-31-21(37)9-13(25)11(23(39)40)17(29)19(15(9)27)33-7(35)5-3-4-6-8(36)34-20-16(28)10(22(38)32-2)14(26)12(18(20)30)24(41)42/h3-6H2,1-2H3,(H,31,37)(H,32,38)(H,33,35)(H,34,36)(H,39,40)(H,41,42)/f/h31-34,39,41H"	SMQYOVYWPWASGU-KUUASEJXCV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	100	0.079753439	1.098250579	23	Low	Low	form of drug administered not known			
23149	3149	23149	609_FDAMDD_v3b	C12H13I3N2O3	613.95663	defined organic	parent	tested chemical	Iocetamic acid	16034-77-8	single chemical compound		"3-[acetyl(3-amino-2,4,6-triiodophenyl)amino]-2-methylpropanoic acid"	CC(CN(C(C)=O)C1=C(I)C=C(I)C(N)=C1I)C(O)=O	CC(CN(C(C)=O)C1=C(I)C=C(I)C(N)=C1I)C(O)=O	"InChI=1/C12H13I3N2O3/c1-5(12(19)20)4-17(6(2)18)11-8(14)3-7(13)10(16)9(11)15/h3,5H,4,16H2,1-2H3,(H,19,20)/f/h19H"	GSVQIUGOUKJHRC-LILDFLRNCK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	75	0.122158466	0.91307643	21	Low	Low	form of drug administered not known			
23150	3150	23150	610_FDAMDD_v3b	C12H11I3N2O4	627.94015	defined organic	parent	tested chemical	Iodamide	440-58-4	single chemical compound		"3-(acetylamino)-5-[(acetylamino)methyl]-2,4,6-triiodobenzoic acid"	C1(I)=C(CNC(C)=O)C(I)=C(NC(C)=O)C(I)=C1C(O)=O	C1(I)=C(CNC(C)=O)C(I)=C(NC(C)=O)C(I)=C1C(O)=O	"InChI=1/C12H11I3N2O4/c1-4(18)16-3-6-8(13)7(12(20)21)10(15)11(9(6)14)17-5(2)19/h3H2,1-2H3,(H,16,18)(H,17,19)(H,20,21)/f/h16-17,20H"	VVDGWALACJEJKG-JZEDVTDOCV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	100	0.159250846	0.797918252	20	Low	Low	form of drug administered not known			
23151	3151	23151	611_FDAMDD_v3b	C6H11IO3	258.05421	defined organic	parent	tested chemical	Iodinated Glycerol A	5634-39-9	single chemical compound	CASRN for mixture of isomers; A form; 2-iodoethyl shown	"[2-(2-iodoethyl)-1,3-dioxolan-4-yl]methanol"	O1C(CO)COC1CCI	O1C(CO)COC1CCI	"InChI=1/C6H11IO3/c7-2-1-6-9-4-5(3-8)10-6/h5-6,8H,1-4H2"	YPSNTKGTKXXRGU-UHFFFAOYAA	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Iodinated Glycerol	expectorant	4	0.015500619	1.809650957	31	Moderate	Moderate	form of drug administered not known			
23152	741	23152	612_FDAMDD_v3b	C6H11IO3	258.05421	defined organic	parent	tested chemical	Iodinated Glycerol B	5634-39-9	single chemical compound	CASRN for mixture of isomers; B form; 1-iodoethyl shown	"[2-(1-iodoethyl)-1,3-dioxolan-4-yl]methanol"	C1C(OC(O1)C(C)I)CO	C1C(OC(O1)C(C)I)CO	"InChI=1/C6H11IO3/c1-4(7)6-9-3-5(2-8)10-6/h4-6,8H,2-3H2,1H3"	LTINPJMVDKPJJI-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Iodinated Glycerol	expectorant	4	0.015500619	1.809650957	31	Moderate	Moderate	form of drug administered not known			
23153	3153	23153	613_FDAMDD_v3b	C20H14I6N2O6	1139.76178	defined organic	parent	tested chemical	Iodipamide	606-17-7	single chemical compound		"3,3'-[(1,6-dioxohexane-1,6-diyl)diimino]bis(2,4,6-triiodobenzoic acid)"	C2(I)=CC(I)=C(NC(=O)CCCCC(=O)NC1=C(I)C(C(=O)O)=C(I)C=C1I)C(I)=C2C(O)=O	C2(I)=CC(I)=C(NC(=O)CCCCC(=O)NC1=C(I)C(C(=O)O)=C(I)C=C1I)C(I)=C2C(O)=O	"InChI=1/C20H14I6N2O6/c21-7-5-9(23)17(15(25)13(7)19(31)32)27-11(29)3-1-2-4-12(30)28-18-10(24)6-8(22)14(16(18)26)20(33)34/h5-6H,1-4H2,(H,27,29)(H,28,30)(H,31,32)(H,33,34)/f/h27-28,31,33H"	FFINMCNLQNTKLU-VMAYPPGMCC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	167	0.146521846	0.834097618	20	Low	Low	form of drug administered not known			
23154	3154	23154	614_FDAMDD_v3b	C11H16I2N2O5	510.06408	defined organic	complex diethanolamine (C4H11NO2)	tested chemical	Iodopyracet	300-37-8	single chemical compound		"(3,5-diiodo-4-oxopyridin-1(4H)-yl)acetic acid - 2,2'-iminodiethanol (1:1)"	O=C(O)CN/1/C=C(/I)C(=O)C(\I)=C\1.OCCNCCO	O=C(O)CN/1/C=C(/I)C(=O)C(\I)=C\1	"InChI=1/C7H5I2NO3.C4H11NO2/c8-4-1-10(3-6(11)12)2-5(9)7(4)13;6-3-1-5-2-4-7/h1-2H,3H2,(H,11,12);5-7H,1-4H2/f/h11H;"	RERHJVNYJKZHLJ-NQMCVLBDCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	100	0.196053798	0.70762474	19	Low	Low	form of drug administered not known			
23155	3155	23155	615_FDAMDD_v3b	C9H5I2NO	396.95104	defined organic	parent	tested chemical	Iodoquinol	83-73-8	single chemical compound		"5,7-diiodoquinolin-8-ol"	C1(I)=CC(I)=C2C(=C1O)N=CC=C2	C1(I)=CC(I)=C2C(=C1O)N=CC=C2	"InChI=1/C9H5I2NO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H"	UXZFQZANDVDGMM-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiamebic	30	0.075576071	1.121615689	24	Low	Low	form of drug administered not known			
23156	3156	23156	616_FDAMDD_v3b	C4H3IN2OS	254.04889	defined organic	parent	tested chemical	Iodothiouracil	5984-97-4	single chemical compound	tautomers	5-iodo-2-mercaptopyrimidin-4-ol	C1(O)=C(I)C=NC(S)=N1	C1(O)=C(I)C=NC(S)=N1	"InChI=1/C4H3IN2OS/c5-2-1-6-4(9)7-3(2)8/h1H,(H2,6,7,8,9)/f/h8-9H"	MYUHSNVSHMCUMD-DEPUQRHOCO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		thyroid inhibitor	5	0.019681251	1.705947297	30	Moderate	Low	form of drug administered not known			
23157	3157	23157	617_FDAMDD_v3b	C19H26I3N3O9	821.13785	defined organic	parent	tested chemical	Iohexol	66108-95-0	single chemical compound		"5-[acetyl(2,3-dihydroxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide"	C1(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(C)=O)CC(O)CO	C1(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(C)=O)CC(O)CO	"InChI=1/C19H26I3N3O9/c1-8(29)25(4-11(32)7-28)17-15(21)12(18(33)23-2-9(30)5-26)14(20)13(16(17)22)19(34)24-3-10(31)6-27/h9-11,26-28,30-32H,2-7H2,1H3,(H,23,33)(H,24,34)/f/h23-24H"	NTHXOOBQLCIOLC-DVIAZDKACW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	110	0.133960455	0.873023386	21	Low	Low	form of drug administered not known			
23158	3158	23158	618_FDAMDD_v3b	C17H22I3N3O8	777.08529	defined organic	parent	tested chemical	Iopamidol	60166-93-0	single chemical compound	stereochem	"N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-{[(2S)-2-hydroxypropanoyl]amino}-2,4,6-triiodobenzene-1,3-dicarboxamide"	O=C(NC(CO)CO)C1=C(I)C(NC([C@H](C)O)=O)=C(I)C(C(NC(CO)CO)=O)=C1I	O=C(NC(CO)CO)C1=C(I)C(NC([C@H](C)O)=O)=C(I)C(C(NC(CO)CO)=O)=C1I	"InChI=1/C17H22I3N3O8/c1-6(28)15(29)23-14-12(19)9(16(30)21-7(2-24)3-25)11(18)10(13(14)20)17(31)22-8(4-26)5-27/h6-8,24-28H,2-5H2,1H3,(H,21,30)(H,22,31)(H,23,29)/t6-/m0/s1/f/h21-23H"	XQZXYNRDCRIARQ-HQPPUDHIDN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	100	0.128686003	0.890468688	21	Low	Low	"form of drug administered not known; 2R,S [62883-00-5]; CASRN changed v3b"			
23159	3159	23159	619_FDAMDD_v3b	C11H12I3NO2	570.93189	defined organic	parent	tested chemical	Iopanoic acid	96-83-3	single chemical compound		"2-[(3-amino-2,4,6-triiodophenyl)methyl]butanoic acid"	C1=C(I)C(N)=C(I)C(CC(C(=O)O)CC)=C1I	C1=C(I)C(N)=C(I)C(CC(C(=O)O)CC)=C1I	"InChI=1/C11H12I3NO2/c1-2-5(11(16)17)3-6-7(12)4-8(13)10(15)9(6)14/h4-5H,2-3,15H2,1H3,(H,16,17)/f/h16H"	OIRFJRBSRORBCM-WYUMXYHSCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	100	0.175152241	0.756584302	20	Low	Low	form of drug administered not known			
23160	3160	23160	620_FDAMDD_v3b	C19H29IO2	416.33683	defined organic	parent	tested chemical	"Iophendylate, m-"	1320-11-2	single chemical compound	CASRN for ortho and meta mixture	ethyl 10-(3-iodophenyl)undecanoate	C1(I)=CC=CC(C(C)CCCCCCCCC(=O)OCC)=C1	C1(I)=CC=CC(C(C)CCCCCCCCC(=O)OCC)=C1	"InChI=1/C19H29IO2/c1-3-22-19(21)14-9-7-5-4-6-8-11-16(2)17-12-10-13-18(20)15-17/h10,12-13,15-16H,3-9,11,14H2,1-2H3"	QEDKWPVYINBWKH-UHFFFAOYAH	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 3	Iophendylate	diagnostic aid	125	0.300237671	0.522534818	17	Low	Low	form of drug administered not known			
23161	3161	23161	621_FDAMDD_v3b	C19H29IO2	416.33683	defined organic	parent	tested chemical	"Iophendylate, o-"	1320-11-2	single chemical compound	CASRN for ortho and meta mixture	ethyl 10-(2-iodophenyl)undecanoate	C1=CC=CC(C(C)CCCCCCCCC(=O)OCC)=C1I	C1=CC=CC(C(C)CCCCCCCCC(=O)OCC)=C1I	"InChI=1/C19H29IO2/c1-3-22-19(21)15-9-7-5-4-6-8-12-16(2)17-13-10-11-14-18(17)20/h10-11,13-14,16H,3-9,12,15H2,1-2H3"	IWRUDYQZPTVTPA-UHFFFAOYAP	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 3	Iophendylate	diagnostic aid	125	0.300237671	0.522534818	17	Low	Low	form of drug administered not known			
23162	3162	23162	622_FDAMDD_v3b	C19H29IO2	416.33683	defined organic	parent	tested chemical	"Iophendylate, p-"	99-79-6	single chemical compound		ethyl 10-(4-iodophenyl)undecanoate	C1=C(I)C=CC(C(C)CCCCCCCCC(=O)OCC)=C1	C1=C(I)C=CC(C(C)CCCCCCCCC(=O)OCC)=C1	"InChI=1/C19H29IO2/c1-3-22-19(21)11-9-7-5-4-6-8-10-16(2)17-12-14-18(20)15-13-17/h12-16H,3-11H2,1-2H3"	LAYLQVBQIBQVLL-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	3 of 3	Iophendylate	diagnostic aid	125	0.300237671	0.522534818	17	Low	Low	form of drug administered not known			
23163	3163	23163	623_FDAMDD_v3b	C18H24I3N3O8	791.11187	defined organic	parent	tested chemical	Iopromide	73334-07-3	single chemical compound		"N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-N-methyl-5-{[(methyloxy)acetyl]amino}benzene-1,3-dicarboxamide"	C1(NC(=O)COC)=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I	C1(NC(=O)COC)=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I	"InChI=1/C18H24I3N3O8/c1-24(4-9(28)6-26)18(31)12-13(19)11(17(30)22-3-8(27)5-25)14(20)16(15(12)21)23-10(29)7-32-2/h8-9,25-28H,3-7H2,1-2H3,(H,22,30)(H,23,29)/f/h22-23H"	DGAIEPBNLOQYER-PDJAEHLQCK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	100	0.126404373	0.898237901	21	Low	Low	form of drug administered not known			
23164	3164	23164	624_FDAMDD_v3b	C11H9I3N2O4	613.91357	defined organic	parent	tested chemical	Iothalamic acid	2276-90-6	single chemical compound		"3-(acetylamino)-2,4,6-triiodo-5-[(methylamino)carbonyl]benzoic acid"	C1(I)=C(NC(C)=O)C(I)=C(C(=O)NC)C(I)=C1C(=O)O	C1(I)=C(NC(C)=O)C(I)=C(C(=O)NC)C(I)=C1C(=O)O	"InChI=1/C11H9I3N2O4/c1-3(17)16-9-7(13)4(10(18)15-2)6(12)5(8(9)14)11(19)20/h1-2H3,(H,15,18)(H,16,17)(H,19,20)/f/h15-16,19H"	UXIGWFXRQKWHHA-KAWPVFOWCM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	100	0.162889379	0.788107233	20	Low	Low	form of drug administered not known			
23165	3165	23165	625_FDAMDD_v3b	C37H48I6N6O18	1626.23324	defined organic	parent	tested chemical	Iotrolan	79770-24-4	single chemical compound		"5,5'-[(1,3-dioxopropane-1,3-diyl)bis(methylimino)]bis{N,N'-bis[2,3-dihydroxy-1-(hydroxymethyl)propyl]-2,4,6-triiodobenzene-1,3-dicarboxamide}"	C2(I)=C(C(=O)NC(C(O)CO)CO)C(I)=C(N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(C(O)CO)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I)C(I)=C2C(=O)NC(CO)C(O)CO	C2(I)=C(C(=O)NC(C(O)CO)CO)C(I)=C(N(C)C(=O)CC(=O)N(C)C1=C(I)C(C(=O)NC(C(O)CO)CO)=C(I)C(C(=O)NC(CO)C(O)CO)=C1I)C(I)=C2C(=O)NC(CO)C(O)CO	"InChI=1/C37H48I6N6O18/c1-48(32-28(40)22(34(64)44-12(4-50)16(58)8-54)26(38)23(29(32)41)35(65)45-13(5-51)17(59)9-55)20(62)3-21(63)49(2)33-30(42)24(36(66)46-14(6-52)18(60)10-56)27(39)25(31(33)43)37(67)47-15(7-53)19(61)11-57/h12-19,50-61H,3-11H2,1-2H3,(H,44,64)(H,45,65)(H,46,66)(H,47,67)/f/h44-47H"	XUHXFSYUBXNTHU-CTWMIZMTCF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	100	0.061491794	1.211182834	25	Low-Moderate	Low	form of drug administered not known			
23166	3166	23166	626_FDAMDD_v3b	C24H21I6N5O8	1268.87906	defined organic	parent	tested chemical	Ioxaglic acid	59017-64-0	single chemical compound		"3-{[N-({3-[acetyl(methyl)amino]-2,4,6-triiodo-5-[(methylamino)carbonyl]phenyl}carbonyl)glycyl]amino}-5-{[(2-hydroxyethyl)amino]carbonyl}-2,4,6-triiodobenzoic acid"	Ic1c(c(I)c(c(I)c1N(C)C(C)=O)C(=O)NCC(=O)Nc2c(I)c(C(=O)NCCO)c(I)c(C(O)=O)c2I)C(=O)NC	Ic1c(c(I)c(c(I)c1N(C)C(C)=O)C(=O)NCC(=O)Nc2c(I)c(C(=O)NCCO)c(I)c(C(O)=O)c2I)C(=O)NC	"InChI=1/C24H21I6N5O8/c1-7(37)35(3)20-17(29)10(21(39)31-2)13(25)11(18(20)30)23(41)33-6-8(38)34-19-15(27)9(22(40)32-4-5-36)14(26)12(16(19)28)24(42)43/h36H,4-6H2,1-3H3,(H,31,39)(H,32,40)(H,33,41)(H,34,38)(H,42,43)/f/h31-34,42H"	TYYBFXNZMFNZJT-JKGJSJLMCE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	100	0.078809717	1.10342023	24	Low	Low	form of drug administered not known			
23167	3167	23167	627_FDAMDD_v3b	C12H13I3N2O2	597.95723	defined organic	parent	tested chemical	Ipodic acid	5587-89-3	single chemical compound	stereochem	"3-(3-{[(1E)-(dimethylamino)methylidene]amino}-2,4,6-triiodophenyl)propanoic acid"	C1(N=CN(C)C)=C(I)C=C(I)C(CCC(O)=O)=C1I	C1(N=CN(C)C)=C(I)C=C(I)C(CCC(O)=O)=C1I	"InChI=1/C12H13I3N2O2/c1-17(2)6-16-12-9(14)5-8(13)7(11(12)15)3-4-10(18)19/h5-6H,3-4H2,1-2H3,(H,18,19)/b16-6+/f/h18H"	YQNFBOJPTAXAKV-HFSORDEADQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	100	0.167236041	0.776670121	20	Low	Low	form of drug administered not known			
23168	3168	23168	628_FDAMDD_v3b	C9H13N3O	179.21902	defined organic	parent	tested chemical	Iproniazid	54-92-2	single chemical compound		N'-(1-methylethyl)pyridine-4-carbohydrazide	C1=CC(C(=O)NNC(C)C)=CC=N1	C1=CC(C(=O)NNC(C)C)=CC=N1	"InChI=1/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13)/f/h12H"	NYMGNSNKLVNMIA-XWKXFZRBCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		monoamine oxidase inhibitor; antidepressant	2.5	0.013949412	1.85544409	32	Moderate	High-Moderate	form of drug administered not known			
23169	3169	23169	629_FDAMDD_v3b	C25H28N6O	428.52942	defined organic	parent	tested chemical	Irbesartan	138402-11-6	single chemical compound		"2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one"	C5(CN1C(CCCC)=NC2(C1=O)CCCC2)=CC=C(C4=CC=CC=C4C3NN=NN=3)C=C5	C5(CN1C(CCCC)=NC2(C1=O)CCCC2)=CC=C(C4=CC=CC=C4C3NN=NN=3)C=C5	"InChI=1/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)/f/h27H"	YOSHYTLCDANDAN-LELJVTLKCS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	5	0.01166781	1.933010639	33	Moderate	Low	form of drug administered not known			
23170	3170	23170	630_FDAMDD_v3b	C11H15NO2	193.2423	defined organic	parent	tested chemical	Isocaine	94-14-4	single chemical compound		2-methylpropyl 4-aminobenzoate	C1=C(N)C=CC(C(=O)OCC(C)C)=C1	C1=C(N)C=CC(C(=O)OCC(C)C)=C1	"InChI=1/C11H15NO2/c1-8(2)7-14-11(13)9-3-5-10(12)6-4-9/h3-6,8H,7,12H2,1-2H3"	PUYOAVGNCWPANW-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		topical anesthetic	6.67	0.034516252	1.461976364	28	Low-Moderate	Low	form of drug administered not known			
23171	3171	23171	631_FDAMDD_v3b	C12H13N3O2	231.25052	defined organic	parent	tested chemical	Isocarboxazid	59-63-2	single chemical compound		5-methyl-N'-(phenylmethyl)isoxazole-3-carbohydrazide	C2(CNNC(=O)C1C=C(C)ON=1)=CC=CC=C2	C2(CNNC(=O)C1C=C(C)ON=1)=CC=CC=C2	"InChI=1/C12H13N3O2/c1-9-7-11(15-17-9)12(16)14-13-8-10-5-3-2-4-6-10/h2-7,13H,8H2,1H3,(H,14,16)/f/h14H"	XKFPYPQQHFEXRZ-YHMJCDSICF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	1	0.004324315	2.364082718	38	Moderate	High	form of drug administered not known			
23172	3172	23172	632_FDAMDD_v3b	C9H19N	141.25386	defined organic	parent	tested chemical	Isometheptene	503-01-5	single chemical compound		"N,6-dimethylhept-5-en-2-amine"	CC(C)=CCCC(C)NC	CC(C)=CCCC(C)NC	"InChI=1/C9H19N/c1-8(2)6-5-7-9(3)10-4/h6,9-10H,5,7H2,1-4H3"	XVQUOJBERHHONY-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		adrenergic; bronchodilator; mydriatic; antiglaucoma	5.42	0.038370633	1.416001038	27	Low-Moderate	Low	form of drug administered not known			
23173	755	20755	633_FDAMDD_v3b	C6H7N3O	137.1393	defined organic	parent	tested chemical	Isoniazid	54-85-3	single chemical compound		isonicotinohydrazide	O=C(C1=CC=NC=C1)NN	O=C(C1=CC=NC=C1)NN	"InChI=1/C6H7N3O/c7-9-6(10)5-1-3-8-4-2-5/h1-4H,7H2,(H,9,10)/f/h9H"	QRXWMOHMRWLFEY-BGGKNDAXCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	10	0.072918558	1.137161928	24	Low	Low	form of drug administered not known			
23174	3174	23174	634_FDAMDD_v3b	C23H33N2O	353.52092	defined organic	parent	tested chemical	Isopropamide	7492-32-2	single chemical compound	ammonium	"4-amino-N-methyl-N,N-bis(1-methylethyl)-4-oxo-3,3-diphenylbutan-1-aminium"	C(C(=O)N)(CC[N+](C)(C(C)C)C(C)C)(C1=CC=CC=C1)C2=CC=CC=C2	C(C(=O)N)(CC[N+](C)(C(C)C)C(C)C)(C1=CC=CC=C1)C2=CC=CC=C2	"InChI=1/C23H32N2O/c1-18(2)25(5,19(3)4)17-16-23(22(24)26,20-12-8-6-9-13-20)21-14-10-7-11-15-21/h6-15,18-19H,16-17H2,1-5H3,(H-,24,26)/p+1/fC23H33N2O/h24H2/q+1"	JTPUMZTWMWIVPA-RUUSUVOICS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	0.167	0.000472391	3.325698648	48	High-Moderate	High	form of drug administered not known			
23175	3175	23175	635_FDAMDD_v3b	C11H17NO3	211.25758	defined organic	parent	tested chemical	Isoproterenol	7683-59-2	single chemical compound		"4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol"	C1=C(O)C(O)=CC(C(O)CNC(C)C)=C1	C1=C(O)C(O)=CC(C(O)CNC(C)C)=C1	"InChI=1/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3"	JWZZKOKVBUJMES-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator	0.167	0.000790504	3.102095829	46	High-Moderate	High	form of drug administered not known; L- form [51-31-0]			
23176	3176	23176	636_FDAMDD_v3b	C6H9NO6	191.13876	defined organic	parent	tested chemical	Isosorbide mononitrate	16051-77-7	single chemical compound	stereochem	"1,4:3,6-dianhydro-5-O-nitro-D-glucitol"	[N+](O[C@H]2[C@@H]1[C@@H]([C@@H](O)CO1)OC2)([O-])=O	[N+](O[C@H]2[C@@H]1[C@@H]([C@@H](O)CO1)OC2)([O-])=O	"InChI=1/C6H9NO6/c8-3-1-11-6-4(13-7(9)10)2-12-5(3)6/h3-6,8H,1-2H2/t3-,4+,5+,6+/m0/s1"	YWXYYJSYQOXTPL-SLPGGIOYBW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antianginal	2	0.010463602	1.980318769	33	Moderate	High	form of drug administered not known			
23177	3177	23177	637_FDAMDD_v3b	C20H28O2	300.43512	defined organic	parent	tested chemical	Isotretinoin	4759-48-2	single chemical compound	stereochem	(13cis)-retinoic acid	OC(/C=C(C)\C=C\C=C(C)\C=C\C1=C(C)CCCC(C)1C)=O	OC(/C=C(C)\C=C\C=C(C)\C=C\C1=C(C)CCCC(C)1C)=O	"InChI=1/C20H28O2/c1-15(8-6-9-16(2)14-19(21)22)11-12-18-17(3)10-7-13-20(18,4)5/h6,8-9,11-12,14H,7,10,13H2,1-5H3,(H,21,22)/b9-6+,12-11+,15-8+,16-14-/f/h21H"	SHGAZHPCJJPHSC-WWZGNHTLDJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		keratolytic	2	0.006657011	2.176720703	36	Moderate	High	form of drug administered not known; structure modified v3b			
23178	3178	23178	638_FDAMDD_v3b	C18H23NO3	301.38012	defined organic	parent	tested chemical	Isoxsuprine	395-28-8	single chemical compound		4-(1-hydroxy-2-{[1-methyl-2-(phenyloxy)ethyl]amino}propyl)phenol	C2=C(O)C=CC(C(O)C(C)NC(C)COC1=CC=CC=C1)=C2	C2=C(O)C=CC(C(O)C(C)NC(C)COC1=CC=CC=C1)=C2	"InChI=1/C18H23NO3/c1-13(12-22-17-6-4-3-5-7-17)19-14(2)18(21)15-8-10-16(20)11-9-15/h3-11,13-14,18-21H,12H2,1-2H3"	BMUKKTUHUDJSNZ-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vasodilator	1.33	0.004413032	2.35526296	38	Moderate	High	form of drug administered not known			
23179	3179	23179	639_FDAMDD_v3b	C19H21N3O5	371.38714	defined organic	parent	tested chemical	Isradipine	75695-93-1	single chemical compound	stereochem	"methyl 1-methylethyl 4-(2,1,3-benzoxadiazol-4-yl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate"	C=1(C(\C(C(=O)OC)=C(/NC=1C)C)c3c2c(non2)ccc3)C(OC(C)C)=O	C=1(C(\C(C(=O)OC)=C(/NC=1C)C)c3c2c(non2)ccc3)C(OC(C)C)=O	"InChI=1/C19H21N3O5/c1-9(2)26-19(24)15-11(4)20-10(3)14(18(23)25-5)16(15)12-7-6-8-13-17(12)22-27-21-13/h6-9,16,20H,1-5H3"	HMJIYCCIJYRONP-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal	0.167	0.000449666	3.34711039	49	High-Moderate	High	form of drug administered not known			
23180	3180	23180	640_FDAMDD_v3b	C35H38Cl2N8O4	705.6334	defined organic	parent	tested chemical	Itraconazole	84625-61-6	single chemical compound	stereochem	"4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one"	N\1(C(N(C(CC)C)/N=C/1)=O)c7ccc(N2CCN(CC2)c6ccc(OC[C@@H]5O[C@](c3c(cc(cc3)Cl)Cl)(Cn4ncnc4)OC5)cc6)cc7	N\1(C(N(C(CC)C)/N=C/1)=O)c7ccc(N2CCN(CC2)c6ccc(OC[C@@H]5O[C@](c3c(cc(cc3)Cl)Cl)(Cn4ncnc4)OC5)cc6)cc7	"InChI=1/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1"	VHVPQPYKVGDNFY-ZPGVKDDIBW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antifungal	10	0.014171665	1.848579129	32	Moderate	Low	form of drug administered not known			
23181	3181	23181	641_FDAMDD_v3b	C48H74O14	875.09276	defined organic	parent	tested chemical	Ivermectin B1a	71827-03-7	single chemical compound	stereochem	"(2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,8,19-tetramethyl-6'-[(1S)-1-methylpropyl]-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside"	O[C@@]12[C@]3([H])C(O[C@@](C[C@]5(CC[C@H](C)[C@]([C@@H](C)CC)([H])O5)O4)([H])C[C@@]4([H])C/C=C(C)/[C@@H](O[C@]6([H])O[C@@H](C)[C@H](O[C@@]7([H])C[C@H](OC)[C@@H](O)[C@H](C)O7)[C@@H](OC)C6)[C@@H](C)/C=C/C=C1\CO[C@@]([H])2[C@H](O)C(C)=C3)=O	O[C@@]12[C@]3([H])C(O[C@@](C[C@]5(CC[C@H](C)[C@]([C@@H](C)CC)([H])O5)O4)([H])C[C@@]4([H])C/C=C(C)/[C@@H](O[C@]6([H])O[C@@H](C)[C@H](O[C@@]7([H])C[C@H](OC)[C@@H](O)[C@H](C)O7)[C@@H](OC)C6)[C@@H](C)/C=C/C=C1\CO[C@@]([H])2[C@H](O)C(C)=C3)=O	"InChI=1/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1"	AZSNMRSAGSSBNP-XPNPUAGNBT	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Ivermectin	anthelmintic	0.15	0.00017141	3.765962832	53	High	High	form of drug administered not known			
23182	3182	23182	642_FDAMDD_v3b	C47H72O14	861.06618	defined organic	parent	tested chemical	Ivermectin B1b	70209-81-3	single chemical compound	stereochem	"(2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,8,19-tetramethyl-6'-(1-methylethyl)-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside"	O[C@@]12[C@]3([H])C(O[C@@](C[C@]5(CC[C@H](C)[C@](C(C)C)([H])O5)O4)([H])C[C@@]4([H])C/C=C(C)/[C@@H](O[C@]6([H])O[C@@H](C)[C@H](O[C@@]7([H])C[C@H](OC)[C@@H](O)[C@H](C)O7)[C@@H](OC)C6)[C@@H](C)/C=C/C=C1\CO[C@@]([H])2[C@H](O)C(C)=C3)=O	O[C@@]12[C@]3([H])C(O[C@@](C[C@]5(CC[C@H](C)[C@](C(C)C)([H])O5)O4)([H])C[C@@]4([H])C/C=C(C)/[C@@H](O[C@]6([H])O[C@@H](C)[C@H](O[C@@]7([H])C[C@H](OC)[C@@H](O)[C@H](C)O7)[C@@H](OC)C6)[C@@H](C)/C=C/C=C1\CO[C@@]([H])2[C@H](O)C(C)=C3)=O	"InChI=1/C47H72O14/c1-24(2)41-27(5)16-17-46(61-41)22-33-19-32(60-46)15-14-26(4)42(25(3)12-11-13-31-23-54-44-39(48)28(6)18-34(45(50)57-33)47(31,44)51)58-38-21-36(53-10)43(30(8)56-38)59-37-20-35(52-9)40(49)29(7)55-37/h11-14,18,24-25,27,29-30,32-44,48-49,51H,15-17,19-23H2,1-10H3/b12-11+,26-14+,31-13+/t25-,27-,29-,30-,32+,33-,34-,35-,36-,37-,38-,39+,40-,41+,42-,43-,44+,46+,47+/m0/s1"	VARHUCVRRNANBD-PVVXTEPVBF	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Ivermectin	anthelmintic	0.15	0.000174203	3.758945273	53	High	High	form of drug administered not known			
23183	3183	23183	643_FDAMDD_v3b	C42H69NO15	827.99496	defined organic	parent	tested chemical	Josamycin	16846-24-5	single chemical compound	stereochem	"4-(acetyloxy)-6-((3,6-dideoxy-4-O-(2,6-dideoxy-3-C-methyl-4-O-(3-methyl-1-oxobutyl)-alpha-L-ribo-hexopyranosyl)-3-(dimethylamino)-beta-D-glucopyranosyl)oxy)-10-hydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-diene-7-acetaldehyde"	CC(=O)O[C@@H]3CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]1C[C@@](C)(O)[C@H](OC(=O)CC(C)C)[C@H](C)O1)[C@H](N(C)C)[C@H]2O)C3OC	CC(=O)O[C@@H]3CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]1C[C@@](C)(O)[C@H](OC(=O)CC(C)C)[C@H](C)O1)[C@H](N(C)C)[C@H]2O)C3OC	"InChI=1/C42H69NO15/c1-23(2)19-32(47)56-40-27(6)53-34(22-42(40,8)50)57-37-26(5)54-41(36(49)35(37)43(9)10)58-38-29(17-18-44)20-24(3)30(46)16-14-12-13-15-25(4)52-33(48)21-31(39(38)51-11)55-28(7)45/h12-14,16,18,23-27,29-31,34-41,46,49-50H,15,17,19-22H2,1-11H3/b13-12+,16-14+/t24-,25-,26-,27+,29+,30+,31-,34+,35-,36-,37-,38+,39?,40-,41+,42-/m1/s1"	XJSFLOJWULLJQS-HTYUZQQABV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	50	0.060386841	1.219057689	25	Low-Moderate	Low	form of drug administered not known			
23184	3184	23184	644_FDAMDD_v3b	C18H36N4O11	484.49864	defined organic	parent	tested chemical	Kanamycin A	8063-07-8	single chemical compound	stereochem	"(1S,2R,3R,4S,6R)-4,6-diamino-3-[(6-amino-6-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside"	O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]3O[C@H]2[C@H](O)[C@@H](O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O)[C@H](N)C[C@@H]2N	O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]3O[C@H]2[C@H](O)[C@@H](O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O)[C@H](N)C[C@@H]2N	"InChI=1/C18H36N4O11/c19-2-6-10(25)12(27)13(28)18(30-6)33-16-5(21)1-4(20)15(14(16)29)32-17-11(26)8(22)9(24)7(3-23)31-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6-,7-,8+,9-,10-,11-,12+,13-,14-,15+,16-,17-,18-/m1/s1"	SBUJHOSQTJFQJX-NOAMYHISBU	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 3	Kanamycin	antibacterial	15	0.030959839	1.509201303	28	Low-Moderate	Low	form of drug administered not known; sulfate [59-01-8; 25389-94-0]; A sulfate [133-92-6]; B form [4696-76-8]; C form [2280-32-2]; 1413-65-6; related forms			
23185	3185	23185	645_FDAMDD_v3b	C18H37N5O10	483.51388	defined organic	parent	tested chemical	Kanamycin B	4696-76-8	single chemical compound	stereochem	"(1R,2S,3S,4R,6S)-4,6-diamino-3-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside"	N[C@@H]3[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]3O[C@H]2[C@H](O)[C@@H](O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O)[C@H](N)C[C@@H]2N	N[C@@H]3[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]3O[C@H]2[C@H](O)[C@@H](O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O)[C@H](N)C[C@@H]2N	"InChI=1/C18H37N5O10/c19-2-6-11(26)12(27)9(23)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)8(22)10(25)7(3-24)31-18/h4-18,24-29H,1-3,19-23H2/t4-,5+,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1"	SKKLOUVUUNMCJE-FQSMHNGLBM	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 3	Kanamycin	antibacterial	15	0.031022894	1.508317687	28	Low-Moderate	Low	form of drug administered not known; A form [8063-07-8]; C form [2280-32-2]; related forms			
23186	3186	23186	646_FDAMDD_v3b	C18H36N4O11	484.49864	defined organic	parent	tested chemical	Kanamycin C	2280-32-2	single chemical compound	stereochem	"(1R,2S,3S,4R,6S)-4,6-diamino-3-[(3-amino-3-deoxy-alpha-D-glucopyranosyl)oxy]-2-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside"	N[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]3O[C@H]2[C@H](O)[C@@H](O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O)[C@H](N)C[C@@H]2N	N[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]3O[C@H]2[C@H](O)[C@@H](O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O)[C@H](N)C[C@@H]2N	"InChI=1/C18H36N4O11/c19-4-1-5(20)16(33-18-13(28)8(21)10(25)6(2-23)31-18)14(29)15(4)32-17-9(22)12(27)11(26)7(3-24)30-17/h4-18,23-29H,1-3,19-22H2/t4-,5+,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1"	WZDRWYJKESFZMB-FQSMHNGLBR	Clinical Reports 	Maximum Recommended Daily Dose	human	3 of 3	Kanamycin	antibacterial	15	0.030959839	1.509201303	28	Low-Moderate	Low	form of drug administered not known; A form [8063-07-8]; B form [4696-76-8]; related forms			
23187	3187	23187	647_FDAMDD_v3b	C13H16ClNO	237.72524	defined organic	parent	tested chemical	Ketamine	6740-88-1	single chemical compound		2-(2-chlorophenyl)-2-(methylamino)cyclohexanone	C2CCCC(NC)(C1=C(Cl)C=CC=C1)C2=O	C2CCCC(NC)(C1=C(Cl)C=CC=C1)C2=O	"InChI=1/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3"	YQEZLKZALYSWHR-UHFFFAOYAB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anesthetic	2	0.008413074	2.075045299	34	Moderate	High	form of drug administered not known; HCl [1867-66-9]			
23188	3188	23188	648_FDAMDD_v3b	C22H22FN3O3	395.4267832	defined organic	parent	tested chemical	Ketanserin	74050-98-9	single chemical compound		"3-(2-{4-[(4-fluorophenyl)carbonyl]piperidin-1-yl}ethyl)quinazoline-2,4(1H,3H)-dione"	C1=CC=C4C(=C1)NC(=O)N(CCN3CCC(C(=O)C2=CC=C(F)C=C2)CC3)C4=O	C1=CC=C4C(=C1)NC(=O)N(CCN3CCC(C(=O)C2=CC=C(F)C=C2)CC3)C4=O	"InChI=1/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)/f/h24H"	FPCCSQOGAWCVBH-LQFNOIFHCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	1.33	0.003363455	2.473214441	39	Moderate	High	form of drug administered not known; tartrate [83846-83-7]			
23189	3189	23189	649_FDAMDD_v3b	C15H13NO3	255.26862	defined organic	parent	tested chemical	Ketorolac	74103-06-3	single chemical compound		"5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid"	C3=CC=CC=C3C(=O)C1=CC=C2N1CCC2C(=O)O	C3=CC=CC=C3C(=O)C1=CC=C2N1CCC2C(=O)O	"InChI=1/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)/f/h18H"	OZWKMVRBQXNZKK-GPQMBLKYCT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; anti inflammatory	2.5	0.009793605	2.009057422	34	Moderate	High-Moderate	form of drug administered not known; tromethamine [74103-07-4]			
23190	3190	23190	650_FDAMDD_v3b	C19H19NOS	309.42526	defined organic	parent	tested chemical	Ketotifen	34580-13-7	single chemical compound		"4-(1-methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one"	C1=CC=C3C(=C1)CC(=O)C4=C(C3=C2CCN(C)CC2)C=CS4	C1=CC=C3C(=C1)CC(=O)C4=C(C3=C2CCN(C)CC2)C=CS4	"InChI=1/C19H19NOS/c1-20-9-6-13(7-10-20)18-15-5-3-2-4-14(15)12-17(21)19-16(18)8-11-22-19/h2-5,8,11H,6-7,9-10,12H2,1H3"	ZCVMWBYGMWKGHF-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiasthmatic	0.0333	0.000107619	3.968111531	56	High	High	form of drug administered not known; fumarate [34580-14-8]			
23191	3191	23191	651_FDAMDD_v3b	C19H24N2O3	328.40546	defined organic	parent	tested chemical	Labetalol	36894-69-6	single chemical compound		2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide	C2=CC=CC(CCC(C)NCC(O)C1=CC=C(O)C(C(N)=O)=C1)=C2	C2=CC=CC(CCC(C)NCC(O)C1=CC=C(O)C(C(N)=O)=C1)=C2	"InChI=1/C19H24N2O3/c1-13(7-8-14-5-3-2-4-6-14)21-12-18(23)15-9-10-17(22)16(11-15)19(20)24/h2-6,9-11,13,18,21-23H,7-8,12H2,1H3,(H2,20,24)/f/h20H2"	SGUAFYQXFOLMHL-HPHMPNDVCQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	40	0.121800655	0.914350378	21	Low	Low	form of drug administered not known; HCl [32780-64-6]			
23192	3192	23192	652_FDAMDD_v3b	C3H6O3	90.0779	defined organic	parent	tested chemical	Lactic acid	50-21-5	single chemical compound		2-hydroxypropanoic acid	C(O)(=O)C(C)O	C(O)(=O)C(C)O	"InChI=1/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)/f/h5H"	JVTAAEKCZFNVCJ-JSWHHWTPCE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		acidulant	100	1.110150214	-0.045381747	11	Low	Low	form of drug administered not known; dimer 5H2O Ca salt [5743-47-5]; dimer Ca salt [814-80-2]; dl form [598-82-3]; l form [79-33-4]; l form Na salt [867-56-1]; dl form Na salt [72-17-3]; Zn [16039-53-5]; 41372-22-9			
23193	3193	23193	653_FDAMDD_v3b	C12H22O11	342.29648	defined organic	parent	tested chemical	Lactose	63-42-3	single chemical compound	stereochem	4-O-beta-D-galactopyranosyl-beta-D-glucopyranose	[C@@H]1([C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2CO)O)O)O	[C@@H]1([C@@H]([C@H]([C@H]([C@H](O1)CO)O)O)O)O[C@H]2[C@@H]([C@H]([C@@H](O[C@@H]2CO)O)O)O	"InChI=1/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5+,6+,7-,8-,9-,10-,11-,12+/m1/s1"	GUBGYTABKSRVRQ-DCSYEGIMBP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	100	0.292144401	0.534402433	17	Low	Low	form of drug administered not known; H2O [5989-81-1]			
23194	3194	23194	654_FDAMDD_v3b	C8H11N3O3S	229.2562	defined organic	parent	tested chemical	Lamivudine	134678-17-4	single chemical compound	stereochem	"4-amino-1-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one"	[C@@H]1(O[C@H](CS1)N\2C(\N=C(/C=C/2)N)=O)CO	[C@@H]1(O[C@H](CS1)N\2C(\N=C(/C=C/2)N)=O)CO	"InChI=1/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m1/s1/f/h9H2"	JTEGQNOMFQHVDC-JKGQTJJJDI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiviral	5	0.021809661	1.661351085	30	Moderate	Low	form of drug administered not known			
23195	3195	23195	655_FDAMDD_v3b	C9H7Cl2N5	256.09138	defined organic	parent	tested chemical	Lamotrigine	84057-84-1	single chemical compound		"6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine"	C2=CC=C(C1=C(N)N=C(N)N=N1)C(Cl)=C2Cl	C2=CC=C(C1=C(N)N=C(N)N=N1)C(Cl)=C2Cl	"InChI=1/C9H7Cl2N5/c10-5-3-1-2-4(6(5)11)7-8(12)14-9(13)16-15-7/h1-3H,(H4,12,13,14,16)/f/h12-13H2"	PYZRQGJRPPTADH-KGJHZMDYCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	6.67	0.026045391	1.584269127	29	Low-Moderate	Low	form of drug administered not known			
23196	3196	23196	656_FDAMDD_v3b	C49H76O19	969.11634	defined organic	parent	tested chemical	Lanatoside A	17575-20-1	single chemical compound	stereochem	"(5beta)-3-{[beta-D-glucopyranosyl-(1->4)-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14-hydroxycard-20(22)-enolide"	[C@@]82([C@@]([C@@H](/C1=C/C(=O)OC1)CC2)(CC[C@@H]9[C@]7(CCC(O[C@@H]3O[C@@H]([C@H]([C@H](C3)O)O[C@@H]6O[C@@H]([C@@H](O[C@@H]5O[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O)[C@@H]([C@H](O4)CO)O)O)[C@H](C5)OC(=O)C)C)[C@H](C6)O)C)C)C[C@H]7CC[C@@H]89)C)C)O	[C@@]82([C@@]([C@@H](/C1=C/C(=O)OC1)CC2)(CC[C@@H]9[C@]7(CCC(O[C@@H]3O[C@@H]([C@H]([C@H](C3)O)O[C@@H]6O[C@@H]([C@@H](O[C@@H]5O[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O)[C@@H]([C@H](O4)CO)O)O)[C@H](C5)OC(=O)C)C)[C@H](C6)O)C)C)C[C@H]7CC[C@@H]89)C)C)O	"InChI=1/C49H76O19/c1-22-43(66-38-18-33(53)44(23(2)61-38)67-39-19-34(63-25(4)51)45(24(3)62-39)68-46-42(57)41(56)40(55)35(20-50)65-46)32(52)17-37(60-22)64-28-9-12-47(5)27(16-28)7-8-31-30(47)10-13-48(6)29(11-14-49(31,48)58)26-15-36(54)59-21-26/h15,22-24,27-35,37-46,50,52-53,55-58H,7-14,16-21H2,1-6H3/t22-,23-,24-,27-,28?,29-,30+,31-,32+,33+,34+,35-,37+,38+,39+,40-,41+,42-,43-,44-,45-,46+,47+,48-,49+/m1/s1"	YFGQJKBUXPKSAW-XBBQASNWBV	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 4	Lanatoside	cardiotonic	0.0333	3.43612E-05	4.463931683	61	High	High	form of drug administered not known			
23197	3197	23197	657_FDAMDD_v3b	C49H76O20	985.11574	defined organic	parent	tested chemical	Lanatoside B	17575-21-2	single chemical compound	stereochem	"(16beta)-3-{[beta-D-glucopyranosyl-(1->4)-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-14,16-dihydroxycard-20(22)-enolide"	O[C@]([C@@]3([H])[C@@]4([H])[C@@](C(C6)CC3)(C)CCC6O[C@@H]1O[C@H](C)[C@@H](O[C@@H](C[C@@H]9O)O[C@H](C)[C@H]9O[C@@H]8O[C@H](C)[C@H]([C@@H](OC(C)=O)C8)O[C@H](O[C@H](CO)[C@H]7O)[C@H](O)[C@H]7O)[C@@H](O)C1)(C[C@@H]2O)[C@@](CC4)(C)[C@H]2[C@@]5=CC(OC5)=O	O[C@]([C@@]3([H])[C@@]4([H])[C@@](C(C6)CC3)(C)CCC6O[C@@H]1O[C@H](C)[C@@H](O[C@@H](C[C@@H]9O)O[C@H](C)[C@H]9O[C@@H]8O[C@H](C)[C@H]([C@@H](OC(C)=O)C8)O[C@H](O[C@H](CO)[C@H]7O)[C@H](O)[C@H]7O)[C@@H](O)C1)(C[C@@H]2O)[C@@](CC4)(C)[C@H]2[C@@]5=CC(OC5)=O	"InChI=1/C49H76O20/c1-21-43(67-37-16-31(53)44(22(2)62-37)68-38-17-33(64-24(4)51)45(23(3)63-38)69-46-42(58)41(57)40(56)34(19-50)66-46)30(52)15-36(61-21)65-27-9-11-47(5)26(14-27)7-8-29-28(47)10-12-48(6)39(25-13-35(55)60-20-25)32(54)18-49(29,48)59/h13,21-23,26-34,36-46,50,52-54,56-59H,7-12,14-20H2,1-6H3/t21-,22-,23-,26?,27?,28+,29-,30+,31+,32+,33+,34-,36+,37+,38+,39+,40-,41+,42-,43-,44-,45-,46+,47+,48-,49+/m1/s1"	XVAPNQFQPDAROQ-KBADXSOQBD	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 4	Lanatoside	cardiotonic	0.0333	3.38031E-05	4.471043025	61	High	High	form of drug administered not known; structure modified v3b			
23198	3198	23198	658_FDAMDD_v3b	C49H76O20	985.11574	defined organic	parent	tested chemical	Lanatoside C	17575-22-3	single chemical compound	stereochem	"(3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide"	[C@@]32([C@@]([C@@H](/C1=C/C(=O)OC1)CC2)([C@H](O)C[C@H]4[C@H]3CC[C@H]9[C@@]4(CC[C@H](O[C@@H]5O[C@@H]([C@H]([C@H](C5)O)O[C@@H]8O[C@@H]([C@@H](O[C@@H]7O[C@@H]([C@@H](O[C@H]6[C@@H]([C@@H](O)[C@@H]([C@H](O6)CO)O)O)[C@H](C7)OC(=O)C)C)C(C8)O)C)C)C9)C)C)O	[C@@]32([C@@]([C@@H](/C1=C/C(=O)OC1)CC2)([C@H](O)C[C@H]4[C@H]3CC[C@H]9[C@@]4(CC[C@H](O[C@@H]5O[C@@H]([C@H]([C@H](C5)O)O[C@@H]8O[C@@H]([C@@H](O[C@@H]7O[C@@H]([C@@H](O[C@H]6[C@@H]([C@@H](O)[C@@H]([C@H](O6)CO)O)O)[C@H](C7)OC(=O)C)C)C(C8)O)C)C)C9)C)C)O	"InChI=1/C49H76O20/c1-21-43(67-38-17-32(53)44(22(2)62-38)68-39-18-33(64-24(4)51)45(23(3)63-39)69-46-42(58)41(57)40(56)34(19-50)66-46)31(52)16-37(61-21)65-27-9-11-47(5)26(14-27)7-8-29-30(47)15-35(54)48(6)28(10-12-49(29,48)59)25-13-36(55)60-20-25/h13,21-23,26-35,37-46,50,52-54,56-59H,7-12,14-20H2,1-6H3/t21-,22-,23-,26-,27+,28-,29-,30+,31+,32+,33+,34-,35-,37+,38+,39+,40-,41+,42-,43-,44-,45-,46+,47+,48+,49+/m1/s1"	JAYAGJDXJIDEKI-PTGWOZRBBX	Clinical Reports 	Maximum Recommended Daily Dose	human	3 of 4	Lanatoside	cardiotonic	0.0333	3.38031E-05	4.471043025	61	High	High	form of drug administered not known			
23199	3199	23199	659_FDAMDD_v3b	C49H76O21	1001.11514	defined organic	parent	tested chemical	Lanatoside D	11030-31-2	single chemical compound	stereochem	"(12beta,16beta)-3-{[beta-D-glucopyranosyl-(1->4)-3-O-acetyl-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14,16-trihydroxycard-20(22)-enolide"	O[C@]([C@@](CC6)([H])[C@]([C@](CC5)(C)C6CC5O[C@@H]2O[C@H](C)[C@@H](O[C@@H](C[C@@H]9O)O[C@H](C)[C@H]9O[C@@H]8O[C@H](C)[C@H]([C@@H](OC(C)=O)C8)O[C@H](O[C@H](CO)[C@H]7O)[C@H](O)[C@H]7O)[C@@H](O)C2)([H])C[C@H]1O)(C[C@@H]3O)[C@@]1(C)[C@H]3[C@@]4=CC(OC4)=O	O[C@]([C@@](CC6)([H])[C@]([C@](CC5)(C)C6CC5O[C@@H]2O[C@H](C)[C@@H](O[C@@H](C[C@@H]9O)O[C@H](C)[C@H]9O[C@@H]8O[C@H](C)[C@H]([C@@H](OC(C)=O)C8)O[C@H](O[C@H](CO)[C@H]7O)[C@H](O)[C@H]7O)[C@@H](O)C2)([H])C[C@H]1O)(C[C@@H]3O)[C@@]1(C)[C@H]3[C@@]4=CC(OC4)=O	"InChI=1/C49H76O21/c1-20-43(68-37-15-30(53)44(21(2)63-37)69-38-16-32(65-23(4)51)45(22(3)64-38)70-46-42(59)41(58)40(57)33(18-50)67-46)29(52)14-36(62-20)66-26-9-10-47(5)25(12-26)7-8-27-28(47)13-34(55)48(6)39(24-11-35(56)61-19-24)31(54)17-49(27,48)60/h11,20-22,25-34,36-46,50,52-55,57-60H,7-10,12-19H2,1-6H3/t20-,21-,22-,25?,26?,27-,28+,29+,30+,31+,32+,33-,34-,36+,37+,38+,39+,40-,41+,42-,43-,44-,45-,46+,47+,48-,49+/m1/s1"	CMJNCFRBMBTRSY-CRXYFKOTBQ	Clinical Reports 	Maximum Recommended Daily Dose	human	4 of 4	Lanatoside	cardiotonic	0.0333	3.32629E-05	4.478039796	61	High	High	form of drug administered not known; structure modified v3b			
23200	3200	23200	660_FDAMDD_v3b	C16H14F3N3O2S	369.3614696	defined organic	parent	tested chemical	Lansoprazole	103577-45-3	single chemical compound		"2-[({3-methyl-4-[(2,2,2-trifluoroethyl)oxy]pyridin-2-yl}methyl)sulfinyl]-1H-benzimidazole"	C1=CC=C3C(=C1)N=C(S(=O)CC2=NC=CC(OCC(F)(F)F)=C2C)N3	C1=CC=C3C(=C1)N=C(S(=O)CC2=NC=CC(OCC(F)(F)F)=C2C)N3	"InChI=1/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/f/h21H"	MJIHNNLFOKEZEW-PKSOQXRJCC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiulcerative; anti infective	0.5	0.001353687	2.868481585	43	Moderate	High	form of drug administered not known			
23201	3201	23201	661_FDAMDD_v3b	C12H9F3N2O2	270.2072696	defined organic	parent	tested chemical	Leflunomide	75706-12-6	single chemical compound		5-methyl-N-[4-(trifluoromethyl)phenyl]isoxazole-4-carboxamide	C2(C(=O)NC1=CC=C(C(F)(F)F)C=C1)C=NOC=2C	C2(C(=O)NC1=CC=C(C(F)(F)F)C=C1)C=NOC=2C	"InChI=1/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)/f/h17H"	VHOGYURTWQBHIL-HCKMINDGCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antirheuematic; immunosuppressant	0.333	0.001232387	2.909252796	44	Moderate	High	form of drug administered not known			
23202	3202	23202	662_FDAMDD_v3b	C17H11N5	285.30274	defined organic	parent	tested chemical	Letrozole	112809-51-5	single chemical compound		"4,4'-(1H-1,2,4-triazol-1-ylmethanediyl)dibenzonitrile"	C3=CC(C#N)=CC=C3C(C1=CC=C(C#N)C=C1)N2N=CN=C2	C3=CC(C#N)=CC=C3C(C1=CC=C(C#N)C=C1)N2N=CN=C2	"InChI=1/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H"	HPJKCIUCZWXJDR-UHFFFAOYAB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.0417	0.000146161	3.835169888	54	High	High	form of drug administered not known			
23203	3203	23203	663_FDAMDD_v3b	C6H13NO2	131.17292	defined organic	parent	tested chemical	Leucine	61-90-5	single chemical compound	stereochem	L-leucine	CC(C)C[C@H](N)C(O)=O	CC(C)C[C@H](N)C(O)=O	"InChI=1/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1/f/h8H"	ROHFNLRQFUQHCH-ZEYBBFMUDN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		nutrient	100	0.762352473	0.117844186	12	Low	Low	form of drug administered not known			
23204	3204	23204	664_FDAMDD_v3b	C20H23N7O7	473.43932	defined organic	parent	tested chemical	Leucovorin	58-05-9	single chemical compound		"N-[(4-{[(2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl)methyl]amino}phenyl)carbonyl]glutamic acid"	C1(N)=NC(=O)C3=C(N1)NCC(CNC2=CC=C(C(=O)NC(C(O)=O)CCC(O)=O)C=C2)N3C=O	C1(N)=NC(=O)C3=C(N1)NCC(CNC2=CC=C(C(=O)NC(C(O)=O)CCC(O)=O)C=C2)N3C=O	"InChI=1/C20H23N7O7/c21-20-25-16-15(18(32)26-20)27(9-28)12(8-23-16)7-22-11-3-1-10(2-4-11)17(31)24-13(19(33)34)5-6-14(29)30/h1-4,9,12-13,22H,5-8H2,(H,24,31)(H,29,30)(H,33,34)(H4,21,23,25,26,32)/f/h23-25,29,33H,21H2"	VVIAGPKUTFNRDU-YNVBRWNNCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidote to folic acid antagonists; antianemic	5.41	0.011427019	1.942067059	33	Moderate	Low	form of drug administered not known			
23205	3205	23205	665_FDAMDD_v3b	C19H25NO	283.4079	defined organic	parent	tested chemical	Levallorphan	152-02-3	single chemical compound	stereochem	17-prop-2-en-1-ylmorphinan-3-ol	[C@]243c1c(ccc(c1)O)C[C@H]([C@@H]2CCCC3)N(CC4)CC=C	[C@]243c1c(ccc(c1)O)C[C@H]([C@@H]2CCCC3)N(CC4)CC=C	"InChI=1/C19H25NO/c1-2-10-20-11-9-19-8-4-3-5-16(19)18(20)12-14-6-7-15(21)13-17(14)19/h2,6-7,13,16,18,21H,1,3-5,8-12H2/t16-,18+,19+/m0/s1"	OZYUPQUCAUTOBP-QXAKKESOBE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic antagonist	0.0667	0.00023535	3.628286118	52	High	High	form of drug administered not known			
23206	3206	23206	666_FDAMDD_v3b	C11H12N2S	204.29138	defined organic	parent	tested chemical	Levamisole	14769-73-4	single chemical compound	stereochem	"(6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole"	N\1=C3/SCCN3C[C@@H]/1c2ccccc2	N\1=C3/SCCN3C[C@@H]/1c2ccccc2	"InChI=1/C11H12N2S/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10/h1-5,10H,6-8H2/t10-/m1/s1"	HLFSDGLLUJUHTE-SNVBAGLBBU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anthelmintic	0.833	0.004077509	2.389605041	38	Moderate	High	form of drug administered not known			
23207	3207	23207	667_FDAMDD_v3b	C8H14N2O2	170.209	defined organic	parent	tested chemical	Levetiracetam	102767-28-2	single chemical compound	stereochem	(2S)-2-(2-oxopyrrolidin-1-yl)butanamide	O=C1CCCN1[C@@H](CC)C(=O)N	O=C1CCCN1[C@@H](CC)C(=O)N	"InChI=1/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1/f/h9H2"	HPHUVLMMVZITSG-CPXYJBNRDM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	60	0.352507799	0.45283127	16	Low	Low	form of drug administered not known			
23208	3208	23208	668_FDAMDD_v3b	C7H15NO3	161.1989	defined organic	parent	tested chemical	Levocarnitine	541-15-1	single chemical compound	stereochem; zwitterion; ammonium	(3R)-3-hydroxy-4-(trimethylammonio)butanoate	C[N+](C)(C)C[C@H](O)CC([O-])=O	C[N+](C)(C)C[C@H](O)CC([O-])=O	"InChI=1/C7H15NO3/c1-8(2,3)5-6(9)4-7(10)11/h6,9H,4-5H2,1-3H3/t6-/m1/s1"	PHIQHXFUZVPYII-ZCFIWIBFBS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihyperlipoproteinemic	49.5	0.307074056	0.512756875	17	Low	Low	form of drug administered not known			
23209	3209	23209	669_FDAMDD_v3b	C9H11NO4	197.1879	defined organic	parent	tested chemical	Levodopa	59-92-7	single chemical compound	stereochem	3-hydroxy-L-tyrosine	Oc1ccc(C[C@H](N)C(O)=O)cc1O	Oc1ccc(C[C@H](N)C(O)=O)cc1O	"InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1/f/h13H"	WTDRDQBEARUVNC-UDXUTFKQDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiparkinsonian	133	0.674483576	0.171028621	13	Low	Low	form of drug administered not known			
23210	3210	23210	670_FDAMDD_v3b	C13H20N2O2	236.3101	defined organic	parent	tested chemical	Levodropropizine	99291-25-5	single chemical compound	S(-)- form shown; stereochem	"(2S)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol"	O[C@@H](CN1CCN(CC1)c2ccccc2)CO	O[C@@H](CN1CCN(CC1)c2ccccc2)CO	"InChI=1/C13H20N2O2/c16-11-13(17)10-14-6-8-15(9-7-14)12-4-2-1-3-5-12/h1-5,13,16-17H,6-11H2/t13-/m0/s1"	PTVWPYVOOKLBCG-ZDUSSCGKBV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antitussive	3	0.012695183	1.896361029	32	Moderate	Moderate	form of drug administered not known			
23211	3211	23211	671_FDAMDD_v3b	C23H31NO2	353.49774	defined organic	parent	tested chemical	Levomethadyl acetate	34433-66-4	single chemical compound	stereochem	"(1S,4S)-4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate"	O=C(C)O[C@@H](CC)C(C[C@@H](N(C)C)C)(C2=CC=CC=C2)C1=CC=CC=C1	O=C(C)O[C@@H](CC)C(C[C@@H](N(C)C)C)(C2=CC=CC=C2)C1=CC=CC=C1	"InChI=1/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3/t18-,22-/m0/s1"	XBMIVRRWGCYBTQ-AVRDEDQJBI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		treatment of narcotic addiction	4	0.01131549	1.94632665	33	Moderate	Moderate	form of drug administered not known			
23212	3212	23212	672_FDAMDD_v3b	C22H29NO2	339.47116	defined organic	parent	tested chemical	Levopropoxyphene	2338-37-6	single chemical compound	stereochem	"(1R,2S)-3-(dimethylamino)-2-methyl-1-phenyl-1-(phenylmethyl)propyl propanoate"	[C@]([C@H](CN(C)C)C)(OC(=O)CC)(Cc1ccccc1)c2ccccc2	[C@]([C@H](CN(C)C)C)(OC(=O)CC)(Cc1ccccc1)c2ccccc2	"InChI=1/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m0/s1"	XLMALTXPSGQGBX-PGRDOPGGBE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antitussive	1.67	0.004919416	2.308086413	37	Moderate	High	form of drug administered not known			
23213	3213	23213	673_FDAMDD_v3b	C17H23NO	257.37062	defined organic	parent	tested chemical	Levorphanol	77-07-6	single chemical compound	stereochem	17-methylmorphinan-3-ol	[C@]243c1c(ccc(c1)O)C[C@H]([C@@H]2CCCC3)N(CC4)C	[C@]243c1c(ccc(c1)O)C[C@H]([C@@H]2CCCC3)N(CC4)C	"InChI=1/C17H23NO/c1-18-9-8-17-7-3-2-4-14(17)16(18)10-12-5-6-13(19)11-15(12)17/h5-6,11,14,16,19H,2-4,7-10H2,1H3/t14-,16+,17+/m0/s1"	JAQUASYNZVUNQP-USXIJHARBM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	0.15	0.000582817	3.23446771	47	High-Moderate	High	form of drug administered not known			
23214	3214	23214	674_FDAMDD_v3b	C15H11I4NO4	776.87002	defined organic	parent	tested chemical	Levothyroxine	51-48-9	single chemical compound	stereochem	"O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-L-tyrosine"	OC(=O)[C@@H](N)Cc2cc(I)c(Oc1cc(I)c(O)c(I)c1)c(I)c2	OC(=O)[C@@H](N)Cc2cc(I)c(Oc1cc(I)c(O)c(I)c1)c(I)c2	"InChI=1/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/t12-/m0/s1/f/h22H"	XUIIKFGFIJCVMT-LXHGQMKLDQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		hyperthyroidism	0.00833	1.07225E-05	4.969703361	67	High	High	form of drug administered not known			
23215	3215	23215	675_FDAMDD_v3b	C18H34N2O6S	406.53736	defined organic	parent	tested chemical	Lincomycin	154-21-2	single chemical compound	stereochem	"methyl 6,8-dideoxy-6-{[(4R)-1-methyl-4-propyl-L-prolyl]amino}-1-thio-D-erythro-alpha-D-galacto-octopyranoside"	[C@H]1([C@@H]([C@H]([C@H]([C@H](O1)[C@@H]([C@@H](C)O)NC(=O)[C@@H]2C[C@H](CN2C)CCC)O)O)O)SC	[C@H]1([C@@H]([C@H]([C@H]([C@H](O1)[C@@H]([C@@H](C)O)NC(=O)[C@@H]2C[C@H](CN2C)CCC)O)O)O)SC	"InChI=1/C18H34N2O6S/c1-5-6-10-7-11(20(3)8-10)17(25)19-12(9(2)21)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,21-24H,5-8H2,1-4H3,(H,19,25)/t9-,10-,11+,12-,13+,14-,15-,16-,18-/m1/s1/f/h19H"	OJMMVQQUTAEWLP-IWZVTJAUDJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	33.3	0.081911291	1.086656229	23	Low	Low	form of drug administered not known			
23216	3216	23216	676_FDAMDD_v3b	C15H12I3NO4	650.9735	defined organic	parent	tested chemical	Liothyronine	6893-02-3	single chemical compound	stereochem	"O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine"	OC(=O)[C@@H](N)Cc2cc(I)c(Oc1cc(I)c(O)cc1)c(I)c2	OC(=O)[C@@H](N)Cc2cc(I)c(Oc1cc(I)c(O)cc1)c(I)c2	"InChI=1/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1/f/h21H"	AUYYCJSJGJYCDS-YROMPDBNDH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		thyroid hormone	0.00167	2.56539E-06	5.590846838	74	High	High	form of drug administered not known			
23217	3217	23217	677_FDAMDD_v3b	C20H26N4O	338.44664	defined organic	parent	tested chemical	Lisuride	18016-80-3	single chemical compound	stereochem	"1,1-diethyl-3-[(8alpha)-6-methyl-9,10-didehydroergolin-8-yl]urea"	CCN(CC)C(=O)N[C@H]2/C=C1/c3cccc4N\C=C(\C[C@H]1N(C)C2)c34	CCN(CC)C(=O)N[C@H]2/C=C1/c3cccc4N\C=C(\C[C@H]1N(C)C2)c34	"InChI=1/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1/f/h22H"	BKRGVLQUQGGVSM-WPXWUSHPDR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimigraine; prolactin inhibitor	0.0833	0.000246124	3.608845205	52	High	High	form of drug administered not known			
23218	3218	23218	678_FDAMDD_v3b	C29H55N5O18	761.7697	defined organic	parent	tested chemical	Lividomycin	36441-41-5	single chemical compound	stereochem	"(1R,2R,3S,4R,6S)-4,6-diamino-3-hydroxy-2-{[alpha-D-mannopyranosyl-(1->4)-2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl-(1->3)-beta-D-ribofuranosyl]oxy}cyclohexyl 2-amino-2,3-dideoxy-alpha-D-ribo-hexopyranoside"	[H][C@]([C@@H](C(CC1N)N)O)([C@]([H])1O[C@@H](O2)[C@@H](C[C@@H]([C@@H]2CO)O)N)O[C@@H]3O[C@@H](CO)[C@H]([C@H]3O)O[C@]([H])(O[C@@H]4CN)C(N)[C@H](O)[C@]([H])4O[C@H]5[C@H](O)[C@H](O)[C@@H](O)[C@@H](O5)CO	[H][C@]([C@@H](C(CC1N)N)O)([C@]([H])1O[C@@H](O2)[C@@H](C[C@@H]([C@@H]2CO)O)N)O[C@@H]3O[C@@H](CO)[C@H]([C@H]3O)O[C@]([H])(O[C@@H]4CN)C(N)[C@H](O)[C@]([H])4O[C@H]5[C@H](O)[C@H](O)[C@@H](O)[C@@H](O5)CO	"InChI=1/C29H55N5O18/c30-3-11-23(51-28-20(43)19(42)17(40)13(5-36)47-28)18(41)15(34)27(45-11)50-24-14(6-37)48-29(21(24)44)52-25-16(39)7(31)1-8(32)22(25)49-26-9(33)2-10(38)12(4-35)46-26/h7-29,35-44H,1-6,30-34H2/t7-,8+,9-,10+,11+,12-,13-,14-,15-,16+,17-,18-,19+,20+,21-,22-,23-,24-,25-,26-,27-,28-,29+/m1/s1"	DBLVDAUGBTYDFR-SWMBIRFSBD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	16.7	0.021922636	1.659107223	30	Moderate	Low	form of drug administered not known			
23219	3219	23219	679_FDAMDD_v3b	C22H27NO2	337.45528	defined organic	parent	tested chemical	Lobeline	90-69-7	single chemical compound	stereochem	"2-{(2R,6S)-6-[(2S)-2-hydroxy-2-phenylethyl]-1-methylpiperidin-2-yl}-1-phenylethanone"	N2([C@@H](CC(=O)c1ccccc1)CCC[C@H]2C[C@@H](c3ccccc3)O)C	N2([C@@H](CC(=O)c1ccccc1)CCC[C@H]2C[C@@H](c3ccccc3)O)C	"InChI=1/C22H27NO2/c1-23-19(15-21(24)17-9-4-2-5-10-17)13-8-14-20(23)16-22(25)18-11-6-3-7-12-18/h2-7,9-12,19-21,24H,8,13-16H2,1H3/t19-,20+,21-/m0/s1"	MXYUKLILVYORSK-HBMCJLEFBS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		respiratory stimulant	0.167	0.00049488	3.305499757	48	High-Moderate	High	form of drug administered not known			
23220	3220	23220	680_FDAMDD_v3b	C26H27ClN2O	418.95838	defined organic	parent	tested chemical	Lofepramine	23047-25-8	single chemical compound		"1-(4-chlorophenyl)-2-{[3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl](methyl)amino}ethanone"	C1=CC=C3C(=C1)CCC4=C(N3CCCN(C)CC(=O)C2=CC=C(Cl)C=C2)C=CC=C4	C1=CC=C3C(=C1)CCC4=C(N3CCCN(C)CC(=O)C2=CC=C(Cl)C=C2)C=CC=C4	"InChI=1/C26H27ClN2O/c1-28(19-26(30)22-13-15-23(27)16-14-22)17-6-18-29-24-9-4-2-7-20(24)11-12-21-8-3-5-10-25(21)29/h2-5,7-10,13-16H,6,11-12,17-19H2,1H3"	SAPNXPWPAUFAJU-UHFFFAOYAS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	3.5	0.008354052	2.078102837	34	Moderate	Moderate	form of drug administered not known			
23221	3221	23221	681_FDAMDD_v3b	C11H12Cl2N2O	259.13178	defined organic	parent	tested chemical	Lofexidine	31036-80-3	single chemical compound		"2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole"	C2(Cl)=CC=CC(Cl)=C2OC(C)C1=NCCN1	C2(Cl)=CC=CC(Cl)=C2OC(C)C1=NCCN1	"InChI=1/C11H12Cl2N2O/c1-7(11-14-5-6-15-11)16-10-8(12)3-2-4-9(10)13/h2-4,7H,5-6H2,1H3,(H,14,15)/f/h14H"	KSMAGQUYOIHWFS-YHMJCDSICQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.04	0.000154362	3.811460687	54	High	High	form of drug administered not known			
23222	3222	23222	682_FDAMDD_v3b	C9H16ClN3O2	233.6952	defined organic	parent	tested chemical	Lomustine	13010-47-4	single chemical compound		1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea	C1CCC(NC(=O)N(N=O)CCCl)CC1	C1CCC(NC(=O)N(N=O)CCCl)CC1	"InChI=1/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)/f/h11H"	GQYIWUVLTXOXAJ-WXRBYKJCCV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	3.51	0.015019564	1.823342676	32	Moderate	Moderate	form of drug administered not known			
23223	3223	23223	683_FDAMDD_v3b	C16H18ClN3O5	367.78422	defined organic	complex H2O	tested chemical	Loracarbef	76470-66-1	single chemical compound	stereochem	"(6R,7S)-7-{[(2R)-2-amino-2-phenylacetyl]amino}-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid hydrate"	O=C1N(C(C(O)=O)=C2Cl)[C@@](CC2)([H])[C@@]([H])1NC([C@H](N)C(\C=C/C)=C)=O.O	O=C1N(C(C(O)=O)=C2Cl)[C@@](CC2)([H])[C@@]([H])1NC([C@H](N)C(\C=C/C)=C)=O	"InChI=1/C16H16ClN3O4.H2O/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8;/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24);1H2/t10-,11-,12+;/m1./s1/f/h19,23H;"	GPYKKBAAPVOCIW-RHVLZJHWDR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	6.67	0.018135634	1.741467258	31	Moderate	Low	form of drug administered not known; structure modified v3b			
23224	3224	23224	684_FDAMDD_v3b	C22H23ClN2O2	382.88322	defined organic	parent	tested chemical	Loratadine	79794-75-5	single chemical compound		"ethyl 4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidine-1-carboxylate"	C4(=C1C3=C(CCC2=C1C=CC(Cl)=C2)C=CC=N3)CCN(C(=O)OCC)CC4	C4(=C1C3=C(CCC2=C1C=CC(Cl)=C2)C=CC=N3)CCN(C(=O)OCC)CC4	"InChI=1/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3"	JCCNYMKQOSZNPW-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	0.167	0.000436164	3.360349862	49	High-Moderate	High	form of drug administered not known			
23225	3225	23225	685_FDAMDD_v3b	C15H10Cl2N2O2	321.1581	defined organic	parent	tested chemical	Lorazepam	846-49-1	single chemical compound		"7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2H-1,4-benzodiazepin-2-one"	C1=C(Cl)C=C3C(=C1)NC(=O)C(O)N=C3C2=CC=CC=C2Cl	C1=C(Cl)C=C3C(=C1)NC(=O)C(O)N=C3C2=CC=CC=C2Cl	"InChI=1/C15H10Cl2N2O2/c16-8-5-6-12-10(7-8)13(19-15(21)14(20)18-12)9-3-1-2-4-11(9)17/h1-7,15,21H,(H,18,20)/f/h18H"	DIWRORZWFLOCLC-GPQMBLKYCT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	0.167	0.000519993	3.284002409	48	High-Moderate	High	form of drug administered not known			
23226	3226	23226	686_FDAMDD_v3b	C22H27ClN2O	370.91558	defined organic	parent	tested chemical	Lorcainide	59729-31-6	single chemical compound		N-(4-chlorophenyl)-N-[1-(1-methylethyl)piperidin-4-yl]-2-phenylacetamide	C3=CC=CC(CC(=O)N(C1=CC=C(Cl)C=C1)C2CCN(C(C)C)CC2)=C3	C3=CC=CC(CC(=O)N(C1=CC=C(Cl)C=C1)C2CCN(C(C)C)CC2)=C3	"InChI=1/C22H27ClN2O/c1-17(2)24-14-12-21(13-15-24)25(20-10-8-19(23)9-11-20)22(26)16-18-6-4-3-5-7-18/h3-11,17,21H,12-16H2,1-2H3"	XHOJAWVAWFHGHL-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cardiac depressant	6.67	0.017982529	1.745149242	31	Moderate	Low	form of drug administered not known			
23227	3227	23227	687_FDAMDD_v3b	C22H23ClN6O	422.91062	defined organic	parent	tested chemical	Losartan	114798-26-4	single chemical compound		(2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol	N4(CC3C=CC(C2C(C1NN=NN=1)=CC=CC=2)=CC=3)C(CO)=C(Cl)N=C4CCCC	N4(CC3C=CC(C2C(C1NN=NN=1)=CC=CC=2)=CC=3)C(CO)=C(Cl)N=C4CCCC	"InChI=1/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)/f/h25H"	PSIFNNKUMBGKDQ-LNNLXFCOCF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	1.67	0.003948825	2.40353212	38	Moderate	High	form of drug administered not known			
23228	784	20784	688_FDAMDD_v3b	C24H36O5	404.5396	defined organic	parent	tested chemical	Lovastatin	75330-75-5	single chemical compound	stereochem	"(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (2S)-2-methylbutanoate"	C[C@@H](CC)C(=O)O[C@H]2C[C@@H](C)\C=C3\C=C/[C@H](C)[C@H](CC[C@@H]1C[C@@H](O)CC(=O)O1)[C@@H]23	C[C@@H](CC)C(=O)O[C@H]2C[C@@H](C)\C=C3\C=C/[C@H](C)[C@H](CC[C@@H]1C[C@@H](O)CC(=O)O1)[C@@H]23	"InChI=1/C24H36O5/c1-5-15(3)24(27)29-21-11-14(2)10-17-7-6-16(4)20(23(17)21)9-8-19-12-18(25)13-22(26)28-19/h6-7,10,14-16,18-21,23,25H,5,8-9,11-13H2,1-4H3/t14-,15-,16-,18+,19+,20-,21-,23-/m0/s1"	PCZOHLXUXFIOCF-BXMDZJJMBQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypercholesterolemic	1.33	0.003287688	2.4831094	39	Moderate	High	form of drug administered not known			
23229	3229	23229	689_FDAMDD_v3b	C18H18ClN3O	327.80802	defined organic	parent	tested chemical	Loxapine	1977-10-2	single chemical compound		"2-chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine"	C1=CC=C3C(=C1)N=C(N2CCN(C)CC2)C4=C(O3)C=CC(Cl)=C4	C1=CC=C3C(=C1)N=C(N2CCN(C)CC2)C4=C(O3)C=CC(Cl)=C4	"InChI=1/C18H18ClN3O/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18/h2-7,12H,8-11H2,1H3"	XJGVXQDUIWGIRW-UHFFFAOYAR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	4.17	0.01272086	1.89548352	32	Moderate	Moderate	form of drug administered not known			
23230	3230	23230	690_FDAMDD_v3b	C20H24N2OS	340.48236	defined organic	parent	tested chemical	Lucanthone	479-50-5	single chemical compound		1-{[2-(diethylamino)ethyl]amino}-4-methyl-9H-thioxanthen-9-one	C1=CC=C2C(=C1)C(=O)C3=C(S2)C(C)=CC=C3NCCN(CC)CC	C1=CC=C2C(=C1)C(=O)C3=C(S2)C(C)=CC=C3NCCN(CC)CC	"InChI=1/C20H24N2OS/c1-4-22(5-2)13-12-21-16-11-10-14(3)20-18(16)19(23)15-8-6-7-9-17(15)24-20/h6-11,21H,4-5,12-13H2,1-3H3"	FBQPGGIHOFZRGH-UHFFFAOYAP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihelmintic	33.3	0.097802424	1.009650383	22	Low	Low	form of drug administered not known			
23231	3231	23231	691_FDAMDD_v3b	C20H25N3O	323.432	defined organic	parent	tested chemical	Lysergide	50-37-3	single chemical compound	stereochem	"(8beta)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide"	CCN(CC)C(=O)[C@@H]2/C=C1/c3cccc4N\C=C(\C[C@H]1N(C)C2)c34	CCN(CC)C(=O)[C@@H]2/C=C1/c3cccc4N\C=C(\C[C@H]1N(C)C2)c34	"InChI=1/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18-/m1/s1"	VAYOSLLFUXYJDT-RDTXWAMCBY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic; seratonin receptor antagonist	0.0125	3.8648E-05	4.412872973	61	High	High	form of drug administered not known			
23232	3232	23232	692_FDAMDD_v3b	C6H14N2O2	146.18756	defined organic	parent	tested chemical	Lysine	56-87-1	single chemical compound	stereochem	L-lysine	N[C@@H](CCCCN)C(O)=O	N[C@@H](CCCCN)C(O)=O	"InChI=1/C6H14N2O2/c7-4-2-1-3-5(8)6(9)10/h5H,1-4,7-8H2,(H,9,10)/t5-/m0/s1/f/h9H"	KDXKERNSBIXSRK-RJFJIGAVDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		nutrient	100	0.684052733	0.164910417	13	Low	Low	form of drug administered not known			
23233	3233	23233	693_FDAMDD_v3b	C12H22O11	342.29648	defined organic	parent	tested chemical	Maltose	69-79-4	single chemical compound	stereochem	4-O-alpha-D-glucopyranosyl-beta-D-glucopyranose	[C@@H]1([C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O	[C@@H]1([C@@H]([C@H]([C@@H]([C@H](O1)CO)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O)O)O	"InChI=1/C12H22O11/c13-1-3-5(15)6(16)9(19)12(22-3)23-10-4(2-14)21-11(20)8(18)7(10)17/h3-20H,1-2H2/t3-,4-,5-,6+,7-,8-,9-,10-,11-,12-/m1/s1"	GUBGYTABKSRVRQ-QUYVBRFLBF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	100	0.292144401	0.534402433	17	Low	Low	form of drug administered not known			
23234	3234	23234	694_FDAMDD_v3b	C8H8O3	152.14732	defined organic	parent	tested chemical	Mandelic acid	90-64-2	single chemical compound		hydroxy(phenyl)acetic acid	C1=CC=CC(C(O)C(=O)O)=C1	C1=CC=CC(C(O)C(=O)O)=C1	"InChI=1/C8H8O3/c9-7(8(10)11)6-4-2-1-3-5-6/h1-5,7,9H,(H,10,11)/f/h10H"	IWYDHOAUDWTVEP-KZFATGLACD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		urinary antiseptic	66.7	0.438390896	0.358138473	15	Low	Low	form of drug administered not known			
23235	3235	23235	695_FDAMDD_v3b	C6H14O6	182.1718	defined organic	parent	tested chemical	"Mannitol, D-"	69-65-8	single chemical compound	stereochem	D-mannitol	O[C@@H]([C@H](O)[C@H](O)CO)[C@H](O)CO	O[C@@H]([C@H](O)[C@H](O)CO)[C@H](O)CO	"InChI=1/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1"	FBPFZTCFMRRESA-KVTDHHQDBH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic; diagnostic aid	999	5.48383449	-0.739084339	3	Low	Low	form of drug administered not known			
23236	798	20798	696_FDAMDD_v3b	C10H22Cl2N2O4	305.19868	defined organic	parent	tested chemical	Mannomustine	576-68-1	single chemical compound	stereochem	"1,6-bis[(2-chloroethyl)amino]-1,6-dideoxy-D-mannitol"	O[C@H]([C@H](O)CNCCCl)[C@H](O)[C@H](O)CNCCCl	O[C@H]([C@H](O)CNCCCl)[C@H](O)[C@H](O)CNCCCl	"InChI=1/C10H22Cl2N2O4/c11-1-3-13-5-7(15)9(17)10(18)8(16)6-14-4-2-12/h7-10,13-18H,1-6H2/t7-,8-,9-,10-/m1/s1"	MQXVYODZCMMZEM-ZYUZMQFOBO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	3.33	0.010910925	1.962138417	33	Moderate	Moderate	form of drug administered not known			
23237	3237	23237	697_FDAMDD_v3b	C16H13ClN2O	284.74022	defined organic	parent	tested chemical	Mazindol	22232-71-9	single chemical compound		"5-(4-chlorophenyl)-2,5-dihydro-3H-imidazo[2,1-a]isoindol-5-ol"	C1=CC=C3C(=C1)C4N(C3(O)C2=CC=C(Cl)C=C2)CCN=4	C1=CC=C3C(=C1)C4N(C3(O)C2=CC=C(Cl)C=C2)CCN=4	"InChI=1/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2"	ZPXSCAKFGYXMGA-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anorexic	0.0333	0.000116949	3.932004583	55	High	High	form of drug administered not known			
23238	3238	23238	698_FDAMDD_v3b	C25H35NO5	429.5491	defined organic	parent	tested chemical	Mebeverine	3625-06-7	single chemical compound		"4-(ethyl{1-methyl-2-[4-(methyloxy)phenyl]ethyl}amino)butyl 3,4-bis(methyloxy)benzoate"	C2=C(OC)C=CC(CC(C)N(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)CC)=C2	C2=C(OC)C=CC(CC(C)N(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)CC)=C2	"InChI=1/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3"	VYVKHNNGDFVQGA-UHFFFAOYAR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antispasmodic	6.75	0.015714152	1.803709041	31	Moderate	Low	form of drug administered not known			
23239	3239	23239	699_FDAMDD_v3b	C10H20N2O4	232.2768	defined organic	parent	tested chemical	Mebutamate	64-55-1	single chemical compound		"2-[(carbamoyloxy)methyl]-2,3-dimethylpentyl carbamate"	NC(=O)OCC(C)(C(C)CC)COC(N)=O	NC(=O)OCC(C)(C(C)CC)COC(N)=O	"InChI=1/C10H20N2O4/c1-4-7(2)10(3,5-15-8(11)13)6-16-9(12)14/h7H,4-6H2,1-3H3,(H2,11,13)(H2,12,14)/f/h11-12H2"	LEROTMJVBFSIMP-LLDOCCBOCX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	20	0.086104165	1.064975839	23	Low	Low	form of drug administered not known			
23240	3240	23240	700_FDAMDD_v3b	C11H21N	167.29114	defined organic	parent	tested chemical	Mecamylamine	60-40-2	single chemical compound		"N,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine"	C1CC2C(C)(C)C(C)(NC)C1C2	C1CC2C(C)(C)C(C)(NC)C1C2	"InChI=1/C11H21N/c1-10(2)8-5-6-9(7-8)11(10,3)12-4/h8-9,12H,5-7H2,1-4H3"	IMYZQPCYWPFTAG-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.417	0.00249266	2.603336886	40	Moderate	High	form of drug administered not known			
23241	975	20975	701_FDAMDD_v3b	C5H11Cl2N	156.0546	defined organic	parent	tested chemical	Mechlorethamine	51-75-2	single chemical compound		2-chloro-N-(2-chloroethyl)-N-methylethanamine	ClCCN(C)CCCl	ClCCN(C)CCCl	"InChI=1/C5H11Cl2N/c1-8(4-2-6)5-3-7/h2-5H2,1H3"	HAWPXGHAZFHHAD-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.4	0.002563205	2.591216584	40	Moderate	High	form of drug administered not known			
23242	3242	23242	702_FDAMDD_v3b	C25H27ClN2	390.94828	defined organic	parent	tested chemical	Meclizine	569-65-3	single chemical compound		1-[(4-chlorophenyl)(phenyl)methyl]-4-[(3-methylphenyl)methyl]piperazine	C4=C(Cl)C=CC(C(C1=CC=CC=C1)N3CCN(CC2=CC=CC(C)=C2)CC3)=C4	C4=C(Cl)C=CC(C(C1=CC=CC=C1)N3CCN(CC2=CC=CC(C)=C2)CC3)=C4	"InChI=1/C25H27ClN2/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23/h2-13,18,25H,14-17,19H2,1H3"	OCJYIGYOJCODJL-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiemetic	1.67	0.004271665	2.369402836	38	Moderate	High	form of drug administered not known			
23243	3243	23243	703_FDAMDD_v3b	C15H15NO2	241.2851	defined organic	parent	tested chemical	Mefenamic acid	61-68-7	single chemical compound		"2-[(2,3-dimethylphenyl)amino]benzoic acid"	C2=CC=CC(NC1=CC=CC(C)=C1C)=C2C(=O)O	C2=CC=CC(NC1=CC=CC(C)=C1C)=C2C(=O)O	"InChI=1/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)/f/h17H"	HYYBABOKPJLUIN-HCKMINDGCV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	20.8	0.086205074	1.064467169	23	Low	Low	form of drug administered not known			
23244	3244	23244	704_FDAMDD_v3b	C7H17NO5	195.21358	defined organic	parent	tested chemical	Meglumine	6284-40-8	single chemical compound	stereochem	1-deoxy-1-(methylamino)-D-glucitol	[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)(CNC)O	[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)(CNC)O	"InChI=1/C7H17NO5/c1-8-2-4(10)6(12)7(13)5(11)3-9/h4-13H,2-3H2,1H3/t4-,5+,6+,7+/m0/s1"	MBBZMMPHUWSWHV-BDVNFPICBL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	100	0.512259444	0.290510026	14	Low	Low	form of drug administered not known			
23245	2421	22421	705_FDAMDD_v3b	C13H16N2O2	232.2783	defined organic	parent	tested chemical	Melatonin	73-31-4	single chemical compound		N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide	O=C(C)NCCC1=CNC2=C1C=C(OC)C=C2	O=C(C)NCCC1=CNC2=C1C=C(OC)C=C2	"InChI=1/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)/f/h14H"	DRLFMBDRBRZALE-YHMJCDSICX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antioxidant	0.0833	0.000358622	3.445363637	50	High	High	form of drug administered not known			
23246	804	20804	706_FDAMDD_v3b	C13H18Cl2N2O2	305.2002	defined organic	parent	tested chemical	Melphalan	148-82-3	single chemical compound	l form shown; stereochem	4-[bis(2-chloroethyl)amino]-L-phenylalanine	OC([C@H](CC1=CC=C(N(CCCl)CCCl)C=C1)N)=O	OC([C@H](CC1=CC=C(N(CCCl)CCCl)C=C1)N)=O	"InChI=1/C13H18Cl2N2O2/c14-5-7-17(8-6-15)11-3-1-10(2-4-11)9-12(16)13(18)19/h1-4,12H,5-9,16H2,(H,18,19)/t12-/m0/s1/f/h18H"	SGDBTWWWUNNDEQ-MUSVCJDDDI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.1	0.000327654	3.484584814	50	High	High	form of drug administered not known			
23247	3247	23247	707_FDAMDD_v3b	C11H10O2	174.1959	defined organic	parent	tested chemical	Menadiol	481-85-6	single chemical compound		"2-methylnaphthalene-1,4-diol"	OC1=C(C)C=C(O)C2=CC=CC=C12	OC1=C(C)C=C(O)C2=CC=CC=C12	"InChI=1/C11H10O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6,12-13H,1H3"	ZJTLZYDQJHKRMQ-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		prothrombogenic vitamin	0.167	0.000958691	3.018321458	45	High-Moderate	High	form of drug administered not known			
23248	1715	21715	708_FDAMDD_v3b	C11H8O2	172.183	defined organic	parent	tested chemical	Menadione	58-27-5	single chemical compound		"2-methylnaphthalene-1,4-dione"	C1=CC=C2C(=C1)C(=O)C(C)=CC2=O	C1=CC=C2C(=C1)C(=O)C(C)=CC2=O	"InChI=1/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H3"	MJVAVZPDRWSRRC-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		prothrombogenic vitamin	0.0333	0.000193399	3.713546037	53	High	High	form of drug administered not known			
23249	3249	23249	709_FDAMDD_v3b	C12H6Cl2N2O6	345.09184	defined organic	parent	tested chemical	Menichlopholan	10331-57-4	single chemical compound		"5,5'-dichloro-3,3'-dinitrobiphenyl-2,2'-diol"	Clc1cc(c(O)c(c1)c2cc(Cl)cc(c2O)[N+]([O-])=O)[N+]([O-])=O	Clc1cc(c(O)c(c1)c2cc(Cl)cc(c2O)[N+]([O-])=O)[N+]([O-])=O	"InChI=1/C12H6Cl2N2O6/c13-5-1-7(11(17)9(3-5)15(19)20)8-2-6(14)4-10(12(8)18)16(21)22/h1-4,17-18H"	XULACPAEUUWKFX-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	2	0.005795559	2.236904694	36	Moderate	High	form of drug administered not known			
23250	805	20805	710_FDAMDD_v3b	C10H20O	156.2674	defined organic	parent	tested chemical	"Menthol, DL-"	89-78-1	single chemical compound	retired CASRN [15356-70-4]; absolute stereoconfiguration not known only relative configuration of stereo centers; structure shown without stereochem	5-methyl-2-(1-methylethyl)cyclohexanol	OC(CC(C1)C)C(C1)C(C)C	OC(CC(C1)C)C(C1)C(C)C	"InChI=1/C10H20O/c1-7(2)9-5-4-8(3)6-10(9)11/h7-11H,4-6H2,1-3H3"	NOOLISFMXDJSKH-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		topical antipruritic	2	0.012798575	1.892838391	32	Moderate	High	form of drug administered not known			
23251	1756	21756	711_FDAMDD_v3b	C6H10O	98.1444	defined organic	parent	tested chemical	Meparfynol	77-75-8	single chemical compound		3-methylpent-1-yn-3-ol	C#CC(O)(C)CC	C#CC(O)(C)CC	"InChI=1/C6H10O/c1-4-6(3,7)5-2/h1,7H,5H2,2-3H3"	QXLPXWSKPNOQLE-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		hypnotic; sedative	16.7	0.170157441	0.769149053	20	Low	Low	form of drug administered not known			
23252	3252	23252	712_FDAMDD_v3b	C21H26BrNO3	420.34004	defined organic	salt Br	tested chemical	Mepenzolate	76-90-4	single chemical compound	ammonium; parent [25990-43-6]	"3-{[hydroxy(diphenyl)acetyl]oxy}-1,1-dimethylpiperidinium bromide"	C3=CC=C(C(O)(C(=O)OC1C[N+](C)(C)CCC1)C2=CC=CC=C2)C=C3.[Br-]	C3=CC=C(C(O)(C(=O)OC1C[N+](C)(C)CCC1)C2=CC=CC=C2)C=C3	"InChI=1/C21H26NO3.BrH/c1-22(2)15-9-14-19(16-22)25-20(23)21(24,17-10-5-3-6-11-17)18-12-7-4-8-13-18;/h3-8,10-13,19,24H,9,14-16H2,1-2H3;1H/q+1;/p-1/fC21H26NO3.Br/h;1h/qm;-1"	JRRNZNSGDSFFIR-SZBLCOMZCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	3.33	0.007922157	2.101156528	35	Moderate	Moderate	form of drug administered not known			
23253	3253	23253	713_FDAMDD_v3b	C15H21NO2	247.33274	defined organic	parent	tested chemical	Meperidine	57-42-1	single chemical compound		ethyl 1-methyl-4-phenylpiperidine-4-carboxylate	C2CC(C(=O)OCC)(C1=CC=CC=C1)CCN2C	C2CC(C(=O)OCC)(C1=CC=CC=C1)CCN2C	"InChI=1/C15H21NO2/c1-3-18-14(17)15(9-11-16(2)12-10-15)13-7-5-4-6-8-13/h4-8H,3,9-12H2,1-2H3"	XADCESSVHJOZHK-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	15	0.060647046	1.21719035	25	Low-Moderate	Low	form of drug administered not known			
23254	3254	23254	714_FDAMDD_v3b	C10H14O3	182.21636	defined organic	parent	tested chemical	Mephenesin	59-47-2	single chemical compound		"3-[(2-methylphenyl)oxy]propane-1,2-diol"	C1=CC=C(C)C(OCC(O)CO)=C1	C1=CC=C(C)C(OCC(O)CO)=C1	"InChI=1/C10H14O3/c1-8-4-2-3-5-10(8)13-7-9(12)6-11/h2-5,9,11-12H,6-7H2,1H3"	JWDYCNIAQWPBHD-UHFFFAOYAQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	50	0.274399072	0.561617362	17	Low	Low	form of drug administered not known			
23255	3255	23255	715_FDAMDD_v3b	C11H13NO4	223.22522	defined organic	parent	tested chemical	Mephenoxalone	70-07-5	single chemical compound		"5-({[2-(methyloxy)phenyl]oxy}methyl)-1,3-oxazolidin-2-one"	C2=CC=C(OCC1OC(=O)NC1)C(OC)=C2	C2=CC=C(OCC1OC(=O)NC1)C(OC)=C2	"InChI=1/C11H13NO4/c1-14-9-4-2-3-5-10(9)15-7-8-6-12-11(13)16-8/h2-5,8H,6-7H2,1H3,(H,12,13)/f/h12H"	ZMNSRFNUONFLSP-XWKXFZRBCS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic; skeletal muscle relaxant	20	0.089595611	1.047713264	23	Low	Low	form of drug administered not known			
23256	3256	23256	716_FDAMDD_v3b	C11H17N	163.25938	defined organic	parent	tested chemical	Mephentermine	100-92-5	single chemical compound		"N,2-dimethyl-1-phenylpropan-2-amine"	C1=CC=CC(CC(C)(C)NC)=C1	C1=CC=CC(CC(C)(C)NC)=C1	"InChI=1/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3"	RXQCGGRTAILOIN-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		adrenergic	1	0.006125222	2.212878143	36	Moderate	High	form of drug administered not known			
23257	3257	23257	717_FDAMDD_v3b	C12H14N2O2	218.25176	defined organic	parent	tested chemical	Mephenytoin	50-12-4	single chemical compound		"5-ethyl-3-methyl-5-phenylimidazolidine-2,4-dione"	C2=CC=CC(C1(CC)NC(=O)N(C)C1=O)=C2	C2=CC=CC(C1(CC)NC(=O)N(C)C1=O)=C2	"InChI=1/C12H14N2O2/c1-3-12(9-7-5-4-6-8-9)10(15)14(2)11(16)13-12/h4-8H,3H2,1-2H3,(H,13,16)/f/h13H"	GMHKMTDVRCWUDX-NDKGDYFDCX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	10	0.045818645	1.338957755	26	Low-Moderate	Low	form of drug administered not known			
23258	3258	23258	718_FDAMDD_v3b	C13H14N2O3	246.26186	defined organic	parent	tested chemical	Mephobarbital	115-38-8	single chemical compound		"5-ethyl-1-methyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione"	C2(=O)C(C1=CC=CC=C1)(CC)C(=O)NC(=O)N2C	C2(=O)C(C1=CC=CC=C1)(CC)C(=O)NC(=O)N2C	"InChI=1/C13H14N2O3/c1-3-13(9-7-5-4-6-8-9)10(16)14-12(18)15(2)11(13)17/h4-8H,3H2,1-2H3,(H,14,16,18)/f/h14H"	ALARQZQTBTVLJV-YHMJCDSICC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant; sedative; hypnotic	10	0.040607181	1.391397155	27	Low-Moderate	Low	form of drug administered not known			
23259	3259	23259	719_FDAMDD_v3b	C15H22N2O	246.34798	defined organic	parent	tested chemical	Mepivacaine	96-88-8	single chemical compound		"N-(2,6-dimethylphenyl)-1-methylpiperidine-2-carboxamide"	C2CCCC(C(=O)NC1=C(C)C=CC=C1C)N2C	C2CCCC(C(=O)NC1=C(C)C=CC=C1C)N2C	"InChI=1/C15H22N2O/c1-11-7-6-8-12(2)14(11)16-15(18)13-9-4-5-10-17(13)3/h6-8,13H,4-5,9-10H2,1-3H3,(H,16,18)/f/h16H"	INWLQCZOYSRPNW-WYUMXYHSCD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		local anesthetic	6.67	0.027075521	1.567423172	29	Low-Moderate	Low	form of drug administered not known			
23260	3260	23260	720_FDAMDD_v3b	C22H28O5	372.45472	defined organic	parent	tested chemical	Meprednisone	1247-42-3	single chemical compound	stereochem; tautomers	"(16beta)-17,21-dihydroxy-16-methylpregna-1,4-diene-3,11,20-trione"	[C@@]42([C@H]([C@@H]1CCC=3[C@@]([C@H]1C(C2)=O)(\C=C/C(C=3)=O)C)C[C@@H]([C@@]4(C(=O)CO)O)C)C	[C@@]42([C@H]([C@@H]1CCC=3[C@@]([C@H]1C(C2)=O)(\C=C/C(C=3)=O)C)C[C@@H]([C@@]4(C(=O)CO)O)C)C	"InChI=1/C22H28O5/c1-12-8-16-15-5-4-13-9-14(24)6-7-20(13,2)19(15)17(25)10-21(16,3)22(12,27)18(26)11-23/h6-7,9,12,15-16,19,23,27H,4-5,8,10-11H2,1-3H3/t12-,15-,16-,19+,20-,21-,22-/m0/s1"	PIDANAQULIKBQS-RNUIGHNZBC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		glucocorticoid	0.8	0.002147912	2.667983495	41	Moderate	High	form of drug administered not known			
23261	3261	23261	721_FDAMDD_v3b	C9H18N2O4	218.2502	defined organic	parent	tested chemical	Meprobamate	57-53-4	single chemical compound		2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate	NC(=O)OCC(C)(CCC)COC(N)=O	NC(=O)OCC(C)(CCC)COC(N)=O	"InChI=1/C9H18N2O4/c1-3-4-9(2,5-14-7(10)12)6-15-8(11)13/h3-6H2,1-2H3,(H2,10,12)(H2,11,13)/f/h10-11H2"	NPPQSCRMBWNHMW-OUBFLUSYCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	40	0.183275892	0.736894659	19	Low	Low	form of drug administered not known			
23262	3262	23262	722_FDAMDD_v3b	C20H22N2S	322.46708	defined organic	parent	tested chemical	Mequitazine	29216-28-2	single chemical compound		10-(1-azabicyclo[2.2.2]oct-3-ylmethyl)-10H-phenothiazine	C1=CC=C4C(=C1)N(CC2CN3CCC2CC3)C5=C(S4)C=CC=C5	C1=CC=C4C(=C1)N(CC2CN3CCC2CC3)C5=C(S4)C=CC=C5	"InChI=1/C20H22N2S/c1-3-7-19-17(5-1)22(18-6-2-4-8-20(18)23-19)14-16-13-21-11-9-15(16)10-12-21/h1-8,15-16H,9-14H2"	HOKDBMAJZXIPGC-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	0.167	0.000517882	3.285768914	48	High-Moderate	High	form of drug administered not known			
23263	810	20810	723_FDAMDD_v3b	C5H4N4S	152.1771	defined organic	parent	tested chemical	"Mercaptopurine, 6-"	50-44-2	single chemical compound	tautomers	"1,9-dihydro-6H-purine-6-thione"	S=C1NC=NC2=C1N=CN2	S=C1NC=NC2=C1N=CN2	"InChI=1/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10)/f/h7,9H"	GLVAUDGFNGKCSF-AUDIXQRPCF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	2.5	0.016428227	1.784409295	31	Moderate	High-Moderate	form of drug administered not known			
23264	3264	23264	724_FDAMDD_v3b	C2H6O3S2	142.19724	defined organic	parent	tested chemical	Mesna	3375-50-6	single chemical compound		2-mercaptoethanesulfonic acid	SCCS(=O)(=O)O	SCCS(=O)(=O)O	"InChI=1/C2H6O3S2/c3-7(4,5)2-1-6/h6H,1-2H2,(H,3,4,5)/f/h3H"	ZNEWHQLOPFWXOF-TULZNQERCW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		mucolytic; uroprotective	4	0.028129941	1.550831176	29	Low-Moderate	Moderate	form of drug administered not known			
23265	3265	23265	725_FDAMDD_v3b	C21H26N2OS2	386.57394	defined organic	parent	tested chemical	Mesoridazine	5588-33-0	single chemical compound		10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfinyl)-10H-phenothiazine	C1=CC=C3C(=C1)N(CCC2CCCCN2C)C4=C(S3)C=CC(S(=O)C)=C4	C1=CC=C3C(=C1)N(CCC2CCCCN2C)C4=C(S3)C=CC(S(=O)C)=C4	"InChI=1/C21H26N2OS2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(26(2)24)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3"	SLVMESMUVMCQIY-UHFFFAOYAC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	5	0.012934136	1.888262569	32	Moderate	Low	form of drug administered not known			
23266	814	20814	726_FDAMDD_v3b	C21H26O2	310.4352	defined organic	parent	tested chemical	Mestranol	72-33-3	single chemical compound	stereochem	"(17beta)-17-ethynyl-3-(methyloxy)estra-1,3,5(10)-trien-17-ol"	COc3cc4CC[C@@H]1[C@H](CC[C@]2(C)[C@@](O)(CC[C@@H]12)C#C)c4cc3	COc3cc4CC[C@@H]1[C@H](CC[C@]2(C)[C@@](O)(CC[C@@H]12)C#C)c4cc3	"InChI=1/C21H26O2/c1-4-21(22)12-10-19-18-7-5-14-13-15(23-3)6-8-16(14)17(18)9-11-20(19,21)2/h1,6,8,13,17-19,22H,5,7,9-12H2,2-3H3/t17-,18-,19+,20+,21+/m1/s1"	IMSSROKUHAOUJS-MJCUULBUBS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		estrogen	0.00083	2.67367E-06	5.572892867	74	High	High	form of drug administered not known			
23267	3267	23267	727_FDAMDD_v3b	C14H21N3O3S	311.39984	defined organic	parent	tested chemical	Metahexamide	565-33-3	single chemical compound		3-amino-N-[(cyclohexylamino)carbonyl]-4-methylbenzenesulfonamide	C2(N)=C(C)C=CC(S(=O)(=O)NC(=O)NC1CCCCC1)=C2	C2(N)=C(C)C=CC(S(=O)(=O)NC(=O)NC1CCCCC1)=C2	"InChI=1/C14H21N3O3S/c1-10-7-8-12(9-13(10)15)21(19,20)17-14(18)16-11-5-3-2-4-6-11/h7-9,11H,2-6,15H2,1H3,(H2,16,17,18)/f/h16-17H"	XXYTXQGCRQLRHA-XQMQJMAZCQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	3.33	0.010693647	1.970874152	33	Moderate	Moderate	form of drug administered not known			
23268	3268	23268	728_FDAMDD_v3b	C9H13NO2	167.20502	defined organic	parent	tested chemical	Metaraminol	54-49-9	single chemical compound	stereochem	"3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol"	c1(cc(ccc1)O)[C@H]([C@H](C)N)O	c1(cc(ccc1)O)[C@H]([C@H](C)N)O	"InChI=1/C9H13NO2/c1-6(10)9(12)7-3-2-4-8(11)5-7/h2-6,9,11-12H,10H2,1H3/t6-,9-/m0/s1"	WXFIGDLSSYIKKV-RCOVLWMOBW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		adrenergic	8.33	0.049819078	1.302604311	26	Low-Moderate	Low	form of drug administered not known			
23269	3269	23269	729_FDAMDD_v3b	C12H15NO3	221.2524	defined organic	parent	tested chemical	Metaxalone	1665-48-1	single chemical compound		"5-{[(3,5-dimethylphenyl)oxy]methyl}-1,3-oxazolidin-2-one"	C2(C)=CC(C)=CC(OCC1OC(=O)NC1)=C2	C2(C)=CC(C)=CC(OCC1OC(=O)NC1)=C2	"InChI=1/C12H15NO3/c1-8-3-9(2)5-10(4-8)15-7-11-6-13-12(14)16-11/h3-5,11H,6-7H2,1-2H3,(H,13,14)/f/h13H"	IMWZZHHPURKASS-NDKGDYFDCE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	107	0.483610573	0.315504213	15	Low	Low	form of drug administered not known			
23270	3270	23270	730_FDAMDD_v3b	C4H11N5	129.16364	defined organic	parent	tested chemical	Metformin	657-24-9	single chemical compound		"N,N-dimethylimidodicarbonimidic diamide"	CN(C)C(=N)NC(N)=N	CN(C)C(=N)NC(N)=N	"InChI=1/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)/f/h5,7-8H,6H2"	XZWYZXLIPXDOLR-WXQAPKLBCT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	50	0.387105845	0.412170271	16	Low	Low	form of drug administered not known			
23271	3271	23271	731_FDAMDD_v3b	C8H18ClNO2	195.68702	defined organic	salt Cl	tested chemical	Methacholine	62-51-1	single chemical compound	ammonium; parent [55-92-5]	"2-(acetyloxy)-N,N,N-trimethylpropan-1-aminium chloride"	CC(=O)OC(C)C[N+](C)(C)C.[Cl-]	CC(=O)OC(C)C[N+](C)(C)C	"InChI=1/C8H18NO2.ClH/c1-7(11-8(2)10)6-9(3,4)5;/h7H,6H2,1-5H3;1H/q+1;/p-1/fC8H18NO2.Cl/h;1h/qm;-1"	JHPHVAVFUYTVCL-GMXYKTMFCS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cholinergic; diagnostic aid	0.417	0.002130954	2.671425965	41	Moderate	High	form of drug administered not known			
23272	3272	23272	732_FDAMDD_v3b	C22H22N2O8	442.41868	defined organic	parent	tested chemical	Methacycline	914-00-1	single chemical compound	stereochem; tautomers	"(4S,4aR,5S,5aR,12aS)-4-(dimethylamino)-3,5,10,12,12a-pentahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide"	[C@]\21([C@H]([C@@H](C(=C(/C1=O)C(=O)N)\O)N(C)C)[C@H]([C@H]3/C(=C/2O)C(c4c(C3=C)cccc4O)=O)O)O	[C@]\21([C@H]([C@@H](C(=C(/C1=O)C(=O)N)\O)N(C)C)[C@H]([C@H]3/C(=C/2O)C(c4c(C3=C)cccc4O)=O)O)O	"InChI=1/C22H22N2O8/c1-7-8-5-4-6-9(25)11(8)16(26)12-10(7)17(27)14-15(24(2)3)18(28)13(21(23)31)20(30)22(14,32)19(12)29/h4-6,10,14-15,17,25,27-29,32H,1H2,2-3H3,(H2,23,31)/t10-,14-,15+,17+,22+/m1/s1/f/h23H2"	MHIGBKBJSQVXNH-JLTGGIJNDH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	15	0.033904536	1.469742197	28	Low-Moderate	Low	form of drug administered not known			
23273	3273	23273	733_FDAMDD_v3b	C21H27NO	309.44518	defined organic	parent	tested chemical	Methadone	76-99-3	single chemical compound		"6-(dimethylamino)-4,4-diphenylheptan-3-one"	C(=O)(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)CC	C(=O)(C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2)CC	"InChI=1/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3"	USSIQXCVUWKGNF-UHFFFAOYAH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	0.5	0.001615795	2.791613718	42	Moderate	High	form of drug administered not known			
23274	3274	23274	734_FDAMDD_v3b	C23H31NO2	353.49774	defined organic	parent	tested chemical	Methadyl acetate	509-74-0	single chemical compound		"4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate"	C2=CC=CC(C(CC(C)N(C)C)(C(CC)OC(=O)C)C1=CC=CC=C1)=C2	C2=CC=CC(C(CC(C)N(C)C)(C(CC)OC(=O)C)C1=CC=CC=C1)=C2	"InChI=1/C23H31NO2/c1-6-22(26-19(3)25)23(17-18(2)24(4)5,20-13-9-7-10-14-20)21-15-11-8-12-16-21/h7-16,18,22H,6,17H2,1-5H3"	XBMIVRRWGCYBTQ-UHFFFAOYAM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	2.33	0.006591273	2.181030721	36	Moderate	High	form of drug administered not known			
23275	3275	23275	735_FDAMDD_v3b	C18H22O3	286.36548	defined organic	parent	tested chemical	Methallenestril	517-18-0	single chemical compound		"2,2-dimethyl-3-[6-(methyloxy)naphthalen-2-yl]pentanoic acid"	C1=C(OC)C=C2C(=C1)C=C(C(C(C)(C)C(O)=O)CC)C=C2	C1=C(OC)C=C2C(=C1)C=C(C(C(C)(C)C(O)=O)CC)C=C2	"InChI=1/C18H22O3/c1-5-16(18(2,3)17(19)20)14-7-6-13-11-15(21-4)9-8-12(13)10-14/h6-11,16H,5H2,1-4H3,(H,19,20)/f/h19H"	KHLJKRBMZVNZOC-LILDFLRNCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		estrogen	0.15	0.000523806	3.280829406	48	High-Moderate	High	form of drug administered not known			
23276	3276	23276	736_FDAMDD_v3b	C20H28O2	300.43512	defined organic	parent	tested chemical	Methandrostenolone	72-63-9	single chemical compound	stereochem	"(17beta)-17-hydroxy-17-methylandrosta-1,4-dien-3-one"	[C@@]2\1(\C(=C/C(/C=C/1)=O)CC[C@@H]4[C@@H]2CC[C@@]3([C@](O)(C)CC[C@H]34)C)C	[C@@]2\1(\C(=C/C(/C=C/1)=O)CC[C@@H]4[C@@H]2CC[C@@]3([C@](O)(C)CC[C@H]34)C)C	"InChI=1/C20H28O2/c1-18-9-6-14(21)12-13(18)4-5-15-16(18)7-10-19(2)17(15)8-11-20(19,3)22/h6,9,12,15-17,22H,4-5,7-8,10-11H2,1-3H3/t15-,16+,17+,18+,19+,20+/m1/s1"	XWALNWXLMVGSFR-HLXURNFRBZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		androgen	0.0667	0.000222011	3.653624865	52	High	High	form of drug administered not known			
23277	3277	23277	737_FDAMDD_v3b	C21H26BrNO3	420.34004	defined organic	salt Br	tested chemical	Methantheline bromide	53-46-3	single chemical compound	ammonium	"N,N-diethyl-N-methyl-2-[(9H-xanthen-9-ylcarbonyl)oxy]ethanaminium bromide"	C1=CC=C2C(=C1)C(C(=O)OCC[N+](C)(CC)CC)C3=C(O2)C=CC=C3.[Br-]	C1=CC=C2C(=C1)C(C(=O)OCC[N+](C)(CC)CC)C3=C(O2)C=CC=C3	"InChI=1/C21H26NO3.BrH/c1-4-22(3,5-2)14-15-24-21(23)20-16-10-6-8-12-18(16)25-19-13-9-7-11-17(19)20;/h6-13,20H,4-5,14-15H2,1-3H3;1H/q+1;/p-1/fC21H26NO3.Br/h;1h/qm;-1"	PQMWYJDJHJQZDE-SZBLCOMZCH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	6.67	0.015868105	1.799474927	31	Moderate	Low	form of drug administered not known			
23278	3278	23278	738_FDAMDD_v3b	C14H19N3S	261.3858	defined organic	parent	tested chemical	Methapyrilene	91-80-5	single chemical compound		"N,N-dimethyl-N'-pyridin-2-yl-N'-(2-thienylmethyl)ethane-1,2-diamine"	C2C=CSC=2CN(CCN(C)C)C1=CC=CC=N1	C2C=CSC=2CN(CCN(C)C)C1=CC=CC=N1	"InChI=1/C14H19N3S/c1-16(2)9-10-17(12-13-6-5-11-18-13)14-7-3-4-8-15-14/h3-8,11H,9-10,12H2,1-2H3"	HNJJXZKZRAWDPF-UHFFFAOYAC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	6.67	0.025517836	1.593156157	29	Low-Moderate	Low	form of drug administered not known			
23279	3279	23279	739_FDAMDD_v3b	C16H14N2O	250.29516	defined organic	parent	tested chemical	Methaqualone	72-44-6	single chemical compound		2-methyl-3-(2-methylphenyl)quinazolin-4(3H)-one	C1=CC=C3C(=C1)N=C(C)N(C2=C(C)C=CC=C2)C3=O	C1=CC=C3C(=C1)N=C(C)N(C2=C(C)C=CC=C2)C3=O	"InChI=1/C16H14N2O/c1-11-7-3-6-10-15(11)18-12(2)17-14-9-5-4-8-13(14)16(18)19/h3-10H,1-2H3"	JEYCTXHKTXCGPB-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		hypnotic; sedative	5	0.019976415	1.699482447	30	Moderate	Low	form of drug administered not known			
23280	3280	23280	740_FDAMDD_v3b	C9H14N2O3	198.21906	defined organic	parent	tested chemical	Metharbital	50-11-3	single chemical compound		"5,5-diethyl-1-methylpyrimidine-2,4,6(1H,3H,5H)-trione"	C1(=O)C(CC)(CC)C(=O)NC(=O)N1C	C1(=O)C(CC)(CC)C(=O)NC(=O)N1C	"InChI=1/C9H14N2O3/c1-4-9(5-2)6(12)10-8(14)11(3)7(9)13/h4-5H2,1-3H3,(H,10,12,14)/f/h10H"	FWJKNZONDWOGMI-KZFATGLACX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	5	0.025224618	1.598175408	29	Low-Moderate	Low	form of drug administered not known			
23281	3281	23281	741_FDAMDD_v3b	C5H8N4O3S2	236.27202	defined organic	parent	tested chemical	Methazolamide	554-57-4	single chemical compound	stereochem	"N-[(2E)-5-(aminosulfonyl)-3-methyl-1,3,4-thiadiazol-2(3H)-ylidene]acetamide"	N1N(C)C(=NC(=O)C)SC=1S(=O)(=O)N	N1N(C)C(=NC(=O)C)SC=1S(=O)(=O)N	"InChI=1/C5H8N4O3S2/c1-3(10)7-4-9(2)8-5(13-4)14(6,11)12/h1-2H3,(H2,6,11,12)/b7-4+/f/h6H2"	FLOSMHQXBMRNHR-RHAUKQJADE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic	5	0.021162049	1.67444229	30	Moderate	Low	form of drug administered not known			
23282	3282	23282	742_FDAMDD_v3b	C18H20N2S	296.4298	defined organic	parent	tested chemical	Methdilazine	1982-37-2	single chemical compound		10-[(1-methylpyrrolidin-3-yl)methyl]-10H-phenothiazine	C1=CC=C3C(=C1)N(CC2CCN(C)C2)C4=C(S3)C=CC=C4	C1=CC=C3C(=C1)N(CC2CCN(C)C2)C4=C(S3)C=CC=C4	"InChI=1/C18H20N2S/c1-19-11-10-14(12-19)13-20-15-6-2-4-8-17(15)21-18-9-5-3-7-16(18)20/h2-9,14H,10-13H2,1H3"	HTMIBDQKFHUPSX-UHFFFAOYAR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipruritic	0.5	0.00168674	2.772951857	42	Moderate	High	form of drug administered not known			
23283	3283	23283	743_FDAMDD_v3b	C20H25N3O2	339.4314	defined organic	parent	tested chemical	Methergine	113-42-8	single chemical compound	stereochem	"(8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-6-methyl-9,10-didehydroergoline-8-carboxamide"	OC[C@H](CC)NC(=O)[C@@H]2/C=C1/c3cccc4N\C=C(\C[C@H]1N(C)C2)c34	OC[C@H](CC)NC(=O)[C@@H]2/C=C1/c3cccc4N\C=C(\C[C@H]1N(C)C2)c34	"InChI=1/C20H25N3O2/c1-3-14(11-24)22-20(25)13-7-16-15-5-4-6-17-19(15)12(9-21-17)8-18(16)23(2)10-13/h4-7,9,13-14,18,21,24H,3,8,10-11H2,1-2H3,(H,22,25)/t13-,14+,18-/m1/s1/f/h22H"	UNBRKDKAWYKMIV-OVMROKANDC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		oxytocic	0.0133	3.91832E-05	4.406900374	60	High	High	form of drug administered not known			
23284	3284	23284	744_FDAMDD_v3b	C17H20N2O6S	380.4155	defined organic	parent	tested chemical	Methicillin	61-32-5	single chemical compound	stereochem	"(2S,5R,6R)-6-{[(2,6-dimethoxyphenyl)carbonyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	O=C2N1[C@]([C@@]([H])2NC(C(C(OC)=CC=C3)=C3OC)=O)([H])SC(C)(C)[C@@H]1[C@@](O)=O	O=C2N1[C@]([C@@]([H])2NC(C(C(OC)=CC=C3)=C3OC)=O)([H])SC(C)(C)[C@@H]1[C@@](O)=O	"InChI=1/C17H20N2O6S/c1-17(2)12(16(22)23)19-14(21)11(15(19)26-17)18-13(20)10-8(24-3)6-5-7-9(10)25-4/h5-7,11-12,15H,1-4H3,(H,18,20)(H,22,23)/t11-,12+,15-/m1/s1/f/h18,22H"	RJQXTJLFIWVMTO-GIVDZMQGDW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	200	0.525740933	0.279228208	14	Low	Low	form of drug administered not known; structure modified v3b			
23285	820	20820	745_FDAMDD_v3b	C4H6N2S	114.1648	defined organic	parent	tested chemical	Methimazole	60-56-0	single chemical compound	tautomers	"1-methyl-1,3-dihydro-2H-imidazole-2-thione"	N/1C(N(\C=C\1)C)=S	N\1C(N(/C=C/1)C)=S	"InChI=1/C4H6N2S/c1-6-3-2-5-4(6)7/h2-3H,1H3,(H,5,7)/f/h5H"	PMRYVIKBURPHAH-JSWHHWTPCU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihyperthyroid	1	0.008759267	2.05753222	34	Moderate	High	form of drug administered not known			
23286	3286	23286	746_FDAMDD_v3b	C11H15NO5	241.2405	defined organic	parent	tested chemical	Methocarbamol	532-03-6	single chemical compound		2-hydroxy-3-{[2-(methyloxy)phenyl]oxy}propyl carbamate	C1(OC)=CC=CC=C1OCC(O)COC(N)=O	C1(OC)=CC=CC=C1OCC(O)COC(N)=O	"InChI=1/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14)/f/h12H2"	GNXFOGHNGIVQEH-GAJRPKRDCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	100	0.414524095	0.38245022	15	Low	Low	form of drug administered not known			
23287	3287	23287	747_FDAMDD_v3b	C14H18N2O3	262.30432	defined organic	parent	tested chemical	Methohexital	151-83-7	single chemical compound		"1-methyl-5-(1-methylpent-2-yn-1-yl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione"	C1(=O)N(C)C(=O)NC(=O)C1(C(C)C#CCC)CC=C	C1(=O)N(C)C(=O)NC(=O)C1(C(C)C#CCC)CC=C	"InChI=1/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19)/f/h15H"	NZXKDOXHBHYTKP-YAQRNVERCV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anesthetic	2	0.007624731	2.117775448	35	Moderate	High	form of drug administered not known			
23288	822	20822	748_FDAMDD_v3b	C20H22N8O5	454.4393	defined organic	parent	tested chemical	Methotrexate	59-05-2	single chemical compound	stereochem	"N-[(4-{[(2,4-diaminopteridin-6-yl)methyl](methyl)amino}phenyl)carbonyl]-L-glutamic acid"	NC1=C2C(=NC(=N1)N)N=CC(=N2)CN(C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C	NC1=C2C(=NC(=N1)N)N=CC(=N2)CN(C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O)C	"InChI=1/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1/f/h25,29,32H,21-22H2"	FBOZXECLQNJBKD-SGDZJVHDDX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic; antirheumatic	0.5	0.001100257	2.958505878	44	Moderate	High	form of drug administered not known			
23289	3289	23289	749_FDAMDD_v3b	C19H24N2OS	328.47166	defined organic	parent	tested chemical	Methotrimeprazine	60-99-1	single chemical compound	stereochem	"(2R)-3-(2-methoxy-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine"	COC2=CC1=C(C=C2)SC3=C(C=CC=C3)N1C[C@H](C)CN(C)C	COC2=CC1=C(C=C2)SC3=C(C=CC=C3)N1C[C@H](C)CN(C)C	"InChI=1/C19H24N2OS/c1-14(12-20(2)3)13-21-16-7-5-6-8-18(16)23-19-10-9-15(22-4)11-17(19)21/h5-11,14H,12-13H2,1-4H3/t14-/m1/s1"	VRQVVMDWGGWHTJ-CQSZACIVBE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic	3.33	0.010137861	1.994053672	33	Moderate	Moderate	form of drug administered not known; structure modified v3b			
23290	3290	23290	750_FDAMDD_v3b	C11H17NO3	211.25758	defined organic	parent	tested chemical	Methoxamine	390-28-3	single chemical compound		"2-amino-1-[2,5-bis(methyloxy)phenyl]propan-1-ol"	C1(OC)=CC=C(OC)C(C(O)C(C)N)=C1	C1(OC)=CC=C(OC)C(C(O)C(C)N)=C1	"InChI=1/C11H17NO3/c1-7(12)11(13)9-6-8(14-2)4-5-10(9)15-3/h4-7,11,13H,12H2,1-3H3"	WJAJPNHVVFWKKL-UHFFFAOYAM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		adrenergic	0.333	0.001576275	2.802368067	43	Moderate	High	form of drug administered not known			
23291	830	20830	751_FDAMDD_v3b	C12H8O4	216.1895	defined organic	parent	tested chemical	"Methoxsalen, 8-"	298-81-7	single chemical compound		"9-(methyloxy)-7H-furo[3,2-g]chromen-7-one"	COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2	COC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2	"InChI=1/C12H8O4/c1-14-12-10-8(4-5-15-10)6-7-2-3-9(13)16-11(7)12/h2-6H,1H3"	QXKHYNVANLEOEG-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		pigmentation agent	0.6	0.002775343	2.556683347	40	Moderate	High	form of drug administered not known			
23292	3292	23292	752_FDAMDD_v3b	C11H17NO	179.25878	defined organic	parent	tested chemical	Methoxyphenamine	93-30-1	single chemical compound		N-methyl-1-[2-(methyloxy)phenyl]propan-2-amine	C1=CC=C(OC)C(CC(C)NC)=C1	C1=CC=C(OC)C(CC(C)NC)=C1	"InChI=1/C11H17NO/c1-9(12-2)8-10-6-4-5-7-11(10)13-3/h4-7,9,12H,8H2,1-3H3"	OEHAYUOVELTAPG-UHFFFAOYAK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator	10	0.055785273	1.253480436	25	Low-Moderate	Low	form of drug administered not known			
23293	3293	23293	753_FDAMDD_v3b	C12H13NO2	203.23712	defined organic	parent	tested chemical	Methsuximide	77-41-8	single chemical compound		"1,3-dimethyl-3-phenylpyrrolidine-2,5-dione"	C2=CC=CC(C1(C)C(=O)N(C)C(=O)C1)=C2	C2=CC=CC(C1(C)C(=O)N(C)C(=O)C1)=C2	"InChI=1/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3"	AJXPJJZHWIXJCJ-UHFFFAOYAR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	20	0.09840722	1.006973036	22	Low	Low	form of drug administered not known			
23294	3294	23294	754_FDAMDD_v3b	C42H66O14	794.96504	defined organic	parent	tested chemical	Methyldigoxin	30685-43-9	single chemical compound	stereochem; tautomers	"(3beta,5beta,12beta)-3-{[2,6-dideoxy-4-O-methyl-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide"	O[C@H]2C[C@@H](O[C@H](C)[C@H]2O[C@@H]3O[C@H](C)[C@@H](O[C@H]4C[C@H](O)[C@H](OC)[C@@H](C)O4)[C@@H](O)C3)O[C@H]1CC[C@@]5(C)[C@@](CC[C@]6([H])[C@@]([H])5C[C@@H](O)[C@@]7(C)[C@@](O)6CC[C@@H]7[C@@](CO8)=CC8=O)([H])C1	O[C@H]2C[C@@H](O[C@H](C)[C@H]2O[C@@H]3O[C@H](C)[C@@H](O[C@H]4C[C@H](O)[C@H](OC)[C@@H](C)O4)[C@@H](O)C3)O[C@H]1CC[C@@]5(C)[C@@](CC[C@]6([H])[C@@]([H])5C[C@@H](O)[C@@]7(C)[C@@](O)6CC[C@@H]7[C@@](CO8)=CC8=O)([H])C1	"InChI=1/C42H66O14/c1-20-37(49-6)29(43)16-35(51-20)55-39-22(3)53-36(18-31(39)45)56-38-21(2)52-34(17-30(38)44)54-25-9-11-40(4)24(14-25)7-8-27-28(40)15-32(46)41(5)26(10-12-42(27,41)48)23-13-33(47)50-19-23/h13,20-22,24-32,34-39,43-46,48H,7-12,14-19H2,1-6H3/t20-,21-,22-,24-,25+,26-,27-,28+,29+,30+,31+,32-,34+,35+,36+,37-,38-,39-,40+,41+,42+/m1/s1"	IYJMSDVSVHDVGT-PEQKVOOWBC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cardiotonic	0.00667	8.39031E-06	5.076222196	68	High	High	form of drug administered not known; CASRN changed v3b			
23295	3295	23295	755_FDAMDD_v3b	C10H13NO4	211.2145	defined organic	parent	tested chemical	Methyldopa	555-30-6	single chemical compound	stereochem	3-hydroxy-alpha-methyl-L-tyrosine	O=C(O)[C@](N)(C)CC1=CC=C(O)C(O)=C1	O=C(O)[C@](N)(C)CC1=CC=C(O)C(O)=C1	"InChI=1/C10H13NO4/c1-10(11,9(14)15)5-6-2-3-7(12)8(13)4-6/h2-4,12-13H,5,11H2,1H3,(H,14,15)/t10-/m0/s1/f/h14H"	CJCSPKMFHVPWAR-RILOQBQWDC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	33.3	0.15765963	0.802279496	20	Low	Low	form of drug administered not known			
23296	3296	23296	756_FDAMDD_v3b	C16H18ClN3S	319.85222	defined organic	salt Cl	tested chemical	Methylene blue	61-73-4	single chemical compound		"3,7-bis(dimethylamino)phenothiazin-5-ium chloride"	[Cl-].CN(C)c1ccc2nc3ccc(cc3[s+]c2c1)N(C)C	CN(C)c1ccc2nc3ccc(cc3[s+]c2c1)N(C)C	"InChI=1/C16H18N3S.ClH/c1-18(2)11-5-7-13-15(9-11)20-16-10-12(19(3)4)6-8-14(16)17-13;/h5-10H,1-4H3;1H/q+1;/p-1/fC16H18N3S.Cl/h;1h/qm;-1"	CXKWCBBOMKCUKX-UZXDRTCCCS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimethemoglobinemic	6.5	0.020321885	1.692036013	30	Moderate	Low	form of drug administered not known			
23297	2529	22529	757_FDAMDD_v3b	C8H8O3	152.1473	defined organic	parent	tested chemical	Methylparaben	99-76-3	single chemical compound		methyl 4-hydroxybenzoate	C(C1=CC=C(C=C1)O)(=O)OC	C(C1=CC=C(C=C1)O)(=O)OC	"InChI=1/C8H8O3/c1-11-8(10)6-2-4-7(9)5-3-6/h2-5,9H,1H3"	LXCFILQKKLGQFO-UHFFFAOYAH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	10	0.06572578	1.18226425	24	Low	Low	form of drug administered not known			
23298	3298	23298	758_FDAMDD_v3b	C16H22FNO	263.3503832	defined organic	parent	tested chemical	Methylperone	3575-80-2	single chemical compound		1-(4-fluorophenyl)-4-(4-methylpiperidin-1-yl)butan-1-one	C2C(C)CCN(CCCC(=O)C1=CC=C(F)C=C1)C2	C2C(C)CCN(CCCC(=O)C1=CC=C(F)C=C1)C2	"InChI=1/C16H22FNO/c1-13-8-11-18(12-9-13)10-2-3-16(19)14-4-6-15(17)7-5-14/h4-7,13H,2-3,8-12H2,1H3"	DKMFBWQBDIGMHM-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		neuroleptic	6.67	0.025327474	1.596408121	29	Low-Moderate	Low	form of drug administered not known			
23299	3299	23299	759_FDAMDD_v3b	C14H19NO2	233.30616	defined organic	parent	tested chemical	Methylphenidate	113-45-1	single chemical compound		methyl phenyl(piperidin-2-yl)acetate	C2=CC=CC(C(C(=O)OC)C1CCCCN1)=C2	C2=CC=CC(C(C(=O)OC)C1CCCCN1)=C2	"InChI=1/C14H19NO2/c1-17-14(16)13(11-7-3-2-4-8-11)12-9-5-6-10-15-12/h2-4,7-8,12-13,15H,5-6,9-10H2,1H3"	DUGOZIWVEXMGBE-UHFFFAOYAU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		CNS stimulant	1	0.004286213	2.367926206	38	Moderate	High	form of drug administered not known			
23300	3300	23300	760_FDAMDD_v3b	C22H30O5	374.4706	defined organic	parent	tested chemical	Methylprednisolone	83-43-2	single chemical compound	stereochem; tautomers	"(6alpha,11beta)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione"	[C@@]2\1(\C(=C/C(/C=C/1)=O)[C@H](C[C@@H]4[C@@H]2[C@H](C[C@@]3([C@](C(=O)CO)(O)CC[C@H]34)C)O)C)C	[C@@]2\1(\C(=C/C(/C=C/1)=O)[C@H](C[C@@H]4[C@@H]2[C@H](C[C@@]3([C@](C(=O)CO)(O)CC[C@H]34)C)O)C)C	"InChI=1/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1"	VHRSUDSXCMQTMA-PJHHCJLFBP	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 5	Methylprednisolone	glucocorticoid	4.17	0.011135721	1.953281672	33	Moderate	Moderate	form of drug administered not known			
23301	3301	23301	761_FDAMDD_v3b	C27H36O7	472.57054	defined organic	parent	tested chemical	Methylprednisolone aceponate	86401-95-8	single chemical compound	stereochem; tautomers	"(6alpha,11beta)-21-(acetyloxy)-11-hydroxy-6-methyl-3,20-dioxopregna-1,4-dien-17-yl propanoate"	C=1C(=O)\C=C2/[C@](C)(C=1)[C@@H]3[C@@H](C[C@@H]2C)C4[C@](C)(C[C@H]3O)[C@](C(=O)COC(=O)C)(OC(=O)CC)CC4	C=1C(=O)\C=C2/[C@](C)(C=1)[C@@H]3[C@@H](C[C@@H]2C)C4[C@](C)(C[C@H]3O)[C@](C(=O)COC(=O)C)(OC(=O)CC)CC4	"InChI=1/C27H36O7/c1-6-23(32)34-27(22(31)14-33-16(3)28)10-8-19-18-11-15(2)20-12-17(29)7-9-25(20,4)24(18)21(30)13-26(19,27)5/h7,9,12,15,18-19,21,24,30H,6,8,10-11,13-14H2,1-5H3/t15-,18-,19-,21-,24+,25-,26-,27-/m0/s1"	DALKLAYLIPSCQL-YPYQNWSCBG	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 5	Methylprednisolone	glucocorticoid	4.17	0.008824079	2.054330589	34	Moderate	Moderate	form of drug administered not known			
23302	3302	23302	762_FDAMDD_v3b	C24H32O6	416.50728	defined organic	parent	tested chemical	Methylprednisolone acetate	53-36-1	single chemical compound	stereochem; tautomers	"(6alpha,11beta)-11,17-dihydroxy-6-methyl-3,20-dioxopregna-1,4-dien-21-yl acetate"	[C@@]2\1(\C(=C/C(/C=C/1)=O)[C@H](C[C@@H]4[C@@H]2[C@H](C[C@@]3([C@](C(COC(=O)C)=O)(O)CC[C@H]34)C)O)C)C	[C@@]2\1(\C(=C/C(/C=C/1)=O)[C@H](C[C@@H]4[C@@H]2[C@H](C[C@@]3([C@](C(COC(=O)C)=O)(O)CC[C@H]34)C)O)C)C	"InChI=1/C24H32O6/c1-13-9-16-17-6-8-24(29,20(28)12-30-14(2)25)23(17,4)11-19(27)21(16)22(3)7-5-15(26)10-18(13)22/h5,7,10,13,16-17,19,21,27,29H,6,8-9,11-12H2,1-4H3/t13-,16-,17-,19-,21+,22-,23-,24-/m0/s1"	PLBHSZGDDKCEHR-LFYFAGGJBD	Clinical Reports 	Maximum Recommended Daily Dose	human	3 of 5	Methylprednisolone	glucocorticoid	4.17	0.01001183	1.999486542	34	Moderate	Moderate	form of drug administered not known			
23303	3303	23303	763_FDAMDD_v3b	C26H33NaO8	496.5252	defined organic	salt Na	tested chemical	Methylprednisolone succinate 	2375-03-3	single chemical compound	stereochem; tautomers	"sodium 4-{[(6alpha,11beta)-11,17-dihydroxy-6-methyl-3,20-dioxopregna-1,4-dien-21-yl]oxy}-4-oxobutanoate"	[Na+].[O-]C(=O)CCC(=O)OCC(=O)[C@@]4(O)CC[C@H]3[C@@H]2C[C@H](C)\C1=C\C(=O)/C=C\[C@]1(C)[C@H]2[C@@H](O)C[C@@]34C	OC(=O)CCC(=O)OCC(=O)[C@@]4(O)CC[C@H]3[C@@H]2C[C@H](C)\C1=C\C(=O)/C=C\[C@]1(C)[C@H]2[C@@H](O)C[C@@]34C	"InChI=1/C26H34O8.Na/c1-14-10-16-17-7-9-26(33,20(29)13-34-22(32)5-4-21(30)31)25(17,3)12-19(28)23(16)24(2)8-6-15(27)11-18(14)24;/h6,8,11,14,16-17,19,23,28,33H,4-5,7,9-10,12-13H2,1-3H3,(H,30,31);/q;+1/p-1/t14-,16-,17-,19-,23+,24-,25-,26-;/m0./s1/fC26H33O8.Na/q-1;m"	FQISKWAFAHGMGT-BRNZUSBGDH	Clinical Reports 	Maximum Recommended Daily Dose	human	4 of 5	Methylprednisolone	glucocorticoid	4.17	0.008398365	2.07580524	34	Moderate	Moderate	form of drug administered not known			
23304	3304	23304	764_FDAMDD_v3b	C33H48NNaO10S	683.7897	defined organic	salt Na	tested chemical	Methylprednisolone suleptanate	90350-40-6	single chemical compound	stereochem; tautomers	"sodium 2-[(8-{[(6alpha,11beta)-11,17-dihydroxy-6-methyl-3,20-dioxopregna-1,4-dien-21-yl]oxy}-8-oxooctanoyl)(methyl)amino]ethanesulfonate"	O=C(COC(CCCCCCC(N(C)CCS([O-])(=O)=O)=O)=O)[C@]2(O)[C@@]1(C)C[C@H](O)[C@]([C@](C[C@@H]4C)([H])[C@@]([H])1CC2)([H])[C@](C=C3)(C)C4=CC3=O.[Na+]	O=C(COC(CCCCCCC(N(C)CCS(O)(=O)=O)=O)=O)[C@]2(O)[C@@]1(C)C[C@H](O)[C@]([C@](C[C@@H]4C)([H])[C@@]([H])1CC2)([H])[C@](C=C3)(C)C4=CC3=O	"InChI=1/C33H49NO10S.Na/c1-21-17-23-24-12-14-33(40,32(24,3)19-26(36)30(23)31(2)13-11-22(35)18-25(21)31)27(37)20-44-29(39)10-8-6-5-7-9-28(38)34(4)15-16-45(41,42)43;/h11,13,18,21,23-24,26,30,36,40H,5-10,12,14-17,19-20H2,1-4H3,(H,41,42,43);/q;+1/p-1/t21-,23-,24-,26-,30+,31-,32-,33-;/m0./s1/fC33H48NO10S.Na/q-1;m"	CDMLLMOLWUKNEK-VLKQOADGDG	Clinical Reports 	Maximum Recommended Daily Dose	human	5 of 5	Methylprednisolone	glucocorticoid	4.17	0.006098366	2.2147865	36	Moderate	Moderate	form of drug administered not known; structure modified v3b			
23305	890	20890	765_FDAMDD_v3b	C5H6N2OS	142.1789	defined organic	parent	tested chemical	Methylthiouracil	56-04-2	single chemical compound		"6-methyl-2-thioxo-2,3-dihydropyrimidin-4(1H)-one"	CC1=CC(=O)NC(=S)N1	CC1=CC(=O)NC(=S)N1	"InChI=1/C5H6N2OS/c1-3-2-4(8)7-5(9)6-3/h2H,1H3,(H2,6,7,8,9)/f/h6-7H"	HWGBHCRJGXAGEU-ZDKSUBDRCM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		thyroid inhibitor	10	0.070333924	1.15283515	24	Low	Low	form of drug administered not known			
23306	3306	23306	766_FDAMDD_v3b	C10H17NO2	183.24748	defined organic	parent	tested chemical	Methyprylon	125-64-4	single chemical compound		"3,3-diethyl-5-methylpiperidine-2,4-dione"	C1C(C)C(=O)C(CC)(CC)C(=O)N1	C1C(C)C(=O)C(CC)(CC)C(=O)N1	"InChI=1/C10H17NO2/c1-4-10(5-2)8(12)7(3)6-11-9(10)13/h7H,4-6H2,1-3H3,(H,11,13)/f/h11H"	SIDLZWOQUZRBRU-WXRBYKJCCA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	6.67	0.036398863	1.438912177	27	Low-Moderate	Low	form of drug administered not known			
23307	3307	23307	767_FDAMDD_v3b	C21H27N3O2	353.45798	defined organic	parent	tested chemical	Methysergide	361-37-5	single chemical compound	stereochem	"(8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide"	C1=2c4c3c(C[C@H]1N(C)C[C@@H](C=2)C(N[C@H](CO)CC)=O)cn(c3ccc4)C	C1=2c4c3c(C[C@H]1N(C)C[C@@H](C=2)C(N[C@H](CO)CC)=O)cn(c3ccc4)C	"InChI=1/C21H27N3O2/c1-4-15(12-25)22-21(26)14-8-17-16-6-5-7-18-20(16)13(10-23(18)2)9-19(17)24(3)11-14/h5-8,10,14-15,19,25H,4,9,11-12H2,1-3H3,(H,22,26)/t14-,15+,19-/m1/s1/f/h22H"	KPJZHOPZRAFDTN-YBSCGTCVDI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimigraine	0.1	0.000282919	3.548337791	51	High	High	form of drug administered not known			
23308	3308	23308	768_FDAMDD_v3b	C15H13NO2S	271.33422	defined organic	parent	tested chemical	Metiazinic acid	13993-65-2	single chemical compound		(10-methyl-10H-phenothiazin-2-yl)acetic acid	C1=CC=C2C(=C1)N(C)C3=C(S2)C=CC(CC(O)=O)=C3	C1=CC=C2C(=C1)N(C)C3=C(S2)C=CC(CC(O)=O)=C3	"InChI=1/C15H13NO2S/c1-16-11-4-2-3-5-13(11)19-14-7-6-10(8-12(14)16)9-15(17)18/h2-8H,9H2,1H3,(H,17,18)/f/h17H"	LMINNBXUMGNKMM-HCKMINDGCO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	12.5	0.046068646	1.336594556	26	Low-Moderate	Low	form of drug administered not known			
23309	3309	23309	769_FDAMDD_v3b	C15H25NO3	267.3639	defined organic	parent	tested chemical	Metoprolol	37350-58-6	single chemical compound		1-[(1-methylethyl)amino]-3-({4-[2-(methyloxy)ethyl]phenyl}oxy)propan-2-ol	C1(CCOC)=CC=C(OCC(O)CNC(C)C)C=C1	C1(CCOC)=CC=C(OCC(O)CNC(C)C)C=C1	"InChI=1/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3"	IUBSYMUCCVWXPE-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal	6.67	0.024947272	1.602976934	29	Low-Moderate	Low	form of drug administered not known			
23310	3310	23310	770_FDAMDD_v3b	C18H22I3N3O8	789.09599	defined organic	parent	tested chemical	Metrizamide	31112-62-6	single chemical compound	stereochem	"2-[({3-(acetylamino)-5-[acetyl(methyl)amino]-2,4,6-triiodophenyl}carbonyl)amino]-2-deoxy-D-glucopyranose"	c2(C(N[C@H]1C(O[C@@H]([C@H]([C@@H]1O)O)CO)O)=O)c(c(N(C(=O)C)C)c(c(c2I)NC(=O)C)I)I	c2(C(N[C@H]1C(O[C@@H]([C@H]([C@@H]1O)O)CO)O)=O)c(c(N(C(=O)C)C)c(c(c2I)NC(=O)C)I)I	"InChI=1/C18H22I3N3O8/c1-5(26)22-12-9(19)8(10(20)14(11(12)21)24(3)6(2)27)17(30)23-13-16(29)15(28)7(4-25)32-18(13)31/h7,13,15-16,18,25,28-29,31H,4H2,1-3H3,(H,22,26)(H,23,30)/t7-,13-,15-,16-,18?/m1/s1/f/h22-23H"	BAQCROVBDNBEEB-MJIPKUKJDJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	104	0.131796386	0.880096497	21	Low	Low	form of drug administered not known			
23311	3311	23311	771_FDAMDD_v3b	C12H11I3N2O4	627.94015	defined organic	parent	tested chemical	Metrizoic acid	1949-45-7	single chemical compound		"3-(acetylamino)-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoic acid"	C1(I)=C(NC(C)=O)C(I)=C(N(C)C(C)=O)C(I)=C1C(O)=O	C1(I)=C(NC(C)=O)C(I)=C(N(C)C(C)=O)C(I)=C1C(O)=O	"InChI=1/C12H11I3N2O4/c1-4(18)16-10-7(13)6(12(20)21)8(14)11(9(10)15)17(3)5(2)19/h1-3H3,(H,16,18)(H,20,21)/f/h16,20H"	GGGDNPWHMNJRFN-YDDJAZEHCT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	100	0.159250846	0.797918252	20	Low	Low	form of drug administered not known			
23312	892	20892	772_FDAMDD_v3b	C6H9N3O3	171.154	defined organic	parent	tested chemical	Metronidazole	443-48-1	single chemical compound		2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanol	N1(C(=CN=C1C)[N+](=O)[O-])CCO	N1(C(=CN=C1C)[N+](=O)[O-])CCO	"InChI=1/C6H9N3O3/c1-5-7-4-6(9(11)12)8(5)2-3-10/h4,10H,2-3H2,1H3"	VAOCPAMSLUNLGC-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiprotozoal	33.3	0.194561623	0.71094282	19	Low	Low	form of drug administered not known			
23313	3313	23313	773_FDAMDD_v3b	C9H11Cl2N3O4S2	360.23734	defined organic	parent	tested chemical	Methyclothiazide	135-07-9	single chemical compound		"6-chloro-3-(chloromethyl)-2-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide"	C1(S(N)(=O)=O)=C(Cl)C=C2C(=C1)S(=O)(=O)N(C)C(CCl)N2	C1(S(N)(=O)=O)=C(Cl)C=C2C(=C1)S(=O)(=O)N(C)C(CCl)N2	"InChI=1/C9H11Cl2N3O4S2/c1-14-9(4-10)13-6-2-5(11)7(19(12,15)16)3-8(6)20(14,17)18/h2-3,9,13H,4H2,1H3,(H2,12,15,16)/f/h12H2"	CESYKOGBSMNBPD-GAJRPKRDCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic; antihypertensive	0.167	0.000463583	3.333872256	48	High-Moderate	High	form of drug administered not known			
23314	3314	23314	774_FDAMDD_v3b	C14H14N2O	226.27376	defined organic	parent	tested chemical	Metyrapone	54-36-4	single chemical compound		"2-methyl-1,2-dipyridin-3-ylpropan-1-one"	N2=CC=CC(C(=O)C(C)(C)C1=CN=CC=C1)=C2	N2=CC=CC(C(=O)C(C)(C)C1=CN=CC=C1)=C2	"InChI=1/C14H14N2O/c1-14(2,12-6-4-8-16-10-12)13(17)11-5-3-7-15-9-11/h3-10H,1-2H3"	FJLBFSROUSIWMA-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	75	0.331456904	0.47957293	17	Low	Low	form of drug administered not known			
23315	3315	23315	775_FDAMDD_v3b	C10H13NO3	195.21512	defined organic	parent	tested chemical	Metyrosine	672-87-7	single chemical compound	stereochem	alpha-methyl-L-tyrosine	O=C(O)[C@](N)(C)CC(C=C1)=CC=C1O	O=C(O)[C@](N)(C)CC(C=C1)=CC=C1O	"InChI=1/C10H13NO3/c1-10(11,9(13)14)6-7-2-4-8(12)5-3-7/h2-5,12H,6,11H2,1H3,(H,13,14)/t10-/m0/s1/f/h13H"	NHTGHBARYWONDQ-WSLRCUSADI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		tyrosine hydroxylase inhibitor	66.7	0.341674354	0.466387618	16	Low	Low	form of drug administered not known; structure modified v3b			
23316	3316	23316	776_FDAMDD_v3b	C21H25N5O8S2	539.5819	defined organic	parent	tested chemical	Mezlocillin	51481-65-3	single chemical compound	stereochem	"(2S,5R,6R)-3,3-dimethyl-6-{[(2R)-2-({[3-(methylsulfonyl)-2-oxoimidazolidin-1-yl]carbonyl}amino)-2-phenylacetyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	N21[C@H](SC([C@@H]1C(=O)O)(C)C)[C@@H](C2=O)NC([C@H](NC(N3C(N(S(=O)(=O)C)CC3)=O)=O)c4ccccc4)=O	N21[C@H](SC([C@@H]1C(=O)O)(C)C)[C@@H](C2=O)NC([C@H](NC(N3C(N(S(=O)(=O)C)CC3)=O)=O)c4ccccc4)=O	"InChI=1/C21H25N5O8S2/c1-21(2)14(18(29)30)26-16(28)13(17(26)35-21)22-15(27)12(11-7-5-4-6-8-11)23-19(31)24-9-10-25(20(24)32)36(3,33)34/h4-8,12-14,17H,9-10H2,1-3H3,(H,22,27)(H,23,31)(H,29,30)/t12-,13-,14+,17-/m1/s1/f/h22-23,29H"	YPBATNHYBCGSSN-PMFPZNEVDZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	267	0.494827569	0.305546112	15	Low	Low	form of drug administered not known			
23317	3317	23317	777_FDAMDD_v3b	C18H20N2	264.3648	defined organic	parent	tested chemical	Mianserin	24219-97-4	single chemical compound		"2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine"	C1=CC=C2C(=C1)C4N(C3=C(C2)C=CC=C3)CCN(C)C4	C1=CC=C2C(=C1)C4N(C3=C(C2)C=CC=C3)CCN(C)C4	"InChI=1/C18H20N2/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19/h2-9,18H,10-13H2,1H3"	UEQUQVLFIPOEMF-UHFFFAOYAO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	1.5	0.005673978	2.24611237	36	Moderate	High	form of drug administered not known			
23318	3318	23318	778_FDAMDD_v3b	C29H38FN3O3	495.6287232	defined organic	parent	tested chemical	Mibefradil	116644-53-2	single chemical compound	stereochem	"(1S,2S)-2-(2-{[3-(1H-benzimidazol-2-yl)propyl](methyl)amino}ethyl)-6-fluoro-1-(1-methylethyl)-1,2,3,4-tetrahydronaphthalen-2-yl (methyloxy)acetate"	CC(C)[C@H]3c4ccc(F)cc4CC[C@]3(OC(=O)COC)CCN(C)CCCC=1Nc2ccccc2N=1	CC(C)[C@H]3c4ccc(F)cc4CC[C@]3(OC(=O)COC)CCN(C)CCCC=1Nc2ccccc2N=1	"InChI=1/C29H38FN3O3/c1-20(2)28-23-12-11-22(30)18-21(23)13-14-29(28,36-27(34)19-35-4)15-17-33(3)16-7-10-26-31-24-8-5-6-9-25(24)32-26/h5-6,8-9,11-12,18,20,28H,7,10,13-17,19H2,1-4H3,(H,31,32)/t28-,29-/m0/s1/f/h31H"	HBNPJJILLOYFJU-FXQWKTRKDO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; Ca channel blocker	1.67	0.003369458	2.472439996	39	Moderate	High	form of drug administered not known			
23319	3319	23319	779_FDAMDD_v3b	C18H14Cl4N2O	416.1286	defined organic	parent	tested chemical	Miconazole	22916-47-8	single chemical compound		"1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole"	C3=C(Cl)C(C(CN1C=NC=C1)OCC2=CC=C(Cl)C=C2Cl)=CC=C3Cl	C3=C(Cl)C(C(CN1C=NC=C1)OCC2=CC=C(Cl)C=C2Cl)=CC=C3Cl	"InChI=1/C18H14Cl4N2O/c19-13-2-1-12(16(21)7-13)10-25-18(9-24-6-5-23-11-24)15-4-3-14(20)8-17(15)22/h1-8,11,18H,9-10H2"	BYBLEWFAAKGYCD-UHFFFAOYAA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		topical antifungal	60	0.144186196	0.841076315	21	Low	Low	form of drug administered not known			
23320	3320	23320	780_FDAMDD_v3b	C18H13ClFN3	325.7673232	defined organic	parent	tested chemical	Midazolam	59467-70-8	single chemical compound		"8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine"	C1=C(Cl)C=C3C(=C1)N4C(CN=C3C2=CC=CC=C2F)=CN=C4C	C1=C(Cl)C=C3C(=C1)N4C(CN=C3C2=CC=CC=C2F)=CN=C4C	"InChI=1/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3"	DDLIGBOFAVUZHB-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anesthetic	0.0833	0.000255704	3.592262518	51	High	High	form of drug administered not known			
23321	3321	23321	781_FDAMDD_v3b	C12H18N2O4	254.28232	defined organic	parent	tested chemical	Midodrine	42794-76-3	single chemical compound		"N-{2-[2,5-bis(methyloxy)phenyl]-2-hydroxyethyl}glycinamide"	C1(OC)=CC=C(OC)C(C(O)CNC(=O)CN)=C1	C1(OC)=CC=C(OC)C(C(O)CNC(=O)CN)=C1	"InChI=1/C12H18N2O4/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16)/f/h14H"	PTKSEFOSCHHMPD-YHMJCDSICD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		adrenergic; antihypotensive	0.25	0.000983159	3.007376156	45	High-Moderate	High	form of drug administered not known			
23322	3322	23322	782_FDAMDD_v3b	C29H35NO2	429.5937	defined organic	parent	tested chemical	Mifepristone	84371-65-3	single chemical compound	stereochem	"(11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one"	C/23=C1/C(=C\C(CC1)=O)CC[C@H]\2[C@H]5[C@](C[C@@H]3c4ccc(cc4)N(C)C)([C@@](C#CC)(O)CC5)C	C/23=C1/C(=C\C(CC1)=O)CC[C@H]\2[C@H]5[C@](C[C@@H]3c4ccc(cc4)N(C)C)([C@@](C#CC)(O)CC5)C	"InChI=1/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1"	VKHAHZOOUSRJNA-GCNJZUOMBS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		abortifacient	10	0.023277809	1.633057904	29	Low-Moderate	Low	form of drug administered not known			
23323	3323	23323	783_FDAMDD_v3b	C8H17NO5	207.22428	defined organic	parent	tested chemical	Miglitol	72432-03-2	single chemical compound	stereochem	"(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol"	C1[C@@H]([C@H]([C@@H]([C@H]([N@]1CCO)CO)O)O)O	C1[C@@H]([C@H]([C@@H]([C@H]([N@]1CCO)CO)O)O)O	"InChI=1/C8H17NO5/c10-2-1-9-3-6(12)8(14)7(13)5(9)4-11/h5-8,10-14H,1-4H2/t5-,6+,7-,8-/m1/s1"	IBAQFPQHRJAVAV-ULAWRXDQBK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	5	0.024128447	1.617470635	29	Low-Moderate	Low	form of drug administered not known			
23324	3324	23324	784_FDAMDD_v3b	C12H9N3O	211.21936	defined organic	parent	tested chemical	Milrinone	78415-72-2	single chemical compound		"2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile"	C2(C)NC(=O)C(C#N)=CC=2C1=CC=NC=C1	C2(C)NC(=O)C(C#N)=CC=2C1=CC=NC=C1	"InChI=1/C12H9N3O/c1-8-11(9-2-4-14-5-3-9)6-10(7-13)12(16)15-8/h2-6H,1H3,(H,15,16)/f/h15H"	PZRHRDRVRGEVNW-YAQRNVERCW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cardiotonic	0.05	0.000236721	3.625763718	52	High	High	form of drug administered not known			
23325	3325	23325	785_FDAMDD_v3b	C17H19N3	265.35286	defined organic	parent	tested chemical	Mirtazapine	61337-67-5	single chemical compound		"2-methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine"	C1=CC=C2C(=C1)C4N(C3=C(C2)C=CC=N3)CCN(C)C4	C1=CC=C2C(=C1)C4N(C3=C(C2)C=CC=N3)CCN(C)C4	"InChI=1/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3"	RONZAEMNMFQXRA-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	0.75	0.002826425	2.548762509	40	Moderate	High	form of drug administered not known			
23326	897	20897	786_FDAMDD_v3b	C22H38O5	382.53412	defined organic	parent	tested chemical	Misoprostol	59122-46-2	single chemical compound	stereochem	"methyl (11alpha,13E)-11,16-dihydroxy-16-methyl-9-oxoprost-13-en-1-oate"	C1(C[C@H]([C@@H]([C@H]1CCCCCCC(=O)OC)/C=C/CC(O)(CCCC)C)O)=O	C1(C[C@H]([C@@H]([C@H]1CCCCCCC(=O)OC)/C=C/CC(O)(CCCC)C)O)=O	"InChI=1/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1"	OJLOPKGSLYJEMD-URPKTTJQBH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiulcerative	0.0133	3.47681E-05	4.458818537	61	High	High	form of drug administered not known			
23327	898	20898	787_FDAMDD_v3b	C15H18N4O5	334.3272	defined organic	parent	tested chemical	Mitomycin C	50-07-7	single chemical compound	stereochem; tautomers	"[(1aS,8S,8aR,8bS)-6-amino-8a-methoxy-5-methyl-4,7-dioxo-1,1a,2,4,7,8,8a,8b-octahydroazireno[2',3':3,4]pyrrolo[1,2-a]indol-8-yl]methyl carbamate"	O=C(C(C)=C4N)C2=C(C4=O)[C@](COC(N)=O)([H])[C@@](N2C3)(OC)[C@@]1([H])N[C@@]31[H]	O=C(C(C)=C4N)C2=C(C4=O)[C@](COC(N)=O)([H])[C@@](N2C3)(OC)[C@@]1([H])N[C@@]31[H]	"InChI=1/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1/f/h17H2"	NWIBSHFKIJFRCO-XPNHIKBZDF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.541	0.001618175	2.790974446	42	Moderate	High	form of drug administered not known			
23328	3328	23328	788_FDAMDD_v3b	C58H80Cl2N2O14	1100.1668	defined organic	salt Cl	tested chemical	Mivacurium chloride	106861-44-3	single chemical compound	ammonium; stereochem	"2,2'-{[(4E)-1,8-dioxooct-4-ene-1,8-diyl]bis(oxypropane-3,1-diyl)}bis[6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxybenzyl)-1,2,3,4-tetrahydroisoquinolinium] dichloride"	O=C(CC/C=C/CCC(OCCC[N+]4(C)C(CC6=CC(OC)=C(OC)C(OC)=C6)C3=CC(OC)=C(OC)C=C3CC4)=O)OCCC[N+]1(C)C(CC5=CC(OC)=C(OC)C(OC)=C5)C(C=C2OC)=C(C=C2OC)CC1.[Cl-].[Cl-]	O=C(CC/C=C/CCC(OCCC[N+]4(C)C(CC6=CC(OC)=C(OC)C(OC)=C6)C3=CC(OC)=C(OC)C=C3CC4)=O)OCCC[N+]1(C)C(CC5=CC(OC)=C(OC)C(OC)=C5)C(C=C2OC)=C(C=C2OC)CC1	"InChI=1/C58H80N2O14.2ClH/c1-59(25-21-41-35-47(63-3)49(65-5)37-43(41)45(59)29-39-31-51(67-7)57(71-11)52(32-39)68-8)23-17-27-73-55(61)19-15-13-14-16-20-56(62)74-28-18-24-60(2)26-22-42-36-48(64-4)50(66-6)38-44(42)46(60)30-40-33-53(69-9)58(72-12)54(34-40)70-10;;/h13-14,31-38,45-46H,15-30H2,1-12H3;2*1H/q+2;;/p-2/b14-13+;;/fC58H80N2O14.2Cl/h;2*1h/qm;2*-1"	WMSYWJSZGVOIJW-FNBGJRLTDV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant; neuromuscular blocker	0.25	0.000227238	3.643518526	52	High	High	form of drug administered not known; structure modified v3b			
23329	3329	23329	789_FDAMDD_v3b	C15H15NO2S	273.3501	defined organic	parent	tested chemical	Modafinil	68693-11-8	single chemical compound		2-[(diphenylmethyl)sulfinyl]acetamide	C2=CC=CC(C(S(=O)CC(N)=O)C1=CC=CC=C1)=C2	C2=CC=CC(C(S(=O)CC(N)=O)C1=CC=CC=C1)=C2	"InChI=1/C15H15NO2S/c16-14(17)11-19(18)15(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-10,15H,11H2,(H2,16,17)/f/h16H2"	YFGHCGITMMYXAQ-ZHLVXTBQCM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		CNS stimulant; adrenergic	3.33	0.01218218	1.914275004	33	Moderate	Moderate	form of drug administered not known			
23330	3330	23330	790_FDAMDD_v3b	C27H34N2O7	498.56806	defined organic	parent	tested chemical	Moexipril	103775-10-6	single chemical compound	stereochem	"(3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-6,7-bis(methyloxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid"	c1(c(cc2c(c1)C[C@@H](C(=O)O)N(C2)C([C@@H](N[C@H](C(=O)OCC)CCc3ccccc3)C)=O)OC)OC	c1(c(cc2c(c1)C[C@@H](C(=O)O)N(C2)C([C@@H](N[C@H](C(=O)OCC)CCc3ccccc3)C)=O)OC)OC	"InChI=1/C27H34N2O7/c1-5-36-27(33)21(12-11-18-9-7-6-8-10-18)28-17(2)25(30)29-16-20-15-24(35-4)23(34-3)14-19(20)13-22(29)26(31)32/h6-10,14-15,17,21-22,28H,5,11-13,16H2,1-4H3,(H,31,32)/t17-,21-,22-/m0/s1/f/h31H"	UWWDHYUMIORJTA-FKTCGPEFDJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; ACE inhibitor	0.833	0.001670785	2.777079451	42	Moderate	High	form of drug administered not known			
23331	3331	23331	791_FDAMDD_v3b	C13H16N2O2	232.27834	defined organic	parent	tested chemical	Mofebutazone	2210-63-1	single chemical compound		"4-butyl-1-phenylpyrazolidine-3,5-dione"	C2(=O)C(CCCC)C(=O)N(C1=CC=CC=C1)N2	C2(=O)C(CCCC)C(=O)N(C1=CC=CC=C1)N2	"InChI=1/C13H16N2O2/c1-2-3-9-11-12(16)14-15(13(11)17)10-7-5-4-6-8-10/h4-8,11H,2-3,9H2,1H3,(H,14,16)/f/h14H"	REOJLIXKJWXUGB-YHMJCDSICZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	5	0.021525899	1.667038709	30	Moderate	Low	form of drug administered not known			
23332	3332	23332	792_FDAMDD_v3b	C16H24N2O2	276.37396	defined organic	parent	tested chemical	Molindone	7416-34-4	single chemical compound		"3-ethyl-2-methyl-5-(morpholin-4-ylmethyl)-1,5,6,7-tetrahydro-4H-indol-4-one"	C2(CN1CCOCC1)CCC3=C(C2=O)C(CC)=C(C)N3	C2(CN1CCOCC1)CCC3=C(C2=O)C(CC)=C(C)N3	"InChI=1/C16H24N2O2/c1-3-13-11(2)17-14-5-4-12(16(19)15(13)14)10-18-6-8-20-9-7-18/h12,17H,3-10H2,1-2H3"	KLPWJLBORRMFGK-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	3.75	0.013568572	1.867465854	32	Moderate	Moderate	form of drug administered not known			
23333	3333	23333	793_FDAMDD_v3b	C27H30Cl2O6	521.4295	defined organic	parent	tested chemical	Mometasone furoate	83919-23-7	single chemical compound	stereochem	"(11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate"	[C@]23([C@](OC(c1occc1)=O)([C@H](C)C[C@H]2[C@H]5[C@]([C@H](C3)O)([C@@]\4(\C(=C/C(/C=C/4)=O)CC5)C)Cl)C(=O)CCl)C	[C@]23([C@](OC(c1occc1)=O)([C@H](C)C[C@H]2[C@H]5[C@]([C@H](C3)O)([C@@]\4(\C(=C/C(/C=C/4)=O)CC5)C)Cl)C(=O)CCl)C	"InChI=1/C27H30Cl2O6/c1-15-11-19-18-7-6-16-12-17(30)8-9-24(16,2)26(18,29)21(31)13-25(19,3)27(15,22(32)14-28)35-23(33)20-5-4-10-34-20/h4-5,8-10,12,15,18-19,21,31H,6-7,11,13-14H2,1-3H3/t15-,18+,19+,21+,24+,25+,26+,27+/m1/s1"	WOFMFGQZHJDGCX-ZULDAHANBU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		topical anti inflammatory	0.015	2.87671E-05	4.541104339	62	High	High	form of drug administered not known			
23334	3334	23334	794_FDAMDD_v3b	C35H36ClNO3S	586.18324	defined organic	parent	tested chemical	Montelukast	158966-92-8	single chemical compound	stereochem	{1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid	ClC2=CC=C1C=CC(/C=C/C3=CC=CC([C@H](SCC5(CC5)CC(O)=O)CCC4=C(C(O)(C)C)C=CC=C4)=C3)=NC1=C2	ClC2=CC=C1C=CC(/C=C/C3=CC=CC([C@H](SCC5(CC5)CC(O)=O)CCC4=C(C(O)(C)C)C=CC=C4)=C3)=NC1=C2	"InChI=1/C35H36ClNO3S/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39)/b15-10+/t32-/m1/s1/f/h38H"	UCHDWCPVSPXUMX-WCQBWMPADJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiasthmatic	0.167	0.000284894	3.545316926	51	High	High	form of drug administered not known; structure modified v3b			
23335	3335	23335	795_FDAMDD_v3b	C22H25N3O4S	427.5166	defined organic	parent	tested chemical	Moricizine	31883-05-3	single chemical compound		ethyl [10-(3-morpholin-4-ylpropanoyl)-10H-phenothiazin-2-yl]carbamate	C1=CC=C3C(=C1)SC4=C(N3C(=O)CCN2CCOCC2)C=C(NC(=O)OCC)C=C4	C1=CC=C3C(=C1)SC4=C(N3C(=O)CCN2CCOCC2)C=C(NC(=O)OCC)C=C4	"InChI=1/C22H25N3O4S/c1-2-29-22(27)23-16-7-8-20-18(15-16)25(17-5-3-4-6-19(17)30-20)21(26)9-10-24-11-13-28-14-12-24/h3-8,15H,2,9-14H2,1H3,(H,23,27)/f/h23H"	FUBVWMNBEHXPSU-MPIMZMORCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiarrhythmic	15	0.035086357	1.454861724	27	Low-Moderate	Low	form of drug administered not known			
23336	3336	23336	796_FDAMDD_v3b	C17H19NO3	285.33766	defined organic	parent	tested chemical	Morphine	57-27-2	single chemical compound	stereochem	"(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol"	OC1=C3C([C@]([C@H]4O3)5[C@](C=C[C@@H]4O)([H])[C@H](N(C)CC5)C2)=C2C=C1	OC1=C3C([C@]([C@H]4O3)5[C@](C=C[C@@H]4O)([H])[C@H](N(C)CC5)C2)=C2C=C1	"InChI=1/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2-5,10-11,13,16,19-20H,6-8H2,1H3/t10-,11+,13-,16-,17-/m0/s1"	BQJCRHHNABKAKU-KBQPJGBKBH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	1.67	0.005852715	2.232642624	36	Moderate	High	form of drug administered not known; structure modified v3b			
23337	3337	23337	797_FDAMDD_v3b	C19H30N2O5S	398.5169	defined organic	parent	tested chemical	Moveltipril	85856-54-8	single chemical compound	stereochem	1-[(2S)-3-{[N-(cyclohexylcarbonyl)-D-alanyl]thio}-2-methylpropanoyl]-L-proline	N2(C([C@@H](CSC([C@H](NC(=O)C1CCCCC1)C)=O)C)=O)[C@H](C(=O)O)CCC2	N2(C([C@@H](CSC([C@H](NC(=O)C1CCCCC1)C)=O)C)=O)[C@H](C(=O)O)CCC2	"InChI=1/C19H30N2O5S/c1-12(17(23)21-10-6-9-15(21)18(24)25)11-27-19(26)13(2)20-16(22)14-7-4-3-5-8-14/h12-15H,3-11H2,1-2H3,(H,20,22)(H,24,25)/t12-,13-,15+/m1/s1/f/h20,24H"	QIJLJZOGPPQCOG-PPRDCYNPDA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	1	0.002509304	2.600446743	40	Moderate	High	form of drug administered not known			
23338	3338	23338	798_FDAMDD_v3b	C20H20N6O9S	520.4726	defined organic	parent	tested chemical	Moxalactam	64952-97-2	single chemical compound	stereochem	"(6R,7R)-7-{[carboxy(4-hydroxyphenyl)acetyl]amino}-7-(methyloxy)-3-{[(1-methyl-1H-tetrazol-5-yl)thio]methyl}-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid"	O=C3N1/C(=C(\CO[C@@H]1[C@]3(OC)NC(=O)C(c2ccc(O)cc2)C(O)=O)CSc4nnnn4C)C(O)=O	O=C3N1/C(=C(\CO[C@@H]1[C@]3(OC)NC(=O)C(c2ccc(O)cc2)C(O)=O)CSc4nnnn4C)C(O)=O	"InChI=1/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1/f/h21,29,31H"	JWCSIUVGFCSJCK-CLCJSHKYDD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.12815276	0.892272037	21	Low	Low	form of drug administered not known			
23339	3339	23339	799_FDAMDD_v3b	C16H25NO3	279.3746	defined organic	parent	tested chemical	Moxisylyte	54-32-0	single chemical compound		4-{[2-(dimethylamino)ethyl]oxy}-2-methyl-5-(1-methylethyl)phenyl acetate	C1=C(OCCN(C)C)C(C(C)C)=CC(OC(C)=O)=C1C	C1=C(OCCN(C)C)C(C(C)C)=CC(OC(C)=O)=C1C	"InChI=1/C16H25NO3/c1-11(2)14-10-15(20-13(4)18)12(3)9-16(14)19-8-7-17(5)6/h9-11H,7-8H2,1-6H3"	VRYMTAVOXVTQEF-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vasodilator	5.33	0.019078327	1.71945971	30	Moderate	Low	form of drug administered not known			
23340	3340	23340	800_FDAMDD_v3b	C23H31NO7	433.49474	defined organic	parent	tested chemical	Mycophenolate mofetil	128794-94-5	single chemical compound	stereochem	"2-morpholin-4-ylethyl (4E)-6-[4-hydroxy-7-methyl-6-(methyloxy)-3-oxo-1,3-dihydro-2-benzofuran-5-yl]-4-methylhex-4-enoate"	C2(C)=C(OC)C(CC=C(C)CCC(=O)OCCN1CCOCC1)=C(O)C3=C2COC3=O	C2(C)=C(OC)C(CC=C(C)CCC(=O)OCCN1CCOCC1)=C(O)C3=C2COC3=O	"InChI=1/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+"	RTGDFNSFWBGLEC-SYZQJQIIBO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	120	0.276819968	0.557802586	17	Low	Low	form of drug administered not known			
23341	3341	23341	801_FDAMDD_v3b	C24H36O3	372.54084	defined organic	parent	tested chemical	Nabilone	51022-71-0	single chemical compound	stereochem	"(6aR,10aR)-3-(1,1-dimethylheptyl)-1-hydroxy-6,6-dimethyl-6,6a,7,8,10,10a-hexahydro-9H-benzo[c]chromen-9-one"	c12[C@H]3[C@H](C(Oc1cc(cc2O)C(CCCCCC)(C)C)(C)C)CCC(C3)=O	c12[C@H]3[C@H](C(Oc1cc(cc2O)C(CCCCCC)(C)C)(C)C)CCC(C3)=O	"InChI=1/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1"	GECBBEABIDMGGL-RTBURBONBZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiemetic	0.1	0.000268427	3.571173889	51	High	High	form of drug administered not known			
23342	3342	23342	802_FDAMDD_v3b	C17H27NO4	309.40058	defined organic	parent	tested chemical	Nadolol	42200-33-9	single chemical compound	stereochem	"(2R,3S)-5-({3-[(1,1-dimethylethyl)amino]-2-hydroxypropyl}oxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol"	CC(C)(C)NCC(O)COc2cccc1C[C@@H](O)[C@@H](O)Cc12	CC(C)(C)NCC(O)COc2cccc1C[C@@H](O)[C@@H](O)Cc12	"InChI=1/C17H27NO4/c1-17(2,3)18-9-12(19)10-22-16-6-4-5-11-7-14(20)15(21)8-13(11)16/h4-6,12,14-15,18-21H,7-10H2,1-3H3/t12?,14-,15+/m1/s1"	VWPOSFSPZNDTMJ-UCWKZMIHBD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal	10.7	0.034582999	1.461137346	28	Low-Moderate	Low	form of drug administered not known			
23343	3343	23343	803_FDAMDD_v3b	C21H22N2O5S	414.47478	defined organic	parent	tested chemical	Nafcillin	147-52-4	single chemical compound	stereochem	"(2S,5R,6R)-6-({[2-(ethyloxy)naphthalen-1-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)c1c2ccccc2ccc1OCC)[C@H]4SC3(C)C	O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)c1c2ccccc2ccc1OCC)[C@H]4SC3(C)C	"InChI=1/C21H22N2O5S/c1-4-28-13-10-9-11-7-5-6-8-12(11)14(13)17(24)22-15-18(25)23-16(20(26)27)21(2,3)29-19(15)23/h5-10,15-16,19H,4H2,1-3H3,(H,22,24)(H,26,27)/t15-,16+,19-/m1/s1/f/h22,26H"	GPXLMGHLHQJAGZ-UQADEMIGDV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	100	0.241269203	0.61749811	18	Low	Low	form of drug administered not known			
23344	3344	23344	804_FDAMDD_v3b	C24H33NO3	383.52372	defined organic	parent	tested chemical	Nafronyl	31329-57-4	single chemical compound		2-(diethylamino)ethyl 3-naphthalen-1-yl-2-(tetrahydrofuran-2-ylmethyl)propanoate	C1=CC=C3C(=C1)C(CC(C(=O)OCCN(CC)CC)CC2OCCC2)=CC=C3	C1=CC=C3C(=C1)C(CC(C(=O)OCCN(CC)CC)CC2OCCC2)=CC=C3	"InChI=1/C24H33NO3/c1-3-25(4-2)14-16-28-24(26)21(18-22-12-8-15-27-22)17-20-11-7-10-19-9-5-6-13-23(19)20/h5-7,9-11,13,21-22H,3-4,8,12,14-18H2,1-2H3"	KBAFPSLPKGSANY-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vasodilator	10	0.026074007	1.583792229	29	Low-Moderate	Low	form of drug administered not known			
23345	3345	23345	805_FDAMDD_v3b	C21H27NO4	357.44338	defined organic	parent	tested chemical	Nalbuphine	20594-83-6	single chemical compound	stereochem	"(5alpha,6alpha)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol"	O[C@@]1(CC[C@@H]4O)[C@]2([C@H]4OC3=C6O)C3=C(C=C6)C[C@H]1N(CC5CCC5)CC2	O[C@@]1(CC[C@@H]4O)[C@]2([C@H]4OC3=C6O)C3=C(C=C6)C[C@H]1N(CC5CCC5)CC2	"InChI=1/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1"	NETZHAKZCGBWSS-CEDHKZHLBZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	1	0.002797646	2.553207258	40	Moderate	High	form of drug administered not known; structure modified v3b			
23346	912	20912	806_FDAMDD_v3b	C12H12N2O3	232.2353	defined organic	parent	tested chemical	Nalidixic acid	389-08-2	single chemical compound		"1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid"	O=C1C2=C(N=C(C=C2)C)N(C=C1C(=O)O)CC	O=C1C2=C(N=C(C=C2)C)N(C=C1C(=O)O)CC	"InChI=1/C12H12N2O3/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14/h4-6H,3H2,1-2H3,(H,16,17)/f/h16H"	MHWLWQUZZRMNGJ-WYUMXYHSCS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.287208706	0.5418024	17	Low	Low	form of drug administered not known			
23347	3347	23347	807_FDAMDD_v3b	C21H25NO3	339.4281	defined organic	parent	tested chemical	Nalmefene	55096-26-9	single chemical compound	stereochem	"(5alpha)-17-(cyclopropylmethyl)-6-methylidene-4,5-epoxymorphinan-3,14-diol"	O[C@@]1(CC4)[C@]2([C@H](C4=C)OC3=C6O)C3=C(C=C6)C[C@H]1N(CC5CC5)CC2	O[C@@]1(CC4)[C@]2([C@H](C4=C)OC3=C6O)C3=C(C=C6)C[C@H]1N(CC5CC5)CC2	"InChI=1/C21H25NO3/c1-12-6-7-21(24)16-10-14-4-5-15(23)18-17(14)20(21,19(12)25-18)8-9-22(16)11-13-2-3-13/h4-5,13,16,19,23-24H,1-3,6-11H2/t16-,19+,20+,21-/m1/s1"	WJBLNOPPDWQMCH-MBPVOVBZBG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic antagonist	0.833	0.002454128	2.610102792	40	Moderate	High	form of drug administered not known			
23348	3348	23348	808_FDAMDD_v3b	C19H21NO3	311.37494	defined organic	parent	tested chemical	Nalorphine	62-67-9	single chemical compound	stereochem	"(5alpha,6alpha)-17-prop-2-en-1-yl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol"	OC1=C3C([C@]([C@H]4O3)5[C@](C=C[C@@H]4O)([H])[C@H](N(CC=C)CC5)C2)=C2C=C1	OC1=C3C([C@]([C@H]4O3)5[C@](C=C[C@@H]4O)([H])[C@H](N(CC=C)CC5)C2)=C2C=C1	"InChI=1/C19H21NO3/c1-2-8-20-9-7-19-12-4-6-15(22)18(19)23-17-14(21)5-3-11(16(17)19)10-13(12)20/h2-6,12-13,15,18,21-22H,1,7-10H2/t12-,13+,15-,18-,19-/m0/s1"	UIQMVEYFGZJHCZ-SSTWWWIQBT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic antagonist	0.667	0.002142112	2.669157823	41	Moderate	High	form of drug administered not known			
23349	3349	23349	809_FDAMDD_v3b	C19H21NO4	327.37434	defined organic	parent	tested chemical	Naloxone	465-65-6	single chemical compound	stereochem; tautomers	"(5alpha)-3,14-dihydroxy-17-prop-2-en-1-yl-4,5-epoxymorphinan-6-one"	O[C@@]1(CCC4=O)[C@@]([C@H]4OC2=C5O)(CC3)C2=C(C=C5)C[C@H]1N3CC=C	O[C@@]1(CCC4=O)[C@@]([C@H]4OC2=C5O)(CC3)C2=C(C=C5)C[C@H]1N3CC=C	"InChI=1/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1"	UZHSEJADLWPNLE-GRGSLBFTBH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic antagonist	0.1	0.000305461	3.515044636	51	High	High	form of drug administered not known			
23350	3350	23350	810_FDAMDD_v3b	C18H26O2	274.39784	defined organic	parent	tested chemical	Nandrolone	434-22-0	single chemical compound	stereochem	(17beta)-17-hydroxyestr-4-en-3-one	O=C\1CC[C@H]4C(=C/1)/CC[C@@H]2[C@@H]4CC[C@]3(C)[C@@H](O)CC[C@@H]23	O=C\1CC[C@H]4C(=C/1)/CC[C@@H]2[C@@H]4CC[C@]3(C)[C@@H](O)CC[C@@H]23	"InChI=1/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1"	NPAGDVCDWIYMMC-IZPLOLCNBQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 4	Nandrolone	anabolic	3.33	0.012135664	1.915936455	33	Moderate	Moderate	form of drug administered not known			
23351	3351	23351	811_FDAMDD_v3b	C28H38O3	422.59952	defined organic	parent	tested chemical	Nandrolone cyclotate	22263-51-0	single chemical compound	stereochem	(17beta)-3-oxoestr-4-en-17-yl 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylate	CC12/C=C\C(CC1)(CC2)C(=O)O[C@H]4CC[C@H]5[C@@H]6CC\C3=C\C(=O)CC[C@@H]3[C@H]6CC[C@]45C	CC12/C=C\C(CC1)(CC2)C(=O)O[C@H]4CC[C@H]5[C@@H]6CC\C3=C\C(=O)CC[C@@H]3[C@H]6CC[C@]45C	"InChI=1/C28H38O3/c1-26-11-14-28(15-12-26,16-13-26)25(30)31-24-8-7-23-22-5-3-18-17-19(29)4-6-20(18)21(22)9-10-27(23,24)2/h11,14,17,20-24H,3-10,12-13,15-16H2,1-2H3/t20-,21+,22+,23-,24-,26?,27-,28?/m0/s1"	REACBNMPQDINOF-YBBIQVIJBD	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 4	Nandrolone	anabolic	3.33	0.007879801	2.103484766	35	Moderate	Moderate	form of drug administered not known; chemical name corrected in v3a			
23352	3352	23352	812_FDAMDD_v3b	C28H44O3	428.64716	defined organic	parent	tested chemical	Nandrolone decanoate	360-70-3	single chemical compound	stereochem	(17beta)-3-oxoestr-4-en-17-yl decanoate	CCCCCCCCCC(=O)O[C@H]2CC[C@H]3[C@@H]4CC\C1=C\C(=O)CC[C@@H]1[C@H]4CC[C@]23C	CCCCCCCCCC(=O)O[C@H]2CC[C@H]3[C@@H]4CC\C1=C\C(=O)CC[C@@H]1[C@H]4CC[C@]23C	"InChI=1/C28H44O3/c1-3-4-5-6-7-8-9-10-27(30)31-26-16-15-25-24-13-11-20-19-21(29)12-14-22(20)23(24)17-18-28(25,26)2/h19,22-26H,3-18H2,1-2H3/t22-,23+,24+,25-,26-,28-/m0/s1"	JKWKMORAXJQQSR-MOPIKTETBC	Clinical Reports 	Maximum Recommended Daily Dose	human	3 of 4	Nandrolone	anabolic	3.33	0.007768627	2.109655717	35	Moderate	Moderate	form of drug administered not known			
23353	3353	23353	813_FDAMDD_v3b	C27H34O3	406.55706	defined organic	parent	tested chemical	Nandrolone phenpropionate	62-90-8	single chemical compound	stereochem	(17beta)-3-oxoestr-4-en-17-yl 3-phenylpropanoate	O=C\1CC[C@H]5C(=C/1)/CC[C@@H]2[C@@H]5CC[C@]3(C)[C@H](CC[C@@H]23)OC(=O)CCc4ccccc4	O=C\1CC[C@H]5C(=C/1)/CC[C@@H]2[C@@H]5CC[C@]3(C)[C@H](CC[C@@H]23)OC(=O)CCc4ccccc4	"InChI=1/C27H34O3/c1-27-16-15-22-21-11-9-20(28)17-19(21)8-10-23(22)24(27)12-13-25(27)30-26(29)14-7-18-5-3-2-4-6-18/h2-6,17,21-25H,7-16H2,1H3/t21-,22+,23+,24-,25-,27-/m0/s1"	UBWXUGDQUBIEIZ-QNTYDACNBX	Clinical Reports 	Maximum Recommended Daily Dose	human	4 of 4	Nandrolone	anabolic steroid	3.33	0.008190732	2.086677274	35	Moderate	Moderate	form of drug administered not known			
23354	3354	23354	814_FDAMDD_v3b	C17H25N3O2S	335.4643	defined organic	parent	tested chemical	Naratriptan	121679-13-8	single chemical compound		N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide	C1=C(CCS(=O)(=O)NC)C=C3C(=C1)NC=C3C2CCN(C)CC2	C1=C(CCS(=O)(=O)NC)C=C3C(=C1)NC=C3C2CCN(C)CC2	"InChI=1/C17H25N3O2S/c1-18-23(21,22)10-7-13-3-4-17-15(11-13)16(12-19-17)14-5-8-20(2)9-6-14/h3-4,11-12,14,18-19H,5-10H2,1-2H3"	AMKVXSZCKVJAGH-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimigraine; vasoconstrictor	0.0833	0.000248313	3.605001308	52	High	High	form of drug administered not known			
23355	1163	21163	815_FDAMDD_v3b	C33H47NO13	665.72518	defined organic	parent	tested chemical	Natamycin	7681-93-8	single chemical compound	stereochem	"(1R,3S,5R,7R,8E,12R,14E,16E,18E,20E,22R,24S,25R,26S)-22-[(3-amino-3,6-dideoxy-beta-D-mannopyranosyl)oxy]-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0~5,7~]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid"	C\1=C/C(O[C@@H](C/C=C/C=C/C=C/C=C/[C@@H](C[C@@H]3O[C@](C[C@H](C[C@H]2O[C@H]/12)O)(C[C@@H]([C@H]3C(O)=O)O)O)O[C@@H]4O[C@@H]([C@H]([C@@H]([C@@H]4O)N)O)C)C)=O	C\1=C/C(O[C@@H](C/C=C/C=C/C=C/C=C/[C@@H](C[C@@H]3O[C@](C[C@H](C[C@H]2O[C@H]/12)O)(C[C@@H]([C@H]3C(O)=O)O)O)O[C@@H]4O[C@@H]([C@H]([C@@H]([C@@H]4O)N)O)C)C)=O	"InChI=1/C33H47NO13/c1-18-10-8-6-4-3-5-7-9-11-21(45-32-30(39)28(34)29(38)19(2)44-32)15-25-27(31(40)41)22(36)17-33(42,47-25)16-20(35)14-24-23(46-24)12-13-26(37)43-18/h3-9,11-13,18-25,27-30,32,35-36,38-39,42H,10,14-17,34H2,1-2H3,(H,40,41)/b4-3+,7-5+,8-6+,11-9+,13-12+/t18-,19-,20+,21+,22+,23-,24-,25+,27-,28+,29-,30+,32+,33-/m1/s1/f/h40H"	NCXMLFZGDNKEPB-FRHPVQHODF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	0.275	0.000413083	3.38396229	49	High-Moderate	High	form of drug administered not known			
23356	3356	23356	816_FDAMDD_v3b	C19H17NO7	371.34078	defined organic	parent	tested chemical	Nedocromil	69049-73-6	single chemical compound		"9-ethyl-4,6-dioxo-10-propyl-6,9-dihydro-4H-pyrano[3,2-g]quinoline-2,8-dicarboxylic acid"	C1=C(C(=O)O)OC2=C(C1=O)C=C3C(=C2CCC)N(CC)C(C(O)=O)=CC3=O	C1=C(C(=O)O)OC2=C(C1=O)C=C3C(=C2CCC)N(CC)C(C(O)=O)=CC3=O	"InChI=1/C19H17NO7/c1-3-5-9-16-10(13(21)7-12(18(23)24)20(16)4-2)6-11-14(22)8-15(19(25)26)27-17(9)11/h6-8H,3-5H2,1-2H3,(H,23,24)(H,25,26)/f/h23,25H"	RQTOOFIXOKYGAN-HPRFPMAVCM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiallergic; antiasthmatic	0.233	0.000627456	3.202416724	47	High-Moderate	High	form of drug administered not known			
23357	3357	23357	817_FDAMDD_v3b	C25H32ClN5O2	470.00688	defined organic	parent	tested chemical	Nefazodone	83366-66-9	single chemical compound		"2-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-5-ethyl-4-[2-(phenyloxy)ethyl]-2,4-dihydro-3H-1,2,4-triazol-3-one"	Clc1cccc(c1)N4CCN(CCCN3/N=C(/CC)N(CCOc2ccccc2)C3=O)CC4	Clc1cccc(c1)N4CCN(CCCN3/N=C(/CC)N(CCOc2ccccc2)C3=O)CC4	"InChI=1/C25H32ClN5O2/c1-2-24-27-31(25(32)30(24)18-19-33-23-10-4-3-5-11-23)13-7-12-28-14-16-29(17-15-28)22-9-6-8-21(26)20-22/h3-6,8-11,20H,2,7,12-19H2,1H3"	VRBKIVRKKCLPHA-UHFFFAOYAP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant; seratonin receptor antagonist	10	0.021276284	1.672104215	30	Moderate	Low	form of drug administered not known			
23358	3358	23358	818_FDAMDD_v3b	C12H26N4O6	322.35804	defined organic	parent	tested chemical	Neomycin A	3947-65-7	single chemical compound	stereochem	"(1R,2R,3S,4R,6S)-4,6-diamino-2,3-dihydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside"	N[C@H]2C[C@@H](N)[C@H](O)[C@@H](O)[C@@H]2O[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1N	N[C@H]2C[C@@H](N)[C@H](O)[C@@H](O)[C@@H]2O[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1N	"InChI=1/C12H26N4O6/c13-2-5-8(18)9(19)6(16)12(21-5)22-11-4(15)1-3(14)7(17)10(11)20/h3-12,17-20H,1-2,13-16H2/t3-,4+,5-,6-,7+,8-,9-,10-,11-,12-/m1/s1"	SYJXFKPQNSDJLI-HKEUSBCWBS	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Neomycin	antibacterial	100	0.310214071	0.508338507	17	Low	Low	form of drug administered not known; CASRN changed v3b			
23359	3359	23359	819_FDAMDD_v3b	C23H46N6O13	614.64374	defined organic	parent	tested chemical	Neomycin B	119-04-0	single chemical compound	stereochem	"(1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside"	N[C@@H]4[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]4O[C@H]1[C@@H](O)[C@@H](O[C@@H]1CO)O[C@H]3[C@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2N)[C@@H](N)C[C@@H](N)[C@@H]3O	N[C@@H]4[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]4O[C@H]1[C@@H](O)[C@@H](O[C@@H]1CO)O[C@H]3[C@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2N)[C@@H](N)C[C@@H](N)[C@@H]3O	"InChI=1/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1"	PGBHMTALBVVCIT-VCIWKGPPBG	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Neomycin	antibacterial	100	0.162695873	0.788623463	20	Low	Low	form of drug administered not known			
23360	3360	23360	820_FDAMDD_v3b	C12H19N2O2	223.29146	defined organic	parent	tested chemical	Neostigmine	59-99-4	single chemical compound	ammonium	"3-{[(dimethylamino)carbonyl]oxy}-N,N,N-trimethylanilinium"	C1(OC(=O)N(C)C)=CC=CC([N+](C)(C)C)=C1	C1(OC(=O)N(C)C)=CC=CC([N+](C)(C)C)=C1	"InChI=1/C12H19N2O2/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5/h6-9H,1-5H3/q+1"	ALWKGYPQUAPLQC-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cholinergic	6.25	0.027990323	1.552992096	29	Low-Moderate	Low	form of drug administered not known			
23361	929	20929	821_FDAMDD_v3b	C6H6N2O	122.1246	defined organic	parent	tested chemical	Niacinamide	98-92-0	single chemical compound		nicotinamide	NC(=O)C1=CC=CN=C1	NC(=O)C1=CC=CN=C1	"InChI=1/C6H6N2O/c7-6(9)5-2-1-3-8-4-5/h1-4H,(H2,7,9)/f/h7H2"	DFPAKSUCGFBDDF-IAUQMDSZCD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vitamin	8.33	0.068209026	1.166158153	24	Low	Low	form of drug administered not known			
23362	3362	23362	822_FDAMDD_v3b	C16H18N4O2	298.33972	defined organic	parent	tested chemical	Nialamide	51-12-7	single chemical compound		N-(phenylmethyl)-3-[2-(pyridin-4-ylcarbonyl)hydrazino]propanamide	C2=NC=CC(C(=O)NNCCC(=O)NCC1=CC=CC=C1)=C2	C2=NC=CC(C(=O)NNCCC(=O)NCC1=CC=CC=C1)=C2	"InChI=1/C16H18N4O2/c21-15(18-12-13-4-2-1-3-5-13)8-11-19-20-16(22)14-6-9-17-10-7-14/h1-7,9-10,19H,8,11-12H2,(H,18,21)(H,20,22)/f/h18,20H"	NOIIUHRQUVNIDD-CMLSCEPHCX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	3.33	0.011161772	1.952266844	33	Moderate	Moderate	form of drug administered not known			
23363	3363	23363	823_FDAMDD_v3b	C26H29N3O6	479.52496	defined organic	parent	tested chemical	Nicardipine	55985-32-5	single chemical compound		"methyl 2-[methyl(phenylmethyl)amino]ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate"	C3(C)=C(C(=O)OC)C(C1=CC=CC(N(=O)=O)=C1)C(C(=O)OCCN(C)CC2=CC=CC=C2)=C(C)N3	C3(C)=C(C(=O)OC)C(C1=CC=CC(N(=O)=O)=C1)C(C(=O)OCCN(C)CC2=CC=CC=C2)=C(C)N3	"InChI=1/C26H29N3O6/c1-17-22(25(30)34-4)24(20-11-8-12-21(15-20)29(32)33)23(18(2)27-17)26(31)35-14-13-28(3)16-19-9-6-5-7-10-19/h5-12,15,24,27H,13-14,16H2,1-4H3"	ZBBHBTPTTSWHBA-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antianginal; antihypertensive	2	0.004170794	2.379781222	38	Moderate	High	form of drug administered not known			
23364	3364	23364	824_FDAMDD_v3b	C29H24N4O8	556.52286	defined organic	parent	tested chemical	Niceritrol	5868-05-3	single chemical compound		"3-Pyridinecarboxylic acid, 2,2-bis(((3-pyridinylcarbonyl)oxy)methyl)-1,3-propanediyl ester"	C(C(COC(=O)C1=CC=CN=C1)(COC(=O)C2=CC=CN=C2)COC(=O)C3=CC=CN=C3)OC(=O)C4=CC=CN=C4	C(C(COC(=O)C1=CC=CN=C1)(COC(=O)C2=CC=CN=C2)COC(=O)C3=CC=CN=C3)OC(=O)C4=CC=CN=C4	"InChI=1/C29H24N4O8/c34-25(21-5-1-9-30-13-21)38-17-29(18-39-26(35)22-6-2-10-31-14-22,19-40-27(36)23-7-3-11-32-15-23)20-41-28(37)24-8-4-12-33-16-24/h1-16H,17-20H2"	KUEUWHJGRZKESU-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihyperlipoproteinemic	4	0.007187486	2.143423017	35	Moderate	Moderate	form of drug administered not known			
23365	3365	23365	825_FDAMDD_v3b	C30H24N4O10	600.53236	defined organic	parent	tested chemical	Nicofuranose	15351-13-0	single chemical compound	stereochem	"1,3,4,6-tetrakis-O-(pyridin-3-ylcarbonyl)-beta-D-fructofuranose"	[C@@H]1(O[C@@]([C@H]([C@@H]1OC(c2cnccc2)=O)OC(c3cnccc3)=O)(COC(c4cnccc4)=O)O)COC(c5cnccc5)=O	[C@@H]1(O[C@@]([C@H]([C@@H]1OC(c2cnccc2)=O)OC(c3cnccc3)=O)(COC(c4cnccc4)=O)O)COC(c5cnccc5)=O	"InChI=1/C30H24N4O10/c35-26(19-5-1-9-31-13-19)40-17-23-24(42-28(37)21-7-3-11-33-15-21)25(43-29(38)22-8-4-12-34-16-22)30(39,44-23)18-41-27(36)20-6-2-10-32-14-20/h1-16,23-25,39H,17-18H2/t23-,24-,25+,30-/m1/s1"	FUWFSXZKBMCSKF-ZASNTINBBX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		peripheral vasodilator	66.7	0.11106812	0.954410581	22	Low	Low	form of drug administered not known			
23366	932	20932	826_FDAMDD_v3b	C6H5NO2	123.1094	defined organic	parent	tested chemical	Nicotinic acid	59-67-6	single chemical compound		pyridine-3-carboxylic acid	OC(=O)C1=CC=CN=C1	OC(=O)C1=CC=CN=C1	"InChI=1/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9)/f/h8H"	PVNIIMVLHYAWGP-FZOZFQFYCF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vitamin	12.5	0.101535707	0.993381202	22	Low	Low	form of drug administered not known			
23367	3367	23367	827_FDAMDD_v3b	C6H7NO	109.12588	defined organic	parent	tested chemical	Nicotinyl alcohol	100-55-0	single chemical compound		pyridin-3-ylmethanol	C1=CC=C(CO)C=N1	C1=CC=C(CO)C=N1	"InChI=1/C6H7NO/c8-5-6-2-1-3-7-4-6/h1-4,8H,5H2"	MVQVNTPHUGQQHK-UHFFFAOYAK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vasodilator	5	0.045818645	1.338957755	26	Low-Moderate	Low	form of drug administered not known			
23368	3368	23368	828_FDAMDD_v3b	C13H9F3N2O2	282.2179696	defined organic	parent	tested chemical	Niflumic acid	4394-00-7	single chemical compound		2-{[3-(trifluoromethyl)phenyl]amino}pyridine-3-carboxylic acid	C2=CC=C(C(=O)O)C(NC1=CC=CC(C(F)(F)F)=C1)=N2	C2=CC=C(C(=O)O)C(NC1=CC=CC(C(F)(F)F)=C1)=N2	"InChI=1/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)/f/h18-19H"	JZFPYUNJRRFVQU-VEWCPZSHCT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	12.5	0.044292006	1.35367465	26	Low-Moderate	Low	form of drug administered not known			
23369	3369	23369	829_FDAMDD_v3b	C16H13N3O3	295.29272	defined organic	parent	tested chemical	Nimetazepam	2011-67-8	single chemical compound		"1-methyl-7-nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one"	C1=C(N(=O)=O)C=C3C(=C1)N(C)C(=O)CN=C3C2=CC=CC=C2	C1=C(N(=O)=O)C=C3C(=C1)N(C)C(=O)CN=C3C2=CC=CC=C2	"InChI=1/C16H13N3O3/c1-18-14-8-7-12(19(21)22)9-13(14)16(17-10-15(18)20)11-5-3-2-4-6-11/h2-9H,10H2,1H3"	GWUSZQUVEVMBPI-UHFFFAOYAS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant; skeletal muscle relaxant	0.0833	0.000282093	3.549607739	51	High	High	form of drug administered not known			
23370	3370	23370	830_FDAMDD_v3b	C21H26N2O7	418.44034	defined organic	parent	tested chemical	Nimodipine	66085-59-4	single chemical compound		"1-methylethyl 2-(methyloxy)ethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate"	C2=CC(C1C(C(=O)OC(C)C)=C(C)NC(C)=C1C(=O)OCCOC)=CC(N(=O)=O)=C2	C2=CC(C1C(C(=O)OC(C)C)=C(C)NC(C)=C1C(=O)OCCOC)=CC(N(=O)=O)=C2	"InChI=1/C21H26N2O7/c1-12(2)30-21(25)18-14(4)22-13(3)17(20(24)29-10-9-28-5)19(18)15-7-6-8-16(11-15)23(26)27/h6-8,11-12,19,22H,9-10H2,1-5H3"	UIAGMCDKSXEBJQ-UHFFFAOYAP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cerebral vasodilator	6	0.014338962	1.843482296	32	Moderate	Low	form of drug administered not known			
23371	3371	23371	831_FDAMDD_v3b	C20H24N2O6	388.41436	defined organic	parent	tested chemical	Nisoldipine	63675-72-9	single chemical compound	tautomers	"methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate"	C2(C)=C(C(=O)OC)C(C1=CC=CC=C1N(=O)=O)C(C(=O)OCC(C)C)=C(C)N2	C2(C)=C(C(=O)OC)C(C1=CC=CC=C1N(=O)=O)C(C(=O)OCC(C)C)=C(C)N2	"InChI=1/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3"	VKQFCGNPDRICFG-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal	0.667	0.001717238	2.765169444	42	Moderate	High	form of drug administered not known			
23372	3372	23372	832_FDAMDD_v3b	C15H11N3O3	281.26614	defined organic	parent	tested chemical	Nitrazepam	146-22-5	single chemical compound		"7-nitro-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one"	C1=C(N(=O)=O)C=C3C(=C1)NC(=O)CN=C3C2=CC=CC=C2	C1=C(N(=O)=O)C=C3C(=C1)NC(=O)CN=C3C2=CC=CC=C2	"InChI=1/C15H11N3O3/c19-14-9-16-15(10-4-2-1-3-5-10)12-8-11(18(20)21)6-7-13(12)17-14/h1-8H,9H2,(H,17,19)/f/h17H"	KJONHKAYOJNZEC-HCKMINDGCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant; hypnotic	0.333	0.001183932	2.92667322	44	Moderate	High	form of drug administered not known			
23373	3373	23373	833_FDAMDD_v3b	C18H20N2O6	360.3612	defined organic	parent	tested chemical	Nitrendipine	39562-70-4	single chemical compound		"ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate"	C2(C)=C(C(=O)OC)C(C1=CC=CC(N(=O)=O)=C1)C(C(=O)OCC)=C(C)N2	C2(C)=C(C(=O)OC)C(C1=CC=CC(N(=O)=O)=C1)C(C(=O)OCC)=C(C)N2	"InChI=1/C18H20N2O6/c1-5-26-18(22)15-11(3)19-10(2)14(17(21)25-4)16(15)12-7-6-8-13(9-12)20(23)24/h6-9,16,19H,5H2,1-4H3"	PVHUJELLJLJGLN-UHFFFAOYAU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.333	0.000924073	3.034293791	45	High-Moderate	High	form of drug administered not known			
23374	972	20972	834_FDAMDD_v3b	C8H6N4O5	238.157	defined organic	parent	tested chemical	Nitrofurantoin	67-20-9	single chemical compound	stereochem	"1-{[(1E)-(5-nitrofuran-2-yl)methylidene]amino}imidazolidine-2,4-dione"	O=C1N(CC(=O)N1)/N=C/C2=CC=C(O2)[N+](=O)[O-]	O=C1N(CC(=O)N1)/N=C/C2=CC=C(O2)[N+](=O)[O-]	"InChI=1/C8H6N4O5/c13-6-4-11(8(14)10-6)9-3-5-1-2-7(17-5)12(15)16/h1-3H,4H2,(H,10,13,14)/b9-3+/f/h10H"	NXFQHRVNIOXGAQ-FLZDIJAGDD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	6.67	0.028006735	1.552737517	29	Low-Moderate	Low	form of drug administered not known; Nitrofurantoin; H2O [17140-81-7]; Na [54-87-5]			
23375	3375	23375	835_FDAMDD_v3b	C5H12Cl3NO	208.51388	defined organic	complex HCl	tested chemical	Nitrogen mustard oxide	302-70-5	single chemical compound	charge separated form	bis(2-chloroethyl)methylamine oxide hydrochloride	CN(=O)(CCCl)CCCl.Cl	C(N(=O)(C)CCCl)CCl	"InChI=1/C5H11Cl2NO.ClH/c1-8(9,4-2-6)5-3-7;/h2-5H2,1H3;1H"	SYNHCENRCUAUNM-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.4	0.001918338	2.717074978	42	Moderate	High	form of drug administered not known; Mechlorethamine oxide HCl			
23376	3376	23376	836_FDAMDD_v3b	C12H21N5O2S2	331.45744	defined organic	parent	tested chemical	Nizatidine	76963-41-2	single chemical compound	stereochem; tautomers	"(E)-N-{2-[({2-[(dimethylamino)methyl]-1,3-thiazol-4-yl}methyl)thio]ethyl}-N'-methyl-2-nitroethene-1,1-diamine"	C1(CN(C)C)=NC(CSCCNC(NC)=CN(=O)=O)=CS1	C1(CN(C)C)=NC(CSCCNC(NC)=CN(=O)=O)=CS1	"InChI=1/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6+"	SGXXNSQHWDMGGP-IZZDOVSWBC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiulcerative	5	0.015084893	1.821457767	32	Moderate	Low	form of drug administered not known			
23377	3377	23377	837_FDAMDD_v3b	C16H18N2	238.32752	defined organic	parent	tested chemical	Nomifensine	24526-64-5	single chemical compound		"2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinolin-8-amine"	C1=CC=C3C(=C1N)CN(C)CC3C2=CC=CC=C2	C1=CC=C3C(=C1N)CN(C)CC3C2=CC=CC=C2	"InChI=1/C16H18N2/c1-18-10-14(12-6-3-2-4-7-12)13-8-5-9-16(17)15(13)11-18/h2-9,14H,10-11,17H2,1H3"	XXPANQJNYNUNES-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	3.33	0.013972369	1.85472996	32	Moderate	Moderate	form of drug administered not known; maleate [32795-47-4]			
23378	3378	23378	838_FDAMDD_v3b	C8H11NO3	169.17784	defined organic	parent	tested chemical	Norepinephrine	51-41-2	single chemical compound	stereochem	"4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol"	Oc1ccc(cc1O)[C@@H](O)CN	Oc1ccc(cc1O)[C@@H](O)CN	"InChI=1/C8H11NO3/c9-4-8(12)5-1-2-6(10)7(11)3-5/h1-3,8,10-12H,4,9H2/t8-/m0/s1"	SFLSHLFXELFNJZ-QMMMGPOBBL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		adrenergic; antihypotensive	0.0667	0.00039426	3.404217642	49	High-Moderate	High	form of drug administered not known; alternate CASRN [66197-73-7] and [4899-05-2]; R form shown; dl form [138-65-8]; bitartrate [69815-49-2]; l-tartrate [51-40-1]			
23379	3379	23379	839_FDAMDD_v3b	C20H30O2	302.451	defined organic	parent	tested chemical	Norethandrolone	52-78-8	single chemical compound	stereochem	(17beta)-17-ethyl-17-hydroxyestr-4-en-3-one	[C@@]42([C@H]([C@@H]1CCC=3[C@@H]([C@H]1CC2)CCC(C=3)=O)CC[C@@]4(O)CC)C	[C@@]42([C@H]([C@@H]1CCC=3[C@@H]([C@H]1CC2)CCC(C=3)=O)CC[C@@]4(O)CC)C	"InChI=1/C20H30O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h12,15-18,22H,3-11H2,1-2H3/t15-,16+,17+,18-,19-,20-/m0/s1"	ZDHCJEIGTNNEMY-XGXHKTLJBJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		androgen	0.5	0.00165316	2.78168502	42	Moderate	High	form of drug administered not known			
23380	3380	23380	840_FDAMDD_v3b	C20H26O2	298.4192	defined organic	parent	tested chemical	Norethindrone	68-22-4	single chemical compound	stereochem	(17beta)-17-ethynyl-17-hydroxyestr-4-en-3-one	[C@@]42([C@H]([C@@H]1CCC=3[C@@H]([C@H]1CC2)CCC(C=3)=O)CC[C@]4(C#C)O)C	[C@@]42([C@H]([C@@H]1CCC=3[C@@H]([C@H]1CC2)CCC(C=3)=O)CC[C@]4(C#C)O)C	"InChI=1/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,12,15-18,22H,4-11H2,2H3/t15-,16+,17+,18-,19-,20-/m0/s1"	VIKNJXKGJWUCNN-XGXHKTLJBN	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Norethindrone	progestogen	0.0167	5.59615E-05	4.252110291	59	High	High	form of drug administered not known			
23381	1071	23381	841_FDAMDD_v3b	C22H28O3	340.45592	defined organic	parent	tested chemical	Norethindrone acetate	51-98-9	single chemical compound	stereochem	(17beta)-17-ethynyl-3-oxoestr-4-en-17-yl acetate	O=C4C=C2[C@@](CC4)([H])[C@]1([H])[C@](CC2)([H])[C@@](CC3)([H])[C@@](CC1)(C)[C@]3(OC(C)=O)C#C	O=C4C=C2[C@@](CC4)([H])[C@]1([H])[C@](CC2)([H])[C@@](CC3)([H])[C@@](CC1)(C)[C@]3(OC(C)=O)C#C	"InChI=1/C22H28O3/c1-4-22(25-14(2)23)12-10-20-19-7-5-15-13-16(24)6-8-17(15)18(19)9-11-21(20,22)3/h1,13,17-20H,5-12H2,2-3H3/t17-,18+,19+,20-,21-,22-/m0/s1"	IMONTRJLAWHYGT-ZCPXKWAGBE	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Norethindrone	progestogen	0.0167	4.90519E-05	4.309344419	59	High	High	form of drug administered not known			
23382	563	21069	842_FDAMDD_v3b	C20H26O2	298.4192	defined organic	parent	tested chemical	Norethynodrel	68-23-5	single chemical compound	stereochem	(17beta)-17-ethynyl-17-hydroxyestr-5(10)-en-3-one	O=C2CC3=C(CC2)[C@]1([H])[C@](CC3)([H])[C@@](CC4)([H])[C@]([C@]4(O)C#C)(C)CC1	O=C4CC\C3=C(\CC[C@@H]2[C@@H]3CC[C@@]1(C)[C@H]2CC[C@@]1(O)C#C)C4	"InChI=1/C20H26O2/c1-3-20(22)11-9-18-17-6-4-13-12-14(21)5-7-15(13)16(17)8-10-19(18,20)2/h1,16-18,22H,4-12H2,2H3/t16-,17-,18+,19+,20+/m1/s1"	ICTXHFFSOAJUMG-SLHNCBLABT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		progestogen	0.667	0.002235111	2.650700928	41	Moderate	High	form of drug administered not known			
23383	3383	23383	843_FDAMDD_v3b	C19H28O2	288.42442	defined organic	parent	tested chemical	Normethandrone	514-61-4	single chemical compound	stereochem	(17beta)-17-hydroxy-17-methylestr-4-en-3-one	[C@@]42([C@H]([C@@H]1CCC=3[C@@H]([C@H]1CC2)CCC(C=3)=O)CC[C@@]4(O)C)C	[C@@]42([C@H]([C@@H]1CCC=3[C@@H]([C@H]1CC2)CCC(C=3)=O)CC[C@@]4(O)C)C	"InChI=1/C19H28O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h11,14-17,21H,3-10H2,1-2H3/t14-,15+,16+,17-,18-,19-/m0/s1"	ZXSWTMLNIIZPET-ZOFHRBRSBU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		androgen	0.5	0.001733556	2.761062024	42	Moderate	High	form of drug administered not known			
23384	3384	23384	844_FDAMDD_v3b	C19H21N	263.37674	defined organic	parent	tested chemical	Nortriptyline	72-69-5	single chemical compound		"3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine"	C1C=CC2=C(C=1)CCC3=C(C2=CCCNC)C=CC=C3	C1C=CC2=C(C=1)CCC3=C(C2=CCCNC)C=CC=C3	"InChI=1/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3"	PHVGLTMQBUFIQQ-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	1.67	0.006340727	2.197860947	36	Moderate	High	form of drug administered not known			
23385	3385	23385	845_FDAMDD_v3b	C22H23NO7	413.42052	defined organic	parent	tested chemical	Noscapine	128-62-1	single chemical compound	stereochem	"(3S)-3-[(5R)-6-methyl-4-(methyloxy)-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-5-yl]-6,7-bis(methyloxy)-2-benzofuran-1(3H)-one"	C1N([C@H](c3c(C1)cc2OCOc2c3OC)[C@@H]5c4ccc(c(c4C(O5)=O)OC)OC)C	C1N([C@H](c3c(C1)cc2OCOc2c3OC)[C@@H]5c4ccc(c(c4C(O5)=O)OC)OC)C	"InChI=1/C22H23NO7/c1-23-8-7-11-9-14-20(29-10-28-14)21(27-4)15(11)17(23)18-12-5-6-13(25-2)19(26-3)16(12)22(24)30-18/h5-6,9,17-18H,7-8,10H2,1-4H3/t17-,18+/m1/s1"	AKNNEGZIBPJZJG-MSOLQXFVBO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antitussive	2.5	0.006047112	2.21845202	36	Moderate	High-Moderate	form of drug administered not known			
23386	3386	23386	846_FDAMDD_v3b	C31H35N2NaO11	634.60617	defined organic	salt Na	tested chemical	Novobiocin	1476-53-5	single chemical compound	stereochem; parent [303-81-1]	"7-(4-(Carbamoyloxy)tetrahydro-3-hydroxy-5-methoxy-6,6-dimethylpyran-2-yloxy)-4-hydroxy-3-(4-hydroxy-3-(4-hydroxy-3-(3-methyl-2-butenyl)benzamido)-8-methylcoumarin monosodium salt"	[Na+].C/C(C)=C\Cc1cc(ccc1O)C(=O)N\C3=C(/[O-])c4ccc(O[C@@H]2OC(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@H]2O)c(C)c4OC3=O	C/C(C)=C\Cc1cc(ccc1O)C(=O)N\C3=C(/O)c4ccc(O[C@@H]2OC(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@H]2O)c(C)c4OC3=O	"InChI=1/C31H36N2O11.Na/c1-14(2)7-8-16-13-17(9-11-19(16)34)27(37)33-21-22(35)18-10-12-20(15(3)24(18)42-28(21)38)41-29-23(36)25(43-30(32)39)26(40-6)31(4,5)44-29;/h7,9-13,23,25-26,29,34-36H,8H2,1-6H3,(H2,32,39)(H,33,37);/q;+1/p-1/t23-,25+,26-,29-;/m1./s1/fC31H35N2O11.Na/h35h,33H,32H2;/q-1;m"	WWPRGAYLRGSOSU-PRVPFANWDA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	25	0.039394511	1.404564282	27	Low-Moderate	Low	form of drug administered not known			
23387	3387	23387	847_FDAMDD_v3b	C19H25NO2	299.4073	defined organic	parent	tested chemical	Nylidrin	447-41-6	single chemical compound		4-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]propyl}phenol	C2=C(O)C=CC(C(O)C(C)NC(C)CCC1=CC=CC=C1)=C2	C2=C(O)C=CC(C(O)C(C)NC(C)CCC1=CC=CC=C1)=C2	"InChI=1/C19H25NO2/c1-14(8-9-16-6-4-3-5-7-16)20-15(2)19(22)17-10-12-18(21)13-11-17/h3-7,10-15,19-22H,8-9H2,1-2H3"	PTGXAUBQBSGPKF-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vasodilator	0.8	0.002671946	2.573172398	40	Moderate	High	form of drug administered not known			
23388	3388	23388	848_FDAMDD_v3b	C17H20N4S	312.4325	defined organic	parent	tested chemical	Olanzapine	132539-06-1	single chemical compound		"2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine"	C2(N1CCN(C)CC1)=NC4=C(NC3=C2C=C(C)S3)C=CC=C4	C2(N1CCN(C)CC1)=NC4=C(NC3=C2C=C(C)S3)C=CC=C4	"InChI=1/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3"	KVWDHTXUZHCGIO-UHFFFAOYAQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	0.25	0.000800173	3.096816195	46	High-Moderate	High	form of drug administered not known			
23389	3389	23389	849_FDAMDD_v3b	C35H61NO12	687.85834	defined organic	parent	tested chemical	Oleandomycin	3922-90-5	single chemical compound	stereochem	"(3S,5R,6S,7R,8R,11R,12S,13R,14S,15S)-6-hydroxy-5,7,8,11,13,15-hexamethyl-4,10-dioxo-14-{[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-1,9-dioxaspiro[2.13]hexadec-12-yl 2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranoside"	CN(C)[C@H]4C[C@@H](C)O[C@@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]1C[C@H](OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@@]2(CO2)C[C@@H]3C)[C@@H]4O	CN(C)[C@H]4C[C@@H](C)O[C@@H](O[C@@H]3[C@@H](C)[C@H](O[C@H]1C[C@H](OC)[C@@H](O)[C@H](C)O1)[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@@]2(CO2)C[C@@H]3C)[C@@H]4O	"InChI=1/C35H61NO12/c1-16-14-35(15-43-35)32(40)19(4)27(37)18(3)22(7)46-33(41)21(6)31(47-26-13-25(42-11)28(38)23(8)45-26)20(5)30(16)48-34-29(39)24(36(9)10)12-17(2)44-34/h16-31,34,37-39H,12-15H2,1-11H3/t16-,17+,18-,19+,20+,21+,22+,23-,24-,25-,26-,27-,28-,29+,30-,31-,34-,35-/m0/s1"	RZPAKFUAFGMUPI-KGIGTXTPBQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	33.3	0.048411131	1.315054774	26	Low-Moderate	Low	form of drug administered not known			
23390	3390	23390	850_FDAMDD_v3b	C21H23NO3	337.41222	defined organic	parent	tested chemical	Olopatadine	113806-05-6	single chemical compound	stereochem	"{(11E)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid"	O1CC3=C(C(=CCCN(C)C)C2=C1C=CC(CC(O)=O)=C2)C=CC=C3	O1CC3=C(C(=CCCN(C)C)C2=C1C=CC(CC(O)=O)=C2)C=CC=C3	"InChI=1/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8+/f/h23H"	JBIMVDZLSHOPLA-XDBXKQQJDC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic; antiallergic	0.333	0.000986923	3.005716574	45	High-Moderate	High	form of drug administered not known			
23391	3391	23391	851_FDAMDD_v3b	C14H10N2O6	302.239	defined organic	parent	tested chemical	Olsalazine	15722-48-2	single chemical compound	stereochem	"3,3'-(E)-diazene-1,2-diylbis(6-hydroxybenzoic acid)"	C2=C(C(O)=O)C(O)=CC=C2N=NC1=CC(C(=O)O)=C(O)C=C1	C2=C(C(O)=O)C(O)=CC=C2N=NC1=CC(C(=O)O)=C(O)C=C1	"InChI=1/C14H10N2O6/c17-11-3-1-7(5-9(11)13(19)20)15-16-8-2-4-12(18)10(6-8)14(21)22/h1-6,17-18H,(H,19,20)(H,21,22)/b16-15+/f/h19,21H"	QQBDLJCYGRGAKP-SDWOBJKFDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		treatment of ulcerative colitis	16.7	0.055254286	1.257634033	25	Low-Moderate	Low	form of drug administered not known			
23392	1080	21080	852_FDAMDD_v3b	C17H19N3O3S	345.4154	defined organic	parent	tested chemical	Omeprazole	73590-58-6	single chemical compound		"2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole"	O=S(C1=NC2=C(C=CC(=C2)OC)N1)CC3=C(C(=C(C=N3)C)OC)C	O=S(C1=NC2=C(C=CC(=C2)OC)N1)CC3=C(C(=C(C=N3)C)OC)C	"InChI=1/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)/f/h19H"	SUBDBMMJDZJVOS-LILDFLRNCA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiulcerative	2	0.00579013	2.237311701	36	Moderate	High	form of drug administered not known			
23393	3393	23393	853_FDAMDD_v3b	C18H19N3O	293.36296	defined organic	parent	tested chemical	Ondansetron	99614-02-5	single chemical compound		"9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one"	C1=CC=C2C(=C1)C4=C(N2C)CCC(CN3C(C)=NC=C3)C4=O	C1=CC=C2C(=C1)C4=C(N2C)CCC(CN3C(C)=NC=C3)C4=O	"InChI=1/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3"	FELGMEQIXOGIFQ-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiemetic	0.4	0.001363499	2.865345288	43	Moderate	High	form of drug administered not known; CASRN changed v3b			
23394	3394	23394	854_FDAMDD_v3b	C23H29N3O	363.49586	defined organic	parent	tested chemical	Opipramol	315-72-0	single chemical compound		"2-{4-[3-(5H-dibenzo[b,f]azepin-5-yl)propyl]piperazin-1-yl}ethanol"	C1=CC=C3C(=C1)C=CC4=C(N3CCCN2CCN(CCO)CC2)C=CC=C4	C1=CC=C3C(=C1)C=CC4=C(N3CCCN2CCN(CCO)CC2)C=CC=C4	"InChI=1/C23H29N3O/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26/h1-4,6-11,27H,5,12-19H2"	YNZFUWZUGRBMHL-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant; antipsychotic	5	0.013755315	1.861529465	32	Moderate	Low	form of drug administered not known			
23395	3395	23395	855_FDAMDD_v3b	C29H53NO5	495.73482	defined organic	parent	tested chemical	Orlistat	96829-58-2	single chemical compound	stereochem	"(1S)-1-{[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]methyl}dodecyl N-formylleucinate"	C1([C@@H](CCCCCC)[C@H](C[C@@H](OC(=O)C(CC(C)C)NC=O)CCCCCCCCCCC)O1)=O	C1([C@@H](CCCCCC)[C@H](C[C@@H](OC(=O)C(CC(C)C)NC=O)CCCCCCCCCCC)O1)=O	"InChI=1/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26?,27-/m0/s1/f/h30H"	AHLBNYSZXLDEJQ-FOCHDIOHDJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiobesity	6	0.012103245	1.917098174	33	Moderate	Low	form of drug administered not known			
23396	3396	23396	856_FDAMDD_v3b	C18H23NO	269.38132	defined organic	parent	tested chemical	Orphenadrine	83-98-7	single chemical compound		"N,N-dimethyl-2-{[(2-methylphenyl)(phenyl)methyl]oxy}ethanamine"	C2=CC=CC(C(OCCN(C)C)C1=CC=CC=C1)=C2C	C2=CC=CC(C(OCCN(C)C)C1=CC=CC=C1)=C2C	"InChI=1/C18H23NO/c1-15-9-7-8-12-17(15)18(20-14-13-19(2)3)16-10-5-4-6-11-16/h4-12,18H,13-14H2,1-3H3"	QVYRGXJJSLMXQH-UHFFFAOYAX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant; antihistiminic	6.67	0.02476044	1.606241643	29	Low-Moderate	Low	form of drug administered not known			
23397	3397	23397	857_FDAMDD_v3b	C19H19N3O5S	401.43626	defined organic	parent	tested chemical	Oxacillin	66-79-5	single chemical compound	stereochem	"(2S,5R,6R)-3,3-dimethyl-6-{[(5-methyl-3-phenylisoxazol-4-yl)carbonyl]amino}-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	[C@@H]1([C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)O)NC(c4c(c3ccccc3)noc4C)=O	[C@@H]1([C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)O)NC(c4c(c3ccccc3)noc4C)=O	"InChI=1/C19H19N3O5S/c1-9-11(12(21-27-9)10-7-5-4-6-8-10)15(23)20-13-16(24)22-14(18(25)26)19(2,3)28-17(13)22/h4-8,13-14,17H,1-3H3,(H,20,23)(H,25,26)/t13-,14+,17-/m1/s1/f/h20,25H"	UWYHMGVUTGAWSP-RYUVHSDCDI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	100	0.249105549	0.603616598	18	Low	Low	form of drug administered not known			
23398	3398	23398	858_FDAMDD_v3b	C14H21N3O3	279.33484	defined organic	parent	tested chemical	Oxamniquine	21738-42-1	single chemical compound		"(2-{[(1-methylethyl)amino]methyl}-7-nitro-1,2,3,4-tetrahydroquinolin-6-yl)methanol"	C1(N(=O)=O)=C(CO)C=C2C(=C1)NC(CNC(C)C)CC2	C1(N(=O)=O)=C(CO)C=C2C(=C1)NC(CNC(C)C)CC2	"InChI=1/C14H21N3O3/c1-9(2)15-7-12-4-3-10-5-11(8-18)14(17(19)20)6-13(10)16-12/h5-6,9,12,15-16,18H,3-4,7-8H2,1-2H3"	XCGYUJZMCCFSRP-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anthelmintic	60	0.214795977	0.667973856	19	Low	Low	form of drug administered not known			
23399	3399	23399	859_FDAMDD_v3b	C19H30O3	306.4397	defined organic	parent	tested chemical	Oxandrolone	53-39-4	single chemical compound	stereochem	"(4aS,4bS,6aS,7S,9aS,9bR,11aS)-7-hydroxy-4a,6a,7-trimethyltetradecahydroindeno[4,5-h]isochromen-2(1H)-one"	[C@]34([C@@H]1[C@H]([C@H]2[C@](CC1)([C@](O)(C)CC2)C)CC[C@H]3CC(OC4)=O)C	[C@]34([C@@H]1[C@H]([C@H]2[C@](CC1)([C@](O)(C)CC2)C)CC[C@H]3CC(OC4)=O)C	"InChI=1/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1"	QSLJIVKCVHQPLV-PEMPUTJUBY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		androgen	0.333	0.001086674	2.963900795	44	Moderate	High	form of drug administered not known			
23400	1087	21087	860_FDAMDD_v3b	C15H11ClN2O2	286.713	defined organic	parent	tested chemical	Oxazepam	604-75-1	single chemical compound	tautomers	"7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one"	ClC1=CC=C2C(=C1)C(=NC(O)C(=O)N2)C3=CC=CC=C3	ClC1=CC=C2C(=C1)C(=NC(O)C(=O)N2)C3=CC=CC=C3	"InChI=1/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)/f/h17H"	ADIMAYPTOBDMTL-HCKMINDGCL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	2	0.006975617	2.156417389	35	Moderate	High	form of drug administered not known			
23401	3401	23401	861_FDAMDD_v3b	C18H17ClN2O2	328.79278	defined organic	parent	tested chemical	Oxazolam	24143-17-7	single chemical compound	stereochem	"(2R,11bS)-10-chloro-2-methyl-11b-phenyl-2,3,7,11b-tetrahydro[1,3]oxazolo[3,2-d][1,4]benzodiazepin-6(5H)-one"	[C@@]12(c3c(NC(CN1C[C@H](O2)C)=O)ccc(c3)Cl)c4ccccc4	[C@@]12(c3c(NC(CN1C[C@H](O2)C)=O)ccc(c3)Cl)c4ccccc4	"InChI=1/C18H17ClN2O2/c1-12-10-21-11-17(22)20-16-8-7-14(19)9-15(16)18(21,23-12)13-5-3-2-4-6-13/h2-9,12H,10-11H2,1H3,(H,20,22)/t12-,18+/m1/s1/f/h20H"	VCCZBYPHZRWKFY-SHMIVNSCDJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	1	0.003041429	2.516922272	39	Moderate	High	form of drug administered not known			
23402	3402	23402	862_FDAMDD_v3b	C19H26BrNO4	412.31804	defined organic	salt Br	tested chemical	Oxitropium bromide	30286-75-0	single chemical compound	ammonium; stereochem	"(1R,2R,4S,5S,7S)-9-ethyl-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9-methyl-3-oxa-9-azoniatricyclo[3.3.1.0~2,4~]nonane bromide"	[Br-].[C@H]21[C@H]3C[C@H](C[C@@H]([C@@H]1O2)[N+]3(C)CC)OC([C@@H](c4ccccc4)CO)=O	[C@H]21[C@H]3C[C@H](C[C@@H]([C@@H]1O2)[N+]3(C)CC)OC([C@@H](c4ccccc4)CO)=O	"InChI=1/C19H26NO4.BrH/c1-3-20(2)15-9-13(10-16(20)18-17(15)24-18)23-19(22)14(11-21)12-7-5-4-6-8-12;/h4-8,13-18,21H,3,9-11H2,1-2H3;1H/q+1;/p-1/t13-,14-,15-,16+,17-,18+,20?;/m1./s1/fC19H26NO4.Br/h;1h/qm;-1"	LCELQERNWLBPSY-LSUKXYBCDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator	0.01	2.42531E-05	4.615232337	63	High	High	form of drug administered not known			
23403	3403	23403	863_FDAMDD_v3b	C14H19N3O	245.32016	defined organic	parent	tested chemical	Oxolamine	959-14-8	single chemical compound		"N,N-diethyl-2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethanamine"	C2(C1=CC=CC=C1)N=C(CCN(CC)CC)ON=2	C2(C1=CC=CC=C1)N=C(CCN(CC)CC)ON=2	"InChI=1/C14H19N3O/c1-3-17(4-2)11-10-13-15-14(16-18-13)12-8-6-5-7-9-12/h5-9H,3-4,10-11H2,1-2H3"	IDCHQQSVJAAUQQ-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	3.33	0.013574098	1.867289006	32	Moderate	Moderate	form of drug administered not known			
23404	1089	21089	864_FDAMDD_v3b	C13H11NO5	261.2336	defined organic	parent	tested chemical	Oxolinic acid	14698-29-4	single chemical compound		"5-ethyl-8-oxo-5,8-dihydro[1,3]dioxolo[4,5-g]quinoline-7-carboxylic acid"	O=C1C2=CC3=C(C=C2N(C=C1C(=O)O)CC)OCO3	O=C1C2=CC3=C(C=C2N(C=C1C(=O)O)CC)OCO3	"InChI=1/C13H11NO5/c1-2-14-5-8(13(16)17)12(15)7-3-10-11(4-9(7)14)19-6-18-10/h3-5H,2,6H2,1H3,(H,16,17)/f/h16H"	KYGZCKSPAKDVKC-WYUMXYHSCH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	25	0.095699787	1.019089027	23	Low	Low	form of drug administered not known			
23405	3405	23405	865_FDAMDD_v3b	C18H22N2O2S	330.4445	defined organic	parent	tested chemical	Oxomemazine	3689-50-7	single chemical compound		"3-(5,5-dioxido-10H-phenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine"	CN(C)CC(C)CN2c1ccccc1S(=O)(=O)c3ccccc23	CN(C)CC(C)CN2c1ccccc1S(=O)(=O)c3ccccc23	"InChI=1/C18H22N2O2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)23(21,22)18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3"	QTQPVLDZQVPLGV-UHFFFAOYAR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	0.667	0.002018493	2.694972694	41	Moderate	High	form of drug administered not known			
23406	3406	23406	866_FDAMDD_v3b	C22H31NO3	357.48644	defined organic	parent	tested chemical	Oxybutynin	5633-20-5	single chemical compound		4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate	C(O)(C(=O)OCC#CCN(CC)CC)(C1=CC=CC=C1)C2CCCCC2	C(O)(C(=O)OCC#CCN(CC)CC)(C1=CC=CC=C1)C2CCCCC2	"InChI=1/C22H31NO3/c1-3-23(4-2)17-11-12-18-26-21(24)22(25,19-13-7-5-8-14-19)20-15-9-6-10-16-20/h5,7-8,13-14,20,25H,3-4,6,9-10,15-18H2,1-2H3"	XIQVNETUBQGFHX-UHFFFAOYAB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	0.333	0.000931504	3.030815339	45	High-Moderate	High	form of drug administered not known			
23407	3407	23407	867_FDAMDD_v3b	C18H21NO4	315.36364	defined organic	parent	tested chemical	Oxycodone	76-42-6	single chemical compound	stereochem; tautomers	"(5alpha)-14-hydroxy-17-methyl-3-(methyloxy)-4,5-epoxymorphinan-6-one"	O[C@@]1(CCC4=O)[C@]2([C@H]4OC3=C5OC)C3=C(C=C5)C[C@H]1N(C)CC2	O[C@@]1(CCC4=O)[C@]2([C@H]4OC3=C5OC)C3=C(C=C5)C[C@H]1N(C)CC2	"InChI=1/C18H21NO4/c1-19-8-7-17-14-10-3-4-12(22-2)15(14)23-16(17)11(20)5-6-18(17,21)13(19)9-10/h3-4,13,16,21H,5-9H2,1-2H3/t13-,16+,17+,18-/m1/s1"	BRUQQQPBMZOVGD-XFKAJCMBBP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	5.33	0.016901124	1.772084411	31	Moderate	High	form of drug administered not known; activity value changed in v3a; ActivityCategory_MRDD_mmol unchanged in v3a			
23408	3408	23408	868_FDAMDD_v3b	C19H23NO3	313.39082	defined organic	parent	tested chemical	Oxyfedrine	15687-41-9	single chemical compound	dl form shown; stereochem	"3-{[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]amino}-1-[3-(methyloxy)phenyl]propan-1-one"	c2(C(=O)CCN[C@H]([C@@H](c1ccccc1)O)C)cc(OC)ccc2	c2(C(=O)CCN[C@H]([C@@H](c1ccccc1)O)C)cc(OC)ccc2	"InChI=1/C19H23NO3/c1-14(19(22)15-7-4-3-5-8-15)20-12-11-18(21)16-9-6-10-17(13-16)23-2/h3-10,13-14,19-20,22H,11-12H2,1-2H3/t14-,19-/m0/s1"	GDYUVHBMFVMBAF-LIRRHRJNBZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antianginal	0.8	0.002552723	2.592996284	40	Moderate	High	form of drug administered not known			
23409	3409	23409	869_FDAMDD_v3b	C17H19NO4	301.33706	defined organic	parent	tested chemical	Oxymorphone	76-41-5	single chemical compound	stereochem; tautomers	"(5alpha)-3,14-dihydroxy-17-methyl-4,5-epoxymorphinan-6-one"	O[C@@]1(CCC4=O)[C@]2([C@H]4OC3=C5O)C3=C(C=C5)C[C@H]1N(C)CC2	O[C@@]1(CCC4=O)[C@]2([C@H]4OC3=C5O)C3=C(C=C5)C[C@H]1N(C)CC2	"InChI=1/C17H19NO4/c1-18-7-6-16-13-9-2-3-10(19)14(13)22-15(16)11(20)4-5-17(16,21)12(18)8-9/h2-3,12,15,19,21H,4-8H2,1H3/t12-,15+,16+,17-/m1/s1"	UQCNKQCJZOAFTQ-ISWURRPUBQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	0.15	0.000497781	3.302961288	48	High-Moderate	High	form of drug administered not known			
23410	3410	23410	870_FDAMDD_v3b	C20H28N2O3	344.44792	defined organic	parent	tested chemical	Oxyphencyclimine	125-53-1	single chemical compound		"(1-methyl-1,4,5,6-tetrahydropyrimidin-2-yl)methyl cyclohexyl(hydroxy)phenylacetate"	C3=CC=C(C(O)(C(=O)OCC1=NCCCN1C)C2CCCCC2)C=C3	C3=CC=C(C(O)(C(=O)OCC1=NCCCN1C)C2CCCCC2)C=C3	"InChI=1/C20H28N2O3/c1-22-14-8-13-21-18(22)15-25-19(23)20(24,16-9-4-2-5-10-16)17-11-6-3-7-12-17/h2,4-5,9-10,17,24H,3,6-8,11-15H2,1H3"	DUDKAZCAISNGQN-UHFFFAOYAU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	0.5	0.001451598	2.838153562	43	Moderate	High	form of drug administered not known			
23411	3411	23411	871_FDAMDD_v3b	C24H19NO5	401.41136	defined organic	parent	tested chemical	Oxyphenisatin acetate	115-33-3	single chemical compound		"(2-oxo-2,3-dihydro-1H-indole-3,3-diyl)dibenzene-4,1-diyl diacetate"	C1=CC=C4C(=C1)NC(=O)C4(C2=CC=C(OC(=O)C)C=C2)C3=CC=C(OC(C)=O)C=C3	C1=CC=C4C(=C1)NC(=O)C4(C2=CC=C(OC(=O)C)C=C2)C3=CC=C(OC(C)=O)C=C3	"InChI=1/C24H19NO5/c1-15(26)29-19-11-7-17(8-12-19)24(18-9-13-20(14-10-18)30-16(2)27)21-5-3-4-6-22(21)25-23(24)28/h3-14H,1-2H3,(H,25,28)/f/h25H"	PHPUXYRXPHEJDF-LNNLXFCOCM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cathartic	0.833	0.002075178	2.682944658	41	Moderate	High	form of drug administered not known			
23412	3412	23412	872_FDAMDD_v3b	C22H28N2O11	496.46452	defined organic	complex 2H2O	tested chemical	Oxytetracycline	6153-64-6	single chemical compound	stereochem; tautomers; parent [79-57-2]	"(4S,4aR,5S,5aR,6S,12aS)-4-(dimethylamino)-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide dihydrate"	O=C1[C@](C(O)=C2[C@@]3([H])[C@@](O)(C)C4=C(C(O)=CC=C4)C2=O)(O)[C@]([C@H]3O)([H])[C@H](N(C)C)C(O)=C1C(N)=O.O.O	[C@]\21([C@H]([C@@H](C(=C(/C1=O)C(=O)N)\O)N(C)C)[C@H]([C@H]3/C(=C/2O)C(c4c([C@]3(O)C)cccc4O)=O)O)O	"InChI=1/C22H24N2O9.2H2O/c1-21(32)7-5-4-6-8(25)9(7)15(26)10-12(21)17(28)13-14(24(2)3)16(27)11(20(23)31)19(30)22(13,33)18(10)29;;/h4-6,12-14,17,25,27-29,32-33H,1-3H3,(H2,23,31);2*1H2/t12-,13-,14+,17+,21-,22+;;/m1../s1/f/h23H2;;"	SRRPEXWCHWWJOC-YAUCRECTDQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	33.3	0.06707428	1.173443983	24	Low	Low	form of drug administered not known			
23413	3413	23413	873_FDAMDD_v3b	C47H51NO14	853.9061	defined organic	parent	tested chemical	Paclitaxel	33069-62-4	single chemical compound	stereochem; tautomers	"(2alpha,5beta,7beta,10beta,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate"	O=C(N[C@@H](c1ccccc1)[C@@H](O)C(=O)O[C@H]3C[C@@]4(O)[C@@H](OC(=O)c2ccccc2)[C@@H]5[C@]6(OC(C)=O)CO[C@@H]6C[C@H](O)[C@@]5(C)C(=O)[C@H](OC(C)=O)\C(=C3/C)C4(C)C)c7ccccc7	O=C(N[C@@H](c1ccccc1)[C@@H](O)C(=O)O[C@H]3C[C@@]4(O)[C@@H](OC(=O)c2ccccc2)[C@@H]5[C@]6(OC(C)=O)CO[C@@H]6C[C@H](O)[C@@]5(C)C(=O)[C@H](OC(C)=O)\C(=C3/C)C4(C)C)c7ccccc7	"InChI=1/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1/f/h48H"	RCINICONZNJXQF-GXKQXQCDDN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	4.73	0.005539251	2.256548975	36	Moderate	Moderate	form of drug administered not known			
23414	3414	23414	874_FDAMDD_v3b	C3H11NO7P2	235.069462	defined organic	parent	tested chemical	Pamidronic acid	40391-99-9	single chemical compound		"(3-amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid)"	NCCC(O)(P(O)(=O)O)P(O)(=O)O	NCCC(O)(P(O)(=O)O)P(O)(=O)O	"InChI=1/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)/f/h6-7,9-10H"	WRUUGTRCQOWXEG-RWPUQTAPCP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipagetic	1.5	0.006381093	2.195104954	36	Moderate	High	form of drug administered not known			
23415	3415	23415	875_FDAMDD_v3b	C35H60Br2N2O4	732.6699	defined organic	salt 2Br	tested chemical	Pancuronium bromide	15500-66-0	single chemical compound	ammonium; stereochem	"(2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2,16-bis(1-methylpiperidinium-1-yl)androstane dibromide"	[Br-].[Br-].[N+]1(C)(CCCCC1)[C@@H]6[C@@H]([C@@]5([C@H]([C@H]4[C@@H]([C@]3(C[C@H]([N+]2(C)CCCCC2)[C@H](C[C@@H]3CC4)OC(=O)C)C)CC5)C6)C)OC(=O)C	[N+]1(C)(CCCCC1)[C@@H]6[C@@H]([C@@]5([C@H]([C@H]4[C@@H]([C@]3(C[C@H]([N+]2(C)CCCCC2)[C@H](C[C@@H]3CC4)OC(=O)C)C)CC5)C6)C)OC(=O)C	"InChI=1/C35H60N2O4.2BrH/c1-24(38)40-32-21-26-13-14-27-28(35(26,4)23-31(32)37(6)19-11-8-12-20-37)15-16-34(3)29(27)22-30(33(34)41-25(2)39)36(5)17-9-7-10-18-36;;/h26-33H,7-23H2,1-6H3;2*1H/q+2;;/p-2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-;;/m0../s1/fC35H60N2O4.2Br/h;2*1h/qm;2*-1"	NPIJXCQZLFKBMV-VGNXDVIWDM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	0.1	0.000136487	3.86490835	54	High	High	form of drug administered not known			
23416	3416	23416	876_FDAMDD_v3b	C16H15F2N3O4S	383.3698064	defined organic	parent	tested chemical	Pantoprazole	102625-70-7	single chemical compound	tautomers	"5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole"	FC(F)OC(C=C2)=CC1=C2NC(S(CC3=NC=CC(OC)=C3OC)=O)=N1	FC(F)OC(C=C2)=CC1=C2NC(S(CC3=NC=CC(OC)=C3OC)=O)=N1	"InChI=1/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)/f/h20H"	IQPSEEYGBUAQFF-UYBDAZJACX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiulcerative	0.667	0.001739834	2.759492072	42	Moderate	High	form of drug administered not known; structure modified v3b			
23417	3417	23417	877_FDAMDD_v3b	C9H17NO5	219.23498	defined organic	parent	tested chemical	Pantothenic acid	79-83-4	single chemical compound	stereochem	"N-[(2R)-2,4-dihydroxy-3,3-dimethylbutanoyl]-beta-alanine"	O=C(NCCC(O)=O)[C@H](O)C(C)(C)CO	O=C(NCCC(O)=O)[C@H](O)C(C)(C)CO	"InChI=1/C9H17NO5/c1-9(2,5-11)7(14)8(15)10-4-3-6(12)13/h7,11,14H,3-5H2,1-2H3,(H,10,15)(H,12,13)/t7-/m0/s1/f/h10,12H"	GHOKWGTUZJEAQD-NMAXEMPDDV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vitamin	0.117	0.000533674	3.272723987	48	High-Moderate	High	form of drug administered not known			
23418	3418	23418	878_FDAMDD_v3b	C20H21NO4	339.38504	defined organic	parent	tested chemical	Papaverine	58-74-2	single chemical compound		"1-{[3,4-bis(methyloxy)phenyl]methyl}-6,7-bis(methyloxy)isoquinoline"	C1(OC)=C(OC)C=C3C(=C1)C(CC2=CC=C(OC)C(OC)=C2)=NC=C3	C1(OC)=C(OC)C=C3C(=C1)C(CC2=CC=C(OC)C(OC)=C2)=NC=C3	"InChI=1/C20H21NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-8,10-12H,9H2,1-4H3"	XQYZDYMELSJDRZ-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		smooth muscle relaxant; cerebral vasodilator	10	0.029465058	1.530692695	28	Low-Moderate	Low	form of drug administered not known			
23419	3419	23419	879_FDAMDD_v3b	C6H12O3	132.1577	defined organic	parent	tested chemical	Paraldehyde	123-63-7	single chemical compound		"2,4,6-trimethyl-1,3,5-trioxane"	C1(C)OC(C)OC(C)O1	C1(C)OC(C)OC(C)O1	"InChI=1/C6H12O3/c1-4-7-5(2)9-6(3)8-4/h4-6H,1-3H3"	SQYNKIJPMDEDEG-UHFFFAOYAO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	250	1.89167941	-0.276847537	8	Low	Low	form of drug administered not known			
23420	3420	23420	880_FDAMDD_v3b	C7H11NO3	157.16714	defined organic	parent	tested chemical	Paramethadione	115-67-3	single chemical compound		"5-ethyl-3,5-dimethyl-1,3-oxazolidine-2,4-dione"	N1(C)C(=O)C(C)(CC)OC1=O	N1(C)C(=O)C(C)(CC)OC1=O	"InChI=1/C7H11NO3/c1-4-7(2)5(9)8(3)6(10)11-7/h4H2,1-3H3"	VQASKUSHBVDKGU-UHFFFAOYAM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	40	0.254506126	0.594301759	18	Low	Low	form of drug administered not known			
23421	3421	23421	881_FDAMDD_v3b	C22H29FO5	392.4610632	defined organic	parent	tested chemical	Paramethasone	53-33-8	single chemical compound	stereochem; tautomers	"(6alpha,11beta,16alpha)-6-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione"	OCC(=O)[C@@]2(O)[C@H](C)C[C@H]3[C@@H]4C[C@H](F)\C1=C\C(=O)\C=C/[C@]1(C)[C@H]4[C@@H](O)C[C@]23C	OCC(=O)[C@@]2(O)[C@H](C)C[C@H]3[C@@H]4C[C@H](F)\C1=C\C(=O)\C=C/[C@]1(C)[C@H]4[C@@H](O)C[C@]23C	"InChI=1/C22H29FO5/c1-11-6-14-13-8-16(23)15-7-12(25)4-5-20(15,2)19(13)17(26)9-21(14,3)22(11,28)18(27)10-24/h4-5,7,11,13-14,16-17,19,24,26,28H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19-,20+,21+,22+/m1/s1"	MKPDWECBUAZOHP-AFYJWTTEBS	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Paramethasone	glucocorticoid	0.4	0.001019209	2.991736585	45	High-Moderate	High	form of drug administered not known			
23422	3422	23422	882_FDAMDD_v3b	C24H31FO6	434.4977432	defined organic	parent	tested chemical	Paramethasone acetate	1597-82-6	single chemical compound	stereochem; tautomers	"(6alpha,11beta,16alpha)-6-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl acetate"	CC(=O)OCC(=O)[C@@]2(O)[C@H](C)C[C@H]3[C@@H]4C[C@H](F)\C1=C\C(=O)\C=C/[C@]1(C)[C@H]4[C@@H](O)C[C@]23C	CC(=O)OCC(=O)[C@@]2(O)[C@H](C)C[C@H]3[C@@H]4C[C@H](F)\C1=C\C(=O)\C=C/[C@]1(C)[C@H]4[C@@H](O)C[C@]23C	"InChI=1/C24H31FO6/c1-12-7-16-15-9-18(25)17-8-14(27)5-6-22(17,3)21(15)19(28)10-23(16,4)24(12,30)20(29)11-31-13(2)26/h5-6,8,12,15-16,18-19,21,28,30H,7,9-11H2,1-4H3/t12-,15+,16+,18+,19+,21-,22+,23+,24+/m1/s1"	HYRKAAMZBDSJFJ-LFDBJOOHBU	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Paramethasone	glucocorticoid	0.4	0.000920603	3.035927534	45	High-Moderate	High	form of drug administered not known			
23423	3423	23423	883_FDAMDD_v3b	C11H13N	159.22762	defined organic	parent	tested chemical	Pargyline	555-57-7	single chemical compound		N-methyl-N-(phenylmethyl)prop-2-yn-1-amine	C1=CC=CC(CN(C)CC#C)=C1	C1=CC=CC(CN(C)CC#C)=C1	"InChI=1/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3"	DPWPWRLQFGFJFI-UHFFFAOYAA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	3.33	0.020913457	1.67957417	30	Moderate	Moderate	form of drug administered not known			
23424	3424	23424	884_FDAMDD_v3b	C23H45N5O14	615.6285	defined organic	parent	tested chemical	Paromomycin	7542-37-2	single chemical compound	stereochem; tautomers	"(1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2-amino-2-deoxy-alpha-D-glucopyranoside"	N[C@@H]4[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]4O[C@H]1[C@@H](O)[C@@H](O[C@@H]1CO)O[C@H]3[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2N)[C@@H](N)C[C@@H](N)[C@@H]3O	N[C@@H]4[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]4O[C@H]1[C@@H](O)[C@@H](O[C@@H]1CO)O[C@H]3[C@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2N)[C@@H](N)C[C@@H](N)[C@@H]3O	"InChI=1/C23H45N5O14/c24-2-7-13(32)15(34)10(27)21(37-7)41-19-9(4-30)39-23(17(19)36)42-20-12(31)5(25)1-6(26)18(20)40-22-11(28)16(35)14(33)8(3-29)38-22/h5-23,29-36H,1-4,24-28H2/t5-,6+,7+,8-,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1"	UOZODPSAJZTQNH-LSWIJEOBBF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial; antiamebic	35	0.056852469	1.245250673	25	Low-Moderate	Low	form of drug administered not known			
23425	3425	23425	885_FDAMDD_v3b	C19H20FNO3	329.3654032	defined organic	parent	tested chemical	Paroxetine	61869-08-7	single chemical compound	stereochem	"(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine"	FC3=CC=[C@@](C=C3)[C@H]4[C@@H](CNCC4)COC2=CC1=C(C=C2)OCO1	FC3=CC=[C@@](C=C3)[C@H]4[C@@H](CNCC4)COC2=CC1=C(C=C2)OCO1	"InChI=1/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1"	AHOUBRCZNHFOSL-YOEHRIQHBL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	0.833	0.002529106	2.597032977	40	Moderate	High	form of drug administered not known; structure modified v3b			
23426	3426	23426	886_FDAMDD_v3b	C9H10O2	150.1745	defined organic	parent	tested chemical	Paroxypropione	70-70-2	single chemical compound		1-(4-hydroxyphenyl)propan-1-one	C1=C(O)C=CC(C(=O)CC)=C1	C1=C(O)C=CC(C(=O)CC)=C1	"InChI=1/C9H10O2/c1-2-9(11)7-3-5-8(10)6-4-7/h3-6,10H,2H2,1H3"	RARSHUDCJQSEFJ-UHFFFAOYAU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		pituitary gonadotrophic hormone inhibitor	50	0.332946006	0.47762619	16	Low	Low	form of drug administered not known			
23427	3427	23427	887_FDAMDD_v3b	C9H8N2O2	176.17202	defined organic	parent	tested chemical	Pemoline	2152-34-3	single chemical compound		"2-amino-5-phenyl-1,3-oxazol-4(5H)-one"	N2C(=O)C(C1=CC=CC=C1)OC=2N	N2C(=O)C(C1=CC=CC=C1)OC=2N	"InChI=1/C9H8N2O2/c10-9-11-8(12)7(13-9)6-4-2-1-3-5-6/h1-5,7H,(H2,10,11,12)/f/h10H2"	NRNCYVBFPDDJNE-GIMVELNWCP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		CNS stimulant	1.88	0.010671388	1.971779085	33	Moderate	High	form of drug administered not known			
23428	3428	23428	888_FDAMDD_v3b	C18H29NO2	291.42836	defined organic	parent	tested chemical	Penbutolol	38363-40-5	single chemical compound	stereochem	(2S)-1-(tert-butylamino)-3-(2-cyclopentylphenoxy)propan-2-ol	O[C@@H](CNC(C)(C)C)COC1=CC=CC=C1C2CCCC2	O[C@@H](CNC(C)(C)C)COC1=CC=CC=C1C2CCCC2	"InChI=1/C18H29NO2/c1-18(2,3)19-12-15(20)13-21-17-11-7-6-10-16(17)14-8-4-5-9-14/h6-7,10-11,14-15,19-20H,4-5,8-9,12-13H2,1-3H3/t15-/m0/s1"	KQXKVJAGOJTNJS-HNNXBMFYBN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal; antiarrhythmic	1.33	0.004563729	2.340680171	37	Moderate	High	form of drug administered not known; structure modified v3b			
23429	3429	23429	889_FDAMDD_v3b	C16H18N2O5S	350.3895	defined organic	parent	tested chemical	Penicillin V	87-08-1	single chemical compound	stereochem	"(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(phenyloxy)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	[H][C@@]12[C@]([H])(NC(COC3=CC=CC=C3)=O)C(N1[C@@H]([C@@](O)=O)[C@@](C)(C)S2)=O	[H][C@@]12[C@]([H])(NC(COC3=CC=CC=C3)=O)C(N1[C@@H]([C@@](O)=O)[C@@](C)(C)S2)=O	"InChI=1/C16H18N2O5S/c1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t11-,12+,14-/m1/s1/f/h17,21H"	BPLBGHOLXOTWMN-JGBPDRTNDY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	25	0.07134917	1.146611075	24	Low	Low	form of drug administered not known; structure modified v3b			
23430	1109	23430	890_FDAMDD_v3b	C5H8N4O12	316.1366	defined organic	parent	tested chemical	Pentaerythritol tetranitrate	78-11-5	single chemical compound		"2,2-Bisdihydroxymethyl-1,3-propanediol tetranitrate"	[O-][N+](OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O)=O	[O-][N+](OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O)=O	"InChI=1/C5H8N4O12/c10-6(11)18-1-5(2-19-7(12)13,3-20-8(14)15)4-21-9(16)17/h1-4H2"	TZRXHJWUDPFEEY-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vasodilator	4	0.012652758	1.897814787	32	Moderate	Moderate	form of drug administered not known			
23431	3431	23431	891_FDAMDD_v3b	C19H24N4O2	340.41946	defined organic	parent	tested chemical	Pentamidine	100-33-4	single chemical compound		"4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide"	C2=C(C(N)=N)C=CC(OCCCCCOC1=CC=C(C(=N)N)C=C1)=C2	C2=C(C(N)=N)C=CC(OCCCCCOC1=CC=C(C(=N)N)C=C1)=C2	"InChI=1/C19H24N4O2/c20-18(21)14-4-8-16(9-5-14)24-12-2-1-3-13-25-17-10-6-15(7-11-17)19(22)23/h4-11H,1-3,12-13H2,(H3,20,21)(H3,22,23)/f/h20,22H,21,23H2"	XDRYMKDFEDOLFX-JODGMDMNCA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiprotozoal	4	0.01175021	1.929954387	33	Moderate	Moderate	form of drug administered not known			
23432	3432	23432	892_FDAMDD_v3b	C18H27NO2	289.41248	defined organic	parent	tested chemical	Pentapiperide	7009-54-3	single chemical compound		1-methylpiperidin-4-yl 3-methyl-2-phenylpentanoate	C2=CC(C(C(C)CC)C(=O)OC1CCN(C)CC1)=CC=C2	C2=CC(C(C(C)CC)C(=O)OC1CCN(C)CC1)=CC=C2	"InChI=1/C18H27NO2/c1-4-14(2)17(15-8-6-5-7-9-15)18(20)21-16-10-12-19(3)13-11-16/h5-9,14,16-17H,4,10-13H2,1-3H3"	UKQYEYCQIQBHBC-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	0.5	0.001727638	2.76254725	42	Moderate	High	form of drug administered not known			
23433	3433	23433	893_FDAMDD_v3b	C19H27NO	285.42378	defined organic	parent	tested chemical	Pentazocine	359-83-1	single chemical compound	stereochem	"(2R,6R,11R)-6,11-dimethyl-3-(3-methylbut-2-en-1-yl)-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-8-ol"	OC1=CC([C@@]3(C)[C@@H](C)[C@@](N(C\C=C(C)/C)CC3)([H])C2)=C2C=C1	OC1=CC([C@@]3(C)[C@@H](C)[C@@](N(C\C=C(C)/C)CC3)([H])C2)=C2C=C1	"InChI=1/C19H27NO/c1-13(2)7-9-20-10-8-19(4)14(3)18(20)11-15-5-6-16(21)12-17(15)19/h5-7,12,14,18,21H,8-11H2,1-4H3/t14-,18+,19+/m0/s1"	VOKSWYLNZZRQPF-GDIGMMSIBX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	2.5	0.008758906	2.057550145	34	Moderate	High-Moderate	form of drug administered not known			
23434	3434	23434	894_FDAMDD_v3b	C14H23N3O10	393.34652	defined organic	parent	tested chemical	Pentetic acid	67-43-6	single chemical compound		"N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine"	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O	OC(=O)CN(CCN(CC(O)=O)CC(O)=O)CCN(CC(O)=O)CC(O)=O	"InChI=1/C14H23N3O10/c18-10(19)5-15(1-3-16(6-11(20)21)7-12(22)23)2-4-17(8-13(24)25)9-14(26)27/h1-9H2,(H,18,19)(H,20,21)(H,22,23)(H,24,25)(H,26,27)/f/h18,20,22,24,26H"	QPCDCPDFJACHGM-CHRVJHJLCV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		chelating agent	16.7	0.042456204	1.372058841	27	Low-Moderate	Low	form of drug administered not known			
23435	3435	23435	895_FDAMDD_v3b	C11H18N2O3	226.27222	defined organic	parent	tested chemical	Pentobarbital	76-74-4	single chemical compound	tautomers	"5-ethyl-2-hydroxy-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione"	C1(=O)C(CC)(C(C)CCC)C(=O)N=C(O)N1	C1(=O)C(CC)(C(C)CCC)C(=O)N=C(O)N1	"InChI=1/C11H18N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)/f/h12,16H"	WEXRUCMBJFQVBZ-KSKJGAJJCE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	3.33	0.014716787	1.832187004	32	Moderate	Moderate	form of drug administered not known			
23436	3436	23436	896_FDAMDD_v3b	C11H16N4O4	268.26914	defined organic	parent	tested chemical	Pentostatin	53910-25-1	single chemical compound	stereochem; tautomers; retired CASRN [63677-95-2]	"(8R)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol"	n2(c\1c([C@@H](CN/C=N/1)O)nc2)[C@@H]3O[C@H](CO)[C@H](C3)O	n2(c\1c([C@@H](CN/C=N/1)O)nc2)[C@@H]3O[C@H](CO)[C@H](C3)O	"InChI=1/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1/f/h12H"	FPVKHBSQESCIEP-JMGJDRJUDT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.0667	0.000248631	3.604444883	52	High	High	form of drug administered not known			
23437	3437	23437	897_FDAMDD_v3b	C13H18N4O3	278.30702	defined organic	parent	tested chemical	Pentoxifylline	6493-05-6	single chemical compound		"3,7-dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione"	N1(CCCCC(C)=O)C(=O)N(C)C2=C(C1=O)N(C)C=N2	N1(CCCCC(C)=O)C(=O)N(C)C2=C(C1=O)N(C)C=N2	"InChI=1/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3"	BYPFEZZEUUWMEJ-UHFFFAOYAP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vasodilator	20	0.071863081	1.143494165	24	Low	Low	form of drug administered not known			
23438	3438	23438	898_FDAMDD_v3b	C19H26N2S	314.48814	defined organic	parent	tested chemical	Pergolide	66104-22-1	single chemical compound	stereochem	(8beta)-8-[(methylthio)methyl]-6-propylergoline	CSC[C@@H]1C[C@@H]2c3cccc4N\C=C(\C[C@H]2N(C1)CCC)c34	CSC[C@@H]1C[C@@H]2c3cccc4N\C=C(\C[C@H]2N(C1)CCC)c34	"InChI=1/C19H26N2S/c1-3-7-21-11-13(12-22-2)8-16-15-5-4-6-17-19(15)14(10-20-17)9-18(16)21/h4-6,10,13,16,18,20H,3,7-9,11-12H2,1-2H3/t13-,16-,18-/m1/s1"	YEHCICAEULNIGD-MZMPZRCHBJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiparkinsonian; dopamine receptor agonist	0.05	0.000158989	3.798634268	54	High	High	form of drug administered not known			
23439	3439	23439	899_FDAMDD_v3b	C19H35N	277.4879	defined organic	parent	tested chemical	Perhexiline	6621-47-2	single chemical compound		"2-(2,2-dicyclohexylethyl)piperidine"	C3CCCC(CC(C1CCCCC1)C2CCCCC2)N3	C3CCCC(CC(C1CCCCC1)C2CCCCC2)N3	"InChI=1/C19H35N/c1-3-9-16(10-4-1)19(17-11-5-2-6-12-17)15-18-13-7-8-14-20-18/h16-20H,1-15H2"	CYXKNKQEMFBLER-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vasodilator; Ca channel blocker; diuretic	5	0.018018804	1.744274046	31	Moderate	Low	form of drug administered not known			
23440	3440	23440	900_FDAMDD_v3b	C19H32N2O5	368.46778	defined organic	parent	tested chemical	Perindopril	82834-16-0	single chemical compound	stereochem	"(2S)-2-[(1S)-1-Carbethoxybutylamino]-1-oxopropyl-(2S,3aS,7aS)-perhydroindole-2-carboxylic acid"	N1([C@@H](C[C@H]2[C@@H]1CCCC2)C(=O)O)C([C@@H](N[C@H](C(=O)OCC)CCC)C)=O	N1([C@@H](C[C@H]2[C@@H]1CCCC2)C(=O)O)C([C@@H](N[C@H](C(=O)OCC)CCC)C)=O	"InChI=1/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1/f/h23H"	IPVQLZZIHOAWMC-ZILWVIQXDO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; ACE inhibitor	0.133	0.000360954	3.442547877	50	High	High	form of drug administered not known			
23441	3441	23441	901_FDAMDD_v3b	C21H26ClN3OS	403.96864	defined organic	parent	tested chemical	Perphenazine	58-39-9	single chemical compound		2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethanol	C1=CC=C3C(=C1)N(CCCN2CCN(CCO)CC2)C4=C(S3)C=CC(Cl)=C4	C1=CC=C3C(=C1)N(CCCN2CCN(CCO)CC2)C4=C(S3)C=CC(Cl)=C4	"InChI=1/C21H26ClN3OS/c22-17-6-7-21-19(16-17)25(18-4-1-2-5-20(18)27-21)9-3-8-23-10-12-24(13-11-23)14-15-26/h1-2,4-7,16,26H,3,8-15H2"	RGCVKNLCSQQDEP-UHFFFAOYAP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic; dopamine receptor antagonist	0.4	0.000990176	3.004287661	45	High-Moderate	High	form of drug administered not known			
23442	3442	23442	902_FDAMDD_v3b	C9H10N2O2	178.1879	defined organic	parent	tested chemical	Phenacemide	63-98-9	single chemical compound		N-(aminocarbonyl)-2-phenylacetamide	C1=CC=CC(CC(=O)NC(N)=O)=C1	C1=CC=CC(CC(=O)NC(N)=O)=C1	"InChI=1/C9H10N2O2/c10-9(13)11-8(12)6-7-4-2-1-3-5-7/h1-5H,6H2,(H3,10,11,12,13)/f/h11H,10H2"	XPFRXWCVYUEORT-XGEAKUCACW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	50	0.280602667	0.551908205	17	Low	Low	form of drug administered not known			
23443	1116	21116	903_FDAMDD_v3b	C10H13NO2	179.2157	defined organic	parent	tested chemical	Phenacetin	62-44-2	single chemical compound		N-[4-(ethyloxy)phenyl]acetamide	CC(=O)NC1=CC=C(C=C1)OCC	CC(=O)NC1=CC=C(C=C1)OCC	"InChI=1/C10H13NO2/c1-3-13-10-6-4-9(5-7-10)11-8(2)12/h4-7H,3H2,1-2H3,(H,11,12)/f/h11H"	CPJSUEIXXCENMM-WXRBYKJCCO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant; analgesic; antipyretic	50	0.278993414	0.554406049	17	Low	Low	form of drug administered not known			
23444	3444	23444	904_FDAMDD_v3b	C11H15ClO2	214.6886	defined organic	parent	tested chemical	Phenaglycodol	79-93-6	single chemical compound		"2-(4-chlorophenyl)-3-methylbutane-2,3-diol"	C1=C(Cl)C=CC(C(O)(C)C(C)(C)O)=C1	C1=C(Cl)C=CC(C(O)(C)C(C)(C)O)=C1	"InChI=1/C11H15ClO2/c1-10(2,13)11(3,14)8-4-6-9(12)7-5-8/h4-7,13-14H,1-3H3"	HTYIXCKSEQQCJO-UHFFFAOYAB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic; anticonvulsant	20	0.093158184	1.030778988	23	Low	Low	form of drug administered not known			
23445	3445	23445	905_FDAMDD_v3b	C11H11N5	213.23854	defined organic	parent	tested chemical	Phenazopyridine	94-78-0	single chemical compound	stereochem	"3-[(E)-phenyldiazenyl]pyridine-2,6-diamine"	C2(N)=NC(N)=CC=C2N=NC1=CC=CC=C1	C2(N)=NC(N)=CC=C2N=NC1=CC=CC=C1	"InChI=1/C11H11N5/c12-10-7-6-9(11(13)14-10)16-15-8-4-2-1-3-5-8/h1-7H,(H4,12,13,14)/b16-15+/f/h12-13H2"	QPFYXYFORQJZEC-BKQDAPJRDQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic	6.67	0.031279524	1.504739866	28	Low-Moderate	Low	form of drug administered not known			
23446	3446	23446	906_FDAMDD_v3b	C17H25N	243.3871	defined organic	parent	tested chemical	Phencyclidine	77-10-1	single chemical compound		1-(1-phenylcyclohexyl)piperidine	C3=CC=CC=C3C2(N1CCCCC1)CCCCC2	C3=CC=CC=C3C2(N1CCCCC1)CCCCC2	"InChI=1/C17H25N/c1-4-10-16(11-5-1)17(12-6-2-7-13-17)18-14-8-3-9-15-18/h1,4-5,10-11H,2-3,6-9,12-15H2"	JTJMJGYZQZDUJJ-UHFFFAOYAC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; anesthetic	0.2	0.000821736	3.08526756	46	High-Moderate	High	form of drug administered not known			
23447	3447	23447	907_FDAMDD_v3b	C12H17NO	191.26948	defined organic	parent	tested chemical	Phendimetrazine	634-03-7	single chemical compound		"3,4-dimethyl-2-phenylmorpholine"	C2=CC=CC(C1C(C)N(C)CCO1)=C2	C2=CC=CC(C1C(C)N(C)CCO1)=C2	"InChI=1/C12H17NO/c1-10-12(14-9-8-13(10)2)11-6-4-3-5-7-11/h3-7,10,12H,8-9H2,1-2H3"	MFOCDFTXLCYLKU-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anorexic	3.5	0.01829879	1.737577633	31	Moderate	Moderate	form of drug administered not known			
23448	3448	23448	908_FDAMDD_v3b	C17H20N2O5S	364.4161	defined organic	parent	tested chemical	Phenethicillin	147-55-7	single chemical compound	stereochem	"(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[2-(phenyloxy)propanoyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	O=C(O)[C@@H]2N3C(=O)[C@@H](NC(=O)C(C)Oc1ccccc1)[C@H]3SC2(C)C	O=C(O)[C@@H]2N3C(=O)[C@@H](NC(=O)C(C)Oc1ccccc1)[C@H]3SC2(C)C	"InChI=1/C17H20N2O5S/c1-9(24-10-7-5-4-6-8-10)13(20)18-11-14(21)19-12(16(22)23)17(2,3)25-15(11)19/h4-9,11-12,15H,1-3H3,(H,18,20)(H,22,23)/t9?,11-,12+,15-/m1/s1/f/h18,22H"	NONJJLVGHLVQQM-CRWREQTNDX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	50	0.137205793	0.862627552	21	Low	Low	form of drug administered not known			
23449	3449	23449	909_FDAMDD_v3b	C10H15N5	205.2596	defined organic	parent	tested chemical	Phenformin	114-86-3	single chemical compound		N-(2-phenylethyl)imidodicarbonimidic diamide	C1=CC=CC=C1CCNC(=N)NC(N)=N	C1=CC=CC=C1CCNC(=N)NC(N)=N	"InChI=1/C10H15N5/c11-9(12)15-10(13)14-7-6-8-4-2-1-3-5-8/h1-5H,6-7H2,(H6,11,12,13,14,15)/f/h11,13-15H,12H2"	ICFJFFQQTFMIBG-RWBDPUOCCC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	1.67	0.008136038	2.089587007	35	Moderate	High	form of drug administered not known			
23450	3450	23450	910_FDAMDD_v3b	C17H24N2O2	288.38466	defined organic	parent	tested chemical	Phenglutarimide	1156-05-4	single chemical compound		"3-[2-(diethylamino)ethyl]-3-phenylpiperidine-2,6-dione"	C2(=O)CCC(CCN(CC)CC)(C1=CC=CC=C1)C(=O)N2	C2(=O)CCC(CCN(CC)CC)(C1=CC=CC=C1)C(=O)N2	"InChI=1/C17H24N2O2/c1-3-19(4-2)13-12-17(14-8-6-5-7-9-14)11-10-15(20)18-16(17)21/h5-9H,3-4,10-13H2,1-2H3,(H,18,20,21)/f/h18H"	BFMBKRQFMIILCH-GPQMBLKYCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic; antiparkinsonian	0.833	0.002888503	2.539327154	40	Moderate	High	form of drug administered not known			
23451	245	20245	911_FDAMDD_v3b	C7H9N3O	151.1676	defined organic	parent	tested chemical	Phenicarbazide	103-03-7	single chemical compound		2-phenylhydrazinecarboxamide	NC(=O)NNC1=CC=CC=C1	NC(=O)NNC1=CC=CC=C1	"InChI=1/C7H9N3O/c8-7(11)10-9-6-4-2-1-3-5-6/h1-5,9H,(H3,8,10,11)/f/h10H,8H2"	AVKHCKXGKPAGEI-HBHMGDMRCY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipyretic	25	0.165379354	0.781518709	20	Low	Low	form of drug administered not known			
23452	3452	23452	912_FDAMDD_v3b	C19H19N	261.36086	defined organic	parent	tested chemical	Phenindamine	82-88-2	single chemical compound		"2-methyl-9-phenyl-2,3,4,9-tetrahydro-1H-indeno[2,1-c]pyridine"	C1=CC=C3C(=C1)C(C2=CC=CC=C2)C4=C3CCN(C)C4	C1=CC=C3C(=C1)C(C2=CC=CC=C2)C4=C3CCN(C)C4	"InChI=1/C19H19N/c1-20-12-11-16-15-9-5-6-10-17(15)19(18(16)13-20)14-7-3-2-4-8-14/h2-10,19H,11-13H2,1H3"	ISFHAYSTHMVOJR-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	2.5	0.009565319	2.019300542	34	Moderate	High-Moderate	form of drug administered not known			
23453	3453	23453	913_FDAMDD_v3b	C15H10O2	222.2387	defined organic	parent	tested chemical	Phenindione	83-12-5	single chemical compound		"2-phenyl-1H-indene-1,3(2H)-dione"	C1=CC=C3C(=C1)C(=O)C(C2=CC=CC=C2)C3=O	C1=CC=C3C(=C1)C(=O)C(C2=CC=CC=C2)C3=O	"InChI=1/C15H10O2/c16-14-11-8-4-5-9-12(11)15(17)13(14)10-6-2-1-3-7-10/h1-9,13H"	NFBAXHOPROOJAW-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticoagulant	3.33	0.014983889	1.824375454	32	Moderate	Moderate	form of drug administered not known			
23454	3454	23454	914_FDAMDD_v3b	C16H20N2	240.3434	defined organic	parent	tested chemical	Pheniramine	86-21-5	single chemical compound		"N,N-dimethyl-3-phenyl-3-pyridin-2-ylpropan-1-amine"	C2=CC=CC(C(CCN(C)C)C1=CC=CC=C1)=N2	C2=CC=CC(C(CCN(C)C)C1=CC=CC=C1)=N2	"InChI=1/C16H20N2/c1-18(2)13-11-15(14-8-4-3-5-9-14)16-10-6-7-12-17-16/h3-10,12,15H,11,13H2,1-2H3"	IJHNSHDBIRRJRN-UHFFFAOYAU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic; antipruritic	0.625	0.002600446	2.584952183	40	Moderate	High	form of drug administered not known			
23455	3455	23455	915_FDAMDD_v3b	C11H15NO	177.2429	defined organic	parent	tested chemical	Phenmetrazine	134-49-6	single chemical compound		3-methyl-2-phenylmorpholine	C2CNC(C)C(C1=CC=CC=C1)O2	C2CNC(C)C(C1=CC=CC=C1)O2	"InChI=1/C11H15NO/c1-9-11(13-8-7-12-9)10-5-3-2-4-6-10/h2-6,9,11-12H,7-8H2,1H3"	OOBHFESNSZDWIU-UHFFFAOYAX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anorexic; CNS stimulant	1.25	0.007052469	2.151658834	35	Moderate	High	form of drug administered not known			
23456	1122	21122	916_FDAMDD_v3b	C12H12N2O3	232.2353	defined organic	parent	tested chemical	Phenobarbitol	50-06-6	single chemical compound		"5-ethyl-5-phenylpyrimidine-2,4,6(1H,3H,5H)-trione"	O=C1C(C2=CC=CC=C2)(C(=O)NC(=O)N1)CC	O=C1C(C2=CC=CC=C2)(C(=O)NC(=O)N1)CC	"InChI=1/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)/f/h13-14H"	DDBREPKUVSBGFI-KGCNKATMCV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant; sedative; hypnotic	2.16	0.009300912	2.031474482	34	Moderate	High	form of drug administered not known			
23457	1125	21125	917_FDAMDD_v3b	C20H14O4	318.3282	defined organic	parent	tested chemical	Phenolphthalein	77-09-8	single chemical compound	furanone form shown [77-09-8]; acid form [81-90-3]	"3,3-bis(4-hydroxyphenyl)-2-benzofuran-1(3H)-one"	O=C1OC(C2=C1C=CC=C2)(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O	O=C1OC(C2=C1C=CC=C2)(C3=CC=C(C=C3)O)C4=CC=C(C=C4)O	"InChI=1/C20H14O4/c21-15-9-5-13(6-10-15)20(14-7-11-16(22)12-8-14)18-4-2-1-3-17(18)19(23)24-20/h1-12,21-22H"	KJFMBFZCATUALV-UHFFFAOYAH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cathartic	2.17	0.006816864	2.16641538	35	Moderate	High	form of drug administered not known			
23458	3458	23458	918_FDAMDD_v3b	C18H22ClNO	303.82638	defined organic	parent	tested chemical	Phenoxybenzamine	59-96-1	single chemical compound		N-(2-chloroethyl)-N-(phenylmethyl)-1-(phenyloxy)propan-2-amine	C2=CC=CC(OCC(C)N(CCCl)CC1=CC=CC=C1)=C2	C2=CC=CC(OCC(C)N(CCCl)CC1=CC=CC=C1)=C2	"InChI=1/C18H22ClNO/c1-16(15-21-18-10-6-3-7-11-18)20(13-12-19)14-17-8-4-2-5-9-17/h2-11,16H,12-15H2,1H3"	QZVCTJOXCFMACW-UHFFFAOYAX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	2	0.006582707	2.181595484	36	Moderate	High	form of drug administered not known			
23459	3459	23459	919_FDAMDD_v3b	C18H16O3	280.31784	defined organic	parent	tested chemical	Phenprocoumon	435-97-2	single chemical compound		4-hydroxy-3-(1-phenylpropyl)-2H-chromen-2-one	C1=CC=C3C(=C1)OC(=O)C(C(CC)C2=CC=CC=C2)=C3O	C1=CC=C3C(=C1)OC(=O)C(C(CC)C2=CC=CC=C2)=C3O	"InChI=1/C18H16O3/c1-2-13(12-8-4-3-5-9-12)16-17(19)14-10-6-7-11-15(14)21-18(16)20/h3-11,13,19H,2H2,1H3"	DQDAYGNAKTZFIW-UHFFFAOYAX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticoagulant	0.4	0.001426952	2.845590747	43	Moderate	High	form of drug administered not known			
23460	3460	23460	920_FDAMDD_v3b	C11H11NO2	189.21054	defined organic	parent	tested chemical	Phensuximide	86-34-0	single chemical compound		"1-methyl-3-phenylpyrrolidine-2,5-dione"	C2=CC=CC(C1C(=O)N(C)C(=O)C1)=C2	C2=CC=CC(C1C(=O)N(C)C(=O)C1)=C2	"InChI=1/C11H11NO2/c1-12-10(13)7-9(11(12)14)8-5-3-2-4-6-8/h2-6,9H,7H2,1H3"	WLWFNJKHKGIJNW-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	50	0.264255892	0.577975321	18	Low	Low	form of drug administered not known			
23461	3461	23461	921_FDAMDD_v3b	C10H15N	149.2328	defined organic	parent	tested chemical	Phentermine	122-09-8	single chemical compound		2-methyl-1-phenylpropan-2-amine	C1=CC=CC(CC(C)(C)N)=C1	C1=CC=CC(CC(C)(C)N)=C1	"InChI=1/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3"	DHHVAGZRUROJKS-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anorexic	0.625	0.004188087	2.37798427	38	Moderate	High	form of drug administered not known			
23462	3462	23462	922_FDAMDD_v3b	C17H19N3O	281.35226	defined organic	parent	tested chemical	Phentolamine	50-60-2	single chemical compound		"3-[(4,5-dihydro-1H-imidazol-2-ylmethyl)(4-methylphenyl)amino]phenol"	C3=C(C)C=CC(N(CC1=NCCN1)C2=CC(O)=CC=C2)=C3	C3=C(C)C=CC(N(CC1=NCCN1)C2=CC(O)=CC=C2)=C3	"InChI=1/C17H19N3O/c1-13-5-7-14(8-6-13)20(12-17-18-9-10-19-17)15-3-2-4-16(21)11-15/h2-8,11,21H,9-10,12H2,1H3,(H,18,19)/f/h18H"	MRBDMNSDAVCSSF-GPQMBLKYCH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; diagnostic aid	0.167	0.000593562	3.226533937	47	High-Moderate	High	form of drug administered not known			
23463	3463	23463	923_FDAMDD_v3b	C9H11NO2	165.18914	defined organic	parent	tested chemical	Phenylalanine	150-30-1	single chemical compound		phenylalanine	C1=CC=CC(CC(N)C(O)=O)=C1	C1=CC=CC(CC(N)C(O)=O)=C1	"InChI=1/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/f/h11H"	COLNVLDHVKWLRT-WXRBYKJCCL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	100	0.605366672	0.217981492	14	Low	Low	form of drug administered not known			
23464	1136	21136	924_FDAMDD_v3b	C19H20N2O2	308.3743	defined organic	parent	tested chemical	Phenylbutazone	50-33-9	single chemical compound		"4-butyl-1,2-diphenylpyrazolidine-3,5-dione"	O=C1N(C2=CC=CC=C2)N(C3=CC=CC=C3)C(=O)C1CCCC	O=C1N(C2=CC=CC=C2)N(C3=CC=CC=C3)C(=O)C1CCCC	"InChI=1/C19H20N2O2/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16/h4-13,17H,2-3,14H2,1H3"	VYMDGNCVAMGZFE-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	10	0.032428124	1.489078177	28	Low-Moderate	Low	form of drug administered not known			
23465	3465	23465	925_FDAMDD_v3b	C9H13NO2	167.20502	defined organic	parent	tested chemical	Phenylephrine	59-42-7	single chemical compound	stereochem	3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol	O[C@@H](CNC)c1cc(O)ccc1	O[C@@H](CNC)c1cc(O)ccc1	"InChI=1/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1"	SONNWYBIRXJNDC-VIFPVBQEBB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		mydriatic; decongestant	0.833	0.004981908	2.302604311	37	Moderate	High	form of drug administered not known			
23466	3466	23466	926_FDAMDD_v3b	C9H13NO	151.20562	defined organic	parent	tested chemical	Phenylpropanolamine	14838-15-4	single chemical compound	stereochem	"(1S,2R)-2-amino-1-phenylpropan-1-ol"	O[C@H]([C@@H](C)N)c1ccccc1	O[C@H]([C@@H](C)N)c1ccccc1	"InChI=1/C9H13NO/c1-7(10)9(11)8-5-3-2-4-6-8/h2-7,9,11H,10H2,1H3/t7-,9-/m1/s1"	DLNKOYKMWOXYQA-VXNVDRBHBW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		decongestant; anorexic	3	0.019840532	1.702446679	30	Moderate	Moderate	form of drug administered not known			
23467	3467	23467	927_FDAMDD_v3b	C17H21NO	255.35474	defined organic	parent	tested chemical	Phenyltoloxamine	92-12-6	single chemical compound		"N,N-dimethyl-2-{[2-(phenylmethyl)phenyl]oxy}ethanamine"	C2=CC=CC(OCCN(C)C)=C2CC1=CC=CC=C1	C2=CC=CC(OCCN(C)C)=C2CC1=CC=CC=C1	"InChI=1/C17H21NO/c1-18(2)12-13-19-17-11-7-6-10-16(17)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3"	IZRPKIZLIFYYKR-UHFFFAOYAC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	3.33	0.013040682	1.88469969	32	Moderate	Moderate	form of drug administered not known			
23468	541	20541	928_FDAMDD_v3b	C15H12N2O2	252.268	defined organic	parent	tested chemical	Phenytoin	57-41-0	single chemical compound		"5,5-diphenylimidazolidine-2,4-dione"	O=C1C(C2=CC=CC=C2)(C3=CC=CC=C3)NC(=O)N1	O=C1C(C2=CC=CC=C2)(C3=CC=CC=C3)NC(=O)N1	"InChI=1/C15H12N2O2/c18-13-15(17-14(19)16-13,11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H,(H2,16,17,18,19)/f/h16-17H"	CXOFVDLJLONNDW-XQMQJMAZCS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant; antiepileptic	5	0.019820191	1.70289216	30	Moderate	Low	form of drug administered not known			
23469	3469	23469	929_FDAMDD_v3b	C14H16N2O4	276.2878	defined organic	parent	tested chemical	Phthalazinol	56611-65-5	single chemical compound		"ethyl 1-(hydroxymethyl)-5,7-dimethyl-4-oxo-3,4-dihydrophthalazine-6-carboxylate"	CCOC(=O)c1c(C)cc2c(c1C)C(=O)N\N=C2\CO	CCOC(=O)c1c(C)cc2c(c1C)C(=O)N\N=C2\CO	"InChI=1/C14H16N2O4/c1-4-20-14(19)11-7(2)5-9-10(6-17)15-16-13(18)12(9)8(11)3/h5,17H,4,6H2,1-3H3,(H,16,18)/f/h16H"	DUQOOLBWGUKRAJ-WYUMXYHSCC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		phosphodiesterase inhibitor	200	0.72388285	0.140331713	13	Low	Low	form of drug administered not known			
23470	3470	23470	930_FDAMDD_v3b	C17H13N3O5S2	403.43222	defined organic	parent	tested chemical	Phthalylsulfathiazole	85-73-4	single chemical compound		"2-[({4-[(1,3-thiazol-2-ylamino)sulfonyl]phenyl}amino)carbonyl]benzoic acid"	C3=CC=CC(C(=O)NC2=CC=C(S(=O)(=O)NC1SC=CN=1)C=C2)=C3C(=O)O	C3=CC=CC(C(=O)NC2=CC=C(S(=O)(=O)NC1SC=CN=1)C=C2)=C3C(=O)O	"InChI=1/C17H13N3O5S2/c21-15(13-3-1-2-4-14(13)16(22)23)19-11-5-7-12(8-6-11)27(24,25)20-17-18-9-10-26-17/h1-10H,(H,18,20)(H,19,21)(H,22,23)/f/h19-20,22H"	PBMSWVPMRUJMPE-OTJKMEOQCC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	200	0.495746225	0.304740584	15	Low	Low	form of drug administered not known			
23471	3471	23471	931_FDAMDD_v3b	C15H21N3O2	275.34614	defined organic	parent	tested chemical	Physostigmine	57-47-6	single chemical compound	stereochem	"(3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate"	[C@]13([C@@H](N(C)c2c1cc(OC(=O)NC)cc2)N(C)CC3)C	[C@]13([C@@H](N(C)c2c1cc(OC(=O)NC)cc2)N(C)CC3)C	"InChI=1/C15H21N3O2/c1-15-7-8-17(3)13(15)18(4)12-6-5-10(9-11(12)15)20-14(19)16-2/h5-6,9,13H,7-8H2,1-4H3,(H,16,19)/t13-,15+/m1/s1/f/h16H"	PIJVFDBKTWXHHD-GFWSYVERDM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cholinergic; miotic	0.0167	6.06509E-05	4.217162521	58	High	High	form of drug administered not known			
23472	3472	23472	932_FDAMDD_v3b	C31H46O2	450.69574	defined organic	parent	tested chemical	"Phytonadione, K1"	84-80-0	single chemical compound	stereochem	"2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl]naphthalene-1,4-dione"	C/1(=C(/C(=O)c2c(C\1=O)cccc2)C)C/C=C(/CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)C	C/1(=C(/C(=O)c2c(C\1=O)cccc2)C)C/C=C(/CCC[C@@H](CCC[C@@H](CCCC(C)C)C)C)C	"InChI=1/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1"	MBWXNTAXLNYFJB-NKFFZRIABL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		prothrombogenic vitamin	0.417	0.000925236	3.033747398	45	High-Moderate	High	form of drug administered not known			
23473	1162	21162	933_FDAMDD_v3b	C11H16N2O2	208.2596	defined organic	parent	tested chemical	Pilocarpine	92-13-7	single chemical compound	stereochem	"(3S,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one"	c1(n(cnc1)C)C[C@@H]2[C@@H](C(=O)OC2)CC	c1(n(cnc1)C)C[C@@H]2[C@@H](C(=O)OC2)CC	"InChI=1/C11H16N2O2/c1-3-10-8(6-15-11(10)14)4-9-5-12-7-13(9)2/h5,7-8,10H,3-4,6H2,1-2H3/t8-,10-/m0/s1"	QCHFTSOMWOSFHM-WPRPVWTQBQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiglaucoma; miotic	0.5	0.00240085	2.619635026	40	Moderate	High	form of drug administered not known			
23474	3474	23474	934_FDAMDD_v3b	C28H29F2N3O	461.5461664	defined organic	parent	tested chemical	Pimozide	2062-78-4	single chemical compound		"1-{1-[4,4-bis(4-fluorophenyl)butyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one"	C1=CC5=C(C=C1)N(C4CCN(CCCC(C2=CC=C(F)C=C2)C3=CC=C(F)C=C3)CC4)C(=O)N5	C1=CC5=C(C=C1)N(C4CCN(CCCC(C2=CC=C(F)C=C2)C3=CC=C(F)C=C3)CC4)C(=O)N5	"InChI=1/C28H29F2N3O/c29-22-11-7-20(8-12-22)25(21-9-13-23(30)14-10-21)4-3-17-32-18-15-24(16-19-32)33-27-6-2-1-5-26(27)31-28(33)34/h1-2,5-14,24-25H,3-4,15-19H2,(H,31,34)/f/h31H"	YVUQSNJEYSNKRX-VJSLDGLSCK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	0.167	0.000361827	3.441498677	50	High	High	form of drug administered not known			
23475	3475	23475	935_FDAMDD_v3b	C18H13ClN2O	308.76162	defined organic	parent	tested chemical	Pinazepam	52463-83-9	single chemical compound		"7-chloro-5-phenyl-1-prop-2-yn-1-yl-1,3-dihydro-2H-1,4-benzodiazepin-2-one"	C1=C(Cl)C=C3C(=C1)N(CC#C)C(=O)CN=C3C2=CC=CC=C2	C1=C(Cl)C=C3C(=C1)N(CC#C)C(=O)CN=C3C2=CC=CC=C2	"InChI=1/C18H13ClN2O/c1-2-10-21-16-9-8-14(19)11-15(16)18(20-12-17(21)22)13-6-4-3-5-7-13/h1,3-9,11H,10,12H2"	MFZOSKPPVCIFMT-UHFFFAOYAQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	0.333	0.001078502	2.967179077	44	Moderate	High	form of drug administered not known			
23476	3476	23476	936_FDAMDD_v3b	C14H20N2O2	248.3208	defined organic	parent	tested chemical	Pindolol	13523-86-9	single chemical compound		1-(1H-indol-4-yloxy)-3-[(1-methylethyl)amino]propan-2-ol	C1C=CC(OCC(O)CNC(C)C)=C2C=1NC=C2	C1C=CC(OCC(O)CNC(C)C)=C2C=1NC=C2	"InChI=1/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3"	JZQKKSLKJUAGIC-UHFFFAOYAP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal; antiarrhythmic; antiglaucomic	1	0.004027049	2.395013099	38	Moderate	High	form of drug administered not known			
23477	3477	23477	937_FDAMDD_v3b	C21H24ClN3OS	401.95276	defined organic	parent	tested chemical	Pipamazine	84-04-8	single chemical compound		1-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperidine-4-carboxamide	C1=CC=C3C(=C1)N(CCCN2CCC(C(N)=O)CC2)C4=C(S3)C=CC(Cl)=C4	C1=CC=C3C(=C1)N(CCCN2CCC(C(N)=O)CC2)C4=C(S3)C=CC(Cl)=C4	"InChI=1/C21H24ClN3OS/c22-16-6-7-20-18(14-16)25(17-4-1-2-5-19(17)27-20)11-3-10-24-12-8-15(9-13-24)21(23)26/h1-2,4-7,14-15H,3,8-13H2,(H2,23,26)/f/h23H2"	OSJJYEUEJRVVOD-TWSYTRIPCE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiemetic	0.25	0.000621964	3.206235006	47	High-Moderate	High	form of drug administered not known			
23478	3478	23478	938_FDAMDD_v3b	C35H62Br2N4O4	762.69918	defined organic	salt 2Br	tested chemical	Pipecuronium bromide	52212-02-9	single chemical compound	ammonium; stereochem	"(2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)-2,16-bis(4,4-dimethylpiperazin-4-ium-1-yl)androstane dibromide"	O=C(C)O[C@@H]4[C@@]3(C)CC[C@]2([H])[C@@]1(C)C[C@H](N6CC[N+](C)(C)CC6)[C@@H](OC(C)=O)C[C@@]([H])1CC[C@]([H])2[C@@]([H])3C[C@@H]4N5CC[N+](C)(C)CC5.[Br-].[Br-]	O=C(C)O[C@@H]4[C@@]3(C)CC[C@]2([H])[C@@]1(C)C[C@H](N6CC[N+](C)(C)CC6)[C@@H](OC(C)=O)C[C@@]([H])1CC[C@]([H])2[C@@]([H])3C[C@@H]4N5CC[N+](C)(C)CC5	"InChI=1/C35H62N4O4.2BrH/c1-24(40)42-32-21-26-9-10-27-28(35(26,4)23-31(32)37-15-19-39(7,8)20-16-37)11-12-34(3)29(27)22-30(33(34)43-25(2)41)36-13-17-38(5,6)18-14-36;;/h26-33H,9-23H2,1-8H3;2*1H/q+2;;/p-2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-;;/m0../s1/fC35H62N4O4.2Br/h;2*1h/qm;2*-1"	TXWBOBJCRVVBJF-WCJDNHNBDF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	0.09	0.000118002	3.92811077	55	High	High	form of drug administered not known; structure modified v3b			
23479	3479	23479	939_FDAMDD_v3b	C14H17N5O3	303.31648	defined organic	parent	tested chemical	Pipemidic acid	51940-44-4	single chemical compound		"8-ethyl-5-oxo-2-piperazin-1-yl-5,8-dihydropyrido[2,3-d]pyrimidine-6-carboxylic acid"	C1=C(C(O)=O)C(=O)C3=C(N1CC)N=C(N2CCNCC2)N=C3	C1=C(C(O)=O)C(=O)C3=C(N1CC)N=C(N2CCNCC2)N=C3	"InChI=1/C14H17N5O3/c1-2-18-8-10(13(21)22)11(20)9-7-16-14(17-12(9)18)19-5-3-15-4-6-19/h7-8,15H,2-6H2,1H3,(H,21,22)/f/h21H"	JOHZPMXAZQZXHR-PKSOQXRJCF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	13.3	0.04384859	1.358044366	26	Low-Moderate	Low	form of drug administered not known			
23480	3480	23480	940_FDAMDD_v3b	C22H28BrNO3	434.36662	defined organic	salt Br	tested chemical	Pipenzolate bromide	125-51-9	single chemical compound	ammonium; parent [13473-38-6]	1-ethyl-3-{[hydroxy(diphenyl)acetyl]oxy}-1-methylpiperidinium bromide	C3CCC(OC(=O)C(O)(C1=CC=CC=C1)C2=CC=CC=C2)C[N+]3(C)CC.[Br-]	C3CCC(OC(=O)C(O)(C1=CC=CC=C1)C2=CC=CC=C2)C[N+]3(C)CC	"InChI=1/C22H28NO3.BrH/c1-3-23(2)16-10-15-20(17-23)26-21(24)22(25,18-11-6-4-7-12-18)19-13-8-5-9-14-19;/h4-9,11-14,20,25H,3,10,15-17H2,1-2H3;1H/q+1;/p-1/fC22H28NO3.Br/h;1h/qm;-1"	XEDCWWFPZMHXCM-RHMOPZFYCJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	0.25	0.000575551	3.239916435	47	High-Moderate	High	form of drug administered not known			
23481	3481	23481	941_FDAMDD_v3b	C24H30N2O2S	410.5722	defined organic	parent	tested chemical	Piperacetazine	3819-00-9	single chemical compound		1-(10-{3-[4-(2-hydroxyethyl)piperidin-1-yl]propyl}-10H-phenothiazin-2-yl)ethanone	C1=CC=C3C(=C1)N(CCCN2CCC(CCO)CC2)C4=C(S3)C=CC(C(C)=O)=C4	C1=CC=C3C(=C1)N(CCCN2CCC(CCO)CC2)C4=C(S3)C=CC(C(C)=O)=C4	"InChI=1/C24H30N2O2S/c1-18(28)20-7-8-24-22(17-20)26(21-5-2-3-6-23(21)29-24)13-4-12-25-14-9-19(10-15-25)11-16-27/h2-3,5-8,17,19,27H,4,9-16H2,1H3"	BTFMCMVEUCGQDX-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	2.67	0.006503119	2.186878278	36	Moderate	High-Moderate	form of drug administered not known			
23482	3482	23482	942_FDAMDD_v3b	C23H27N5O7S	517.55478	defined organic	parent	tested chemical	Piperacillin	61477-96-1	single chemical compound	stereochem	"(2S,5R,6R)-6-{[(2R)-2-{[(4-ethyl-2,3-dioxopiperazin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)c2ccccc2)[C@H]4SC3(C)C	O=C(O)[C@@H]3N4C(=O)[C@@H](NC(=O)[C@H](NC(=O)N1CCN(CC)C(=O)C1=O)c2ccccc2)[C@H]4SC3(C)C	"InChI=1/C23H27N5O7S/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34)/t13-,14-,15+,20-/m1/s1/f/h24-25,33H"	IVBHGBMCVLDMKU-CDRBOOGFDZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	400	0.772865048	0.111896333	12	Low	Low	form of drug administered not known			
23483	1164	21164	943_FDAMDD_v3b	C4H10N2	86.1356	defined organic	parent	tested chemical	Piperazine	110-85-0	single chemical compound		piperazine	C1CNCCN1	C1CNCCN1	"InChI=1/C4H10N2/c1-2-6-4-3-5-1/h5-6H,1-4H2"	GLUUGHFHXGJENI-UHFFFAOYAS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anthelmintic	66.7	0.774360427	0.111056849	12	Low	Low	form of drug administered not known			
23484	3484	23484	944_FDAMDD_v3b	C21H25NO3	339.4281	defined organic	parent	tested chemical	Piperilate	4546-39-8	single chemical compound		2-piperidin-1-ylethyl hydroxy(diphenyl)acetate	OC(C(=O)OCCN1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3	OC(C(=O)OCCN1CCCCC1)(C2=CC=CC=C2)C3=CC=CC=C3	"InChI=1/C21H25NO3/c23-20(25-17-16-22-14-8-3-9-15-22)21(24,18-10-4-1-5-11-18)19-12-6-2-7-13-19/h1-2,4-7,10-13,24H,3,8-9,14-17H2"	RZWPJFMNFATBEG-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic; antispasmodic	1.33	0.003918356	2.406896152	38	Moderate	High	form of drug administered not known			
23485	3485	23485	945_FDAMDD_v3b	C10H16Br2N2O2	356.05424	defined organic	parent	tested chemical	Pipobroman	54-91-1	single chemical compound		"1,4-bis(3-bromopropanoyl)piperazine"	C1N(C(=O)CCBr)CCN(C(=O)CCBr)C1	C1N(C(=O)CCBr)CCN(C(=O)CCBr)C1	InChI=1/C10H16Br2N2O2/c11-3-1-9(15)13-5-7-14(8-6-13)10(16)2-4-12/h1-8H2	NJBFOOCLYDNZJN-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	3	0.008425683	2.074394907	34	Moderate	Moderate	form of drug administered not known			
23486	3486	23486	946_FDAMDD_v3b	C18H21NO	267.36544	defined organic	parent	tested chemical	Pipradrol	467-60-7	single chemical compound		diphenyl(piperidin-2-yl)methanol	C3=CC=C(C(O)(C1=CC=CC=C1)C2CCCCN2)C=C3	C3=CC=C(C(O)(C1=CC=CC=C1)C2CCCCN2)C=C3	"InChI=1/C18H21NO/c20-18(15-9-3-1-4-10-15,16-11-5-2-6-12-16)17-13-7-8-14-19-17/h1-6,9-12,17,19-20H,7-8,13-14H2"	XSWHNYGMWWVAIE-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		CNS stimulant	0.1	0.00037402	3.427105269	50	High-Moderate	High	form of drug administered not known			
23487	3487	23487	947_FDAMDD_v3b	C19H21N5O2	351.40234	defined organic	parent	tested chemical	Pirenzepine	28797-61-7	single chemical compound		"11-[(4-methylpiperazin-1-yl)acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4]benzodiazepin-6-one"	C1=CC=C3C(=C1)N(C(=O)CN2CCN(C)CC2)C4=C(NC3=O)C=CC=N4	C1=CC=C3C(=C1)N(C(=O)CN2CCN(C)CC2)C4=C(NC3=O)C=CC=N4	"InChI=1/C19H21N5O2/c1-22-9-11-23(12-10-22)13-17(25)24-16-7-3-2-5-14(16)19(26)21-15-6-4-8-20-18(15)24/h2-8H,9-13H2,1H3,(H,21,26)/f/h21H"	RMHMFHUVIITRHF-PKSOQXRJCW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiulcerative	2.5	0.007114352	2.14786464	35	Moderate	High-Moderate	form of drug administered not known			
23488	3488	23488	948_FDAMDD_v3b	C17H18N2O5S	362.40022	defined organic	parent	tested chemical	Piretanide	55837-27-9	single chemical compound		3-(aminosulfonyl)-4-(phenyloxy)-5-pyrrolidin-1-ylbenzoic acid	C3(S(=O)(=O)N)=C(OC1=CC=CC=C1)C(N2CCCC2)=CC(C(=O)O)=C3	C3(S(=O)(=O)N)=C(OC1=CC=CC=C1)C(N2CCCC2)=CC(C(=O)O)=C3	"InChI=1/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)/f/h20H,18H2"	UJEWTUDSLQGTOA-VFSNKAIFCE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic	0.2	0.000551876	3.258158457	48	High-Moderate	High	form of drug administered not known			
23489	3489	23489	949_FDAMDD_v3b	C13H14ClNO2	251.70876	defined organic	parent	tested chemical	Pirprofen	31793-07-4	single chemical compound		"2-[3-chloro-4-(2,5-dihydro-1H-pyrrol-1-yl)phenyl]propanoic acid"	C2(Cl)=C(N1CC=CC1)C=CC(C(C)C(O)=O)=C2	C2(Cl)=C(N1CC=CC1)C=CC(C(C)C(O)=O)=C2	"InChI=1/C13H14ClNO2/c1-9(13(16)17)10-4-5-12(11(14)8-10)15-6-2-3-7-15/h2-5,8-9H,6-7H2,1H3,(H,16,17)/f/h16H"	PIDSZXPFGCURGN-WYUMXYHSCP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	13.3	0.052838844	1.277046689	25	Low-Moderate	Low	form of drug administered not known			
23490	3490	23490	950_FDAMDD_v3b	C19H21NS	295.44174	defined organic	parent	tested chemical	Pizotyline	15574-96-6	single chemical compound		"4-(9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thien-4-ylidene)-1-methylpiperidine"	C1=CC=C3C(=C1)CCC4=C(C3=C2CCN(C)CC2)C=CS4	C1=CC=C3C(=C1)CCC4=C(C3=C2CCN(C)CC2)C=CS4	"InChI=1/C19H21NS/c1-20-11-8-15(9-12-20)19-16-5-3-2-4-14(16)6-7-18-17(19)10-13-21-18/h2-5,10,13H,6-9,11-12H2,1H3"	FIADGNVRKBPQEU-UHFFFAOYAO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anabolic; antidepressant; serotonin inhibitor	0.05	0.000169238	3.771501848	53	High	High	form of drug administered not known			
23491	3491	23491	951_FDAMDD_v3b	C16H22ClN3O4	355.81658	defined organic	parent	tested chemical	Plafibride	63394-05-8	single chemical compound		2-[(4-chlorophenyl)oxy]-2-methyl-N-{[(morpholin-4-ylmethyl)amino]carbonyl}propanamide	C2=C(Cl)C=CC(OC(C)(C)C(=O)NC(=O)NCN1CCOCC1)=C2	C2=C(Cl)C=CC(OC(C)(C)C(=O)NC(=O)NCN1CCOCC1)=C2	"InChI=1/C16H22ClN3O4/c1-16(2,24-13-5-3-12(17)4-6-13)14(21)19-15(22)18-11-20-7-9-23-10-8-20/h3-6H,7-11H2,1-2H3,(H2,18,19,21,22)/f/h18-19H"	DDDQVDIPBFGVIG-VEWCPZSHCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antithrombotic	40	0.112417471	0.94916619	22	Low	Low	form of drug administered not known			
23492	3492	23492	952_FDAMDD_v3b	C52H76O24	1085.14544	defined organic	parent	tested chemical	Plicamycin	18378-89-7	single chemical compound	stereochem	"(1S)-5-deoxy-1-C-[(2S,3S)-7-{[2,6-dideoxy-3-O-(2,6-dideoxy-beta-D-arabino-hexopyranosyl)-beta-D-lyxo-hexopyranosyl]oxy}-3-{[2,6-dideoxy-3-C-methyl-beta-D-ribo-hexopyranosyl-(1->3)-2,6-dideoxy-beta-D-arabino-hexopyranosyl-(1->3)-2,6-dideoxy-beta-D-arabino-hexopyranosyl]oxy}-5,10-dihydroxy-6-methyl-4-oxo-1,2,3,4-tetrahydroanthracen-2-yl]-1-O-methyl-D-xylulose"	O=C([C@H]2O[C@H]3C[C@@H](O[C@H]7C[C@@H](O[C@H]8C[C@@](O)(C)[C@H](O)[C@@H](C)O8)[C@H](O)[C@@H](C)O7)[C@H](O)[C@@H](C)O3)C1=C(O)C(C(O)=C(C(O[C@H]5C[C@@H](O[C@H]6C[C@@H](O)[C@H](O)[C@@H](C)O6)[C@@H](O)[C@@H](C)O5)=C4)C)=C4C=C1C[C@@]2([H])[C@H](OC)C([C@@H](O)[C@@H](C)O)=O	O=C([C@H]2O[C@H]3C[C@@H](O[C@H]7C[C@@H](O[C@H]8C[C@@](O)(C)[C@H](O)[C@@H](C)O8)[C@H](O)[C@@H](C)O7)[C@H](O)[C@@H](C)O3)C1=C(O)C(C(O)=C(C(O[C@H]5C[C@@H](O[C@H]6C[C@@H](O)[C@H](O)[C@@H](C)O6)[C@@H](O)[C@@H](C)O5)=C4)C)=C4C=C1C[C@@]2([H])[C@H](OC)C([C@@H](O)[C@@H](C)O)=O	"InChI=1/C52H76O24/c1-18-29(72-34-14-30(43(58)21(4)68-34)73-33-13-28(54)42(57)20(3)67-33)12-26-10-25-11-27(49(66-9)48(63)41(56)19(2)53)50(47(62)39(25)46(61)38(26)40(18)55)76-36-16-31(44(59)23(6)70-36)74-35-15-32(45(60)22(5)69-35)75-37-17-52(8,65)51(64)24(7)71-37/h10,12,19-24,27-28,30-37,41-45,49-51,53-61,64-65H,11,13-17H2,1-9H3/t19-,20-,21-,22-,23-,24-,27?,28-,30-,31-,32-,33+,34+,35+,36+,37+,41+,42-,43+,44-,45-,49+,50+,51-,52+/m1/s1"	CFCUWKMKBJTWLW-GWRQQDNDBX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.03	2.76461E-05	4.558366695	62	High	High	form of drug administered not known; structure modified v3b			
23493	1175	21175	953_FDAMDD_v3b	C32H60O10	604.8128	defined organic	parent	monomer of polymer	Polysorbate 80	9005-65-6	macromolecule	approx of polymer; see Merck v12 no 7742; stereochem	"2-hydroxyethyl 2-deoxy-3,5-bis-O-(2-hydroxyethyl)-6-O-{2-[(9E)-octadec-9-enoyloxy]ethyl}hexofuranoside"	C1(C(COCCOC(=O)CCCCCCCC=CCCCCCCCC)OCCO)OC(OCCO)CC1OCCO	C1(C(COCCOC(=O)CCCCCCCC=CCCCCCCCC)OCCO)OC(OCCO)CC1OCCO	"InChI=1/C32H60O10/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-30(36)40-25-24-37-27-29(39-22-19-34)32-28(38-21-18-33)26-31(42-32)41-23-20-35/h9-10,28-29,31-35H,2-8,11-27H2,1H3/b10-9+"	RGPBUVUVZKQNHD-MDZDMXLPBT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		pharmaceutic aid	25	0.041335104	1.383680965	27	Low-Moderate	Low	form of drug administered not known			
23494	3494	23494	954_FDAMDD_v3b	C23H33N2O2	369.52032	defined organic	parent	tested chemical	Prajmalium	35080-11-6	single chemical compound	ammonium; stereochem	"(3beta,5alpha,7alpha,16xi,17S,21alpha)-4-propylajmalan-4-ium-17,21-diol"	O[C@H]3[N+]1(CCC)[C@H](C6)C2[C@H](O)[C@]46[C@](N(C)C5=C4C=CC=C5)([H])[C@H]1C[C@H]2[C@@H]3CC	O[C@H]3[N+]1(CCC)[C@H](C6)C2[C@H](O)[C@]46[C@](N(C)C5=C4C=CC=C5)([H])[C@H]1C[C@H]2[C@@H]3CC	"InChI=1/C23H33N2O2/c1-4-10-25-17-11-14(13(5-2)22(25)27)19-18(25)12-23(21(19)26)15-8-6-7-9-16(15)24(3)20(17)23/h6-9,13-14,17-22,26-27H,4-5,10-12H2,1-3H3/q+1/t13-,14-,17+,18+,19?,20-,21-,22+,23-,25?/m0/s1"	UAUHEPXILIZYCU-FKWBDHECBT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiarryhthmic	1.33	0.003599261	2.443786684	39	Moderate	High	form of drug administered not known; structure modified v3b			
23495	3495	23495	955_FDAMDD_v3b	C7H9ClN2O	172.61216	defined organic	salt Cl	tested chemical	Pralidoxime	51-15-0	single chemical compound	ammonium	2-[(E)-(hydroxyimino)methyl]-1-methylpyridinium chloride	C1=CC=CC(C=NO)=[N+]1C.[Cl-]	C1=CC=CC(C=NO)=[N+]1C	"InChI=1/C7H8N2O.ClH/c1-9-5-3-2-4-7(9)6-8-10;/h2-6H,1H3;1H/fC7H9N2O.Cl/h10H;1h/q+1;-1/b8-6+;"	HIGSLXSBYYMVKI-NAXVJXEMDE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cholinesterase inhibitor 	33.3	0.192918042	0.714627154	19	Low	Low	form of drug administered not known			
23496	3496	23496	956_FDAMDD_v3b	C10H17N3S	211.32708	defined organic	parent	tested chemical	Pramipexole	104632-26-0	single chemical compound	stereochem	"(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine"	NC2=NC1=C(S2)C[C@@H](NCCC)CC1	NC2=NC1=C(S2)C[C@@H](NCCC)CC1	"InChI=1/C10H17N3S/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8/h7,12H,2-6H2,1H3,(H2,11,13)/t7-/m0/s1/f/h11H2"	FASDKYOPVNHBLU-YIVNQYFNDM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiparkinsonian; dopamine receptor agonist	0.1	0.0004732	3.324955152	48	High-Moderate	High	form of drug administered not known; structure modified v3b			
23497	3497	23497	957_FDAMDD_v3b	C15H13NO3	255.26862	defined organic	parent	tested chemical	Pranoprofen	52549-17-4	single chemical compound		"2-(5H-chromeno[2,3-b]pyridin-7-yl)propanoic acid"	C1=CN=C2C(=C1)CC3=C(O2)C=CC(C(C)C(=O)O)=C3	C1=CN=C2C(=C1)CC3=C(O2)C=CC(C(C)C(=O)O)=C3	"InChI=1/C15H13NO3/c1-9(15(17)18)10-4-5-13-12(7-10)8-11-3-2-6-16-14(11)19-13/h2-7,9H,8H2,1H3,(H,17,18)/f/h17H"	TVQZAMVBTVNYLA-HCKMINDGCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	3.75	0.014690407	1.832966163	32	Moderate	Moderate	form of drug administered not known			
23498	3498	23498	958_FDAMDD_v3b	C23H36O7	424.52774	defined organic	parent	tested chemical	Pravastatin	81093-37-0	single chemical compound	stereochem	"(3R,5R)-3,5-dihydroxy-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]heptanoic acid"	C\2=1[C@H]([C@@H](OC(=O)[C@H](CC)C)C[C@@H](C=1)O)[C@@H](CC[C@H](C[C@H](CC(O)=O)O)O)[C@H](/C=C/2)C	C\2=1[C@H]([C@@H](OC(=O)[C@H](CC)C)C[C@@H](C=1)O)[C@@H](CC[C@H](C[C@H](CC(O)=O)O)O)[C@H](/C=C/2)C	"InChI=1/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1/f/h27H"	TUZYXOIXSAXUGO-FJJUNYOKDB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihyperlipoproteinemic	0.667	0.001571158	2.80378024	43	Moderate	High	form of drug administered not known			
23499	1181	21181	959_FDAMDD_v3b	C19H17ClN2O	324.8091	defined organic	parent	tested chemical	Prazepam	2955-38-6	single chemical compound		"7-chloro-1-(cyclopropylmethyl)-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one"	O=C1N(C2=CC=C(C=C2C(=NC1)C3=CC=CC=C3)Cl)CC4CC4	O=C1N(C2=CC=C(C=C2C(=NC1)C3=CC=CC=C3)Cl)CC4CC4	"InChI=1/C19H17ClN2O/c20-15-8-9-17-16(10-15)19(14-4-2-1-3-5-14)21-11-18(23)22(17)12-13-6-7-13/h1-5,8-10,13H,6-7,11-12H2"	MWQCHHACWWAQLJ-UHFFFAOYAP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	1	0.003078731	2.511628188	39	Moderate	High	form of drug administered not known			
23500	1183	21183	960_FDAMDD_v3b	C35H45Cl2NO6	646.6496	defined organic	parent	tested chemical	Prednimustine	29069-24-7	single chemical compound	stereochem; tautomers	"(11beta)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl 4-{4-[bis(2-chloroethyl)amino]phenyl}butanoate"	[C@]24([C@@](C(COC(=O)CCCc1ccc(cc1)N(CCCl)CCCl)=O)(CC[C@H]2[C@@H]3CCC=5[C@@]([C@H]3[C@H](C4)O)(\C=C/C(C=5)=O)C)O)C	[C@]24([C@@](C(COC(=O)CCCc1ccc(cc1)N(CCCl)CCCl)=O)(CC[C@H]2[C@@H]3CCC=5[C@@]([C@H]3[C@H](C4)O)(\C=C/C(C=5)=O)C)O)C	"InChI=1/C35H45Cl2NO6/c1-33-14-12-26(39)20-24(33)8-11-27-28-13-15-35(43,34(28,2)21-29(40)32(27)33)30(41)22-44-31(42)5-3-4-23-6-9-25(10-7-23)38(18-16-36)19-17-37/h6-7,9-10,12,14,20,27-29,32,40,43H,3-5,8,11,13,15-19,21-22H2,1-2H3/t27-,28-,29-,32+,33-,34-,35-/m0/s1"	HFVNWDWLWUCIHC-GUPDPFMOBT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	3.33	0.00514962	2.28822478	37	Moderate	Moderate	form of drug administered not known			
23501	1184	21184	961_FDAMDD_v3b	C21H28O5	360.444	defined organic	parent	tested chemical	Prednisolone	50-24-8	single chemical compound	stereochem; tautomers	"(11beta)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione"	[C@]13([C@@](C(=O)CO)(CC[C@H]1[C@@H]2CCC=4[C@@]([C@H]2[C@H](C3)O)(\C=C/C(C=4)=O)C)O)C	[C@]13([C@@](C(=O)CO)(CC[C@H]1[C@@H]2CCC=4[C@@]([C@H]2[C@H](C3)O)(\C=C/C(C=4)=O)C)O)C	"InChI=1/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1"	OIGNJSKKLXVSLS-VWUMJDOOBF	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 6	Prednisolone	glucocorticoid	3.33	0.009238606	2.034393567	34	Moderate	Moderate	form of drug administered not known			
23502	3502	23502	962_FDAMDD_v3b	C23H30O6	402.4807	defined organic	parent	tested chemical	Prednisolone acetate	52-21-1	single chemical compound	stereochem; tautomers	"(11beta)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl acetate"	O=[C@](COC(C)=O)[C@](CC4)(O)[C@]2(C)[C@]4([H])[C@]1([H])CCC([C@@](C=C3)(C)[C@]([H])1[C@@H](O)C2)=CC3=O	O=[C@](COC(C)=O)[C@](CC4)(O)[C@]2(C)[C@]4([H])[C@]1([H])CCC([C@@](C=C3)(C)[C@]([H])1[C@@H](O)C2)=CC3=O	"InChI=1/C23H30O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-18,20,26,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,18-,20+,21-,22-,23-/m0/s1"	LRJOMUJRLNCICJ-JZYPGELDBZ	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 6	Prednisolone	glucocorticoid	3.33	0.008273689	2.082300826	34	Moderate	Moderate	form of drug administered not known; related forms; family parent [50-24-8]; structure modified v3b			
23503	3503	23503	963_FDAMDD_v3b	C25H31NaO8	482.49861	defined organic	salt Na	tested chemical	Prednisolone sodium succinate	1715-33-9	single chemical compound	stereochem; tautomers	"sodium 4-{[(11beta)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl]oxy}-4-oxobutanoate"	O=[C@](COC(CCC([O-])=O)=O)[C@](CC4)(O)[C@]2(C)[C@]4([H])[C@]1([H])CCC([C@@](C=C3)(C)[C@]([H])1[C@@H](O)C2)=CC3=O.[Na+]	O=[C@](COC(CCC(O)=O)=O)[C@](CC4)(O)[C@]2(C)[C@]4([H])[C@]1([H])CCC([C@@](C=C3)(C)[C@]([H])1[C@@H](O)C2)=CC3=O	"InChI=1/C25H32O8.Na/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30;/h7,9,11,16-18,22,27,32H,3-6,8,10,12-13H2,1-2H3,(H,29,30);/q;+1/p-1/t16-,17-,18-,22+,23-,24-,25-;/m0./s1/fC25H31O8.Na/q-1;m"	FKKAEMQFOIDZNY-LMCZBDRVDP	Clinical Reports 	Maximum Recommended Daily Dose	human	3 of 6	Prednisolone	glucocorticoid	3.33	0.006901574	2.161051833	35	Moderate	Moderate	form of drug administered not known; related forms; family parent [50-24-8]; structure modified v3b			
23504	3504	23504	964_FDAMDD_v3b	C41H64O8	684.94206	defined organic	parent	tested chemical	Prednisolone steaglate	5060-55-9	single chemical compound	stereochem; tautomers	"2-{[(11beta)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl]oxy}-2-oxoethyl octadecanoate"	O=[C@](COC(COC(CCCCCCCCCCCCCCCCC)=O)=O)[C@](CC4)(O)[C@]2(C)[C@]4([H])[C@]1([H])CCC([C@@](C=C3)(C)[C@]([H])1[C@@H](O)C2)=CC3=O	O=[C@](COC(COC(CCCCCCCCCCCCCCCCC)=O)=O)[C@](CC4)(O)[C@]2(C)[C@]4([H])[C@]1([H])CCC([C@@](C=C3)(C)[C@]([H])1[C@@H](O)C2)=CC3=O	"InChI=1/C41H64O8/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-36(45)49-29-37(46)48-28-35(44)41(47)25-23-33-32-21-20-30-26-31(42)22-24-39(30,2)38(32)34(43)27-40(33,41)3/h22,24,26,32-34,38,43,47H,4-21,23,25,27-29H2,1-3H3/t32-,33-,34-,38+,39-,40-,41-/m0/s1"	RBJROVWIRLFZFC-PNLFXGMVBO	Clinical Reports 	Maximum Recommended Daily Dose	human	4 of 6	Prednisolone	glucocorticoid	3.33	0.004861725	2.313209602	37	Moderate	Moderate	form of drug administered not known; related forms; family parent [50-24-8]; structure modified v3b			
23505	3505	23505	965_FDAMDD_v3b	C27H38O6	458.58702	defined organic	parent	tested chemical	Prednisolone tebutate	7681-14-3	single chemical compound	stereochem; tautomers	"(11beta)-11,17-dihydroxy-3,20-dioxopregna-1,4-dien-21-yl 3,3-dimethylbutanoate"	CC(C)(C)CC(=O)OCC(=O)[C@@]2(O)CC[C@H]3[C@@H]4CC\C1=C\C(=O)\C=C/[C@]1(C)[C@H]4[C@@H](O)C[C@]23C	CC(C)(C)CC(=O)OCC(=O)[C@@]2(O)CC[C@H]3[C@@H]4CC\C1=C\C(=O)\C=C/[C@]1(C)[C@H]4[C@@H](O)C[C@]23C	"InChI=1/C27H38O6/c1-24(2,3)14-22(31)33-15-21(30)27(32)11-9-19-18-7-6-16-12-17(28)8-10-25(16,4)23(18)20(29)13-26(19,27)5/h8,10,12,18-20,23,29,32H,6-7,9,11,13-15H2,1-5H3/t18-,19-,20-,23+,25-,26-,27-/m0/s1"	HUMXXHTVHHLNRO-KAJVQRHHBK	Clinical Reports 	Maximum Recommended Daily Dose	human	5 of 6	Prednisolone	glucocorticoid	3.33	0.007261435	2.138977525	35	Moderate	Moderate	form of drug administered not known; related forms; family parent [50-24-8]			
23506	3506	23506	966_FDAMDD_v3b	C28H38O7	486.59712	defined organic	parent	tested chemical	Prednisolone valerate acetate	72064-79-0	single chemical compound	stereochem; tautomers	"(11beta)-21-(acetyloxy)-11-hydroxy-3,20-dioxopregna-1,4-dien-17-yl pentanoate"	CC(=O)OCC(=O)[C@]2(CC[C@H]3[C@@H]4CC\C1=C\C(=O)\C=C/[C@]1(C)[C@H]4[C@@H](O)C[C@]23C)OC(=O)CCCC	CC(=O)OCC(=O)[C@]2(CC[C@H]3[C@@H]4CC\C1=C\C(=O)\C=C/[C@]1(C)[C@H]4[C@@H](O)C[C@]23C)OC(=O)CCCC	"InChI=1/C28H38O7/c1-5-6-7-24(33)35-28(23(32)16-34-17(2)29)13-11-21-20-9-8-18-14-19(30)10-12-26(18,3)25(20)22(31)15-27(21,28)4/h10,12,14,20-22,25,31H,5-9,11,13,15-16H2,1-4H3/t20-,21-,22-,25+,26-,27-,28-/m0/s1"	DGYSDXLCLKPUBR-SLPNHVECBD	Clinical Reports 	Maximum Recommended Daily Dose	human	6 of 6	Prednisolone	glucocorticoid	3.33	0.006843444	2.164725301	35	Moderate	Moderate	form of drug administered not known; related forms; family parent [50-24-8]			
23507	3507	23507	967_FDAMDD_v3b	C12H19NO3	225.28416	defined organic	parent	tested chemical	Prenalterol	57526-81-5	single chemical compound		4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenol	C1=C(O)C=CC(OCC(O)CNC(C)C)=C1	C1=C(O)C=CC(OCC(O)CNC(C)C)=C1	"InChI=1/C12H19NO3/c1-9(2)13-7-11(15)8-16-12-5-3-10(14)4-6-12/h3-6,9,11,13-15H,7-8H2,1-2H3"	ADUKCCWBEDSMEB-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cardiotonic	0.333	0.001478133	2.830286424	43	Moderate	High	form of drug administered not known; HCl [61260-05-7]			
23508	3508	23508	968_FDAMDD_v3b	C22H28BrN	386.36842	defined organic	salt Br	tested chemical	Prifinium bromide	4630-95-9	single chemical compound	ammonium	"3-(diphenylmethylidene)-1,1-diethyl-2-methylpyrrolidinium bromide"	C(C1=CC=CC=C1)(C2=CC=CC=C2)=C3CC[N+](CC)(CC)C3C.[Br-]	C(C1=CC=CC=C1)(C2=CC=CC=C2)=C3CC[N+](CC)(CC)C3C	"InChI=1/C22H28N.BrH/c1-4-23(5-2)17-16-21(18(23)3)22(19-12-8-6-9-13-19)20-14-10-7-11-15-20;/h6-15,18H,4-5,16-17H2,1-3H3;1H/q+1;/p-1/fC22H28N.Br/h;1h/qm;-1"	UCGJZJXOPSNTGZ-OCBWOWHCCF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antispasmodic	2	0.005176406	2.285971626	37	Moderate	High	form of drug administered not known			
23509	3509	23509	969_FDAMDD_v3b	C15H21N3O	259.34674	defined organic	parent	tested chemical	Primaquine	90-34-6	single chemical compound		"N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine"	C1(OC)C=C2C(=C(NC(C)CCCN)C=1)N=CC=C2	C1(OC)C=C2C(=C(NC(C)CCCN)C=1)N=CC=C2	"InChI=1/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3"	INDBQLZJXZLFIT-UHFFFAOYAU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimalarial	0.75	0.002891881	2.53881953	40	Moderate	High	form of drug administered not known			
23510	3510	23510	970_FDAMDD_v3b	C12H14N2O2	218.2518	defined organic	parent	tested chemical	Primidone	125-33-7	single chemical compound		"5-ethyl-5-phenyldihydropyrimidine-4,6(1H,5H)-dione"	C2(=O)C(C1=CC=CC=C1)(CC)C(=O)NCN2	C2(=O)C(C1=CC=CC=C1)(CC)C(=O)NCN2	"InChI=1/C12H14N2O2/c1-2-12(9-6-4-3-5-7-9)10(15)13-8-14-11(12)16/h3-7H,2,8H2,1H3,(H,13,15)(H,14,16)/f/h13-14H"	DQMZLTXERSFNPB-KGCNKATMCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	8.33	0.038166925	1.418312833	27	Low-Moderate	Low	form of drug administered not known			
23511	1188	21188	971_FDAMDD_v3b	C13H19NO4S	285.3593	defined organic	parent	tested chemical	Probenecid	57-66-9	single chemical compound		4-[(dipropylamino)sulfonyl]benzoic acid	O=S(=O)(C1=CC=C(C=C1)C(=O)O)N(CCC)CCC	O=S(=O)(C1=CC=C(C=C1)C(=O)O)N(CCC)CCC	"InChI=1/C13H19NO4S/c1-3-9-14(10-4-2)19(17,18)12-7-5-11(6-8-12)13(15)16/h5-8H,3-4,9-10H2,1-2H3,(H,15,16)/f/h15H"	DBABZHXKTCFAPX-YAQRNVERCP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		uricosuric	16.7	0.058522712	1.23267556	25	Low-Moderate	Low	form of drug administered not known			
23512	3512	23512	972_FDAMDD_v3b	C13H21N3O	235.32534	defined organic	parent	tested chemical	Procainamide	51-06-9	single chemical compound		4-amino-N-[2-(diethylamino)ethyl]benzamide	C1=C(N)C=CC(C(=O)NCCN(CC)CC)=C1	C1=C(N)C=CC(C(=O)NCCN(CC)CC)=C1	"InChI=1/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)/f/h15H"	REQCZEXYDRLIBE-YAQRNVERCK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiarrhythmic	50	0.212471806	0.67269869	19	Low	Low	form of drug administered not known			
23513	1189	21189	973_FDAMDD_v3b	C12H19N3O	221.3016	defined organic	parent	tested chemical	Procarbazine	671-16-9	single chemical compound		N-(1-methylethyl)-4-[(2-methylhydrazino)methyl]benzamide	CNNCC1=CC=C(C=C1)C(=O)NC(C)C	CNNCC1=CC=C(C=C1)C(=O)NC(C)C	"InChI=1/C12H19N3O/c1-9(2)15-12(16)11-6-4-10(5-7-11)8-14-13-3/h4-7,9,13-14H,8H2,1-3H3,(H,15,16)/f/h15H"	CPTBDICYNRMXFX-YAQRNVERCI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	6	0.027112321	1.566833303	29	Low-Moderate	Low	form of drug administered not known			
23514	3514	23514	974_FDAMDD_v3b	C20H24ClN3S	373.94266	defined organic	parent	tested chemical	Prochlorperazine	58-38-8	single chemical compound		2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine	C1=CC=C3C(=C1)N(CCCN2CCN(C)CC2)C4=C(S3)C=CC(Cl)=C4	C1=CC=C3C(=C1)N(CCCN2CCN(C)CC2)C4=C(S3)C=CC(Cl)=C4	"InChI=1/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3"	WIKYUJGCLQQFNW-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiemetic	1.67	0.004465925	2.350088542	37	Moderate	High	form of drug administered not known			
23515	3515	23515	975_FDAMDD_v3b	C19H29NO	287.43966	defined organic	parent	tested chemical	Procyclidine	77-37-2	single chemical compound		1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol	C3=CC=CC(C(O)(CCN1CCCC1)C2CCCCC2)=C3	C3=CC=CC(C(O)(CCN1CCCC1)C2CCCCC2)=C3	"InChI=1/C19H29NO/c21-19(17-9-3-1-4-10-17,18-11-5-2-6-12-18)13-16-20-14-7-8-15-20/h1,3-4,9-10,18,21H,2,5-8,11-16H2"	WYDUSKDSKCASEF-UHFFFAOYAC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	0.333	0.001158504	2.936102457	44	Moderate	High	form of drug administered not known			
23516	3516	23516	976_FDAMDD_v3b	C18H26N2O4	334.41004	defined organic	parent	tested chemical	Proglumide	6620-60-6	single chemical compound		"N~2~-(phenylcarbonyl)-N,N-dipropyl-alpha-glutamine"	N(C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1)(CCC)CCC	N(C(=O)C(CCC(O)=O)NC(=O)C1=CC=CC=C1)(CCC)CCC	"InChI=1/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22)/f/h19,21H"	DGMKFQYCZXERLX-PXPUHDKACP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	26.7	0.0798421	1.097768046	23	Low	Low	form of drug administered not known			
23517	3517	23517	977_FDAMDD_v3b	C17H20N2S	284.4191	defined organic	parent	tested chemical	Promazine	58-40-2	single chemical compound		"N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine"	C1=CC=C2C(=C1)N(CCCN(C)C)C3=C(S2)C=CC=C3	C1=CC=C2C(=C1)N(CCCN(C)C)C3=C(S2)C=CC=C3	"InChI=1/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3"	ZGUGWUXLJSTTMA-UHFFFAOYAX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	16.7	0.058716169	1.231242287	25	Low-Moderate	Low	form of drug administered not known			
23518	3518	23518	978_FDAMDD_v3b	C17H20N2S	284.4191	defined organic	parent	tested chemical	Promethazine	60-87-7	single chemical compound		"N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine"	C1=CC2=C(C=C1)N(CC(C)N(C)C)C3=C(S2)C=CC=C3	C1=CC2=C(C=C1)N(CC(C)N(C)C)C3=C(S2)C=CC=C3	"InChI=1/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3"	PWWVAXIEGOYWEE-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	1.67	0.005871617	2.231242287	36	Moderate	High	form of drug administered not known			
23519	3519	23519	979_FDAMDD_v3b	C23H30BrNO3	448.3932	defined organic	salt Br	tested chemical	Propantheline bromide	50-34-0	single chemical compound	ammonium; parent [298-50-0]	N-methyl-N-(1-methylethyl)-N-{2-[(9H-xanthen-9-ylcarbonyl)oxy]ethyl}propan-2-aminium bromide	C1=CC=C2C(=C1)C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=C(O2)C=CC=C3.[Br-]	C1=CC=C2C(=C1)C(C(=O)OCC[N+](C)(C(C)C)C(C)C)C3=C(O2)C=CC=C3	"InChI=1/C23H30NO3.BrH/c1-16(2)24(5,17(3)4)14-15-26-23(25)22-18-10-6-8-12-20(18)27-21-13-9-7-11-19(21)22;/h6-13,16-17,22H,14-15H2,1-5H3;1H/q+1;/p-1/fC23H30NO3.Br/h;1h/qm;-1"	XLBIBBZXLMYSFF-FOMPPATQCT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	1.25	0.002787732	2.554749005	40	Moderate	High	form of drug administered not known			
23520	3520	23520	980_FDAMDD_v3b	C20H24N2OS	340.48236	defined organic	parent	tested chemical	Propiomazine	362-29-8	single chemical compound		1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}propan-1-one	C1=CC=C2C(=C1)N(CC(C)N(C)C)C3=C(S2)C=CC(C(=O)CC)=C3	C1=CC=C2C(=C1)N(CC(C)N(C)C)C3=C(S2)C=CC(C(=O)CC)=C3	"InChI=1/C20H24N2OS/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20/h6-12,14H,5,13H2,1-4H3"	UVOIBTBFPOZKGP-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	0.833	0.002446529	2.611449615	40	Moderate	High	form of drug administered not known			
23521	3521	23521	981_FDAMDD_v3b	C42H69NO15	827.99496	defined organic	parent	tested chemical	Propionylleucomycin	74014-51-0	single chemical compound	stereochem	"((4R,5S,6S,7R,9R,10R,11E,13E,16R)-7-(Formylmethyl)-4,10-dihydroxy-5-methoxy-9,16-dimethyl-2-oxooxacyclohexadeca-11,13-dien-6-yl)-3,6-dideoxy-4-O-(2,6-dideoxy-3-C-methyl-alpha-L-ribo-hexopyranosyl)-3-(dimethylamino)-beta-D-glucopyranoside 4''-butyrate 3''-propionate"	[C@@H]3(O[C@H]2[C@@H]([C@H]([C@H](O[C@H]1C[C@]([C@H]([C@@H](O1)C)OC(=O)CCC)(OC(=O)CC)C)[C@H](O2)C)N(C)C)O)[C@H]([C@@H](CC(O[C@@H](C/C=C/C=C/[C@@H]([C@@H](C[C@@H]3CC=O)C)O)C)=O)O)OC	[C@@H]3(O[C@H]2[C@@H]([C@H]([C@H](O[C@H]1C[C@]([C@H]([C@@H](O1)C)OC(=O)CCC)(OC(=O)CC)C)[C@H](O2)C)N(C)C)O)[C@H]([C@@H](CC(O[C@@H](C/C=C/C=C/[C@@H]([C@@H](C[C@@H]3CC=O)C)O)C)=O)O)OC	"InChI=1/C42H69NO15/c1-11-16-32(48)55-40-27(6)53-34(23-42(40,7)58-31(47)12-2)56-37-26(5)54-41(36(50)35(37)43(8)9)57-38-28(19-20-44)21-24(3)29(45)18-15-13-14-17-25(4)52-33(49)22-30(46)39(38)51-10/h13-15,18,20,24-30,34-41,45-46,50H,11-12,16-17,19,21-23H2,1-10H3/b14-13+,18-15+/t24-,25-,26-,27+,28+,29+,30-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1"	VYWWNRMSAPEJLS-MDWYKHENBZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	20	0.024154736	1.616997698	29	Low-Moderate	Low	form of drug administered not known			
23522	3522	23522	982_FDAMDD_v3b	C16H25N3O	275.3892	defined organic	parent	tested chemical	Propiram	15686-91-6	single chemical compound		N-(1-methyl-2-piperidin-1-ylethyl)-N-pyridin-2-ylpropanamide	C2=CC=NC(N(C(C)CN1CCCCC1)C(=O)CC)=C2	C2=CC=NC(N(C(C)CN1CCCCC1)C(=O)CC)=C2	"InChI=1/C16H25N3O/c1-3-16(20)19(15-9-5-6-10-17-15)14(2)13-18-11-7-4-8-12-18/h5-6,9-10,14H,3-4,7-8,11-13H2,1-2H3"	ZBAFFZBKCMWUHM-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	2.5	0.009078061	2.042006896	34	Moderate	High-Moderate	form of drug administered not known			
23523	3523	23523	983_FDAMDD_v3b	C12H18O	178.2707	defined organic	parent	tested chemical	Propofol	2078-54-8	single chemical compound		"2,6-bis(1-methylethyl)phenol"	C1(C(C)C)=CC=CC(C(C)C)=C1O	C1(C(C)C)=CC=CC(C(C)C)=C1O	"InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3"	OLBCVFGFOZPWHH-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anesthetic	2.5	0.014023617	1.853139961	32	Moderate	High-Moderate	form of drug administered not known			
23524	3524	23524	984_FDAMDD_v3b	C22H29NO2	339.47116	defined organic	parent	tested chemical	Propoxyphene	469-62-5	single chemical compound	stereochem	"(1S,2R)-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate"	O=C(CC)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C	O=C(CC)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C	"InChI=1/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1"	XLMALTXPSGQGBX-GCJKJVERBA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	6.5	0.019147429	1.717889528	30	Moderate	Low	form of drug administered not known			
23525	3525	23525	985_FDAMDD_v3b	C16H21NO2	259.34344	defined organic	parent	tested chemical	Propranolol	525-66-6	single chemical compound		1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol	C1=CC2C(C=C1)=C(OCC(O)CNC(C)C)C=CC=2	C1=CC2C(C=C1)=C(OCC(O)CNC(C)C)C=CC=2	"InChI=1/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3"	AQHHHDLHHXJYJD-UHFFFAOYAS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal; antiarrhythmic	10.7	0.041258032	1.384491489	27	Low-Moderate	Low	form of drug administered not known			
23526	3526	23526	986_FDAMDD_v3b	C10H21N	155.28044	defined organic	parent	tested chemical	Propylhexedrine	101-40-6	single chemical compound		1-cyclohexyl-N-methylpropan-2-amine	C1CCCC(CC(C)NC)C1	C1CCCC(CC(C)NC)C1	"InChI=1/C10H21N/c1-9(11-2)8-10-6-4-3-5-7-10/h9-11H,3-8H2,1-2H3"	JCRIVQIOJSSCQD-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		andrenergic; nasal decongestant	2.5	0.016099903	1.793176744	31	Moderate	High-Moderate	form of drug administered not known			
23527	3527	23527	987_FDAMDD_v3b	C10H11I2NO3	447.00818	defined organic	parent	tested chemical	Propyliodone	587-61-1	single chemical compound		"propyl (3,5-diiodo-4-oxopyridin-1(4H)-yl)acetate"	C1(I)C(=O)C(I)=CN(CC(=O)OCCC)C=1	C1(I)C(=O)C(I)=CN(CC(=O)OCCC)C=1	"InChI=1/C10H11I2NO3/c1-2-3-16-9(14)6-13-4-7(11)10(15)8(12)5-13/h4-5H,2-3,6H2,1H3"	ROSXARVHJNYYDO-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	100	0.223709553	0.650315471	18	Low	Low	form of drug administered not known			
23528	2527	22527	988_FDAMDD_v3b	C10H12O3	180.2005	defined organic	parent	tested chemical	Propylparaben	94-13-3	single chemical compound		propyl 4-hydroxybenzoate	C(C1=CC=C(C=C1)O)(=O)OCCC	C(C1=CC=C(C=C1)O)(=O)OCCC	"InChI=1/C10H12O3/c1-2-7-13-10(12)8-3-5-9(11)6-4-8/h3-6,11H,2,7H2,1H3"	QELSKZZBTMNZEB-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		pharmaceutic aid	10	0.055493742	1.255755992	25	Low-Moderate	Low	form of drug administered not known			
23529	3529	23529	989_FDAMDD_v3b	C14H18N2O	230.30552	defined organic	parent	tested chemical	Propyphenazone	479-92-5	single chemical compound		"1,5-dimethyl-4-(1-methylethyl)-2-phenyl-1,2-dihydro-3H-pyrazol-3-one"	C2=CC(N1N(C)C(C)=C(C(C)C)C1=O)=CC=C2	C2=CC(N1N(C)C(C)=C(C(C)C)C1=O)=CC=C2	"InChI=1/C14H18N2O/c1-10(2)13-11(3)15(4)16(14(13)17)12-8-6-5-7-9-12/h5-10H,1-4H3"	PXWLVJLKJGVOKE-UHFFFAOYAH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; antipyretic; antiphlogistic	30	0.13026175	0.885183093	21	Low	Low	form of drug administered not known			
23530	1210	21210	990_FDAMDD_v3b	C18H18N2O	278.353	defined organic	parent	tested chemical	Proquazone	22760-18-5	single chemical compound		7-methyl-1-(1-methylethyl)-4-phenylquinazolin-2(1H)-one	C1(=CC=C2C(=C1)N(C(\N=C/2C3=CC=CC=C3)=O)C(C)C)C	C1(=CC=C2C(=C1)N(C(\N=C/2C3=CC=CC=C3)=O)C(C)C)C	"InChI=1/C18H18N2O/c1-12(2)20-16-11-13(3)9-10-15(16)17(19-18(20)21)14-7-5-4-6-8-14/h4-12H,1-3H3"	JTIGKVIOEQASGT-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	20	0.071851211	1.143565911	24	Low	Low	form of drug administered not known			
23531	1211	21211	991_FDAMDD_v3b	C24H30N2O8	474.5036	defined organic	parent	tested chemical	Proreside	1508-45-8	single chemical compound	stereochem	"(5R,6R,7R,8R)-N'-ethyl-8-hydroxy-7-(hydroxymethyl)-5-[3,4,5-tris(methyloxy)phenyl]-5,6,7,8-tetrahydronaphtho[2,3-d][1,3]dioxole-6-carbohydrazide"	c12[C@H]([C@@H](C(=O)NNCC)[C@@H]([C@H](c1cc3c(c2)OCO3)O)CO)c4cc(c(c(c4)OC)OC)OC	c12[C@H]([C@@H](C(=O)NNCC)[C@@H]([C@H](c1cc3c(c2)OCO3)O)CO)c4cc(c(c(c4)OC)OC)OC	"InChI=1/C24H30N2O8/c1-5-25-26-24(29)21-15(10-27)22(28)14-9-17-16(33-11-34-17)8-13(14)20(21)12-6-18(30-2)23(32-4)19(7-12)31-3/h6-9,15,20-22,25,27-28H,5,10-11H2,1-4H3,(H,26,29)/t15-,20+,21-,22-/m0/s1/f/h26H"	CPTIBDHUFVHUJK-NPFIBQQBDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	3.33	0.00701786	2.153795278	35	Moderate	Moderate	form of drug administered not known			
23532	3532	23532	992_FDAMDD_v3b	C30H42O8	530.64968	defined organic	parent	tested chemical	Proscillaridin	466-06-8	single chemical compound	stereochem	"(3beta)-3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-14-hydroxybufa-4,20,22-trienolide"	[C@@]42([C@@]([C@@H](/C/1=C/OC(\C=C\1)=O)CC2)(CC[C@@H]5[C@]\3(CC[C@@H](/C=C/3CC[C@@H]45)O[C@H]6[C@@H]([C@@H]([C@H]([C@@H](O6)C)O)O)O)C)C)O	[C@@]42([C@@]([C@@H](/C/1=C/OC(\C=C\1)=O)CC2)(CC[C@@H]5[C@]\3(CC[C@@H](/C=C/3CC[C@@H]45)O[C@H]6[C@@H]([C@@H]([C@H]([C@@H](O6)C)O)O)O)C)C)O	"InChI=1/C30H42O8/c1-16-24(32)25(33)26(34)27(37-16)38-19-8-11-28(2)18(14-19)5-6-22-21(28)9-12-29(3)20(10-13-30(22,29)35)17-4-7-23(31)36-15-17/h4,7,14-16,19-22,24-27,32-35H,5-6,8-13H2,1-3H3/t16-,19-,20+,21-,22+,24-,25+,26+,27-,28-,29+,30-/m0/s1"	MYEJFUXQJGHEQK-ALRJYLEOBX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cardiotonic	0.0417	7.85829E-05	4.104671852	57	High	High	form of drug administered not known			
23533	3533	23533	993_FDAMDD_v3b	C16H22N6O4	362.38368	defined organic	parent	tested chemical	Protirelin	24305-27-9	single chemical compound	stereochem; tautomers	5-oxo-L-prolyl-L-histidyl-L-prolinamide	O=C([C@H](CC1=CN=CN1)N[C@]([C@H](CC2)NC2=O)=O)N(CCC3)[C@@H]3[C@](N)=O	O=C([C@H](CC1=CN=CN1)N[C@]([C@H](CC2)NC2=O)=O)N(CCC3)[C@@H]3[C@](N)=O	"InChI=1/C16H22N6O4/c17-14(24)12-2-1-5-22(12)16(26)11(6-9-7-18-8-19-9)21-15(25)10-3-4-13(23)20-10/h7-8,10-12H,1-6H2,(H2,17,24)(H,18,19)(H,20,23)(H,21,25)/t10-,11-,12-/m0/s1/f/h19-21H,17H2"	XNSAINXGIQZQOO-BIRUZPGADF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		prohormone	0.00833	2.29867E-05	4.63852363	63	High	High	form of drug administered not known			
23534	3534	23534	994_FDAMDD_v3b	C27H43NO9	525.63162	defined organic	parent	tested chemical	Protoverine	76-45-9	single chemical compound	stereochem	"(3beta,4alpha,6alpha,7alpha,15alpha,16beta)-4,9-epoxycevane-3,4,6,7,14,15,16,20-octol"	[C@@]572[C@H]([C@@]1([C@H]([C@@H]([C@H]3[C@H]([C@@H]1C2)CN4[C@H]([C@]3(O)C)CC[C@@H](C4)C)O)O)O)[C@@H]([C@@H]([C@H]6[C@@]5(CC[C@@H]([C@]6(O7)O)O)C)O)O	[C@@]572[C@H]([C@@]1([C@H]([C@@H]([C@H]3[C@H]([C@@H]1C2)CN4[C@H]([C@]3(O)C)CC[C@@H](C4)C)O)O)O)[C@@H]([C@@H]([C@H]6[C@@]5(CC[C@@H]([C@]6(O7)O)O)C)O)O	"InChI=1/C27H43NO9/c1-11-4-5-14-24(3,34)16-12(10-28(14)9-11)13-8-25-21(26(13,35)22(33)17(16)30)19(32)18(31)20-23(25,2)7-6-15(29)27(20,36)37-25/h11-22,29-36H,4-10H2,1-3H3/t11-,12-,13-,14-,15-,16+,17+,18-,19+,20-,21+,22-,23-,24+,25+,26-,27+/m0/s1"	CKJAABZFXLMMCS-MKKPLVDTBX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	0.025	4.75618E-05	4.322741474	60	High	High	form of drug administered not known			
23535	3535	23535	995_FDAMDD_v3b	C19H21N	263.37674	defined organic	parent	tested chemical	Protriptyline	438-60-8	single chemical compound		"3-(5H-dibenzo[a,d][7]annulen-5-yl)-N-methylpropan-1-amine"	C1=CC=C2C(=C1)C(CCCNC)C3=C(C=C2)C=CC=C3	C1=CC=C2C(=C1)C(CCCNC)C3=C(C=C2)C=CC=C3	"InChI=1/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-10,12-13,19-20H,6,11,14H2,1H3"	BWPIARFWQZKAIA-UHFFFAOYAS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	1	0.003796843	2.420577418	38	Moderate	High	form of drug administered not known			
23536	3536	23536	996_FDAMDD_v3b	C10H14N4O3	238.24316	defined organic	parent	tested chemical	Proxyphylline	603-00-9	single chemical compound		"7-(2-hydroxypropyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione"	N1(C)C(=O)N(C)C2=C(C1=O)N(CC(C)O)C=N2	N1(C)C(=O)N(C)C2=C(C1=O)N(CC(C)O)C=N2	"InChI=1/C10H14N4O3/c1-6(15)4-14-5-11-8-7(14)9(16)13(3)10(17)12(8)2/h5-6,15H,4H2,1-3H3"	KYHQZNGJUGFTGR-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator; vasodilator; smooth muscle relaxant	40	0.167895691	0.774960449	20	Low	Low	form of drug administered not known			
23537	3537	23537	997_FDAMDD_v3b	C10H15NO	165.2322	defined organic	parent	tested chemical	Pseudoephedrine	90-82-4	single chemical compound	stereochem	"(1S,2S)-2-(methylamino)-1-phenylpropan-1-ol"	O[C@H]([C@H](C)NC)c1ccccc1	O[C@H]([C@H](C)NC)c1ccccc1	"InChI=1/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10+/m0/s1"	KWGRBVOPPLSCSI-WCBMZHEXBE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		l-form as bronchodilator; d-form as decongestant	4	0.024208356	1.616034694	29	Low-Moderate	Moderate	form of drug administered not known			
23538	3538	23538	998_FDAMDD_v3b	C11H14N2S	206.30726	defined organic	parent	tested chemical	Pyrantel	15686-83-6	single chemical compound		"1-methyl-2-[(E)-2-(2-thienyl)ethenyl]-1,4,5,6-tetrahydropyrimidine"	C2(C=CC1=CC=CS1)=NCCCN2C	C2(C=CC1=CC=CS1)=NCCCN2C	"InChI=1/C11H14N2S/c1-13-8-3-7-12-11(13)6-5-10-4-2-9-14-10/h2,4-6,9H,3,7-8H2,1H3/b6-5+"	YSAUAVHXTIETRK-AATRIKPKBR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anthelmintic	20	0.096942783	1.013484516	22	Low	Low	form of drug administered not known			
23539	1215	21215	999_FDAMDD_v3b	C5H5N3O	123.1127	defined organic	parent	tested chemical	Pyrazinamide	98-96-4	single chemical compound		pyrazine-2-carboxamide	NC(=O)C1=NC=CN=C1	NC(=O)C1=NC=CN=C1	"InChI=1/C5H5N3O/c6-5(9)4-3-7-1-2-8-4/h1-3H,(H2,6,9)/f/h6H2"	IPEHBUMCGVEMRF-MDVJYLRGCE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	30	0.243679166	0.613181601	18	Low	Low	form of drug administered not known			
23540	3540	23540	1000_FDAMDD_v3b	C9H13BrN2O2	261.1157	defined organic	salt Br	tested chemical	Pyridostigmine bromide	101-26-8	single chemical compound	ammonium; parent [155-97-5]	3-{[(dimethylamino)carbonyl]oxy}-1-methylpyridinium bromide	C1=CC=C(OC(=O)N(C)C)C=[N+]1C.[Br-]	C1=CC=C(OC(=O)N(C)C)C=[N+]1C	"InChI=1/C9H13N2O2.BrH/c1-10(2)9(12)13-8-5-4-6-11(3)7-8;/h4-7H,1-3H3;1H/q+1;/p-1/fC9H13N2O2.Br/h;1h/qm;-1"	VNYBTNPBYXSMOO-GDTAVRJECE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cholinergic	20	0.076594399	1.11580299	24	Low	Low	form of drug administered not known			
23541	3541	23541	1001_FDAMDD_v3b	C8H11NO3	169.17784	defined organic	parent	tested chemical	Pyridoxine	65-23-6	single chemical compound		"4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol"	C1(C)=C(O)C(CO)=C(CO)C=N1	C1(C)=C(O)C(CO)=C(CO)C=N1	"InChI=1/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3"	LXNHXLLTXMVWPM-UHFFFAOYAQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		enzyme cofactor vitamin	6.67	0.039425967	1.404217642	27	Low-Moderate	Low	form of drug administered not known			
23542	3542	23542	1002_FDAMDD_v3b	C17H23N3O	285.384	defined organic	parent	tested chemical	Pyrilamine	91-84-9	single chemical compound		"N,N-dimethyl-N'-{[4-(methyloxy)phenyl]methyl}-N'-pyridin-2-ylethane-1,2-diamine"	C2(OC)=CC=C(CN(CCN(C)C)C1=NC=CC=C1)C=C2	C2(OC)=CC=C(CN(CCN(C)C)C1=NC=CC=C1)C=C2	"InChI=1/C17H23N3O/c1-19(2)12-13-20(17-6-4-5-11-18-17)14-15-7-9-16(21-3)10-8-15/h4-11H,12-14H2,1-3H3"	YECBIJXISLIIDS-UHFFFAOYAS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	1.25	0.004380063	2.358519608	38	Moderate	High	form of drug administered not known			
23543	1217	21217	1003_FDAMDD_v3b	C12H13ClN4	248.7114	defined organic	parent	tested chemical	Pyrimethamine	58-14-0	single chemical compound		"5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine"	NC1=C(C(=NC(=N1)N)CC)C2=CC=C(C=C2)Cl	NC1=C(C(=NC(=N1)N)CC)C2=CC=C(C=C2)Cl	"InChI=1/C12H13ClN4/c1-2-9-10(11(14)17-12(15)16-9)7-3-5-8(13)6-4-7/h3-6H,2H2,1H3,(H4,14,15,16,17)/f/h14-15H2"	WKSAUQYGYAYLPV-KHCWMJRFCQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimalarial	1.25	0.005025906	2.298785679	37	Moderate	High	form of drug administered not known			
23544	3544	23544	1004_FDAMDD_v3b	C20H22ClN	311.84838	defined organic	parent	representative isomer in mixture	Pyrrobutamine	91-82-7	mixture or formulation	"mixture of Z,E isomers; structure shown E; stereochem"	1-[(2E)-4-(4-chlorophenyl)-3-phenylbut-2-en-1-yl]pyrrolidine	C3=C(Cl)C=CC(CC(=CCN1CCCC1)C2=CC=CC=C2)=C3	C3=C(Cl)C=CC(CC(=CCN1CCCC1)C2=CC=CC=C2)=C3	"InChI=1/C20H22ClN/c21-20-10-8-17(9-11-20)16-19(18-6-2-1-3-7-18)12-15-22-13-4-5-14-22/h1-3,6-12H,4-5,13-16H2/b19-12+"	WDYYVNNRTDZKAZ-XDHOZWIPBI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	1.5	0.00481003	2.317852233	37	Moderate	High	form of drug administered not known			
23545	3545	23545	1005_FDAMDD_v3b	C75H70N6O6	1151.3949	defined organic	complex dimer pamoate [2(C26H28N3)]	tested chemical	Pyrvinium pamoate	3546-41-6	single chemical compound	ammonium; stereochem; parent [7187-62-4]	"bis{6-(dimethylamino)-2-[(E)-2-(2,5-dimethyl-1-phenyl-1H-pyrrol-3-yl)ethenyl]-1-methylquinolinium} 4,4'-methanediylbis(3-hydroxynaphthalene-2-carboxylate)"	[O-]C(=O)c4cc1ccccc1c(Cc2c3ccccc3cc(C([O-])=O)c2O)c4O.CN(C)c1ccc2[n+](C)c(ccc2c1)/C=C/c4cc(C)n(c3ccccc3)c4C.CN(C)c1ccc2[n+](C)c(ccc2c1)/C=C/c4cc(C)n(c3ccccc3)c4C	CN(C)c1ccc2[n+](C)c(ccc2c1)/C=C/c4cc(C)n(c3ccccc3)c4C	"InChI=1/2C26H28N3.C23H16O6/c2*1-19-17-21(20(2)29(19)24-9-7-6-8-10-24)11-13-23-14-12-22-18-25(27(3)4)15-16-26(22)28(23)5;24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h2*6-18H,1-5H3;1-10,24-25H,11H2,(H,26,27)(H,28,29)/q2*+1;/p-2/f2C26H28N3.C23H14O6/q2m;-2"	OOPDAHSJBRZRPH-REKGJBOICO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anthelmintic	5	0.004342559	2.362254297	38	Moderate	Low	form of drug administered not known			
23546	3546	23546	1006_FDAMDD_v3b	C21H25N3O2S	383.5071	defined organic	parent	tested chemical	Quetiapine	111974-69-7	single chemical compound		"2-{[2-(4-dibenzo[b,f][1,4]thiazepin-11-ylpiperazin-1-yl)ethyl]oxy}ethanol"	S2C4=C(N=C(N1CCN(CCOCCO)CC1)C3=C2C=CC=C3)C=CC=C4	S2C4=C(N=C(N1CCN(CCOCCO)CC1)C3=C2C=CC=C3)C=CC=C4	"InChI=1/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2"	URKOMYMAXPYINW-UHFFFAOYAD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	13.3	0.034679932	1.459921768	27	Low-Moderate	Low	form of drug administered not known			
23547	3547	23547	1007_FDAMDD_v3b	C25H30N2O5	438.5161	defined organic	parent	tested chemical	Quinapril	85441-61-8	single chemical compound	stereochem	"(3S)-2-(N-{(1S)-1-[(ethyloxy)carbonyl]-3-phenylpropyl}-L-alanyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid"	N2(C([C@@H](N[C@H](C(=O)OCC)CCc1ccccc1)C)=O)[C@@H](Cc3c(C2)cccc3)C(=O)O	N2(C([C@@H](N[C@H](C(=O)OCC)CCc1ccccc1)C)=O)[C@@H](Cc3c(C2)cccc3)C(=O)O	"InChI=1/C25H30N2O5/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30)/t17-,21-,22-/m0/s1/f/h29H"	JSDRRTOADPPCHY-YHZYPMOJDP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; ACE inhibitor	1.33	0.003032956	2.518133902	39	Moderate	High	form of drug administered not known			
23548	3548	23548	1008_FDAMDD_v3b	C10H12ClN3O3S	289.7386	defined organic	parent	tested chemical	Quinethazone	73-49-4	single chemical compound		"7-chloro-2-ethyl-4-oxo-1,2,3,4-tetrahydroquinazoline-6-sulfonamide"	C1(Cl)=C(S(N)(=O)=O)C=C2C(=C1)NC(CC)NC2=O	C1(Cl)=C(S(N)(=O)=O)C=C2C(=C1)NC(CC)NC2=O	"InChI=1/C10H12ClN3O3S/c1-2-9-13-7-4-6(11)8(18(12,16)17)3-5(7)10(15)14-9/h3-4,9,13H,2H2,1H3,(H,14,15)(H2,12,16,17)/f/h14H,12H2"	AGMMTXLNIQSRCG-RWJRRMEYCY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic	3.33	0.011493118	1.939562124	33	Moderate	Moderate	form of drug administered not known			
23549	3549	23549	1009_FDAMDD_v3b	C20H24N2O2	324.4168	defined organic	parent	tested chemical	Quinidine	56-54-2	single chemical compound	stereochem	(9S)-6'-methoxycinchonan-9-ol	[H][C@]([C@@H](O)C1=C(C=C(OC)C=C4)C4=NC=C1)(C[C@@H]2CC3)N3C[C@@H]2C=C	[H][C@]([C@@H](O)C1=C(C=C(OC)C=C4)C4=NC=C1)(C[C@@H]2CC3)N3C[C@@H]2C=C	"InChI=1/C20H24N2O2/c1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18/h3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3/t13-,14-,19+,20-/m0/s1"	LOUPRKONTZGTKE-LHHVKLHABX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anthiarrythmic	10	0.030824544	1.511103336	28	Low-Moderate	Low	form of drug administered not known			
23550	3550	23550	1010_FDAMDD_v3b	C28H27NO4S	473.58328	defined organic	parent	tested chemical	Raloxifene	84449-90-1	single chemical compound		[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothien-3-yl]{4-[(2-piperidin-1-ylethyl)oxy]phenyl}methanone	Oc1ccc(cc1)c3sc2cc(O)ccc2c3C(=O)c5ccc(OCCN4CCCCC4)cc5	Oc1ccc(cc1)c3sc2cc(O)ccc2c3C(=O)c5ccc(OCCN4CCCCC4)cc5	"InChI=1/C28H27NO4S/c30-21-8-4-20(5-9-21)28-26(24-13-10-22(31)18-25(24)34-28)27(32)19-6-11-23(12-7-19)33-17-16-29-14-2-1-3-15-29/h4-13,18,30-31H,1-3,14-17H2"	GZUITABIAKMVPG-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiosteoporotic; antiestrogen	10	0.02111561	1.675396361	30	Moderate	Low	form of drug administered not known			
23551	3551	23551	1011_FDAMDD_v3b	C23H32N2O5	416.51058	defined organic	parent	tested chemical	Ramipril	87333-19-5	single chemical compound	stereochem	"N-(1S-carboethoxy-3-phenylpropyl)-S-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3S-carboxylic Acid"	N1([C@@H](C[C@H]2[C@@H]1CCC2)C(=O)O)C([C@@H](N[C@H](C(=O)OCC)CCc3ccccc3)C)=O	N1([C@@H](C[C@H]2[C@@H]1CCC2)C(=O)O)C([C@@H](N[C@H](C(=O)OCC)CCc3ccccc3)C)=O	"InChI=1/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1/f/h27H"	HDACQVRGBOVJII-ZUWNEQGUDP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.333	0.000799499	3.097181804	46	High-Moderate	High	form of drug administered not known			
23552	3552	23552	1012_FDAMDD_v3b	C27H36N2O4	452.58574	defined organic	parent	tested chemical	Repaglinide	135062-02-1	single chemical compound	stereochem	2-ethoxy-4-(2-{[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino}-2-oxoethyl)benzoic acid	O=C(CC3=CC(OCC)=C(C(O)=O)C=C3)N[C@@H](CC(C)C)C1=C(N2CCCCC2)C=CC=C1	O=C(CC3=CC(OCC)=C(C(O)=O)C=C3)N[C@@H](CC(C)C)C1=C(N2CCCCC2)C=CC=C1	"InChI=1/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1/f/h28,31H"	FAEKWTJYAYMJKF-DUDVQEBDDW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	0.267	0.000589943	3.229189605	47	High-Moderate	High	form of drug administered not known; structure modified v3b			
23553	3553	23553	1013_FDAMDD_v3b	C18H23N5O5	389.40572	defined organic	parent	tested chemical	Reproterol	54063-54-6	single chemical compound		"7-(3-{[2-(3,5-dihydroxyphenyl)-2-hydroxyethyl]amino}propyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione"	N1(C)C(=O)N(C)C3=C(C1=O)N(CCCNCC(O)C2=CC(O)=CC(O)=C2)C=N3	N1(C)C(=O)N(C)C3=C(C1=O)N(CCCNCC(O)C2=CC(O)=CC(O)=C2)C=N3	"InChI=1/C18H23N5O5/c1-21-16-15(17(27)22(2)18(21)28)23(10-20-16)5-3-4-19-9-14(26)11-6-12(24)8-13(25)7-11/h6-8,10,14,19,24-26H,3-5,9H2,1-2H3"	WVLAAKXASPCBGT-UHFFFAOYAX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator	1	0.002568016	2.590402327	40	Moderate	High	form of drug administered not known			
23554	3554	23554	1014_FDAMDD_v3b	C35H42N2O9	634.716	defined organic	parent	tested chemical	Rescinnamine	24815-24-5	single chemical compound	stereochem	"methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-({(2E)-3-[3,4,5-tris(methyloxy)phenyl]prop-2-enoyl}oxy)yohimban-16-carboxylate"	COc1cc(cc(OC)c1OC)/C=C/C(=O)O[C@@H]4C[C@@H]5CN6CC\C3=C(\Nc2cc(OC)ccc23)[C@H]6C[C@@H]5[C@H](C(=O)OC)[C@H]4OC	COc1cc(cc(OC)c1OC)/C=C/C(=O)O[C@@H]4C[C@@H]5CN6CC\C3=C(\Nc2cc(OC)ccc23)[C@H]6C[C@@H]5[C@H](C(=O)OC)[C@H]4OC	"InChI=1/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/b10-7+/t20-,24+,26-,29-,31+,34+/m1/s1"	SZLZWPPUNLXJEA-QEGASFHIBN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.0167	2.6311E-05	4.579862975	62	High	High	form of drug administered not known			
23555	1237	21237	1015_FDAMDD_v3b	C33H40N2O9	608.6787	defined organic	parent	tested chemical	Reserpine	50-55-5	single chemical compound	stereochem	"methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-bis(methyloxy)-18-({[3,4,5-tris(methyloxy)phenyl]carbonyl}oxy)yohimban-16-carboxylate"	O=C(C4=CC(OC)=C(OC)C(OC)=C4)O[C@@H]1C[C@@]3([H])[C@@](C[C@](N5C3)([H])C2=C(CC5)C(C=C6)=C(C=C6OC)N2)([H])[C@H]([C@](OC)=O)[C@H]1OC	O=C(C4=CC(OC)=C(OC)C(OC)=C4)O[C@@H]1C[C@@]3([H])[C@@](C[C@](N5C3)([H])C2=C(CC5)C(C=C6)=C(C=C6OC)N2)([H])[C@H]([C@](OC)=O)[C@H]1OC	"InChI=1/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1"	QEVHRUUCFGRFIF-MDEJGZGSBW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.01	1.6429E-05	4.784388104	65	High	High	form of drug administered not known			
23556	3556	23556	1016_FDAMDD_v3b	C20H30O	286.4516	defined organic	parent	tested chemical	Retinol	68-26-8	single chemical compound	stereochem	retinol	C1CCC(C)=C(C=CC(C)=CC=CC(C)=CCO)C1(C)C	C1CCC(C)=C(C=CC(C)=CC=CC(C)=CCO)C1(C)C	"InChI=1/C20H30O/c1-16(8-6-9-17(2)13-15-21)11-12-19-18(3)10-7-14-20(19,4)5/h6,8-9,11-13,21H,7,10,14-15H2,1-5H3/b9-6+,12-11+,16-8+,17-13+"	FPIPGXGPPPQFEQ-OVSJKPMPBW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antixerophthalmic vitamin	0.917	0.003201239	2.494681917	39	Moderate	High	form of drug administered not known			
23557	3557	23557	1017_FDAMDD_v3b	C8H12N4O5	244.2047	defined organic	parent	tested chemical	Ribavirin	36791-04-5	single chemical compound	stereochem	"1-beta-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide"	n2([C@H]1[C@@H]([C@H](O)[C@H](O1)CO)O)nc(C(=O)N)nc2	n2([C@H]1[C@@H]([C@H](O)[C@H](O1)CO)O)nc(C(=O)N)nc2	"InChI=1/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1/f/h9H2"	IWUCXVSUMQZMFG-OHVMRBAQDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiviral	200	0.818985056	0.086724023	12	Low	Low	form of drug administered not known			
23558	1777	21777	1018_FDAMDD_v3b	C17H20N4O6	376.3639	defined organic	parent	tested chemical	Riboflavin	83-88-5	single chemical compound	stereochem	"1-deoxy-1-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)-D-ribitol"	O=C2C1=NC3=C(C=C(C)C(C)=C3)N(C[C@H](O)[C@H](O)[C@H](O)CO)C1=NC(N2)=O	O=C2C1=NC3=C(C=C(C)C(C)=C3)N(C[C@H](O)[C@H](O)[C@H](O)CO)C1=NC(N2)=O	"InChI=1/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m0/s1/f/h20H"	AUNGANRZJHBGPY-QHBRKJKEDE	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Riboflavin	enzyme cofactor vitamin	0.5	0.001328501	2.876637956	43	Moderate	High	form of drug administered not known			
23559	3559	23559	1019_FDAMDD_v3b	C17H21N4O9P	456.343801	defined organic	parent	tested chemical	Riboflavin phosphate	146-17-8	single chemical compound	stereochem; parent [83-88-5]	"1-deoxy-1-(7,8-dimethyl-2,4-dioxo-3,4-dihydrobenzo[g]pteridin-10(2H)-yl)-5-O-phosphono-D-ribitol"	O=C2C1=NC3=C(C=C(C)C(C)=C3)N(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)C1=NC(N2)=O	O=C2C1=NC3=C(C=C(C)C(C)=C3)N(C[C@H](O)[C@H](O)[C@H](O)COP(O)(O)=O)C1=NC(N2)=O	"InChI=1/C17H21N4O9P/c1-7-3-9-10(4-8(7)2)21(15-13(18-9)16(25)20-17(26)19-15)5-11(22)14(24)12(23)6-30-31(27,28)29/h3-4,11-12,14,22-24H,5-6H2,1-2H3,(H,20,25,26)(H2,27,28,29)/t11-,12+,14-/m0/s1/f/h20,27-28H"	FVTCRASFADXXNN-DDLGOASUDN	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Riboflavin	enzyme cofactor vitamin	0.5	0.001095665	2.960322151	44	Moderate	High	form of drug administered not known			
23560	1244	21244	1020_FDAMDD_v3b	C43H58N4O12	822.9402	defined organic	parent	tested chemical	Rifampin	13292-46-1	single chemical compound	stereochem	"(2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate"	O=C1C(C2=C(C(O)=C3C)C(O)=C(NC(\C(C)=C/C=C/[C@@H]5C)=O)C(/C=N/N4CCN(C)CC4)=C2O)=C3O[C@@](C)1O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@H]5O	O=C1C(C2=C(C(O)=C3C)C(O)=C(NC(\C(C)=C/C=C/[C@@H]5C)=O)C(/C=N/N4CCN(C)CC4)=C2O)=C3O[C@@](C)1O/C=C/[C@H](OC)[C@@H](C)[C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@H]5O	"InChI=1/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1/f/h45H"	JQXXHWHPUNPDRT-SUOBQDSDDO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	20	0.024303102	1.614338282	29	Low-Moderate	Low	form of drug administered not known			
23561	3561	23561	1021_FDAMDD_v3b	C12H21N	179.30184	defined organic	parent	tested chemical	Rimantadine	13392-28-4	single chemical compound		"1-tricyclo[3.3.1.1~3,7~]dec-1-ylethanamine"	C1C2CC3CC1CC(C(N)C)(C2)C3	C1C2CC3CC1CC(C(N)C)(C2)C3	"InChI=1/C12H21N/c1-8(13)12-5-9-2-10(6-12)4-11(3-9)7-12/h8-11H,2-7,13H2,1H3"	UBCHPRBFMUDMNC-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiviral	3.33	0.018572035	1.731140513	31	Moderate	Moderate	form of drug administered not known			
23562	1245	21245	1022_FDAMDD_v3b	C15H16N4O	268.3176	defined organic	parent	tested chemical	Ripazepam	26308-28-1	single chemical compound		"1-ethyl-3-methyl-8-phenyl-4,6-dihydropyrazolo[4,3-e][1,4]diazepin-5(1H)-one"	O=C(CN=C2C3=CC=CC=C3)NC1=C2N(N=C1C)CC	O=C(CN=C2C3=CC=CC=C3)NC1=C2N(N=C1C)CC	"InChI=1/C15H16N4O/c1-3-19-15-13(10(2)18-19)17-12(20)9-16-14(15)11-7-5-4-6-8-11/h4-8H,3,9H2,1-2H3,(H,17,20)/f/h17H"	YFHYNLHGFKXAIQ-HCKMINDGCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antianxiolytic	1.33	0.004956812	2.30479752	37	Moderate	High	form of drug administered not known			
23563	3563	23563	1023_FDAMDD_v3b	C7H11NO7P2	283.112262	defined organic	parent	tested chemical	Risedronic acid	105462-24-6	single chemical compound		"(1-hydroxy-2-pyridin-3-ylethane-1,1-diyl)bis(phosphonic acid)"	N1=CC(CC(O)(P(O)(O)=O)P(O)(=O)O)=CC=C1	N1=CC(CC(O)(P(O)(O)=O)P(O)(=O)O)=CC=C1	"InChI=1/C7H11NO7P2/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15)/f/h10-11,13-14H"	IIDJRNMFWXDHID-WZXCJNMECG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiosteoporotic; Ca regulator; Ca channel blocker	0.0833	0.00029423	3.531313678	51	High	High	form of drug administered not known			
23564	3564	23564	1024_FDAMDD_v3b	C14H22N2O2	250.33668	defined organic	parent	tested chemical	Rivastigmine	123441-03-2	single chemical compound	stereochem	3-[(1S)-1-(dimethylamino)ethyl]phenyl ethyl(methyl)carbamate	O=C(N(CC)C)OC1=CC([C@H](C)N(C)C)=CC=C1	O=C(N(CC)C)OC1=CC([C@H](C)N(C)C)=CC=C1	"InChI=1/C14H22N2O2/c1-6-16(5)14(17)18-13-9-7-8-12(10-13)11(2)15(3)4/h7-11H,6H2,1-5H3/t11-/m0/s1"	XSVMFMHYUFZWBK-NSHDSACABE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cholinesterase inhibitor	0.2	0.000798924	3.097494493	46	High-Moderate	High	form of drug administered not known; structure modified v3b			
23565	3565	23565	1025_FDAMDD_v3b	C15H19N5	269.34486	defined organic	parent	tested chemical	Rizatriptan	144034-80-0	single chemical compound		"N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine"	CN(C)CC\C2=C\Nc1ccc(cc12)Cn3cncn3	CN(C)CC\C2=C\Nc1ccc(cc12)Cn3cncn3	"InChI=1/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3"	ULFRLSNUDGIQQP-UHFFFAOYAA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimigraine	0.5	0.001856356	2.731338688	42	Moderate	High	form of drug administered not known			
23566	3566	23566	1026_FDAMDD_v3b	C32H53BrN2O4	609.67822	defined organic	salt Br	tested chemical	Rocuronium bromide	119302-91-9	single chemical compound	stereochem; ammonium; parent [143558-00-3]	"(2beta,3alpha,5alpha,16beta,17beta)-17-(acetyloxy)-3-hydroxy-2-morpholin-4-yl-16-(1-prop-2-en-1-ylpyrrolidinium-1-yl)androstane bromide"	[Br-].C=CC[N+]1(CCCC1)[C@H]6C[C@@H]5[C@](C)(CC[C@H]2[C@H]5CC[C@H]3C[C@H](O)[C@H](C[C@]23C)N4CCOCC4)[C@H]6OC(C)=O	C=CC[N+]1(CCCC1)[C@H]6C[C@@H]5[C@](C)(CC[C@H]2[C@H]5CC[C@H]3C[C@H](O)[C@H](C[C@]23C)N4CCOCC4)[C@H]6OC(C)=O	"InChI=1/C32H53N2O4.BrH/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35;/h5,23-30,36H,1,6-21H2,2-4H3;1H/q+1;/p-1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-;/m0./s1/fC32H53N2O4.Br/h;1h/qm;-1"	OYTJKRAYGYRUJK-YXGKFIRYDM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant; neuromuscular blocker	1.2	0.001968251	2.705919435	41	Moderate	High	form of drug administered not known			
23567	3567	23567	1027_FDAMDD_v3b	C17H14O4S	314.35566	defined organic	parent	tested chemical	Rofecoxib	162011-90-7	single chemical compound		4-[4-(methylsulfonyl)phenyl]-3-phenylfuran-2(5H)-one	C3(=O)C(C1=CC=CC=C1)=C(C2C=CC(S(=O)(=O)C)=CC=2)CO3	C3(=O)C(C1=CC=CC=C1)=C(C2C=CC(S(=O)(=O)C)=CC=2)CO3	"InChI=1/C17H14O4S/c1-22(19,20)14-9-7-12(8-10-14)15-11-21-17(18)16(15)13-5-3-2-4-6-13/h2-10H,11H2,1H3"	RZJQGNCSTQAWON-UHFFFAOYAR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; anti inflammatory	0.833	0.002649865	2.576776283	40	Moderate	High	form of drug administered not known			
23568	3568	23568	1028_FDAMDD_v3b	C27H33N3O8	527.56622	defined organic	parent	tested chemical	Rolitetracycline	751-97-3	single chemical compound	stereochem	"(4S,4aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-N-(pyrrolidin-1-ylmethyl)-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide"	[C@]43(\C(=C2\C(c1c(O)cccc1[C@](C2C[C@H]3[C@@H](/C(=C(\C4=O)C(NCN5CCCC5)=O)O)N(C)C)(O)C)=O)O)O	[C@]43(\C(=C2\C(c1c(O)cccc1[C@](C2C[C@H]3[C@@H](/C(=C(\C4=O)C(NCN5CCCC5)=O)O)N(C)C)(O)C)=O)O)O	"InChI=1/C27H33N3O8/c1-26(37)13-7-6-8-16(31)17(13)21(32)18-14(26)11-15-20(29(2)3)22(33)19(24(35)27(15,38)23(18)34)25(36)28-12-30-9-4-5-10-30/h6-8,14-15,20,31,33-34,37-38H,4-5,9-12H2,1-3H3,(H,28,36)/t14?,15-,20-,26+,27-/m0/s1/f/h28H"	HMEYVGGHISAPJR-UALDFFAIDO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	5.83	0.011050745	1.956608425	33	Moderate	Low	form of drug administered not known			
23569	3569	23569	1029_FDAMDD_v3b	C22H23N3O7S	473.49892	defined organic	complex maleate (C4H3O4)	tested chemical	Rosiglitazone maleate	155141-29-0	single chemical compound	stereochem	"5-{[4-({2-[methyl(pyridin-2-yl)amino]ethyl}oxy)phenyl]methyl}-1,3-thiazolidine-2,4-dione (2Z)-but-2-enedioate"	O=C3NC(=O)SC3Cc2ccc(OCCN(C)c1ccccn1)cc2.OC(=O)/C=C\C(O)=O	O=C3NC(=O)SC3Cc2ccc(OCCN(C)c1ccccn1)cc2	"InChI=1/C18H19N3O3S.C4H4O4/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;5-3(6)1-2-4(7)8/h2-9,15H,10-12H2,1H3,(H,20,22,23);1-2H,(H,5,6)(H,7,8)/b;2-1-/f/h20H;5,7H"	SUFUKZSWUHZXAV-AXPBYXKSDU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	0.133	0.000280888	3.551467352	51	High	High	form of drug administered not known			
23570	1726	21726	1030_FDAMDD_v3b	C7H7NO2	137.136	defined organic	parent	tested chemical	Salicylamide	65-45-2	single chemical compound		2-hydroxybenzamide	C1(O)=CC=CC=C1C(=O)N	C1(O)=CC=CC=C1C(=O)N	"InChI=1/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10)/f/h8H2"	SKZKKFZAGNVIMN-FSHFIPFOCM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic	43.3	0.315744954	0.500663581	17	Low	Low	form of drug administered not known			
23571	3571	23571	1031_FDAMDD_v3b	C25H37NO4	415.56558	defined organic	parent	tested chemical	Salmeterol	89365-50-4	single chemical compound		2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol	C2(CO)=C(O)C=CC(C(O)CNCCCCCCOCCCCC1=CC=CC=C1)=C2	C2(CO)=C(O)C=CC(C(O)CNCCCCCCOCCCCC1=CC=CC=C1)=C2	"InChI=1/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2"	GIIZNNXWQWCKIB-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator	0.0014	3.3689E-06	5.472511533	72	High	High	form of drug administered not known			
23572	3572	23572	1032_FDAMDD_v3b	C14H10O5	258.2262	defined organic	parent	tested chemical	Salsalate	552-94-3	single chemical compound		2-{[(2-hydroxyphenyl)carbonyl]oxy}benzoic acid	C2=CC=CC(OC(=O)C1=C(O)C=CC=C1)=C2C(=O)O	C2=CC=CC(OC(=O)C1=C(O)C=CC=C1)=C2C(=O)O	"InChI=1/C14H10O5/c15-11-7-3-1-5-9(11)14(18)19-12-8-4-2-6-10(12)13(16)17/h1-8,15H,(H,16,17)/f/h16H"	WVYADZUPLLSGPU-WYUMXYHSCY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; anti inflammatory	66.7	0.258300668	0.58787447	18	Low	Low	form of drug administered not known			
23573	3573	23573	1033_FDAMDD_v3b	C17H21NO4	303.35294	defined organic	parent	tested chemical	Scopolamine	51-34-3	single chemical compound	stereochem	"(1R,2R,4S,5S,7S)-9-methyl-3-oxa-9-azatricyclo[3.3.1.0~2,4~]non-7-yl (2S)-3-hydroxy-2-phenylpropanoate"	[C@H]1(C[C@@H]2[C@@H]3[C@H]([C@H](C1)N2C)O3)OC([C@H](CO)c4ccccc4)=O	[C@H]1(C[C@@H]2[C@@H]3[C@H]([C@H](C1)N2C)O3)OC([C@H](CO)c4ccccc4)=O	"InChI=1/C17H21NO4/c1-18-13-7-11(8-14(18)16-15(13)22-16)21-17(20)12(9-19)10-5-3-2-4-6-10/h2-6,11-16,19H,7-9H2,1H3/t11-,12-,13-,14+,15-,16+/m1/s1"	STECJAGHUSJQJN-FWXGHANABA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	0.00033	1.08784E-06	5.963434268	78	High	High	form of drug administered not known			
23574	2019	22019	1034_FDAMDD_v3b	C12H17N2NaO3	260.26767	defined organic	salt Na	tested chemical	Secobarbital	309-43-3	single chemical compound	tautomers	"sodium 5-(1-methylbutyl)-4,6-dioxo-5-prop-2-en-1-yl-1,4,5,6-tetrahydropyrimidin-2-olate"	[O-]C(N1)=NC(C(C(CCC)C)(CC=C)C1=O)=O.[Na+]	OC(N1)=NC(C(C(CCC)C)(CC=C)C1=O)=O	"InChI=1/C12H18N2O3.Na/c1-4-6-8(3)12(7-5-2)9(15)13-11(17)14-10(12)16;/h5,8H,2,4,6-7H2,1,3H3,(H2,13,14,15,16,17);/q;+1/p-1/fC12H17N2O3.Na/h13H;/q-1;m"	AXXJTNXVUHVOJW-JWNNSCIOCO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	3.33	0.01279452	1.892975991	32	Moderate	Moderate	form of drug administered not known			
23575	3575	23575	1035_FDAMDD_v3b	C13H17N	187.28078	defined organic	parent	tested chemical	Selegiline	14611-51-9	single chemical compound	stereochem	N-methyl-N-[(1R)-1-methyl-2-phenylethyl]prop-2-yn-1-amine	C#CCN(C)[C@H](C)CC1=CC=CC=C1	C#CCN(C)[C@H](C)CC1=CC=CC=C1	"InChI=1/C13H17N/c1-4-10-14(3)12(2)11-13-8-6-5-7-9-13/h1,5-9,12H,10-11H2,2-3H3/t12-/m1/s1"	MEZLKOACVSPNER-GFCCVEGCBI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiparkinsonian	0.167	0.000891709	3.049776738	45	High-Moderate	High	form of drug administered not known; structure modified v3b			
23576	3576	23576	1036_FDAMDD_v3b	C42H38O20	862.73912	defined organic	parent	tested chemical	Sennoside	81-27-6	single chemical compound	stereochem	"(9R,9'R)-5,5'-bis(beta-D-glucopyranosyloxy)-4,4'-dihydroxy-10,10'-dioxo-9,9',10,10'-tetrahydro-9,9'-bianthracene-2,2'-dicarboxylic acid"	c12C(c7c([C@H](c1cc(cc2O)C(=O)O)[C@H]4c3c(c(O)cc(c3)C(=O)O)C(c5c4cccc5O[C@H]6[C@@H]([C@H]([C@H](O)[C@H](O6)CO)O)O)=O)cccc7O[C@H]8[C@@H]([C@H]([C@H](O)[C@H](O8)CO)O)O)=O	c12C(c7c([C@H](c1cc(cc2O)C(=O)O)[C@H]4c3c(c(O)cc(c3)C(=O)O)C(c5c4cccc5O[C@H]6[C@@H]([C@H]([C@H](O)[C@H](O6)CO)O)O)=O)cccc7O[C@H]8[C@@H]([C@H]([C@H](O)[C@H](O8)CO)O)O)=O	"InChI=1/C42H38O20/c43-11-23-31(47)35(51)37(53)41(61-23)59-21-5-1-3-15-25(17-7-13(39(55)56)9-19(45)27(17)33(49)29(15)21)26-16-4-2-6-22(60-42-38(54)36(52)32(48)24(12-44)62-42)30(16)34(50)28-18(26)8-14(40(57)58)10-20(28)46/h1-10,23-26,31-32,35-38,41-48,51-54H,11-12H2,(H,55,56)(H,57,58)/t23-,24-,25-,26-,31-,32-,35+,36+,37-,38-,41-,42-/m1/s1/f/h55,57H"	IPQVTOJGNYVQEO-PLPZMRSYDJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cathartic	16.7	0.019356952	1.71316302	30	Moderate	Low	form of drug administered not known			
23577	3577	23577	1037_FDAMDD_v3b	C17H17Cl2N	306.22958	defined organic	parent	tested chemical	Sertraline	79617-96-2	single chemical compound	stereochem	"(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine"	c23[C@H](c1cc(Cl)c(cc1)Cl)CC[C@@H](c2cccc3)NC	c23[C@H](c1cc(Cl)c(cc1)Cl)CC[C@@H](c2cccc3)NC	"InChI=1/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1"	VGKDLMBJGBXTGI-SJCJKPOMBV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	3.33	0.010874194	1.963602905	33	Moderate	Moderate	form of drug administered not known			
23578	3578	23578	1038_FDAMDD_v3b	C17H26ClN	279.84804	defined organic	parent	tested chemical	Sibutramine	106650-56-0	single chemical compound		"1-[1-(4-chlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine"	C2=C(Cl)C=CC(C1(C(N(C)C)CC(C)C)CCC1)=C2	C2=C(Cl)C=CC(C1(C(N(C)C)CC(C)C)CCC1)=C2	"InChI=1/C17H26ClN/c1-13(2)12-16(19(3)4)17(10-5-11-17)14-6-8-15(18)9-7-14/h6-9,13,16H,5,10-12H2,1-4H3"	UNAANXDKBXWMLN-UHFFFAOYAP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anorexic	0.25	0.000893342	3.048982261	45	High-Moderate	High	form of drug administered not known			
23579	3579	23579	1039_FDAMDD_v3b	C22H30N6O4S	474.5764	defined organic	parent	tested chemical	Sildenafil	139755-83-2	single chemical compound		"5-{2-(ethyloxy)-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl}-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one"	N3C(C2=CC(S(=O)(=O)N1CCN(C)CC1)=CC=C2OCC)=NC4=C(C3=O)N(C)N=C4CCC	N3C(C2=CC(S(=O)(=O)N1CCN(C)CC1)=CC=C2OCC)=NC4=C(C3=O)N(C)N=C4CCC	"InChI=1/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)/f/h24H"	BNRNXUUZRGQAQC-LQFNOIFHCL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		erectile disfunction treatment	1.67	0.003518928	2.453589666	39	Moderate	High	form of drug administered not known			
23580	3580	23580	1040_FDAMDD_v3b	C25H22O10	482.4362	defined organic	parent	representative component in mixture	Silymarin	65666-07-1	mixture or formulation	mixture of silybinin [22888-70-6] (which is a mixture of silybin A [13-16%] and B [21-24%]); silydianin [29782-68-1] (1-17%); and silychristin [33889-69-9] (12-17%); structure shown silybin B; stereochem; tautomers	"(2R,3R)-3,5,7-trihydroxy-2-[(2S,3S)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-2,3-dihydro-4H-chromen-4-one"	O=C1C(C(O)=CC(O)=C2)=C2O[C@H]([C@](C=C5)=CC3=C5O[C@@H](CO)[C@H]([C@]4=CC(OC)=C(O)C=C4)O3)[C@H]1O	O=C1C(C(O)=CC(O)=C2)=C2O[C@H]([C@](C=C5)=CC3=C5O[C@@H](CO)[C@H]([C@]4=CC(OC)=C(O)C=C4)O3)[C@H]1O	"InChI=1/C25H22O10/c1-32-17-6-11(2-4-14(17)28)24-20(10-26)33-16-5-3-12(7-18(16)34-24)25-23(31)22(30)21-15(29)8-13(27)9-19(21)35-25/h2-9,20,23-29,31H,10H2,1H3/t20-,23-,24-,25+/m0/s1"	SEBFKMXJBCUCAI-WAABAYLZBG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		treatment of liver disfunction	7	0.014509691	1.838341848	32	Moderate	Low	form of drug administered not known			
23581	3581	23581	1041_FDAMDD_v3b	C25H38O5	418.5662	defined organic	parent	tested chemical	Simvastatin	79902-63-9	single chemical compound	stereochem	"(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate"	O=C(C(C)(C)CC)O[C@@H]1[C@@]2([H])C(C=C[C@H](C)[C@@H]2CC[C@H]3OC(C[C@H](O)C3)=O)=C[C@H](C)C1	O=C(C(C)(C)CC)O[C@@H]1[C@@]2([H])C(C=C[C@H](C)[C@@H]2CC[C@H]3OC(C[C@H](O)C3)=O)=C[C@H](C)C1	"InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1"	RYMZZMVNJRMUDD-HGQWONQEBD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihyperlipoproteinemic	0.667	0.001593535	2.797638321	42	Moderate	High	form of drug administered not known			
23582	3582	23582	1042_FDAMDD_v3b	C51H79NO13	914.17186	defined organic	parent	tested chemical	Sirolimus	53123-88-9	single chemical compound	stereochem; tautomers	"(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate"	C3([C@@H]1CCCCN1C(=O)C([C@@]2(O[C@@H](CC[C@H]2C)C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@H](C([C@@H]([C@@H](/C(=C/[C@H](C(C[C@H](O3)[C@@H](C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)=O)C)C)O)OC)=O)C)C)OC)O)=O)=O	C3([C@@H]1CCCCN1C(=O)C([C@@]2(O[C@@H](CC[C@H]2C)C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@H](C([C@@H]([C@@H](/C(=C/[C@H](C(C[C@H](O3)[C@@H](C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)=O)C)C)O)OC)=O)C)C)OC)O)=O)=O	"InChI=1/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1"	QFJCIRLUMZQUOT-HPLJOQBZBU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		immunosuppressant	0.135	0.000147675	3.83069408	54	High	High	form of drug administered not known			
23583	3583	23583	1043_FDAMDD_v3b	C19H37N5O7	447.52638	defined organic	parent	tested chemical	Sisomicin	32385-11-8	single chemical compound	stereochem	"(1S,2S,3R,4S,6R)-4,6-diamino-3-{[3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy}-2-hydroxycyclohexyl 3-deoxy-4-C-methyl-3-(methylamino)-beta-L-arabinopyranoside"	C1[C@@]([C@@H]([C@H]([C@H](O1)O[C@H]3[C@@H](C[C@@H]([C@@H](OC2O\C(CN)=C/CC2N)[C@@H]3O)N)N)O)NC)(O)C	C1[C@@]([C@@H]([C@H]([C@H](O1)O[C@H]3[C@@H](C[C@@H]([C@@H](OC2O\C(CN)=C/CC2N)[C@@H]3O)N)N)O)NC)(O)C	"InChI=1/C19H37N5O7/c1-19(27)7-28-18(13(26)16(19)24-2)31-15-11(23)5-10(22)14(12(15)25)30-17-9(21)4-3-8(6-20)29-17/h3,9-18,24-27H,4-7,20-23H2,1-2H3/t9?,10-,11+,12-,13+,14+,15-,16+,17?,18+,19-/m0/s1"	URWAJWIAIPFPJE-URXFYSGNBA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	3	0.006703515	2.173697386	35	Moderate	Moderate	form of drug administered not known			
23584	3584	23584	1044_FDAMDD_v3b	C30H50O	426.7174	defined organic	parent	tested chemical	Sitosterol alpha1	474-40-8	single chemical compound	stereochem	"(3beta,4alpha5alpha,24Z)-4-methylstigmasta-7,24(28)-dien-3-ol"	O[C@@H]3[C@@H](C)[C@@]1([H])[C@@](CC3)(C)[C@]2([H])C([C@@](CC4)([H])[C@@](CC2)(C)[C@@]4([H])[C@H](C)CC/C(C(C)C)=C/C)=CC1	O[C@@H]3[C@@H](C)[C@@]1([H])[C@@](CC3)(C)[C@]2([H])C([C@@](CC4)([H])[C@@](CC2)(C)[C@@]4([H])[C@H](C)CC/C(C(C)C)=C/C)=CC1	"InChI=1/C30H50O/c1-8-22(19(2)3)10-9-20(4)24-13-14-26-23-11-12-25-21(5)28(31)16-18-30(25,7)27(23)15-17-29(24,26)6/h8,11,19-21,24-28,31H,9-10,12-18H2,1-7H3/b22-8-/t20-,21+,24-,25+,26+,27+,28+,29-,30+/m1/s1"	LPZCCMIISIBREI-JXMPMKKEBW	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Sitosterol	anticholinesteremic	100	0.234347135	0.630140352	18	Low	Low	form of drug administered not known; structure modified v3b			
23585	2481	22481	1045_FDAMDD_v3b	C29H50O	414.7067	defined organic	parent	tested chemical	Sitosterol beta	83-46-5	single chemical compound	stereochem	(3beta)-stigmast-5-en-3-ol	CC(C)[C@H](CC)CC[C@@H](C)[C@H]3CC[C@H]2[C@@H]4C\C=C1\C[C@@H](O)CC[C@]1(C)[C@H]4CC[C@@]23C	CC(C)[C@H](CC)CC[C@@H](C)[C@H]3CC[C@H]2[C@@H]4C\C=C1\C[C@@H](O)CC[C@]1(C)[C@H]4CC[C@@]23C	"InChI=1/C29H50O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h10,19-21,23-27,30H,7-9,11-18H2,1-6H3/t20-,21-,23+,24+,25-,26+,27+,28+,29-/m1/s1"	KZJWDPNRJALLNS-VJSFXXLFBZ	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Sitosterol	anticholinesteremic	100	0.241134276	0.617741052	18	Low	Low	form of drug administered not known			
23586	3586	23586	1046_FDAMDD_v3b	C27H30O6	450.5235	defined organic	parent	tested chemical	Sofalcone	64506-49-6	single chemical compound		({5-[(3-methylbut-2-en-1-yl)oxy]-2-[(2E)-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}prop-2-enoyl]phenyl}oxy)acetic acid	CC(C)=CCOC2=CC=C(C=CC(=O)C1=CC=C(OCC=C(C)C)C=C1OCC(O)=O)C=C2	CC(C)=CCOC2=CC=C(C=CC(=O)C1=CC=C(OCC=C(C)C)C=C1OCC(O)=O)C=C2	"InChI=1/C27H30O6/c1-19(2)13-15-31-22-8-5-21(6-9-22)7-12-25(28)24-11-10-23(32-16-14-20(3)4)17-26(24)33-18-27(29)30/h5-14,17H,15-16,18H2,1-4H3,(H,29,30)/b12-7+/f/h29H"	GFWRVVCDTLRWPK-XPWVOZFLDR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiulcerative	5	0.0110982	1.954747445	33	Moderate	Low	form of drug administered not known			
23587	3587	23587	1047_FDAMDD_v3b	C11H9FN2O3	236.1991632	defined organic	parent	tested chemical	Sorbinil	68367-52-2	single chemical compound	stereochem	"(4S)-6-fluoro-2,3-dihydro-2'H,5'H-spiro[chromene-4,4'-imidazolidine]-2',5'-dione"	O=[C@@](NC2=O)[C@](N2)3C1=C(OCC3)C=CC(F)=C1	O=[C@@](NC2=O)[C@](N2)3C1=C(OCC3)C=CC(F)=C1	"InChI=1/C11H9FN2O3/c12-6-1-2-8-7(5-6)11(3-4-17-8)9(15)13-10(16)14-11/h1-2,5H,3-4H2,(H2,13,14,15,16)/t11-/m0/s1/f/h13-14H"	LXANPKRCLVQAOG-BTXWKOGIDA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	4.17	0.017654593	1.7531423	31	Moderate	Moderate	form of drug administered not known; structure modified v3b			
23588	3588	23588	1048_FDAMDD_v3b	C6H14O6	182.1718	defined organic	parent	tested chemical	Sorbitol	50-70-4	single chemical compound	stereochem	D-glucitol	[C@H]([C@@H]([C@@H](O)CO)O)([C@H](O)CO)O	[C@H]([C@@H]([C@@H](O)CO)O)([C@H](O)CO)O	"InChI=1/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4+,5-,6-/m1/s1"	FBPFZTCFMRRESA-JGWLITMVBN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cathartic	833	4.572606737	-0.660163852	4	Low	Low	form of drug administered not known			
23589	3589	23589	1049_FDAMDD_v3b	C12H20N2O3S	272.3638	defined organic	parent	tested chemical	Sotalol	3930-20-9	single chemical compound		N-(4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}phenyl)methanesulfonamide	S(=O)(C)(=O)NC1=CC=C(C(O)CNC(C)C)C=C1	S(=O)(C)(=O)NC1=CC=C(C(O)CNC(C)C)C=C1	"InChI=1/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3"	ZBMZVLHSJCTVON-UHFFFAOYAR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antianginal; antiarrhythmic; antihypertensive	5.33	0.019569414	1.708422176	30	Moderate	Low	form of drug administered not known			
23590	3590	23590	1050_FDAMDD_v3b	C19H22F2N4O3	392.3997864	defined organic	parent	tested chemical	Sparfloxacin	110871-86-8	single chemical compound	stereochem	"5-amino-1-cyclopropyl-7-[(3R,5S)-3,5-dimethylpiperazin-1-yl]-6,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid"	c13c(C(\C(=C/N1C2CC2)C(O)=O)=O)c(c(c(c3F)N4C[C@@H](N[C@@H](C4)C)C)F)N	c13c(C(\C(=C/N1C2CC2)C(O)=O)=O)c(c(c(c3F)N4C[C@@H](N[C@@H](C4)C)C)F)N	"InChI=1/C19H22F2N4O3/c1-8-5-24(6-9(2)23-8)17-13(20)15(22)12-16(14(17)21)25(10-3-4-10)7-11(18(12)26)19(27)28/h7-10,23H,3-6,22H2,1-2H3,(H,27,28)/t8-,9+/f/h27H"	DZZWHBIBMUVIIW-JLDXHAFDDQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	6.67	0.016997971	1.769602928	31	Moderate	Low	form of drug administered not known; CASRN changed v3b			
23591	3591	23591	1051_FDAMDD_v3b	C15H26N2	234.3803	defined organic	parent	tested chemical	Sparteine	90-39-1	single chemical compound	stereochem	sparteine	C3CCCN4C[C@@H]2C[C@@H](CN1CCCC[C@H]12)[C@@H]34	C3CCCN4C[C@@H]2C[C@@H](CN1CCCC[C@H]12)[C@@H]34	"InChI=1/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14-,15+/m0/s1"	SLRCCWJSBJZJBV-ZQDZILKHBW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		oxytocic	10	0.042665702	1.369921106	26	Low-Moderate	Low	form of drug administered not known			
23592	3592	23592	1052_FDAMDD_v3b	C14H24N2O7	332.34956	defined organic	parent	tested chemical	Spectinomycin	1695-77-8	single chemical compound	stereochem	"(2R,4aR,5aR,6S,7S,8R,9S,9aR,10aS)-4a,7,9-trihydroxy-2-methyl-6,8-bis(methylamino)decahydro-4H-pyrano[2,3-b][1,4]benzodioxin-4-one"	[C@@]13([C@H](O[C@H]2[C@H](O1)[C@H]([C@H]([C@H]([C@@H]2O)NC)O)NC)O[C@@H](CC3=O)C)O	[C@@]13([C@H](O[C@H]2[C@H](O1)[C@H]([C@H]([C@H]([C@@H]2O)NC)O)NC)O[C@@H](CC3=O)C)O	"InChI=1/C14H24N2O7/c1-5-4-6(17)14(20)13(21-5)22-12-10(19)7(15-2)9(18)8(16-3)11(12)23-14/h5,7-13,15-16,18-20H,4H2,1-3H3/t5-,7-,8+,9+,10+,11-,12-,13+,14+/m1/s1"	UNFWWIHTNXNPBV-WXKVUWSEBO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.200692307	0.697469274	19	Low	Low	form of drug administered not known			
23593	3593	23593	1053_FDAMDD_v3b	C22H25Cl2N3OS2	482.4894	defined organic	complex HCl	tested chemical	Spiclomazine	27007-85-8	single chemical compound	parent [24527-27-3]	"8-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]-1-thia-4,8-diazaspiro[4.5]decan-3-one hydrochloride"	Cl.Clc4ccc5Sc1ccccc1N(CCCN2CCC3(CC2)NC(=O)CS3)c5c4	C1=CC=C4C(=C1)N(CCCN2CCC3(CC2)NC(=O)CS3)C5=C(S4)C=CC(Cl)=C5	"InChI=1/C22H24ClN3OS2.ClH/c23-16-6-7-20-18(14-16)26(17-4-1-2-5-19(17)29-20)11-3-10-25-12-8-22(9-13-25)24-21(27)15-28-22;/h1-2,4-7,14H,3,8-13,15H2,(H,24,27);1H/f/h24H;"	JRSBQVOEILNXGS-TUJBSLPGCB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	7.5	0.015544383	1.808426513	31	Moderate	Low	form of drug administered not known			
23594	3594	23594	1054_FDAMDD_v3b	C43H74N2O14	843.05266	defined organic	parent	tested chemical	Spiramycin I	24916-50-5	single chemical compound	stereochem	"Leucomycin V, 9-O-((2R,5S,6R)-5-(dimethylamino)tetrahydro-6-methyl-2H-pyran-2-yl)-"	[C@H]1(C[C@@H]([C@@H]([C@@H](OC)[C@@H](CC(=O)O[C@@H](C/C=C/C=C/[C@@H]1O[C@@H]2CC[C@@H]([C@H](O2)C)N(C)C)C)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C)O[C@H]4C[C@@]([C@H]([C@@H](O4)C)O)(C)O)N(C)C)O)CC=O)C	[C@H]1(C[C@@H]([C@@H]([C@@H](OC)[C@@H](CC(=O)O[C@@H](C/C=C/C=C/[C@@H]1O[C@@H]2CC[C@@H]([C@H](O2)C)N(C)C)C)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C)O[C@H]4C[C@@]([C@H]([C@@H](O4)C)O)(C)O)N(C)C)O)CC=O)C	"InChI=1/C43H74N2O14/c1-24-21-29(19-20-46)39(59-42-37(49)36(45(9)10)38(27(4)56-42)58-35-23-43(6,51)41(50)28(5)55-35)40(52-11)31(47)22-33(48)53-25(2)15-13-12-14-16-32(24)57-34-18-17-30(44(7)8)26(3)54-34/h12-14,16,20,24-32,34-42,47,49-51H,15,17-19,21-23H2,1-11H3/b13-12+,16-14+/t24-,25-,26-,27-,28+,29+,30+,31-,32+,34-,35+,36-,37-,38-,39+,40+,41+,42+,43-/m1/s1"	ACTOXUHEUCPTEW-BWHGAVFKBD	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 3	Spiramycin	antibacterial	66.7	0.07911724	1.101728869	23	Low	Low	form of drug administered not known			
23595	3595	23595	1055_FDAMDD_v3b	C45H76N2O15	885.08934	defined organic	parent	tested chemical	Spiramycin II	24916-51-6	single chemical compound	stereochem	"Leucomycin V, 9-O-((2R,5S,6R)-5-(dimethylamino)tetrahydro-6-methyl-2H-pyran-2-yl)-, 3-acetate"	[C@H]1(C[C@@H]([C@@H]([C@@H](OC)[C@@H](CC(=O)O[C@@H](C/C=C/C=C/[C@@H]1O[C@@H]2CC[C@@H]([C@H](O2)C)N(C)C)C)OC(=O)C)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C)O[C@H]4C[C@@]([C@H]([C@@H](O4)C)O)(C)O)N(C)C)O)CC=O)C	[C@H]1(C[C@@H]([C@@H]([C@@H](OC)[C@@H](CC(=O)O[C@@H](C/C=C/C=C/[C@@H]1O[C@@H]2CC[C@@H]([C@H](O2)C)N(C)C)C)OC(=O)C)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C)O[C@H]4C[C@@]([C@H]([C@@H](O4)C)O)(C)O)N(C)C)O)CC=O)C	"InChI=1/C45H76N2O15/c1-25-22-31(20-21-48)41(62-44-39(51)38(47(10)11)40(28(4)58-44)61-37-24-45(7,53)43(52)29(5)57-37)42(54-12)34(59-30(6)49)23-35(50)55-26(2)16-14-13-15-17-33(25)60-36-19-18-32(46(8)9)27(3)56-36/h13-15,17,21,25-29,31-34,36-44,51-53H,16,18-20,22-24H2,1-12H3/b14-13+,17-15+/t25-,26-,27-,28-,29+,31+,32+,33+,34-,36-,37+,38-,39-,40-,41+,42+,43+,44+,45-/m1/s1"	ZPCCSZFPOXBNDL-TXJOLGFOBF	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 3	Spiramycin	antibacterial	66.7	0.075359624	1.122861276	24	Low	Low	form of drug administered not known			
23596	3596	23596	1056_FDAMDD_v3b	C46H78N2O15	899.11592	defined organic	parent	tested chemical	Spiramycin III	24916-52-7	single chemical compound	stereochem	"Leucomycin V, 9-O-((2R,5S,6R)-5-(dimethylamino)tetrahydro-6-methyl-2H-pyran-2-yl)-, 3-propanoate"	[C@H]1(C[C@@H]([C@@H]([C@@H](OC)[C@@H](CC(=O)O[C@@H](C/C=C/C=C/[C@@H]1O[C@@H]2CC[C@@H]([C@H](O2)C)N(C)C)C)OC(=O)CC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C)O[C@H]4C[C@@]([C@H]([C@@H](O4)C)O)(C)O)N(C)C)O)CC=O)C	[C@H]1(C[C@@H]([C@@H]([C@@H](OC)[C@@H](CC(=O)O[C@@H](C/C=C/C=C/[C@@H]1O[C@@H]2CC[C@@H]([C@H](O2)C)N(C)C)C)OC(=O)CC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)C)O[C@H]4C[C@@]([C@H]([C@@H](O4)C)O)(C)O)N(C)C)O)CC=O)C	"InChI=1/C46H78N2O15/c1-13-35(50)60-34-24-36(51)56-27(3)17-15-14-16-18-33(61-37-20-19-32(47(8)9)28(4)57-37)26(2)23-31(21-22-49)42(43(34)55-12)63-45-40(52)39(48(10)11)41(29(5)59-45)62-38-25-46(7,54)44(53)30(6)58-38/h14-16,18,22,26-34,37-45,52-54H,13,17,19-21,23-25H2,1-12H3/b15-14+,18-16+/t26-,27-,28-,29-,30+,31+,32+,33+,34-,37-,38+,39-,40-,41-,42+,43+,44+,45+,46-/m1/s1"	HSZLKTCKAYXVBX-HHTHJJQKBY	Clinical Reports 	Maximum Recommended Daily Dose	human	3 of 3	Spiramycin	antibacterial	66.7	0.074183983	1.129689854	24	Low	Low	form of drug administered not known; I form [24916-50-5]; form II [24916-51-6]; general [8025-81-8]; related forms			
23597	3597	23597	1057_FDAMDD_v3b	C21H39N7O12	581.5741	defined organic	parent	tested chemical	Streptomycin A	57-92-1	single chemical compound	stereochem; tautomers	"N,N'''-[(1R,2R,3S,4R,5R,6S)-4-({5-deoxy-2-O-[2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl]-3-C-formyl-alpha-L-lyxofuranosyl}oxy)-2,5,6-trihydroxycyclohexane-1,3-diyl]diguanidine"	NC(=N)N[C@@H]3[C@@H](O[C@@H]2O[C@@H](C)[C@](O)(C=O)[C@H]2O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1NC)[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@H]3O	NC(=N)N[C@@H]3[C@@H](O[C@@H]2O[C@@H](C)[C@](O)(C=O)[C@H]2O[C@@H]1O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]1NC)[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@H]3O	"InChI=1/C21H39N7O12/c1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35/h4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28)/t5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+/m0/s1/f/h22,24,27-28H,23,25H2"	UCSJYZPVAKXKNQ-WYVOKUTCDY	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Streptomycin	antibacterial	20	0.034389427	1.463575062	28	Low-Moderate	Low	form of drug administered not known; B form [128-45-0]; sesquisulfate [3810-74-0]; related forms			
23598	3598	23598	1058_FDAMDD_v3b	C27H49N7O17	743.71466	defined organic	parent	tested chemical	Streptomycin B	128-45-0	single chemical compound	stereochem; tautomers	"N,N'''-[(1S,2R,3R,4S,5R,6R)-2,4,5-trihydroxy-6-{[beta-D-mannopyranosyl-(1->4)-2-deoxy-2-(methylamino)-alpha-L-glucopyranosyl-(1->2)-5-deoxy-3-C-formyl-alpha-L-lyxofuranosyl]oxy}cyclohexane-1,3-diyl]diguanidine"	O[C@@H]1[C@@H](O)[C@H](O[C@@H]2O[C@@H](C)[C@](O)(C=O)[C@H]2O[C@H]3[C@@H](NC)[C@H](O)[C@@H](O[C@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@H](CO)O3)[C@@H](NC(N)=N)[C@H](O)[C@H]1NC(N)=N	O[C@@H]1[C@@H](O)[C@H](O[C@@H]2O[C@@H](C)[C@](O)(C=O)[C@H]2O[C@H]3[C@@H](NC)[C@H](O)[C@@H](O[C@H]4[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@H](CO)O3)[C@@H](NC(N)=N)[C@H](O)[C@H]1NC(N)=N	"InChI=1/C27H49N7O17/c1-6-27(45,5-37)21(24(46-6)50-20-10(34-26(30)31)13(39)9(33-25(28)29)14(40)17(20)43)51-22-11(32-2)15(41)19(8(4-36)48-22)49-23-18(44)16(42)12(38)7(3-35)47-23/h5-24,32,35-36,38-45H,3-4H2,1-2H3,(H4,28,29,33)(H4,30,31,34)/t6-,7+,8-,9+,10-,11-,12+,13+,14-,15-,16-,17+,18-,19-,20+,21-,22-,23-,24-,27+/m0/s1/f/h28,30,33-34H,29,31H2"	HQXKELRFXWJXNP-QOYYVFILDV	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Streptomycin	antibacterial	20	0.026892034	1.570376347	29	Low-Moderate	Low	form of drug administered not known; A form [57-92-1]; related forms			
23599	1282	21282	1059_FDAMDD_v3b	C8H15N3O7	265.2206	defined organic	parent	tested chemical	Streptozocin	18883-66-4	single chemical compound	stereochem	2-deoxy-2-({[methyl(nitroso)amino]carbonyl}amino)-alpha-D-glucopyranose	[C@@H]1(NC(N(N=O)C)=O)[C@H]([C@H](O)[C@H](O[C@@H]1O)CO)O	[C@@H]1(NC(N(N=O)C)=O)[C@H]([C@H](O)[C@H](O[C@@H]1O)CO)O	"InChI=1/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1/f/h9H"	ZSJLQEPLLKMAKR-CQRXUCDYDU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	108	0.407208188	0.390183498	16	Low	Low	form of drug administered not known; tetraacetate [18977-95-2]			
23600	3600	23600	1060_FDAMDD_v3b	C21H22N2O2	334.4116	defined organic	parent	tested chemical	Strychnine	57-24-9	single chemical compound	stereochem	strychnidin-10-one	[C@@H]12C=6CN7[C@@H](C1)[C@@]4([C@@H]3[C@@H]2[C@H](CC(N3c5ccccc45)=O)OCC=6)CC7	[C@@H]12C=6CN7[C@@H](C1)[C@@]4([C@@H]3[C@@H]2[C@H](CC(N3c5ccccc45)=O)OCC=6)CC7	"InChI=1/C21H22N2O2/c24-18-10-16-19-13-9-17-21(6-7-22(17)11-12(13)5-8-25-16)14-3-1-2-4-15(14)23(18)20(19)21/h1-5,13,16-17,19-20H,6-11H2/t13-,16-,17-,19-,20-,21+/m0/s1"	QMGVPVSNSZLJIA-FVWCLLPLBR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		rat poison	0.7	0.002093229	2.679183294	41	Moderate	High	form of drug administered not known; dimer sulfate [60-41-3]; HCl [1421-86-9]; nitrate [66-32-0]; glycerophosphate [1323-31-5]; N-oxide [7248-28-4]; phosphate [509-42-2]			
23601	3601	23601	1061_FDAMDD_v3b	C4H6O4S2	182.21804	defined organic	parent	tested chemical	Succimer	304-55-2	single chemical compound		"2,3-dimercaptobutanedioic acid"	OC(=O)C(S)C(S)C(O)=O	OC(=O)C(S)C(S)C(O)=O	"InChI=1/C4H6O4S2/c5-3(6)1(9)2(10)4(7)8/h1-2,9-10H,(H,5,6)(H,7,8)/f/h5,7H"	ACTRVOBWPAIOHC-AOTPWWKUCD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidote for heavy metal poisoning; radioactive imaging agent	10	0.054879308	1.260591371	25	Low-Moderate	Low	form of drug administered not known			
23602	3602	23602	1062_FDAMDD_v3b	C4H6O4	118.088	defined organic	parent	tested chemical	Succinic acid	110-15-6	single chemical compound		butanedioic acid	C(O)(=O)CCC(O)=O	C(O)(=O)CCC(O)=O	"InChI=1/C4H6O4/c5-3(6)1-2-4(7)8/h1-2H2,(H,5,6)(H,7,8)/f/h5,7H"	KDYFGRWQOYBRFD-AOTPWWKUCA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiulcerative	100	0.846826096	0.072205767	12	Low	Low	form of drug administered not known			
23603	3603	23603	1063_FDAMDD_v3b	C14H30Cl2N2O4	361.305	defined organic	salt 2Cl	tested chemical	Succinylcholine	71-27-2	single chemical compound	ammonium; parent [306-40-1]	"2,2'-[(1,4-dioxobutane-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium) dichloride"	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C.[Cl-].[Cl-]	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	"InChI=1/C14H30N2O4.2ClH/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6;;/h7-12H2,1-6H3;2*1H/q+2;;/p-2/fC14H30N2O4.2Cl/h;2*1h/qm;2*-1"	YOEWQQVKRJEPAE-ZKCONWRWCU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	1.1	0.003044519	2.516481287	39	Moderate	High	form of drug administered not known			
23604	3604	23604	1064_FDAMDD_v3b	C22H30N2O2S	386.5508	defined organic	parent	tested chemical	Sufentanil	56030-54-7	single chemical compound		N-{4-[(methyloxy)methyl]-1-[2-(2-thienyl)ethyl]piperidin-4-yl}-N-phenylpropanamide	C3=CC=CC(N(C(=O)CC)C2(COC)CCN(CCC1SC=CC=1)CC2)=C3	C3=CC=CC(N(C(=O)CC)C2(COC)CCN(CCC1SC=CC=1)CC2)=C3	"InChI=1/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3"	GGCSSNBKKAUURC-UHFFFAOYAS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	0.025	6.46746E-05	4.189266568	58	High	High	form of drug administered not known			
23605	3605	23605	1065_FDAMDD_v3b	C8H11NO5S	233.24164	defined organic	parent	tested chemical	Sulbactam	68373-14-8	single chemical compound	stereochem	"(2S,5R)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide"	C1C(=O)N2C1S(=O)(=O)C(C)(C)C2C(=O)O	C1C(=O)N2C1S(=O)(=O)C(C)(C)C2C(=O)O	"InChI=1/C8H11NO5S/c1-8(2)6(7(11)12)9-4(10)3-5(9)15(8,13)14/h5-6H,3H2,1-2H3,(H,11,12)/t5-,6+/m1/s1/f/h11H"	FKENQMMABCRJMK-XUSGLBLMDH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		combination to form antibacterial	66.7	0.285969521	0.543680253	17	Low	Low	form of drug administered not known			
23606	3606	23606	1066_FDAMDD_v3b	C12H14N4O3S	294.32956	defined organic	parent	tested chemical	Sulfacytine	17784-12-2	single chemical compound		"4-amino-N-(1-ethyl-2-oxo-1,2-dihydropyrimidin-4-yl)benzenesulfonamide"	C2=CC(NS(=O)(=O)C1=CC=C(N)C=C1)=NC(=O)N2CC	C2=CC(NS(=O)(=O)C1=CC=C(N)C=C1)=NC(=O)N2CC	"InChI=1/C12H14N4O3S/c1-2-16-8-7-11(14-12(16)17)15-20(18,19)10-5-3-9(13)4-6-10/h3-8H,2,13H2,1H3,(H,14,15,17)/f/h15H"	SIBQAECNSSQUOD-YAQRNVERCY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	16.7	0.056739119	1.24611741	25	Low-Moderate	Low	form of drug administered not known			
23607	3607	23607	1067_FDAMDD_v3b	C12H14N4O4S	310.32896	defined organic	parent	tested chemical	Sulfadimethoxine	122-11-2	single chemical compound		"4-amino-N-[2,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide"	C2=C(N)C=CC(S(=O)(=O)NC1=CC(OC)=NC(OC)=N1)=C2	C2=C(N)C=CC(S(=O)(=O)NC1=CC(OC)=NC(OC)=N1)=C2	"InChI=1/C12H14N4O4S/c1-19-11-7-10(14-12(15-11)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)/f/h16H"	ZZORFUFYDOWNEF-WYUMXYHSCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	33.3	0.107305486	0.969378072	22	Low	Low	form of drug administered not known			
23608	3608	23608	1068_FDAMDD_v3b	C12H14N4O4S	310.32896	defined organic	parent	tested chemical	Sulfadoxine	2447-57-6	single chemical compound		"4-amino-N-[5,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide"	C2=C(N)C=CC(S(=O)(=O)NC1=C(OC)C(OC)=NC=N1)=C2	C2=C(N)C=CC(S(=O)(=O)NC1=C(OC)C(OC)=NC=N1)=C2	"InChI=1/C12H14N4O4S/c1-19-10-11(14-7-15-12(10)20-2)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,15,16)/f/h16H"	PJSFRIWCGOHTNF-WYUMXYHSCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	25	0.080559674	1.093882297	23	Low	Low	form of drug administered not known			
23609	3609	23609	1069_FDAMDD_v3b	C7H10N4O2S	214.2449	defined organic	parent	tested chemical	Sulfaguanidine	57-67-0	single chemical compound		4-amino-N-[amino(imino)methyl]benzenesulfonamide	C1=C(N)C=CC(S(=O)(=O)NC(N)=N)=C1	C1=C(N)C=CC(S(=O)(=O)NC(N)=N)=C1	"InChI=1/C7H10N4O2S/c8-5-1-3-6(4-2-5)14(12,13)11-7(9)10/h1-4H,8H2,(H4,9,10,11)/f/h9,11H,10H2"	BRBKOPJOKNSWSG-ZMZQLXLHCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	20	0.093351114	1.029880497	23	Low	Low	form of drug administered not known			
23610	3610	23610	1070_FDAMDD_v3b	C12H15N5O3S	309.3442	defined organic	parent	tested chemical	Sulfaguanole	27031-08-9	single chemical compound	tautomers	"4-amino-N-{[(4,5-dimethyl-1,3-oxazol-2-yl)amino](imino)methyl}benzenesulfonamide"	C2=C(N)C=CC(S(=O)(=O)NC(=N)NC1OC(C)=C(C)N=1)=C2	C2=C(N)C=CC(S(=O)(=O)NC(=N)NC1OC(C)=C(C)N=1)=C2	"InChI=1/C12H15N5O3S/c1-7-8(2)20-12(15-7)16-11(14)17-21(18,19)10-5-3-9(13)4-6-10/h3-6H,13H2,1-2H3,(H3,14,15,16,17)/f/h14,16-17H"	IJZUQDQOAFUFJY-DNYHJGITCI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	40	0.129305802	0.888381986	21	Low	Low	form of drug administered not known			
23611	3611	23611	1071_FDAMDD_v3b	C11H12N4O3S	280.30298	defined organic	parent	tested chemical	Sulfamethoxypyridazine	80-35-3	single chemical compound		4-amino-N-[6-(methyloxy)pyridazin-3-yl]benzenesulfonamide	O=S(=O)(Nc1ccc(OC)nn1)c2ccc(N)cc2	O=S(=O)(Nc1ccc(OC)nn1)c2ccc(N)cc2	"InChI=1/C11H12N4O3S/c1-18-11-7-6-10(13-14-11)15-19(16,17)9-4-2-8(12)3-5-9/h2-7H,12H2,1H3,(H,13,15)/f/h15H"	VLYWMPOKSSWJAL-YAQRNVERCI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	25	0.089189205	1.049687706	23	Low	Low	form of drug administered not known			
23612	3612	23612	1072_FDAMDD_v3b	C11H12N4O2S	264.30358	defined organic	parent	tested chemical	Sulfamerazine	127-79-7	single chemical compound		4-amino-N-(4-methylpyrimidin-2-yl)benzenesulfonamide	N(S(=O)(=O)C1=CC=C(N)C=C1)C2=NC(C)=CC=N2	N(S(=O)(=O)C1=CC=C(N)C=C1)C2=NC(C)=CC=N2	"InChI=1/C11H12N4O2S/c1-8-6-7-13-11(14-8)15-18(16,17)10-4-2-9(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)/f/h15H"	QPPBRPIAZZHUNT-YAQRNVERCL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.252361319	0.597977212	18	Low	Low	form of drug administered not known			
23613	3613	23613	1073_FDAMDD_v3b	C11H12N4O3S	280.30298	defined organic	parent	tested chemical	Sulfameter	651-06-9	single chemical compound		4-amino-N-[5-(methyloxy)pyrimidin-2-yl]benzenesulfonamide	N(S(=O)(=O)C1=CC=C(N)C=C1)C2=NC=C(OC)C=N2	N(S(=O)(=O)C1=CC=C(N)C=C1)C2=NC=C(OC)C=N2	"InChI=1/C11H12N4O3S/c1-18-9-6-13-11(14-7-9)15-19(16,17)10-4-2-8(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)/f/h15H"	GPTONYMQFTZPKC-YAQRNVERCC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	25	0.089189205	1.049687706	23	Low	Low	form of drug administered not known			
23614	1290	21290	1074_FDAMDD_v3b	C12H14N4O2S	278.3302	defined organic	parent	tested chemical	Sulfamethazine	57-68-1	single chemical compound		"4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide"	O=S(=O)(C1=CC=C(C=C1)N)NC2=NC(=CC(=N2)C)C	O=S(=O)(C1=CC=C(C=C1)N)NC2=NC(=CC(=N2)C)C	"InChI=1/C12H14N4O2S/c1-8-7-9(2)15-12(14-8)16-19(17,18)11-5-3-10(13)4-6-11/h3-7H,13H2,1-2H3,(H,14,15,16)/f/h16H"	ASWVTGNCAZCNNR-WYUMXYHSCK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	50	0.179642741	0.745590327	19	Low	Low	form of drug administered not known			
23615	3615	23615	1075_FDAMDD_v3b	C9H10N4O2S2	270.3313	defined organic	parent	tested chemical	Sulfamethizole	144-82-1	single chemical compound		"4-amino-N-(5-methyl-1,3,4-thiadiazol-2-yl)benzenesulfonamide"	N(S(=O)(=O)C1=CC=C(N)C=C1)C2=NN=C(C)S2	N(S(=O)(=O)C1=CC=C(N)C=C1)C2=NN=C(C)S2	"InChI=1/C9H10N4O2S2/c1-6-11-12-9(16-6)13-17(14,15)8-4-2-7(10)3-5-8/h2-5H,10H2,1H3,(H,12,13)/f/h13H"	VACCAVUAMIDAGB-NDKGDYFDCM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.246734285	0.607770499	18	Low	Low	form of drug administered not known			
23616	3616	23616	1076_FDAMDD_v3b	C12H14N4O3S	294.32956	defined organic	parent	tested chemical	Sulfamethomidine	3772-76-7	single chemical compound		4-amino-N-[2-methyl-6-(methyloxy)pyrimidin-4-yl]benzenesulfonamide	C2=C(N)C=CC(S(=O)(=O)NC1=CC(OC)=NC(C)=N1)=C2	C2=C(N)C=CC(S(=O)(=O)NC1=CC(OC)=NC(C)=N1)=C2	"InChI=1/C12H14N4O3S/c1-8-14-11(7-12(15-8)19-2)16-20(17,18)10-5-3-9(13)4-6-10/h3-7H,13H2,1-2H3,(H,14,15,16)/f/h16H"	QKLSCPPJEVXONT-WYUMXYHSCH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	33.3	0.113138483	0.946389648	22	Low	Low	form of drug administered not known			
23617	3617	23617	1077_FDAMDD_v3b	C11H13N3O3S	267.30422	defined organic	parent	tested chemical	Sulfamoxole	729-99-7	single chemical compound		"4-amino-N-(4,5-dimethyl-1,3-oxazol-2-yl)benzenesulfonamide"	C2=C(N)C=CC(S(=O)(=O)NC1OC(C)=C(C)N=1)=C2	C2=C(N)C=CC(S(=O)(=O)NC1OC(C)=C(C)N=1)=C2	"InChI=1/C11H13N3O3S/c1-7-8(2)17-11(13-7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6H,12H2,1-2H3,(H,13,14)/f/h14H"	CYFLXLSBHQBMFT-YHMJCDSICT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	33.3	0.124577158	0.904561582	21	Low	Low	form of drug administered not known			
23618	3618	23618	1078_FDAMDD_v3b	C23H20N2O3S	404.4815	defined organic	parent	tested chemical	Sulfinpyrazone	57-96-5	single chemical compound		"1,2-diphenyl-4-[2-(phenylsulfinyl)ethyl]pyrazolidine-3,5-dione"	C4=CC=C(N3C(=O)C(CCS(=O)C1=CC=CC=C1)C(=O)N3C2=CC=CC=C2)C=C4	C4=CC=C(N3C(=O)C(CCS(=O)C1=CC=CC=C1)C(=O)N3C2=CC=CC=C2)C=C4	"InChI=1/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2"	MBGGBVCUIVRRBF-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		uricosuric	13.3	0.032881603	1.483047022	28	Low-Moderate	Low	form of drug administered not known			
23619	1292	21292	1079_FDAMDD_v3b	C11H13N3O3S	267.3042	defined organic	parent	tested chemical	Sulfisoxazole	127-69-5	single chemical compound		"4-amino-N-(3,4-dimethylisoxazol-5-yl)benzenesulfonamide"	C2=C(N)C=CC(S(=O)(=O)NC1ON=C(C)C=1C)=C2	C2=C(N)C=CC(S(=O)(=O)NC1ON=C(C)C=1C)=C2	"InChI=1/C11H13N3O3S/c1-7-8(2)13-17-11(7)14-18(15,16)10-5-3-9(12)4-6-10/h3-6,14H,12H2,1-2H3"	NHUHCSRWZMLRLA-UHFFFAOYAP	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Sulfisoxazole	antibacterial	66.7	0.24952844	0.602879949	18	Low	Low	form of drug administered not known			
23620	3620	23620	1080_FDAMDD_v3b	C13H15N3O4S	309.3409	defined organic	parent	tested chemical	Sulfisoxazole acetal	80-74-0	single chemical compound		"N-[(4-aminophenyl)sulfonyl]-N-(3,4-dimethylisoxazol-5-yl)acetamide"	C2=C(N)C=CC(S(=O)(=O)N(C1ON=C(C)C=1C)C(=O)C)=C2	C2=C(N)C=CC(S(=O)(=O)N(C1ON=C(C)C=1C)C(=O)C)=C2	"InChI=1/C13H15N3O4S/c1-8-9(2)15-20-13(8)16(10(3)17)21(18,19)12-6-4-11(14)5-7-12/h4-7H,14H2,1-3H3"	JFNWFXVFBDDWCX-UHFFFAOYAM	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Sulfisoxazole	antibacterial	66.7	0.215619726	0.666311511	19	Low	Low	form of drug administered not known			
23621	3621	23621	1081_FDAMDD_v3b	C20H8Br4Na2O10S2	837.99706	defined organic	salt 2Na	tested chemical	Sulfobromophthalein	71-67-0	single chemical compound	parent [297-83-6]	"disodium 3,3'-(4,5,6,7-tetrabromo-3-oxo-1,3-dihydro-2-benzofuran-1,1-diyl)bis(6-hydroxybenzenesulfonate)"	[Na+].[Na+].[O-]S(=O)(=O)c1cc(ccc1O)C3(OC(=O)c2c(Br)c(Br)c(Br)c(Br)c23)c4ccc(O)c(c4)S([O-])(=O)=O	OS(=O)(=O)c1cc(ccc1O)C3(OC(=O)c2c(Br)c(Br)c(Br)c(Br)c23)c4ccc(O)c(c4)S(O)(=O)=O	"InChI=1/C20H10Br4O10S2.2Na/c21-15-13-14(16(22)18(24)17(15)23)20(34-19(13)27,7-1-3-9(25)11(5-7)35(28,29)30)8-2-4-10(26)12(6-8)36(31,32)33;;/h1-6,25-26H,(H,28,29,30)(H,31,32,33);;/q;2*+1/p-2/fC20H8Br4O10S2.2Na/q-2;2m"	GHAFORRTMVIXHS-WLGYWUDYCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	5	0.005966608	2.224272491	36	Moderate	Low	form of drug administered not known			
23622	17615	37615	1082_FDAMDD_v3b	C12H14N4O4NS	310.329	defined organic	parent	tested chemical	Sulfonamide CS61	1230-33-7	single chemical compound		"4-amino-N-(3,6-dimethoxypyridazin-4-yl)benzenesulfonamide"	O=S(C1=CC=C(N)C=C1)(NC2=C(OC)N=NC(OC)=C2)=O	O=S(C1=CC=C(N)C=C1)(NC2=C(OC)N=NC(OC)=C2)=O	"InChI=1/C12H14N4O4S/c1-19-11-7-10(12(20-2)15-14-11)16-21(17,18)9-5-3-8(13)4-6-9/h3-7H,13H2,1-2H3,(H,14,16)/f/h16H"	HSPPDULLZBLHRE-WYUMXYHSCO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	50	0.161119328	0.792852358	20	Low	Low	form of drug administered not known			
23623	3623	23623	1083_FDAMDD_v3b	C14H14N2Na2O6S3	448.4453	defined organic	salt 2Na	tested chemical	Sulfoxone	144-75-2	single chemical compound		"disodium [sulfonylbis(benzene-4,1-diylimino)]dimethanesulfinate"	[Na+].[Na+].[O-]S(=O)CNc1ccc(cc1)S(=O)(=O)c2ccc(NCS([O-])=O)cc2	OS(=O)CNc1ccc(cc1)S(=O)(=O)c2ccc(NCS(O)=O)cc2	"InChI=1/C14H16N2O6S3.2Na/c17-23(18)9-15-11-1-5-13(6-2-11)25(21,22)14-7-3-12(4-8-14)16-10-24(19)20;;/h1-8,15-16H,9-10H2,(H,17,18)(H,19,20);;/q;2*+1/p-2/fC14H14N2O6S3.2Na/q-2;2m"	AZBNFLZFSZDPQF-ISJFMEIJCV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	5	0.011149632	1.952739472	33	Moderate	Low	form of drug administered not known			
23624	3624	23624	1084_FDAMDD_v3b	C20H17FO3S	356.4105832	defined organic	parent	tested chemical	Sulindac	38194-50-2	single chemical compound	stereochem	[(1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl]acetic acid	C3=C(S(C)=O)C=CC(C=C1C(C)=C(CC(O)=O)C2=C1C=CC(F)=C2)=C3	C3=C(S(C)=O)C=CC(C=C1C(C)=C(CC(O)=O)C2=C1C=CC(F)=C2)=C3	"InChI=1/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9+/f/h22H"	MLKXDPUZXIRXEP-VHKGTHMQDT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	6.67	0.018714371	1.727824758	30	Moderate	Low	form of drug administered not known			
23625	1256	21256	1085_FDAMDD_v3b	C18H14N4O5S	398.3926	defined organic	parent	tested chemical	"Sulphasalazine, N-"	599-79-1	single chemical compound		2-hydroxy-5-[(E)-{4-[(pyridin-2-ylamino)sulfonyl]phenyl}diazenyl]benzoic acid	C3=CC=CC(NS(=O)(=O)C2=CC=C(N=NC1=CC=C(O)C(C(O)=O)=C1)C=C2)=N3	C3=CC=CC(NS(=O)(=O)C2=CC=C(N=NC1=CC=C(O)C(C(O)=O)=C1)C=C2)=N3	"InChI=1/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)/b21-20+/f/h22,24H"	NCEXYHBECQHGNR-VRAPHGCZDS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		treatment of ulcerative colitis and Crohn's disease	133	0.333841542	0.476459622	16	Low	Low	form of drug administered not known			
23626	3626	23626	1086_FDAMDD_v3b	C10H14N2O4S2	290.35916	defined organic	parent	tested chemical	Sulthiame	61-56-3	single chemical compound		"4-(1,1-dioxido-1,2-thiazinan-2-yl)benzenesulfonamide"	C2CCCN(C1=CC=C(S(N)(=O)=O)C=C1)S2(=O)=O	C2CCCN(C1=CC=C(S(N)(=O)=O)C=C1)S2(=O)=O	"InChI=1/C10H14N2O4S2/c11-18(15,16)10-5-3-9(4-6-10)12-7-1-2-8-17(12,13)14/h3-6H,1-2,7-8H2,(H2,11,15,16)/f/h11H2"	HMHVCUVYZFYAJI-QMLCPYSLCB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	10	0.034440105	1.462935531	28	Low-Moderate	Low	form of drug administered not known			
23627	3627	23627	1087_FDAMDD_v3b	C17H26N2O4S	354.46434	defined organic	parent	tested chemical	Sultopride	53583-79-2	single chemical compound		N-[(1-ethylpyrrolidin-2-yl)methyl]-5-(ethylsulfonyl)-2-(methyloxy)benzamide	C2(C(=O)NCC1CCCN1CC)=CC(S(=O)(=O)CC)=CC=C2OC	C2(C(=O)NCC1CCCN1CC)=CC(S(=O)(=O)CC)=CC=C2OC	"InChI=1/C17H26N2O4S/c1-4-19-10-6-7-13(19)12-18-17(20)15-11-14(24(21,22)5-2)8-9-16(15)23-3/h8-9,11,13H,4-7,10,12H2,1-3H3,(H,18,20)/f/h18H"	UNRHXEPDKXPRTM-GPQMBLKYCW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	20	0.056423165	1.248542555	25	Low-Moderate	Low	form of drug administered not known			
23628	3628	23628	1088_FDAMDD_v3b	C14H21N3O2S	295.40044	defined organic	parent	tested chemical	Sumatriptan	103628-46-2	single chemical compound		1-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}-N-methylmethanesulfonamide	C1=C(CS(=O)(=O)NC)C=C2C(=C1)NC=C2CCN(C)C	C1=C(CS(=O)(=O)NC)C=C2C(=C1)NC=C2CCN(C)C	"InChI=1/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3"	KQKPFRSPSRPDEB-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antimigraine	0.2	0.000677047	3.169381142	47	High-Moderate	High	form of drug administered not known			
23629	3629	23629	1089_FDAMDD_v3b	C35H42N2O11	666.71478	defined organic	parent	tested chemical	Syrosingopine	84-36-6	single chemical compound	stereochem	"methyl (3beta,16beta,17alpha,18beta,20alpha)-18-({[4-{[(ethyloxy)carbonyl]oxy}-3,5-bis(methyloxy)phenyl]carbonyl}oxy)-11,17-bis(methyloxy)yohimban-16-carboxylate"	CCOC(=O)Oc1c(OC)cc(cc1OC)C(=O)O[C@@H]4C[C@@H]5CN6CC\C3=C(\Nc2cc(OC)ccc23)[C@H]6C[C@@H]5[C@H](C(=O)OC)[C@H]4OC	CCOC(=O)Oc1c(OC)cc(cc1OC)C(=O)O[C@@H]4C[C@@H]5CN6CC\C3=C(\Nc2cc(OC)ccc23)[C@H]6C[C@@H]5[C@H](C(=O)OC)[C@H]4OC	"InChI=1/C35H42N2O11/c1-7-46-35(40)48-31-26(42-3)12-18(13-27(31)43-4)33(38)47-28-14-19-17-37-11-10-22-21-9-8-20(41-2)15-24(21)36-30(22)25(37)16-23(19)29(32(28)44-5)34(39)45-6/h8-9,12-13,15,19,23,25,28-29,32,36H,7,10-11,14,16-17H2,1-6H3/t19-,23+,25-,28-,29+,32+/m1/s1"	ZCDNRPPFBQDQHR-SSYATKPKBX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.05	7.49946E-05	4.124970079	57	High	High	form of drug administered not known			
23630	3630	23630	1090_FDAMDD_v3b	C11H16N2O3	224.25634	defined organic	parent	tested chemical	Talbutal	115-44-6	single chemical compound		"5-(1-methylpropyl)-5-prop-2-en-1-ylpyrimidine-2,4,6(1H,3H,5H)-trione"	C1(=O)C(CC=C)(C(C)CC)C(=O)NC(=O)N1	C1(=O)C(CC=C)(C(C)CC)C(=O)NC(=O)N1	"InChI=1/C11H16N2O3/c1-4-6-11(7(3)5-2)8(14)12-10(16)13-9(11)15/h4,7H,1,5-6H2,2-3H3,(H2,12,13,14,15,16)/f/h12-13H"	BJVVMKUXKQHWJK-BAINRFMOCS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	3.33	0.014849079	1.828300496	32	Moderate	Moderate	form of drug administered not known			
23631	3631	23631	1091_FDAMDD_v3b	C20H28N2O5S	408.51172	defined organic	parent	tested chemical	Tamsulosin	106133-20-4	single chemical compound	stereochem	5-{(2R)-2-[(2-{[2-(ethyloxy)phenyl]oxy}ethyl)amino]propyl}-2-(methyloxy)benzenesulfonamide	NS(=O)(=O)c1cc(ccc1OC)C[C@@H](C)NCCOc2ccccc2OCC	NS(=O)(=O)c1cc(ccc1OC)C[C@@H](C)NCCOc2ccccc2OCC	"InChI=1/C20H28N2O5S/c1-4-26-17-7-5-6-8-18(17)27-12-11-22-15(2)13-16-9-10-19(25-3)20(14-16)28(21,23)24/h5-10,14-15,22H,4,11-13H2,1-3H3,(H2,21,23,24)/t15-/m1/s1/f/h21H2"	DRHKJLXJIQTDTD-XYFPIJJGDQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		alpha 1A androceptor antagonist	0.0133	3.25572E-05	4.48735288	61	High	High	form of drug administered not known			
23632	3632	23632	1092_FDAMDD_v3b	C4H6O6	150.08684	defined organic	parent	tested chemical	Tartaric acid	87-69-4	single chemical compound		"2,3-dihydroxybutanedioic acid"	C(O)(=O)C(O)C(O)C(O)=O	C(O)(=O)C(O)C(O)C(O)=O	"InChI=1/C4H6O6/c5-1(3(7)8)2(6)4(9)10/h1-2,5-6H,(H,7,8)(H,9,10)/f/h7,9H"	FEWJPZIEWOKRBE-AUDIXQRPCT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	30	0.19988428	0.699221359	19	Low	Low	form of drug administered not known			
23633	1455	21455	1093_FDAMDD_v3b	C16H9N4Na3O9S2	534.3634	defined organic	salt 3Na	tested chemical	Tartrazine	1934-21-0	single chemical compound	C.I. 19140; tautomers	"trisodium 5-oxo-1-(4-sulfonatophenyl)-4-[(E)-(4-sulfonatophenyl)diazenyl]-2,5-dihydro-1H-pyrazole-3-carboxylate"	O=C([O-])C(NN1C2=CC=C(S(=O)([O-])=O)C=C2)=C(/N=N/C3=CC=C(S(=O)([O-])=O)C=C3)C1=O.[Na+].[Na+].[Na+]	O=C(O)C(NN1C2=CC=C(S(=O)(O)=O)C=C2)=C(/N=N/C3=CC=C(S(=O)(O)=O)C=C3)C1=O	"InChI=1/C16H12N4O9S2.3Na/c21-15-13(18-17-9-1-5-11(6-2-9)30(24,25)26)14(16(22)23)19-20(15)10-3-7-12(8-4-10)31(27,28)29;;;/h1-8,19H,(H,22,23)(H,24,25,26)(H,27,28,29);;;/q;3*+1/p-3/b18-17+;;;/fC16H9N4O9S2.3Na/q-3;3m"	ZLWLTDZLUVBSRJ-LLOMATKJDN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		dye	7.5	0.014035392	1.852775441	32	Moderate	Low	form of drug administered not known			
23634	3634	23634	1094_FDAMDD_v3b	C10H12N4O5S	300.29108	defined organic	parent	tested chemical	Tazobactam	89786-04-9	single chemical compound	stereochem	"(2S,3S,5R)-3-methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide"	O=S([C@](CN1C=CN=N1)(C)[C@H]([C@](O)=O)N2C3=O)([C@@]([H])2C3)=O	O=S([C@](CN1C=CN=N1)(C)[C@H]([C@](O)=O)N2C3=O)([C@@]([H])2C3)=O	"InChI=1/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1/f/h16H"	LPQZKKCYTLCDGQ-OIUVGDJLDS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	25	0.083252556	1.079602423	23	Low	Low	form of drug administered not known; structure modified v3b			
23635	3635	23635	1095_FDAMDD_v3b	C12H13FN4O5	312.2538232	defined organic	complex uracil (C4H4N2O2)	tested chemical	Tegafur-Uracil	74578-38-4	single chemical compound	parent [17902-23-7]	"5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione - pyrimidine-2,4(1H,3H)-dione (1:1)"	O=C1\C=C/NC(=O)N1.F\C1=C\N(C(=O)NC1=O)C2CCCO2	F\C1=C\N(C(=O)NC1=O)C2CCCO2	"InChI=1/C8H9FN2O3.C4H4N2O2/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12;7-3-1-2-5-4(8)6-3/h4,6H,1-3H2,(H,10,12,13);1-2H,(H2,5,6,7,8)/f/h10H;5-6H"	DHMYGZIEILLVNR-SOWKFPPICE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	20	0.064050457	1.193477769	25	Low	Low	form of drug administered not known			
23636	3636	23636	1096_FDAMDD_v3b	C33H30N4O2	514.6169	defined organic	parent	tested chemical	Telmisartan	144701-48-4	single chemical compound		"4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl]biphenyl-2-carboxylic acid"	C1=CC=C6C(=C1)N=C(C2=CC5=C(C(C)=C2)N=C(CCC)N5CC4=CC=C(C3=CC=CC=C3C(O)=O)C=C4)N6C	C1=CC=C6C(=C1)N=C(C2=CC5=C(C(C)=C2)N=C(CCC)N5CC4=CC=C(C3=CC=CC=C3C(O)=O)C=C4)N6C	"InChI=1/C33H30N4O2/c1-4-9-30-35-31-21(2)18-24(32-34-27-12-7-8-13-28(27)36(32)3)19-29(31)37(30)20-22-14-16-23(17-15-22)25-10-5-6-11-26(25)33(38)39/h5-8,10-19H,4,9,20H2,1-3H3,(H,38,39)/f/h38H"	RMMXLENWKUUMAY-GLAYEKRECL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	1.33	0.002584447	2.587632403	40	Moderate	High	form of drug administered not known			
23637	1309	21309	1097_FDAMDD_v3b	C16H13ClN2O2	300.7439	defined organic	parent	tested chemical	Temazepam	846-50-4	single chemical compound		"7-chloro-3-hydroxy-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one"	CN1C2=CC=C(C=C2C(=NC(C1=O)O)C3=CC=CC=C3)Cl	CN1C2=CC=C(C=C2C(=NC(C1=O)O)C3=CC=CC=C3)Cl	"InChI=1/C16H13ClN2O2/c1-19-13-8-7-11(17)9-12(13)14(18-15(20)16(19)21)10-5-3-2-4-6-10/h2-9,15,20H,1H3"	SEQDDYPDSLOBDC-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	0.25	0.000831272	3.080256819	46	High-Moderate	High	form of drug administered not known			
23638	3638	23638	1098_FDAMDD_v3b	C32H32O13S	656.65368	defined organic	parent	tested chemical	Teniposide	29767-20-2	single chemical compound	stereochem	"(8aR,9R)-9-[4-hydroxy-3,5-bis(methyloxy)phenyl]-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-(2-thienylmethylidene)-beta-D-glucopyranoside"	C23C(c1cc5c(cc1[C@H]([C@H]2C(=O)OC3)c4cc(c(c(c4)OC)O)OC)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)COC(O7)c8sccc8)O)O	C23C(c1cc5c(cc1[C@H]([C@H]2C(=O)OC3)c4cc(c(c(c4)OC)O)OC)OCO5)O[C@H]6[C@@H]([C@H]([C@H]7[C@H](O6)COC(O7)c8sccc8)O)O	"InChI=1/C32H32O13S/c1-37-19-6-13(7-20(38-2)25(19)33)23-14-8-17-18(42-12-41-17)9-15(14)28(16-10-39-30(36)24(16)23)44-32-27(35)26(34)29-21(43-32)11-40-31(45-29)22-4-3-5-46-22/h3-9,16,21,23-24,26-29,31-35H,10-12H2,1-2H3/t16?,21-,23-,24+,26-,27-,28?,29-,31?,32+/m1/s1"	NRUKOCRGYNPUPR-NFIYYIGVBC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	7	0.010660109	1.972238342	33	Moderate	Low	form of drug administered not known			
23639	3639	23639	1099_FDAMDD_v3b	C19H25N5O4	387.4329	defined organic	parent	tested chemical	Terazosin	63590-64-7	single chemical compound		"6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine"	C1(OC)=C(OC)C=C4C(=C1)C(N)=NC(N3CCN(C(=O)C2CCCO2)CC3)=N4	C1(OC)=C(OC)C=C4C(=C1)C(N)=NC(N3CCN(C(=O)C2CCCO2)CC3)=N4	"InChI=1/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)/f/h20H2"	VCKUSRYTPJJLNI-HPHMPNDVCS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.333	0.000859504	3.065752264	45	High-Moderate	High	form of drug administered not known			
23640	3640	23640	1100_FDAMDD_v3b	C21H25N	291.4299	defined organic	parent	tested chemical	Terbinafine	91161-71-6	single chemical compound	stereochem	"(2E)-N,6,6-trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine"	C1=CC=C2C(=C1)C(CN(C)CC=CC#CC(C)(C)C)=CC=C2	C1=CC=C2C(=C1)C(CN(C)CC=CC#CC(C)(C)C)=CC=C2	"InChI=1/C21H25N/c1-21(2,3)15-8-5-9-16-22(4)17-19-13-10-12-18-11-6-7-14-20(18)19/h5-7,9-14H,16-17H2,1-4H3/b9-5+"	DOMXUEMWDBAQBQ-WEVVVXLNBZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		topical antifungal	27	0.092646636	1.033170343	23	Low	Low	form of drug administered not known			
23641	1310	21310	1101_FDAMDD_v3b	C12H19NO3	225.2842	defined organic	parent	tested chemical	Terbutaline	23031-25-6	single chemical compound		"5-{2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl}benzene-1,3-diol"	CC(C)(C)NCC(O)C1=CC(O)=CC(=C1)O	CC(C)(C)NCC(O)C1=CC(O)=CC(=C1)O	"InChI=1/C12H19NO3/c1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8/h4-6,11,13-16H,7H2,1-3H3"	XWTYSIMOBUGWOL-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator; tocolytic	0.25	0.001109709	2.954790725	44	Moderate	High	form of drug administered not known			
23642	3642	23642	1102_FDAMDD_v3b	C32H41NO2	471.67344	defined organic	parent	tested chemical	Terfenadine	50679-08-8	single chemical compound		"1-[4-(1,1-dimethylethyl)phenyl]-4-{4-[hydroxy(diphenyl)methyl]piperidin-1-yl}butan-1-ol"	C4=CC=CC(C(O)(C1=CC=CC=C1)C3CCN(CCCC(O)C2=CC=C(C(C)(C)C)C=C2)CC3)=C4	C4=CC=CC(C(O)(C1=CC=CC=C1)C3CCN(CCCC(O)C2=CC=C(C(C)(C)C)C=C2)CC3)=C4	"InChI=1/C32H41NO2/c1-31(2,3)26-18-16-25(17-19-26)30(34)15-10-22-33-23-20-29(21-24-33)32(35,27-11-6-4-7-12-27)28-13-8-5-9-14-28/h4-9,11-14,16-19,29-30,34-35H,10,15,20-24H2,1-3H3"	GUGOEEXESWIERI-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	2	0.004240222	2.372611426	38	Moderate	High	form of drug administered not known			
23643	3643	23643	1103_FDAMDD_v3b	C10H20O2	172.2646	defined organic	parent	tested chemical	Terpin	80-53-5	single chemical compound		4-(1-hydroxy-1-methylethyl)-1-methylcyclohexanol	C1CC(C(C)(C)O)CCC1(O)C	C1CC(C(C)(C)O)CCC1(O)C	"InChI=1/C10H20O2/c1-9(2,11)8-4-6-10(3,12)7-5-8/h8,11-12H,4-7H2,1-3H3"	RBNWAMSGVWEHFP-UHFFFAOYAM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cis form hydrate as expectorant	20	0.116100464	0.935166044	22	Low	Low	form of drug administered not known			
23644	3644	23644	1104_FDAMDD_v3b	C19H24O3	300.39206	defined organic	parent	tested chemical	Testolactone	968-93-4	single chemical compound	stereochem	"(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione"	[C@@]2\1(\C(=C/C(/C=C/1)=O)CC[C@@H]4[C@@H]2CC[C@@]3(OC(=O)CC[C@H]34)C)C	[C@@]2\1(\C(=C/C(/C=C/1)=O)CC[C@@H]4[C@@H]2CC[C@@]3(OC(=O)CC[C@H]34)C)C	"InChI=1/C19H24O3/c1-18-9-7-13(20)11-12(18)3-4-14-15(18)8-10-19(2)16(14)5-6-17(21)22-19/h7,9,11,14-16H,3-6,8,10H2,1-2H3/t14-,15+,16+,18+,19+/m1/s1"	BPEWUONYVDABNZ-DZBHQSCQBA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	4.17	0.013881858	1.857552394	32	Moderate	Moderate	form of drug administered not known			
23645	3645	23645	1105_FDAMDD_v3b	C22H24N2O8	444.43456	defined organic	parent	tested chemical	Tetracycline	60-54-8	single chemical compound	stereochem; tautomers	"(4S,4aS,5aS,6S,12aS)-4-(dimethylamino)-3,6,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide"	[C@]43(\C(=C2\C(c1c(O)cccc1[C@]([C@H]2C[C@H]3[C@@H](/C(=C(\C4=O)C(=O)N)O)N(C)C)(O)C)=O)O)O	[C@]43(\C(=C2\C(c1c(O)cccc1[C@]([C@H]2C[C@H]3[C@@H](/C(=C(\C4=O)C(=O)N)O)N(C)C)(O)C)=O)O)O	"InChI=1/C22H24N2O8/c1-21(31)8-5-4-6-11(25)12(8)16(26)13-9(21)7-10-15(24(2)3)17(27)14(20(23)30)19(29)22(10,32)18(13)28/h4-6,9-10,15,25,27-28,31-32H,7H2,1-3H3,(H2,23,30)/t9-,10-,15-,21+,22-/m0/s1/f/h23H2"	OFVLGDICTFRJMM-PZOPXDMEDB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiamebic; antibacterial; antirickettsial	33.3	0.074926666	1.12536359	24	Low	Low	form of drug administered not known			
23646	2524	22524	1106_FDAMDD_v3b	C13H10N2O4	258.2295	defined organic	parent	tested chemical	Thalidomide	50-35-1	single chemical compound		"2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione"	N1(C(C2=CC=CC=C(C1=O)2)=O)C3C(NC(CC3)=O)=O	N1(C(C2=CC=CC=C(C1=O)2)=O)C3C(NC(CC3)=O)=O	"InChI=1/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)/f/h14H"	UEJJHQNACJXSKW-YHMJCDSICW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	6.67	0.025829737	1.58788002	29	Low-Moderate	Low	form of drug administered not known			
23647	1336	21336	1107_FDAMDD_v3b	C7H8N4O2	180.164	defined organic	parent	tested chemical	Theophylline	58-55-9	single chemical compound	tautomers	"1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione"	O=C2C=1/N=C\NC=1N(C)C(=O)N2C	O=C2C=1/N=C\NC=1N(C)C(=O)N2C	"InChI=1/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)/f/h8H"	ZFXYFBGIUFBOJW-FZOZFQFYCY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator	8.67	0.048122821	1.317648918	26	Low-Moderate	Low	form of drug administered not known			
23648	3648	23648	1108_FDAMDD_v3b	C12H17ClN4OS	300.80758	defined organic	salt Cl	tested chemical	Thiamine	59-43-8	single chemical compound	ammonium	"3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-5-(2-hydroxyethyl)-4-methyl-1,3-thiazol-3-ium chloride"	S2C(CCO)=C(C)[N+](CC1=CN=C(C)N=C1N)=C2.[Cl-]	S2C(CCO)=C(C)[N+](CC1=CN=C(C)N=C1N)=C2	"InChI=1/C12H17N4OS.ClH/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13;/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15);1H/q+1;/p-1/fC12H17N4OS.Cl/h13H2;1h/qm;-1"	MYVIATVLJGTBFV-RJLNRQKHCC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		enzyme cofactor vitamin	1.67	0.005551722	2.255572305	36	Moderate	High	form of drug administered not known			
23649	1338	21338	1109_FDAMDD_v3b	C12H15Cl2NO5S	356.2222	defined organic	parent	tested chemical	Thiamphenicol	15318-45-3	single chemical compound	stereochem	"2,2-dichloro-N-{(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-[4-(methylsulfonyl)phenyl]ethyl}acetamide"	OC[C@@H](NC(C(Cl)Cl)=O)[C@H](O)C1=CC=C(S(=O)(C)=O)C=C1	OC[C@@H](NC(C(Cl)Cl)=O)[C@H](O)C1=CC=C(S(=O)(C)=O)C=C1	"InChI=1/C12H15Cl2NO5S/c1-21(19,20)8-4-2-7(3-5-8)10(17)9(6-16)15-12(18)11(13)14/h2-5,9-11,16-17H,6H2,1H3,(H,15,18)/t9-,10-/m1/s1/f/h15H"	OTVAEFIXJLOWRX-VIFFNPKKDD	Clinical Reports 	Maximum Recommended Daily Dose	human	1 of 2	Thiamphenicol	antibacterial	50	0.14036183	0.852750977	21	Low	Low	form of drug administered not known			
23650	3650	23650	1110_FDAMDD_v3b	C14H19Cl3N2O6S	449.73446	defined organic	complex HCl	tested chemical	Thiamphenicol glycinate	2611-61-2	single chemical compound	stereochem; parent [2393-92-2]	"(2R,3R)-2-[(dichloroacetyl)amino]-3-hydroxy-3-[4-(methylsulfonyl)phenyl]propyl glycinate hydrochloride"	O[C@H](C1=CC=C(S(=O)(C)=O)C=C1)[C@H](NC(C(Cl)Cl)=O)COC(CN)=O.Cl	O[C@H](C1=CC=C(S(=O)(C)=O)C=C1)[C@H](NC(C(Cl)Cl)=O)COC(CN)=O	"InChI=1/C14H18Cl2N2O6S.ClH/c1-25(22,23)9-4-2-8(3-5-9)12(20)10(7-24-11(19)6-17)18-14(21)13(15)16;/h2-5,10,12-13,20H,6-7,17H2,1H3,(H,18,21);1H/t10-,12-;/m1./s1/f/h18H;"	DKXJDBJNAXSJDH-JIBAQLOJDR	Clinical Reports 	Maximum Recommended Daily Dose	human	2 of 2	Thiamphenicol	antibacterial	50	0.111176715	0.953986161	22	Low	Low	form of drug administered not known; structure modified v3b			
23651	3651	23651	1111_FDAMDD_v3b	C22H29N3S2	399.61576	defined organic	parent	tested chemical	Thiethylperazine	1420-55-9	single chemical compound		2-(ethylthio)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine	C1=CC=C3C(=C1)N(CCCN2CCN(C)CC2)C4=C(S3)C=CC(SCC)=C4	C1=CC=C3C(=C1)N(CCCN2CCN(C)CC2)C4=C(S3)C=CC(SCC)=C4	"InChI=1/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3"	XCTYLCDETUVOIP-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiemetic	0.5	0.001251202	2.902672603	44	Moderate	High	form of drug administered not known			
23652	3652	23652	1112_FDAMDD_v3b	C5H5N5S	167.1917	defined organic	parent	tested chemical	Thioguanine	154-42-7	single chemical compound	tautomers	"2-amino-1,7-dihydro-6H-purine-6-thione"	S=C1C2=C(N=CN2)N=C(N)N1	S=C1C2=C(N=CN2)N=C(N)N1	"InChI=1/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)/f/h7,10H,6H2"	WYWHKKSPHMUBEB-CQCWYMDMCX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	5.41	0.032358066	1.490017449	28	Low-Moderate	Low	form of drug administered not known; structure modified v3b			
23653	3653	23653	1113_FDAMDD_v3b	C11H18N2O2S	242.33782	defined organic	parent	tested chemical	Thiopental	76-75-5	single chemical compound		"5-ethyl-2-mercapto-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione"	C1(=O)C(CC)(C(C)CCC)C(=O)N=C(S)N1	C1(=O)C(CC)(C(C)CCC)C(=O)N=C(S)N1	"InChI=1/C11H18N2O2S/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h7H,4-6H2,1-3H3,(H2,12,13,14,15,16)/f/h12,16H"	IUJDSEJGGMCXSG-KSKJGAJJCE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		short acting anesthetic	4.17	0.017207384	1.764285142	31	Moderate	Moderate	form of drug administered not known			
23654	3654	23654	1114_FDAMDD_v3b	C23H28ClN3O2S	446.00532	defined organic	parent	tested chemical	Thiopropazate	84-06-0	single chemical compound		2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethyl acetate	C1=CC=C3C(=C1)N(CCCN2CCN(CCOC(C)=O)CC2)C4=C(S3)C=CC(Cl)=C4	C1=CC=C3C(=C1)N(CCCN2CCN(CCOC(C)=O)CC2)C4=C(S3)C=CC(Cl)=C4	"InChI=1/C23H28ClN3O2S/c1-18(28)29-16-15-26-13-11-25(12-14-26)9-4-10-27-20-5-2-3-6-22(20)30-23-8-7-19(24)17-21(23)27/h2-3,5-8,17H,4,9-16H2,1H3"	AIUHRQHVWSUTGJ-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	1.5	0.003363189	2.47324878	39	Moderate	High	form of drug administered not known			
23655	3655	23655	1115_FDAMDD_v3b	C22H30N4O2S2	446.6292	defined organic	parent	tested chemical	Thioproperazine	316-81-4	single chemical compound		"N,N-dimethyl-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine-2-sulfonamide"	C1=CC=C3C(=C1)N(CCCN2CCN(C)CC2)C4=C(S3)C=CC(S(=O)(=O)N(C)C)=C4	C1=CC=C3C(=C1)N(CCCN2CCN(C)CC2)C4=C(S3)C=CC(S(=O)(=O)N(C)C)=C4	"InChI=1/C22H30N4O2S2/c1-23(2)30(27,28)18-9-10-22-20(17-18)26(19-7-4-5-8-21(19)29-22)12-6-11-25-15-13-24(3)14-16-25/h4-5,7-10,17H,6,11-16H2,1-3H3"	VZYCZNZBPPHOFY-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		neuroleptic; antiemetic	0.667	0.001493409	2.825821279	43	Moderate	High	form of drug administered not known			
23656	3656	23656	1116_FDAMDD_v3b	C21H26N2S2	370.57454	defined organic	parent	tested chemical	Thioridazine	50-52-2	single chemical compound		10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10H-phenothiazine	C1=CC=C3C(=C1)N(CCC2CCCCN2C)C4=C(S3)C=CC(SC)=C4	C1=CC=C3C(=C1)N(CCC2CCCCN2C)C4=C(S3)C=CC(SC)=C4	"InChI=1/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-20(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H2,1-2H3"	KLBQZWRITKRQQV-UHFFFAOYAE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	13.3	0.035890215	1.445023937	27	Low-Moderate	Low	form of drug administered not known			
23657	1339	21339	1117_FDAMDD_v3b	C6H12N3PS	189.2183	defined organic	parent	tested chemical	Thio-TEPA	52-24-4	single chemical compound		"1,1',1''-phosphorothioyltriaziridine"	S=P(N1CC1)(N1CC1)N1CC1	S=P(N1CC1)(N1CC1)N1CC1	"InChI=1/C6H12N3PS/c11-10(7-1-2-7,8-3-4-8)9-5-6-9/h1-6H2"	FOCVUCIESVLUNU-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.4	0.00211396	2.674903145	41	Moderate	High	form of drug administered not known			
23658	3658	23658	1118_FDAMDD_v3b	C23H29N3O2S2	443.62526	defined organic	parent	tested chemical	Thiothixene	5591-45-7	single chemical compound	stereochem	"(9E)-N,N-dimethyl-9-[3-(4-methylpiperazin-1-yl)propylidene]-9H-thioxanthene-2-sulfonamide"	C1=CC=C3C(=C1)C(=CCCN2CCN(C)CC2)C4=C(S3)C=CC(S(=O)(=O)N(C)C)=C4	C1=CC=C3C(=C1)C(=CCCN2CCN(C)CC2)C4=C(S3)C=CC(S(=O)(=O)N(C)C)=C4	"InChI=1/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3/b19-8+"	GFBKORZTTCHDGY-UFWORHAWBL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic; dopamine receptor antagonist	0.5	0.001127077	2.948046263	44	Moderate	High	form of drug administered not known			
23659	1347	21347	1119_FDAMDD_v3b	C4H4N2OS	128.1484	defined organic	parent	tested chemical	Thiouracil	141-90-2	single chemical compound	tautomers	"2-thioxo-2,3-dihydropyrimidin-4(1H)-one"	O=C1NC(=S)NC=C1	O=C1NC(=S)NC=C1	"InChI=1/C4H4N2OS/c7-3-1-2-5-4(8)6-3/h1-2H,(H2,5,6,7,8)/f/h5-6H"	ZEMGGZBWXRYJHK-JYEHRPOACM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		thyroid depressant	3.33	0.025985498	1.585268955	29	Low-Moderate	Moderate	form of drug administered not known			
23660	3660	23660	1120_FDAMDD_v3b	C20H25NOS	327.4836	defined organic	parent	tested chemical	Thiphenamil	82-99-5	single chemical compound		S-[2-(diethylamino)ethyl] diphenylethanethioate	C2=CC=C(C(C(=O)SCCN(CC)CC)C1=CC=CC=C1)C=C2	C2=CC=C(C(C(=O)SCCN(CC)CC)C1=CC=CC=C1)C=C2	"InChI=1/C20H25NOS/c1-3-21(4-2)15-16-23-20(22)19(17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,19H,3-4,15-16H2,1-2H3"	WHLUQAYNVOGZST-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic; smooth muscle relaxant	5	0.01526794	1.816219552	31	Moderate	Low	form of drug administered not known			
23661	3661	23661	1121_FDAMDD_v3b	C10H14N2O5	242.22856	defined organic	parent	tested chemical	Thymidine	50-89-5	single chemical compound	stereochem	thymidine	N\1(C(NC(/C(=C/1)C)=O)=O)[C@@H]2O[C@H](CO)[C@H](C2)O	N\1(C(NC(/C(=C/1)C)=O)=O)[C@@H]2O[C@H](CO)[C@H](C2)O	"InChI=1/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8+/m0/s1/f/h11H"	IQFYYKKMVGJFEH-COVMAPGZDS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	100	0.412833235	0.384225347	15	Low	Low	form of drug administered not known			
23662	3662	23662	1122_FDAMDD_v3b	C15H11I4NO4	776.87002	defined organic	parent	tested chemical	Thyroxine	7488-70-2	single chemical compound		"O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodotyrosine"	C2(I)=C(O)C(I)=CC(OC1=C(I)C=C(CC(N)C(O)=O)C=C1I)=C2	C2(I)=C(O)C(I)=CC(OC1=C(I)C=C(CC(N)C(O)=O)C=C1I)=C2	"InChI=1/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H,3,20H2,(H,22,23)/f/h22H"	XUIIKFGFIJCVMT-QWOVJGMICH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		thyroid hormone; antihyperlipoproteinemic	0.005	6.43608E-06	5.191378358	69	High	High	form of drug administered not known			
23663	3663	23663	1123_FDAMDD_v3b	C20H25NO2S2	375.548	defined organic	parent	tested chemical	Tiagabine	115103-54-3	single chemical compound	stereochem	"(3R)-1-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]piperidine-3-carboxylic acid"	Cc3ccsc3C(=C\CCN1C[C@@H](CCC1)C(O)=O)\c2sccc2C	Cc3ccsc3C(=C\CCN1C[C@@H](CCC1)C(O)=O)\c2sccc2C	"InChI=1/C20H25NO2S2/c1-14-7-11-24-18(14)17(19-15(2)8-12-25-19)6-4-10-21-9-3-5-16(13-21)20(22)23/h6-8,11-12,16H,3-5,9-10,13H2,1-2H3,(H,22,23)/t16-/m1/s1/f/h22H"	PBJUNZJWGZTSKL-RJKQBDLPDP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	1.07	0.00284917	2.545281676	40	Moderate	High	form of drug administered not known			
23664	3664	23664	1124_FDAMDD_v3b	C15H24N2O4S	328.42706	defined organic	parent	tested chemical	Tiapride	51012-32-9	single chemical compound		N-[2-(diethylamino)ethyl]-2-(methyloxy)-5-(methylsulfonyl)benzamide	C1(S(=O)(=O)C)=CC=C(OC)C(C(=O)NCCN(CC)CC)=C1	C1(S(=O)(=O)C)=CC=C(OC)C(C(=O)NCCN(CC)CC)=C1	"InChI=1/C15H24N2O4S/c1-5-17(6-2)10-9-16-15(18)13-11-12(22(4,19)20)7-8-14(13)21-3/h7-8,11H,5-6,9-10H2,1-4H3,(H,16,18)/f/h16H"	JTVPZMFULRWINT-WYUMXYHSCN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidyskinetic	6.67	0.020308923	1.692313099	30	Moderate	Low	form of drug administered not known; HCl [51012-33-0]			
23665	3665	23665	1125_FDAMDD_v3b	C14H12O3S	260.30828	defined organic	parent	tested chemical	Tiaprofenic acid	33005-95-7	single chemical compound		2-[5-(phenylcarbonyl)-2-thienyl]propanoic acid	C2=CC=CC(C(=O)C1SC(C(C)C(=O)O)=CC=1)=C2	C2=CC=CC(C(=O)C1SC(C(C)C(=O)O)=CC=1)=C2	"InChI=1/C14H12O3S/c1-9(14(16)17)11-7-8-12(18-11)13(15)10-5-3-2-4-6-10/h2-9H,1H3,(H,16,17)/f/h16H"	GUHPRPJDBZHYCJ-WYUMXYHSCF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anti inflammatory	10	0.038415989	1.415487983	27	Low-Moderate	Low	form of drug administered not known			
23666	3666	23666	1126_FDAMDD_v3b	C15H18ClN3O3S	355.83972	defined organic	parent	tested chemical	Tiaramide	32527-55-2	single chemical compound		"5-chloro-3-{2-[4-(2-hydroxyethyl)piperazin-1-yl]-2-oxoethyl}-1,3-benzothiazol-2(3H)-one"	C1=C(Cl)C=C3C(=C1)SC(=O)N3CC(=O)N2CCN(CCO)CC2	C1=C(Cl)C=C3C(=C1)SC(=O)N3CC(=O)N2CCN(CCO)CC2	"InChI=1/C15H18ClN3O3S/c16-11-1-2-13-12(9-11)19(15(22)23-13)10-14(21)18-5-3-17(4-6-18)7-8-20/h1-2,9,20H,3-8,10H2"	HTJXMOGUGMSZOG-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiasthmatic; anti inflammatry	5	0.01405127	1.852284419	32	Moderate	Low	form of drug administered not known; HCl [35941-71-0]			
23667	3667	23667	1127_FDAMDD_v3b	C21H28O2	312.44582	defined organic	parent	tested chemical	Tibolone	5630-53-5	single chemical compound	stereochem	"(7beta,8xi,9beta,13alpha,14beta,17alpha)-17-ethynyl-17-hydroxy-7-methylestr-5(10)-en-3-one"	C/14=C(/C[C@H]([C@H]2[C@H]3[C@](CC[C@H]\12)([C@@](C#C)(O)CC3)C)C)CC(CC4)=O	C/14=C(/C[C@H]([C@H]2[C@H]3[C@](CC[C@H]\12)([C@@](C#C)(O)CC3)C)C)CC(CC4)=O	"InChI=1/C21H28O2/c1-4-21(23)10-8-18-19-13(2)11-14-12-15(22)5-6-16(14)17(19)7-9-20(18,21)3/h1,13,17-19,23H,5-12H2,2-3H3/t13-,17-,18+,19-,20+,21+/m1/s1"	WZDGZWOAQTVYBX-XOINTXKNBA	Clinical Reports 	Maximum Recommended Daily Dose	human	1		treatment of menopausal syndrome	0.0417	0.000133463	3.874638664	55	High	High	form of drug administered not known			
23668	3668	23668	1128_FDAMDD_v3b	C15H16N2O6S2	384.42734	defined organic	parent	tested chemical	Ticarcillin	34787-01-4	single chemical compound	stereochem	"(2S,5R,6R)-6-{[(2R)-2-carboxy-2-(3-thienyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid"	O=C2N1[C@]([C@@]([H])2NC([C@H]([C@](O)=O)C3=CSC=C3)=O)([H])SC(C)(C)[C@@H]1[C@@](O)=O	O=C2N1[C@]([C@@]([H])2NC([C@H]([C@](O)=O)C3=CSC=C3)=O)([H])SC(C)(C)[C@@H]1[C@@](O)=O	"InChI=1/C15H16N2O6S2/c1-15(2)9(14(22)23)17-11(19)8(12(17)25-15)16-10(18)7(13(20)21)6-3-4-24-5-6/h3-5,7-9,12H,1-2H3,(H,16,18)(H,20,21)(H,22,23)/t7-,8-,9+,12-/m1/s1/f/h16,20,22H"	OHKOGUYZJXTSFX-MRFNKDAEDD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	300	0.780381541	0.107693012	12	Low	Low	form of drug administered not known; 2Na [4697-14-7]; Na salt [74682-62-5]; cresyl Na [59070-06-3]; structure modified v3b			
23669	3669	23669	1129_FDAMDD_v3b	C14H14ClNS	263.78566	defined organic	parent	tested chemical	Ticlopidine	55142-85-3	single chemical compound		"5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridine"	C3=CC=C(CN1CC2=C(CC1)SC=C2)C(Cl)=C3	C3=CC=C(CN1CC2=C(CC1)SC=C2)C(Cl)=C3	"InChI=1/C14H14ClNS/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14/h1-4,6,8H,5,7,9-10H2"	PHWBOXQYWZNQIN-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		platelet aggregation inhibitor	4.17	0.015808289	1.801115128	31	Moderate	Moderate	form of drug administered not known; HCl [53885-35-1]			
23670	3670	23670	1130_FDAMDD_v3b	C13H8Cl2O4S	331.17122	defined organic	parent	tested chemical	Ticrynafen	40180-04-9	single chemical compound		"{[2,3-dichloro-4-(2-thienylcarbonyl)phenyl]oxy}acetic acid"	C2C=CSC=2C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1	C2C=CSC=2C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1	"InChI=1/C13H8Cl2O4S/c14-11-7(13(18)9-2-1-5-20-9)3-4-8(12(11)15)19-6-10(16)17/h1-5H,6H2,(H,16,17)/f/h16H"	AGHANLSBXUWXTB-WYUMXYHSCF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic; uricosuric; antihypertensive	8.33	0.025153152	1.599407587	29	Low-Moderate	Low	form of drug administered not known			
23671	3671	23671	1131_FDAMDD_v3b	C17H23NO2	273.37002	defined organic	parent	tested chemical	Tilidine	20380-58-9	single chemical compound	stereochem	"ethyl (1S,2R)-2-(dimethylamino)-1-phenylcyclohex-3-ene-1-carboxylate"	[C@]1([C@H](N(C)C)\C=C/CC1)(C(=O)OCC)c2ccccc2	[C@]1([C@H](N(C)C)\C=C/CC1)(C(=O)OCC)c2ccccc2	"InChI=1/C17H23NO2/c1-4-20-16(19)17(14-10-6-5-7-11-14)13-9-8-12-15(17)18(2)3/h5-8,10-12,15H,4,9,13H2,1-3H3/t15-,17+/m1/s1"	WDEFBBTXULIOBB-WBVHZDCIBS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		narcotic analgesic	3.33	0.012181292	1.914306651	33	Moderate	Moderate	form of drug administered not known; fumarate [55567-81-2]; HCl [24357-97-9]; trans form HCl [27107-79-5]			
23672	3672	23672	1132_FDAMDD_v3b	C17H22BrNOS2	400.39668	defined organic	salt Br	tested chemical	Timepidium bromide	35035-05-3	single chemical compound	ammonium	"3-(di-2-thienylmethylidene)-1,1-dimethyl-5-(methyloxy)piperidinium bromide"	[Br-].C3C(OC)CC(=C(C1=CC=CS1)C2SC=CC=2)C[N+]3(C)C	C3C(OC)CC(=C(C1=CC=CS1)C2SC=CC=2)C[N+]3(C)C	"InChI=1/C17H22NOS2.BrH/c1-18(2)11-13(10-14(12-18)19-3)17(15-6-4-8-20-15)16-7-5-9-21-16;/h4-9,14H,10-12H2,1-3H3;1H/q+1;/p-1/fC17H22NOS2.Br/h;1h/qm;-1"	QTSXMEPZSHLZFF-RCRJSGGUCH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	1.5	0.003746285	2.426399209	38	Moderate	High	form of drug administered not known			
23673	3673	23673	1133_FDAMDD_v3b	C22H24FN3OS	397.5088632	defined organic	parent	tested chemical	Timiperone	57648-21-2	single chemical compound		"1-(4-fluorophenyl)-4-[4-(2-thioxo-2,3-dihydro-1H-benzimidazol-1-yl)piperidin-1-yl]butan-1-one"	C(=O)(CCCN3CCC(N1C(=S)NC2=C1C=CC=C2)CC3)C4=CC=C(F)C=C4	C(=O)(CCCN3CCC(N1C(=S)NC2=C1C=CC=C2)CC3)C4=CC=C(F)C=C4	"InChI=1/C22H24FN3OS/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28/h1-2,4-5,7-10,18H,3,6,11-15H2,(H,24,28)/f/h24H"	YDLQKLWVKKFPII-LQFNOIFHCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	0.2	0.000503133	3.298316821	48	High-Moderate	High	form of drug administered not known			
23674	3674	23674	1134_FDAMDD_v3b	C13H24N4O3S	316.41966	defined organic	parent	tested chemical	Timolol	26839-75-8	single chemical compound	stereochem	"(2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol"	O[C@H](COc1nsnc1N2CCOCC2)CNC(C)(C)C	O[C@H](COc1nsnc1N2CCOCC2)CNC(C)(C)C	"InChI=1/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m0/s1"	BLJRIMJGRPQVNF-JTQLQIEIBV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive; antianginal; antiarrhythmic; antiglaucomic	1	0.00316036	2.50026346	39	Moderate	High	form of drug administered not known; hemihydrate [91524-16-2]; maleate [26921-17-5]			
23675	3675	23675	1135_FDAMDD_v3b	C4H7NO2S	133.16888	defined organic	parent	tested chemical	Timonacic	444-27-9	single chemical compound		"1,3-thiazolidine-4-carboxylic acid"	N1C(C(=O)O)CSC1	N1C(C(=O)O)CSC1	"InChI=1/C4H7NO2S/c6-4(7)3-1-8-2-5-3/h3,5H,1-2H2,(H,6,7)/f/h6H"	DZLNHFMRPBPULJ-BRMMOCHJCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		choleretic	10	0.075092619	1.124402747	24	Low	Low	form of drug administered not known			
23676	3676	23676	1136_FDAMDD_v3b	C8H13N3O4S	247.27152	defined organic	parent	tested chemical	Tinidazole	19387-91-8	single chemical compound		1-[2-(ethylsulfonyl)ethyl]-2-methyl-5-nitro-1H-imidazole	N1C=C(N(=O)=O)N(CCS(=O)(=O)CC)C=1C	N1C=C(N(=O)=O)N(CCS(=O)(=O)CC)C=1C	"InChI=1/C8H13N3O4S/c1-3-16(14,15)5-4-10-7(2)9-6-8(10)11(12)13/h6H,3-5H2,1-2H3"	HJLSLZFTEKNLFI-UHFFFAOYAT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiprotozoal; antiamebic	33.3	0.134669775	0.870729865	21	Low	Low	form of drug administered not known			
23677	3677	23677	1137_FDAMDD_v3b	C17H20N2O2S	316.4179	defined organic	parent	tested chemical	Tinoridine	24237-54-5	single chemical compound		"ethyl 2-amino-6-(phenylmethyl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate"	C3=CC=CC(CN1CCC2=C(C1)SC(N)=C2C(=O)OCC)=C3	C3=CC=CC(CN1CCC2=C(C1)SC(N)=C2C(=O)OCC)=C3	"InChI=1/C17H20N2O2S/c1-2-21-17(20)15-13-8-9-19(11-14(13)22-16(15)18)10-12-6-4-3-5-7-12/h3-7H,2,8-11,18H2,1H3"	PFENFDGYVLAFBR-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; antipyretic; anti inflammatory	5	0.015801887	1.80129104	31	Moderate	Low	form of drug administered not known; HCl [25913-34-2]			
23678	3678	23678	1138_FDAMDD_v3b	C5H9NO3S	163.19486	defined organic	parent	tested chemical	Tiopronin	1953-02-2	single chemical compound		N-(2-mercaptopropanoyl)glycine	CC(S)C(=O)NCC(O)=O	CC(S)C(=O)NCC(O)=O	"InChI=1/C5H9NO3S/c1-3(10)5(9)6-2-4(7)8/h3,10H,2H2,1H3,(H,6,9)(H,7,8)/f/h6-7H"	YTGJWQPHMWSCST-ZDKSUBDRCR	Clinical Reports 	Maximum Recommended Daily Dose	human	1		hepatoprotectant; mucolytic; antidote to heavy metal poisoning	33.3	0.204050544	0.690262243	19	Low	Low	form of drug administered not known			
23679	3679	23679	1139_FDAMDD_v3b	C9H8ClN5S	253.71132	defined organic	parent	tested chemical	Tizanidine	51322-75-9	single chemical compound		"5-chloro-N-(4,5-dihydro-1H-imidazol-2-yl)-2,1,3-benzothiadiazol-4-amine"	C2C(Cl)=C(NC1=NCCN1)C3C(C=2)=NSN=3	C2C(Cl)=C(NC1=NCCN1)C3C(C=2)=NSN=3	"InChI=1/C9H8ClN5S/c10-5-1-2-6-8(15-16-14-6)7(5)13-9-11-3-4-12-9/h1-2H,3-4H2,(H2,11,12,13)/f/h11,13H"	XFYDIVBRZNQMJC-KZZMUEETCJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	0.6	0.002364893	2.626188594	41	Moderate	High	form of drug administered not known; HCl [64461-82-1]			
23680	3680	23680	1140_FDAMDD_v3b	C18H37N5O9	467.51448	defined organic	parent	tested chemical	Tobramycin	32986-56-4	single chemical compound	stereochem	"(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside"	N[C@@H]3C[C@H](O)[C@@H](CN)O[C@@H]3O[C@H]2[C@H](O)[C@@H](O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O)[C@H](N)C[C@@H]2N	N[C@@H]3C[C@H](O)[C@@H](CN)O[C@@H]3O[C@H]2[C@H](O)[C@@H](O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O)[C@H](N)C[C@@H]2N	"InChI=1/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1"	NLVFBUXFDBBNBW-PBSUHMDJBB	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	9	0.019250741	1.715552557	30	Moderate	Low	form of drug administered not known; sulfate [79645-27-5]			
23681	3681	23681	1141_FDAMDD_v3b	C22H26N2O4	382.45284	defined organic	parent	tested chemical	Tofisopam	22345-47-7	single chemical compound		"1-[3,4-bis(methyloxy)phenyl]-5-ethyl-4-methyl-7,8-bis(methyloxy)-5H-2,3-benzodiazepine"	C1(OC)=C(OC)C=C3C(=C1)C(CC)C(C)=NN=C3C2=CC=C(OC)C(OC)=C2	C1(OC)=C(OC)C=C3C(=C1)C(CC)C(C)=NN=C3C2=CC=C(OC)C(OC)=C2	"InChI=1/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3"	RUJBDQSFYCKFAA-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	2.5	0.006536754	2.184637882	36	Moderate	High-Moderate	form of drug administered not known			
23682	1358	21358	1142_FDAMDD_v3b	C14H21N3O3S	311.3998	defined organic	parent	tested chemical	Tolazamide	1156-19-0	single chemical compound		N-[(azepan-1-ylamino)carbonyl]-4-methylbenzenesulfonamide	O=S(=O)(C1=CC=C(C=C1)C)NC(=O)NN2CCCCCC2	O=S(=O)(C1=CC=C(C=C1)C)NC(=O)NN2CCCCCC2	"InChI=1/C14H21N3O3S/c1-12-6-8-13(9-7-12)21(19,20)16-14(18)15-17-10-4-2-3-5-11-17/h6-9H,2-5,10-11H2,1H3,(H2,15,16,18)/f/h15-16H"	OUDSBRTVNLOZBN-LUXCBXFACS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	16.7	0.053628808	1.270601858	25	Low-Moderate	Low	form of drug administered not known			
23683	3683	23683	1143_FDAMDD_v3b	C10H12N2	160.21568	defined organic	parent	tested chemical	Tolazoline	59-98-3	single chemical compound		"2-(phenylmethyl)-4,5-dihydro-1H-imidazole"	C2=CC=CC(CC1=NCCN1)=C2	C2=CC=CC(CC1=NCCN1)=C2	"InChI=1/C10H12N2/c1-2-4-9(5-3-1)8-10-11-6-7-12-10/h1-5H,6-8H2,(H,11,12)/f/h11H"	JIVZKJJQOZQXQB-WXRBYKJCCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiadrenergic	2	0.012483173	1.903675022	32	Moderate	High	form of drug administered not known; HCl [59-97-2]			
23684	1359	21359	1144_FDAMDD_v3b	C12H18N2O3S	270.3479	defined organic	parent	tested chemical	Tolbutamide	64-77-7	single chemical compound		N-[(butylamino)carbonyl]-4-methylbenzenesulfonamide	O=S(=O)(C1=CC=C(C=C1)C)NC(=O)NCCCC	O=S(=O)(C1=CC=C(C=C1)C)NC(=O)NCCCC	"InChI=1/C12H18N2O3S/c1-3-4-9-13-12(15)14-18(16,17)11-7-5-10(2)6-8-11/h5-8H,3-4,9H2,1-2H3,(H2,13,14,15)/f/h13-14H"	JLRGJRBPOGGCBT-KGCNKATMCC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		hypoglycemic agent	33.3	0.123174621	0.909478767	21	Low	Low	form of drug administered not known; Na salt [473-41-6]			
23685	3685	23685	1145_FDAMDD_v3b	C14H11NO5	273.24084	defined organic	parent	tested chemical	Tolcapone	134308-13-7	single chemical compound		"(3,4-dihydroxy-5-nitrophenyl)(4-methylphenyl)methanone"	C2(O)=C(O)C=C(C(=O)C1=CC=C(C)C=C1)C=C2N(=O)=O	C2(O)=C(O)C=C(C(=O)C1=CC=C(C)C=C1)C=C2N(=O)=O	"InChI=1/C14H11NO5/c1-8-2-4-9(5-3-8)13(17)10-6-11(15(19)20)14(18)12(16)7-10/h2-7,16,18H,1H3"	MIQPIUSUKVNLNT-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant; catechol-O-methyltransferase inhibitor	3.33	0.012187051	1.914101378	33	Moderate	Moderate	form of drug administered not known			
23686	3686	23686	1146_FDAMDD_v3b	C16H23NO	245.35992	defined organic	parent	tested chemical	Tolperisone	728-88-1	single chemical compound		2-methyl-1-(4-methylphenyl)-3-piperidin-1-ylpropan-1-one	C2CCCN(CC(C)C(=O)C1=CC=C(C)C=C1)C2	C2CCCN(CC(C)C(=O)C1=CC=C(C)C=C1)C2	"InChI=1/C16H23NO/c1-13-6-8-15(9-7-13)16(18)14(2)12-17-10-4-3-5-11-17/h6-9,14H,3-5,10-12H2,1-2H3"	FSKFPVLPFLJRQB-UHFFFAOYAY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	5	0.020378226	1.690833617	30	Moderate	Low	form of drug administered not known; HCl [3644-61-9]			
23687	3687	23687	1147_FDAMDD_v3b	C22H31NO	325.48764	defined organic	parent	tested chemical	Tolterodine	124937-51-5	single chemical compound	stereochem	2-{(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl}-4-methylphenol	OC(C=C2)=C(C=C2C)[C@@](CCN(C(C)C)C(C)C)([H])C1=CC=CC=C1	OC(C=C2)=C(C=C2C)[C@@](CCN(C(C)C)C(C)C)([H])C1=CC=CC=C1	"InChI=1/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1"	OOGJQPCLVADCPB-HXUWFJFHBV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cholinergic (acetyl-choline) receptor blockers	8	0.024578506	1.609444514	29	Low-Moderate	Low	form of drug administered not known; tartrate [124937-52-6]; structure modified v3b			
23688	3688	23688	1148_FDAMDD_v3b	C12H21NO8S	339.36204	defined organic	parent	tested chemical	Topiramate	97240-79-4	single chemical compound	stereochem	"[(3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis[1,3]dioxolo[4,5-b:4',5'-d]pyran-3a-yl]methyl sulfamate"	[C@]32([C@H]([C@@H]1OC(C)(C)O[C@@H]1CO2)OC(O3)(C)C)COS(=O)(=O)N	[C@]32([C@H]([C@@H]1OC(C)(C)O[C@@H]1CO2)OC(O3)(C)C)COS(=O)(=O)N	"InChI=1/C12H21NO8S/c1-10(2)18-7-5-16-12(6-17-22(13,14)15)9(8(7)19-10)20-11(3,4)21-12/h7-9H,5-6H2,1-4H3,(H2,13,14,15)/t7-,8-,9+,12+/m1/s1/f/h13H2"	KJADKKWYZYXHBB-OBCVYQOWDF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiepileptic	6.67	0.019654526	1.706537428	30	Moderate	Low	form of drug administered not known			
23689	3689	23689	1149_FDAMDD_v3b	C26H28ClNO	405.95962	defined organic	parent	tested chemical	Toremifene	89778-26-7	single chemical compound	stereochem	"2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine"	CN(C)CCOc1ccc(cc1)/C(c2ccccc2)=C(/CCCl)c3ccccc3	CN(C)CCOc1ccc(cc1)/C(c2ccccc2)=C(/CCCl)c3ccccc3	"InChI=1/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-"	XFCLJVABOIYOMF-QPLCGJKRBL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiestrogen; antineoplastic	3.33	0.008202786	2.086038604	35	Moderate	Moderate	form of drug administered not known; citrate [89778-27-8]			
23690	3690	23690	1150_FDAMDD_v3b	C16H20N4O3S	348.42	defined organic	parent	tested chemical	Torsemide	56211-40-6	single chemical compound		N-{[(1-methylethyl)amino]carbonyl}-4-[(3-methylphenyl)amino]pyridine-3-sulfonamide	C2=CC=C(C)C=C2NC1=C(S(=O)(=O)NC(=O)NC(C)C)C=NC=C1	C2=CC=C(C)C=C2NC1=C(S(=O)(=O)NC(=O)NC(C)C)C=NC=C1	"InChI=1/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)/f/h18-20H"	NGBFQHCMQULJNZ-KGASAFGOCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic	3.33	0.009557431	2.019658843	34	Moderate	Moderate	form of drug administered not known			
23691	3691	23691	1151_FDAMDD_v3b	C16H25NO2	263.3752	defined organic	parent	tested chemical	Tramadol	27203-92-5	single chemical compound	stereochem	"(1R,2R)-2-[(dimethylamino)methyl]-1-[3-(methyloxy)phenyl]cyclohexanol"	[C@@]1([C@@H](CN(C)C)CCCC1)(c2cc(OC)ccc2)O	[C@@]1([C@@H](CN(C)C)CCCC1)(c2cc(OC)ccc2)O	"InChI=1/C16H25NO2/c1-17(2)12-14-7-4-5-10-16(14,18)13-8-6-9-15(11-13)19-3/h6,8-9,11,14,18H,4-5,7,10,12H2,1-3H3/t14-,16+/m1/s1"	TVYLLZQTGLZFBW-ZBFHGGJFBS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic	6.67	0.025325088	1.596449044	29	Low-Moderate	Low	form of drug administered not known; HCl [22204-88-2; 22204-88-2]			
23692	3692	23692	1152_FDAMDD_v3b	C24H34N2O5	430.53716	defined organic	parent	tested chemical	Trandolapril	87679-37-6	single chemical compound	stereochem	"(2S,3aR,7aS)-1-(N-((1S)-1-((Ethyloxy)carbonyl)-3-phenylpropyl)-L-alanyl)octahydro-1H-indole-2-carboxylic Acid"	O=[C@](O)[C@H]2N(C([C@H](C)N[C@H]([C@@](OCC)=O)CCC3=CC=CC=C3)=O)[C@@]1([H])CCCC[C@@]([H])1C2	O=[C@](O)[C@H]2N(C([C@H](C)N[C@H]([C@@](OCC)=O)CCC3=CC=CC=C3)=O)[C@@]1([H])CCCC[C@@]([H])1C2	"InChI=1/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1/f/h28H"	VXFJYXUZANRPDJ-ZUVJKGQHDJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.533	0.001237988	2.907283433	44	Moderate	High	form of drug administered not known; diacid [87679-71-8]; structure modified v3b			
23693	3693	23693	1153_FDAMDD_v3b	C18H17NO5	327.33128	defined organic	parent	tested chemical	Tranilast	53902-12-8	single chemical compound	stereochem	"2-({(2E)-3-[3,4-bis(methyloxy)phenyl]prop-2-enoyl}amino)benzoic acid"	C2=CC=CC(NC(=O)C=CC1=CC=C(OC)C(OC)=C1)=C2C(O)=O	C2=CC=CC(NC(=O)C=CC1=CC=C(OC)C(OC)=C1)=C2C(O)=O	"InChI=1/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+/f/h19,21H"	NZHGWWWHIYHZNX-QKQQQBNFDV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiallergic	5	0.015275045	1.816017504	31	Moderate	Low	form of drug administered not known			
23694	3694	23694	1154_FDAMDD_v3b	C9H11N	133.19034	defined organic	parent	tested chemical	Tranylcypromine	155-09-9	single chemical compound	stereochem	"(1R,2S)-2-phenylcyclopropanamine"	[C@H]1(C[C@H]1N)c2ccccc2	[C@H]1(C[C@H]1N)c2ccccc2	"InChI=1/C9H11N/c10-9-6-8(9)7-4-2-1-3-5-7/h1-5,8-9H,6,10H2/t8-,9+/m0/s1"	AELCINSCMGFISI-DTWKUNHWBH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	1	0.007508052	2.124472728	35	Moderate	High	form of drug administered not known; sulfate [13492-01-8; 7081-36-9]; HCl [95-62-5]			
23695	3695	23695	1155_FDAMDD_v3b	C19H23NO5	345.38962	defined organic	parent	tested chemical	Tretoquinol	30418-38-3	single chemical compound	stereochem	"(1S)-1-{[3,4,5-tris(methyloxy)phenyl]methyl}-1,2,3,4-tetrahydroisoquinoline-6,7-diol"	COc1cc(cc(OC)c1OC)C[C@@H]2NCCc3cc(O)c(O)cc23	COc1cc(cc(OC)c1OC)C[C@@H]2NCCc3cc(O)c(O)cc23	"InChI=1/C19H23NO5/c1-23-17-7-11(8-18(24-2)19(17)25-3)6-14-13-10-16(22)15(21)9-12(13)4-5-20-14/h7-10,14,20-22H,4-6H2,1-3H3/t14-/m0/s1"	RGVPOXRFEPSFGH-AWEZNQCLBM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		bronchodilator	0.3	0.000868584	3.061188027	45	High-Moderate	High	form of drug administered not known; dl form hydrochloride [18559-63-2]; l form hydrochloride [18559-59-6]			
23696	1373	21373	1156_FDAMDD_v3b	C12H11N7	253.2626	defined organic	parent	tested chemical	Triamterene	396-01-0	single chemical compound		"6-phenylpteridine-2,4,7-triamine"	NC1=C2C(=NC(=N1)N)N=C(C(=N2)C3=CC=CC=C3)N	NC1=C2C(=NC(=N1)N)N=C(C(=N2)C3=CC=CC=C3)N	"InChI=1/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)/f/h13-15H2"	FNYLWPVRPXGIIP-VLYIBAHHCJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic	3.33	0.013148408	1.881126828	32	Moderate	Moderate	form of drug administered not known			
23697	3697	23697	1157_FDAMDD_v3b	C29H34O6	478.57666	defined organic	parent	tested chemical	Tribenoside	10310-32-4	single chemical compound	stereochem	"ethyl 3,5,6-tris-O-(phenylmethyl)-beta-D-glucofuranoside"	O[C@@H]2[C@@H](OCc1ccccc1)[C@H](O[C@H]2OCC)C(COCc3ccccc3)OCc4ccccc4	O[C@@H]2[C@@H](OCc1ccccc1)[C@H](O[C@H]2OCC)C(COCc3ccccc3)OCc4ccccc4	"InChI=1/C29H34O6/c1-2-32-29-26(30)28(34-20-24-16-10-5-11-17-24)27(35-29)25(33-19-23-14-8-4-9-15-23)21-31-18-22-12-6-3-7-13-22/h3-17,25-30H,2,18-21H2,1H3/t25?,26-,27-,28-,29-/m1/s1"	ULLNJSBQMBKOJH-SCNPRXQJBN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sclerosing agent	13.3	0.027790741	1.556099873	29	Low-Moderate	Low	form of drug administered not known			
23698	3698	23698	1158_FDAMDD_v3b	C2H3Br3O	282.75662	defined organic	parent	tested chemical	"Tribromoethanol, 2,2,2-"	75-80-9	single chemical compound		"2,2,2-tribromoethanol"	C(Br)(Br)(Br)CO	C(Br)(Br)(Br)CO	"InChI=1/C2H3Br3O/c3-2(4,5)1-6/h6H,1H2"	YFDSDPIBEUFTMI-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anesthetic	100	0.353661039	0.451412782	16	Low	Low	form of drug administered not known			
23699	3699	23699	1159_FDAMDD_v3b	C8H8Cl3N3O4S2	380.65582	defined organic	parent	tested chemical	Trichlormethiazide	133-67-5	single chemical compound		"6-chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide"	C1(S(=O)(=O)N)=C(Cl)C=C2C(=C1)S(=O)(=O)NC(C(Cl)Cl)N2	C1(S(=O)(=O)N)=C(Cl)C=C2C(=C1)S(=O)(=O)NC(C(Cl)Cl)N2	"InChI=1/C8H8Cl3N3O4S2/c9-3-1-4-6(2-5(3)19(12,15)16)20(17,18)14-8(13-4)7(10)11/h1-2,7-8,13-14H,(H2,12,15,16)/f/h12H2"	LMJSLTNSBFUCMU-GAJRPKRDCL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic; antihypertensive	0.0667	0.000175224	3.75640664	53	High	High	form of drug administered not known			
23700	3700	23700	1160_FDAMDD_v3b	C2H4Cl3O4P	229.383521	defined organic	parent	tested chemical	Triclofos	306-52-5	single chemical compound		"2,2,2-trichloroethyl dihydrogen phosphate"	C(C(Cl)(Cl)Cl)OP(O)(=O)O	C(C(Cl)(Cl)Cl)OP(O)(=O)O	"InChI=1/C2H4Cl3O4P/c3-2(4,5)1-9-10(6,7)8/h1H2,(H2,6,7,8)/f/h6-7H"	YYQRGCZGSFRBAM-ZDKSUBDRCH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	33.3	0.145171719	0.838117981	21	Low	Low	form of drug administered not known; Na salt [7246-20-0]			
23701	3701	23701	1161_FDAMDD_v3b	C21H36ClNO	353.96964	defined organic	salt Cl	tested chemical	Tridihexethyl	4310-35-4	single chemical compound	ammonium; parent [60-49-1]	"3-cyclohexyl-N,N,N-triethyl-3-hydroxy-3-phenylpropan-1-aminium chloride"	C2=CC=C(C(O)(CC[N+](CC)(CC)CC)C1CCCCC1)C=C2.[Cl-]	C2=CC=C(C(O)(CC[N+](CC)(CC)CC)C1CCCCC1)C=C2	"InChI=1/C21H36NO.ClH/c1-4-22(5-2,6-3)18-17-21(23,19-13-9-7-10-14-19)20-15-11-8-12-16-20;/h7,9-10,13-14,20,23H,4-6,8,11-12,15-18H2,1-3H3;1H/q+1;/p-1/fC21H36NO.Cl/h;1h/qm;-1"	XJGONMZLEDGBRM-KNSHLIPFCE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic	3.33	0.009407586	2.026521781	34	Moderate	Moderate	form of drug administered not known; parent [60-49-1]; I salt [125-99-5]			
23702	3702	23702	1162_FDAMDD_v3b	C6H18N4	146.2339	defined organic	parent	tested chemical	Trientine	112-24-3	single chemical compound		"N,N'-bis(2-aminoethyl)ethane-1,2-diamine"	NCCNCCNCCN	NCCNCCNCCN	"InChI=1/C6H18N4/c7-1-3-9-5-6-10-4-2-8/h9-10H,1-8H2"	VILCJCGEZXAXTO-UHFFFAOYAI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		chelating agent; treatmemt of Wilson's disease	33.3	0.227717376	0.642603829	18	Low	Low	form of drug administered not known; triethylenetetramine; 2HCl [38260-01-4]			
23703	3703	23703	1163_FDAMDD_v3b	C22H23F4NO2	409.4171328	defined organic	parent	tested chemical	Trifluperidol	749-13-3	single chemical compound		1-(4-fluorophenyl)-4-{4-hydroxy-4-[3-(trifluoromethyl)phenyl]piperidin-1-yl}butan-1-one	C3=C(F)C=CC(C(=O)CCCN2CCC(O)(C1=CC(C(F)(F)F)=CC=C1)CC2)=C3	C3=C(F)C=CC(C(=O)CCCN2CCC(O)(C1=CC(C(F)(F)F)=CC=C1)CC2)=C3	"InChI=1/C22H23F4NO2/c23-19-8-6-16(7-9-19)20(28)5-2-12-27-13-10-21(29,11-14-27)17-3-1-4-18(15-17)22(24,25)26/h1,3-4,6-9,15,29H,2,5,10-14H2"	GPMXUUPHFNMNDH-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	0.133	0.000324852	3.488314372	50	High	High	form of drug administered not known; HCl [2062-77-3]			
23704	3704	23704	1164_FDAMDD_v3b	C18H19F3N2S	352.4170696	defined organic	parent	tested chemical	Triflupromazine	146-54-3	single chemical compound		"N,N-dimethyl-3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propan-1-amine"	C1=CC=C2C(=C1)N(CCCN(C)C)C3=C(S2)C=CC(C(F)(F)F)=C3	C1=CC=C2C(=C1)N(CCCN(C)C)C3=C(S2)C=CC(C(F)(F)F)=C3	"InChI=1/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3"	XSCGXQMFQXDFCW-UHFFFAOYAV	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	2.5	0.007093868	2.149116927	35	Moderate	High-Moderate	form of drug administered not known; HCl [1098-60-8]			
23705	3705	23705	1165_FDAMDD_v3b	C20H31NO	301.46624	defined organic	parent	tested chemical	Trihexyphenidyl	144-11-6	single chemical compound		1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol	C3CC(C(O)(CCN1CCCCC1)C2=CC=CC=C2)CCC3	C3CC(C(O)(CCN1CCCCC1)C2=CC=CC=C2)CCC3	"InChI=1/C20H31NO/c22-20(18-10-4-1-5-11-18,19-12-6-2-7-13-19)14-17-21-15-8-3-9-16-21/h1,4-5,10-11,19,22H,2-3,6-9,12-17H2"	HWHLPVGTWGOCJO-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholinergic; antiparkinsonian	0.25	0.00082928	3.081298676	46	High-Moderate	High	form of drug administered not known; HCl [52-49-3]			
23706	3706	23706	1166_FDAMDD_v3b	C20H27NO3	329.43328	defined organic	parent	tested chemical	Trilostane	13647-35-3	single chemical compound	stereochem	"(4alpha,5alpha,17beta)-3,17-dihydroxy-4,5-epoxyandrost-2-ene-2-carbonitrile"	[C@@]153[C@@H](\C(O)=C(/C[C@@]1([C@H]2CC[C@]4([C@H]([C@@H]2CC3)CC[C@@H]4O)C)C)C#N)O5	[C@@]153[C@@H](\C(O)=C(/C[C@@]1([C@H]2CC[C@]4([C@H]([C@@H]2CC3)CC[C@@H]4O)C)C)C#N)O5	"InChI=1/C20H27NO3/c1-18-7-6-14-12(13(18)3-4-15(18)22)5-8-20-17(24-20)16(23)11(10-21)9-19(14,20)2/h12-15,17,22-23H,3-9H2,1-2H3/t12-,13-,14-,15-,17+,18-,19+,20+/m0/s1"	KVJXBPDAXMEYOA-CXANFOAXBX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		adrenocortical suppressant; treatment of breast cancer	8	0.024284128	1.614677483	29	Low-Moderate	Low	form of drug administered not known			
23707	3707	23707	1167_FDAMDD_v3b	C22H29NO5	387.46936	defined organic	parent	tested chemical	Trimebutine	39133-31-8	single chemical compound		"2-(dimethylamino)-2-phenylbutyl 3,4,5-tris(methyloxy)benzoate"	C2(OC)=C(OC)C(OC)=CC(C(=O)OCC(CC)(N(C)C)C1=CC=CC=C1)=C2	C2(OC)=C(OC)C(OC)=CC(C(=O)OCC(CC)(N(C)C)C1=CC=CC=C1)=C2	"InChI=1/C22H29NO5/c1-7-22(23(2)3,17-11-9-8-10-12-17)15-28-21(24)16-13-18(25-4)20(27-6)19(14-16)26-5/h8-14H,7,15H2,1-6H3"	LORDFXWUHHSAQU-UHFFFAOYAO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antispasmodic	10	0.025808492	1.588237365	29	Low-Moderate	Low	form of drug administered not known; maleate [34140-59-5]			
23708	3708	23708	1168_FDAMDD_v3b	C18H22N2S	298.44568	defined organic	parent	tested chemical	Trimeprazine	84-96-8	single chemical compound		"N,N,2-trimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine"	C1=CC=C2C(=C1)N(CC(C)CN(C)C)C3=C(S2)C=CC=C3	C1=CC=C2C(=C1)N(CC(C)CN(C)C)C3=C(S2)C=CC=C3	"InChI=1/C18H22N2S/c1-14(12-19(2)3)13-20-15-8-4-6-10-17(15)21-18-11-7-5-9-16(18)20/h4-11,14H,12-13H2,1-3H3"	ZZHLYYDVIOPZBE-UHFFFAOYAQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipruritic	1.67	0.005595658	2.252148826	36	Moderate	High	form of drug administered not known; tartrate [41375-66-0; 4330-99-8]			
23709	1396	21396	1169_FDAMDD_v3b	C6H9NO3	143.142	defined organic	parent	tested chemical	Trimethadione	127-48-0	single chemical compound		"3,5,5-trimethyl-1,3-oxazolidine-2,4-dione"	CC1(C(=O)N(C)C(=O)O1)C	CC1(C(=O)N(C)C(=O)O1)C	InChI=1/C6H9NO3/c1-6(2)4(8)7(3)5(9)10-6/h1-3H3	IRYJRGCIQBGHIV-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	40	0.279442791	0.55370709	17	Low	Low	form of drug administered not known			
23710	3710	23710	1170_FDAMDD_v3b	C32H40N2O5S2	596.8004	defined organic	complex camphorsulfanate (C10H15O4S)	tested chemical	Trimethaphan	68-91-7	single chemical compound		"2-oxo-1,3-bis(phenylmethyl)decahydrothieno[1',2':1,2]thieno[3,4-d]imidazol-5-ium (7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)methanesulfonate"	[O-]S(=O)(=O)CC12CCC(CC1=O)C2(C)C.O=C5N(Cc1ccccc1)C3C[S+]2CCCC2C3N5Cc4ccccc4	O=C5N(Cc1ccccc1)C3C[S+]2CCCC2C3N5Cc4ccccc4	"InChI=1/C22H25N2OS.C10H16O4S/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18;1-9(2)7-3-4-10(9,8(11)5-7)6-15(12,13)14/h1-6,8-11,19-21H,7,12-16H2;7H,3-6H2,1-2H3,(H,12,13,14)/q+1;/p-1/fC22H25N2OS.C10H15O4S/qm;-1"	HALWUDBBYKMYPW-IYVLAKBACQ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	0.0667	0.000111763	3.951703272	55	High	High	form of drug administered not known			
23711	3711	23711	1171_FDAMDD_v3b	C21H28N2O5	388.45742	defined organic	parent	tested chemical	Trimethobenzamide	138-56-7	single chemical compound		"N-[(4-{[2-(dimethylamino)ethyl]oxy}phenyl)methyl]-3,4,5-tris(methyloxy)benzamide"	C2=C(OCCN(C)C)C=CC(CNC(=O)C1=CC(OC)=C(OC)C(OC)=C1)=C2	C2=C(OCCN(C)C)C=CC(CNC(=O)C1=CC(OC)=C(OC)C(OC)=C1)=C2	"InChI=1/C21H28N2O5/c1-23(2)10-11-28-17-8-6-15(7-9-17)14-22-21(24)16-12-18(25-3)20(27-5)19(13-16)26-4/h6-9,12-13H,10-11,14H2,1-5H3,(H,22,24)/f/h22H"	FEZBIKUBAYAZIU-QWOVJGMICI	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiemetic	16.7	0.042990555	1.36662695	26	Low-Moderate	Low	form of drug administered not known; HCl [554-92-7]			
23712	3712	23712	1172_FDAMDD_v3b	C14H18N4O3	290.3177	defined organic	parent	tested chemical	Trimethoprim	738-70-5	single chemical compound		"5-{[3,4,5-tris(methyloxy)phenyl]methyl}pyrimidine-2,4-diamine"	C2(OC)=C(OC)C=C(CC1=C(N)N=C(N)N=C1)C=C2OC	C2(OC)=C(OC)C=C(CC1=C(N)N=C(N)N=C1)C=C2OC	"InChI=1/C14H18N4O3/c1-19-10-5-8(6-11(20-2)12(10)21-3)4-9-7-17-14(16)18-13(9)15/h5-7H,4H2,1-3H3,(H4,15,16,17,18)/f/h15-16H2"	IEDVJHCEMCRBQM-CLRGVMNRCM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	5.33	0.018359198	1.736146306	31	Moderate	Low	form of drug administered not known; with lactic acid [23256-42-0]; sulfate [56585-33-2]			
23713	3713	23713	1173_FDAMDD_v3b	C14H19NO5	281.30436	defined organic	parent	tested chemical	Trimetozine	635-41-6	single chemical compound		"4-{[3,4,5-tris(methyloxy)phenyl]carbonyl}morpholine"	C2OCCN(C(=O)C1=CC(OC)=C(OC)C(OC)=C1)C2	C2OCCN(C(=O)C1=CC(OC)=C(OC)C(OC)=C1)C2	"InChI=1/C14H19NO5/c1-17-11-8-10(9-12(18-2)13(11)19-3)14(16)15-4-6-20-7-5-15/h8-9H,4-7H2,1-3H3"	XWVOEFLBOSSYGM-UHFFFAOYAS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative	50	0.177743424	0.750206459	20	Low	Low	form of drug administered not known			
23714	3714	23714	1174_FDAMDD_v3b	C19H23N5O3	369.41762	defined organic	parent	tested chemical	Trimetrexate	52128-35-5	single chemical compound		"5-methyl-6-({[3,4,5-tris(methyloxy)phenyl]amino}methyl)quinazoline-2,4-diamine"	C2=C(CNC1=CC(OC)=C(OC)C(OC)=C1)C(C)=C3C(=C2)N=C(N)N=C3N	C2=C(CNC1=CC(OC)=C(OC)C(OC)=C1)C(C)=C3C(=C2)N=C(N)N=C3N	"InChI=1/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)/f/h20-21H2"	NOYPYLRCIDNJJB-WAVZXACUCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	1.22	0.003302495	2.481157775	39	Moderate	High	form of drug administered not known; glucuronate [82952-64-5]			
23715	3715	23715	1175_FDAMDD_v3b	C20H26N2	294.43384	defined organic	parent	tested chemical	Trimipramine	739-71-9	single chemical compound		"3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine"	N1(CC(C)CN(C)C)C3=C(CCC2=C1C=CC=C2)C=CC=C3	N1(CC(C)CN(C)C)C3=C(CCC2=C1C=CC=C2)C=CC=C3	"InChI=1/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3"	ZSCDBOWYZJWBIY-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	3.33	0.011309841	1.94654349	33	Moderate	Moderate	form of drug administered not known; maleate [521-78-8]			
23716	3716	23716	1176_FDAMDD_v3b	C14H12O3	228.24328	defined organic	parent	tested chemical	Trioxsalen	3902-71-4	single chemical compound		"2,5,9-trimethyl-7H-furo[3,2-g]chromen-7-one"	C1(=O)C=C(C)C2=C(O1)C(C)=C3C(=C2)C=C(C)O3	C1(=O)C=C(C)C2=C(O1)C(C)=C3C(=C2)C=C(C)O3	"InChI=1/C14H12O3/c1-7-4-12(15)17-14-9(3)13-10(6-11(7)14)5-8(2)16-13/h4-6H,1-3H3"	FMHHVULEAZTJMA-UHFFFAOYAF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		pigmentation agent	0.167	0.000731675	3.135681529	46	High-Moderate	High	form of drug administered not known			
23717	3717	23717	1177_FDAMDD_v3b	C16H21N3	255.35804	defined organic	parent	tested chemical	Tripelennamine	91-81-6	single chemical compound		"N,N-dimethyl-N'-(phenylmethyl)-N'-pyridin-2-ylethane-1,2-diamine"	C2=CC=CC(CN(CCN(C)C)C1=NC=CC=C1)=C2	C2=CC=CC(CN(CCN(C)C)C1=NC=CC=C1)=C2	"InChI=1/C16H21N3/c1-18(2)12-13-19(16-10-6-7-11-17-16)14-15-8-4-3-5-9-15/h3-11H,12-14H2,1-2H3"	UFLGIAIHIAPJJC-UHFFFAOYAZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	10	0.039160702	1.407149536	27	Low-Moderate	Low	form of drug administered not known; citrate [6138-56-3]; HCl [154-69-8]			
23718	3718	23718	1178_FDAMDD_v3b	C19H22N2	278.3914	defined organic	parent	tested chemical	Triprolidine	486-12-4	single chemical compound	stereochem	2-[(1Z)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridine	C3=CC=NC(C(=CCN1CCCC1)C2=CC=C(C)C=C2)=C3	C3=CC=NC(C(=CCN1CCCC1)C2=CC=C(C)C=C2)=C3	"InChI=1/C19H22N2/c1-16-7-9-17(10-8-16)18(19-6-2-3-12-20-19)11-15-21-13-4-5-14-21/h2-3,6-12H,4-5,13-15H2,1H3/b18-11-"	CBEQULMOCCWAQT-WQRHYEAKBP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihistaminic	0.167	0.000599875	3.221939344	47	High-Moderate	High	form of drug administered not known; HCl H2O [6138-79-0]; HCl [550-70-9]			
23719	3719	23719	1179_FDAMDD_v3b	C24H27NO5S	441.5399	defined organic	parent	tested chemical	Troglitazone	97322-87-7	single chemical compound		"5-[(4-{[(6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromen-2-yl)methyl]oxy}phenyl)methyl]-1,3-thiazolidine-2,4-dione"	C1(C)=C(O)C(C)=C4C(=C1C)OC(C)(COC3=CC=C(CC2SC(=O)NC2=O)C=C3)CC4	C1(C)=C(O)C(C)=C4C(=C1C)OC(C)(COC3=CC=C(CC2SC(=O)NC2=O)C=C3)CC4	"InChI=1/C24H27NO5S/c1-13-14(2)21-18(15(3)20(13)26)9-10-24(4,30-21)12-29-17-7-5-16(6-8-17)11-19-22(27)25-23(28)31-19/h5-8,19,26H,9-12H2,1-4H3,(H,25,27,28)/f/h25H"	GXPHKUHSUJUWKP-LNNLXFCOCP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidiabetic	10	0.02264801	1.644969955	30	Moderate	Low	form of drug administered not known			
23720	1392	21392	1180_FDAMDD_v3b	C6H15NO3	149.1882	defined organic	parent	tested chemical	Trolamine	102-71-6	single chemical compound		"2,2',2''-nitrilotriethanol"	OCCN(CCO)CCO	OCCN(CCO)CCO	"InChI=1/C6H15NO3/c8-4-1-7(2-5-9)3-6-10/h8-10H,1-6H2"	GSEJCLTVZPLZKY-UHFFFAOYAL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic	10	0.06702943	1.173734474	24	Low	Low	form of drug administered not known; Trolamine; HCl [637-39-8]; phosphate [10017-56-8]; acetate [14806-72-5]; titanium salt [15879-01-3]; sulfate [20261-61-4; 7376-31-0]; citrate [29340-81-6]; copper salt [31089-39-1]; maleate [41397-50-6]; citrate [571			
23721	3721	23721	1181_FDAMDD_v3b	C41H67NO15	813.9684	defined organic	parent	tested chemical	Troleandomycin	2751-09-9	single chemical compound	stereochem	"(3S,5R,6S,7S,8R,11R,12S,13R,14S,15S)-12-[(4-O-acetyl-2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)oxy]-14-{[2-O-acetyl-3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-5,7,8,11,13,15-hexamethyl-4,10-dioxo-1,9-dioxaspiro[2.13]hexadec-6-yl acetate"	[C@@]14(C[C@@H]([C@@H]([C@@H](C)[C@@H]([C@H](C(O[C@@H]([C@@H]([C@H](OC(=O)C)[C@H](C1=O)C)C)C)=O)C)O[C@H]2C[C@@H]([C@H]([C@@H](O2)C)OC(=O)C)OC)O[C@@H]3O[C@@H](C[C@@H]([C@H]3OC(=O)C)N(C)C)C)C)OC4	[C@@]14(C[C@@H]([C@@H]([C@@H](C)[C@@H]([C@H](C(O[C@@H]([C@@H]([C@H](OC(=O)C)[C@H](C1=O)C)C)C)=O)C)O[C@H]2C[C@@H]([C@H]([C@@H](O2)C)OC(=O)C)OC)O[C@@H]3O[C@@H](C[C@@H]([C@H]3OC(=O)C)N(C)C)C)C)OC4	"InChI=1/C41H67NO15/c1-19-17-41(18-49-41)38(46)23(5)34(53-27(9)43)21(3)25(7)52-39(47)24(6)35(56-32-16-31(48-14)36(26(8)51-32)54-28(10)44)22(4)33(19)57-40-37(55-29(11)45)30(42(12)13)15-20(2)50-40/h19-26,30-37,40H,15-18H2,1-14H3/t19-,20+,21-,22+,23+,24+,25+,26-,30-,31-,32-,33-,34-,35-,36-,37+,40-,41-/m0/s1"	LQCLVBQBTUVCEQ-MCQAQMIOBT	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	33.3	0.040910679	1.388163311	27	Low-Moderate	Low	form of drug administered not known			
23722	3722	23722	1182_FDAMDD_v3b	C6H12N4O9	284.18088	defined organic	parent	tested chemical	Trolnitrate	7077-34-1	single chemical compound		"nitrilotriethane-2,1-diyl trinitrate"	O=[N+]([O-])OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O	O=[N+]([O-])OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O	InChI=1/C6H12N4O9/c11-8(12)17-4-1-7(2-5-18-9(13)14)3-6-19-10(15)16/h1-6H2	HWKQNAWCHQMZHK-UHFFFAOYAG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		vasodilator	0.267	0.000939542	3.027083593	45	High-Moderate	High	form of drug administered not known; phosphate [588-42-1]			
23723	3723	23723	1183_FDAMDD_v3b	C4H11NO3	121.135	defined organic	parent	tested chemical	Tromethamine	77-86-1	single chemical compound		"2-amino-2-(hydroxymethyl)propane-1,3-diol"	NC(CO)(CO)CO	NC(CO)(CO)CO	"InChI=1/C4H11NO3/c5-4(1-6,2-7)3-8/h6-8H,1-3,5H2"	LENZDBCJOHFCAS-UHFFFAOYAN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		alkalizer	300	2.476575721	-0.393851611	7	Low	Low	form of drug administered not known			
23724	3724	23724	1184_FDAMDD_v3b	C25H30ClNO3	427.9636	defined organic	salt Cl	tested chemical	Trospium chloride	10405-02-4	single chemical compound	ammonium; stereochem	"3-((hydroxydiphenylacetyl)oxy)-spiro(8-azoniabicyclo(3.2.1)octane-8,1'-pyrrolidinium chloride"	[Cl-].OC(c1ccccc1)(c2ccccc2)C(=O)O[C@@H]3C[C@@H]5CC[C@H](C3)[N+]45CCCC4	OC(c1ccccc1)(c2ccccc2)C(=O)O[C@@H]3C[C@@H]5CC[C@H](C3)[N+]45CCCC4	"InChI=1/C25H30NO3.ClH/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26;/h1-6,9-12,21-23,28H,7-8,13-18H2;1H/q+1;/p-1/t21-,22+,23+;/fC25H30NO3.Cl/h;1h/qm;-1"	RVCSYOQWLPPAOA-UKUBMBCHDW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antispasmodic	0.2	0.000467329	3.330376836	48	High-Moderate	High	form of drug administered not known			
23725	3725	23725	1185_FDAMDD_v3b	C15H22N2O4	294.34618	defined organic	parent	tested chemical	Troxipide	30751-05-4	single chemical compound		"3,4,5-tris(methyloxy)-N-piperidin-3-ylbenzamide"	C2(C(=O)NC1CNCCC1)=CC(OC)=C(OC)C(OC)=C2	C2(C(=O)NC1CNCCC1)=CC(OC)=C(OC)C(OC)=C2	"InChI=1/C15H22N2O4/c1-19-12-7-10(8-13(20-2)14(12)21-3)15(18)17-11-5-4-6-16-9-11/h7-8,11,16H,4-6,9H2,1-3H3,(H,17,18)/f/h17H"	YSIITVVESCNIPR-HCKMINDGCG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiulcerative	5	0.016986801	1.7698884	31	Moderate	Low	form of drug administered not known; HCl hemihydrate (unknown CAS)			
23726	1419	21419	1186_FDAMDD_v3b	C11H12N2O2	204.2252	defined organic	parent	tested chemical	Tryptophan	73-22-3	single chemical compound	stereochem	L-tryptophan	O=C(O)[C@@H](N)CC1=CNC2=C1C=CC=C2	O=C(O)[C@@H](N)CC1=CNC2=C1C=CC=C2	"InChI=1/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1/f/h14H"	QIVBCDIJIAJPQS-FKOBDKTLDJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant; nutrient	100	0.489655537	0.31010933	15	Low	Low	form of drug administered not known			
23727	3727	23727	1187_FDAMDD_v3b	C37H42Cl2N2O6	681.64518	defined organic	salt 2Cl	tested chemical	Tubocurarine	57-94-3	single chemical compound	ammonium; stereochem; parent [1370-17-8]	"2,2',2'-trimethyl-6,6'-bis(methyloxy)tubocuraran-2,2'-diium-7',12'-diol dichloride"	[Cl-].[Cl-].Oc7ccc1cc7Oc6cc5c(CC[NH+](C)[C@H]5Cc4ccc(Oc3c2c(CC[N+](C)(C)[C@@H]2C1)cc(OC)c3O)cc4)cc6OC	Oc7ccc1cc7Oc6cc5c(CC[NH+](C)[C@H]5Cc4ccc(Oc3c2c(CC[N+](C)(C)[C@@H]2C1)cc(OC)c3O)cc4)cc6OC	"InChI=1/C37H40N2O6.2ClH/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33;;/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41);2*1H/t28-,29+;;/m0../s1/fC37H42N2O6.2Cl/h38,40-41H;2*1h/q+2;2*-1"	GXFZCDMWGMFGFL-HXOWSAKRDW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant; diagnostic aid	0.667	0.000978515	3.009432534	45	High-Moderate	High	form of drug administered not known; parent [1370-17-8; 57-94-3];HCl 5H2O [41354-45-4]; HCl [6159-33-7]			
23728	3728	23728	1188_FDAMDD_v3b	C13H26N2O4	274.35654	defined organic	parent	tested chemical	Tybamate	4268-36-4	single chemical compound		2-[(carbamoyloxy)methyl]-2-methylpentyl butylcarbamate	CCCCNC(=O)OCC(C)(COC(N)=O)CCC	CCCCNC(=O)OCC(C)(COC(N)=O)CCC	"InChI=1/C13H26N2O4/c1-4-6-8-15-12(17)19-10-13(3,7-5-2)9-18-11(14)16/h4-10H2,1-3H3,(H2,14,16)(H,15,17)/f/h15H,14H2"	PRBORDFJHHAISJ-NLMIROKBCZ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anxiolytic	50	0.182244608	0.739345313	19	Low	Low	form of drug administered not known			
23729	3729	23729	1189_FDAMDD_v3b	C15H17I3NNaO3	663.00356	defined organic	salt Na	tested chemical	Tyropanoic acid	7246-21-1	single chemical compound		"sodium 2-{[3-(butanoylamino)-2,4,6-triiodophenyl]methyl}butanoate"	[Na+].Ic1c(NC(=O)CCC)c(I)cc(I)c1CC(CC)C([O-])=O	Ic1c(NC(=O)CCC)c(I)cc(I)c1CC(CC)C(O)=O	"InChI=1/C15H18I3NO3.Na/c1-3-5-12(20)19-14-11(17)7-10(16)9(13(14)18)6-8(4-2)15(21)22;/h7-8H,3-6H2,1-2H3,(H,19,20)(H,21,22);/q;+1/p-1/fC15H17I3NO3.Na/h19H;/q-1;m"	KTVKGXZZBQCBGD-HENOKVKCCK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diagnostic aid	50	0.075414376	1.122545856	24	Low	Low	form of drug administered not known			
23730	3730	23730	1190_FDAMDD_v3b	C9H11NO3	181.18854	defined organic	parent	tested chemical	Tyrosine	60-18-4	single chemical compound	stereochem	L-tyrosine	Oc1ccc(C[C@H](N)C(O)=O)cc1	Oc1ccc(C[C@H](N)C(O)=O)cc1	"InChI=1/C9H11NO3/c10-8(9(12)13)5-6-1-3-7(11)4-2-6/h1-4,8,11H,5,10H2,(H,12,13)/t8-/m0/s1/f/h12H"	OUYCCCASQSFEME-QAXLLPJCDY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		none	100	0.551911285	0.258130726	14	Low	Low	form of drug administered not known; d-form [556-02-5]; dl-tyrosine [556-03-6]			
23731	3731	23731	1191_FDAMDD_v3b	C24H40O4	392.572	defined organic	parent	tested chemical	Ursodiol	128-13-2	single chemical compound	stereochem	"(3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid"	[C@@]43([C@H]([C@H]2[C@@H]([C@@]1([C@@H](C[C@@H](CC1)O)C[C@@H]2O)C)CC3)CC[C@@H]4[C@@H](CCC(=O)O)C)C	[C@@]43([C@H]([C@H]2[C@@H]([C@@]1([C@@H](C[C@@H](CC1)O)C[C@@H]2O)C)CC3)CC[C@@H]4[C@@H](CCC(=O)O)C)C	"InChI=1/C24H40O4/c1-14(4-7-21(27)28)17-5-6-18-22-19(9-11-24(17,18)3)23(2)10-8-16(25)12-15(23)13-20(22)26/h14-20,22,25-26H,4-13H2,1-3H3,(H,27,28)/t14-,15+,16-,17-,18+,19+,20+,22+,23+,24-/m1/s1/f/h27H"	RUDATBOHQWOJDD-QERVUZFQDS	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticholelithogenic	10	0.025473034	1.593919321	29	Low-Moderate	Low	form of drug administered not known			
23732	3732	23732	1192_FDAMDD_v3b	C13H20N6O4	324.3357	defined organic	parent	tested chemical	Valacyclovir	124832-26-4	single chemical compound	stereochem; tautomers	"2-{[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methyl]oxy}ethyl L-valinate"	CC(C)[C@H](N)C(=O)OCCOCn2cnc1c2\N=C(\N)NC1=O	CC(C)[C@H](N)C(=O)OCCOCn2cnc1c2\N=C(\N)NC1=O	"InChI=1/C13H20N6O4/c1-7(2)8(14)12(21)23-4-3-22-6-19-5-16-9-10(19)17-13(15)18-11(9)20/h5,7-8H,3-4,6,14H2,1-2H3,(H3,15,17,18,20)/t8-/m0/s1/f/h18H,15H2"	HDOVUKNUBWVHOX-ALYQVPJWDE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiviral	50	0.154161259	0.81202475	20	Low	Low	form of drug administered not known; HCl [124832-27-5]			
23733	3733	23733	1193_FDAMDD_v3b	C8H16O2	144.2114	defined organic	parent	tested chemical	Valproic acid	99-66-1	single chemical compound		2-propylpentanoic acid	C(=O)(O)C(CCC)CCC	C(=O)(O)C(CCC)CCC	"InChI=1/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)/f/h9H"	NIJJYAXOARWZEE-BGGKNDAXCP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant; antiepileptic	41.7	0.289158832	0.538863538	17	Low	Low	form of drug administered not known; Na salt [1069-66-5]			
23734	3734	23734	1194_FDAMDD_v3b	C8H17NO	143.22668	defined organic	parent	tested chemical	Valpromide	2430-27-5	single chemical compound		2-propylpentanamide	CCCC(C(N)=O)CCC	CCCC(C(N)=O)CCC	"InChI=1/C8H17NO/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H2,9,10)/f/h9H2"	OMOMUFTZPTXCHP-JSGPKCTECG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticonvulsant	33.3	0.232498582	0.633579692	18	Low	Low	form of drug administered not known			
23735	3735	23735	1195_FDAMDD_v3b	C24H29N5O3	435.51876	defined organic	parent	tested chemical	Valsartan	137862-53-4	single chemical compound	stereochem	N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-D-valine	OC(=O)[C@@H](C(C)C)N(Cc1ccc(cc1)c2ccccc2C\3=N\N=N/N/3)C(=O)CCCC	OC(=O)[C@@H](C(C)C)N(Cc1ccc(cc1)c2ccccc2C\3=N\N=N/N/3)C(=O)CCCC	"InChI=1/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m1/s1/f/h25,31H"	ACWBQPMHZXGDFX-XGTKQLMADF	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antihypertensive	5.33	0.012238279	1.912279658	33	Moderate	Low	form of drug administered not known			
23736	3736	23736	1196_FDAMDD_v3b	C34H57BrN2O4	637.73138	defined organic	salt Br	tested chemical	Vecuronium bromide	50700-72-6	single chemical compound	ammonium; stereochem	"(3alpha,5alpha)-3,17-bis(acetyloxy)-16-(1-methylpiperidinium-1-yl)-2-piperidin-1-ylandrostane bromide"	[C@@]54([C@H]([C@H]3[C@@H]([C@]2(CC(N1CCCCC1)[C@H](C[C@@H]2CC3)OC(=O)C)C)CC4)CC(C5OC(=O)C)[N+]6(C)CCCCC6)C.[Br-]	[C@@]54([C@H]([C@H]3[C@@H]([C@]2(CC(N1CCCCC1)[C@H](C[C@@H]2CC3)OC(=O)C)C)CC4)CC(C5OC(=O)C)[N+]6(C)CCCCC6)C	"InChI=1/C34H57N2O4.BrH/c1-23(37)39-31-20-25-12-13-26-27(34(25,4)22-29(31)35-16-8-6-9-17-35)14-15-33(3)28(26)21-30(32(33)40-24(2)38)36(5)18-10-7-11-19-36;/h25-32H,6-22H2,1-5H3;1H/q+1;/p-1/t25-,26+,27-,28-,29?,30?,31-,32?,33-,34-;/m0./s1/fC34H57N2O4.Br/h;1h/qm;-1"	VEPSYABRBFXYIB-FERNDZDODU	Clinical Reports 	Maximum Recommended Daily Dose	human	1		skeletal muscle relaxant	0.1	0.000156806	3.804637787	54	High	High	form of drug administered not known			
23737	3737	23737	1197_FDAMDD_v3b	C17H27NO2	277.40178	defined organic	parent	tested chemical	Venlafaxine	93413-69-5	single chemical compound		1-{2-(dimethylamino)-1-[4-(methyloxy)phenyl]ethyl}cyclohexanol	C(C1(O)CCCCC1)(C2C=CC(OC)=CC=2)CN(C)C	C(C1(O)CCCCC1)(C2C=CC(OC)=CC=2)CN(C)C	"InChI=1/C17H27NO2/c1-18(2)13-16(17(19)11-5-4-6-12-17)14-7-9-15(20-3)10-8-14/h7-10,16,19H,4-6,11-13H2,1-3H3"	PNVNVHUZROJLTJ-UHFFFAOYAJ	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antidepressant	6.25	0.022530497	1.647229226	30	Moderate	Low	form of drug administered not known; HCl [ 99300-78-4]			
23738	3738	23738	1198_FDAMDD_v3b	C11H16N2O3	224.25634	defined organic	parent	tested chemical	Vinbarbital	125-42-8	single chemical compound	stereochem	"5-ethyl-5-[(1E)-1-methylbut-1-en-1-yl]pyrimidine-2,4,6(1H,3H,5H)-trione"	C1(=O)C(CC)(C(C)=CCC)C(=O)NC(=O)N1	C1(=O)C(CC)(C(C)=CCC)C(=O)NC(=O)N1	"InChI=1/C11H16N2O3/c1-4-6-7(3)11(5-2)8(14)12-10(16)13-9(11)15/h6H,4-5H2,1-3H3,(H2,12,13,14,15,16)/b7-6+/f/h12-13H"	RAFOHKSPUDGZPR-QVNHUIMEDH	Clinical Reports 	Maximum Recommended Daily Dose	human	1		sedative; hypnotic	3.33	0.014849079	1.828300496	32	Moderate	Moderate	form of drug administered not known; Na salt [125-44-0]			
23739	3739	23739	1199_FDAMDD_v3b	C43H55N5O7	753.9261	defined organic	parent	tested chemical	Vindesine	53643-48-4	single chemical compound	stereochem; tautomers	"methyl (5S,7S,9S)-9-[(2b,3b,4b,5a,12b,19a)-3-carbamoyl-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidin-15-yl]-5-ethyl-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indole-9-carboxylate"	O[C@@H]([C@](O)(C(N)=O)[C@@]([H])3N(C)C5=C4C=C([C@@]6([C@](OC)=O)C[C@H](C9)C[C@](CC)(O)CN9CCC7=C6NC8=C7C=CC=C8)C(OC)=C5)[C@]1(CC)C=CCN2[C@@]([H])1[C@]34CC2	O[C@@H]([C@](O)(C(N)=O)[C@@]([H])3N(C)C5=C4C=C([C@@]6([C@](OC)=O)C[C@H](C9)C[C@](CC)(O)CN9CCC7=C6NC8=C7C=CC=C8)C(OC)=C5)[C@]1(CC)C=CCN2[C@@]([H])1[C@]34CC2	"InChI=1/C43H55N5O7/c1-6-39(52)21-25-22-42(38(51)55-5,33-27(13-17-47(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)54-4)46(3)35-41(28)15-18-48-16-10-14-40(7-2,34(41)48)36(49)43(35,53)37(44)50/h8-12,14,19-20,25,34-36,45,49,52-53H,6-7,13,15-18,21-24H2,1-5H3,(H2,44,50)/t25-,34+,35-,36-,39+,40-,41-,42+,43+/m1/s1/f/h44H2"	HHJUWIANJFBDHT-ZRQMQZBUDE	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	0.108	0.00014325	3.843905023	54	High	High	form of drug administered not known; sulfate [59917-39-4]; structure modified v3b			
23740	3740	23740	1200_FDAMDD_v3b	C22H26N2O2	350.45404	defined organic	parent	tested chemical	Vinpocetine	42971-09-5	single chemical compound	stereochem	"ethyl (3alpha,16alpha)-eburnamenine-14-carboxylate"	n\24c1c(CCN3[C@H]1[C@](/C=C/2C(=O)OCC)(CCC3)CC)c5c4cccc5	n\24c1c(CCN3[C@H]1[C@](/C=C/2C(=O)OCC)(CCC3)CC)c5c4cccc5	"InChI=1/C22H26N2O2/c1-3-22-11-7-12-23-13-10-16-15-8-5-6-9-17(15)24(19(16)20(22)23)18(14-22)21(25)26-4-2/h5-6,8-9,14,20H,3-4,7,10-13H2,1-2H3/t20-,22+/m1/s1"	DDNCQMVWWZOMLN-IRLDBZIGBY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		cerebral vasodilator	0.5	0.001426721	2.845661067	43	Moderate	High	form of drug administered not known			
23741	3741	23741	1201_FDAMDD_v3b	C25H43N13O10	685.69002	defined organic	parent	tested chemical	Viomycin	32988-50-4	single chemical compound	stereochem; tautomers	"(3S)-3,6-diamino-N-[(3S,6Z,9S,12S,15S)-6-{[(aminocarbonyl)amino]methylidene}-3-[(4R,6S)-2-amino-6-hydroxy-3,4,5,6-tetrahydropyrimidin-4-yl]-9,12-bis(hydroxymethyl)-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentaazacyclohexadecan-15-yl]hexanamide"	C1(/NC(C(NC(C(NC(C(CNC(C(NC1=O)[C@@H]2NC(=N)N[C@H](C2)O)=O)NC(CC(CCCN)N)=O)=O)CO)=O)CO)=O)=C/NC(=O)N	C1(/NC(C(NC(C(NC(C(CNC(C(NC1=O)[C@@H]2NC(=N)N[C@H](C2)O)=O)NC(CC(CCCN)N)=O)=O)CO)=O)CO)=O)=C/NC(=O)N	"InChI=1/C25H43N13O10/c26-3-1-2-10(27)4-16(41)32-12-6-30-23(47)18(11-5-17(42)37-24(28)36-11)38-20(44)13(7-31-25(29)48)33-21(45)14(8-39)35-22(46)15(9-40)34-19(12)43/h7,10-12,14-15,17-18,39-40,42H,1-6,8-9,26-27H2,(H,30,47)(H,32,41)(H,33,45)(H,34,43)(H,35,46)(H,38,44)(H3,28,36,37)(H3,29,31,48)/b13-7-/t10-,11+,12-,14-,15-,17-,18-/m0/s1/f/h30-36,38H,28-29H2"	GXFAIFRPOKBQRV-WPJYROCYDN	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antibacterial	66.7	0.097274276	1.012001995	22	Low	Low	form of drug administered not known; sulfate [37883-00-4]			
23742	3742	23742	1202_FDAMDD_v3b	C19H16O4	308.3279	defined organic	parent	tested chemical	Warfarin	81-81-2	single chemical compound	tautomers	4-hydroxy-3-(3-oxo-1-phenylbutyl)-2H-chromen-2-one	C1=CC=C3C(=C1)OC(=O)C(C(CC(C)=O)C2=CC=CC=C2)=C3O	C1=CC=C3C(=C1)OC(=O)C(C(CC(C)=O)C2=CC=CC=C2)=C3O	"InChI=1/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3"	PJVWKTKQMONHTI-UHFFFAOYAW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anticoagulant	0.167	0.000541631	3.266296354	48	High-Moderate	High	form of drug administered not known; K salt [2610-86-8]; Na salt [129-06-6]			
23743	3743	23743	1203_FDAMDD_v3b	C19H26N6O6	434.44634	defined organic	complex nicotinate (C6H4NO2)	tested chemical	Xanthinol niacinate	437-74-1	single chemical compound		"pyridine-3-carboxylic acid - 7-{2-hydroxy-3-[(2-hydroxyethyl)(methyl)amino]propyl}-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione (1:1)"	OC(=O)c1cccnc1.OCCN(C)CC(O)Cn2cnc1N(C)C(=O)N(C)C(=O)c12	OCCN(C)CC(O)Cn2cnc1N(C)C(=O)N(C)C(=O)c12	"InChI=1/C13H21N5O4.C6H5NO2/c1-15(4-5-19)6-9(20)7-18-8-14-11-10(18)12(21)17(3)13(22)16(11)2;8-6(9)5-2-1-3-7-4-5/h8-9,19-20H,4-7H2,1-3H3;1-4H,(H,8,9)/f/h;8H"	GEPMAHVDJHFBJI-JBXJCYQCCY	Clinical Reports 	Maximum Recommended Daily Dose	human	1		peripheral vasodilator	25	0.057544506	1.239996134	25	Low-Moderate	Low	form of drug administered not known; 2HCl [437-74-1]; HCl [17162-32-2]			
23744	3744	23744	1204_FDAMDD_v3b	C15H15ClN2O4S	354.8086	defined organic	parent	tested chemical	Xipamide	14293-44-8	single chemical compound		"5-(aminosulfonyl)-4-chloro-N-(2,6-dimethylphenyl)-2-hydroxybenzamide"	C2(S(N)(=O)=O)=C(Cl)C=C(O)C(C(=O)NC1=C(C)C=CC=C1C)=C2	C2(S(N)(=O)=O)=C(Cl)C=C(O)C(C(=O)NC1=C(C)C=CC=C1C)=C2	"InChI=1/C15H15ClN2O4S/c1-8-4-3-5-9(2)14(8)18-15(20)10-6-13(23(17,21)22)11(16)7-12(10)19/h3-7,19H,1-2H3,(H,18,20)(H2,17,21,22)/f/h18H,17H2"	MTZBBNMLMNBNJL-VRGMUVNCCK	Clinical Reports 	Maximum Recommended Daily Dose	human	1		diuretic; antihypertensive	0.667	0.001879887	2.725868304	42	Moderate	High	form of drug administered not known			
23745	3745	23745	1205_FDAMDD_v3b	C5H10O5	150.1299	defined organic	parent	tested chemical	Xylose	58-86-6	single chemical compound	stereochem	D-xylopyranose	C1([C@@H]([C@H]([C@@H](CO1)O)O)O)O	C1([C@@H]([C@H]([C@@H](CO1)O)O)O)O	"InChI=1/C5H10O5/c6-2-1-10-5(9)4(8)3(2)7/h2-9H,1H2/t2-,3+,4-,5?/m1/s1"	SRBFZHDQGSBBOR-IOVATXLUBL	Clinical Reports 	Maximum Recommended Daily Dose	human	1		intestinal function diagnostic aid	417	2.777594603	-0.44366886	6	Low	Low	form of drug administered not known			
23746	3746	23746	1206_FDAMDD_v3b	C31H33N3O6S	575.67522	defined organic	parent	tested chemical	Zafirlukast	107753-78-6	single chemical compound		cyclopentyl (1-methyl-3-{[2-(methyloxy)-4-({[(2-methylphenyl)sulfonyl]amino}carbonyl)phenyl]methyl}-1H-indol-5-yl)carbamate	C5=CC=CC(C)=C5S(=O)(=O)NC(=O)C4=CC=C(CC1=CN(C)C3=C1C=C(NC(=O)OC2CCCC2)C=C3)C(OC)=C4	C5=CC=CC(C)=C5S(=O)(=O)NC(=O)C4=CC=C(CC1=CN(C)C3=C1C=C(NC(=O)OC2CCCC2)C=C3)C(OC)=C4	"InChI=1/C31H33N3O6S/c1-20-8-4-7-11-29(20)41(37,38)33-30(35)22-13-12-21(28(17-22)39-3)16-23-19-34(2)27-15-14-24(18-26(23)27)32-31(36)40-25-9-5-6-10-25/h4,7-8,11-15,17-19,25H,5-6,9-10,16H2,1-3H3,(H,32,36)(H,33,35)/f/h32-33H"	YEEZWCHGZNKEEK-MJHPXVFFCO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiasthmatic	0.667	0.001158639	2.936051702	44	Moderate	High	form of drug administered not known			
23747	3747	23747	1207_FDAMDD_v3b	C9H13N3O3	211.2178	defined organic	parent	tested chemical	Zalcitibine	7481-89-2	single chemical compound	stereochem	"4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one"	N\1(C(\N=C(/C=C/1)N)=O)[C@@H]2O[C@@H](CC2)CO	N\1(C(\N=C(/C=C/1)N)=O)[C@@H]2O[C@@H](CC2)CO	"InChI=1/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1/f/h10H2"	WREGKURFCTUGRC-KTIMGQRGDP	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiviral	0.0375	0.000177542	3.750699247	53	High	High	"form of drug administered not known; 2',3'-Dideoxycytidine"			
23748	3748	23748	1208_FDAMDD_v3b	C17H15N5O	305.3339	defined organic	parent	tested chemical	Zaleplon	151319-34-5	single chemical compound		"N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethylacetamide"	C3=CC(C1=CC=NC2N1N=CC=2C#N)=CC(N(CC)C(=O)C)=C3	C3=CC(C1=CC=NC2N1N=CC=2C#N)=CC(N(CC)C(=O)C)=C3	"InChI=1/C17H15N5O/c1-3-21(12(2)23)15-6-4-5-13(9-15)16-7-8-19-17-14(10-18)11-20-22(16)17/h4-9,11H,3H2,1-2H3"	HUNXMJYCHXQEGX-UHFFFAOYAO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		hypnotic; sedative	0.5	0.001637552	2.785805021	42	Moderate	High	form of drug administered not known			
23749	3749	23749	1209_FDAMDD_v3b	C12H20N4O7	332.3098	defined organic	parent	tested chemical	Zanamivir	139110-80-8	single chemical compound	stereochem; tautomers	"5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid"	O[C@@H]([C@@H]1O\C(=C/[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)CO	O[C@@H]([C@@H]1O\C(=C/[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)CO	"InChI=1/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1/f/h13,15-16,21H,14H2"	ARAIBEBZBOPLMB-OFFOERCVDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		neuraminidase inhibitors	0.333	0.001002077	2.999098916	45	High-Moderate	High	form of drug administered not known			
23750	2315	22315	1210_FDAMDD_v3b	C18H26O5	322.396	defined organic	parent	tested chemical	Zeranol	26538-44-3	single chemical compound	stereochem	"(3S,7R)-7,14,16-trihydroxy-3-methyl-3,4,5,6,7,8,9,10,11,12-decahydro-1H-2-benzoxacyclotetradecin-1-one"	Oc1cc(O)cc2CCCCC[C@@H](O)CCC[C@H](C)OC(=O)c12	Oc1cc(O)cc2CCCCC[C@@H](O)CCC[C@H](C)OC(=O)c12	"InChI=1/C18H26O5/c1-12-6-5-9-14(19)8-4-2-3-7-13-10-15(20)11-16(21)17(13)18(22)23-12/h10-12,14,19-21H,2-9H2,1H3/t12-,14+/m0/s1"	DWTTZBARDOXEAM-GXTWGEPZBO	Clinical Reports 	Maximum Recommended Daily Dose	human	1		anabolic	0.0005	1.55089E-06	5.80941964	76	High	High	form of drug administered not known			
23751	127	20127	1211_FDAMDD_v3b	C10H13N5O4	267.2413	defined organic	parent	tested chemical	Zidovudine	30516-87-1	single chemical compound	stereochem	3'-azido-3'-deoxythymidine	C\C1=C\N(C(=O)NC1=O)[C@H]2C[C@H](/N=[N+]=[N-])[C@@H](CO)O2	C\C1=C\N(C(=O)NC1=O)[C@H]2C[C@H](/N=[N+]=[N-])[C@@H](CO)O2	"InChI=1/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1/f/h12H"	HBOMLICNUCNMMY-XTRDCWLADC	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiviral	10	0.037419366	1.426903576	27	Low-Moderate	Low	form of drug administered not known			
23752	3752	23752	1212_FDAMDD_v3b	C11H12N2O2S	236.29018	defined organic	parent	tested chemical	Zileuton	111406-87-2	single chemical compound		1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea	C1(C(C)N(O)C(=O)N)SC2=C(C=1)C=CC=C2	C1(C(C)N(O)C(=O)N)SC2=C(C=1)C=CC=C2	"InChI=1/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)/f/h12H2"	MWLSOWXNZPKENC-GAJRPKRDCM	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antiasthmatic; anti inflammatry	40	0.169283379	0.771385682	20	Low	Low	form of drug administered not known			
23753	3753	23753	1213_FDAMDD_v3b	C21H21ClN4OS	412.93564	defined organic	parent	tested chemical	Ziprasidone	146939-27-7	single chemical compound		"5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one"	C1=CC=C5C(=C1)SN=C5N4CCN(CCC2=C(Cl)C=C3C(=C2)CC(=O)N3)CC4	C1=CC=C5C(=C1)SN=C5N4CCN(CCC2=C(Cl)C=C3C(=C2)CC(=O)N3)CC4	"InChI=1/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)/f/h23H"	MVWVFYHBGMAFLY-MPIMZMORCD	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic; dopamine receptor antagonist; seratonin receptor antagonist	2.67	0.006465899	2.189371107	36	Moderate	High-Moderate	form of drug administered not known; HCl H2O [138982-67-9]			
23754	3754	23754	1214_FDAMDD_v3b	C15H14ClNO3	291.72956	defined organic	parent	tested chemical	Zomepirac	33369-31-2	single chemical compound		"{5-[(4-chlorophenyl)carbonyl]-1,4-dimethyl-1H-pyrrol-2-yl}acetic acid"	C2=C(Cl)C=CC(C(=O)C1N(C)C(CC(O)=O)=CC=1C)=C2	C2=C(Cl)C=CC(C(=O)C1N(C)C(CC(O)=O)=CC=1C)=C2	"InChI=1/C15H14ClNO3/c1-9-7-12(8-13(18)19)17(2)14(9)15(20)10-3-5-11(16)6-4-10/h3-7H,8H2,1-2H3,(H,18,19)/f/h18H"	ZXVNMYWKKDOREA-GPQMBLKYCW	Clinical Reports 	Maximum Recommended Daily Dose	human	1		analgesic; anti inflammatory	10	0.034278323	1.464980437	28	Low-Moderate	Low	form of drug administered not known; Na anhydrous [64092-48-4]; 2H2O Na salt [64092-49-5]			
23755	3755	23755	1215_FDAMDD_v3b	C34H36ClN3O10	682.1167	defined organic	complex HCl	tested chemical	Zorubicin	36508-71-1	single chemical compound	stereochem; parent [54083-22-6]	"N'-[(1E)-1-{(2S,4S)-4-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl}ethylidene]benzohydrazide hydrochloride"	O=C1C(C(O)=C(C[C@](/C(C)=N/NC(C6=CC=CC=C6)=O)(O)C5)C([C@H]5O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)=C3O)=C3C(C2=C1C=CC=C2OC)=O.Cl	O=C1C(C(O)=C(C[C@](/C(C)=N/NC(C6=CC=CC=C6)=O)(O)C5)C([C@H]5O[C@H]4C[C@H](N)[C@H](O)[C@H](C)O4)=C3O)=C3C(C2=C1C=CC=C2OC)=O	"InChI=1/C34H35N3O10.ClH/c1-15-28(38)20(35)12-23(46-15)47-22-14-34(44,16(2)36-37-33(43)17-8-5-4-6-9-17)13-19-25(22)32(42)27-26(30(19)40)29(39)18-10-7-11-21(45-3)24(18)31(27)41;/h4-11,15,20,22-23,28,38,40,42,44H,12-14,35H2,1-3H3,(H,37,43);1H/b36-16+;/t15-,20-,22-,23-,28+,34-;/m0./s1/f/h37H;"	NKFHKYQGZDAKMX-XIXAPMCLDG	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antineoplastic	7	0.010262174	1.988760642	33	Moderate	Low	form of drug administered not known; Rubidazone; structure modified v3b			
23756	3756	23756	1216_FDAMDD_v3b	C18H18ClNOS	331.85962	defined organic	parent	tested chemical	Zotepine	26615-21-4	single chemical compound		"2-[(8-chlorodibenzo[b,f]thiepin-10-yl)oxy]-N,N-dimethylethanamine"	C1(Cl)=CC=C2C(=C1)C(OCCN(C)C)=CC3=C(S2)C=CC=C3	C1(Cl)=CC=C2C(=C1)C(OCCN(C)C)=CC3=C(S2)C=CC=C3	"InChI=1/C18H18ClNOS/c1-20(2)9-10-21-16-11-13-5-3-4-6-17(13)22-18-8-7-14(19)12-15(16)18/h3-8,11-12H,9-10H2,1-2H3"	HDOZVRUNCMBHFH-UHFFFAOYAX	Clinical Reports 	Maximum Recommended Daily Dose	human	1		antipsychotic	7.5	0.022599917	1.645893148	30	Moderate	Low	form of drug administered not known			
